
<html lang="en"     class="pb-page"  data-request-id="e9640bc5-e421-442f-9cfc-6ecbe0448b39"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2021.64.issue-11;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.0c01720;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Intestinal Excretion, Intestinal Recirculation, and Renal Tubule Reabsorption Are Underappreciated Mechanisms That Drive the Distribution and Pharmacokinetic Behavior of Small Molecule Drugs" /></meta><meta name="dc.Creator" content="Donglu  Zhang" /></meta><meta name="dc.Creator" content="Cong  Wei" /></meta><meta name="dc.Creator" content="Cornelis E. C. A.  Hop" /></meta><meta name="dc.Creator" content="Matthew R.  Wright" /></meta><meta name="dc.Creator" content="Ming  Hu" /></meta><meta name="dc.Creator" content="Yurong  Lai" /></meta><meta name="dc.Creator" content="S. Cyrus  Khojasteh" /></meta><meta name="dc.Creator" content="W. Griff  Humphreys" /></meta><meta name="dc.Description" content="Drug reabsorption following biliary excretion is well-known as enterohepatic recirculation (EHR). Renal tubular reabsorption (RTR) following renal excretion is also common but not easily assessed. ..." /></meta><meta name="Description" content="Drug reabsorption following biliary excretion is well-known as enterohepatic recirculation (EHR). Renal tubular reabsorption (RTR) following renal excretion is also common but not easily assessed. ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 19, 2021" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01720" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 The Authors. Published by American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01720" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01720" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01720" /></link>
        
    
    

<title>Intestinal Excretion, Intestinal Recirculation, and Renal Tubule Reabsorption Are Underappreciated Mechanisms That Drive the Distribution and Pharmacokinetic Behavior of Small Molecule Drugs | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01720" /></meta><meta property="og:title" content="Intestinal Excretion, Intestinal Recirculation, and Renal Tubule Reabsorption Are Underappreciated Mechanisms That Drive the Distribution and Pharmacokinetic Behavior of Small Molecule Drugs" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c01720/20210602/images/large/jm0c01720_0003.jpeg" /></meta><meta property="og:description" content="Drug reabsorption following biliary excretion is well-known as enterohepatic recirculation (EHR). Renal tubular reabsorption (RTR) following renal excretion is also common but not easily assessed. Intestinal excretion (IE) and enteroenteric recirculation (EER) have not been recognized as common disposition mechanisms for metabolically stable and permeable drugs. IE and intestinal reabsorption (IR:EHR/EER), as well as RTR, are governed by dug concentration gradients, passive diffusion, active transport, and metabolism, and together they markedly impact disposition and pharmacokinetics (PK) of small molecule drugs. Disruption of IE, IR, or RTR through applications of active charcoal (AC), transporter knockout (KO), and transporter inhibitors can lead to changes in PK parameters. The impacts of intestinal and renal reabsorption on PK are under-appreciated. Although IE and EER/RTR can be an intrinsic drug property, there is no apparent strategy to optimize compounds based on this property. This review seeks to improve understanding and applications of IE, IR, and RTR mechanisms." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01720"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01720">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01720&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01720&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01720&amp;href=/doi/10.1021/acs.jmedchem.0c01720" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 11</span><span class="cit-fg-pageRange">, 7045-7059</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/11" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c02091" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Intestinal Excretion, Intestinal Recirculation, and Renal Tubule Reabsorption Are Underappreciated Mechanisms That Drive the Distribution and Pharmacokinetic Behavior of Small Molecule Drugs</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Donglu Zhang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Donglu Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Drug Metabolism and Pharmacokinetics, Genentech, 1 DNA Way, South San Francisco, California 94080, United States,</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#bbc1d3dad5dc95dfd4d5dcd7cefbdcded5de95d8d4d6"><span class="__cf_email__" data-cfemail="9fe5f7fef1f8b1fbf0f1f8f3eadff8faf1fab1fcf0f2">[email protected]</span></a>. Phone 650-291-0058.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Donglu++Zhang">Donglu Zhang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-8677-9737" title="Orcid link">https://orcid.org/0000-0001-8677-9737</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Cong Wei</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cong Wei</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Metabolism and Pharmacokinetics, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States,</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Cong++Wei">Cong Wei</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Cornelis E. C. A. Hop</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cornelis E. C. A. Hop</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Drug Metabolism and Pharmacokinetics, Genentech, 1 DNA Way, South San Francisco, California 94080, United States,</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Cornelis+E.+C.+A.++Hop">Cornelis E. C. A. Hop</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Matthew R. Wright</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matthew R. Wright</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Drug Metabolism and Pharmacokinetics, Genentech, 1 DNA Way, South San Francisco, California 94080, United States,</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+R.++Wright">Matthew R. Wright</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ming Hu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ming Hu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">University of Houston College of Pharmacy, 4849 Calhoun Road, Houston, Texas 77204, United States,</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ming++Hu">Ming Hu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yurong Lai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yurong Lai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Metabolism and Pharmacokinetics, Gilead Sciences, 333 Lakeside Drive, Foster City, California 94404, United States,</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yurong++Lai">Yurong Lai</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-9505-333X" title="Orcid link">https://orcid.org/0000-0001-9505-333X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">S. Cyrus Khojasteh</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">S. Cyrus Khojasteh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Drug Metabolism and Pharmacokinetics, Genentech, 1 DNA Way, South San Francisco, California 94080, United States,</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=S.+Cyrus++Khojasteh">S. Cyrus Khojasteh</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath7">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">W. Griff Humphreys</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">W. Griff Humphreys</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Aranmore Pharma Consulting, 11 Andrew Drive, Lawrenceville, New Jersey 08648, United States,</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=W.+Griff++Humphreys">W. Griff Humphreys</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath8">View Biography</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01720&amp;href=/doi/10.1021%2Facs.jmedchem.0c01720" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 11</span><span class="cit-pageRange">, 7045–7059</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 19, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>30 September 2020</li><li><span class="item_label"><b>Published</b> online</span>19 May 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 June 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01720" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01720</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 The Authors. Published by American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7045%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DDonglu%2BZhang%252C%2BCong%2BWei%252C%2BCornelis%2BE.%2BC.%2BA.%2BHop%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D11%26contentID%3Dacs.jmedchem.0c01720%26title%3DIntestinal%2BExcretion%252C%2BIntestinal%2BRecirculation%252C%2Band%2BRenal%2BTubule%2BReabsorption%2BAre%2BUnderappreciated%2BMechanisms%2BThat%2BDrive%2Bthe%2BDistribution%2Band%2BPharmacokinetic%2BBehavior%2Bof%2BSmall%2BMolecule%2BDrugs%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7059%26publicationDate%3DJune%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01720"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2136</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01720" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Intestinal Excretion, Intestinal Recirculation, and Renal Tubule Reabsorption Are Underappreciated Mechanisms That Drive the Distribution and Pharmacokinetic Behavior of Small Molecule Drugs&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Donglu&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Cong&quot;,&quot;last_name&quot;:&quot;Wei&quot;},{&quot;first_name&quot;:&quot;Cornelis&quot;,&quot;last_name&quot;:&quot;E. C. A. Hop&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;R. Wright&quot;},{&quot;first_name&quot;:&quot;Ming&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Yurong&quot;,&quot;last_name&quot;:&quot;Lai&quot;},{&quot;first_name&quot;:&quot;S.&quot;,&quot;last_name&quot;:&quot;Cyrus Khojasteh&quot;},{&quot;first_name&quot;:&quot;W.&quot;,&quot;last_name&quot;:&quot;Griff Humphreys&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;19&quot;,&quot;issue&quot;:&quot;11&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;7045-7059&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01720&quot;},&quot;abstract&quot;:&quot;Drug reabsorption following biliary excretion is well-known as enterohepatic recirculation (EHR). Renal tubular reabsorption (RTR) following renal excretion is also common but not easily assessed. Intestinal excretion (IE) and enteroenteric recirculation (EER) have not been recognized as common disposition mechanisms for metabolically stable and permeable drugs. IE and intestinal reabsorption (IR:EHR/EER), as well as RTR, are governed by dug concentration gradients, passive diffusion, active transport, and metabolism, and together they markedly impact disposition and pharmacokinetics (PK) of small molecule drugs. Disruption of IE, IR, or RTR through applications of active charcoal (AC), transporter knockout (KO), and transporter inhibitors can lead to changes in PK parameters. The impacts of intestinal and renal reabsorption on PK are under-appreciated. Although IE and EER/RTR can be an intrinsic drug property, there is no apparent strategy to optimize compounds based on this property. This review seeks to im&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01720&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01720" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01720&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01720" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01720&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01720" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01720&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01720&amp;href=/doi/10.1021/acs.jmedchem.0c01720" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01720" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01720" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (1 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01720%26sid%3Dliteratum%253Aachs%26pmid%3D34010555%26genre%3Darticle%26aulast%3DZhang%26date%3D2021%26atitle%3DIntestinal%2BExcretion%252C%2BIntestinal%2BRecirculation%252C%2Band%2BRenal%2BTubule%2BReabsorption%2BAre%2BUnderappreciated%2BMechanisms%2BThat%2BDrive%2Bthe%2BDistribution%2Band%2BPharmacokinetic%2BBehavior%2Bof%2BSmall%2BMolecule%2BDrugs%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D11%26spage%3D7045%26epage%3D7059%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291716" title="Excretion">Excretion</a>,</li><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292610" title="Antibiotic resistance">Antibiotic resistance</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/11" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/jmcmar.2021.64.issue-11/20210610/jmcmar.2021.64.issue-11.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c01720/20210602/images/medium/jm0c01720_0003.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c01720/20210602/images/large/jm0c01720_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01720&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Drug reabsorption following biliary excretion is well-known as enterohepatic recirculation (EHR). Renal tubular reabsorption (RTR) following renal excretion is also common but not easily assessed. Intestinal excretion (IE) and enteroenteric recirculation (EER) have not been recognized as common disposition mechanisms for metabolically stable and permeable drugs. IE and intestinal reabsorption (IR:EHR/EER), as well as RTR, are governed by dug concentration gradients, passive diffusion, active transport, and metabolism, and together they markedly impact disposition and pharmacokinetics (PK) of small molecule drugs. Disruption of IE, IR, or RTR through applications of active charcoal (AC), transporter knockout (KO), and transporter inhibitors can lead to changes in PK parameters. The impacts of intestinal and renal reabsorption on PK are under-appreciated. Although IE and EER/RTR can be an intrinsic drug property, there is no apparent strategy to optimize compounds based on this property. This review seeks to improve understanding and applications of IE, IR, and RTR mechanisms.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43713" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43713" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Biliary excretion (BE), renal elimination via glomerular filtration (GF) or transporter-facilitated renal excretion, and metabolism are considered the major clearance pathways for small molecule drugs. However, the contribution of the intestine and the kidney to drug distribution can be more complex than initial absorption and excretion. Direct intestinal excretion (IE) has not been widely recognized as a common elimination pathway, because the drug found in feces is often treated as unabsorbed material or biliary excretion of intact drug and because of lack of easy techniques to directly measure the property. Intestinal excretion (IE) contributes to the elimination of endogenous compounds such as bilirubin and cholesterol and drugs such as digoxin and paclitaxel, many of which are efflux transporter substrates.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4 ref5">(1−5)</a></div><div class="NLM_p">The subject of IE was reviewed three decades ago when there was little understanding of drug transporters, and again in 1998 when the breast cancer resistance protein (BCRP) was discovered.<a onclick="showRef(event, 'ref6 ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8 ref9">(6−9)</a> Although studies have been reported to assess IE of selected drugs for the substrates of P-glycoprotein (P-gp), BCRP, and multidrug resistance-associated protein (MRP) 2, mostly in the context of drug absorption, IE has not been widely considered as a disposition mechanism.<a onclick="showRef(event, 'ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12">(10−12)</a></div><div class="NLM_p">Drugs are subject to reabsorption following biliary excretion (BE), glomerular filtration (GF), and intestinal excretion (IE). Concentration gradient-dependent passive permeation is the major determinant for drug absorption and reabsorption to occur in the intestine and distal renal tubule regions.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Passive permeation is a concentration gradient-driven diffusion process that is not saturable and not subject to inhibition. In contrast, active transport is a saturable process and is subject to inhibition by other drugs. Many drugs have both passive and active components. Enterohepatic recirculation (EHR) has been studied and the topic has been extensively reviewed;<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> however, the contribution of enteroenteric recirculation (EER) and renal tubule reabsorption (RTR) on drug disposition has not been fully recognized.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><div class="NLM_p">The investigation of the mechanism of IE and the interplay of drug elimination with intestinal recirculation (IR) and RTR, as well as a literature search for related topics resulted in additional understanding on the complexity of drug recycling mechanisms. Both EHR and EER could contribute to intestinal recirculation or reabsorption (IR), and IR is designated as IR: EHR/EER or IR (EHR/EER) in the following sections. IE, IR (EHR/EER), and RTR contribute to drug distribution and disposition and could be the pharmacokinetic drivers for small molecule drugs. These reabsorption mechanisms can slow down systemic drug clearance. This serves to sustain drug concentrations especially in the elimination phase of the plasma drug concentration–time curve. The reabsorption and drug recycling mechanisms are illustrated in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>. The major drug clearance mechanisms and pharmacokinetic impacts are described in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. Several drugs listed in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> will be discussed in detail as case studies in this manuscript, and their dispositional characteristics are listed in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c01720/20210602/images/medium/jm0c01720_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c01720/20210602/images/large/jm0c01720_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Drug recycling mechanisms through reabsorption in the intestine and renal tubule: enterohepatic recirculation (EHR), enteroenteric recirculation (EER), and renal tubule reabsorption (RTR) and the effect of activated charcoal (AC). The color yellow means urine; green means bile; black arrows from intestine or renal tubule mean reabsorption. Intestine is colored brown. GFR only represents approximately 10% of renal blood flow.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c01720/20210602/images/large/jm0c01720_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01720&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Clearance Mechanisms of Drugs and Pharmacokinetic Impacts of IR (EHR/EER) and RTR<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">clearance pathway</th><th class="colsep0 rowsep0" align="center">organ involved</th><th class="colsep0 rowsep0" align="center">driving force</th><th class="colsep0 rowsep0" align="center">physicochemical properties often associated with CL pathway</th><th class="colsep0 rowsep0" align="center">reabsorption and/or recirculation</th><th class="colsep0 rowsep0" align="center">function of transporters<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">outcomes</th><th class="colsep0 rowsep0" align="center">examples</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Biliary excretion</td><td class="colsep0 rowsep0" align="left">Liver</td><td class="colsep0 rowsep0" align="left">Liver uptake (and canalicular efflux)</td><td class="colsep0 rowsep0" align="left">Low permeability and substrates for hepatic uptake/efflux transporters</td><td class="colsep0 rowsep0" align="left">Intestinal reabsorption, enterohepatic recirculation (EHR)</td><td class="colsep0 rowsep0" align="left">Uptake for gating drug entry, efflux for active secretion</td><td class="colsep0 rowsep0" align="left">Fecal elimination, biliary clearance</td><td class="colsep0 rowsep0" align="left">Digoxin</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">Renal excretion</td><td class="colsep0 rowsep0" rowspan="2" align="left">Kidney</td><td class="colsep0 rowsep0" rowspan="2" align="left">Glomerular filtration from hydrostatic pressure of blood, active tubular secretion</td><td class="colsep0 rowsep0" rowspan="2" align="left">Low protein binding, low permeability and high solubility, substrates of efflux</td><td class="colsep0 rowsep0" rowspan="2" align="left">Tubular reabsorption, renal tubule reabsorption (RTR)</td><td class="colsep0 rowsep0" rowspan="2" align="left">Efflux for active secretion and prevention of reabsorption</td><td class="colsep0 rowsep0" rowspan="2" align="left">Urinary elimination, renal clearance</td><td class="colsep0 rowsep0" align="left">Nitrofurantoin</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Dapagliflozin</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left">Intestinal excretion</td><td class="colsep0 rowsep0" rowspan="3" align="left">Intestine</td><td class="colsep0 rowsep0" rowspan="3" align="left">Concentration gradient-dependent passive diffusion</td><td class="colsep0 rowsep0" rowspan="3" align="left">Moderate to high permeability, substrates of intestinal efflux transporters</td><td class="colsep0 rowsep0" rowspan="3" align="left">Intestinal reabsorption, enteroenteric recirculation (EER)</td><td class="colsep0 rowsep0" rowspan="3" align="left">Efflux for active secretion and prevention of reabsorption</td><td class="colsep0 rowsep0" rowspan="3" align="left">Fecal elimination, intestinal clearance</td><td class="colsep0 rowsep0" align="left">Apixaban</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Vismodegib</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GNE-19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Metabolism</td><td class="colsep0 rowsep0" align="left">Liver, kidney, intestine</td><td class="colsep0 rowsep0" align="left">Drug-metabolizing enzymes</td><td class="colsep0 rowsep0" align="left">Moderate to high lipophilicity, functional groups for conjugation</td><td class="colsep0 rowsep0" align="left">glucuronidation, biliary excretion, intestinal hydrolysis, and reabsorption (EHR)</td><td class="colsep0 rowsep0" align="left">EER and RTR from uptake (and efflux) enhance metabolism</td><td class="colsep0 rowsep0" align="left">Fecal or urinary elimination, overall clearance</td><td class="colsep0 rowsep0" align="left">BMS-823778</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Pharmacokinetic effects of IR (EHR/EER) and RTR: decrease elimination clearance, prolong <i>T</i><sub>1/2</sub>, decrease peak-to-trough ratio, increase volume of distribution and mean resident time, enhance metabolism. Passive permeation is critical for reabsorption.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Basolateral uptake transporters are required for low permeability compounds before apical efflux transport for elimination and can enhance elimination of compounds with low apparent permeability.</p></div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Distribution and Disposition Properties of Selected Drugs<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">drug</th><th class="colsep0 rowsep0" align="center">apparent permeability</th><th class="colsep0 rowsep0" align="center">unbound fraction (<i>f</i><sub>u</sub>)</th><th class="colsep0 rowsep0" align="center">transporter substrate</th><th class="colsep0 rowsep0" align="center"><i>in vitro</i> stability</th><th class="colsep0 rowsep0" align="center">GF</th><th class="colsep0 rowsep0" align="center">RTR</th><th class="colsep0 rowsep0" align="center">BE</th><th class="colsep0 rowsep0" align="center">EHR</th><th class="colsep0 rowsep0" align="center">IE</th><th class="colsep0 rowsep0" align="center">EER</th><th class="colsep0 rowsep0" align="center"><i>in vivo</i> metabolism</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Apixaban</td><td class="colsep0 rowsep0" align="left">High</td><td class="colsep0 rowsep0" align="left">0.07–0.13</td><td class="colsep0 rowsep0" align="left">P-gp, BCRP</td><td class="colsep0 rowsep0" align="left">Yes</td><td class="colsep0 rowsep0" align="left">Yes</td><td class="colsep0 rowsep0" align="left">Yes</td><td class="colsep0 rowsep0" align="left">Low</td><td class="colsep0 rowsep0" align="left">Low</td><td class="colsep0 rowsep0" align="left">25–35%</td><td class="colsep0 rowsep0" align="left">Yes</td><td class="colsep0 rowsep0" align="left">1/3 dose</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Digoxin</td><td class="colsep0 rowsep0" align="left">Low</td><td class="colsep0 rowsep0" align="left">0.2</td><td class="colsep0 rowsep0" align="left">P-gp, OATP</td><td class="colsep0 rowsep0" align="left">Yes</td><td class="colsep0 rowsep0" align="left">Yes</td><td class="colsep0 rowsep0" align="left">No</td><td class="colsep0 rowsep0" align="left">Yes</td><td class="colsep0 rowsep0" align="left">NS</td><td class="colsep0 rowsep0" align="left">Low</td><td class="colsep0 rowsep0" align="left">NS</td><td class="colsep0 rowsep0" align="left">1/2 dose</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Nitrofurantoin</td><td class="colsep0 rowsep0" align="left">Low</td><td class="colsep0 rowsep0" align="left">0.4</td><td class="colsep0 rowsep0" align="left">BCRP</td><td class="colsep0 rowsep0" align="left">Yes</td><td class="colsep0 rowsep0" align="left">Yes</td><td class="colsep0 rowsep0" align="left">No</td><td class="colsep0 rowsep0" align="left">Low</td><td class="colsep0 rowsep0" align="left">NS</td><td class="colsep0 rowsep0" align="left">Low</td><td class="colsep0 rowsep0" align="left">NS</td><td class="colsep0 rowsep0" align="left">1/2 dose</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Dapagliflozin</td><td class="colsep0 rowsep0" align="left">Intermediate</td><td class="colsep0 rowsep0" align="left">0.085</td><td class="colsep0 rowsep0" align="left">NR</td><td class="colsep0 rowsep0" align="left">Yes</td><td class="colsep0 rowsep0" align="left">Yes</td><td class="colsep0 rowsep0" align="left">Yes</td><td class="colsep0 rowsep0" align="left">NS</td><td class="colsep0 rowsep0" align="left">NS</td><td class="colsep0 rowsep0" align="left">NS</td><td class="colsep0 rowsep0" align="left">NS</td><td class="colsep0 rowsep0" align="left">1/5 dose</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GDC-0449</td><td class="colsep0 rowsep0" align="left">Intermediate</td><td class="colsep0 rowsep0" align="left">0.01</td><td class="colsep0 rowsep0" align="left">P-gp</td><td class="colsep0 rowsep0" align="left">Yes</td><td class="colsep0 rowsep0" align="left">NR</td><td class="colsep0 rowsep0" align="left">NR</td><td class="colsep0 rowsep0" align="left">NR</td><td class="colsep0 rowsep0" align="left">NR</td><td class="colsep0 rowsep0" align="left">Yes</td><td class="colsep0 rowsep0" align="left">NR</td><td class="colsep0 rowsep0" align="left">2/3 dose</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GNE-19</td><td class="colsep0 rowsep0" align="left">Intermediate</td><td class="colsep0 rowsep0" align="left">0.01</td><td class="colsep0 rowsep0" align="left">P-gp</td><td class="colsep0 rowsep0" align="left">Yes</td><td class="colsep0 rowsep0" align="left">NR</td><td class="colsep0 rowsep0" align="left">NR</td><td class="colsep0 rowsep0" align="left">NR</td><td class="colsep0 rowsep0" align="left">NR</td><td class="colsep0 rowsep0" align="left">Yes</td><td class="colsep0 rowsep0" align="left">NR</td><td class="colsep0 rowsep0" align="left">Moderate</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BMS-823778</td><td class="colsep0 rowsep0" align="left">High</td><td class="colsep0 rowsep0" align="left">0.15</td><td class="colsep0 rowsep0" align="left">No</td><td class="colsep0 rowsep0" align="left">Yes</td><td class="colsep0 rowsep0" align="left">Yes</td><td class="colsep0 rowsep0" align="left">Yes</td><td class="colsep0 rowsep0" align="left">Low</td><td class="colsep0 rowsep0" align="left">NS</td><td class="colsep0 rowsep0" align="left">NS</td><td class="colsep0 rowsep0" align="left">NS</td><td class="colsep0 rowsep0" align="left">3/4 dose</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">GR, glomerular filtration; RTR, renal tubule reabsorption; BE, biliary excretion; EHR, extrahepatic recirculation; IE, intestinal excretion; EER, enteroenteric recirculation. NS, not studied, NR, not reported.</p></div></div></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c01720/20210602/images/medium/jm0c01720_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c01720/20210602/images/large/jm0c01720_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of selected drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c01720/20210602/images/large/jm0c01720_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01720&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The increased use of physiologically based pharmacokinetics (PBPK) modeling will also require full characterization of elimination pathways and dispositional mechanisms including IE, IR (EHR/EER), and RTR to predict clinical PK profiles and clinical dose. This review is intended to bring awareness to the importance of drug reabsorption and recycling in the intestine and distal renal tubule as an essential mechanism for drug distribution and disposition.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Apparent Permeability and Drug Transporters</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74284" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74284" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Although drug transporters can play an important role in drug distribution and disposition, drug reabsorption is determined by concentration gradient-dependent passive permeation of a drug from the large surface areas of the intestines and renal tubules.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Those molecules of low passive permeability will have low potential for absorption and reabsorption unless it is a substrate of uptake transporters. P-gp, BCRP, and MRP2 are members of the ATP-Binding Cassette (ABC) transporter superfamily that are highly expressed at the luminal brush border membranes of intestinal enterocytes, proximal tubular membranes in the kidney, and canalicular membranes of hepatocytes. These transporters play an important role in drug absorption and elimination.<a onclick="showRef(event, 'ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22">(15−22)</a> The functions of intestinal efflux transporters in preventing drugs from absorption, as well as the roles of efflux transporters in urinary and biliary excretion, have been reviewed extensively.<a onclick="showRef(event, 'ref23 ref24 ref25 ref26 ref27 ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25 ref26 ref27 ref28 ref29 ref30">(23−30)</a> The expression of intestinal efflux transporters is region- and species-dependent.<a onclick="showRef(event, 'ref31 ref32 ref33 ref34 ref35 ref36 ref37 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref33 ref34 ref35 ref36 ref37 ref38 ref39">(31−39)</a> The expression of P-gp and BCRP is organ- and species-dependent, with a lower expression of BCRP in the kidney of human than rat and a higher expression of BCRP than P-gp in the human jejunum.<a onclick="showRef(event, 'ref36 ref40'); return false;" href="javascript:void(0);" class="ref ref36 ref40">(36,40)</a></div><div class="NLM_p last">A meta-analysis of the expression of gut transporters in adult Caucasians showed that the solute carrier peptide transporter 1 (PepT1) showed the highest jejunal abundance, while MRP2 was the highest abundance ATP-binding transporter.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The renal transporters most often involved in active secretion from blood into proximal tubule cells (basolateral) are organic anion transporter (OAT) 1 and 3 and organic cation transporter (OCT) 2 and 3. Transporters involved in moving compounds from tubule cells into the lumen include P-gp, multidrug resistant proteins (MRP2 and MRP4), and multidrug and toxin extrusion protein 1/2-K (MATE1/2-K). Mediating factors for renal tubular secretion could include apparent permeability and basolateral/apical transporters, as well as the urinary pH and a compound’s p<i>K</i><sub>a</sub>.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Drug Recycling Mechanisms</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46470" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46470" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Renal Filtration/Excretion and RTR</h3><div class="NLM_p">Renal blood flow represents about 20% of cardiac output. As much as 10% of renal plasma water is filtered at the glomerulus, which allows filtration of unbound small molecule drugs out of circulation. Reabsorption of water along the nephron creates a large concentration gradient of the filtered drug that drives its passive diffusion from the lumen side to the blood side. Efflux transporters such as P-gp and BCRP are expressed in the tubular epithelium cells<a onclick="showRef(event, 'ref36 ref20'); return false;" href="javascript:void(0);" class="ref ref36 ref20">(36,20)</a> and can drive active secretion of their substrates. Renal clearance is thus the result of glomerular filtration of unbound drug, tubular secretion, and passive diffusion-driven reabsorption of a drug. <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> shows intrinsic and extrinsic factors that could affect renal excretion and renal tubule reabsorption.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Factors That Affect Intestinal and Renal Reabsorption</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">affecting factors</th><th class="colsep0 rowsep0" align="center">intestinal reabsorption</th><th class="colsep0 rowsep0" align="center">renal tubule reabsorption</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Systemic Properties</td><td class="colsep0 rowsep0" align="left">Drug concentration gradient</td><td class="colsep0 rowsep0" align="left">Drug concentration gradient</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Protein binding (<i>f</i><sub>u</sub>)</td><td class="colsep0 rowsep0" align="left">Protein binding (<i>f</i><sub>u</sub>)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Passive permeability (lipohilicity, molecule weight, hydrogen-binding, polar surface areas)</td><td class="colsep0 rowsep0" align="left">Passive permeability (lipophilicity, molecule weight, hydrogen-binding, polar surface areas)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Interferences (charcoal, transporter knockout, drug–drug interaction)</td><td class="colsep0 rowsep0" align="left">Interferences (transporter knockout, drug–drug interaction)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Organ Physiology Properties</td><td class="colsep0 rowsep0" align="left">Bile flow, biliary excretion</td><td class="colsep0 rowsep0" align="left">Glomerular filtration</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Intestinal (microvilli) blood flow</td><td class="colsep0 rowsep0" align="left">Renal tubular blood flow</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Intestinal surface area</td><td class="colsep0 rowsep0" align="left">Renal tubule surface area</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Peristaltic mobility, fluid transit time</td><td class="colsep0 rowsep0" align="left">Urine flow, urine transit time</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Expression of uptake and efflux transporters</td><td class="colsep0 rowsep0" align="left">Expression of uptake and efflux transporters</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Intestine diseases</td><td class="colsep0 rowsep0" align="left">Urine pH, kidney diseases</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Drug Physiochemical Properties</td><td class="colsep0 rowsep0" align="left">Ionization potential, p<i>K</i><sub>a</sub></td><td class="colsep0 rowsep0" align="left">Ionization potential, p<i>K</i><sub>a</sub></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Solubility</td><td class="colsep0 rowsep0" align="left">Solubility</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Metabolic stability</td><td class="colsep0 rowsep0" align="left">Metabolic stability</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Transporter efficiency (<i>K</i><sub>m,</sub><i>V</i><sub>max</sub>)</td><td class="colsep0 rowsep0" align="left">Transporter efficiency (<i>K</i><sub>m</sub>, <i>V</i><sub>max</sub>)</td></tr></tbody></table></div></div><div class="NLM_p">It is very difficult to completely understand all the processes that lead to an observed renal clearance value for established drugs and early development candidates.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Clearance due to glomerular filtration (CL<sub>FILT</sub>) is by far the easiest step to characterize and is usually assumed to be the product of fraction unbound in plasma (<i>f</i><sub>u</sub>) and glomerular filtration rate (GFR) for small molecules. Active renal secretion can often be characterized <i>in vitro</i> using expressed renal transporters, although quantitative translation of <i>in vitro</i> data to <i>in vivo</i> remains challenging. Finally, reabsorption processes are often an underappreciated component in the overall understanding of a drug’s disposition and are typically not included in preclinical predictions. Generally, conclusions regarding the balance of active secretion versus reabsorption are based on comparison of observed renal clearance (CL<sub>R</sub>) to GFR × <i>f</i><sub>u</sub>; net active secretion is indicated if CL<sub>R</sub> > GFR × <i>f</i><sub>u</sub>, and net reabsorption is indicated in cases where CL<sub>R</sub> < GFR × <i>f</i><sub>u</sub>. In addition, secretion and reabsorption could simultaneously happen and cancel out each other.</div><div class="NLM_p">Almost all drugs that have high apparent permeability undergo renal reabsorption mainly due to the distal tubule function of the kidney, where >90% of water is reabsorbed and the resulting drug concentration gradient drives reabsorption through passive permeation. While it does remain challenging to predict reabsorption or to model it effectively with clinical data in hand, there have been efforts to better understand the properties of molecules that favor reabsorption and to construct a general physiological-based mechanistic model to describe the reabsorption process.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a> The modeling gave reasonable estimates for CL<sub>R</sub> for a variety of substrates where GFR × <i>f</i><sub>u</sub> gave a substantially overprediction of CL<sub>R</sub>.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></div><div class="NLM_p last">Urine pH values greatly affect the renal reabsorption of weak acids and weak bases if the renal excretion is an important elimination pathway.<a onclick="showRef(event, 'cit45a'); return false;" href="javascript:void(0);" class="ref cit45a">(45a)</a> Drug in urine as well as disease states can cause urine pH changes.<a onclick="showRef(event, 'cit45b'); return false;" href="javascript:void(0);" class="ref cit45b">(45b)</a> For the weak base memantine, the area-under-plasma concentration–time curve (AUC) increased by 5-fold,<a onclick="showRef(event, 'cit45c'); return false;" href="javascript:void(0);" class="ref cit45c">(45c)</a> in comparison with the weak acid chlorpropamide, where the AUC decreased by 80%,<a onclick="showRef(event, 'cit45d'); return false;" href="javascript:void(0);" class="ref cit45d">(45d.)</a> in alkaline versus acidic urine conditions. These observations are consistent with renal reabsorption depending on passive permeation of noncharged species, which can alter the PK and urinary elimination of ionizable drugs.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Biliary Elimination and EHR</h3><div class="NLM_p">There are two sources of drugs that are subject to EHR.</div><div class="NLM_p last">First, drugs can be directly excreted into bile, although hepatic uptake is required before biliary excretion. Second, drugs can undergo direct glucuronidation/direct sulfation followed by biliary excretion and deglucuronidation/desulfation in the intestine through enzymatic hydrolysis by gut bacteria.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Therefore, the potential for EHR can be determined by analyzing the bile composition for parent drugs and direct glucuronide/sulfate conjugates. Active charcoal (AC) has been shown to block EHR of selective drugs in human and animal studies through preventing drug reabsorption.<a onclick="showRef(event, 'ref14 ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref14 ref47 ref48">(14,47,48)</a> Watanabe et al. described that the hepatic clearance of 12 drugs was predicted to be limited by hepatic uptake; interestingly, 10–35% of the total clearance for each of those 12 hardly metabolized drugs that was not accounted for could be ascribed to IE.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> AC can impact EER for those drugs that have limited biliary excretion like apixaban (to be discussed).</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Intestinal Excretion (IE) and Enteroenteric Reabsorption (EER)</h3><div class="NLM_p">The intestine is a highly perfused organ supplied by the superior mesenteric artery receiving approximately 10–20% of cardiac output in humans and animal species with 60% of mucosal blood flow supplying the epithelial cells of the villi.<a onclick="showRef(event, 'ref50 ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref50 ref51 ref52">(50−52)</a> Shortly after PO dosing, a concentration gradient leads to absorption of drug into circulation. Drug is then subject to passive permeation and/or active transport-depended biliary and intestinal excretion. At the same time the drug clears from circulation, it accumulates in the intestinal lumen during the period of intestinal fluid transit from proximal to distal segments. This causes the concentration gradient to reverse again several hours later in distal intestines for reabsorption. In other words, the concentration gradients defines where and when absorption, excretion, and reabsorption occurs in intestines.</div><div class="NLM_p">The efflux transporters expressed at the apical membranes of the intestinal epithelium cells, including P-gp, BCRP, and MRP2, can prevent reabsorption and facilitate intestinal excretion of substrate drugs such as talinolol, digoxin, and paclitaxel.<a onclick="showRef(event, 'ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5">(3−5)</a> Uptake transporters on the basolateral side of enterocytes have not been described to be convincingly involved in IE.</div><div class="NLM_p"><a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> shows intrinsic and extrinsic factors that could affect IE and IR (EHR/EER). IE and IR depend on several things. Among them are the physiological properties of intestines and physicochemical properties of drugs. They also depend on reabsorption and other factors such as use of AC, drug–drug interactions, and even the luminal unstirred water layer that could limit diffusion and IE of highly permeable compounds.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Both intestinal mobility and efflux transporters can facilitate IE, which works together with intestinal mobility to move drugs out of the lumen. Since a drug has to passively diffuse through the basolateral membrane,<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> being an efflux transporter substrate does not mean that a compound will undergo extensive IE. Therefore, passive permeability is a critical factor, even for an efflux substrate, to have a significant level of IE. Coupling of uptake and efflux transporters could enhance IE for a low permeable compound,<a onclick="showRef(event, 'ref30 ref55'); return false;" href="javascript:void(0);" class="ref ref30 ref55">(30,55)</a> and lack of either uptake or passive permeation and efflux will limit their extent of IE.</div><div class="NLM_p">Inhibition of intestinal efflux transporters can decrease IE.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Induction and polymorphisms of intestinal efflux transporters could in theory affect IE for those compounds such as digoxin that depend on transporters for IE. Induction of intestinal efflux transporters could increase IE, with P-gp induction appearing to depend on PXR activation, and BCRP induction depending on activation of AhR.<a onclick="showRef(event, 'ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref56 ref57">(56,57)</a> Transporter polymorphisms such as P-gp (e.g., C3435T) and BCRP (e.g., C421A) create additional factors that could affect IE of transporter substrates, as there is literature to demonstrate that the polymorphisms of efflux transporters show a marked effect on drug systemic exposures.<a onclick="showRef(event, 'ref28 ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref28 ref58 ref59">(28,58,59)</a> The functional importance of a transporters in contributing to IE may also depend on the involvement of other routes of elimination such as renal excretion, biotransformation, and biliary excretion in the overall elimination of a drug.</div><div class="NLM_p last">The small intestines have a large surface area due to convoluted structures with luminal villi and microvilli for drug absorption and reabsorption. Drug transporters and drug metabolizing enzymes are heterogeneously expressed in the intestine affecting drug absorption and reabsorption.<a onclick="showRef(event, 'ref60 ref61 ref62 ref63 ref64 ref65 ref66 ref67'); return false;" href="javascript:void(0);" class="ref ref60 ref61 ref62 ref63 ref64 ref65 ref66 ref67">(60−67)</a> IR/EER is a dynamic process of concentration gradient-dependent transcellular passive diffusion, transporter-mediated transport, and segment-dependent reabsorption operating in the same or opposite direction to intestinal mobility. Some properties that would favor IE over direct biliary excretion include high permeability, and not being a substrate for active hepatic uptake (that limits biliary excretion).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> P-gp/BCRP/MRP2 can further facilitate IE of their substrates. Considering the lipophilicity for apparent permeability of small molecules, the large intestinal surface area, and concentration gradients in distal intestines, IE is operative to some extent for most small molecule drugs even without being a substrate of drug transporters.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Case Series 1: Renal Filtration/Excretion and RTR</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83802" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83802" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">An example where there is a clear renal reabsorption process is with the disposition of BMS-823778 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>), an 11-β-hydroxysteriod dehydrogenase 1 inhibitor to treat diabetes.<a onclick="showRef(event, 'ref68 ref69'); return false;" href="javascript:void(0);" class="ref ref68 ref69">(68,69)</a> BMS-823778 is directly conjugated by UGT1A4 and hydroxylated by CYP2C19. However, neither of those enzymes are expressed in kidney tissue,<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> so there is low probability for any renal metabolic clearance. The CL<sub>R</sub>/F of BMS-823778 in humans was found to be 0.09 mL/h/kg after PO dose (F not determined in human but predicted to be >50%) and the unbound fraction in plasma was 0.15. The predicted CL<sub>FILT</sub> is thus 16.07 mL/h/kg and an overestimate of observed CL<sub>R</sub>. The compound does have properties similar to other compounds that show net reabsorption,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> i.e., relatively lipophilic (clogP = 2.76) and uncharged at neutral pH. BMS-823778 has excellent passive permeability. More than 90% of the dose of BMS-823778 was eliminated as metabolites in humans.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> This is an example where an <i>in vitro</i> metabolically stable compound was ultimately eliminated as metabolites in excreta <i>in vivo</i> through an excretion–reabsorption–metabolism interplay. The long half-life of this compound (<i>T</i><sub>1/2</sub> = 50 h in humans) was consistent with slow metabolism, and extensive renal tubule reabsorption during which there was minimal renal metabolism.</div><div class="NLM_p">Another interesting example that shows net reabsorption is dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor to treat diabetes.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> In this case, reabsorption plays a role not only in PK but also in the pharmacodynamic effect of the drug. The CL<sub>R</sub> was determined to be 4.8 mL/h/kg, and GFR × <i>f</i><sub>u</sub> calculated to be 9.24 mL/h/kg, so there is net reabsorption, but it is not as extensive as the example above.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> In addition, target-mediated drug binding might have contributed to the small difference between the theoretical calculation and measured data of clearance. However, the balance between filtration and reabsorption is critical as the target for dapagliflozin is the sodium glucose co-transporter 2 (SGLT2) which is located in the proximal tubule. While reabsorption helps to prolong the systemic concentrations of drug, it effectively removes the drug from its site of action. For this reason, there has been considerable interest in building PBPK models that can help to understand both the plasma as well as the proximal tubule pharmacokinetics.<a onclick="showRef(event, 'ref74 ref75'); return false;" href="javascript:void(0);" class="ref ref74 ref75">(74,75)</a></div><div class="NLM_p">GF plays a role for the urinary excretion of digoxin and nitrofurantoin. Urinary excretion of digoxin in rats depends on P-gp expression, since P-gp knockout reduced urinary elimination by 35% (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01720/suppl_file/jm0c01720_si_001.pdf" class="ext-link">Table S1</a>). Urinary excretion of nitrofurantoin in rats was reduced by approximately 30% in BCRP-KO animals (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01720/suppl_file/jm0c01720_si_001.pdf" class="ext-link">Table S1</a>). These drugs were mostly excreted in urine as parent drugs. This suggests minimal reabsorption in the renal tubules due to lack of apparent permeability.</div><div class="NLM_p">GF also appears to play a critical role for apixaban. However, on further investigation, active secretion and reabsorption may also be occurring. Urinary excretion accounted for about 50% of the apixaban dose and about 50% of the systemic clearance in rats following IV administration. Based on GF and plasma protein binding,<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> apixaban clearly shows active renal excretion in rats with GFR × <i>f</i><sub>u</sub> = 13 mL/h/kg. That is much smaller than the urinary clearance of apixaban in rats (710 mL/h/kg). For comparison, urinary excretion only accounted for about 10% of the apixaban dose in dogs, and the renal clearance (∼20 mL/h/kg) represents 13–19% of the systemic clearance. This result is consistent with a low level of net tubular reabsorption (GFR × <i>f</i><sub>u</sub> = 29 mL/h/kg) in dogs. Urinary elimination in humans was moderate (27% of dose),<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> and the renal clearance of apixaban is similar to the GFR. This is likely due to cancellation of active secretion versus reabsorption. Thus, the extent of RTR could be estimated based on the difference between urinary clearance and GFR. The urinary clearance was based on measurements of unlabeled parent in urine in humans and animals species. As apixaban is not a substrate for any uptake in drug transporters, the stronger secretion in rats than in humans or dogs was consistent with a higher level of activity and/or expression of BCRP/P-gp transporters in rats.</div><div class="NLM_p last">A lack of experimental approaches to study RTR clouds the importance of this fundamental drug disposition mechanism. Renal reabsorption is a key process for retaining endogenous molecules, and drugs from urinary elimination. However, it remains challenging sometimes to separate GF and active excretion from RTR.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Case Series 2: IE, EER, and RTR in Apixaban Disposition</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36547" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36547" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Apixaban is a direct inhibitor of Factor Xa and used as an anticoagulant.<a onclick="showRef(event, 'ref78 ref79 ref80'); return false;" href="javascript:void(0);" class="ref ref78 ref79 ref80">(78−80)</a> After oral administration of [<sup>14</sup>C]apixaban in humans, metabolism (25%), urinary excretion (27%), and fecal excretion (34%) are important elimination clearance pathways with biliary excretion as a minor pathway.<a onclick="showRef(event, 'ref77 ref81'); return false;" href="javascript:void(0);" class="ref ref77 ref81">(77,81)</a> The recovery of about 20–50% of the IV-administered [<sup>14</sup>C]apixaban dose as intact drug in feces of bile duct cannulated rats (BDC) and dogs confirmed that there was direct excretion of the drug from blood into the GI tract. Apixaban is a nonionizable molecule, moderately bound to human plasma proteins (<i>f</i><sub>u</sub> = 7–13%) and is metabolically stable in incubations with liver microsomes and hepatocytes. It has a relatively low clearance with total plasma clearance of <5% hepatic blood flow in rat, dog, and human.<a onclick="showRef(event, 'ref76 ref82'); return false;" href="javascript:void(0);" class="ref ref76 ref82">(76,82)</a> In humans, apixaban has an elimination half-life of ∼12 h and a low peak-to-trough plasma concentration ratio (<4) after oral BID administration. Apixaban also has a small volume of distribution (∼0.3 L/kg) and is subject to GF.<a onclick="showRef(event, 'ref82 ref83'); return false;" href="javascript:void(0);" class="ref ref82 ref83">(82,83)</a> Apixaban elimination involves IE, EER, and RTR (summarized in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). This was determined after extensive experimentation to integrate its elimination mechanisms and pharmacokinetic profiles obtained from BDC rats, P-gp-KO/BCRP-KO rats, and dogs following IV administration of [<sup>14</sup>C]apixaban.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> In addition, the effect of a transporter inhibitor and AC on apixaban pharmacokinetics in rats, dogs, and humans was also determined and will be discussed here.<a onclick="showRef(event, 'ref13 ref84'); return false;" href="javascript:void(0);" class="ref ref13 ref84">(13,84)</a></div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> <i>In Vitro</i> and <i>Ex Vivo</i> Permeability Characteristics of Apixaban</h3><div class="NLM_p">Apixaban had a higher apparent permeability (<i>P</i><sub>app</sub>) value in the basolateral-to-apical direction (secretory) than the apical-to-basolateral direction (absorptive). It is a substrate of efflux transporters P-gp and BCRP, but is not a substrate for MRP2.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Apixaban was also not a substrate for known liver or kidney uptake transporters.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> The intestinal permeability of apixaban was studied using isolated rat duodenum, jejunum, ileum, and colon segments.<a onclick="showRef(event, 'ref86 ref87'); return false;" href="javascript:void(0);" class="ref ref86 ref87">(86,87)</a> The results further supported the intestinal efflux transport of apixaban at least in the jejunum segment.</div><div class="NLM_p">Apixaban has a higher apparent permeability in the PAMPA assay with <i>P</i><sub>app</sub> values of >200 nm/s. This was consistent with its high (>70%) <i>in vivo</i> absorption based on the Biopharmaceutical Classification System (BCS).<a onclick="showRef(event, 'ref88 ref89 ref90'); return false;" href="javascript:void(0);" class="ref ref88 ref89 ref90">(88−90)</a> The moderate to good PO bioavailability in rats (30%), dogs (70%), and humans (49%) at clinical relevant doses suggest that passive diffusion plays an important role in absorption and reabsorption of apixaban in animals and humans. This happens despite the efflux effect of intestinal P-gp and BCRP.<a onclick="showRef(event, 'ref81 ref82 cit91a cit91b'); return false;" href="javascript:void(0);" class="ref ref81 ref82 cit91a cit91b">(81,82,91a,b)</a></div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> Elimination Pathways and Pharmacokinetic Profiles of Apixaban in Rats, Dogs, and Humans</h4><div id="sec5_1_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i15" class="anchor-spacer"></div><h5 class="article-section__title" id="_i15">1.  Charcoal Studies</h5><div class="NLM_p">Apixaban <i>T</i><sub>max</sub> and <i>C</i><sub>max</sub> were not markedly affected by subsequent administration of AC in dogs at 0.25, 1, and 3 h after apixaban IV dose. AC treatments caused a decrease in apixaban AUC<sub>0–24h</sub> (24%, 19%, and 37%, respectively) and a decreased <i>T</i><sub>1/2</sub> (5.6 h to <4 h when AC was administered 1 and 3 h after apixaban, respectively). A corresponding increase of the systemic clearance was determined (29–66%), as well as a decrease in the mean resident time (MRT) and the <i>C</i><sub>24h</sub> values.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a></div><div class="NLM_p last">Similar to the results in dogs, apixaban’s <i>T</i><sub>max</sub> (∼2.5 h) and <i>C</i><sub>max</sub> values were not affected in human subjects following a 20 mg PO dose of apixaban with and without subsequent single administration of AC.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> A decrease in apixaban AUC of approximately 50% and 27% and a decrease of <i>T</i><sub>1/2</sub> from 13.4 h to 5.3 and 4.9 h were observed when AC was administered at 2 and 6 h post dose, respectively.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The broad peak of apixaban from multiphases of absorption, distribution, and elimination in the plasma concentration–time profiles in dogs and humans was narrowed following AC treatments. Given that biliary excretion of apixaban was a minor elimination pathway, the impact of AC in humans is consistent with IE as an important elimination pathway. Metabolism and urinary excretion are also important elimination pathways, each accounting for approximately 1/3 of total clearance in humans.</div></div><div id="sec5_1_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i16" class="anchor-spacer"></div><h5 class="article-section__title" id="_i16">2.  BDC Dog Studies</h5><div class="NLM_p last">The 40–50% of the dose that was recovered in feces of BDC dogs following IV administration is consistent with the drug directly excreted into the GI tract and eliminated in the feces. The fecal recovery was increased in BDC dogs upon treatment with AC, with no marked effect on the urinary elimination. The apixaban AUC was reduced by approximately 19–39%, with apparent systemic clearance of apixaban increased by 20–60% by AC treatment. This treatment also increased fecal elimination in BDC dogs and led to a corresponding >50% increase in intestinal clearance (IC) in dogs. These results suggest that AC prevented reabsorption of apixaban, leading to the increase of IE. The <i>T</i><sub>1/2</sub> and mean residence time (MRT) were shorter in dogs after IV than PO. Urinary excretion was a minor pathways in BDC dogs, representing 10–20% of the dose, which was also similar in intact dogs following PO administration of [<sup>14</sup>C]apixaban.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> Combining the results of the studies in BDC dogs of IV dosing with those of oral dosing with administration of AC, the late AC effect in dogs and humans after PO administration is consistent with preventing reabsorption of apixaban from IE.</div></div><div id="sec5_1_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i17" class="anchor-spacer"></div><h5 class="article-section__title" id="_i17">3.  BDC Rat Studies</h5><div class="NLM_p last">IE of apixaban was further investigated in BDC rats following IV administration of [<sup>14</sup>C]apixaban.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Approximately 20–30% of dose was found in the feces of BDC rats following IV administration of [<sup>14</sup>C]apixaban. The direct IE of apixaban led to IC representing 21–28% of the total systemic clearance in rats. Administration of GF-120918,<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> a potent P-gp and BCRP inhibitor, reduced the fecal dose recovery of IV apixaban by 34%. The administration of AC increased the fecal recovery approximately by 36%. The AUC of apixaban was increased (by 100%) with GF-120918 and decreased (by 28%) with AC. The IE and systemic clearance were decreased 66% and 50% by the GF-120918 treatment and increased 80% and 42% by the AC treatment, respectively. These data demonstrated that inhibition of intestinal efflux transporters decreased apixaban IE, while AC increased both clearance values because of disrupted apixaban reabsorption. GF-120918 did not affect the urinary or biliary excretion of apixaban in rats, which could result from a lower kidney exposure of the inhibitor than in the intestine. The increase in intestinal recovery of the apixaban radioactive dose after AC was compensated by the decrease of the urinary excretion in rats. This suggests diversion of apixaban elimination from urinary to the IE route by AC. In rats, the volume of distribution (<i>V</i><sub>d</sub>), <i>T</i><sub>1/2</sub>, and MRT of apixaban decreased after IV versus PO administration; the peak to last time point concentration ratio (<i>C</i><sub>max</sub>/<i>C</i><sub>10</sub>) increased from 15 to 500 after PO versus IV administration.</div></div><div id="sec5_1_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i18" class="anchor-spacer"></div><h5 class="article-section__title" id="_i18">4.  Studies in Drug Transporter-KO Rats</h5><div class="NLM_p last">The urinary elimination decreased from 50% to 27% in the BCRP-KO rats and from 50% to 41% in the P-gp-KO rats following IV administration of apixaban.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The biliary excretion of apixaban, ranging 10–15% of dose, was similar in all types of rats, further supporting that biliary efflux transporters did not affect biliary excretion. The increased fecal elimination of apixaban (from 21% to 39% of dose) in the BCRP-KO and P-gp-KO rats compared to the wild-type rats was consistent with increased IE to balance out the decreased urinary excretion. The apixaban AUC increased by 45% and 66% in P-gp-KO and BCRP-KO rats, respectively, compared to the wild-type rats. GF-120918 increased apixaban exposures (AUC) nearly 400% after PO administration. These results suggest that BCRP plays a more important role than P-gp in apixaban absorption. Consequently, together with apixaban’s good apparent permeability, GF-120918 did not significantly alter apixaban’s urinary excretion in rats. Compared to the broad peaks in the plasma concentration–time profiles of apixaban in dogs, humans, or BCRP-KO rats after PO administration, apixaban showed multiple broad peaks in P-gp-KO and wild-type rats after PO. Collectively, P-gp-KO and BCRP-KO reduced renal elimination, which led to the compensatory increase in apparent IE of apixaban driven by passive diffusion through the loosely packed intestinal epithelium layer.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Even in the presence of GF-120918, there was still 60% of IE compared to that in the control rats, suggesting that passive diffusion of apixaban coupling with intestinal peristaltic movement generated a marked level of IE. Therefore, the passive permeation plays a key role in IE of apixaban.</div></div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Apixaban Absorption and Disposition</h3><div class="NLM_p last">Apixaban appeared to be absorbed quickly, as it has a relatively short <i>T</i><sub>max</sub> of 2–4 h after PO administration. Consequently, AC administration at various times (0.25–6 h) post apixaban oral dose in dogs and humans did not markedly affect its <i>C</i><sub>max</sub> or <i>T</i><sub>max</sub>. A compound with high solubility and high permeability such as apixaban can be absorbed rapidly after PO administration at the proximal intestine, due to saturation of transporters or partially escaping the barrier function of P-gp and BCRP that are highly expressed in the small intestines.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> With high levels of P-gp and BCRP expression in the duodenum, jejunum, and ileum, partial absorption of apixaban is likely to occur along the passage in the small intestine and even in the large intestine where efflux transporter expression appears to be low.<a onclick="showRef(event, 'ref35 ref38'); return false;" href="javascript:void(0);" class="ref ref35 ref38">(35,38)</a> The increase of the <i>C</i><sub>max</sub> values in the P-gp-KO and BCRP-KO rats have demonstrated the importance of intestinal efflux transporters in limiting apixaban absorption. IE represented approximately 20–50% of the IV [<sup>14</sup>C]apixaban dose in rats and dogs. The AC effects of reducing the AUC and shortening <i>T</i><sub>1/2</sub> of apixaban in the BDC rats and dogs after IV administration are consistent with that AC increased apixaban clearance (IC) through preventing reabsorption. The >27% reduction of apixaban AUC by AC in dogs 3 h post drug dose and in humans 6 h post drug dose (late charcoal effect as demonstrated by AC administration beyond 2 h post drug dose) is consistent with IE and the interruption of apixaban reabsorption. The timing of AC administration was well after the initial absorption phase of apixaban in the upper GI tract.</div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Case Series 3. Elimination of Digoxin, Nitrofurantoin, and Others</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76600" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76600" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Digoxin, a substrate of P-gp, is an inotropic agent primarily used to treat congestive heart failure. Nitrofurantoin, a substrate of BCRP, is an antibiotic to treat urinary tract infections.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> [<sup>3</sup>H]Digoxin and [<sup>14</sup>C]nitrofurantoin were administered IV to the BDC transporter-KO and wild-type rats (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01720/suppl_file/jm0c01720_si_001.pdf" class="ext-link">Supporting Information (SI) Tables S1–S4</a>). Fecal elimination of digoxin and nitrofurantoin was reduced by 90% and 50%, respectively, in the P-gp-KO and BCRP-KO rats compared to the wild-type rats. P-gp-KO also markedly decreased urinary excretion of digoxin leading to the increase of biliary elimination (38% to 62%), the major elimination pathway for digoxin in rats. In contrast, the urinary elimination as the major elimination pathway of nitrofurantoin increased to compensate the decrease of IE in BCRP-KO rats. Because of the complementary elimination pathways, transporter-KO did not markedly affect the systemic exposures and other pharmacokinetic parameters of digoxin or nitrofurantoin. Overall, IE represented <20% elimination for digoxin or nitrofurantoin. Similar results have been previously published for the P-gp-KO and BCRP-KO species showing similar functional roles in the rat and mouse models.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> Of note, knockout of P-gp or BCRP did not affect expression of the other transporters in the mouse.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> The large difference in IE for digoxin or nitrofurantoin relative to apixaban, despite all three being substrates of P-gp and/or BCRP, is likely because that apixaban has good apparent permeability and the other two drugs do not.</div><div class="NLM_p">A discovery stage kinase inhibitor (GNE-19) program demonstrated low intrinsic hepatic clearance in both liver microsomes and hepatocytes with moderate to high permeability in MDCK cells, and it was a P-gp substrate.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a><i>In vivo</i>, however, the total clearance was above hepatic blood flow. To further investigate its mechanism, radiolabeled <sup>3</sup>H material was synthesized for conducting expedited mass balance studies in rats. It was determined that the majority of radioactivity in plasma and in excreta was the parent drug following intravenous administration. In bile-cannulated rats, urine and bile accounted for less than 50% of the recovered radioactivity with the majority excreted in feces through IE. Its good apparent permeability together with intestinal drug transporters likely modulated the high level of IE (unpublished report).</div><div class="NLM_p last">Vismodegib (GDC-0449) is a Hedgehog pathway inhibitor. This compound was metabolically stable in <i>in vitro</i> liver microsomes and in the rat, mouse, dog, and human. The biliary clearance of GDC-0449 in dogs was low (2.4 mL/min/kg) and did not account for the majority of the estimated systemic clearance (∼19% of the total systemic clearance). The urinary clearance was also low in dogs. <i>In vitro</i> studies using sandwich-cultured human hepatocytes showed negligible biliary excretion although it was a P-gp substrate. Oral administration of AC to dogs receiving PO or IV GDC-0449 (25 mg) showed a more rapid decrease in plasma concentrations. These results suggest that the concentration gradient driving intestinal membrane permeation was reversible, and that AC removed the drug that was excreted into the intestinal tracts and increased its clearance following IV administration.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Intestinal Excretion Is One of the Fundamental Mechanisms for Drug Clearance</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22865" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22865" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Passive Permeation Determining IE and Uptake Transporters Determining Biliary Excretion (BE)</h3><div class="NLM_p">Passive permeation is the primary route for drug absorption.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> For a compound with a high apparent permeability such as apixaban, passive diffusion coupled with intestinal peristaltic movement as well as intestinal blood flow generated a significant level of IE. Transporters-KO or -inhibition in rats only reduce apixaban IE by <40%.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Therefore, passive permeation is more important than efflux transporters to IE of apixaban or a generally permeable compound. In this case, transporters BCRP and P-gp may only enhance IE. In comparison, nitrofurantoin and digoxin had low levels of IE because of their low apparent permeability. Knockout of BCRP and P-gp further reduced the already low level of IE for nitrofurantoin and digoxin. These comparative studies demonstrated that apparent permeability is a critical factor to have a significant level of IE that can be facilitated by efflux transporters. <a href="/doi/suppl/10.1021/acs.jmedchem.0c01720/suppl_file/jm0c01720_si_001.pdf" class="ext-link">Table S5 and Figure S1</a> lists several major classes of drugs, including apixaban, that are substrates of efflux transporters.</div><div class="NLM_p last">BE is a minor elimination pathway for apixaban in the rat, dog, and human. This is not surprising since liver uptake is the driving force for the biliary elimination,<a onclick="showRef(event, 'ref30 ref49 ref85 ref100'); return false;" href="javascript:void(0);" class="ref ref30 ref49 ref85 ref100">(30,49,85,100)</a> and apixaban is not a substrate for hepatic uptake transporters OATP1B1/3 or OAT1/3 or other hepatic uptake transporters.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> In contrast, digoxin as a substrate of both hepatic uptake (OATP1B3) and efflux transporter (P-gp) mainly underwent biliary excretion in rats.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> In addition, the decrease in urinary and intestinal excretion in the P-gp-KO rats was compensated by the increase in the biliary excretion of digoxin. These results further support that hepatic uptake plays a key role for digoxin hepatic elimination. They also support the important role P-gp plays for renal, biliary, and intestinal excretion of digoxin, a low permeability compound.</div></div><div id="sec7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Charcoal Enhances IE by Preventing Drug Reabsorption</h3><div class="NLM_p last">AC has a large capacity for drug binding due to the large hydrophobic surface area (up to 2000 m<sup>2</sup>/g).<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> Timely administration of AC can sequester drug that is in the lumen to prevent its absorption or reabsorption. The impact of AC is not on the initial absorption phase in intestine but on the IE/EER phase of apixaban since AC did not affect its <i>C</i><sub>max</sub> or <i>T</i><sub>max</sub>. Early application of AC (even at 0.25 h after drug dose) in dogs was less effective to reduce the apixaban AUC than later applications (e.g., 3 h). The result is consistent with insufficient opportunity for AC to mix with preabsorption apixaban, but passed the GI tract before encountering apixaban molecules that were coming from IE. Considering the small intestinal transit time of 2–4 h for substances such as charcoal in dogs,<a onclick="showRef(event, 'ref65 ref103 ref104'); return false;" href="javascript:void(0);" class="ref ref65 ref103 ref104">(65,103,104)</a> application of AC at 2–4 h after the drug dose appears to be the most effective time interval to prevent apixaban reabsorption. In the presence of AC, the shorter half-life and greater clearance in rats and dogs after IV administration of apixaban supports that AC removes apixaban from the body by preventing its reabsorption. This leads to the increases in the apparent systemic clearance of apixaban by 20–40% and increase of IC by 20–60%. The shorter half-life and lower exposures of meloxicam and phenobarbital upon administration of AC in humans and rabbits following IV drug administration has been ascribed to AC blocking enteroenteric recycling of the drugs.<a onclick="showRef(event, 'ref48 ref105'); return false;" href="javascript:void(0);" class="ref ref48 ref105">(48,105)</a></div></div><div id="sec7_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> The Extent of IE Depends on Species and Other Elimination Pathways</h3><div class="NLM_p last">The extent of IE depends on other elimination pathways such as biotransformation, urinary elimination, and biliary excretion. For example, metabolism appeared to be more important for apixaban elimination in humans (25% of dose) than in rats and dogs (<15%).<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> Urinary excretion was the major elimination pathways of apixaban in rat but not in dog or human. Despite these variables which make it hard to determine the exact contributions of various elimination pathways, IE accounted for approximately >20%, >42%, and >27% of dose clearance in rats, dogs, and humans, respectively.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> The gastrointestinal tracts of rats and humans have similar absorption properties for many drugs; intestinal BCRP expression profiles are similar between dog and human.<a onclick="showRef(event, 'ref106 ref107 ref108'); return false;" href="javascript:void(0);" class="ref ref106 ref107 ref108">(106−108)</a> Finally, it is always important to distinguish the rate from the extent of IE, and it is important to examine the extent of change in a particular elimination pathway, as well as the rate.</div></div><div id="sec7_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> IE Studies in the Literature</h3><div class="NLM_p last"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01720/suppl_file/jm0c01720_si_001.pdf" class="ext-link">SI Table S6</a> lists selected drugs that have been investigated for IE, mostly in the context of drug absorption.<a onclick="showRef(event, 'ref109 ref110'); return false;" href="javascript:void(0);" class="ref ref109 ref110">(109,110)</a> Many studies have provided evidence to support regional IE through the use of Ussing chambers, everted intestinal sacs, perfused intestinal segments, and <i>in vivo</i> with AC treatment.<a onclick="showRef(event, 'ref3 ref5 ref38 ref48 ref110 ref111 ref112 ref113 ref114 ref115 ref116 ref117 ref118 ref119 ref120'); return false;" href="javascript:void(0);" class="ref ref3 ref5 ref38 ref48 ref110 ref111 ref112 ref113 ref114 ref115 ref116 ref117 ref118 ref119 ref120">(3,5,38,48,110−120)</a> Several drugs were discovered to undergo extensive intestinal excretion only after investigation using various <i>in vitro</i> and <i>in vivo</i> models, and limited examples have unambiguously demonstrated fecal elimination resulting from regional IE.<a onclick="showRef(event, 'ref3 ref4 ref119'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref119">(3,4,119)</a> The studies with apixaban provide an integrated data set that demonstrated direct IE that is responsible for 20–50% of the systemic clearance in humans and animal species.</div></div><div id="sec7_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Experimental Approaches for Determination of IE</h3><div class="NLM_p">Measuring the amount of a drug in feces after IV administration (preferably with radiolabeled drugs) to BDC animals represents a direct method to assess IE. Although bile cannulation is not commonly used in humans due to patient safety or regulation concern, the T-tube technique had been used to divert bile flow and collect bile in human subjects.<a onclick="showRef(event, 'ref121 ref122'); return false;" href="javascript:void(0);" class="ref ref121 ref122">(121,122)</a> Further, IE of apixaban was assessed by PO administration of AC to BDC rats and dogs receiving IV as well as humans receiving PO doses of apixaban. AC sequestered any drug that was excreted into intestinal lumen in dogs and humans several hours after apixaban PO administration. A selective inhibitor of P-gp and BCRP was evaluated to assess their involvement in IE of apixaban in rats. The role of P-gp and BCRP in apixaban IE was further investigated in P-gp-KO and BCRP-KO rats. The <i>ex vivo</i> rat intestine segment models were used to investigate net transport of apixaban in the jejunum segment. Other <i>ex vivo</i> models such as Ussing Chambers and intestinal perfusion models are also commonly used to investigate transport of drugs.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> The studies with apixaban, digoxin, and nitrofurantoin demonstrated that P-gp-KO and BCRP-KO had a global effect and affected renal, biliary, and intestinal elimination.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> Selected drugs that were tested for charcoal effects are listed in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01720/suppl_file/jm0c01720_si_001.pdf" class="ext-link">Table S6</a>. The effect of AC for some drugs may continue to extend beyond 4 h after drug doses with reduction of drug exposures with >100 studies analyzed.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> The late AC effect could be caused by delayed absorption from sustained-release formulations or enhancing drug elimination through interruption of EHR<a onclick="showRef(event, 'ref126 ref127'); return false;" href="javascript:void(0);" class="ref ref126 ref127">(126,127)</a> and now interruption of EER. Many drugs showing late AC effect are substrates of efflux transporters BCRP, P-gp, or MRP2 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01720/suppl_file/jm0c01720_si_001.pdf" class="ext-link">Table S6</a>). AC has also been used as a research tool in a limited manner to study IE. However, these studies could not separate the drug resulting from IE from the unabsorbed fraction after PO administration or from biliary elimination after IV drug administration<a onclick="showRef(event, 'ref48 ref119 ref128 ref129 ref130'); return false;" href="javascript:void(0);" class="ref ref48 ref119 ref128 ref129 ref130">(48,119,128−130)</a> Therefore, IE can be predicted based on their apparent permeability and <i>in vitro</i> metabolic stability. Experimental AC effects on PK/elimination and intestinal recovery of drug in BDC animals following IV administration would provide final IE assessment.</div><div class="NLM_p last">A recent publication<a onclick="showRef(event, 'cit131a'); return false;" href="javascript:void(0);" class="ref cit131a">(131a)</a> partially analyzed the published data of apixaban using the <i>T</i><sub>max</sub> and mean absorption time (MAT) ratio model they developed. They arrived a conclusion that intestinal efflux transporters needed not to be considered to explain the observed DDI. This supports our earlier assessment that apixaban IE was driven by its good permeability and concentration gradients that could be facilitated by intestinal efflux transporter BCRP/P-gp.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Intestinal efflux transporters did not affect clinic DDI of apixaban, because metabolism, renal excretion, and IE each accounted 30% of apixaban clearance. Balanced clearance pathways rendered insignificant DDI through inhibition of intestinal efflux transporters. As the intestinal clearance is a prominent elimination pathway for apixaban, the elimination rate constant changes when IE changes. The change in MAT or <i>T</i><sub>max</sub> is dependent on both absorption rate constant and elimination rate constant. Therefore, it is possible to have same MAT even though there is an interaction involving efflux transporters when both absorption and elimination rate constants change at the same time. In addition, the BCRP pharmacogenomics studies<a onclick="showRef(event, 'cit131b cit131c'); return false;" href="javascript:void(0);" class="ref cit131b cit131c">(131b,c)</a> and several of our <i>in vivo</i> studies<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> have demonstrated the relevance of BCRP in clinic disposition of apixaban. These data do not support their claim that intestinal efflux transporters are not clinically relevant in apixaban disposition.<a onclick="showRef(event, 'cit131a'); return false;" href="javascript:void(0);" class="ref cit131a">(131a)</a></div></div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">Impacts of IR (EHR/EER), and RTR on Metabolism, Pharmacokinetics, And Pharmacodynamics</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87585" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87585" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Balanced elimination involving multiple pathways is a favorable property of a drug. The increase in IE of furosemide and theophylline has been hypothesized in rats with acute renal failure and with hepatic cirrhosis, using treatment with activated charcoal as the experimental model.<a onclick="showRef(event, 'cit132a cit132b'); return false;" href="javascript:void(0);" class="ref cit132a cit132b">(132a,b)</a></div><div class="NLM_p">The drug metabolizing enzymes will enhance the metabolism during the drug reabsorption involved in the processes of EER, RTR, and EHR.<a onclick="showRef(event, 'ref133 ref134'); return false;" href="javascript:void(0);" class="ref ref133 ref134">(133,134)</a> Drug molecules once eliminated into intestines are subject to further biotransformation in the intestine, kidney, and/or liver upon reabsorption. Some drugs may also be transported from the intestine to the systemic circulation via the intestinal lymph in addition to the portal vein blood.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> Therefore, regional IE, BE, GF, and tubular secretion of drugs will provide opportunities for biotransformation in every cycle of reabsorption. Although some drugs can remain intact through many cycles of excretion and reabsorption processes due to their metabolic stability, eventually, an <i>in vitro</i> metabolically stable compound could be metabolized extensively <i>in vivo</i>. Unfortunately, the currently available <i>in vitro</i> systems could not satisfyingly evaluate the potentially repeated metabolism in intestines as well as livers or kidneys. Many examples of compounds that are stable <i>in vitro</i> and were extensively metabolized in animals and humans are consistent with such an interplay mechanism of reabsorption–biotransformation. In this case, the extent of metabolism was high, but the metabolism rate was low such as for the <i>in vitro</i> and <i>in vivo</i> metabolism discrepancy of BMS-823778. Therefore, the metabolites found in urine and feces might result from multiple cycles of reabsorption in organs that could be different from the metabolizing organ.</div><div class="NLM_p">The excretion and reabsorption processes (IR: EHR/EER, and RTR) reduce apparent clearance and slow down elimination and serve to prolong the elimination <i>T</i><sub>1/2</sub>, as well as to lower the plasma peak-to-trough concentration ratio as observed for apixaban. EER and RTR are a continuous excretion and reabsorption process. This is different from EHR, which depends on the gallbladder-emptying time and often leads to a secondary drug peak at 4–8 h post drug dose.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> A highly permeable and soluble drug such as apixaban overcame the efflux of P-gp and BCRP through absorption from proximal intestines and reabsorption from the distal intestines, showing a broad plasma concentration peak after PO administration in dogs and humans. Once the major absorption limiting transporter, BCRP, was eliminated in rats (by knockout), the peak tailing effect became less obvious for apixaban compared to wild-type rats. Talinolol, a compound with a moderate permeability and low solubility whose reabsorption depends on efflux transporters-deficient regions or segments, together with its EHR potential as a substrate of hepatic uptake OATP1B1/3, showed an even broader peak or multiple peaks in the plasma concentration–time profiles.<a onclick="showRef(event, 'ref64 ref136'); return false;" href="javascript:void(0);" class="ref ref64 ref136">(64,136)</a> Fagerholm has attempted to predict intestinal clearance of digoxin and rosuvastatin without considering regional difference in efflux capacity and reabsorption.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> BMS-823778’s long <i>T</i><sub>1/2</sub>, broad plasma concentration–time profile with a low peak to trough ratio were also consistent with its unique properties of RTR and <i>in vitro</i> metabolic stability.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Therefore, the impact on drug disposition and pharmacokinetics of the intestinal or renal reabsorption can be easily overlooked.</div><div class="NLM_p">IR and RTR could be of a therapeutic advantage. The IE of ivermectin could benefit the therapeutic efficacy against intestinal parasites.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> The low peak-to-trough ratio of apixaban would allow a lower dose to keep the plasma concentration required for efficacy, which is a favorable property for an anticoagulant of narrow therapeutic index for low bleeding potential without sacrificing the efficacy.</div><div class="NLM_p">AC has been used in routine management of oral drug overdoses.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> Since the AC antidote efficacy is dependent on the timing and the length of administration after drug dose, it is recommended that the charcoal is administered as early as possible.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> As AC was effective to reduce apixaban exposures even several hours after the drug dose due to IE and EER in dogs and humans, administration of AC could be a useful strategy in the management of overdose or accidental exposure to apixaban at reversing the anticoagulant effect. Intestinal disease states (e.g., diarrhea) could prevent drug reabsorption, while transporter inhibitors could reduce IE for those drugs who would require drug transporters for IE. Similarly, acidification or alkalization of the urine might prevent reabsorption of basic or acidic drugs.</div><div class="NLM_p">The availability of alternative pathways could mitigate the potential elevation of drug exposure due to blockage of one pathway, such as biotransformation or renal excretion. IE as an elimination pathway of apixaban, in addition to metabolism and urinary excretion in humans, may have moderated the impact of intrinsic and extrinsic factors on apixaban disposition. This includes the clinical observations of <40% increase of exposure in severely renal and hepatic impaired subjects, and the low drug–drug interactions upon modulation of the metabolic clearance of apixaban.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a></div><div class="NLM_p last">For lead optimization in drug discovery, the key <i>in vitro</i> ADME parameters include metabolic clearance and <i>T</i><sub>1/2</sub> based on <i>in vitro</i> metabolic stability, as well as apparent permeability and protein binding. It is also good to know that IE and subsequent reabsorption will play a substantial role if the compound is metabolically stable and permeable, and the drug reabsorption can play an important role in the <i>in vivo</i> drug elimination. IR and RTR could be a determinant when there is an <i>in vitro–in vivo</i> disconnect in preclinical PK studies. Although IR and RTR make prediction/understanding of overall disposition more difficult, these reabsorption mechanisms should be taken into consideration to perform PBPK modeling that is now routinely done with available software tools.<a onclick="showRef(event, 'ref29 ref64 ref65 ref104 ref140 ref141'); return false;" href="javascript:void(0);" class="ref ref29 ref64 ref65 ref104 ref140 ref141">(29,64,65,104,140,141)</a> New drug modalities such as peptides, protein degraders, and oligonucleotides have low apparent permeability, which would prevent their reabsorption, likely leading to their poor systemic PK properties without extended half-life (<i>T</i><sub>1/2</sub>). Therefore, it would be more challenging to deliver these modalities through conventional IV and PO administration for systemic delivery.</div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">Summary</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26481" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26481" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The investigation with several drugs including permeable (apixaban and dapagliflozin) and low-permeability, transporter-dependent (digoxin and nitrofurantoin) properties demonstrated that the overall disposition profiles were mainly governed by a complex and dynamic interplay between absorption, IE, IR (EHR/EER), and RTR. IE, governed by passive diffusion, can be an important elimination pathway for a metabolically stable and permeable compound, and drug transporters can enhance IE. Drug reabsorption and recycling in the intestine and renal tubule is driven by drug concentration gradients between lumen and blood as well as the lipophilicity-dependent passive permeation.</div><div class="NLM_p">Applications of AC in BDC animals following IV drug administration, drug transporter-KO animals, transporter inhibitors, and transporters-cDNA transfected cell and Caco-2 cell models are useful methods to study IE, EHR/EER, and RTR, and the interplay between these drug disposition and recycling mechanisms.</div><div class="NLM_p last">With a greater emphasis on the discovery of molecules of increased metabolic stability through early screening efforts, many NCEs are less susceptible to metabolic clearance. Additional screening also often optimizes permeability. The combination of low metabolic clearance, high permeability, and associated lipophilicity necessary to interact with pharmacological targets often lands NCEs in a range where IE, EHR/EER, and RTR become the important distribution and disposition mechanisms. These mechanisms are often under-appreciated, in part because it is still difficult to come up with quantitative assessments of their contributions. The potential impact of these reabsorption mechanisms on biotransformation and pharmacokinetics is compound dependent and should provide a guide for future investigations like hepatic/renal impaired studies and drug–drug interaction studies.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01720" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54785" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54785" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01720?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01720</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Table S1. Pharmacokinetic parameters of digoxin and nitrofurantoin following single IV dose of radiolabels to male bile-cannulated Sprague–Dawley rats (WT = wild-type) and P-gp-KO or BCRP-KO rats. Table S2. Intestinal clearance, renal clearance, and biliary clearance of apixaban, digoxin, and nitrofurantoin in Sprague–Dawley rats. Table S3. Study designs in dogs and rats following oral and intravenous administration of apixaban, [<sup>14</sup>C]apixaban, [<sup>14</sup>C]digoxin, and [<sup>14</sup>C]nitrofurantoin with and without oral administration of activated charcoal. Table S4. Percent recoveries of radioactivity (±SD) following a single IV dose of [<sup>3</sup>H]digoxin, [<sup>14</sup>C]nitrofurantoin, or [<sup>14</sup>C]apixaban to male bile-cannulated Sprague–Dawley rats (WT = wild-type; P-gp-KO = P-gp-KO; BCRP-KO = BCRP-KO) following a single 1 mg/kg IV dose of [<sup>14</sup>C]apixaban to male intact and bile-cannulated Beagle dogs. Table S5. Classes of drugs that are substrates of intestinal efflux transporters. Table S6. Selected studies that tested the effects of activated charcoal on pharmacokinetics and pharmacodynamics of drugs. Figure S1. Chemical structures used in Table S5 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01720/suppl_file/jm0c01720_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01720/suppl_file/jm0c01720_si_001.pdf">jm0c01720_si_001.pdf (360.77 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01720" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67143" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67143" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Donglu Zhang</span> - <span class="hlFld-Affiliation affiliation">Department
of Drug Metabolism and Pharmacokinetics, Genentech, 1 DNA Way, South San Francisco, California 94080, United States,</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-8677-9737" title="Orcid link">https://orcid.org/0000-0001-8677-9737</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c7bdafa6a9a0e9a3a8a9a0abb287a0a2a9a2e9a4a8aa"><span class="__cf_email__" data-cfemail="fe84969f9099d09a919099928bbe999b909bd09d9193">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cong Wei</span> - <span class="hlFld-Affiliation affiliation">Drug
Metabolism and Pharmacokinetics, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States,</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cornelis E. C. A. Hop</span> - <span class="hlFld-Affiliation affiliation">Department
of Drug Metabolism and Pharmacokinetics, Genentech, 1 DNA Way, South San Francisco, California 94080, United States,</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew R. Wright</span> - <span class="hlFld-Affiliation affiliation">Department
of Drug Metabolism and Pharmacokinetics, Genentech, 1 DNA Way, South San Francisco, California 94080, United States,</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ming Hu</span> - <span class="hlFld-Affiliation affiliation">University
of Houston College of Pharmacy, 4849 Calhoun Road, Houston, Texas 77204, United States,</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yurong Lai</span> - <span class="hlFld-Affiliation affiliation">Drug
Metabolism and Pharmacokinetics, Gilead
Sciences, 333 Lakeside Drive, Foster City, California 94404, United States,</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-9505-333X" title="Orcid link">https://orcid.org/0000-0001-9505-333X</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">S. Cyrus Khojasteh</span> - <span class="hlFld-Affiliation affiliation">Department
of Drug Metabolism and Pharmacokinetics, Genentech, 1 DNA Way, South San Francisco, California 94080, United States,</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">W. Griff Humphreys</span> - <span class="hlFld-Affiliation affiliation">Aranmore
Pharma Consulting, 11
Andrew Drive, Lawrenceville, New Jersey 08648, United States,</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through the contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81134" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81134" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Donglu Zhang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01720&amp;id=BIO-d7e1846-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Donglu Zhang</b> is a staff scientist/senior fellow in DMPK at Genentech. He is interested in deepening understanding of ADME drivers and applying drug metabolism studies in drug design and development of both small molecule drugs and antibody-drug conjugates (ADC). He received the Sir James Black Award for discovery of and original research on Eliquis from British Pharmacological Society (2018) and the Ondetti and Cushman Award for invention of mass defect filtering method (MDF) from Bristol-Myers Squibb (2007). He is on the Editorial Board of Drug Metabolism and Disposition and Xenobiotica. He received his Ph.D. in Organic Chemistry from University of Utah under the direction of C. Dale Poulter.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Cong Wei</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01720&amp;id=BIO-d7e1851-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Cong Wei</b> leads the functions of in vivo pharmacokinetics and large molecule bioanalysis at Biogen. Her research interests include bioanalysis, biodistribution, and biotransformation of xenobiotics and biologics in drug discovery and development. She has coauthored more than 40 peer-reviewed articles and book chapters. She received her Ph.D. in Pharmacology from University of Pennsylvania School of Medicine under the direction of Professor Ian A. Blair.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Cornelis E. C. A. Hop</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01720&amp;id=BIO-d7e1856-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Dr. Cornelis E. C. A. Hop</b> is Vice-President at Genentech and supervising the Drug Metabolism & Pharmacokinetics Department. He leads a team of about 80 scientists involved in acquisition and interpretation of ADME data in support of drug discovery and development ranging from early stage research to NDA and beyond. Before that, he was a Senior Director at Pfizer and a Senior Research Fellow at Merck. He has extensive experience in ADME sciences with a particular focus on PK optimization, human PK prediction, biotransformation, bioanalysis, and, more recently, the use of in silico approaches and AI in drug discovery. He has authored more than 180 publications and made more than 80 external oral presentations. He received his PhD from the University of Utrecht in The Netherlands.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Matthew R. Wright</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01720&amp;id=BIO-d7e1861-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Matthew R. Wright</b> is currently an Executive Director in Small Molecule DMPK at Genentech, Inc. and heads the PK/Transport group. Matt received his Ph.D. in Biopharmaceutics from the Faculty of Pharmaceutical Sciences, University of British Columbia, with postdoctoral training at the University of Alberta. Matt has over 20 years of experience supporting drug discovery and development at Genentech, Gilead, Tularik (now Amgen), and DuPont Merck in a broad variety of therapeutic areas from initiation to market. Prior to joining the pharmaceutical industry, Matt was an Assistant Professor in the College of Pharmacy, Dalhousie University. Matt has authored more than 80 peer-reviewed publications.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Ming Hu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01720&amp;id=BIO-d7e1866-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Ming Hu</b> is a professor at University of Houston and an expert in the bioavailability of drugs, natural chemicals, and dietary ingredients. He is especially interested in the study of drug delivery modalities and/or mechanisms that have tremendous potentials for clinical utility. Dr. Hu has conceptualized the “Enteric Recycling” of glucuronide metabolites as a process of flavonoid disposition, and proposed the “Revolving Door” theory to understand the coupling between conjugating enzyme and efflux transporters. Currently, his laboratory is interested in developing oral delivery of agents for prevention of colon and oral cancers. Dr. Hu has published more than 160 peer reviewed journal and review articles and book chapters. He received his Ph.D. from University of Michigan, 1988.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Yurong Lai</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01720&amp;id=BIO-d7e1871-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yurong Lai</b> is a Sr. Director of Drug Metabolism at Gilead Sciences. He is a fellow of American Association of Pharmaceutical Scientists. He currently leads Gilead DMPK strategies and provides scientific oversight and resource of DMPK function to support R&D efforts to select effective compounds for development to the bedside. He received his M.D. from Fujian Medical University and his Ph.D. (Toxicology) from Sapporo Medical University in Japan in 1998. Previously, he led research programs at Pfizer and BMS in transporter research and ADME-PK-Tox. He is the associate editor/editorial board member of top ranking journals and published over 150 original publications.</p></figure></div><div class="bio" rid="ath7"><figure id="ath7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">S. Cyrus Khojasteh</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01720&amp;id=BIO-d7e1876-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>S. Cyrus Khojasteh</b> heads the Biotransformation Function at Genentech (South San Francisco). His research focuses on the mechanisms of biotransformation in drug discovery and development, from small molecules, antibody drug conjugates, and macrocyclic peptides. Cyrus received his Ph.D. in Medicinal Chemistry from the University of Washington under the direction of Professor Sidney D. Nelson.</p></figure></div><div class="bio" rid="ath8"><figure id="ath8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">W. Griff Humphreys</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01720&amp;id=BIO-d7e1881-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>W. Griffith Humphreys</b> is currently a principal with Aranmore Pharma Consulting. Prior to that he spent 26 years at Bristol-Myers Squibb Pharmaceutical Company in various leadership roles within the DMPK function. He received his graduate training at the University of Virginia in chemistry and completed a postdoctoral fellowship at Vanderbilt University Center in Molecular Toxicology. His interests include predictive metabolism and toxicology models and other aspects of candidate optimization and characterization. He has coauthored over 130 refereed manuscripts and numerous reviews. Griff was on the ISSX Council from 2016–2019 and was Meeting Chair for the 2019 Drug Metabolism Gordon Research Conference.</p></figure></div><div class="ack" id="ACK-d7e1924-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i39">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74404" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74404" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors would like to thank Drs. Christine Bowman, Kim Huard, and Dan Sutherlin from Genentech for their scientific insights and critical review of the manuscript. M.H. is supported by a NIH grant CA246209.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AC</td><td class="NLM_def"><p class="first last">activated charcoal</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, and elimination</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve of drug concentration versus time</p></td></tr><tr><td class="NLM_term">BCS</td><td class="NLM_def"><p class="first last">Biopharmaceutical Classification Systems</p></td></tr><tr><td class="NLM_term">BCRP</td><td class="NLM_def"><p class="first last">breast cancer resistance protein</p></td></tr><tr><td class="NLM_term">BCRP-KO</td><td class="NLM_def"><p class="first last">Abcg2 gene knockout</p></td></tr><tr><td class="NLM_term">P-gp-KO</td><td class="NLM_def"><p class="first last">Abcb1 gene knockout</p></td></tr><tr><td class="NLM_term">BDC</td><td class="NLM_def"><p class="first last">bile-duct cannulation</p></td></tr><tr><td class="NLM_term">BID</td><td class="NLM_def"><p class="first last">twice daily dose</p></td></tr><tr><td class="NLM_term">BE</td><td class="NLM_def"><p class="first last">biliary excretion</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum concentration</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>min</sub></td><td class="NLM_def"><p class="first last">minimum concentration</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">CL<sub>R</sub></td><td class="NLM_def"><p class="first last">renal clearance</p></td></tr><tr><td class="NLM_term">CL<sub>IE</sub></td><td class="NLM_def"><p class="first last">intestinal clearance</p></td></tr><tr><td class="NLM_term">CL<sub>met</sub></td><td class="NLM_def"><p class="first last">metabolism clearance</p></td></tr><tr><td class="NLM_term">CL<sub>b</sub></td><td class="NLM_def"><p class="first last">biliary clearance</p></td></tr><tr><td class="NLM_term">EER</td><td class="NLM_def"><p class="first last">enteroenteric recirculation</p></td></tr><tr><td class="NLM_term">EHR</td><td class="NLM_def"><p class="first last">enterohepatic recirculation</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">efflux ratio - permeability of basolateral to apical versus that of apical to basolateral</p></td></tr><tr><td class="NLM_term">GFR</td><td class="NLM_def"><p class="first last">glomerular filtration rate</p></td></tr><tr><td class="NLM_term">GI</td><td class="NLM_def"><p class="first last">gastrointestinal tract</p></td></tr><tr><td class="NLM_term">IE</td><td class="NLM_def"><p class="first last">intestinal excretion</p></td></tr><tr><td class="NLM_term">IC</td><td class="NLM_def"><p class="first last">intestinal clearance</p></td></tr><tr><td class="NLM_term">IR</td><td class="NLM_def"><p class="first last">intestinal reabsorption</p></td></tr><tr><td class="NLM_term">IVIVC</td><td class="NLM_def"><p class="first last"><i>in vitro</i><i>in vivo</i> correlation</p></td></tr><tr><td class="NLM_term">MDR1</td><td class="NLM_def"><p class="first last">multiple drug resistance protein (P-gp)</p></td></tr><tr><td class="NLM_term">MRT</td><td class="NLM_def"><p class="first last">mean residence time</p></td></tr><tr><td class="NLM_term">NCE</td><td class="NLM_def"><p class="first last">new chemical entity</p></td></tr><tr><td class="NLM_term">Papp<sub>A-B</sub></td><td class="NLM_def"><p class="first last">permeability of apical to basolateral direction</p></td></tr><tr><td class="NLM_term">Papp<sub>B-A</sub></td><td class="NLM_def"><p class="first last">permeability of basolateral to apical direction</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">ratio of Papp<sub>B-A</sub> over Papp<sub>A-B</sub></p></td></tr><tr><td class="NLM_term">PBPK</td><td class="NLM_def"><p class="first last">physiologically based pharmacokinetics</p></td></tr><tr><td class="NLM_term">RTR</td><td class="NLM_def"><p class="first last">renal tubule reabsorption</p></td></tr><tr><td class="NLM_term">SGLT2</td><td class="NLM_def"><p class="first last">sodium-glucose cotransporter-2 (SGLT2)</p></td></tr><tr><td class="NLM_term"><i>T</i><sub>1/2</sub></td><td class="NLM_def"><p class="first last">half-life time</p></td></tr><tr><td class="NLM_term"><i>T</i><sub>max</sub></td><td class="NLM_def"><p class="first last">time to reach maximal concentration</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>d</sub></td><td class="NLM_def"><p class="first last">volume of distribution</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i41">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62373" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62373" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 141 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kotal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Veere, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinaasappel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elferink, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitek, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodanova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fevery, J.</span></span> <span> </span><span class="NLM_article-title">Intestinal excretion of unconjugated bilirubin in man and rats with inherited unconjugated hyperbilirubinemia</span>. <i>Pediatr. Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">200</span>, <span class="refDoi"> DOI: 10.1203/00006450-199708000-00011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1203%2F00006450-199708000-00011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=9262222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK2sXltlKlu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1997&pages=195-200&author=P.+Kotalauthor=C.+N.+Van+der+Veereauthor=M.+Sinaasappelauthor=R.+O.+Elferinkauthor=L.+Vitekauthor=M.+Brodanovaauthor=P.+L.+Jansenauthor=J.+Fevery&title=Intestinal+excretion+of+unconjugated+bilirubin+in+man+and+rats+with+inherited+unconjugated+hyperbilirubinemia&doi=10.1203%2F00006450-199708000-00011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal excretion of unconjugated bilirubin in man and rats with inherited unconjugated hyperbilirubinemia</span></div><div class="casAuthors">Kotal, Petr; Van Der Veere, Crista N.; Sinaasappel, Maarten; Oude Elferink, Ronald; Vitek, Libor; Brodanova, Marie; Jansen, Peter L. M.; Fevery, Johan</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-200</span>CODEN:
                <span class="NLM_cas:coden">PEREBL</span>;
        ISSN:<span class="NLM_cas:issn">0031-3998</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">Patients with Crigler-Najjar syndrome and Gunn rats cannot form bilirubin glucuronides owing to a lack of bilirubin UDP-glucuronosyltransferase activity.  Because increased serum and tissue bilirubin levels remain const., an alternative excretory route has to substitute for this deficiency.  Gunn rats excrete in bile only 2-13% of the bilirubins eliminated in Wistar rats.  In contrast, the biliary excretion rate of urobilinogen in Gunn and Wistar rats is comparable.  The sum of bilirubins and urobilinogen excreted in the bile of Gunn rats amts. to 10-30% of pigments excreted in Wistar rats.  Despite this low biliary excretion, the intestinal content and fecal excretion of bile pigments in Gunn and Wistar rats were similar.  These data support an extrabiliary entrance of unconjugated bilirubin into the intestine.  Addnl. proof for this was found in that the intestinal lumen of Gunn rats still contains a high amt. of bilirubins and urobilinogen after 3 d of external biliary drainage.  A similar procedure in Wistar rats resulted in the complete disappearance of bile pigments from the intestine.  The direct transmural transport of bilirubin from blood to all parts of the intestinal lumen was demonstrated by injecting 14C-bilirubin i.v. into Gunn rats with isolated parts of small and large intestine.  In Crigler-Najjar and Gilbert's syndrome patients, the biliary excretion of bile pigments has previously been shown to be strongly reduced.  Their stools, however, contained approx. the same amt. of bile pigments as in normal subjects.  Although only traces of unconjugated bilirubin were detected in the stool of normal persons (4% of total bile pigments), higher amts. were found in patients with Crigler-Najjar disease (20&).  These results suggest a direct intestinal permeation of unconjugated bilirubin in severe unconjugated hyperbilirubinemia both in man and rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomX8SfW--u1LVg90H21EOLACvtfcHk0lgxVJ1fLryThA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXltlKlu7s%253D&md5=0e31e47adc02b1eb5a8a65a081f02d4d</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1203%2F00006450-199708000-00011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1203%252F00006450-199708000-00011%26sid%3Dliteratum%253Aachs%26aulast%3DKotal%26aufirst%3DP.%26aulast%3DVan%2Bder%2BVeere%26aufirst%3DC.%2BN.%26aulast%3DSinaasappel%26aufirst%3DM.%26aulast%3DElferink%26aufirst%3DR.%2BO.%26aulast%3DVitek%26aufirst%3DL.%26aulast%3DBrodanova%26aufirst%3DM.%26aulast%3DJansen%26aufirst%3DP.%2BL.%26aulast%3DFevery%26aufirst%3DJ.%26atitle%3DIntestinal%2520excretion%2520of%2520unconjugated%2520bilirubin%2520in%2520man%2520and%2520rats%2520with%2520inherited%2520unconjugated%2520hyperbilirubinemia%26jtitle%3DPediatr.%2520Res.%26date%3D1997%26volume%3D42%26spage%3D195%26epage%3D200%26doi%3D10.1203%2F00006450-199708000-00011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
der Velde, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vrins, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Oever, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oude Elferink, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuipers, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groen, A. K.</span></span> <span> </span><span class="NLM_article-title">Direct intestinal cholesterol secretion contributes significantly to total fecal neutral sterol excretion in mice</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">967</span>– <span class="NLM_lpage">975</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2007.06.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1053%2Fj.gastro.2007.06.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=17854600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFars77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2007&pages=967-975&author=A.+E.+van%0Ader+Veldeauthor=C.+L.+Vrinsauthor=K.+van+den+Oeverauthor=C.+Kunneauthor=R.+P.+Oude+Elferinkauthor=F.+Kuipersauthor=A.+K.+Groen&title=Direct+intestinal+cholesterol+secretion+contributes+significantly+to+total+fecal+neutral+sterol+excretion+in+mice&doi=10.1053%2Fj.gastro.2007.06.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Direct intestinal cholesterol secretion contributes significantly to total fecal neutral sterol excretion in mice</span></div><div class="casAuthors">van der Velde, Astrid E.; Vrins, Carlos L. J.; van den Oever, Karin; Kunne, Cindy; Elferink, Ronald P. J. Oude; Kuipers, Folkert; Groen, Albert K.</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">967-975</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background & Aims: Hepatobiliary secretion is generally believed to be an integral step in the pathway of cholesterol excretion from the body.  Here we have investigated the validity of this paradigm in mice.  Methods: Cholesterol balance was assessed by measuring intake, excretion, and biliary output in different mouse models.  Direct secretion of cholesterol from the luminal side of enterocytes was studied by perfusion of isolated segments of the small intestine in mice.  Results: Cholesterol input and output measurements in different mouse models revealed that fecal neutral sterol excretion was higher than the sum of dietary cholesterol intake and biliary cholesterol secretion indicating the existence of an alternative pathway.  Here we show that substantial amts. of cholesterol can be secreted directly by enterocytes.  Transintestinal cholesterol secretion is a specific process obsd. throughout the small intestine (proximal > medial > distal).  Secretion depended on the presence of a cholesterol acceptor and was strongly stimulated by bile salts and phospholipids.  The capacity of the pathway was sufficient to account for the missing cholesterol in the balance studies.  The contribution of this pathway to cholesterol excretion in mice is approx. twice that of the biliary pathway.  Conclusions: In mice, the intestine plays a significant role in removal of cholesterol from the body.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra_m9HZXMLyrVg90H21EOLACvtfcHk0lgxVJ1fLryThA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFars77I&md5=b5b43c8a2c38ce477b9c16f6f13831bc</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2007.06.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2007.06.019%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BVelde%26aufirst%3DA.%2BE.%26aulast%3DVrins%26aufirst%3DC.%2BL.%26aulast%3Dvan%2Bden%2BOever%26aufirst%3DK.%26aulast%3DKunne%26aufirst%3DC.%26aulast%3DOude%2BElferink%26aufirst%3DR.%2BP.%26aulast%3DKuipers%26aufirst%3DF.%26aulast%3DGroen%26aufirst%3DA.%2BK.%26atitle%3DDirect%2520intestinal%2520cholesterol%2520secretion%2520contributes%2520significantly%2520to%2520total%2520fecal%2520neutral%2520sterol%2520excretion%2520in%2520mice%26jtitle%3DGastroenterology%26date%3D2007%26volume%3D133%26spage%3D967%26epage%3D975%26doi%3D10.1053%2Fj.gastro.2007.06.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagenaar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijnen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smit, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Asperen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinkel, A. H.</span></span> <span> </span><span class="NLM_article-title">Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">1038</span>– <span class="NLM_lpage">1044</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.1996.tb15775.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1111%2Fj.1476-5381.1996.tb15775.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=8922756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK28XmvVSmtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=1996&pages=1038-1044&author=U.+Mayerauthor=E.+Wagenaarauthor=J.+H.+Beijnenauthor=J.+W.+Smitauthor=D.+K.+Meijerauthor=J.+van+Asperenauthor=P.+Borstauthor=A.+H.+Schinkel&title=Substantial+excretion+of+digoxin+via+the+intestinal+mucosa+and+prevention+of+long-term+digoxin+accumulation+in+the+brain+by+the+mdr+1a+P-glycoprotein&doi=10.1111%2Fj.1476-5381.1996.tb15775.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr1a P-glycoprotein</span></div><div class="casAuthors">Mayer, Ulrich; Wagenaar, Els; Beijnen, Jos H.; Smit, Johan W.; Meijer, Dirk K. F.; Van Asperen, Judith; Borst, Piet; Schinkel, Alfred H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1038-1044</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">We have used mice with a disrupted mdr1a P-glycoprotein gene (mdr1a (-/-) mice) to study the role of P-glycoprotein in the pharmacokinetics of digoxin, a model P-glycoprotein substrate.  [3H]-digoxin at a dose of 0.2 mg kg-1 was administered as a single i.v. or oral bolus injection.  We focussed on intestinal mucosa and brain endothelial cells, two major pharmacol. barriers, as the mdr1a P-glycoprotein is the only P-glycoprotein normally present in these tissues.  Predominant fecal excretion of [3H]-digoxin in wild-type mice shifted towards predominantly urinary excretion in mdr1a (-/-) mice.  After interruption of the biliary excretion into the intestine, we found a substantial excretion of [3H]-digoxin via the gut mucosa in wild-type mice (16% of administered dose over 90 min).  This was only 2% in mdr1a (-/-) mice.  Biliary excretion of [3H]-digoxin was not dramatically decreased (24% in wild-type mice vs. 16% in mdr1a (-/-) mice).  After a single bolus injection, brain levels of [3H]-digoxin in wild-type mice remained very low, whereas in mdr1a (-/-) mice these levels continuously increased over a period of 3 days, resulting in a ∼200 fold higher concn. than in wild-type mice.  These data demonstrate in vivo contribution of intestinal P-glycoprotein to direct elimination of [3H]-digoxin from the systemic circulation and to the pattern of [3H]-digoxin disposition, and they underline the importance of P-glycoprotein for the blood-brain barrier.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAdILv56pwjrVg90H21EOLACvtfcHk0lhcEJcUYrAvZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmvVSmtrs%253D&md5=6449111aedfb27ef34d6c00ffe4180d4</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1996.tb15775.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1996.tb15775.x%26sid%3Dliteratum%253Aachs%26aulast%3DMayer%26aufirst%3DU.%26aulast%3DWagenaar%26aufirst%3DE.%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3DSmit%26aufirst%3DJ.%2BW.%26aulast%3DMeijer%26aufirst%3DD.%2BK.%26aulast%3Dvan%2BAsperen%26aufirst%3DJ.%26aulast%3DBorst%26aufirst%3DP.%26aulast%3DSchinkel%26aufirst%3DA.%2BH.%26atitle%3DSubstantial%2520excretion%2520of%2520digoxin%2520via%2520the%2520intestinal%2520mucosa%2520and%2520prevention%2520of%2520long-term%2520digoxin%2520accumulation%2520in%2520the%2520brain%2520by%2520the%2520mdr%25201a%2520P-glycoprotein%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1996%26volume%3D119%26spage%3D1038%26epage%3D1044%26doi%3D10.1111%2Fj.1476-5381.1996.tb15775.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sparreboom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Asperen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinkel, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smit, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nooijen, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijnen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Tellingen, O.</span></span> <span> </span><span class="NLM_article-title">Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">2031</span>– <span class="NLM_lpage">2035</span>, <span class="refDoi"> DOI: 10.1073/pnas.94.5.2031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1073%2Fpnas.94.5.2031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=9050899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK2sXhslCjs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1997&pages=2031-2035&author=A.+Sparreboomauthor=J.+van+Asperenauthor=U.+Mayerauthor=A.+H.+Schinkelauthor=J.+W.+Smitauthor=D.+K.+Meijerauthor=P.+Borstauthor=W.+J.+Nooijenauthor=J.+H.+Beijnenauthor=O.+van+Tellingen&title=Limited+oral+bioavailability+and+active+epithelial+excretion+of+paclitaxel+%28Taxol%29+caused+by+P-glycoprotein+in+the+intestine&doi=10.1073%2Fpnas.94.5.2031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Limited oral bioavailability and active epithelial excretion of paclitaxel (taxol) caused by P-glycoprotein in the intestine</span></div><div class="casAuthors">Sparreboom, Alex; van Asperen, Judith; Mayer, Ulrich; Schinkel, Alfred H.; Smit, Johan W.; Meijer, Dirk K.; Borst, Piet; Nooijen, Willem J.; Beijnen, Jos H.; van Tellingen, Olaf</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2031-2035</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">In mice, the mdr1a and mdr1b genes encode drug-transporting proteins that can cause multidrug resistance in tumor cells by lowering intracellular drug levels. These P-glycoproteins are also found in various normal tissues such as the intestine.  Because mdr1b P-glycoprotein is not detectable in the intestine, mice with a homozygously disrupted mdr1a gene [mdr1a(-/-) mice] do not contain functional P-glycoprotein in this organ.  We have used these mdr1a(-/-) mice to study the effect of gut P-glycoprotein on the pharmacokinetics of paclitaxel.  The area under the plasma concn.-time curves was 2- and 6-fold higher in mdr1a(-/-) mice than in wild-type (wt) mice after i.v. and oral drug administration, resp.  Consequently, the oral bioavailability in mice receiving 10 mg paclitaxel per kg body wt. increased from only 11% in wt mice to 35% in mdr1a(-/-) mice.  The cumulative fecal excretion (0-96 h) was markedly reduced from 40% (after i.v. administration) and 87% (after oral administration) of the administered dose in wt mice to below 3% in mdr1a(-/-) mice.  Biliary excretion was not significantly different in wt and mdr1a(-/-) mice.  Interestingly, after i.v. drug administration of paclitaxel (10 mg/kg) to mice with a cannulated gall bladder, 11% of the dose was recovered within 90 min in the intestinal contents of wt mice vs. >3% in mdr1a(-/-) mice.  We conclude that P-glycoprotein limits the oral uptake of paclitaxel and mediates direct excretion of the drug from the systemic circulation into the intestinal lumen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEl7SLdJ6UDLVg90H21EOLACvtfcHk0lhcEJcUYrAvZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhslCjs7o%253D&md5=ef6e923e94df1f148437261b6e5425e1</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1073%2Fpnas.94.5.2031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.94.5.2031%26sid%3Dliteratum%253Aachs%26aulast%3DSparreboom%26aufirst%3DA.%26aulast%3Dvan%2BAsperen%26aufirst%3DJ.%26aulast%3DMayer%26aufirst%3DU.%26aulast%3DSchinkel%26aufirst%3DA.%2BH.%26aulast%3DSmit%26aufirst%3DJ.%2BW.%26aulast%3DMeijer%26aufirst%3DD.%2BK.%26aulast%3DBorst%26aufirst%3DP.%26aulast%3DNooijen%26aufirst%3DW.%2BJ.%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3Dvan%2BTellingen%26aufirst%3DO.%26atitle%3DLimited%2520oral%2520bioavailability%2520and%2520active%2520epithelial%2520excretion%2520of%2520paclitaxel%2520%2528Taxol%2529%2520caused%2520by%2520P-glycoprotein%2520in%2520the%2520intestine%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1997%26volume%3D94%26spage%3D2031%26epage%3D2035%26doi%3D10.1073%2Fpnas.94.5.2031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gramatte, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oertel, R.</span></span> <span> </span><span class="NLM_article-title">Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1016/S0009-9236(99)70031-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1016%2FS0009-9236%2899%2970031-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10511059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK1MXmsFOjtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=1999&pages=239-245&author=T.+Gramatteauthor=R.+Oertel&title=Intestinal+secretion+of+intravenous+talinolol+is+inhibited+by+luminal+R-verapamil&doi=10.1016%2FS0009-9236%2899%2970031-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil</span></div><div class="casAuthors">Gramatte, Thomas; Oertel, Reinhard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">239-245</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">Objective: To examine the secretion of the β1-adrenergic receptor antagonist talinolol into the small intestine during its i.v. administration and to show the relevance of the P-glycoprotein-modulating drug verapamil for this secretory transport mechanism in humans.  Methods: In 6 healthy volunteers, the intestinal steady-state perfusion technique (triple lumen tubing system) was used for measuring the appearance of talinolol within the small intestine while the drug was infused i.v.  During 4 of the 7 perfusions performed, the perfusion fluid was changed from a verapamil-free soln. and talinolol appearance was measured while a R-verapamil-contg. soln. (565 μmol/L) was perfused.  Results: Talinolol was transported into the intestinal lumen up to a concn. gradient between lumen and blood of ∼5.5:1.  While perfusing the small intestine with a verapamil-free soln., the intestinal secretion rate of talinolol ranged from 1.94 to 6.62 μg/min per 30 cm length of the intestine (median values).  Perfusion of a R-verapamil-contg. perfusion fluid resulted in lower secretion rates (0.59-3.71 μg/30 cm·min), corresponding to 29%-56% of the values obtained without verapamil supplied intraluminally.  Conclusion: I.v. administered talinolol is actively secreted into the human small intestine.  This secretion is reduced by the intraluminal supply of the P-glycoprotein-modulating drug R-verapamil.  This gives further rationale for P-glycoprotein-mediated intestinal drug secretion as a cause for incomplete oral bioavailability and for drug interactions during intestinal absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRkb4gR5JfzLVg90H21EOLACvtfcHk0lhcEJcUYrAvZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmsFOjtL8%253D&md5=cca1ec2832077e00ecce3380fc416c49</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0009-9236%2899%2970031-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0009-9236%252899%252970031-7%26sid%3Dliteratum%253Aachs%26aulast%3DGramatte%26aufirst%3DT.%26aulast%3DOertel%26aufirst%3DR.%26atitle%3DIntestinal%2520secretion%2520of%2520intravenous%2520talinolol%2520is%2520inhibited%2520by%2520luminal%2520R-verapamil%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D1999%26volume%3D66%26spage%3D239%26epage%3D245%26doi%3D10.1016%2FS0009-9236%2899%2970031-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dayton, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Israili, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, J. D.</span></span> <span> </span><span class="NLM_article-title">Elimination of drugs by passive diffusion from blood to intestinal lumen: factors influencing nonbiliary excretion by the intestinal tract</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1193</span>– <span class="NLM_lpage">1206</span>, <span class="refDoi"> DOI: 10.3109/03602538308991427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.3109%2F03602538308991427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=6373210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaL2cXlsVehtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1983&pages=1193-1206&author=P.+G.+Daytonauthor=Z.+H.+Israiliauthor=J.+D.+Henderson&title=Elimination+of+drugs+by+passive+diffusion+from+blood+to+intestinal+lumen%3A+factors+influencing+nonbiliary+excretion+by+the+intestinal+tract&doi=10.3109%2F03602538308991427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Elimination of drugs by passive diffusion from blood to intestinal lumen:  factors influencing nonbiliary excretion by the intestinal tract</span></div><div class="casAuthors">Dayton, Peter G.; Israili, Zafar H.; Henderson, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1193-206</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    </div><div class="casAbstract">A review with 80 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopNm7j4ETnZLVg90H21EOLACvtfcHk0liVIeWh_7Wcow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXlsVehtL4%253D&md5=f0aef1e2e8700d2d736793a039d5e9a0</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3109%2F03602538308991427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03602538308991427%26sid%3Dliteratum%253Aachs%26aulast%3DDayton%26aufirst%3DP.%2BG.%26aulast%3DIsraili%26aufirst%3DZ.%2BH.%26aulast%3DHenderson%26aufirst%3DJ.%2BD.%26atitle%3DElimination%2520of%2520drugs%2520by%2520passive%2520diffusion%2520from%2520blood%2520to%2520intestinal%2520lumen%253A%2520factors%2520influencing%2520nonbiliary%2520excretion%2520by%2520the%2520intestinal%2520tract%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D1983%26volume%3D14%26spage%3D1193%26epage%3D1206%26doi%3D10.3109%2F03602538308991427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Israili, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayton, P. G.</span></span> <span> </span><span class="NLM_article-title">Enhancement of xenobiotic elimination: role of intestinal excretion</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1123</span>– <span class="NLM_lpage">1159</span>, <span class="refDoi"> DOI: 10.3109/03602538409033559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.3109%2F03602538409033559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=6396054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaL2MXntlGruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1984&pages=1123-1159&author=Z.+H.+Israiliauthor=P.+G.+Dayton&title=Enhancement+of+xenobiotic+elimination%3A+role+of+intestinal+excretion&doi=10.3109%2F03602538409033559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancement of xenobiotic elimination:  role of intestinal excretion</span></div><div class="casAuthors">Israili, Z. H.; Dayton, P. G.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">1123-59</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    </div><div class="casAbstract">A review with 190 refs. on the exploitation of intestinal excretion as a means of detoxication of xenobiotics in man, including the use of nonabsorbable substances to enhance the excretion process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVhgZWG_yF-rVg90H21EOLACvtfcHk0liVIeWh_7Wcow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXntlGruw%253D%253D&md5=e7906021d447c7e84f6896c32d7470fe</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.3109%2F03602538409033559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03602538409033559%26sid%3Dliteratum%253Aachs%26aulast%3DIsraili%26aufirst%3DZ.%2BH.%26aulast%3DDayton%26aufirst%3DP.%2BG.%26atitle%3DEnhancement%2520of%2520xenobiotic%2520elimination%253A%2520role%2520of%2520intestinal%2520excretion%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D1984%26volume%3D15%26spage%3D1123%26epage%3D1159%26doi%3D10.3109%2F03602538409033559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arimori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, M.</span></span> <span> </span><span class="NLM_article-title">Drug exsorption from blood into the gastrointestinal tract</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">376</span>, <span class="refDoi"> DOI: 10.1023/A:1011959828103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1023%2FA%3A1011959828103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=9563065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK1cXisVGruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1998&pages=371-376&author=K.+Arimoriauthor=M.+Nakano&title=Drug+exsorption+from+blood+into+the+gastrointestinal+tract&doi=10.1023%2FA%3A1011959828103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Drug exsorption from blood into the gastrointestinal tract</span></div><div class="casAuthors">Arimori, Kazuhiko; Nakano, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">371-376</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Plenum Publishing Corp.</span>)
        </div><div class="casAbstract">Drugs are exsorbed from the blood across the gastrointestinal membranes by passive or active processes.  In the case of a passive transport mechanism, the exsorption of drugs depends on the concn. gradients between the serosal and mucosal sides.  The extent of secretion (exsorption) is detd. by numerous factors such as extent of binding to serum proteins, distribution vol., lipophilicity, pKa and mol. size of drugs, and the blood flow rate in the gut.  Specific transport systems such as P-glycoprotein (P-gp), org. cation and org. anion transporters are involved in active intestinal secretion of drugs.  Intestinal secretory transport systems reduce the extent of drug absorption sometimes resulting in low oral bioavailability.  It is, therefore, important to know whether poor drug absorption is due to the involvement of specialized secretory transport systems.  Modulation of intestinal secretory transport can be a means to enhance absorption of drugs with low oral bioavailability if exsorption of drugs is based on active secretion pathways that are open for control from the outside.  A review with 50 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU_woIJZ_s3LVg90H21EOLACvtfcHk0liVIeWh_7Wcow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXisVGruro%253D&md5=7c6fe96dd777ead00f3567e15ea6c29d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1023%2FA%3A1011959828103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1011959828103%26sid%3Dliteratum%253Aachs%26aulast%3DArimori%26aufirst%3DK.%26aulast%3DNakano%26aufirst%3DM.%26atitle%3DDrug%2520exsorption%2520from%2520blood%2520into%2520the%2520gastrointestinal%2520tract%26jtitle%3DPharm.%2520Res.%26date%3D1998%26volume%3D15%26spage%3D371%26epage%3D376%26doi%3D10.1023%2FA%3A1011959828103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abruzzo, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krogmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rishi, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D. D.</span></span> <span> </span><span class="NLM_article-title">A multidrug resistance transporter from human MCF-7 breast cancer cells</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">15665</span>– <span class="NLM_lpage">15670</span>, <span class="refDoi"> DOI: 10.1073/pnas.95.26.15665</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1073%2Fpnas.95.26.15665" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=9861027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK1MXhvFeitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=15665-15670&author=L.+A.+Doyleauthor=W.+Yangauthor=L.+V.+Abruzzoauthor=T.+Krogmannauthor=Y.+Gaoauthor=A.+K.+Rishiauthor=D.+D.+Ross&title=A+multidrug+resistance+transporter+from+human+MCF-7+breast+cancer+cells&doi=10.1073%2Fpnas.95.26.15665"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">A multidrug resistance transporter from human MCF-7 breast cancer cells</span></div><div class="casAuthors">Doyle, L. Austin; Yang, Weidong; Abruzzo, Lynne V.; Krogmann, Tammy; Gao, Yongming; Rishi, Arun K.; Ross, Douglas D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">15665-15670</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">MCF-7/AdrVp is a multidrug-resistant human breast cancer subline that displays an ATP-dependent redn. in the intracellular accumulation of anthracycline anticancer drugs in the absence of overexpression of known multidrug resistance transporters such as P glycoprotein or the multidrug resistance protein.  RNA fingerprinting led to the identification of a 2.4-kb mRNA that is overexpressed in MCF-7/AdrVp cells relative to parental MCF-7 cells.  The mRNA encodes a 663-aa member of the ATP-binding cassette superfamily of transporters that we term breast cancer resistance protein (BCRP).  Enforced expression of the full-length BCRP cDNA in MCF-7 breast cancer cells confers resistance to mitoxantrone, doxorubicin, and daunorubicin, reduces daunorubicin accumulation and retention, and causes an ATP-dependent enhancement of the efflux of rhodamine 123 in the cloned transfected cells.  BCRP is a xenobiotic transporter that appears to play a major role in the multidrug resistance phenotype of MCF-7/AdrVp human breast cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowbckt6jTJYLVg90H21EOLACvtfcHk0liVIeWh_7Wcow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhvFeitQ%253D%253D&md5=ef3e4ddd772833b363ba458401e3331a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.26.15665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.26.15665%26sid%3Dliteratum%253Aachs%26aulast%3DDoyle%26aufirst%3DL.%2BA.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DAbruzzo%26aufirst%3DL.%2BV.%26aulast%3DKrogmann%26aufirst%3DT.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DRishi%26aufirst%3DA.%2BK.%26aulast%3DRoss%26aufirst%3DD.%2BD.%26atitle%3DA%2520multidrug%2520resistance%2520transporter%2520from%2520human%2520MCF-7%2520breast%2520cancer%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26spage%3D15665%26epage%3D15670%26doi%3D10.1073%2Fpnas.95.26.15665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, M.</span></span> <span> </span><span class="NLM_article-title">Clinical relevance of P-glycoprotein in drug therapy</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">417</span>– <span class="NLM_lpage">454</span>, <span class="refDoi"> DOI: 10.1081/DMR-120026871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1081%2FDMR-120026871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=14705869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1ygsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2003&pages=417-454&author=J.+H.+Linauthor=M.+Yamazaki&title=Clinical+relevance+of+P-glycoprotein+in+drug+therapy&doi=10.1081%2FDMR-120026871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Relevance of P-Glycoprotein in Drug Therapy</span></div><div class="casAuthors">Lin, Jiunn H.; Yamazaki, Masayo</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">417-454</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Marcel Dekker, Inc.</span>)
        </div><div class="casAbstract">A review.  The drug efflux transporter P-glycoprotein (P-gp) is known to confer multidrug resistance in cancer chemotherapy.  The P-gp is highly expressed in many types of tumor cells, as well as many normal tissues, including the apical surface of intestinal epithelial cells, and the luminal surface of capillary endothelial cells in the brain.  Because of its expression and localization, it has been suggested that P-gp plays an important role in cancer chemotherapy, intestinal absorption, and brain uptake.  This review addresses the significance of the role of P-gp in cancer chemotherapy, drug absorption, and brain uptake.  Based on the clin. and animal studies with P-gp modulators, it has become apparent that the role of P-gp in multidrug resistance is far less important compared to other biol. factors.  Although P-gp is highly expressed in both intestinal epithelial cells and endothelial cells of brain capillaries and functions as an efflux transporter in both organs, the magnitude of P-gp's impact on intestinal absorption and brain uptake of drugs is quant. very different.  From animal and clin. studies, it is evident that P-gp plays a very important role in CNS penetration of drugs, whereas the effect of P-gp on drug absorption is not as important as generally believed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyF-MM7RjqZLVg90H21EOLACvtfcHk0lhY1v5tJBSapg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1ygsLw%253D&md5=22c8b47bccd0f577ca0f8589d442402f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1081%2FDMR-120026871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1081%252FDMR-120026871%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DJ.%2BH.%26aulast%3DYamazaki%26aufirst%3DM.%26atitle%3DClinical%2520relevance%2520of%2520P-glycoprotein%2520in%2520drug%2520therapy%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2003%26volume%3D35%26spage%3D417%26epage%3D454%26doi%3D10.1081%2FDMR-120026871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forsell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tevell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persson, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedeland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondesson, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lennernas, H.</span></span> <span> </span><span class="NLM_article-title">Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">214</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2006.04.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1016%2Fj.ejps.2006.04.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=16806856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFentrzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2006&pages=205-214&author=E.+Bergmanauthor=P.+Forsellauthor=A.+Tevellauthor=E.+M.+Perssonauthor=M.+Hedelandauthor=U.+Bondessonauthor=L.+Knutsonauthor=H.+Lennernas&title=Biliary+secretion+of+rosuvastatin+and+bile+acids+in+humans+during+the+absorption+phase&doi=10.1016%2Fj.ejps.2006.04.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase</span></div><div class="casAuthors">Bergman, Ebba; Forsell, Patrik; Tevell, Annica; Persson, Eva M.; Hedeland, Mikael; Bondesson, Ulf; Knutson, Lars; Lennernaes, Hans</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">205-214</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Aim: The aim of this study was to investigate the biliary secretion of rosuvastatin in healthy volunteers using an intestinal perfusion method after administration of 10 mg rosuvastatin dispersion in the intestine.  Methods: The Loc-I-Gut tube was positioned in the distal duodenum/proximal jejunum and a semi-open segment was created by inflating the proximal balloon in ten volunteers.  A dispersion of 10 mg rosuvastatin was administered below the inflated balloon and bile was collected proximally of the inflated balloon.  Bile and plasma samples were withdrawn every 20 min during a 4 h period (absorption phase) and addnl. plasma samples were collected 24 and 48 h post-dose.  Results: The study showed that there is a substantial and immediate transport of rosuvastatin into the human bile, with the max. concn. appearing 42 min after dosing, 39,000±31,000 ng/mL.  Approx. 11% of the administered intestinal dose was recovered in the bile after 240 min.  At all time points the biliary concn. exceeded the plasma concn., and the av. bile to plasma ratio was 5200±9200 (range 89-33,900, median 2000).  We were unable to identify any bile-specific metabolites of rosuvastatin in the present study.  Conclusion: Rosuvastatin is excreted via the biliary route in humans, and the transport and accumulation of rosuvastatin in bile compared to that in plasma is rapid and extensive.  This intestinal perfusion technique offers a successful way to est. the biliary secretion for drugs, metabolites and endogenous substances during the absorption phase in healthy volunteers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob6CzYdWMFwLVg90H21EOLACvtfcHk0lhY1v5tJBSapg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFentrzI&md5=74e5da460a1d7df951bd28277b7b2fe5</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2006.04.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2006.04.015%26sid%3Dliteratum%253Aachs%26aulast%3DBergman%26aufirst%3DE.%26aulast%3DForsell%26aufirst%3DP.%26aulast%3DTevell%26aufirst%3DA.%26aulast%3DPersson%26aufirst%3DE.%2BM.%26aulast%3DHedeland%26aufirst%3DM.%26aulast%3DBondesson%26aufirst%3DU.%26aulast%3DKnutson%26aufirst%3DL.%26aulast%3DLennernas%26aufirst%3DH.%26atitle%3DBiliary%2520secretion%2520of%2520rosuvastatin%2520and%2520bile%2520acids%2520in%2520humans%2520during%2520the%2520absorption%2520phase%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2006%26volume%3D29%26spage%3D205%26epage%3D214%26doi%3D10.1016%2Fj.ejps.2006.04.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lennernas, H.</span></span> <span> </span><span class="NLM_article-title">Intestinal permeability and its relevance for absorption and elimination</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1015</span>– <span class="NLM_lpage">1051</span>, <span class="refDoi"> DOI: 10.1080/00498250701704819</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1080%2F00498250701704819" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=17968735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A280%3ADC%252BD2snksVSntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2007&pages=1015-1051&author=H.+Lennernas&title=Intestinal+permeability+and+its+relevance+for+absorption+and+elimination&doi=10.1080%2F00498250701704819"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal permeability and its relevance for absorption and elimination</span></div><div class="casAuthors">Lennernas H</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica; the fate of foreign compounds in biological systems</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">10-11</span>),
    <span class="NLM_cas:pages">1015-51</span>
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    </div><div class="casAbstract">Human jejunal permeability (P(eff)) is determined in the intestinal region with the highest expression of carrier proteins and largest surface area.  Intestinal P(eff) are often based on multiple parallel transport processes.  Site-specific jejunal P(eff) cannot reflect the permeability along the intestinal tract, but they are useful for approximating the fraction oral dose absorbed.  It seems like drugs with a jejunal P(eff) > 1.5 x 10(-4) cm s(-1) will be completely absorbed no matter which transport mechanism(s) are utilized.  Many drugs that are significantly effluxed in vitro have a rapid and complete intestinal absorption (i.e. >85%) mediated by passive transcellular diffusion.  The determined jejunal P(eff) for drugs transported mainly by absorptive carriers (such as peptide and amino acid transporters) will accurately predict the fraction of the dose absorbed as a consequence of the regional expression.  The data also show that: (1) the human intestinal epithelium has a large resistance towards large and hydrophilic compounds; and (2) the paracellular route has a low contribution for compounds larger than approximately molecular weight 200.  There is a need for more exploratory in vivo studies to clarify drug absorption and first-pass extraction along the intestine.  One is encouraged to develop in vivo perfusion techniques for more distal parts of the gastrointestinal tract in humans.  This would stimulate the development of more relevant and complex in vitro absorption models and form the basis for an accurate physiologically based pharmacokinetic modelling of oral drug absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmVh_0AWtT6Oqrn-c4Of3KfW6udTcc2eYHL-M3eQ5TC7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2snksVSntg%253D%253D&md5=27b3346470288543293996b323269642</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1080%2F00498250701704819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00498250701704819%26sid%3Dliteratum%253Aachs%26aulast%3DLennernas%26aufirst%3DH.%26atitle%3DIntestinal%2520permeability%2520and%2520its%2520relevance%2520for%2520absorption%2520and%2520elimination%26jtitle%3DXenobiotica%26date%3D2007%26volume%3D37%26spage%3D1015%26epage%3D1051%26doi%3D10.1080%2F00498250701704819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goosen, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, W. G.</span></span> <span> </span><span class="NLM_article-title">Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">906</span>– <span class="NLM_lpage">915</span>, <span class="refDoi"> DOI: 10.1124/dmd.112.050575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.112.050575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=23386703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3sXkslSktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=906-915&author=D.+Zhangauthor=C.+E.+Frostauthor=K.+Heauthor=A.+D.+Rodriguesauthor=X.+Wangauthor=L.+Wangauthor=T.+C.+Goosenauthor=W.+G.+Humphreys&title=Investigating+the+enteroenteric+recirculation+of+apixaban%2C+a+factor+Xa+inhibitor%3A+administration+of+activated+charcoal+to+bile+duct-cannulated+rats+and+dogs+receiving+an+intravenous+dose+and+use+of+drug+transporter+knockout+rats&doi=10.1124%2Fdmd.112.050575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats</span></div><div class="casAuthors">Zhang, Donglu; Frost, Charles E.; He, Kan; Rodrigues, A. David; Wang, Xiaoli; Wang, Lifei; Goosen, Theunis C.; Humphreys, W. Griffith</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">906-915</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The study described here investigated the impact of intestinal excretion (IE; excretion of drug directly from circulation to intestinal lumen), enteroenteric recirculation (EER), and renal tubule recirculation (RTR) on apixaban pharmacokinetics and disposition.  The exptl. approaches involve integrating apixaban elimination pathways with pharmacokinetic profiles obtained from bile duct-cannulated (BDC) rats and dogs receiving i.v. doses together with oral administration of activated charcoal (AC).  Addnl., the role of P-gp (P-glycoprotein; abcb1) and BCRP (breast cancer resistance protein; abcg2) in apixaban disposition was evaluated in expts. using transporter inhibitors and transporter knockout (KO) rats.  Approx. 20-50% of an apixaban i.v. dose was found in feces of BDC rats and dogs, suggesting IE leading to fecal elimination and intestinal clearance (IC).  The fecal elimination, IC, and systemic clearance of apixaban were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with GF-120918, a dual BCRP and P-gp inhibitor).  BCRP appeared to play a more important role for absorption and intestinal and renal elimination of apixaban than P-gp in transporter-KO rats after oral and i.v. dosing, which led to a higher level of active renal excretion in rat than other species.  These data demonstrate that apixaban undergoes IE, EER, and RTR that are facilitated by efflux transporters.  Intestinal reabsorption of apixaban could be interrupted by AC even at 3 h post-drug dose in dogs (late charcoal effect).  This study demonstrates that the intestine is an organ for direct clearance and redistribution of apixaban.  The IE, EER, and RTR contribute to overall pharmacokinetic profiles of apixaban.  IE as a clearance pathway, balanced with metab. and renal excretion, helps decrease the impacts of intrinsic (renal or hepatic impairment) and extrinsic (drug-drug interactions) factors on apixaban disposition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV6UUBOTf7mLVg90H21EOLACvtfcHk0liAwOFwHpbCNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXkslSktLg%253D&md5=23612e18f5faa52a1ae05abb87d0fbeb</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.050575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.050575%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DFrost%26aufirst%3DC.%2BE.%26aulast%3DHe%26aufirst%3DK.%26aulast%3DRodrigues%26aufirst%3DA.%2BD.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DGoosen%26aufirst%3DT.%2BC.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26atitle%3DInvestigating%2520the%2520enteroenteric%2520recirculation%2520of%2520apixaban%252C%2520a%2520factor%2520Xa%2520inhibitor%253A%2520administration%2520of%2520activated%2520charcoal%2520to%2520bile%2520duct-cannulated%2520rats%2520and%2520dogs%2520receiving%2520an%2520intravenous%2520dose%2520and%2520use%2520of%2520drug%2520transporter%2520knockout%2520rats%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2013%26volume%3D41%26spage%3D906%26epage%3D915%26doi%3D10.1124%2Fdmd.112.050575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burczynski, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, M.</span></span> <span> </span><span class="NLM_article-title">Enterohepatic circulation: physiological, pharmacokinetic and clinical implications</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">751</span>– <span class="NLM_lpage">790</span>, <span class="refDoi"> DOI: 10.2165/00003088-200241100-00005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.2165%2F00003088-200241100-00005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=12162761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD38XntFyru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2002&pages=751-790&author=M.+S.+Robertsauthor=B.+M.+Magnussonauthor=F.+J.+Burczynskiauthor=M.+Weiss&title=Enterohepatic+circulation%3A+physiological%2C+pharmacokinetic+and+clinical+implications&doi=10.2165%2F00003088-200241100-00005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Enterohepatic circulation: physiological, pharmacokinetic and clinical implications</span></div><div class="casAuthors">Roberts, Michael S.; Magnusson, Beatrice M.; Burczynski, Frank J.; Weiss, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">751-790</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Enterohepatic recycling occurs by biliary excretion and intestinal reabsorption of a solute, sometimes with hepatic conjugation and intestinal deconjugation.  Cycling is often assocd. with multiple peaks and a longer apparent half-life in a plasma concn.-time profile.  Factors affecting biliary excretion include drug characteristics (chem. structure, polarity and mol. size), transport across sinusoidal plasma membrane and canniculae membranes, biotransformation and possible reabsorption from intrahepatic bile ductules.  Intestinal reabsorption to complete the enterohepatic cycle may depend on hydrolysis of a drug conjugate by gut bacteria.  Bioavailability is also affected by the extent of intestinal absorption, gut-wall P-glycoprotein efflux and gut-wall metab.  Recently, there has been a considerable increase in our understanding of the role of transporters, of gene expression of intestinal and hepatic enzymes, and of hepatic zonation.  Drugs, disease and genetics may result in induced or inhibited activity of transporters and metabolizing enzymes.  Reduced expression of one transporter, for example hepatic canalicular multidrug resistance-assocd. protein (MRP) 2, is often assocd. with enhanced expression of others, for example the usually quiescent basolateral efflux MRP3, to limit hepatic toxicity.  In addn., physiol. relevant pharmacokinetic models, which describe enterohepatic recirculation in terms of its determinants (such as sporadic gall bladder emptying), have been developed.  In general, enterohepatic recirculation may prolong the pharmacol. effect of certain drugs and drug metabolites.  Of particular importance is the potential amplifying effect of enterohepatic variability in defining differences in the bioavailability, apparent vol. of distribution and clearance of a given compd.  Genetic abnormalities, disease states, orally administered adsorbents and certain co-administered drugs all affect enterohepatic recycling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDmTzuEhf7QLVg90H21EOLACvtfcHk0liAwOFwHpbCNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntFyru78%253D&md5=514a6ffb4ee275ccd2a7082fe2fe3d87</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2165%2F00003088-200241100-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-200241100-00005%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DM.%2BS.%26aulast%3DMagnusson%26aufirst%3DB.%2BM.%26aulast%3DBurczynski%26aufirst%3DF.%2BJ.%26aulast%3DWeiss%26aufirst%3DM.%26atitle%3DEnterohepatic%2520circulation%253A%2520physiological%252C%2520pharmacokinetic%2520and%2520clinical%2520implications%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2002%26volume%3D41%26spage%3D751%26epage%3D790%26doi%3D10.2165%2F00003088-200241100-00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maliepaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffer, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faneyte, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gastelen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pijnenborg, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinkel, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van De
Vijver, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheper, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H.</span></span> <span> </span><span class="NLM_article-title">Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues</span>. <i>Cancer. Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3458</span>– <span class="NLM_lpage">3464</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=11309308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjtFSju7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=3458-3464&author=M.+Maliepaardauthor=G.+L.+Schefferauthor=I.+F.+Faneyteauthor=M.+A.+van+Gastelenauthor=A.+C.+Pijnenborgauthor=A.+H.+Schinkelauthor=M.+J.+van+De%0AVijverauthor=R.+J.+Scheperauthor=J.+H.+Schellens&title=Subcellular+localization+and+distribution+of+the+breast+cancer+resistance+protein+transporter+in+normal+human+tissues"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues</span></div><div class="casAuthors">Maliepaard, Marc; Scheffer, George L.; Faneyte, Ian F.; Van Gastelen, Margot A.; Pijnenborg, Adriana C. L. M.; Schinkel, Alfred H.; Van de Vijver, Marc J.; Scheper, Rik J.; Schellens, Jan H. M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3458-3464</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">High expression of the Breast Cancer Resistance Protein (BCRP) gene has been shown to be involved in resistance to chemotherapeutic drugs.  Knowledge of the localization of BCRP protein in normal tissues may help unravel the normal function of this protein.  Therefore, we characterized the tissue distribution and cellular localization of BCRP in frozen sections of normal human tissues.  For this purpose, we used the recently described monoclonal antibody BXP-34 and another independently developed monoclonal antibody directed against BCRP, BXP-21.  Both monoclonal antibodies show specific BCRP plasma membrane staining on cytospins obtained from topotecan- or mitoxantrone-selected cell lines, as well as from BCRP-transfected cell lines.  Immunopptn. expts. using either BXP-21 or BXP-34 yielded a clear Mr 72,000 BCRP band from BCRP-overexpressing tumor cells.  In the topotecan-selected T8 and mitoxantrone-selected MX3 tumor cell lines, BCRP turned out to be differentially glycosylated.  In contrast to BXP-34, BXP-21 is able to detect the Mr 72,000 BCRP protein on immunoblots and is reactive with BCRP in formalin-fixed, paraffin-embedded tissues.  Using BXP-21 and BXP-34, prominent staining of BCRP was obsd. in placental syncytiotrophoblasts, in the epithelium of the small intestine and colon, in the liver canalicular membrane, and in ducts and lobules of the breast.  Furthermore, BCRP was present in veinous and capillary endothelium, but not in arterial endothelium in all of the tissues investigated.  In the tissues studied, the mRNA levels of BCRP were assessed using reverse transcription-PCR, and these corresponded with the levels of BCRP protein estd. from immunohistochem. staining.  The presence of BCRP at the placental syncytiotrophoblasts is consistent with the hypothesis of a protective role of BCRP for the fetus.  The apical localization in the epithelium of the small intestine and colon indicates a possible role of BCRP in the regulation of the uptake of p.o. administered BCRP substrates by back-transport of substrate drugs entering from the gut lumen.  Therefore, it may be useful to attempt to modulate the uptake of p.o. delivered BCRP substrates, e.g., topotecan or irinotecan, by using a BCRP inhibitor.  Clin. trials testing this hypothesis have been initiated in our institute.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZsMtlFEL7dbVg90H21EOLACvtfcHk0liAwOFwHpbCNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjtFSju7o%253D&md5=91aaea85737ec13ca50a670abdc665d9</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMaliepaard%26aufirst%3DM.%26aulast%3DScheffer%26aufirst%3DG.%2BL.%26aulast%3DFaneyte%26aufirst%3DI.%2BF.%26aulast%3Dvan%2BGastelen%26aufirst%3DM.%2BA.%26aulast%3DPijnenborg%26aufirst%3DA.%2BC.%26aulast%3DSchinkel%26aufirst%3DA.%2BH.%26aulast%3Dvan%2BDe%2BVijver%26aufirst%3DM.%2BJ.%26aulast%3DScheper%26aufirst%3DR.%2BJ.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26atitle%3DSubcellular%2520localization%2520and%2520distribution%2520of%2520the%2520breast%2520cancer%2520resistance%2520protein%2520transporter%2520in%2520normal%2520human%2520tissues%26jtitle%3DCancer.%2520Res.%26date%3D2001%26volume%3D61%26spage%3D3458%26epage%3D3464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Austin
Doyle, L</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D. D</span></span> <span> </span><span class="NLM_article-title">Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">7340</span>– <span class="NLM_lpage">7358</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1206938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1038%2Fsj.onc.1206938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=14576842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotlajur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=7340-7358&author=L+Austin%0ADoyleauthor=D.+D+Ross&title=Multidrug+resistance+mediated+by+the+breast+cancer+resistance+protein+BCRP+%28ABCG2%29&doi=10.1038%2Fsj.onc.1206938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)</span></div><div class="casAuthors">Austin Doyle, L.; Ross, Douglas D.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">7340-7358</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Observations of functional ATP-dependent drug efflux in certain multidrug-resistant cancer cell lines without overexpression of P-glycoprotein or multidrug resistance protein (MRP) family members suggested the existence of another ATP-binding cassette (ABC) transporter capable of causing cancer drug resistance.  In one such cell line (MCF-7/AdrVp), the overexpression of a novel member of the G subfamily of ABC transporters was found.  The new transporter was termed the breast cancer resistance protein (BCRP), because of its identification in MCF-7 human breast carcinoma cells.  BCRP is a 655 amino-acid polypeptide, formally designated as ABCG2.  Like all members of the ABC G (white) subfamily, BCRP is a half transporter.  Transfection and enforced overexpression of BCRP in drug-sensitive MCF-7 or MDA-MB-231 cells recapitulates the drug-resistance phenotype of MCF-7/AdrVp cells, consistent with current evidence suggesting that functional BCRP is a homodimer.  BCRP maps to chromosome 4q22, downstream from a TATA-less promoter.  The spectrum of anticancer drugs effluxed by BCRP includes mitoxantrone, camptothecin-derived and indolocarbazole topoisomerase I inhibitors, methotrexate, flavopiridol, and quinazoline ErbB1 inhibitors.  Transport of anthracyclines is variable and appears to depend on the presence of a BCRP mutation at codon 482.  Potent and specific inhibitors of BCRP are now being developed, opening the door to clin. applications of BCRP inhibition.  Owing to tissue localization in the placenta, bile canaliculi, colon, small bowel, and brain microvessel endothelium, BCRP may play a role in protecting the organism from potentially harmful xenobiotics.  BCRP expression has also been demonstrated in pluripotential side population' stem cells, responsible for the characteristic ability of these cells to exclude Hoechst 33342 dye, and possibly for the maintenance of the stem cell phenotype.  Studies are emerging on the role of BCRP expression in drug resistance in clin. cancers.  More prospective studies are needed, preferably combining BCRP protein or mRNA quantification with functional assays, in order to det. the contribution of BCRP to drug resistance in human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYJbHmQOSZILVg90H21EOLACvtfcHk0liAwOFwHpbCNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotlajur0%253D&md5=fa0c4ae3b5e15c73efd4cba939b847ae</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1206938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1206938%26sid%3Dliteratum%253Aachs%26aulast%3DAustin%2BDoyle%26aufirst%3DL%26aulast%3DRoss%26aufirst%3DD.%2BD%26atitle%3DMultidrug%2520resistance%2520mediated%2520by%2520the%2520breast%2520cancer%2520resistance%2520protein%2520BCRP%2520%2528ABCG2%2529%26jtitle%3DOncogene%26date%3D2003%26volume%3D22%26spage%3D7340%26epage%3D7358%26doi%3D10.1038%2Fsj.onc.1206938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Unadkat, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vijay, S.</span></span> <span> </span><span class="NLM_article-title">Placental drug transporters</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.2174/1389200043489171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.2174%2F1389200043489171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=14965255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvVCisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=125-131&author=J.+D.+Unadkatauthor=A.+Dahlinauthor=S.+Vijay&title=Placental+drug+transporters&doi=10.2174%2F1389200043489171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Placental drug transporters</span></div><div class="casAuthors">Unadkat, Jashvant D.; Dahlin, Amber; Vijay, Shashi</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">125-131</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Any treatment of a pregnant woman with medication (drugs) de facto results in the treatment of her unborn child, even when her unborn child is not the target of drug therapy.  This is because, in most instances, the placenta is not a complete barrier to the passage of drugs from the maternal to the fetal compartment.  This barrier is in part due to the presence of various efflux transporters in the placenta.  The placenta is also richly endowed with influx transporters.  In this article, we will review the physiol. characteristics of the placenta and how it functions as a barrier to passage of drugs into the fetal compartment.  In addn., we will review placental transporters that are important in modulating the exposure of the fetus to drugs and, therefore, the efficacy and toxicity of such drugs towards the fetus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQYs8ns1yx17Vg90H21EOLACvtfcHk0lgF03O_vU41Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvVCisb4%253D&md5=0de1ea445c06e9ef21e122b6a9e57619</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.2174%2F1389200043489171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200043489171%26sid%3Dliteratum%253Aachs%26aulast%3DUnadkat%26aufirst%3DJ.%2BD.%26aulast%3DDahlin%26aufirst%3DA.%26aulast%3DVijay%26aufirst%3DS.%26atitle%3DPlacental%2520drug%2520transporters%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2004%26volume%3D5%26spage%3D125%26epage%3D131%26doi%3D10.2174%2F1389200043489171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unadkat, J. D.</span></span> <span> </span><span class="NLM_article-title">Role of the breast cancer resistance protein (ABCG2) in drug transport</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">E118</span>– <span class="NLM_lpage">133</span>, <span class="refDoi"> DOI: 10.1208/aapsj070112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1208%2Faapsj070112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=16146333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltlOqtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=E118-133&author=Q.+Maoauthor=J.+D.+Unadkat&title=Role+of+the+breast+cancer+resistance+protein+%28ABCG2%29+in+drug+transport&doi=10.1208%2Faapsj070112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the breast cancer resistance protein (ABCG2) in drug transport</span></div><div class="casAuthors">Mao, Qingcheng; Unadkat, Jashvant D.</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">E118-E133</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">American Association of Pharmaceutical Scientists</span>)
        </div><div class="casAbstract">A review.  The 72-kDa breast cancer resistance protein (BCRP) is the second member of the subfamily G of the human ATP binding cassette (ABC) transporter superfamily and thus also designated as ABCG2.  Unlike P-glycoprotein and MRP1, which are arranged in 2 repeated halves, BCRP is a half-transporter consisting of only 1 nucleotide binding domain followed by 1 membrane-spanning domain.  Current exptl. evidence suggests that BCRP may function as a homodimer or homotetramer.  Overexpression of BCRP is assocd. with high levels of resistance to a variety of anticancer agents, including anthracyclines, mitoxantrone, and the camptothecins, by enhancing drug efflux.  BCRP expression has been detected in a large no. of hematol. malignancies and solid tumors, indicating that this transporter may play an important role in clin. drug resistance of cancers.  In addn. to its role to confer resistance against chemotherapeutic agents, BCRP actively transports structurally diverse org. mols., conjugated or unconjugated, such as estrone-3-sulfate, 17β-estradiol 17-(β-D-glucuronide), and methotrexate.  BCRP is highly expressed in the placental syncytiotrophoblasts, in the apical membrane of the epithelium in the small intestine, in the liver canalicular membrane, and at the luminal surface of the endothelial cells of human brain microvessels.  This strategic and substantial tissue localization indicates that BCRP also plays an important role in absorption, distribution, and elimination of drugs that are BCRP substrates.  This review summarizes current knowledge of BCRP and its relevance to multidrug resistance and drug disposition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTv1Fin0ok0bVg90H21EOLACvtfcHk0lgF03O_vU41Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltlOqtrs%253D&md5=3eb43fcf4d36648844d5e729c6ce9487</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1208%2Faapsj070112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Faapsj070112%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DQ.%26aulast%3DUnadkat%26aufirst%3DJ.%2BD.%26atitle%3DRole%2520of%2520the%2520breast%2520cancer%2520resistance%2520protein%2520%2528ABCG2%2529%2520in%2520drug%2520transport%26jtitle%3DAAPS%2520J.%26date%3D2005%26volume%3D7%26spage%3DE118%26epage%3D133%26doi%3D10.1208%2Faapsj070112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krishnamurthy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuetz, J. D.</span></span> <span> </span><span class="NLM_article-title">Role of ABCG2/BCRP in biology and medicine</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">381</span>– <span class="NLM_lpage">410</span>, <span class="refDoi"> DOI: 10.1146/annurev.pharmtox.46.120604.141238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1146%2Fannurev.pharmtox.46.120604.141238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=16402910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD28XisFKltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2006&pages=381-410&author=P.+Krishnamurthyauthor=J.+D.+Schuetz&title=Role+of+ABCG2%2FBCRP+in+biology+and+medicine&doi=10.1146%2Fannurev.pharmtox.46.120604.141238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Role of ABCG2/BCRP in biology and medicine</span></div><div class="casAuthors">Krishnamurthy, P.; Schuetz, J. D.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">381-410, 1 plate</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The protein variously named ABCG2/BCRP/MXR/ABCP is a recently described ATP-binding cassette (ABC) transporter originally identified by its ability to confer drug resistance that is independent of Mrp1 (multidrug-resistance protein 1) and Pgp (P-glycoprotein).  Unlike Mrp1 and Pgp, ABCG2 is a half-transporter that must homodimerize to acquire transport activity.  ABCG2 is found in a variety of stem cells and may protect them from exogenous and endogenous toxins.  ABCG2 expression is upregulated under low-oxygen conditions, consistent with its high expression in tissues exposed to low-oxygen environments.  ABCG2 interacts with heme and other porphyrins and protects cells and/or tissues from protoporphyrin accumulation under hypoxic conditions.  Individuals who carry ABCG2 alleles that have impaired function may be more susceptible to porphyrin-induced toxicity.  Abcg2 knock-out models have allowed in vivo studies of Abcg2 function in host and cellular defense.  In combination with immunohistochem. analyses, these studies have revealed how ABCG2 influences the absorption, distribution, and excretion of drugs and cytotoxins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr74986FK6FwLVg90H21EOLACvtfcHk0lgF03O_vU41Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XisFKltbg%253D&md5=5605477a8544d3a52039c7750956bfb8</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.46.120604.141238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.46.120604.141238%26sid%3Dliteratum%253Aachs%26aulast%3DKrishnamurthy%26aufirst%3DP.%26aulast%3DSchuetz%26aufirst%3DJ.%2BD.%26atitle%3DRole%2520of%2520ABCG2%252FBCRP%2520in%2520biology%2520and%2520medicine%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2006%26volume%3D46%26spage%3D381%26epage%3D410%26doi%3D10.1146%2Fannurev.pharmtox.46.120604.141238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huls, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windass, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den
Heuvel, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heemskerk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russel, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masereeuw, R.</span></span> <span> </span><span class="NLM_article-title">The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane</span>. <i>Kidney Int.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">220</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.1038/sj.ki.5002645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1038%2Fsj.ki.5002645" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=17978814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVyltL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=220-225&author=M.+Hulsauthor=C.+D.+Brownauthor=A.+S.+Windassauthor=R.+Sayerauthor=J.+J.+van+den%0AHeuvelauthor=S.+Heemskerkauthor=F.+G.+Russelauthor=R.+Masereeuw&title=The+breast+cancer+resistance+protein+transporter+ABCG2+is+expressed+in+the+human+kidney+proximal+tubule+apical+membrane&doi=10.1038%2Fsj.ki.5002645"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane</span></div><div class="casAuthors">Huls, M.; Brown, C. D. A.; Windass, A. S.; Sayer, R.; van den Heuvel, J. J. M. W.; Heemskerk, S.; Russel, F. G. M.; Masereeuw, R.</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">220-225</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Breast Cancer Resistance Protein (BCRP/ABCG2) is a transporter restricting absorption and enhancing excretion of many compds. including anticancer drugs.  This transporter is highly expressed in many tissues; however, in human kidney, only the mRNA was found in contrast to the mouse kidney, where the transporter is abundant.  In bcrp/abcg2(-/-) mice, the expression of two sterol transporter genes, abcg5 and abcg8, was strongly increased in the kidney, perhaps as a compensatory mechanism to upregulate efflux.  We found using immunohistochem. anal. clear localization of BCRP/ABCG2 to the proximal tubule brush border membrane of the human kidney comparable to that of other ABC transporters such as P-glycoprotein/ABCB1, MRP2/ABCC2, and MRP4/ABCC4.  Hoechst 33342 dye efflux from primary human proximal tubule cells was significantly reduced by the BCRP/ABCG2 inhibitors fumitremorgin C and nelfinavir.  Our study shows that in addn. to other apical ABC transporters, BCRP/ABCG2 may be important in renal drug excretion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpw55Qg1-1RxrVg90H21EOLACvtfcHk0lixf8BVKAo4zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVyltL7M&md5=2ae7bf9bd93b59bc2cab42a8101bbd11</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fsj.ki.5002645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.ki.5002645%26sid%3Dliteratum%253Aachs%26aulast%3DHuls%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DC.%2BD.%26aulast%3DWindass%26aufirst%3DA.%2BS.%26aulast%3DSayer%26aufirst%3DR.%26aulast%3Dvan%2Bden%2BHeuvel%26aufirst%3DJ.%2BJ.%26aulast%3DHeemskerk%26aufirst%3DS.%26aulast%3DRussel%26aufirst%3DF.%2BG.%26aulast%3DMasereeuw%26aufirst%3DR.%26atitle%3DThe%2520breast%2520cancer%2520resistance%2520protein%2520transporter%2520ABCG2%2520is%2520expressed%2520in%2520the%2520human%2520kidney%2520proximal%2520tubule%2520apical%2520membrane%26jtitle%3DKidney%2520Int.%26date%3D2008%26volume%3D73%26spage%3D220%26epage%3D225%26doi%3D10.1038%2Fsj.ki.5002645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koshiba, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakabayashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, T.</span></span> <span> </span><span class="NLM_article-title">Human ABC transporters ABCG2 (BCRP) and ABCG4</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">863</span>– <span class="NLM_lpage">888</span>, <span class="refDoi"> DOI: 10.1080/00498250801986944</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1080%2F00498250801986944" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=18668433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpt1Snurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2008&pages=863-888&author=S.+Koshibaauthor=R.+Anauthor=H.+Saitoauthor=K.+Wakabayashiauthor=A.+Tamuraauthor=T.+Ishikawa&title=Human+ABC+transporters+ABCG2+%28BCRP%29+and+ABCG4&doi=10.1080%2F00498250801986944"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Human ABC transporters ABCG2 (BCRP) and ABCG4</span></div><div class="casAuthors">Koshiba, S.; An, R.; Saito, H.; Wakabayashi, K.; Tamura, A.; Ishikawa, T.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">863-888</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The human ABC transporter ABCG2 is regarded as a member of the phase III system for xenobiotic metab., and it has been suggested that this efflux pump is responsible for protecting the body from toxic xenobiotics and for removing metabolites.  This review paper will address post-translational modifications (i.e., disulfide bond formation, ubiquitination, and endoplasmic reticulum-assocd. degrdn.) of the ABCG2 protein, high-speed screening, and quant. structure-activity relationship (QSAR) anal. to evaluate ABCG2-drug interactions, and genetic polymorphisms potentially assocd. with photosensitivity.  In addn., new aspects of human ABCG4 and mouse Abcg4 are presented with respect to their mol. properties and potential physiol. roles.  Considering the high sequence similarity between ABCG1 and ABCG4, both Abcg4 and ABCG4 may be involved in the transport of cholesterol from neurons and astrocytes.  Furthermore, high expression of the mouse Abcg4 protein in the testis implicates its involvement in transport of certain sex hormones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGputEgOyfcC_LVg90H21EOLACvtfcHk0lixf8BVKAo4zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpt1Snurg%253D&md5=9937f7ce8258b148975b76e429647cc0</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1080%2F00498250801986944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00498250801986944%26sid%3Dliteratum%253Aachs%26aulast%3DKoshiba%26aufirst%3DS.%26aulast%3DAn%26aufirst%3DR.%26aulast%3DSaito%26aufirst%3DH.%26aulast%3DWakabayashi%26aufirst%3DK.%26aulast%3DTamura%26aufirst%3DA.%26aulast%3DIshikawa%26aufirst%3DT.%26atitle%3DHuman%2520ABC%2520transporters%2520ABCG2%2520%2528BCRP%2529%2520and%2520ABCG4%26jtitle%3DXenobiotica%26date%3D2008%26volume%3D38%26spage%3D863%26epage%3D888%26doi%3D10.1080%2F00498250801986944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S. F.</span></span> <span> </span><span class="NLM_article-title">Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">802</span>– <span class="NLM_lpage">832</span>, <span class="refDoi"> DOI: 10.1080/00498250701867889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1080%2F00498250701867889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=18668431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpt1SnurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2008&pages=802-832&author=S.+F.+Zhou&title=Structure%2C+function+and+regulation+of+P-glycoprotein+and+its+clinical+relevance+in+drug+disposition&doi=10.1080%2F00498250701867889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition</span></div><div class="casAuthors">Zhou, S.-F.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">802-832</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  P-glycoprotein (P-gp/MDR1), one of the most clin. important transmembrane transporters in humans, is encoded by the ABCB1/MDR1 gene.  Recent insights into the structural features of P-gp/MDR1 enable a re-evaluation of the biochem. evidence on the binding and transport of drugs by P-gp/MDR1.  P-gp/MDR1 is found in various human tissues in addn. to being expressed in tumors cells.  It is located on the apical surface of intestinal epithelial cells, bile canaliculi, renal tubular cells, and placenta and the luminal surface of capillary endothelial cells in the brain and testes.  P-gp/MDR1 confers a multi-drug resistance (MDR) phenotype to cancer cells that have developed resistance to chemotherapy drugs.  P-gp/MDR1 activity is also of great clin. importance in non-cancer-related drug therapy due to its wide-ranging effects on the absorption and excretion of a variety of drugs.  P-gp/MDR1 excretes xenobiotics such as cytotoxic compds. into the gastrointestinal tract, bile and urine.  It also participates in the function of the blood-brain barrier.  One of the most interesting characteristics of P-gp/MDR1 is that its many substrates vary greatly in their structure and functionality, ranging from small mols. such as org. cations, carbohydrates, amino acids and some antibiotics to macromols. such as polysaccharides and proteins.  Quite a no. of single nucleotide polymorphisms have been found for the MDR1 gene.  These single nucleotide polymorphisms are assocd. with altered oral bioavailability of P-gp/MDR1 substrates, drug resistance, and a susceptibility to some human diseases.  Altered P-gp/MDR1 activity due to induction and/or inhibition can cause drug-drug interactions with altered drug pharmacokinetics and response.  Further studies are warranted to explore the physiol. function and pharmacol. role of P-gp/MDR1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMHCldae2e9rVg90H21EOLACvtfcHk0lixf8BVKAo4zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpt1SnurY%253D&md5=362c30e9c4fef1b58b1c7fd3ff55603d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1080%2F00498250701867889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00498250701867889%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DS.%2BF.%26atitle%3DStructure%252C%2520function%2520and%2520regulation%2520of%2520P-glycoprotein%2520and%2520its%2520clinical%2520relevance%2520in%2520drug%2520disposition%26jtitle%3DXenobiotica%26date%3D2008%26volume%3D38%26spage%3D802%26epage%3D832%26doi%3D10.1080%2F00498250701867889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphrey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warhurst, G.</span></span> <span> </span><span class="NLM_article-title">Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a (−/−) mice</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">2038</span>– <span class="NLM_lpage">2046</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0704668</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1038%2Fsj.bjp.0704668" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=11959808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD38Xjtlels7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2002&pages=2038-2046&author=R.+H.+Stephensauthor=C.+A.+O%E2%80%99Neillauthor=J.+Bennettauthor=M.+Humphreyauthor=B.+Henryauthor=M.+Rowlandauthor=G.+Warhurst&title=Resolution+of+P-glycoprotein+and+non-P-glycoprotein+effects+on+drug+permeability+using+intestinal+tissues+from+mdr1a+%28%E2%88%92%2F%E2%88%92%29+mice&doi=10.1038%2Fsj.bjp.0704668"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a (-/-) mice</span></div><div class="casAuthors">Stephens, R. H.; O'Neill, C. A.; Bennett, J.; Humphrey, M.; Henry, B.; Rowland, M.; Warhurst, G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2038-2046</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Intestinal xenobiotic transporters are a significant barrier to the absorption of many orally administered drugs.  P-glycoprotein (PGP) is the best known, but several others, including members of the multidrug resistance-assocd. protein (MRP) family, are also expressed.  Definitive information on their precise effect on intestinal drug permeability is scarce due to a lack of specific inhibitors and the difficulty of studying non-PGP activity in the presence of high PGP expression.  We have investigated the in vitro use of intestinal tissues from PGP knockout (mdr1a (-/-)) mice as a tool for dissecting the mechanisms of intestinal drug efflux.  The permeability characteristics of digoxin (DIG), paclitaxel (TAX) and etoposide (ETOP) were measured in ileum from mdr1a (-/-) and wild-type (FVB) mice mounted in Ussing chambers.  DIG and TAX exhibited marked efflux across FVB tissues (B-A:A-B apparent permeability (Papp) ratio 10 and 17 resp.) which was absent in mdr1a (-/-) tissues, confirming that PGP is the sole route of intestinal efflux for these compds.  The A-B Papp of both compds. was 3-5 fold higher in mdr1a (-/-) than in FVB.  Polarized transport of ETOP in FVB tissues was reduced but not abolished in mdr1a (-/-) tissues.  Residual ETOP efflux in mdr1a (-/-) tissues was abolished by the MRP inhibitor MK571, indicating involvement of both PGP and MRP.  MK571 abolished calcein efflux in mdr1a (-/-) tissues, while quinidine had no parallel effect in FVB tissues, suggesting involvement of MRP but not PGP.  Tissues from mdr1a (-/-) mice provide a novel approach for investigating the influence of PGP ablation on intestinal permeability and for resolving PGP and non-PGP mechanisms that modulate drug permeability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq1txHOVMhELVg90H21EOLACvtfcHk0lixf8BVKAo4zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xjtlels7o%253D&md5=3abb5edb89ca2ba6be17cf98002a1f97</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0704668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0704668%26sid%3Dliteratum%253Aachs%26aulast%3DStephens%26aufirst%3DR.%2BH.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DC.%2BA.%26aulast%3DBennett%26aufirst%3DJ.%26aulast%3DHumphrey%26aufirst%3DM.%26aulast%3DHenry%26aufirst%3DB.%26aulast%3DRowland%26aufirst%3DM.%26aulast%3DWarhurst%26aufirst%3DG.%26atitle%3DResolution%2520of%2520P-glycoprotein%2520and%2520non-P-glycoprotein%2520effects%2520on%2520drug%2520permeability%2520using%2520intestinal%2520tissues%2520from%2520mdr1a%2520%2528%25E2%2588%2592%252F%25E2%2588%2592%2529%2520mice%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2002%26volume%3D135%26spage%3D2038%26epage%3D2046%26doi%3D10.1038%2Fsj.bjp.0704668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takano, M.</span></span> <span> </span><span class="NLM_article-title">Intestinal efflux transporters and drug absorption</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">923</span>– <span class="NLM_lpage">939</span>, <span class="refDoi"> DOI: 10.1517/17425255.4.7.923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1517%2F17425255.4.7.923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=18624680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1cXos1Chur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=923-939&author=T.+Murakamiauthor=M.+Takano&title=Intestinal+efflux+transporters+and+drug+absorption&doi=10.1517%2F17425255.4.7.923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal efflux transporters and drug absorption</span></div><div class="casAuthors">Murakami, Teruo; Takano, Mikihisa</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">923-939</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The intestinal epithelial membrane expresses ATP-binding cassette (ABC) transporters such as P-glycoprotein (P-gp), multi-drug resistance-assocd. proteins (MRPs) and breast cancer resistance protein (BCRP), in addn. to various solute carrier (SLC) transporters.  These ABC transporters affect the oral bioavailability of their substrate drugs.  To review the contribution of ABC efflux transporters such as P-gp, MRP2, MRP3, and BCRP in the intestinal absorption of substrate drugs.  Discussion was made by focusing on the site-specific expression and function of these ABC transporters, and the soly. and permeability of their substrate compds.  The increase in the soly. and permeability of orally administered drugs could be the key to escape barrier function of ABC transporters, esp. P-gp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHGPw_FFSMp7Vg90H21EOLACvtfcHk0ljEUkKQ3OxbLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXos1Chur4%253D&md5=d14373b20de260afd5b94042f62dac3d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1517%2F17425255.4.7.923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.4.7.923%26sid%3Dliteratum%253Aachs%26aulast%3DMurakami%26aufirst%3DT.%26aulast%3DTakano%26aufirst%3DM.%26atitle%3DIntestinal%2520efflux%2520transporters%2520and%2520drug%2520absorption%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2008%26volume%3D4%26spage%3D923%26epage%3D939%26doi%3D10.1517%2F17425255.4.7.923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shugarts, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L. Z.</span></span> <span> </span><span class="NLM_article-title">The role of transporters in the pharmacokinetics of orally administered drugs</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2039</span>– <span class="NLM_lpage">2054</span>, <span class="refDoi"> DOI: 10.1007/s11095-009-9924-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1007%2Fs11095-009-9924-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=19568696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnvFKgu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2009&pages=2039-2054&author=S.+Shugartsauthor=L.+Z.+Benet&title=The+role+of+transporters+in+the+pharmacokinetics+of+orally+administered+drugs&doi=10.1007%2Fs11095-009-9924-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs</span></div><div class="casAuthors">Shugarts, Sarah; Benet, Leslie Z.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2039-2054</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Drug transporters are recognized as key players in the processes of drug absorption, distribution, metab., and elimination.  The localization of uptake and efflux transporters in organs responsible for drug biotransformation and excretion gives transporter proteins a unique gatekeeper function in controlling drug access to metabolizing enzymes and excretory pathways.  This review seeks to discuss the influence intestinal and hepatic drug transporters have on pharmacokinetic parameters, including bioavailability, exposure, clearance, vol. of distribution, and half-life, for orally dosed drugs.  This review also describes in detail the Biopharmaceutics Drug Disposition Classification System (BDDCS) and explains how many of the effects drug transporters exert on oral drug pharmacokinetic parameters can be predicted by this classification scheme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG3kU38e57LrVg90H21EOLACvtfcHk0ljEUkKQ3OxbLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnvFKgu7w%253D&md5=5fe75b8025fd8395a8cf722beaf6b62d</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs11095-009-9924-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-009-9924-0%26sid%3Dliteratum%253Aachs%26aulast%3DShugarts%26aufirst%3DS.%26aulast%3DBenet%26aufirst%3DL.%2BZ.%26atitle%3DThe%2520role%2520of%2520transporters%2520in%2520the%2520pharmacokinetics%2520of%2520orally%2520administered%2520drugs%26jtitle%3DPharm.%2520Res.%26date%3D2009%26volume%3D26%26spage%3D2039%26epage%3D2054%26doi%3D10.1007%2Fs11095-009-9924-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schinkel, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonker, J. W.</span></span> <span> </span><span class="NLM_article-title">Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/S0169-409X(02)00169-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1016%2FS0169-409X%2802%2900169-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=12535572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3sXivVWnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2003&pages=3-29&author=A.+H.+Schinkelauthor=J.+W.+Jonker&title=Mammalian+drug+efflux+transporters+of+the+ATP+binding+cassette+%28ABC%29+family%3A+an+overview&doi=10.1016%2FS0169-409X%2802%2900169-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview</span></div><div class="casAuthors">Schinkel, Alfred H.; Jonker, Johan W.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-29</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Active drug efflux transporters of the ATP binding cassette (ABC)-contg. family of proteins have a major impact on the pharmacol. behavior of most of the drugs in use today.  Pharmacol. properties affected by ABC transporters include the oral bioavailability, hepatobiliary, direct intestinal, and urinary excretion of drugs and drug-metabolites and -conjugates.  Moreover, the penetration of drugs into a range of important pharmacol. sanctuaries, such as brain, testis, and fetus, and the penetration into specific cell- and tissue compartments can be extensively limited by ABC transporters.  These interactions with ABC transporters det. to a large extent the clin. usefulness, side effects and toxicity risks of drugs.  Many other xenotoxins, (pre-)carcinogens and endogenous compds. are also influenced by the ABC transporters, with corresponding consequences for the well-being of the individual.  We aim to provide an overview of properties of the mammalian ABC transporters known to mediate significant transport of clin. relevant drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaUGQEMir1wbVg90H21EOLACvtfcHk0lieeqioKDqdOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXivVWnsQ%253D%253D&md5=e5edc6f3a530eab7868e7eb245849c12</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2802%2900169-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252802%252900169-2%26sid%3Dliteratum%253Aachs%26aulast%3DSchinkel%26aufirst%3DA.%2BH.%26aulast%3DJonker%26aufirst%3DJ.%2BW.%26atitle%3DMammalian%2520drug%2520efflux%2520transporters%2520of%2520the%2520ATP%2520binding%2520cassette%2520%2528ABC%2529%2520family%253A%2520an%2520overview%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2003%26volume%3D55%26spage%3D3%26epage%3D29%26doi%3D10.1016%2FS0169-409X%2802%2900169-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinkel, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">923</span>– <span class="NLM_lpage">928</span>, <span class="refDoi"> DOI: 10.1124/mol.104.007393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fmol.104.007393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=15598971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitlaqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2005&pages=923-928&author=Y.+Adachiauthor=H.+Suzukiauthor=A.+H.+Schinkelauthor=Y.+Sugiyama&title=Role+of+breast+cancer+resistance+protein+%28Bcrp1%2FAbcg2%29+in+the+extrusion+of+glucuronide+and+sulfate+conjugates+from+enterocytes+to+intestinal+lumen&doi=10.1124%2Fmol.104.007393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen</span></div><div class="casAuthors">Adachi, Yasuhisa; Suzuki, Hiroshi; Schinkel, Alfred H.; Sugiyama, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">923-928</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The purpose of this study is to examine the significance of efflux transporters in the small intestine to extrude glucuronide (G) and sulfate (S) conjugates into the intestinal lumen.  From this standpoint, we performed in situ intestinal perfusion expts. by using Eisai hyperbilirubinemic rats (EHBRs) in which the multidrug resistance protein 2 (Mrp2/Abcc2) is hereditarily defective and breast cancer resistance protein (Bcrp1/Abcg2) knockout mice.  The intestinal lumen of EHBRs and Bcrp1 (-/-) mice was perfused with medium contg. 4-methylumbelliferone (4MU) and E3040 [6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole] to det. the efflux of metabolites into the outflow.  The efflux of E3040-glucuronide (G) in EHBRs was significantly lower compared with that in normal rats.  However, no significant difference was obsd. for the efflux of 4MU-G, 4MU-sulfate (S), and E3040-S between EHBRs and normal rats.  In contrast, the efflux of intracellularly formed 4MU-G, 4MU-S, and E3040-G in Bcrp1 (-/-) mice was significantly lower than that in normal mice.  Therefore, Bcrp1 has an important role in extruding glucuronide and sulfate conjugates formed in enterocytes into the intestinal lumen, whereas Mrp2 is responsible for the efflux of some glucuronide conjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwHRlDYS21yrVg90H21EOLACvtfcHk0lieeqioKDqdOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitlaqtr8%253D&md5=d3ce43c29e9ad822bf60ace06127e8fe</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1124%2Fmol.104.007393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.104.007393%26sid%3Dliteratum%253Aachs%26aulast%3DAdachi%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DH.%26aulast%3DSchinkel%26aufirst%3DA.%2BH.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DRole%2520of%2520breast%2520cancer%2520resistance%2520protein%2520%2528Bcrp1%252FAbcg2%2529%2520in%2520the%2520extrusion%2520of%2520glucuronide%2520and%2520sulfate%2520conjugates%2520from%2520enterocytes%2520to%2520intestinal%2520lumen%26jtitle%3DMol.%2520Pharmacol.%26date%3D2005%26volume%3D67%26spage%3D923%26epage%3D928%26doi%3D10.1124%2Fmol.104.007393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, R. B.</span></span> <span> </span><span class="NLM_article-title">Transporters and drug therapy: implications for drug disposition and disease</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">260</span>– <span class="NLM_lpage">277</span>, <span class="refDoi"> DOI: 10.1016/j.clpt.2005.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1016%2Fj.clpt.2005.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=16153397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvV2rt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2005&pages=260-277&author=R.+H.+Hoauthor=R.+B.+Kim&title=Transporters+and+drug+therapy%3A+implications+for+drug+disposition+and+disease&doi=10.1016%2Fj.clpt.2005.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Transporters and drug therapy: Implications for drug disposition and disease</span></div><div class="casAuthors">Ho, Richard H.; Kim, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">260-277</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The efficacy of drug therapy results from the complex interplay of multiple processes that govern drug disposition and response.  Most studies to date have focused on the contribution of drug-metabolizing enzymes to the drug disposition process.  However, over the past decade, it has become increasingly apparent that carrier-mediated processes, or transporters, also play crit. roles in the overall disposition of numerous drugs in clin. use.  In addn. to their roles in xenobiotic transport, drug transporters often mediate important physiol. functions via transport of endogenous substrates such as amino acids, bile acids, and hormones that are crit. for maintenance of normal homeostasis.  In this review we focus on the emerging field of transporter proteins in relation to the drug disposition process, with particular emphasis on clin. implications of transporters to drug-drug interactions and subsequent development of adverse effects, interindividual variability in drug response, and human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp32hrC_dzQUrVg90H21EOLACvtfcHk0lieeqioKDqdOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvV2rt78%253D&md5=a2d08e434c1e8ba795f0ae15c463b619</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.clpt.2005.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clpt.2005.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DR.%2BH.%26aulast%3DKim%26aufirst%3DR.%2BB.%26atitle%3DTransporters%2520and%2520drug%2520therapy%253A%2520implications%2520for%2520drug%2520disposition%2520and%2520disease%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2005%26volume%3D78%26spage%3D260%26epage%3D277%26doi%3D10.1016%2Fj.clpt.2005.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusuhara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans</span>. <i>J. Pharmacokinet. Pharmacodyn.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">590</span>, <span class="refDoi"> DOI: 10.1007/s10928-010-9176-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1007%2Fs10928-010-9176-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=21063755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2gurnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2010&pages=575-590&author=T.+Watanabeauthor=H.+Kusuharaauthor=Y.+Sugiyama&title=Application+of+physiologically+based+pharmacokinetic+modeling+and+clearance+concept+to+drugs+showing+transporter-mediated+distribution+and+clearance+in+humans&doi=10.1007%2Fs10928-010-9176-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans</span></div><div class="casAuthors">Watanabe, Takao; Kusuhara, Hiroyuki; Sugiyama, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacokinetics and Pharmacodynamics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">575-590</span>CODEN:
                <span class="NLM_cas:coden">JPPOAH</span>;
        ISSN:<span class="NLM_cas:issn">1567-567X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">This review illustrates the concept of a rate-detg. process in the overall hepatic elimination of anionic drugs that involves transporters in the uptake process.  A kinetic study in rats has demonstrated that uptake is the rate-detg. process for most anionic drugs, and this is likely to hold true for the hepatic elimination of statins in humans.  To simulate the effects of variations in the transporter activities on systemic and liver exposure, a physiol. based pharmacokinetic model was constructed for pravastatin, the overall elimination of which involves OATP1B1 and MRP2 in the hepatic uptake and canalicular efflux, resp.  The plasma concns. of pravastatin in humans were successfully reproduced using the kinetic parameters extrapolated from in vitro data obtained using human hepatocytes and canalicular membrane vesicles and the scaling factors detd. in rats.  Sensitivity analyses showed that a variation in hepatic uptake altered the plasma concn. of pravastatin markedly, but had a small effect on the liver concn., and vice versa for the canalicular efflux.  Therefore, variation in the OATP1B1 activities will have small and large impacts on the therapeutic efficacy and adverse effect (myopathy) of pravastatin, resp., whereas that affecting the MRP2 activities may have an opposite effect (i.e., large and small impacts on the therapeutic efficacy and side effect).  This pharmacokinetic characteristics likely hold true for other anionic statins, i.e., variation of OATP1B1 is assocd. with the risk of adverse reactions, whereas that of sequestration mechanisms causes the variation of their pharmacol. effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDZdm25H13LbVg90H21EOLACvtfcHk0lieeqioKDqdOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2gurnN&md5=2e49d2767ec5aad2135dc7127ae84726</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2Fs10928-010-9176-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10928-010-9176-y%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DKusuhara%26aufirst%3DH.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DApplication%2520of%2520physiologically%2520based%2520pharmacokinetic%2520modeling%2520and%2520clearance%2520concept%2520to%2520drugs%2520showing%2520transporter-mediated%2520distribution%2520and%2520clearance%2520in%2520humans%26jtitle%3DJ.%2520Pharmacokinet.%2520Pharmacodyn.%26date%3D2010%26volume%3D37%26spage%3D575%26epage%3D590%26doi%3D10.1007%2Fs10928-010-9176-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fenner, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempshall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, H. A.</span></span> <span> </span><span class="NLM_article-title">The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.3109/00498254.2011.626464</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.3109%2F00498254.2011.626464" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=22077101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFKgtbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2012&pages=28-45&author=K.+S.+Fennerauthor=H.+M.+Jonesauthor=M.+Ullahauthor=S.+Kempshallauthor=M.+Dickinsauthor=Y.+Laiauthor=P.+Morganauthor=H.+A.+Barton&title=The+evolution+of+the+OATP+hepatic+uptake+transport+protein+family+in+DMPK+sciences%3A+from+obscure+liver+transporters+to+key+determinants+of+hepatobiliary+clearance&doi=10.3109%2F00498254.2011.626464"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance</span></div><div class="casAuthors">Fenner, Katherine S.; Jones, Hannah M.; Ullah, Mohammed; Kempshall, Sarah; Dickins, Maurice; Lai, Yurong; Morgan, Paul; Barton, Hugh A.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-45</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Over the last two decades the impact on drug pharmacokinetics of the org. anion transporting polypeptides (OATPs: OATP-1B1, 1B3 and 2B1), expressed on the sinusoidal membrane of the hepatocyte, has been increasingly recognized.  OATP-mediated uptake into the hepatocyte coupled with subsequent excretion into bile via efflux proteins, such as MRP2, is often referred to as hepatobiliary excretion.  OATP transporter proteins can impact some drugs in several ways including pharmacokinetic variability, pharmacodynamic response and drug-drug interactions (DDIs).  The impact of transporter mediated hepatic clearance is illustrated with case examples, from the literature and also from the Pfizer portfolio.  The currently available in vitro techniques to study the hepatic transporter proteins involved in the hepatobiliary clearance of drugs are reviewed herein along with recent advances in using these in vitro data to predict the human clearance of compds. recognized by hepatic uptake transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKl9Q265UcjrVg90H21EOLACvtfcHk0lh8nGJoLbiZLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFKgtbvK&md5=869e56bc156cb5a548b2cf2135dba562</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.3109%2F00498254.2011.626464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498254.2011.626464%26sid%3Dliteratum%253Aachs%26aulast%3DFenner%26aufirst%3DK.%2BS.%26aulast%3DJones%26aufirst%3DH.%2BM.%26aulast%3DUllah%26aufirst%3DM.%26aulast%3DKempshall%26aufirst%3DS.%26aulast%3DDickins%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DMorgan%26aufirst%3DP.%26aulast%3DBarton%26aufirst%3DH.%2BA.%26atitle%3DThe%2520evolution%2520of%2520the%2520OATP%2520hepatic%2520uptake%2520transport%2520protein%2520family%2520in%2520DMPK%2520sciences%253A%2520from%2520obscure%2520liver%2520transporters%2520to%2520key%2520determinants%2520of%2520hepatobiliary%2520clearance%26jtitle%3DXenobiotica%26date%3D2012%26volume%3D42%26spage%3D28%26epage%3D45%26doi%3D10.3109%2F00498254.2011.626464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gotoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirohashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>292</i></span>,  <span class="NLM_fpage">433</span>– <span class="NLM_lpage">439</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10604980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhslGqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2000&pages=433-439&author=Y.+Gotohauthor=H.+Suzukiauthor=S.+Kinoshitaauthor=T.+Hirohashiauthor=Y.+Katoauthor=Y.+Sugiyama&title=Involvement+of+an+organic+anion+transporter+%28canalicular+multispecific+organic+anion+transporter%2Fmultidrug+resistance-associated+protein+2%29+in+gastrointestinal+secretion+of+glutathione+conjugates+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats</span></div><div class="casAuthors">Gotoh, Yasumasa; Suzuki, Hiroshi; Kinoshita, Setsuo; Hirohashi, Tomoko; Kato, Yukio; Sugiyama, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">433-439</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We investigated the role of cMOAT/MRP2 (canalicular multispecific org. anion transporter/multidrug resistance-assocd. protein 2) in the intestinal secretion of org. anions by comparing the behavior in Sprague-Dawley (SD) rats and Eisai hyperbilirubinemic rat (EHBR) whose cMOAT/MRP2 is hereditarily defective.  After i.v. administration of 1-chloro-2,4-dinitrobenzene (30 μmol/kg), the biliary and intestinal excretion of its glutathione conjugate 2,4-dinitrophenyl-S-glutathione (DNP-SG), a substrate for cMOAT/MRP2, was significantly reduced in EHBR compared with SD rats.  This result also was confirmed by Ussing chamber studies; DNP-SG showed 1.5-fold greater serosal-to-mucosal flux compared with the mucosal-to-serosal flux in SD rats, whereas a similar flux was obsd. in both directions in EHBR.  In addn., metabolic inhibitors reduced the preferential serosal-to-mucosal flux of DNP-SG in SD rats.  In everted sac studies, intestinal secretion clearance, defined as the efflux rate of DNP-SG into the mucosal side divided by the area under the curve on the serosal side, was significantly lower in the jejunum of EHBR than that in SD rats.  Northern blot analyses demonstrated the highest mRNA level of cMOAT/MRP2 in the jejunum, which is in good agreement with the results of the everted sac studies.  These results suggest that cMOAT/MRP2 is involved in the secretion of org. anions in the small intestine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFEdUUlQ4atrVg90H21EOLACvtfcHk0lh8nGJoLbiZLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhslGqtg%253D%253D&md5=390a160e5e02cab9168d93c6b795e496</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGotoh%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DH.%26aulast%3DKinoshita%26aufirst%3DS.%26aulast%3DHirohashi%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DInvolvement%2520of%2520an%2520organic%2520anion%2520transporter%2520%2528canalicular%2520multispecific%2520organic%2520anion%2520transporter%252Fmultidrug%2520resistance-associated%2520protein%25202%2529%2520in%2520gastrointestinal%2520secretion%2520of%2520glutathione%2520conjugates%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2000%26volume%3D292%26spage%3D433%26epage%3D439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mottino, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vore, M.</span></span> <span> </span><span class="NLM_article-title">Expression and localization of multidrug resistant protein mrp2 in rat small intestine</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>293</i></span>,  <span class="NLM_fpage">717</span>– <span class="NLM_lpage">723</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10869369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjsleksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2000&pages=717-723&author=A.+D.+Mottinoauthor=T.+Hoffmanauthor=L.+Jennesauthor=M.+Vore&title=Expression+and+localization+of+multidrug+resistant+protein+mrp2+in+rat+small+intestine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Expression and localization of multidrug resistant protein mrp2 in rat small intestine</span></div><div class="casAuthors">Mottino, Aldo D.; Hoffman, Tim; Jennes, Lothar; Vore, Mary</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">293</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">717-723</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The expression of multidrug resistance-assocd. protein isoform 2 (mrp2), the ATP-dependent export pump that mediates the transport of glucuronic acid-, glutathione-, and sulfate-conjugated derivs., was studied in rat small intestine.  The small intestine was divided into 9 equal segments, and the mrp2 content was analyzed in homogenate and brush border membrane prepns. by Western anal.  The mrp2 protein was present mainly in brush border membrane of the proximal segments and gradually decreased from jejunum to the distal ileum.  The authors also analyzed the content of mrp2 in 3 different populations of proximal enterocytes obtained from the upper and lower villus and the crypt regions.  The export pump was mainly expressed in the villus cells and to a lesser degree in the crypt cells of the epithelium.  Immunohistochem. anal. performed in duodenum, jejunum, and ileum confirmed in situ the Western blot findings.  Anal. of mRNA encoding mrp2 in proximal and distal segments revealed a similar content in both regions, whereas distribution along the villus-crypt axis was similar to the protein gradient.  Because conjugating enzymes were distributed similarly to mrp2, it was concluded that they may act coordinately to contribute to 1st-pass metab. of drugs and other xenobiotics in the proximal small intestine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFh-wvB6pHmbVg90H21EOLACvtfcHk0lh8nGJoLbiZLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjsleksrY%253D&md5=1b7af5c9d564f1dcc29d928fa7361143</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMottino%26aufirst%3DA.%2BD.%26aulast%3DHoffman%26aufirst%3DT.%26aulast%3DJennes%26aufirst%3DL.%26aulast%3DVore%26aufirst%3DM.%26atitle%3DExpression%2520and%2520localization%2520of%2520multidrug%2520resistant%2520protein%2520mrp2%2520in%2520rat%2520small%2520intestine%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2000%26volume%3D293%26spage%3D717%26epage%3D723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mouly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paine, M. F.</span></span> <span> </span><span class="NLM_article-title">P-glycoprotein increases from proximal to distal regions of human small intestine</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1595</span>– <span class="NLM_lpage">1599</span>, <span class="refDoi"> DOI: 10.1023/A:1026183200740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1023%2FA%3A1026183200740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=14620513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotFClsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2003&pages=1595-1599&author=S.+Moulyauthor=M.+F.+Paine&title=P-glycoprotein+increases+from+proximal+to+distal+regions+of+human+small+intestine&doi=10.1023%2FA%3A1026183200740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">P-Glycoprotein Increases from Proximal to Distal Regions of Human Small Intestine</span></div><div class="casAuthors">Mouly, Stephane; Paine, Mary F.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1595-1599</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic/Plenum Publishers</span>)
        </div><div class="casAbstract">The contribution of the efflux transporter P-glycoprotein (P-gp) as a barrier to drug absorption may depend on its level of expression at the site of absorption.  Accordingly, the distribution of P-gp was examd. along the entire length of the human small intestine.  Homogenates prepd. from mucosal scrapings from every other 30-cm segment of 4 unrelated human donor small intestines were analyzed for P-gp and the control protein villin by Western blot.  In each donor intestine, relative P-gp expression (P-gp/villin integrated optical d. ratio) progressively increased from proximal to distal regions.  Among individuals, relative P-gp levels varied 2.1-fold in the duodenal/proximal jejunal region, 1.5- to 2.0-fold in the middle/distal jejunal region, and 1.2- to 1.9-fold in the ileal region.  Within-donor variation was somewhat greater, from 1.5- to 3.0-fold.  These results provide further evidence that the site of absorption can represent another source for the interindividual variation in the oral bioavailability of drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF7jGQikX3P7Vg90H21EOLACvtfcHk0li_jgZtorIgXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotFClsrY%253D&md5=3669fdd5bcada5d89d6dc3ccdadc1c3b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1023%2FA%3A1026183200740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1026183200740%26sid%3Dliteratum%253Aachs%26aulast%3DMouly%26aufirst%3DS.%26aulast%3DPaine%26aufirst%3DM.%2BF.%26atitle%3DP-glycoprotein%2520increases%2520from%2520proximal%2520to%2520distal%2520regions%2520of%2520human%2520small%2520intestine%26jtitle%3DPharm.%2520Res.%26date%3D2003%26volume%3D20%26spage%3D1595%26epage%3D1599%26doi%3D10.1023%2FA%3A1026183200740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Englund, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rorsman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronnblom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlbom, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazorova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasjo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindmark, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span> <span> </span><span class="NLM_article-title">Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">277</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2006.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1016%2Fj.ejps.2006.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=16822659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFentr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2006&pages=269-277&author=G.+Englundauthor=F.+Rorsmanauthor=A.+Ronnblomauthor=U.+Karlbomauthor=L.+Lazorovaauthor=J.+Grasjoauthor=A.+Kindmarkauthor=P.+Artursson&title=Regional+levels+of+drug+transporters+along+the+human+intestinal+tract%3A+co-expression+of+ABC+and+SLC+transporters+and+comparison+with+Caco-2+cells&doi=10.1016%2Fj.ejps.2006.04.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells</span></div><div class="casAuthors">Englund, Gunilla; Rorsman, Fredrik; Roennblom, Anders; Karlbom, Urban; Lazorova, Lucia; Grasjoe, Johan; Kindmark, Andreas; Artursson, Per</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">269-277</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A vast no. of drugs are subjected to active or facilitated transport and multiple transport mechanism may contribute to the net flux during drug absorption.  The main objective of this study was to quantify the regional mRNA expression and det. the co-expression of drug transporters from the ABC (Pgp, BCRP, MRP2, MRP3) and SLC (PEPT1, MCT1, OATPB, OCTN2, OCT1) families along the human intestine (duodenum, jejunum, ileum, and colon).  A second objective was to compare the transporter expression between the different intestinal regions and Caco-2 cells.  Eight out of nine of the investigated transporters exhibited significant regional differences in expression.  OATPB was the only transporter that did not show a region-dependency in the expression along the human intestinal canal.  The expression of Pgp, BCRP, OCTN2 and MCT1 differed along the small intestine, but the expression differences were greater than five-fold only for Pgp.  The rank order of transcript prevalence was identical in the ileum and the jejunum.  Between the ileum and colon, seven transcripts were differentially expressed, and MCT1, OCTN2 and MRP3 were expressed at higher levels in the colon than in the small intestine.  The expression of transporters in Caco-2 was closest to the expression pattern in the small intestine, although the expression of OATPB, BCRP and MRP2 differed more than five-fold between the Caco-2 cells and ileum.  In conclusion, this study provides quant. data on the expression of transporters from the ABC and SLC families along the human intestine, which can be useful in the interpretation of clin. studies where more than one intestinal transporter contribute to the net transport and in the computer modeling of drug absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJACMwULElcLVg90H21EOLACvtfcHk0li_jgZtorIgXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFentr3E&md5=093c6e8695f07b3ad39398731e368d55</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2006.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2006.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DEnglund%26aufirst%3DG.%26aulast%3DRorsman%26aufirst%3DF.%26aulast%3DRonnblom%26aufirst%3DA.%26aulast%3DKarlbom%26aufirst%3DU.%26aulast%3DLazorova%26aufirst%3DL.%26aulast%3DGrasjo%26aufirst%3DJ.%26aulast%3DKindmark%26aufirst%3DA.%26aulast%3DArtursson%26aufirst%3DP.%26atitle%3DRegional%2520levels%2520of%2520drug%2520transporters%2520along%2520the%2520human%2520intestinal%2520tract%253A%2520co-expression%2520of%2520ABC%2520and%2520SLC%2520transporters%2520and%2520comparison%2520with%2520Caco-2%2520cells%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2006%26volume%3D29%26spage%3D269%26epage%3D277%26doi%3D10.1016%2Fj.ejps.2006.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Enokizono, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusuhara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Regional expression and activity of breast cancer resistance protein (Bcrp/Abcg2) in mouse intestine: overlapping distribution with sulfotransferases</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">922</span>– <span class="NLM_lpage">928</span>, <span class="refDoi"> DOI: 10.1124/dmd.106.011239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.106.011239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=17353350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmt1aitLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=922-928&author=J.+Enokizonoauthor=H.+Kusuharaauthor=Y.+Sugiyama&title=Regional+expression+and+activity+of+breast+cancer+resistance+protein+%28Bcrp%2FAbcg2%29+in+mouse+intestine%3A+overlapping+distribution+with+sulfotransferases&doi=10.1124%2Fdmd.106.011239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Regional expression and activity of breast cancer resistance protein (Bcrp/Abcg2) in mouse intestine: overlapping distribution with sulfotransferases</span></div><div class="casAuthors">Enokizono, Junichi; Kusuhara, Hiroyuki; Sugiyama, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">922-928</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Breast cancer resistance protein (Bcrp/Abcg2) is a member of the ATP-binding cassette transporter family with the ability to transport a variety of sulfate conjugates.  In the present study, the regional expression and activity of Bcrp and sulfotransferases (SULTs/Sults) were investigated in mouse intestine.  Western blotting anal. revealed the highest expression of Bcrp in the ileum over the duodenum, jejunum, and colon.  Functional anal. of Bcrp was performed in everted intestinal sacs using 4-methylumbelliferone (4MU).  The mucosal secretion clearance of 4MU sulfate formed in the enterocytes was markedly reduced in the jejunum, ileum, and colon of Bcrp (-/-) mice in comparison with wild-type mice, whereas a slight and nonsignificant redn. was obsd. in the duodenum.  The redn. in the mucosal secretion clearance was most marked in the ileum followed by the colon and jejunum.  In addn., the mucosal secretion clearance of minoxidil sulfate, an active metabolite of minoxidil, was also significantly reduced in the intestine of Bcrp (-/-) mice.  The sulfation activity of 4MU was higher in the colon than in the small intestine where glucuronidation activity was somewhat higher than the sulfation activity.  Real-time polymerase chain reaction anal. showed that the expression of sulfotransferases, such as Sult1a1/2, Sult1b1, and Sult1d1, was also highest in the colon.  These results suggest that Bcrp activity is higher in the mid to lower intestine and that the cooperation of Bcrp and SULT provides an important detoxification pathway, particularly in the colon.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2z118DQNnDbVg90H21EOLACvtfcHk0li_jgZtorIgXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmt1aitLg%253D&md5=863ee317f6eafa5704da37590cdcf664</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1124%2Fdmd.106.011239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.106.011239%26sid%3Dliteratum%253Aachs%26aulast%3DEnokizono%26aufirst%3DJ.%26aulast%3DKusuhara%26aufirst%3DH.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DRegional%2520expression%2520and%2520activity%2520of%2520breast%2520cancer%2520resistance%2520protein%2520%2528Bcrp%252FAbcg2%2529%2520in%2520mouse%2520intestine%253A%2520overlapping%2520distribution%2520with%2520sulfotransferases%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2007%26volume%3D35%26spage%3D922%26epage%3D928%26doi%3D10.1124%2Fdmd.106.011239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hilgendorf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahlin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seithel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungell, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, J.</span></span> <span> </span><span class="NLM_article-title">Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1333</span>– <span class="NLM_lpage">1340</span>, <span class="refDoi"> DOI: 10.1124/dmd.107.014902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.107.014902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=17496207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVKqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=1333-1340&author=C.+Hilgendorfauthor=G.+Ahlinauthor=A.+Seithelauthor=P.+Arturssonauthor=A.+L.+Ungellauthor=J.+Karlsson&title=Expression+of+thirty-six+drug+transporter+genes+in+human+intestine%2C+liver%2C+kidney%2C+and+organotypic+cell+lines&doi=10.1124%2Fdmd.107.014902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines</span></div><div class="casAuthors">Hilgendorf, Constanze; Ahlin, Gustav; Seithel, Annick; Artursson, Per; Ungell, Anna-Lena; Karlsson, Johan</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1333-1340</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">This study was designed to quant. assess the mRNA expression of 36 important drug transporters in human jejunum, colon, liver, and kidney.  Expression of these transporters in human organs was compared with expression in commonly used cell lines (Caco-2, HepG2, and Caki-1) originating from these organs to assess their value as in vitro transporter system models, and was also compared with data obtained from the literature on expression in rat tissues to assess species differences.  Transporters that were highly expressed in the intestine included HPT1, PEPT1, BCRP, MRP2, and MDR1, whereas, in the liver, OCT1, MRP2, OATP-C, NTCP and BSEP were the main transporters.  In the kidney, OAT1 was expressed at the highest levels, followed by OAT3, OAT4, MCT5, MDR1, MRP2, OCT2, and OCTN2.  The best agreement between human tissue and the representative cell line was obsd. for human jejunum and Caco-2 cells.  Expression in liver and kidney orthol. cell lines was not correlated with that in the assocd. tissue.  Comparisons with rat transporter gene expression revealed significant species differences.  Our results allowed a comprehensive quant. comparison of drug transporter expression in human intestine, liver, and kidney.  We suggest that it would be beneficial for predictive pharmacokinetic research to focus on the most highly expressed transporters.  We hope that our comparison of rat and human tissue will help to explain the obsd. species differences in in vivo models, increase understanding of the impact of active transport processes on pharmacokinetics and distribution, and improve the quality of predictions from animal studies to humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC3qvmG8tTf7Vg90H21EOLACvtfcHk0lh6co9CsRc6EQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVKqtbg%253D&md5=edfef89a8c422dbdcc0a097425b2ad2e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1124%2Fdmd.107.014902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.107.014902%26sid%3Dliteratum%253Aachs%26aulast%3DHilgendorf%26aufirst%3DC.%26aulast%3DAhlin%26aufirst%3DG.%26aulast%3DSeithel%26aufirst%3DA.%26aulast%3DArtursson%26aufirst%3DP.%26aulast%3DUngell%26aufirst%3DA.%2BL.%26aulast%3DKarlsson%26aufirst%3DJ.%26atitle%3DExpression%2520of%2520thirty-six%2520drug%2520transporter%2520genes%2520in%2520human%2520intestine%252C%2520liver%252C%2520kidney%252C%2520and%2520organotypic%2520cell%2520lines%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2007%26volume%3D35%26spage%3D1333%26epage%3D1340%26doi%3D10.1124%2Fdmd.107.014902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moenning, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fricker, G.</span></span> <span> </span><span class="NLM_article-title">Closing the gaps: a full scan of the intestinal expression of p-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in male and female rats</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1249</span>– <span class="NLM_lpage">1254</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.020859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.108.020859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=18378562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotVegurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=1249-1254&author=C.+MacLeanauthor=U.+Moenningauthor=A.+Reichelauthor=G.+Fricker&title=Closing+the+gaps%3A+a+full+scan+of+the+intestinal+expression+of+p-glycoprotein%2C+breast+cancer+resistance+protein%2C+and+multidrug+resistance-associated+protein+2+in+male+and+female+rats&doi=10.1124%2Fdmd.108.020859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Closing the gaps: a full scan of the intestinal expression of P-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in male and female rats</span></div><div class="casAuthors">MacLean, Caroline; Moenning, Ulla; Reichel, Andreas; Fricker, Gert</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1249-1254</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Intestinal ATP binding cassette (ABC) transporters may affect the bioavailability and effectiveness of orally administered drugs.  Available studies on regional expression of intestinal efflux transporters were done with selected intestinal segments only and inconsistent with regard to the variability of transporter expression and the course of expression along the intestine.  For an evaluation of the consistency between mRNA and protein expression, relative expression levels of P-glycoprotein (Pgp; ABCB1), breast cancer resistance protein (Bcrp; ABCG2), and multidrug resistance-assocd. protein (Mrp) 2 (ABCC2) were detd. using quant. real-time-polymerase chain reaction and Western blot in rat intestinal segments from duodenum, jejunum, ileum, and colon.  In addn., the protein expression of Pgp, Bcrp, and Mrp2 from the entire rat intestine was studied by a complete 3-cm segmentation to evaluate the predictive power of expression analyses from selected intestinal segments.  Pgp showed an increase from proximal to distal regions, Bcrp showed an arcuate pattern with highest expression toward the end of small intestine, and Mrp2 decreased along the intestinal axis from proximal to distal parts.  No gender specific differences could be obsd.  Regarding the concordance of mRNA and protein expression, Pgp and Bcrp mRNA samples allow good estns. about the corresponding protein expression (for Pgp limited to the mdr1a isoform), but for Mrp2, pronounced deviation could be obsd.  All transporters showed considerable intra- and interindividual variability, esp. at the protein level, making it problematic to take transporter expressions of small sections exemplary for general assumptions on intestinal abundances.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZE4PQg_IZvLVg90H21EOLACvtfcHk0lh6co9CsRc6EQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotVegurk%253D&md5=fd2d9a1e1cdd9cdaa575928a1fa3e7d2</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.020859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.020859%26sid%3Dliteratum%253Aachs%26aulast%3DMacLean%26aufirst%3DC.%26aulast%3DMoenning%26aufirst%3DU.%26aulast%3DReichel%26aufirst%3DA.%26aulast%3DFricker%26aufirst%3DG.%26atitle%3DClosing%2520the%2520gaps%253A%2520a%2520full%2520scan%2520of%2520the%2520intestinal%2520expression%2520of%2520p-glycoprotein%252C%2520breast%2520cancer%2520resistance%2520protein%252C%2520and%2520multidrug%2520resistance-associated%2520protein%25202%2520in%2520male%2520and%2520female%2520rats%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26spage%3D1249%26epage%3D1254%26doi%3D10.1124%2Fdmd.108.020859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haslam, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Reilly, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherlock, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, N. L.</span></span> <span> </span><span class="NLM_article-title">Intestinal ciprofloxacin efflux: the role of breast cancer resistance protein (ABCG2)</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">2321</span>– <span class="NLM_lpage">2328</span>, <span class="refDoi"> DOI: 10.1124/dmd.111.038323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.111.038323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=21930826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCru77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=2321-2328&author=I.+S.+Haslamauthor=J.+A.+Wrightauthor=D.+A.+O%E2%80%99Reillyauthor=D.+J.+Sherlockauthor=T.+Colemanauthor=N.+L.+Simmons&title=Intestinal+ciprofloxacin+efflux%3A+the+role+of+breast+cancer+resistance+protein+%28ABCG2%29&doi=10.1124%2Fdmd.111.038323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal ciprofloxacin efflux: the role of breast cancer resistance protein (ABCG2)</span></div><div class="casAuthors">Haslam, I. S.; Wright, J. A.; O'Reilly, D. A.; Sherlock, D. J.; Coleman, T.; Simmons, N. L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2321-2328</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Intestinal secretory movement of the fluoroquinolone antibiotic, ciprofloxacin, may limit its oral bioavailability.  Active ATP-binding cassette (ABC) transporters such as breast cancer resistance protein (BCRP) have been implicated in ciprofloxacin transport.  The aim of this study was to test the hypothesis that BCRP alone mediates intestinal ciprofloxacin secretion.  The involvement of ABC transport proteins in ciprofloxacin secretory flux was investigated with the combined use of transfected cell lines [bcrp1/BCRP-Madin-Darby canine kidney II (MDCKII) and multidrug resistance-related protein 4 (MRP4)-human embryonic kidney (HEK) 293] and human intestinal Caco-2 cells, combined with pharmacol. inhibition using 3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6, 7,12,12a-octahydropyrazino[1',2':1,6]pyrido[3,4-b]indol-3-yl)-propionic acid tert-Bu ester (Ko143), cyclosporine, 3-[[3-[2-(7-chloroquinolin-2-yl)vinyl]phenyl]-(2-dimethylcarbamoylethylsulfanyl)methylsulfanyl] propionic acid (MK571), and verapamil as ABC-selective inhibitors.  In addn., the regional variation in secretory capacity was investigated using male Han Wistar rat intestine mounted in Ussing chambers, and the first indicative measurements of ciprofloxacin transport by ex vivo human jejunum were made.  Active, Ko143-sensitive ciprofloxacin secretion was obsd. in bcrp1-MDCKII cell layers, but in low-passage (BCRP-expressing) Caco-2 cell layers only a 54% fraction was Ko143-sensitive.  Ciprofloxacin accumulation was lower in MRP4-HEK293 cells than in the parent line, indicating that ciprofloxacin is also a substrate for this transporter.  Ciprofloxacin secretion by Caco-2 cell layers was not inhibited by MK571.  Secretory flux showed marked regional variability in the rat intestine, increasing from the duodenum to peak in the ileum.  Ciprofloxacin secretion was present in human jejunum and was reduced by Ko143 but showed marked interindividual variability.  Ciprofloxacin is a substrate for human and rodent BCRP.  An addnl. pathway for ciprofloxacin secretion exists in Caco-2 cells, which is unlikely to be MRP(4)-mediated.  BCRP is likely to be the dominant transport mechanism for ciprofloxacin efflux in both rat and human jejunum.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWW3kSbnN3sLVg90H21EOLACvtfcHk0lh6co9CsRc6EQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCru77O&md5=9021b5fb2d0675d51416fef22c1c3e65</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.038323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.038323%26sid%3Dliteratum%253Aachs%26aulast%3DHaslam%26aufirst%3DI.%2BS.%26aulast%3DWright%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DD.%2BA.%26aulast%3DSherlock%26aufirst%3DD.%2BJ.%26aulast%3DColeman%26aufirst%3DT.%26aulast%3DSimmons%26aufirst%3DN.%2BL.%26atitle%3DIntestinal%2520ciprofloxacin%2520efflux%253A%2520the%2520role%2520of%2520breast%2520cancer%2520resistance%2520protein%2520%2528ABCG2%2529%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D2321%26epage%3D2328%26doi%3D10.1124%2Fdmd.111.038323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gutmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beglinger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewe, J.</span></span> <span> </span><span class="NLM_article-title">Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">695</span>– <span class="NLM_lpage">699</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2005.05.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1016%2Fj.bcp.2005.05.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=15998509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvFSisrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2005&pages=695-699&author=H.+Gutmannauthor=P.+Hruzauthor=C.+Zimmermannauthor=C.+Beglingerauthor=J.+Drewe&title=Distribution+of+breast+cancer+resistance+protein+%28BCRP%2FABCG2%29+mRNA+expression+along+the+human+GI+tract&doi=10.1016%2Fj.bcp.2005.05.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract</span></div><div class="casAuthors">Gutmann, Heike; Hruz, Petr; Zimmermann, Christian; Beglinger, Christoph; Drewe, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">695-699</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Human breast cancer resistance protein (BCRP/ABCG2) is an ABC-transporter that is present on the luminal membrane of intestinal epithelial cells and restricts absorption of anticancer drugs such as methotrexate, topotecan, mitoxantrone, and doxorubicin.  The exact anat. distribution of BCRP along the gastrointestinal (GI) tract, however, has not been detd. before.  The aim of this study was, therefore to investigate BCRP mRNA expression pattern along the GI tract in 14 healthy subjects.  Furthermore, BCRP duodenal mRNA expression was compared with MDR1/ABCB1 mRNA.  Addnl., BCRP mRNA expression was investigated in two human intestinal cell lines (Caco-2 and LS180).  Since previous animal studies have suggested sex specific differences in BCRP expression, we analyzed intestinal BCRP expression with respect to sex.  Biopsies were taken from different gut segments (duodenum, terminal ileum and ascending, transverse, descending and sigmoid colon).  Gene expression was assessed by quant. real-time PCR (Taqman).  BCRP mRNA expression was maximal in the duodenum and decreased continuously down to the rectum (terminal ileum 93.7%, ascending colon 75.8%, transverse colon 66.6%, descending colon 62.8%, and sigmoid colon 50.1% compared to duodenum, resp.).  BCRP expression in the duodenum was comparable to MDR1/ABCB1 gene expression.  Caco-2 cells showed a comparable expression of BCRP as human duodenal tissue.  Gender specific differences in BCRP expression were not obsd.  These findings represent the first systematic site-specific anal. of BCRP expression along the GI tract.  This information might be helpful to develop target strategies for orally administered anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCnsu7rhgT4LVg90H21EOLACvtfcHk0lhJSFJgIt3r8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvFSisrc%253D&md5=265175e10bd1812474eaf59ab7581093</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2005.05.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2005.05.031%26sid%3Dliteratum%253Aachs%26aulast%3DGutmann%26aufirst%3DH.%26aulast%3DHruz%26aufirst%3DP.%26aulast%3DZimmermann%26aufirst%3DC.%26aulast%3DBeglinger%26aufirst%3DC.%26aulast%3DDrewe%26aufirst%3DJ.%26atitle%3DDistribution%2520of%2520breast%2520cancer%2520resistance%2520protein%2520%2528BCRP%252FABCG2%2529%2520mRNA%2520expression%2520along%2520the%2520human%2520GI%2520tract%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2005%26volume%3D70%26spage%3D695%26epage%3D699%26doi%3D10.1016%2Fj.bcp.2005.05.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taipalensuu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tornblom, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindberg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einarsson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjoqvist, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melhus, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjostrom, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundgren, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span> <span> </span><span class="NLM_article-title">Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>299</i></span>,  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">170</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=11561076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntFWlt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2001&pages=164-170&author=J.+Taipalensuuauthor=H.+Tornblomauthor=G.+Lindbergauthor=C.+Einarssonauthor=F.+Sjoqvistauthor=H.+Melhusauthor=P.+Garbergauthor=B.+Sjostromauthor=B.+Lundgrenauthor=P.+Artursson&title=Correlation+of+gene+expression+of+ten+drug+efflux+proteins+of+the+ATP-binding+cassette+transporter+family+in+normal+human+jejunum+and+in+human+intestinal+epithelial+Caco-2+cell+monolayers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers</span></div><div class="casAuthors">Taipalensuu, Jan; Tornblom, Hans; Lindberg, Greger; Einarsson, Curt; Sjoqvist, Folke; Melhus, Hakan; Garberg, Per; Sjostrom, Brita; Lundgren, Bo; Artursson, Per</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">299</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">164-170</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">This investigation describes the expression and interindividual variability in transcript levels of multiple drug efflux systems in the human jejunum and compares the expression profiles in these cells with that of the commonly used Caco-2 cell drug absorption model.  Transcript levels of ten-drug efflux proteins of the ATP-binding cassette (ABC) transporter family [MDR1, MDR3, ABCB5, MRP1-6, and breast cancer resistance protein (BCRP)], lung resistance-related protein (LRP), and CYP3A4 were detd. using quant. polymerase chain reaction in jejunal biopsies from 13 healthy human subjects and in Caco-2 cells.  All genes except ABCB5 were expressed, and transcript levels varied between individuals only by a factor of 2 to 3.  Surprisingly, BCRP and MRP2 transcripts were more abundant in jejunum than MDR1 transcripts.  Jejunal transcript levels of the different ABC transporters spanned a range of three log units with the rank order: BCRP ≈ MRP2 > MDR1 ≈ MRP3 ≈ MRP6 ≈ MRP5 ≈ MRP1 > MRP4 > MDR3.  Furthermore, transcript levels of 9 of 10 ABC transporters correlated well between jejunum and Caco-2 cells (r2 = 0.90).  However, BCRP exhibited a 100-fold lower transcript level in Caco-2 cells compared with jejunum.  Thus, the expression of a no. of efflux protein transcripts in jejunum are equal to, or even higher than, that of MDR1, suggesting that the roles of these proteins (in particular BCRP and MRP2) in intestinal drug efflux have been underestimated.  Also, we tentatively conclude that the Caco-2 cell line is a useful model of jejunal drug efflux, if the low expression of BCRP is taken into account.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1f-Z1mGAtjbVg90H21EOLACvtfcHk0lhJSFJgIt3r8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntFWlt7Y%253D&md5=1a2ef81848fcaafda43d4980f6987856</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTaipalensuu%26aufirst%3DJ.%26aulast%3DTornblom%26aufirst%3DH.%26aulast%3DLindberg%26aufirst%3DG.%26aulast%3DEinarsson%26aufirst%3DC.%26aulast%3DSjoqvist%26aufirst%3DF.%26aulast%3DMelhus%26aufirst%3DH.%26aulast%3DGarberg%26aufirst%3DP.%26aulast%3DSjostrom%26aufirst%3DB.%26aulast%3DLundgren%26aufirst%3DB.%26aulast%3DArtursson%26aufirst%3DP.%26atitle%3DCorrelation%2520of%2520gene%2520expression%2520of%2520ten%2520drug%2520efflux%2520proteins%2520of%2520the%2520ATP-binding%2520cassette%2520transporter%2520family%2520in%2520normal%2520human%2520jejunum%2520and%2520in%2520human%2520intestinal%2520epithelial%2520Caco-2%2520cell%2520monolayers%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2001%26volume%3D299%26spage%3D164%26epage%3D170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harwood, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pathak, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuhoff, S.</span></span> <span> </span><span class="NLM_article-title">The regional-specific relative and absolute expression of gut transporters in adult caucasians: a meta-analysis</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">854</span>– <span class="NLM_lpage">864</span>, <span class="refDoi"> DOI: 10.1124/dmd.119.086959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.119.086959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=31076413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFSgtr7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2019&pages=854-864&issue=8&author=M.+D.+Harwoodauthor=M.+Zhangauthor=S.+M.+Pathakauthor=S.+Neuhoff&title=The+regional-specific+relative+and+absolute+expression+of+gut+transporters+in+adult+caucasians%3A+a+meta-analysis&doi=10.1124%2Fdmd.119.086959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The regional-specific relative and absolute expression of gut transporters in adult caucasians: a meta-analysis</span></div><div class="casAuthors">Harwood, Matthew D.; Zhang, Mian; Pathak, Shriram M.; Neuhoff, Sibylle</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">854-864</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The aim of this study was to derive region-specific transporter expression data suitable for in vitro-to-in vivo extrapolation (IVIVE) within a physiol. based pharmacokinetic (PBPK) modeling framework.  A meta-anal. was performed whereby literary sources reporting region-specific transporter expression obtained via abs. and relative quantification approaches were considered in healthy adult Caucasian individuals.  Furthermore, intestinal total membrane protein yield was calcd. to enable mechanistic IVIVE via abs. transporter abundances.  Where required, authors were contacted for addnl. information.  A refined database was constructed where samples were excluded based on quantification in, non-Caucasian subjects, disease tissue, subjects <18 years old, duplicated samples, non-total membrane matrix, pooled matrixes, or cDNA.  Demog. data were collected where available.  The weighted and geometric mean, coeff. of variation, and between-study homogeneity was calcd. in each of eight gut segments (duodenum, two jejunum, four ileum, and colon) for 16 transporters.  Expression data were normalized to that in the proximal jejunum.  From a total of 47 articles, the final database consisted of 2238 measurements for 16 transporters.  The solute carrier peptide transporter 1 (PepT1) showed the highest jejunal abundance, while multidrug resistance-assocd. protein (MRP) 2 was the highest abundance ATP-binding cassette transporter.  Transporters displaying significant region-specific expression included the ileal bile acid transporter, which showed 18-fold greater terminal ileum expression compared with the proximal jejunum, while MRP3, org. cation transporter type 1 (OCTN1), and OCT1 showed >2-fold higher expression in other regions compared with the proximal jejunum.  This is the first systematic anal. incorporating abs. quantification methodol. to det. region-specific intestinal transporter expression.  It is expected to be beneficial for mechanistic transporter IVIVE in healthy adult Caucasians.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5agTSyUl4gbVg90H21EOLACvtfcHk0lhJSFJgIt3r8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFSgtr7M&md5=8104f8371cb2544c81ccc6f94936336e</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1124%2Fdmd.119.086959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.119.086959%26sid%3Dliteratum%253Aachs%26aulast%3DHarwood%26aufirst%3DM.%2BD.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DPathak%26aufirst%3DS.%2BM.%26aulast%3DNeuhoff%26aufirst%3DS.%26atitle%3DThe%2520regional-specific%2520relative%2520and%2520absolute%2520expression%2520of%2520gut%2520transporters%2520in%2520adult%2520caucasians%253A%2520a%2520meta-analysis%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2019%26volume%3D47%26issue%3D8%26spage%3D854%26epage%3D864%26doi%3D10.1124%2Fdmd.119.086959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fagerholm, U.</span></span> <span> </span><span class="NLM_article-title">Prediction of human pharmacokinetics - renal metabolic and excretion clearance</span>. <i>J. Pharm. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1463</span>– <span class="NLM_lpage">1471</span>, <span class="refDoi"> DOI: 10.1211/jpp.59.11.0002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1211%2Fjpp.59.11.0002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2010&pages=1463-1471&author=U.+Fagerholm&title=Prediction+of+human+pharmacokinetics+-+renal+metabolic+and+excretion+clearance&doi=10.1211%2Fjpp.59.11.0002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1211%2Fjpp.59.11.0002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1211%252Fjpp.59.11.0002%26sid%3Dliteratum%253Aachs%26aulast%3DFagerholm%26aufirst%3DU.%26atitle%3DPrediction%2520of%2520human%2520pharmacokinetics%2520-%2520renal%2520metabolic%2520and%2520excretion%2520clearance%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D2010%26volume%3D59%26spage%3D1463%26epage%3D1471%26doi%3D10.1211%2Fjpp.59.11.0002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troutman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chupka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan</span></span> <span> </span><span class="NLM_article-title">A physicochemical determinants of human renal clearance</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">4844</span>– <span class="NLM_lpage">4852</span>, <span class="refDoi"> DOI: 10.1021/jm900403j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900403j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlvFOnt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4844-4852&author=M.+V.+Varmaauthor=B.+Fengauthor=R.+S.+Obachauthor=M.+D.+Troutmanauthor=J.+Chupkaauthor=H.+R.+Millerauthor=+El-Kattan&title=A+physicochemical+determinants+of+human+renal+clearance&doi=10.1021%2Fjm900403j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Physicochemical Determinants of Human Renal Clearance</span></div><div class="casAuthors">Varma, Manthena V. S.; Feng, Bo; Obach, R. Scott; Troutman, Matthew D.; Chupka, Jonathan; Miller, Howard R.; El-Kattan, Ayman</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4844-4852</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kidney plays an important role in the elimination of drugs, esp. with low or negligible hepatic clearance.  An anal. of the interrelation of physicochem. properties and the human renal clearance for a data set of 391 drugs or compds. tested in humans is presented.  The data set indicated that lipophilicity shows a neg. relationship while polar descriptors show a pos. relationship with renal clearance.  Anal. of net secreted and net reabsorbed subsets revealed that hydrophilic ionized compds. are probable compds. to show net secretion and a possible drug-drug interaction due to their likely interaction with uptake transporters and inherent low passive reabsorption.  The physicochem. space and renal clearance were also statistically analyzed by therapeutic area.  In conclusion, ionization state, lipophilicity, and polar descriptors are found to be the physicochem. determinants of renal clearance.  These fundamental properties can be valuable in early prediction of human renal clearance and can aid the chemist in structural modifications to optimize drug disposition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorGLq4kYGi_LVg90H21EOLACvtfcHk0liYQWm5c3-Aew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlvFOnt7s%253D&md5=a99ccaa1651d04ed7f7c0a49679f55f6</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm900403j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900403j%26sid%3Dliteratum%253Aachs%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26aulast%3DChupka%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DH.%2BR.%26aulast%3DEl-Kattan%26atitle%3DA%2520physicochemical%2520determinants%2520of%2520human%2520renal%2520clearance%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4844%26epage%3D4852%26doi%3D10.1021%2Fjm900403j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scotcher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rostami-Hodjegan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galetin, A.</span></span> <span> </span><span class="NLM_article-title">Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2016.03.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1016%2Fj.ejps.2016.03.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=27033147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC28XlslelsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2016&pages=59-71&author=D.+Scotcherauthor=C.+Jonesauthor=A.+Rostami-Hodjeganauthor=A.+Galetin&title=Novel+minimal+physiologically-based+model+for+the+prediction+of+passive+tubular+reabsorption+and+renal+excretion+clearance&doi=10.1016%2Fj.ejps.2016.03.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance</span></div><div class="casAuthors">Scotcher, Daniel; Jones, Christopher; Rostami-Hodjegan, Amin; Galetin, Aleksandra</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59-71</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Develop a minimal mechanistic model based on in vitro-in vivo extrapolation (IVIVE) principles to predict extent of passive tubular reabsorption.  Assess the ability of the model developed to predict extent of passive tubular reabsorption (Freab) and renal excretion clearance (CLR) from in vitro permeability data and tubular physiol. parameters.  Model system parameters were informed by physiol. data collated following extensive literature anal.  A database of clin. CLR was collated for 157 drugs.  A subset of 45 drugs was selected for model validation; for those, Caco-2 permeability (Papp) data were measured under pH 6.5-7.4 gradient conditions and used to predict Freab and subsequently CLR.  An empirical calibration approach was proposed to account for the effect of inter-assay/lab. variation in Papp on the IVIVE of Freab.  The 5-compartmental model accounted for regional differences in tubular surface area and flow rates and successfully predicted the extent of tubular reabsorption of 45 drugs for which filtration and reabsorption were contributing to renal excretion.  Subsequently, predicted CLR was within 3-fold of the obsd. values for 87% of drugs in this dataset, with an overall gmfe of 1.96.  Consideration of the empirical calibration method improved overall prediction of CLR (gmfe = 1.73 for 34 drugs in the internal validation dataset), in particular for basic drugs and drugs with low extent of tubular reabsorption.  The novel 5-compartment model represents an important addn. to the IVIVE toolbox for physiol.-based prediction of renal tubular reabsorption and CLR.  Physiol. basis of the model proposed allows its application in future mechanistic kidney models in preclin. species and human.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHGRtkbpoQLrVg90H21EOLACvtfcHk0liYQWm5c3-Aew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlslelsLk%253D&md5=b8bbc2b34ae6aeb297d676322c8bc2e0</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2016.03.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2016.03.018%26sid%3Dliteratum%253Aachs%26aulast%3DScotcher%26aufirst%3DD.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DRostami-Hodjegan%26aufirst%3DA.%26aulast%3DGaletin%26aufirst%3DA.%26atitle%3DNovel%2520minimal%2520physiologically-based%2520model%2520for%2520the%2520prediction%2520of%2520passive%2520tubular%2520reabsorption%2520and%2520renal%2520excretion%2520clearance%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2016%26volume%3D94%26spage%3D59%26epage%3D71%26doi%3D10.1016%2Fj.ejps.2016.03.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czuba, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isoherranen, N.</span></span> <span> </span><span class="NLM_article-title">Mechanistic PBPK modeling of urine pH effect on renal and systemic disposition of methamphetamine and amphetamine</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">488</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1124/jpet.120.264994</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fjpet.120.264994" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=32198137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlejur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2020&pages=488-501&author=W.+Huangauthor=L.+C.+Czubaauthor=N.+Isoherranen&title=Mechanistic+PBPK+modeling+of+urine+pH+effect+on+renal+and+systemic+disposition+of+methamphetamine+and+amphetamine&doi=10.1124%2Fjpet.120.264994"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45aR"><div class="casContent"><span class="casTitleNuber">45a</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic PBPK modeling of urine pH effect on renal and systemic disposition of methamphetamine and amphetamine</span></div><div class="casAuthors">Huang, Weize; Czuba, Lindsay C.; Isoherranen, Nina</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">488-501</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">In this study, we hypothesized that physiol. based pharmacokinetic (PBPK) modeling could be used as a cost-effective method to examine potential urine pH effect on drug and metabolite disposition.  Our previously developed and verified mechanistic kidney model was integrated with a full-body PBPK model to simulate renal clearance and area under the plasma concn.-time curve (AUC) with varying urine pH statuses using methamphetamine and amphetamine as model compds.  We first developed and verified drug models for methamphetamine and amphetamine under normal urine pH condition [abs. av. fold error (AAFE) < 1.25 at study level].  Then, acidic and alk. urine scenarios were simulated.  Our simulation results show that the renal excretion and plasma concn.-time profiles for methamphetamine and amphetamine could be recapitulated under different urine pH (AAFE < 2 at individual level).  The methamphetamine-amphetamine parent-metabolite full-body PBPK model also successfully simulated amphetamine plasma concn.-time profiles (AAFE < 1.25 at study level) and amphetamine/methamphetamine urinary concn. ratios (AAFE < 2 at individual level) after dosing methamphetamine.  This demonstrates that our mechanistic PBPK model can predict urine pH effect on systemic and urinary disposition of drugs and metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7Q73VLmXhxbVg90H21EOLACvtfcHk0liYQWm5c3-Aew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlejur7I&md5=766856f7fda555dd7703d3c5dd5a356e</span></div><a href="/servlet/linkout?suffix=cit45a&amp;dbid=16384&amp;doi=10.1124%2Fjpet.120.264994&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.120.264994%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DCzuba%26aufirst%3DL.%2BC.%26aulast%3DIsoherranen%26aufirst%3DN.%26atitle%3DMechanistic%2520PBPK%2520modeling%2520of%2520urine%2520pH%2520effect%2520on%2520renal%2520and%2520systemic%2520disposition%2520of%2520methamphetamine%2520and%2520amphetamine%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2020%26volume%3D373%26spage%3D488%26epage%3D501%26doi%3D10.1124%2Fjpet.120.264994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit45b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strauss, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caplan, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodico, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, D. M.</span></span> <span> </span><span class="NLM_article-title">Urine pH: the effects of time and temperature after collection</span>. <i>J. Anal. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">496</span>, <span class="refDoi"> DOI: 10.1093/jat/31.8.486</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1093%2Fjat%2F31.8.486" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=17988463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1WnsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2007&pages=486-496&author=J.+D.+Cookauthor=K.+A.+Straussauthor=Y.+H.+Caplanauthor=C.+P.+Lodicoauthor=D.+M.+Bush&title=Urine+pH%3A+the+effects+of+time+and+temperature+after+collection&doi=10.1093%2Fjat%2F31.8.486"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45bR"><div class="casContent"><span class="casTitleNuber">45b</span><div class="casTitle"><span class="NLM_cas:atitle">Urine pH: the effects of time and temperature after collection</span></div><div class="casAuthors">Cook, Janine D.; Strauss, Kathy A.; Caplan, Yale H.; LoDico, Charles P.; Bush, Donna M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Analytical Toxicology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">486-496</span>CODEN:
                <span class="NLM_cas:coden">JATOD3</span>;
        ISSN:<span class="NLM_cas:issn">0146-4760</span>.
    
            (<span class="NLM_cas:orgname">Preston Publications</span>)
        </div><div class="casAbstract">The Mandatory Guidelines for Federal Workplace Drug Testing Programs provide criteria for specimen validity testing, including urine pH cut-offs, to report a urine specimen as adulterated or invalid.  Since the urine pH criteria for invalid classifications, ≥ 3 and < 4.5 or ≥ 9 and < 11, became effective in Nov. 2004, a no. of specimens with results within the upper invalid limits, typically in the range of 9.1 to 9.3, were reported with no evidence of adulteration.  This study evaluated the hypothesis that these pH findings were the result of exposure to increased environmental temps. during specimen standing and transport.  Indeed, increased storage temps. were assocd. with increased urine pH, with the magnitude of the change related to both storage time and temp.  The pH values of specimens stored at -20°C are relatively stable, whereas pH results > 9 are achieved at storage temps. of room temp. or higher.  It is noteworthy that no condition(s) produced a specimen with a pH > 9.5.  Degrdn. of nitrogenous urine analytes is most likely responsible for the noted increases in pH.  These findings are intended to supplement information used by the Medical Review Officers who are responsible for interpreting such marginally invalid pH results.  (c) 2007 Preston Publications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8E9xXtiSa6rVg90H21EOLACvtfcHk0liII34QxPWxeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1WnsbbM&md5=d7908eb28087e36212620d67efc31f4a</span></div><a href="/servlet/linkout?suffix=cit45b&amp;dbid=16384&amp;doi=10.1093%2Fjat%2F31.8.486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjat%252F31.8.486%26sid%3Dliteratum%253Aachs%26aulast%3DCook%26aufirst%3DJ.%2BD.%26aulast%3DStrauss%26aufirst%3DK.%2BA.%26aulast%3DCaplan%26aufirst%3DY.%2BH.%26aulast%3DLodico%26aufirst%3DC.%2BP.%26aulast%3DBush%26aufirst%3DD.%2BM.%26atitle%3DUrine%2520pH%253A%2520the%2520effects%2520of%2520time%2520and%2520temperature%2520after%2520collection%26jtitle%3DJ.%2520Anal.%2520Toxicol.%26date%3D2007%26volume%3D31%26spage%3D486%26epage%3D496%26doi%3D10.1093%2Fjat%2F31.8.486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit45c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Freudenthaler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meineke, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreeb, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boakye, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gundert-Remy, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleiter, G. H.</span></span> <span> </span><span class="NLM_article-title">Influence of urine pH and urinary flow on the renal excretion of memantine</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">541</span>– <span class="NLM_lpage">546</span>, <span class="refDoi"> DOI: 10.1046/j.1365-2125.1998.00819.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1046%2Fj.1365-2125.1998.00819.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK1MXntFOm" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=1998&pages=541-546&author=S.+Freudenthalerauthor=I.+Meinekeauthor=K.+H.+Schreebauthor=E.+Boakyeauthor=U.+Gundert-Remyauthor=G.+H.+Gleiter&title=Influence+of+urine+pH+and+urinary+flow+on+the+renal+excretion+of+memantine&doi=10.1046%2Fj.1365-2125.1998.00819.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45cR"><div class="casContent"><span class="casTitleNuber">45c</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of urine pH and urinary flow on the renal excretion of memantine</span></div><div class="casAuthors">Freudenthaler, S.; Meineke, I.; Schreeb, K.-H.; Boakye, E.; Gundert-Remy, U.; Gleiter, C. H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">541-546</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">The present study assessed the influence of urinary flow rate and urine pH on the renal excretion of the NMDA-receptor antagonist memantine.  In a randomized, open, four-period cross-over trial, 12 healthy male volunteers received 10 mg memantine daily for 43 days.  After reaching steady state conditions the volunteers were allocated to four different regiments to alter urine pH and urinary flow, which were each sepd. by a 1 wk period while the study medication continued (A: acidification of urine pH, low urinary flow; B: acidification of urine pH, high urinary flow; C: alkalinization of urine pH, low urinary flow: D: alkalinization of urine pH, high urinary flow).  The renal clearance of memantine (CLR) in regimen A and B was 7-10 fold higher in comparison with regimen C and D (P<0.05).  There were small but statistically significant differences of CLR between the two regimens with acidic urine pH (A: median: 210.2 mL min-1 vs B: median: 218.7 mL min-1) and between the two regimens with alk. urine pH (C: median: 19.4 mL min-1 vs D: median: 30.5 mL min-1).  The amt. of memantine excreted into the urine within one regimen (Ae0-24 h) was 5.7-7.4 fold higher in regimens A and B than C and D (P<0.05).  Differences of the AUC(0,24 h) and Cmax/AUC(0,24 h) were significant (P<0.05) between each of the regimens with acidic urine pH (A, B) and regimens (C, D) with alk. urine pH (A vs C, A vs D, B vs C, B vs D) but not between regimens A vs B or C vs D.  The present study demonstrated a considerable effect of urine pH, whereas no clin. relevant change of the renal excretion of memantine with urinary flow could be detected.  As the renal excretion of memantine may have an impact on therapeutic efficacy changes of dietary habits that may alter urine pH should be avoided during treatment with memantine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPD7FZws8DybVg90H21EOLACvtfcHk0liII34QxPWxeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntFOm&md5=a19e1cca3cb1d61c0793dfaaeba07589</span></div><a href="/servlet/linkout?suffix=cit45c&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2125.1998.00819.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2125.1998.00819.x%26sid%3Dliteratum%253Aachs%26aulast%3DFreudenthaler%26aufirst%3DS.%26aulast%3DMeineke%26aufirst%3DI.%26aulast%3DSchreeb%26aufirst%3DK.%2BH.%26aulast%3DBoakye%26aufirst%3DE.%26aulast%3DGundert-Remy%26aufirst%3DU.%26aulast%3DGleiter%26aufirst%3DG.%2BH.%26atitle%3DInfluence%2520of%2520urine%2520pH%2520and%2520urinary%2520flow%2520on%2520the%2520renal%2520excretion%2520of%2520memantine%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D1998%26volume%3D46%26spage%3D541%26epage%3D546%26doi%3D10.1046%2Fj.1365-2125.1998.00819.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit45d"><span><span class="NLM_label">d. </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Neuvonen, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karkkainen, S.</span></span> <span> </span><span class="NLM_article-title">Effect of charcoal, sodium bicarbonate, and ammonium chloride on chlorpropamide kinetics</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">386</span>– <span class="NLM_lpage">393</span>, <span class="refDoi"> DOI: 10.1038/clpt.1983.50</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1038%2Fclpt.1983.50" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=6297841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaL3sXhslamsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1983&pages=386-393&author=P.+J.+Neuvonenauthor=S.+Karkkainen&title=Effect+of+charcoal%2C+sodium+bicarbonate%2C+and+ammonium+chloride+on+chlorpropamide+kinetics&doi=10.1038%2Fclpt.1983.50"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45dR"><div class="casContent"><span class="casTitleNuber">45d.</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of charcoal, sodium bicarbonate, and ammonium chloride on chlorpropamide kinetics</span></div><div class="casAuthors">Neuvonen, Pertti J.; Karkkainen, Seija</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">386-93</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    </div><div class="casAbstract">The effects of activated charcoal, Na2CO3, and NH4Cl, given orally, on chlorpropamide (I)  [94-20-2] kinetics was studied in healthy subjects.  Activated charcoal, 50 g, given immediately after 250 mg chlorpropamide reduced its absorption by 90%, but when given in repeated doses from 6 h on (50 g followed by 12.5 g at 6-h intervals) it did not shorten the chlorpropamide half-life (t1/2).  The t1/2 of chlorpropamide was shortened from 49.7 to 12.8 h by Na2CO3 and prolonged to 68.5 h by NH4Cl.  The 72-h urinary excretion of chlorpropamide was increased 4-fold by alkalinization and decreased to 1/20 of baseline by acidification of the urine.  The renal clearance of chlorpropamide correlated with urinary pH, ranging from 1 to 1000 mL/h at the pH from 5 to 8.  Urinary pH is likely to explain at least a part of great interindividual differences in the serum chlorpropamide concns. during steady-state and variations in amt. of urinary metabolites.  In chlorpropamide intoxications, activated charcoal can reduce absorption of the drug and alkalinization of the urine can accelerate its elimination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-JCUEykGZN7Vg90H21EOLACvtfcHk0liII34QxPWxeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXhslamsLs%253D&md5=373098de498d5733bebb75f0940e3c3c</span></div><a href="/servlet/linkout?suffix=cit45d&amp;dbid=16384&amp;doi=10.1038%2Fclpt.1983.50&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.1983.50%26sid%3Dliteratum%253Aachs%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26aulast%3DKarkkainen%26aufirst%3DS.%26atitle%3DEffect%2520of%2520charcoal%252C%2520sodium%2520bicarbonate%252C%2520and%2520ammonium%2520chloride%2520on%2520chlorpropamide%2520kinetics%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D1983%26volume%3D33%26spage%3D386%26epage%3D393%26doi%3D10.1038%2Fclpt.1983.50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shatzer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span> <span> </span><span class="NLM_article-title">Glucuronidation: driving factors and their impact on glucuronide disposition</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1080/03602532.2017.1293682</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1080%2F03602532.2017.1293682" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=28266877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC2sXos1ars7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2017&pages=105-138&author=G.+Yangauthor=S.+Geauthor=R.+Singhauthor=S.+Basuauthor=K.+Shatzerauthor=M.+Zenauthor=J.+Liuauthor=Y.+Tuauthor=C.+Zhangauthor=J.+Weiauthor=J.+Shiauthor=L.+Zhuauthor=Z.+Liuauthor=Y.+Wangauthor=S.+Gaoauthor=M.+Hu&title=Glucuronidation%3A+driving+factors+and+their+impact+on+glucuronide+disposition&doi=10.1080%2F03602532.2017.1293682"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Glucuronidation: driving factors and their impact on glucuronide disposition</span></div><div class="casAuthors">Yang, Guangyi; Ge, Shufan; Singh, Rashim; Basu, Sumit; Shatzer, Katherine; Ming, Zen; Liu, Jiong; Tu, Yifan; Zhang, Chenning; Wei, Jinbao; Shi, Jian; Zhu, Lijun; Liu, Zhongqiu; Wang, Yuan; Gao, Song; Hu, Ming</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">105-138</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Glucuronidation is a well-recognized phase II metabolic pathway for a variety of chems. including drugs and endogenous substances.  Although it is usually the secondary metabolic pathway for a compd. preceded by phase I hydroxylation, glucuronidation alone could serve as the dominant metabolic pathway for many compds., including some with high aq. soly.  Glucuronidation involves the metab. of parent compd. by UDP-glucuronosyltransferases (UGTs) into hydrophilic and neg. charged glucuronides that cannot exit the cell without the aid of efflux transporters.  Therefore, elimination of parent compd. via glucuronidation in a metabolic active cell is controlled by two driving forces: the formation of glucuronides by UGT enzymes and the (polarized) excretion of these glucuronides by efflux transporters located on the cell surfaces in various drug disposition organs.  Contrary to the common assumption that the glucuronides reaching the systemic circulation were destined for urinary excretion, recent evidences suggest that hepatocytes are capable of highly efficient biliary clearance of the gut-generated glucuronides.  Furthermore, the biliary- and enteric-eliminated glucuronides participate into recycling schemes involving intestinal microbes, which often prolong their local and systemic exposure, albeit at low systemic concns.  Taken together, these recent research advances indicate that although UGT dets. the rate and extent of glucuronide generation, the efflux and uptake transporters det. the distribution of these glucuronides into blood and then to various organs for elimination.  Recycling schemes impact the apparent plasma half-life of parent compds. and their glucuronides that reach intestinal lumen, in addn. to prolonging their gut and colon exposure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooH5Ec2SdwRrVg90H21EOLACvtfcHk0ljo5hFBw7_diA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXos1ars7g%253D&md5=ffae3e1cc6210706ff7c833202523084</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1080%2F03602532.2017.1293682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F03602532.2017.1293682%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DG.%26aulast%3DGe%26aufirst%3DS.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DBasu%26aufirst%3DS.%26aulast%3DShatzer%26aufirst%3DK.%26aulast%3DZen%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DM.%26atitle%3DGlucuronidation%253A%2520driving%2520factors%2520and%2520their%2520impact%2520on%2520glucuronide%2520disposition%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2017%26volume%3D49%26spage%3D105%26epage%3D138%26doi%3D10.1080%2F03602532.2017.1293682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gadgil, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damle, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, A. B.</span></span> <span> </span><span class="NLM_article-title">Effect of activated charcoal on the pharmacokinetics of high-dose methotrexate</span>. <i>Cancer Treat Rep.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1169</span>– <span class="NLM_lpage">1171</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=7083219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A280%3ADyaL383gvVensQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=1982&pages=1169-1171&author=S.+D.+Gadgilauthor=S.+R.+Damleauthor=S.+H.+Advaniauthor=A.+B.+Vaidya&title=Effect+of+activated+charcoal+on+the+pharmacokinetics+of+high-dose+methotrexate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of activated charcoal on the pharmacokinetics of high-dose methotrexate</span></div><div class="casAuthors">Gadgil S D; Damle S R; Advani S H; Vaidya A B</div><div class="citationInfo"><span class="NLM_cas:title">Cancer treatment reports</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1169-71</span>
        ISSN:<span class="NLM_cas:issn">0361-5960</span>.
    </div><div class="casAbstract">The serum methotrexate (MTX) concentrations were estimated in two groups of patients after 6-hour iv infusion of 1 g/m2 of MTX and leucovorin rescue.  One group (seven patients) received 25 g of activated charcoal orally at 12, 18, 24, 36, and 48 hours, while the other group served as a control (eight patients).  Pharmacokinetic analysis revealed a significant reduction in the area under concentration curve from 18 hours until the serum MTX levels reached 10(-8) M.  The MTX concentrations were significantly lower in the group that received charcoal than in the control group, at 18, 24, 36, 48, 60, and 72 hours from the end of infusion.  First and second half-life values for the control and the charcoal-treated groups did not differ significantly.  The data suggest that charcoal aids in the elimination of MTX from the body by interruption of the enterohepatic circulation of the drug.  Activated charcoal did not cause any undesirable effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6fL2BdWfWCH6HPRus0rAafW6udTcc2eaLOfnpiWDbMLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL383gvVensQ%253D%253D&md5=08a7c78621575c7b0c9196c3d5892985</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGadgil%26aufirst%3DS.%2BD.%26aulast%3DDamle%26aufirst%3DS.%2BR.%26aulast%3DAdvani%26aufirst%3DS.%2BH.%26aulast%3DVaidya%26aufirst%3DA.%2BB.%26atitle%3DEffect%2520of%2520activated%2520charcoal%2520on%2520the%2520pharmacokinetics%2520of%2520high-dose%2520methotrexate%26jtitle%3DCancer%2520Treat%2520Rep.%26date%3D1982%26volume%3D66%26spage%3D1169%26epage%3D1171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stass, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubitza, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moller, J.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delesen, H.</span></span> <span> </span><span class="NLM_article-title">Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">536</span>– <span class="NLM_lpage">541</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2005.02357.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1111%2Fj.1365-2125.2005.02357.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=15842551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltFGgtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2005&pages=536-541&author=H.+Stassauthor=D.+Kubitzaauthor=J.-G.+Mollerauthor=H.+Delesen&title=Influence+of+activated+charcoal+on+the+pharmacokinetics+of+moxifloxacin+following+intravenous+and+oral+administration+of+a+400+mg+single+dose+to+healthy+males&doi=10.1111%2Fj.1365-2125.2005.02357.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males</span></div><div class="casAuthors">Stass, H.; Kubitza, D.; Moeller, J.-G.; Delesen, H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">536-541</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">To evaluate the extent to which enterohepatic recycling circulation contributes to moxifloxacin bioavailability in healthy, males by administration of activated charcoal and to evaluate the efficacy of activated charcoal administration in decreasing systemic concns. of moxifloxacin in the event of overdose.  Nine healthy males, mean age 34 years (range 23-45 years) participated in a single center, randomized, nonplacebo-controlled, three way crossover study.  The pharmacokinetics of moxifloxacin in plasma and urine were detd. for up to 96 h following a 400 mg single dose randomly administered on three sep. occasions with a min. washout phase of 1 wk.  Treatment A was 400 mg moxifloxacin IV as a 1 h infusion, treatment B was 400 mg moxifloxacin IV as a 1 h infusion with oral activated charcoal (5 g directly before the start of the infusion, 5 g immediately after the end of the infusion, and 10 g at 2, 4 and 8 h after the start of the infusion), treatment C was 400 mg oral moxifloxacin with activated charcoal (10 g 15 min before and at 2, 4 and 8 h after drug administration).  The subjects underwent a series of clin. and lab. tests.  Single 400 mg doses of moxifloxacin (PO and/or IV) were safe and well tolerated.  The bioavailability of moxifloxacin was significantly decreased when given with charcoal (AUC = 35.5 (IV ref.) vs 5.40 (PO) vs 28.5 (IV) mg l-1 h).  Concurrently peak concns. were lowered Cmax = 3.38 (IV ref.) vs 0.62(PO) vs 2.97 (IV) mg l-1 by approx. 85% (P < 0.05) following oral administration and by 20% after IV treatment (P < 0.05).  Bioavailability amounted to 15.4% (95% confidence interval 9.6, 25.0%) for treatment B while it was 80.4% (95% confidence interval 76.3.6, 84.6%) for treatment C.  Terminal half-lives were not affected.  The kinetics of urinary excretion corroborated these findings.  The results of this study show that moxifloxacin undergoes pronounced enteric recycling after systemic uptake.  In addn., these findings confirm that activated charcoal may be useful in treating moxifloxacin overdose by preventing its absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeDX6VMLxibrVg90H21EOLACvtfcHk0ljo5hFBw7_diA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltFGgtrw%253D&md5=accb4ed3be8c230690600a0e06c2d728</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2005.02357.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2005.02357.x%26sid%3Dliteratum%253Aachs%26aulast%3DStass%26aufirst%3DH.%26aulast%3DKubitza%26aufirst%3DD.%26aulast%3DMoller%26aufirst%3DJ.-G.%26aulast%3DDelesen%26aufirst%3DH.%26atitle%3DInfluence%2520of%2520activated%2520charcoal%2520on%2520the%2520pharmacokinetics%2520of%2520moxifloxacin%2520following%2520intravenous%2520and%2520oral%2520administration%2520of%2520a%2520400%2520mg%2520single%2520dose%2520to%2520healthy%2520males%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2005%26volume%3D59%26spage%3D536%26epage%3D541%26doi%3D10.1111%2Fj.1365-2125.2005.02357.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusuhara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Prediction of the hepatic and renal clearance of transporter substrates in rats using in vitro uptake experiments</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1471</span>– <span class="NLM_lpage">1479</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.026062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.108.026062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=19364828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFemsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=1471-1479&author=T.+Watanabeauthor=K.+Maedaauthor=T.+Kondoauthor=H.+Nakayamaauthor=S.+Horitaauthor=H.+Kusuharaauthor=Y.+Sugiyama&title=Prediction+of+the+hepatic+and+renal+clearance+of+transporter+substrates+in+rats+using+in+vitro+uptake+experiments&doi=10.1124%2Fdmd.108.026062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of the hepatic and renal clearance of transporter substrates in rats using in vitro uptake experiments</span></div><div class="casAuthors">Watanabe, Tomoko; Maeda, Kazuya; Kondo, Tsunenori; Nakayama, Hideki; Horita, Shigeru; Kusuhara, Hiroyuki; Sugiyama, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1471-1479</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The clearance route and the abs. values for hepatic and renal clearance of drugs are important criteria for the selection of drug candidates.  Based on pharmacokinetic theory, by assuming that uptake is the rate-detg. process for the billary excretion of drugs, organ intrinsic clearance should be simply estd. by the intrinsic uptake.  In this study, to investigate whether organ clearance can be predicted from the in vitro uptake activity, we performed uptake expts. using isolated hepatocytes and kidney slices, integration plot analyses, and in vivo pharmacokinetic studies using 12 barely metabolized drugs in rats.  The in vivo hepatic and renal clearance could be approximated by uptake clearance estd. from integration plot analyses, except for the renal clearance of some drugs that was relatively small.  The comparison of intrinsic uptake clearance from in vitro expts. and integration plot studies revealed that in vivo hepatic uptake was well explained by uptake into isolated hepatocytes, whereas in kidney, in vivo uptake clearance was 10 to 100 times that in kidney slices and a scaling factor is required for its prediction from in vitro expts.  The organ clearance and the fraction excreted into urine could be predicted from in vitro studies except for drugs whose renal clearance was relatively small.  This study suggests that the uptake process is the detg. factor for organ clearance of minimally metabolized drugs, and uptake assays using isolated hepatocytes and kidney slices are useful for evaluating the uptake clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDk_F4boRQNrVg90H21EOLACvtfcHk0ljY2MJ_ZI670g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFemsrY%253D&md5=c47805a89cab2b3742a533d7d84be0b5</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.026062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.026062%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DKondo%26aufirst%3DT.%26aulast%3DNakayama%26aufirst%3DH.%26aulast%3DHorita%26aufirst%3DS.%26aulast%3DKusuhara%26aufirst%3DH.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DPrediction%2520of%2520the%2520hepatic%2520and%2520renal%2520clearance%2520of%2520transporter%2520substrates%2520in%2520rats%2520using%2520in%2520vitro%2520uptake%2520experiments%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D1471%26epage%3D1479%26doi%3D10.1124%2Fdmd.108.026062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, T.</span></span> <span> </span><span class="NLM_article-title">Physiological parameters in laboratory animals and humans</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1093</span>– <span class="NLM_lpage">1095</span>, <span class="refDoi"> DOI: 10.1023/A:1018943613122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1023%2FA%3A1018943613122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=8378254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A280%3ADyaK3szptFaqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1993&pages=1093-1095&author=B.+Daviesauthor=T.+Morris&title=Physiological+parameters+in+laboratory+animals+and+humans&doi=10.1023%2FA%3A1018943613122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Physiological parameters in laboratory animals and humans</span></div><div class="casAuthors">Davies B; Morris T</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical research</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1093-5</span>
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDDwka3A6hEYYPsCkJIw00fW6udTcc2eYZSF-QHcs0ebntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3szptFaqsg%253D%253D&md5=094cdd17306b58cc17c8cf4fd5db9927</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1023%2FA%3A1018943613122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1018943613122%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DB.%26aulast%3DMorris%26aufirst%3DT.%26atitle%3DPhysiological%2520parameters%2520in%2520laboratory%2520animals%2520and%2520humans%26jtitle%3DPharm.%2520Res.%26date%3D1993%26volume%3D10%26spage%3D1093%26epage%3D1095%26doi%3D10.1023%2FA%3A1018943613122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matheson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrison, R. N.</span></span> <span> </span><span class="NLM_article-title">Regulation of intestinal blood flow</span>. <i>J. Surg. Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">182</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1006/jsre.2000.5862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1006%2Fjsre.2000.5862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10945962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A280%3ADC%252BD3cvlvFGgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2000&pages=182-196&author=P.+J.+Mathesonauthor=M.+A.+Wilsonauthor=R.+N.+Garrison&title=Regulation+of+intestinal+blood+flow&doi=10.1006%2Fjsre.2000.5862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of intestinal blood flow</span></div><div class="casAuthors">Matheson P J; Wilson M A; Garrison R N</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of surgical research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">182-96</span>
        ISSN:<span class="NLM_cas:issn">0022-4804</span>.
    </div><div class="casAbstract">The gastrointestinal system anatomically is positioned to perform two distinct functions: to digest and absorb ingested nutrients and to sustain barrier function to prevent transepithelial migration of bacteria and antigens.  Alterations in these basic functions contribute to a variety of clinical scenarios.  These primary functions intrinsically require splanchnic blood flow at both the macrovascular and microvascular levels of perfusion.  Therefore, a greater understanding of the mechanisms that regulate intestinal vascular perfusion in the normal state and during pathophysiological conditions would be beneficial.  The purpose of this review is to summarize the current understanding regarding the regulatory mechanisms of intestinal blood flow in fasted and fed conditions and during pathological stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTG8HJbt-qWD0NoizSOkG_FfW6udTcc2eYZSF-QHcs0ebntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3cvlvFGgsA%253D%253D&md5=a264cab361d7cdfcd89a2bbece7decd7</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1006%2Fjsre.2000.5862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjsre.2000.5862%26sid%3Dliteratum%253Aachs%26aulast%3DMatheson%26aufirst%3DP.%2BJ.%26aulast%3DWilson%26aufirst%3DM.%2BA.%26aulast%3DGarrison%26aufirst%3DR.%2BN.%26atitle%3DRegulation%2520of%2520intestinal%2520blood%2520flow%26jtitle%3DJ.%2520Surg.%2520Res.%26date%3D2000%26volume%3D93%26spage%3D182%26epage%3D196%26doi%3D10.1006%2Fjsre.2000.5862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jamei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuhoff, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rostami-Hodjegan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, G.</span></span> <span> </span><span class="NLM_article-title">Population-based mechanistic prediction of oral drug absorption</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1208/s12248-009-9099-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1208%2Fs12248-009-9099-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=19381840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVWqs7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=225-237&author=M.+Jameiauthor=D.+Turnerauthor=J.+Yangauthor=S.+Neuhoffauthor=S.+Polakauthor=A.+Rostami-Hodjeganauthor=G.+Tucker&title=Population-based+mechanistic+prediction+of+oral+drug+absorption&doi=10.1208%2Fs12248-009-9099-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Population-based mechanistic prediction of oral drug absorption</span></div><div class="casAuthors">Jamei, Masoud; Turner, David; Yang, Jiansong; Neuhoff, Sibylle; Polak, Sebastian; Rostami-Hodjegan, Amin; Tucker, Geoffrey</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">225-237</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The bioavailability of drugs from oral formulations is influenced by many physiol. factors including gastrointestinal fluid compn., pH and dynamics, transit and motility, and metab. and transport, each of which may vary with age, gender, race, food, and disease.  Therefore, oral bioavailability, particularly of poorly sol. and/or poorly permeable compds. and those that are extensively metabolized, often exhibits a high degree of inter- and intra-individual variability.  While several models and algorithms have been developed to predict bioavailability in an av. person, efforts to accommodate intrinsic variability in the component processes are less common.  An approach that incorporates such variability for human populations within a mechanistic framework is described together with examples of its application to drug and formulation development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovj0j3YTSYCLVg90H21EOLACvtfcHk0ljY2MJ_ZI670g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVWqs7rN&md5=649562cac5b547916fd4362121f3b43d</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1208%2Fs12248-009-9099-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-009-9099-y%26sid%3Dliteratum%253Aachs%26aulast%3DJamei%26aufirst%3DM.%26aulast%3DTurner%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DNeuhoff%26aufirst%3DS.%26aulast%3DPolak%26aufirst%3DS.%26aulast%3DRostami-Hodjegan%26aufirst%3DA.%26aulast%3DTucker%26aufirst%3DG.%26atitle%3DPopulation-based%2520mechanistic%2520prediction%2520of%2520oral%2520drug%2520absorption%26jtitle%3DAAPS%2520J.%26date%3D2009%26volume%3D11%26spage%3D225%26epage%3D237%26doi%3D10.1208%2Fs12248-009-9099-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wohnsland, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faller, B.</span></span> <span> </span><span class="NLM_article-title">High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">923</span>– <span class="NLM_lpage">930</span>, <span class="refDoi"> DOI: 10.1021/jm001020e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm001020e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3MXosFSltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=923-930&author=F.+Wohnslandauthor=B.+Faller&title=High-throughput+permeability+pH+profile+and+high-throughput+alkane%2Fwater+log+P+with+artificial+membranes&doi=10.1021%2Fjm001020e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">High-Throughput Permeability pH Profile and High-Throughput Alkane/Water log P with Artificial Membranes</span></div><div class="casAuthors">Wohnsland, Frank; Faller, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">923-930</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This study reports on a novel, high-throughput assay, designed to predict passive, transcellular permeability in early drug discovery.  The assay is carried out in 96-well microtiterplates and measures the ability of compds. to diffuse from a donor to an acceptor compartment which are sepd. by a 9-10 μm hexadecane liq. layer.  A set of 32 well-characterized, chem. diverse drugs was used to validate the method.  The permeability values derived from the flux factors between donor and acceptor compartments show a good correlation with gastrointestinal absorption in humans.  For comparison, correlations based on exptl. or calcd. octanol/water distribution coeffs. (log Do/w,6.8) were significantly lower.  In addn., this simple and robust assay allows detn. of pH permeability profiles, crit. information to predict gastrointestinal absorption of ionizable drugs and difficult to obtain from cell culture expts.  Correction for the unstirred water layer effect allows to differentiate between effective and intrinsic membrane permeability and opens up the dynamic range of the method.  In addn., alkane/water partition coeffs. can be derived from intrinsic membrane permeabilities, making this assay the first high-throughput method able to measure alkane/water log P in the microtiterplate format.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXoYADWFOUn7Vg90H21EOLACvtfcHk0ljmtQbk4d1oPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXosFSltA%253D%253D&md5=de19e881e03d62d48a8acfea729790b4</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fjm001020e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm001020e%26sid%3Dliteratum%253Aachs%26aulast%3DWohnsland%26aufirst%3DF.%26aulast%3DFaller%26aufirst%3DB.%26atitle%3DHigh-throughput%2520permeability%2520pH%2520profile%2520and%2520high-throughput%2520alkane%252Fwater%2520log%2520P%2520with%2520artificial%2520membranes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D923%26epage%3D930%26doi%3D10.1021%2Fjm001020e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meier, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sztul, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuben, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, J. L.</span></span> <span> </span><span class="NLM_article-title">Structural and functional polarity of canalicular and basolateral plasma membrane vesicles isolated in high yield from rat liver</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">991</span>– <span class="NLM_lpage">1000</span>, <span class="refDoi"> DOI: 10.1083/jcb.98.3.991</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1083%2Fjcb.98.3.991" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=6699096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaL2cXhslWju7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=1984&pages=991-1000&author=P.+J.+Meierauthor=E.+S.+Sztulauthor=A.+Reubenauthor=J.+L.+Boyer&title=Structural+and+functional+polarity+of+canalicular+and+basolateral+plasma+membrane+vesicles+isolated+in+high+yield+from+rat+liver&doi=10.1083%2Fjcb.98.3.991"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and functional polarity of canalicular and basolateral plasma membrane vesicles isolated in high yield from rat liver</span></div><div class="casAuthors">Meier, Peter J.; Sztul, Elizabeth S.; Reuben, Adrian; Boyer, James L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">991-1000</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    </div><div class="casAbstract">A method was developed for routine high yield sepn. of canalicular (cLPM) from basolateral (blLPM) liver plasma membrane vesicles of rat liver.  By using a combination of rate zonal floatation and high speed centrifugation through discontinuous sucrose gradients, 9-16 mg of cLPM and 15-28 mg of blLPM protein can be isolated in 1 day.  CLPM are free of the basolateral markers Na+/K+-ATPase and glucagon-stimulatable adenylate cyclase activities, but are highly enriched with respect to homogenate in the canalicular marker enzyme activities leucylnaphthylamidase (48-fold), γ-glutamyltranspeptidase (60-fold), 5'-nucleotidase (64-fold), alk. phosphatase (71-fold), Mg2+-ATPase (83-fold), and alk. phosphodiesterase I (116-fold).  In contrast, blLPM are 34-fold enriched in Na+/K+-ATPase activity, exhibit considerable glucagon-stimulatable adenylate cyclase activity, and demonstrate a 4- to 15-fold increase over the homogenate in the various canalicular markers.  CLPM have a 2-fold higher content of sialic acids, cholesterol, and sphingomyelin compared with blLPM.  At least three canalicular- (130,000, 100,000, and 58,000 mol. wt.) and several basolateral-specific protein bands have been detected after SDS polyacrylamide gel electrophoresis of the 2 LPM subfractions.  Specifically, the immunoglobin A-binding secretory component is restricted to blLPM as demonstrated by immunochem. techniques.  These data indicate virtually complete sepn. of basolateral from canalicular LPM and demonstrate multiple functional and compositional polarity between the 2 surface domains of hepatocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2VeE25vmdarVg90H21EOLACvtfcHk0ljmtQbk4d1oPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXhslWju7o%253D&md5=bd5010a7b92cdd3f1716abe7b2a70f2e</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1083%2Fjcb.98.3.991&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.98.3.991%26sid%3Dliteratum%253Aachs%26aulast%3DMeier%26aufirst%3DP.%2BJ.%26aulast%3DSztul%26aufirst%3DE.%2BS.%26aulast%3DReuben%26aufirst%3DA.%26aulast%3DBoyer%26aufirst%3DJ.%2BL.%26atitle%3DStructural%2520and%2520functional%2520polarity%2520of%2520canalicular%2520and%2520basolateral%2520plasma%2520membrane%2520vesicles%2520isolated%2520in%2520high%2520yield%2520from%2520rat%2520liver%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D1984%26volume%3D98%26spage%3D991%26epage%3D1000%26doi%3D10.1083%2Fjcb.98.3.991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsushima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>314</i></span>,  <span class="NLM_fpage">1059</span>– <span class="NLM_lpage">1067</span>, <span class="refDoi"> DOI: 10.1124/jpet.105.085589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fjpet.105.085589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=15901800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvFSqsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=314&publication_year=2005&pages=1059-1067&author=S.+Matsushimaauthor=K.+Maedaauthor=C.+Kondoauthor=M.+Hiranoauthor=M.+Sasakiauthor=H.+Suzukiauthor=Y.+Sugiyama&title=Identification+of+the+hepatic+efflux+transporters+of+organic+anions+using+double-transfected+Madin-Darby+canine+kidney+II+cells+expressing+human+organic+anion-transporting+polypeptide+1B1+%28OATP1B1%29%2Fmultidrug+resistance-associated+protein+2%2C+OATP1B1%2Fmultidrug+resistance+1%2C+and+OATP1B1%2Fbreast+cancer+resistance+protein&doi=10.1124%2Fjpet.105.085589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein</span></div><div class="casAuthors">Matsushima, Soichiro; Maeda, Kazuya; Kondo, Chihiro; Hirano, Masaru; Sasaki, Makoto; Suzuki, Hiroshi; Sugiyama, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">314</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1059-1067</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Until recently, it was generally believed that the transport of various org. anions across the bile canalicular membrane was mainly mediated by multidrug resistance-assocd. protein 2 (MRP2/ABCC2).  However, a no. of new reports have shown that some org. anions are also substrates of multidrug resistance 1 (MDR1/ABCB1) and/or breast cancer resistance protein (BCRP/ABCG2), implying MDR1 and BCRP could also be involved in the biliary excretion of org. anions in humans.  In the present study, we constructed new double-transfected Madin-Darby canine kidney II (MDCKII) cells expressing org. anion-transporting polypeptide 1B1 (OATP1B1)/MDR1 and OATP1B1/BCRP, and we investigated the transcellular transport of four kinds of org. anions, estradiol-17β-D-glucuronide (EG), estrone-3-sulfate (ES), pravastatin (PRA), and cerivastatin (CER), to identify which efflux transporters mediate the biliary excretion of compds. using double-transfected cells.  We obsd. the vectorial transport of EG and ES in all the double transfectants.  MRP2 showed the highest efflux clearance of EG among these efflux transporters, whereas BCRP-mediated clearance of ES was the highest in these double transfectants.  In addn., two kinds of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, CER and PRA, were also substrates of all these efflux transporters.  The rank order of the efflux clearance of PRA mediated by each transporter was the same as that of EG, whereas the contribution of MDR1 to the efflux of CER was relatively greater than for PRA.  This exptl. system is very useful for identifying which transporters are involved in the biliary excretion of org. anions that cannot easily penetrate the plasma membrane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpClnguN0ejVrVg90H21EOLACvtfcHk0ljmtQbk4d1oPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvFSqsrk%253D&md5=625443764f3ecaf6a32edc23f1d6d9cd</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.085589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.085589%26sid%3Dliteratum%253Aachs%26aulast%3DMatsushima%26aufirst%3DS.%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DKondo%26aufirst%3DC.%26aulast%3DHirano%26aufirst%3DM.%26aulast%3DSasaki%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DH.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DIdentification%2520of%2520the%2520hepatic%2520efflux%2520transporters%2520of%2520organic%2520anions%2520using%2520double-transfected%2520Madin-Darby%2520canine%2520kidney%2520II%2520cells%2520expressing%2520human%2520organic%2520anion-transporting%2520polypeptide%25201B1%2520%2528OATP1B1%2529%252Fmultidrug%2520resistance-associated%2520protein%25202%252C%2520OATP1B1%252Fmultidrug%2520resistance%25201%252C%2520and%2520OATP1B1%252Fbreast%2520cancer%2520resistance%2520protein%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D314%26spage%3D1059%26epage%3D1067%26doi%3D10.1124%2Fjpet.105.085589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greiner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichelbaum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreichgauer, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Richter, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zundler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, H. K.</span></span> <span> </span><span class="NLM_article-title">The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">153</span>, <span class="refDoi"> DOI: 10.1172/JCI6663</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1172%2FJCI6663" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10411543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK1MXkslSmsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=1999&pages=147-153&author=B.+Greinerauthor=M.+Eichelbaumauthor=P.+Fritzauthor=H.+P.+Kreichgauerauthor=O.+von+Richterauthor=J.+Zundlerauthor=H.+K.+Kroemer&title=The+role+of+intestinal+P-glycoprotein+in+the+interaction+of+digoxin+and+rifampin&doi=10.1172%2FJCI6663"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin</span></div><div class="casAuthors">Greiner, Bernd; Eichelbaum, Michel; Fritz, Peter; Kreichgauer, Hans-Peter; Von Richter, Oliver; Zundler, Johannes; Kroemer, Heyo K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">147-153</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Recent data point to the contribution of P-glycoprotein (P-gp) to digoxin elimination.  On the basis of clin. observations of patients in whom digoxin levels decreased considerably when treated with rifampin, we hypothesized that concomitant rifampin therapy may affect digoxin disposition in humans by induction of P-gp.  We compared single-dose (1 mg oral and 1 mg i.v.) pharmacokinetics of digoxin before and after coadministration of rifampin (600 mg/d for 10 days) in 8 healthy volunteers.  Duodenal biopsies were obtained from each volunteer before and after administration of rifampin.  The area under the plasma concn. time curve (AUC) of oral digoxin was significantly lower during rifampin treatment; the effect was less pronounced after i.v. administration of digoxin.  Renal clearance and half-life of digoxin were not altered by rifampin.  Rifampin treatment increased intestinal P-gp content 3.5±2.1-fold, which correlated with the AUC after oral digoxin but not after i.v. digoxin.  P-gp is a determinant of the disposition of digoxin.  Concomitant administration of rifampin reduced digoxin plasma concns. substantially after oral administration but to a lesser extent after i.v. administration.  The rifampin-digoxin interaction appears to occur largely at the level of the intestine.  Therefore, induction of intestinal P-gp could explain this new type of drug-drug interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn4Eg89l8j67Vg90H21EOLACvtfcHk0liciJJm8Nx61Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXkslSmsb8%253D&md5=e024d8db90e18ebc72cda21d020403f3</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1172%2FJCI6663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI6663%26sid%3Dliteratum%253Aachs%26aulast%3DGreiner%26aufirst%3DB.%26aulast%3DEichelbaum%26aufirst%3DM.%26aulast%3DFritz%26aufirst%3DP.%26aulast%3DKreichgauer%26aufirst%3DH.%2BP.%26aulast%3Dvon%2BRichter%26aufirst%3DO.%26aulast%3DZundler%26aufirst%3DJ.%26aulast%3DKroemer%26aufirst%3DH.%2BK.%26atitle%3DThe%2520role%2520of%2520intestinal%2520P-glycoprotein%2520in%2520the%2520interaction%2520of%2520digoxin%2520and%2520rifampin%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1999%26volume%3D104%26spage%3D147%26epage%3D153%26doi%3D10.1172%2FJCI6663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichelbaum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burk, O.</span></span> <span> </span><span class="NLM_article-title">Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">14581</span>– <span class="NLM_lpage">14587</span>, <span class="refDoi"> DOI: 10.1074/jbc.M010173200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1074%2Fjbc.M010173200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=11297522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjs1OktL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=14581-14587&author=A.+Geickauthor=M.+Eichelbaumauthor=O.+Burk&title=Nuclear+receptor+response+elements+mediate+induction+of+intestinal+MDR1+by+rifampin&doi=10.1074%2Fjbc.M010173200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin</span></div><div class="casAuthors">Geick, Anke; Eichelbaum, Michel; Burk, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">14581-14587</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Intestinal P-glycoprotein, which is encoded by the MDR1 gene, plays an important role in the absorption and presystemic elimination of many xenobiotics.  Hence, an understanding of the factors regulating its expression and function is of substantial interest.  In addn. to genetic factors, exposure to drugs such as rifampin can profoundly affect its expression.  So far, the mechanisms by which rifampin induces MDR1 expression are poorly understood.  Recent studies demonstrate that the nuclear receptor PXR (pregnane X receptor) is involved in xenobiotic induction of CYP3A4.  Because CYP3A4 and MDR1 are often co-induced, we investigated whether a similar mechanism is also involved in MDR1 induction.  The human colon carcinoma cell line LS174T was used as an intestinal model to study induction because in these cells the endogenous MDR1 gene is highly inducible by rifampin.  The 5'-upstream region of human MDR1 was examd. for the presence of potential PXR response elements.  Several binding sites were identified that form a complex regulatory cluster at about -8 kilobase pairs.  Only one DR4 motif within this cluster is necessary for induction by rifampin.  We conclude that induction of MDR1 is mediated by a DR4 motif in the upstream enhancer at about -8 kilobase pairs, to which PXR binds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDciMSSWDvqbVg90H21EOLACvtfcHk0liciJJm8Nx61Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjs1OktL0%253D&md5=756631447fee46a9a89df3bb5a263ea5</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M010173200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M010173200%26sid%3Dliteratum%253Aachs%26aulast%3DGeick%26aufirst%3DA.%26aulast%3DEichelbaum%26aufirst%3DM.%26aulast%3DBurk%26aufirst%3DO.%26atitle%3DNuclear%2520receptor%2520response%2520elements%2520mediate%2520induction%2520of%2520intestinal%2520MDR1%2520by%2520rifampin%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D14581%26epage%3D14587%26doi%3D10.1074%2Fjbc.M010173200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kage, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukahara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuruo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, Y.</span></span> <span> </span><span class="NLM_article-title">C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">611</span>– <span class="NLM_lpage">616</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=12479221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsFSlsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=611-616&author=Y.+Imaiauthor=M.+Nakaneauthor=K.+Kageauthor=S.+Tsukaharaauthor=E.+Ishikawaauthor=T.+Tsuruoauthor=Y.+Mikiauthor=Y.+Sugimoto&title=C421A+polymorphism+in+the+human+breast+cancer+resistance+protein+gene+is+associated+with+low+expression+of+Q141K+protein+and+low-level+drug+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance</span></div><div class="casAuthors">Imai, Yasuo; Nakane, Minoru; Kage, Kumie; Tsukahara, Satomi; Ishikawa, Etsuko; Tsuruo, Takashi; Miki, Yoshio; Sugimoto, Yoshikazu</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">611-616</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Breast cancer resistance protein (BCRP) confers multidrug resistance to cancer cells against agents such as SN-38 (an active metabolite of irinotecan), mitoxantrone, and topotecan.  Among 59 human tumor cell lines tested, 6 cell lines, A549, NCI-H460, KM-12, HT-29, OVCAR-5, and RPMI8226, showed high BCRP expression.  BCRP cDNA was isolated from 11 cancer cell lines and three variant cDNAs [G34A substituting Met for Val-12 (V12M), C421A substituting Lys for Gln-141 (Q141K), and 944-949 deletion lacking Ala-315 and Thr-316 (Δ315-6)] were identified.  G34A and C421A variants were polymorphisms, and 944-949 deletion was a splicing variant.  C421A BCRP-transfected PA317 cells showed markedly decreased protein expression and low-level drug resistance compared with wild-type BCRP-transfected cells when transfectants expressed similar levels of BCRP mRNA.  G34A or 944-949-deleted BCRP-transfected PA317 cells showed similar or somewhat lower protein expression and drug resistance compared with wild-type BCRP-transfected cells.  Of 124 healthy Japanese volunteers, 67 were wild-type, 48 were heterozygous, and 9 were homozygous for the C421A allele.  These results suggest that some people possess the C421A polymorphic BCRP gene and express low amts. of Q141K BCRP.  In addn. to that, C376T polymorphism in exon 4 substituting stop codon for Gln-126 was found in 3 of the 124 general Japanese population.  This C376T polymorphism may also have high impact because active BCRP protein will not be expressed from the C376T allele.  Therefore, people with C376T and/or C421A polymorphisms may express low amts. of BCRP, and this low BCRP expression might result in hypersensitivity of normal cells to such anticancer drugs as irinotecan and mitoxantrone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi90iPFF_n7rVg90H21EOLACvtfcHk0liciJJm8Nx61Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsFSlsr4%253D&md5=48bfdec1e84e6d6d74dad9d54daeee40</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DImai%26aufirst%3DY.%26aulast%3DNakane%26aufirst%3DM.%26aulast%3DKage%26aufirst%3DK.%26aulast%3DTsukahara%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DE.%26aulast%3DTsuruo%26aufirst%3DT.%26aulast%3DMiki%26aufirst%3DY.%26aulast%3DSugimoto%26aufirst%3DY.%26atitle%3DC421A%2520polymorphism%2520in%2520the%2520human%2520breast%2520cancer%2520resistance%2520protein%2520gene%2520is%2520associated%2520with%2520low%2520expression%2520of%2520Q141K%2520protein%2520and%2520low-level%2520drug%2520resistance%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2002%26volume%3D1%26spage%3D611%26epage%3D616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegsmund, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkmann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffeler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weirich, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwab, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichelbaum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burk, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alken, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenpieler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerb, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmeyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brauch, H.</span></span> <span> </span><span class="NLM_article-title">Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors</span>. <i>J. Am. Soc. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1847</span>– <span class="NLM_lpage">1854</span>, <span class="refDoi"> DOI: 10.1097/01.ASN.0000019412.87412.BC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1097%2F01.ASN.0000019412.87412.BC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=12089380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvVSqt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2002&pages=1847-1854&author=M.+Siegsmundauthor=U.+Brinkmannauthor=E.+Schaffelerauthor=G.+Weirichauthor=M.+Schwabauthor=M.+Eichelbaumauthor=P.+Fritzauthor=O.+Burkauthor=J.+Deckerauthor=P.+Alkenauthor=U.+Rothenpielerauthor=R.+Kerbauthor=S.+Hoffmeyerauthor=H.+Brauch&title=Association+of+the+P-glycoprotein+transporter+MDR1%28C3435T%29+polymorphism+with+the+susceptibility+to+renal+epithelial+tumors&doi=10.1097%2F01.ASN.0000019412.87412.BC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Association of the P-glycoprotein transporter MDR1C3435T polymorphism with the susceptibility to renal epithelial tumors</span></div><div class="casAuthors">Siegsmund, Michael; Brinkmann, Ulrich; Schaffeler, Elke; Weirich, Gregor; Schwab, Matthias; Eichelbaum, Michel; Fritz, Peter; Burk, Oliver; Decker, Jochen; Alken, Peter; Rothenpieler, Uwe; Kerb, Reinhold; Hoffmeyer, Sven; Brauch, Hiltrud</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Society of Nephrology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1847-1854</span>CODEN:
                <span class="NLM_cas:coden">JASNEU</span>;
        ISSN:<span class="NLM_cas:issn">1046-6673</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Except for hereditary disease, genetic factors that contribute to the development of renal epithelial tumors are unknown.  There is a possibility that the MDR1 encoded plasma membrane transporter P-glycoprotein (PGP) influences the risk of development of renal neoplasms.  PGP is known to be involved in uptake, binding, transport, and distribution of xenobiotics.  There is evidence that the MDR1C3435T polymorphism drives expression and modulates disease risk.  In an explorational case-control study, constitutional genotype frequencies were established at MDR1C3435T of 537 healthy control subjects and compared with those of 212 patients with renal epithelial tumors.  There were 179 clear cell renal cell carcinoma (CCRCC) and 33 tumors collectively assigned as non-CCRCC.  In a second study, genotypes of another 150 healthy control subjects and 50 patients with three non-CCRCC types (26 papillary RCC, 11 chromophobe RCC, and 13 renal oncocytic adenoma) were compared.  PCR-restriction fragment length polymorphism-based anal. of constitutional DNA, and statistical anal. were applied.  PGP expression was analyzed by quant. immunohistochem.  The explorational study showed a significant assocn. between T allele frequency and the occurrence of tumors (P = 0.007).  When tumors were histopathol. distinguished into frequent CCRCC and less frequent non-CCRCC, both patient groups contributed to this effect with a seemingly strong influence by the latter (P = 0.0419).  The second study established the T allele as a risk factor esp. for non-CCRCC (P = 0.0005) with the highest risk for homozygote TT allele carriers (P < 0.0001).  Independently, MDR1C3435T genotype assocd. variations in PGP expression were shown in normal renal parenchyma with a 1.5-fold difference of median values (TT, 1.9; CC, 2.8; P = 0.0065).  The data provide evidence for PGP to influence the susceptibility to develop renal epithelial tumors by virtue of its MDR1C3435T polymorphism and changes in expression.  Esp. T and TT carriers are at risk for developing non-CCRCC, i.e., papillary and chromophobe RCC as well as oncocytic adenomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC5F-bzIgWjbVg90H21EOLACvtfcHk0lg1uk9UZ57Phg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvVSqt7w%253D&md5=5ccbb9bcd2d00ff7adc101261a5d8aae</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1097%2F01.ASN.0000019412.87412.BC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.ASN.0000019412.87412.BC%26sid%3Dliteratum%253Aachs%26aulast%3DSiegsmund%26aufirst%3DM.%26aulast%3DBrinkmann%26aufirst%3DU.%26aulast%3DSchaffeler%26aufirst%3DE.%26aulast%3DWeirich%26aufirst%3DG.%26aulast%3DSchwab%26aufirst%3DM.%26aulast%3DEichelbaum%26aufirst%3DM.%26aulast%3DFritz%26aufirst%3DP.%26aulast%3DBurk%26aufirst%3DO.%26aulast%3DDecker%26aufirst%3DJ.%26aulast%3DAlken%26aufirst%3DP.%26aulast%3DRothenpieler%26aufirst%3DU.%26aulast%3DKerb%26aufirst%3DR.%26aulast%3DHoffmeyer%26aufirst%3DS.%26aulast%3DBrauch%26aufirst%3DH.%26atitle%3DAssociation%2520of%2520the%2520P-glycoprotein%2520transporter%2520MDR1%2528C3435T%2529%2520polymorphism%2520with%2520the%2520susceptibility%2520to%2520renal%2520epithelial%2520tumors%26jtitle%3DJ.%2520Am.%2520Soc.%2520Nephrol.%26date%3D2002%26volume%3D13%26spage%3D1847%26epage%3D1854%26doi%3D10.1097%2F01.ASN.0000019412.87412.BC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferraris, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, J. M.</span></span> <span> </span><span class="NLM_article-title">Origin of regional and species differences in intestinal glucose uptake</span>. <i>Am. J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>257</i></span>,  <span class="NLM_fpage">G689</span>– <span class="NLM_lpage">697</span>, <span class="refDoi"> DOI: 10.1152/ajpgi.1989.257.5.G689</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1152%2Fajpgi.1989.257.5.G689" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=2596605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK3cXhvFansw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=257&publication_year=1989&pages=G689-697&author=R.+P.+Ferrarisauthor=P.+P.+Leeauthor=J.+M.+Diamond&title=Origin+of+regional+and+species+differences+in+intestinal+glucose+uptake&doi=10.1152%2Fajpgi.1989.257.5.G689"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Origin of regional and species differences in intestinal glucose uptake</span></div><div class="casAuthors">Ferraris, Ronaldo P.; Lee, Peter P.; Diamond, Jared M.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Physiology</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">257</span>
        (<span class="NLM_cas:issue">5, Pt. 1</span>),
    <span class="NLM_cas:pages">G689-G697</span>CODEN:
                <span class="NLM_cas:coden">AJPHAP</span>;
        ISSN:<span class="NLM_cas:issn">0002-9513</span>.
    </div><div class="casAbstract">The origin of differences in glucose (I) absorption was examd. among 3 species (mouse, desert wood rat (Neotoma lepida), and desert iguana (Dipsosaurus dorsalis)) and among 3 intestinal regions in 2 of these species.  Turnover nos. ranged from 6900 to 32,300 I mols./min/site.  Microvilli amplify intestinal area by a larger factor (36-96-fold) than did villi (2-14-fold), so that the intestine's actual area is ≥110-1280-fold the nominal area of the equiv. smooth-bore cylinder.  Species comparisons among mammals yielded the striking result that the area of the whole length of the small intestine at the microvillus level varied nearly linearly with the mammal's metabolic live mass.  For the species studied, all the anatomical and biochem. factors studied proved to make significant contributions to species and regional differences in I uptake.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7mfZilYp9i7Vg90H21EOLACvtfcHk0lg1uk9UZ57Phg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXhvFansw%253D%253D&md5=ab3eafe95f95d35c9d511a68d94d6763</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1152%2Fajpgi.1989.257.5.G689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpgi.1989.257.5.G689%26sid%3Dliteratum%253Aachs%26aulast%3DFerraris%26aufirst%3DR.%2BP.%26aulast%3DLee%26aufirst%3DP.%2BP.%26aulast%3DDiamond%26aufirst%3DJ.%2BM.%26atitle%3DOrigin%2520of%2520regional%2520and%2520species%2520differences%2520in%2520intestinal%2520glucose%2520uptake%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1989%26volume%3D257%26spage%3DG689%26epage%3D697%26doi%3D10.1152%2Fajpgi.1989.257.5.G689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kararli, T. T.</span></span> <span> </span><span class="NLM_article-title">Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">380</span>, <span class="refDoi"> DOI: 10.1002/bdd.2510160502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1002%2Fbdd.2510160502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=8527686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK2MXmvFOls70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1995&pages=351-380&author=T.+T.+Kararli&title=Comparison+of+the+gastrointestinal+anatomy%2C+physiology%2C+and+biochemistry+of+humans+and+commonly+used+laboratory+animals&doi=10.1002%2Fbdd.2510160502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals</span></div><div class="casAuthors">Kararli, Tugrul T.</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">351-80</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">Wiley</span>)
        </div><div class="casAbstract">A review with 79 refs. on the anatomical, physiol., and biochem. differences between the G.I. tracts of humans and commonly used lab. animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm5RocAmNVwLVg90H21EOLACvtfcHk0lg1uk9UZ57Phg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmvFOls70%253D&md5=28a96f8348eadac3ab82ef3248c1bad8</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1002%2Fbdd.2510160502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.2510160502%26sid%3Dliteratum%253Aachs%26aulast%3DKararli%26aufirst%3DT.%2BT.%26atitle%3DComparison%2520of%2520the%2520gastrointestinal%2520anatomy%252C%2520physiology%252C%2520and%2520biochemistry%2520of%2520humans%2520and%2520commonly%2520used%2520laboratory%2520animals%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D1995%26volume%3D16%26spage%3D351%26epage%3D380%26doi%3D10.1002%2Fbdd.2510160502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simons, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renouf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, P. A.</span></span> <span> </span><span class="NLM_article-title">Human gut microbial degradation of flavonoids: structure-function relationships</span>. <i>J. Agric. Food Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">4258</span>– <span class="NLM_lpage">4263</span>, <span class="refDoi"> DOI: 10.1021/jf0500177</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jf0500177" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsFahtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2005&pages=4258-4263&author=A.+L.+Simonsauthor=M.+Renoufauthor=S.+Hendrichauthor=P.+A.+Murphy&title=Human+gut+microbial+degradation+of+flavonoids%3A+structure-function+relationships&doi=10.1021%2Fjf0500177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Human gut microbial degradation of flavonoids: Structure-function relationships</span></div><div class="casAuthors">Simons, Andrean L.; Renouf, Mathieu; Hendrich, Suzanne; Murphy, Patricia A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Agricultural and Food Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4258-4263</span>CODEN:
                <span class="NLM_cas:coden">JAFCAU</span>;
        ISSN:<span class="NLM_cas:issn">0021-8561</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The relationship between chem. structure and gut microbial degrdn. rates of 14 flavonoids, flavone, apigenin, chrysin, naringenin, kaempferol, genistein, daidzein, daidzin, puerarin, 7,4'-dihydroxyflavone, 6,4'-dihydroxyflavone, 5,4'-dihydroxyflavone, 5,3'-dihydroxyflavone, and 4'-hydroxyflavone, was investigated by anaerobically fermenting the flavonoids with human gut microflora (n = 11 subjects).  Degrdn. rates for the 5,7,4'-trihydroxyl flavonoids, apigenin, genistein, naringenin, and kaempferol, were significantly faster than the other structural motifs.  Puerarin was resistant to degrdn. by the gut microflora.  Extensive degrdn. of flavonoids by gut microflora may result in lower overall bioavailability than those flavonoids that are slowly degraded because rapidly degrading flavonoids are less likely to be absorbed intact.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoukQX3NtHVyLVg90H21EOLACvtfcHk0lg1uk9UZ57Phg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsFahtr8%253D&md5=6abf4bccf04ade027476a81bbe1c7ab0</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjf0500177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjf0500177%26sid%3Dliteratum%253Aachs%26aulast%3DSimons%26aufirst%3DA.%2BL.%26aulast%3DRenouf%26aufirst%3DM.%26aulast%3DHendrich%26aufirst%3DS.%26aulast%3DMurphy%26aufirst%3DP.%2BA.%26atitle%3DHuman%2520gut%2520microbial%2520degradation%2520of%2520flavonoids%253A%2520structure-function%2520relationships%26jtitle%3DJ.%2520Agric.%2520Food%2520Chem.%26date%3D2005%26volume%3D53%26spage%3D4258%26epage%3D4263%26doi%3D10.1021%2Fjf0500177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLeod, B. J.</span></span> <span> </span><span class="NLM_article-title">Physiology and pharmacology of the brushtail possum gastrointestinal tract: relationship to the human gastrointestinal tract</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1121</span>– <span class="NLM_lpage">1132</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2007.06.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1016%2Fj.addr.2007.06.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=17870201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1amsL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2007&pages=1121-1132&author=A.+McDowellauthor=B.+J.+McLeod&title=Physiology+and+pharmacology+of+the+brushtail+possum+gastrointestinal+tract%3A+relationship+to+the+human+gastrointestinal+tract&doi=10.1016%2Fj.addr.2007.06.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Physiology and pharmacology of the brushtail possum gastrointestinal tract: Relationship to the human gastrointestinal tract</span></div><div class="casAuthors">McDowell, Arlene; McLeod, Bernie J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1121-1132</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Oral formulations are typically based on studies from eutherian animal models.  This review introduces information relating to oral formulations for a marsupial species, the Australian brushtail possum (Trichosurus vulpecula) that has arisen from research into new methods for controlling this species - a major vertebrate pest in New Zealand.  Morphol., the gastrointestinal tract of the brushtail possum is similar to that of hindgut fermenting eutherian species, but there are some striking differences in function.  Limited data suggests that the pharmacokinetics and bioavailability of administered drugs are similar to that in eutherian species, but there is some evidence that possums may have specific mechanisms for handling the intake of plant toxins and xenobiotics.  The development of oral formulations for a free-ranging pest species presents several challenges above those encountered in the development of therapeutic formulations for humans and domestic animals.  Use of a marsupial animal model may lead to new strategies for oral formulations in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6rd8u6LoLMbVg90H21EOLACvtfcHk0lgWiEjdsu5m5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1amsL7O&md5=74f21941b5c9e8801987676e4e39d1b6</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2007.06.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2007.06.012%26sid%3Dliteratum%253Aachs%26aulast%3DMcDowell%26aufirst%3DA.%26aulast%3DMcLeod%26aufirst%3DB.%2BJ.%26atitle%3DPhysiology%2520and%2520pharmacology%2520of%2520the%2520brushtail%2520possum%2520gastrointestinal%2520tract%253A%2520relationship%2520to%2520the%2520human%2520gastrointestinal%2520tract%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2007%26volume%3D59%26spage%3D1121%26epage%3D1132%26doi%3D10.1016%2Fj.addr.2007.06.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolger, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukacova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woltosz, W. S.</span></span> <span> </span><span class="NLM_article-title">Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">363</span>, <span class="refDoi"> DOI: 10.1208/s12248-009-9111-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1208%2Fs12248-009-9111-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=19434502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVWqs7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=353-363&author=M.+B.+Bolgerauthor=V.+Lukacovaauthor=W.+S.+Woltosz&title=Simulations+of+the+nonlinear+dose+dependence+for+substrates+of+influx+and+efflux+transporters+in+the+human+intestine&doi=10.1208%2Fs12248-009-9111-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine</span></div><div class="casAuthors">Bolger, Michael B.; Lukacova, Viera; Woltosz, Walter S.</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">353-363</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The purpose of this study was to develop simulation and modeling methods for the evaluation of pharmacokinetics when intestinal influx and efflux transporters are involved in gastrointestinal absorption.  The advanced compartmental absorption and transit (ACAT) model as part of the computer program GastroPlus was used to simulate the absorption and pharmacokinetics of valacyclovir, gabapentin, and talinolol.  Each of these drugs is a substrate for an influx or efflux transporter and all show nonlinear dose dependence within the normal therapeutic range.  These simulations incorporated the exptl. derived gastrointestinal distributions of transporter expression levels for oligopeptide transporters PepT1 and HPT1 (valacyclovir): System L-amino acid transporter LAT2 and org. cation transporter OCTN1 (gabapentin); and org. anion transporter (OATP1A2) and P-glycoprotein (talinolol).  By assuming a uniform distribution of oligopeptide transporter and by application of the in vitro Km value for valacyclovir, the simulations accurately reproduced the exptl. nonlinear dose dependence.  For gabapentin, LAT2 distribution produced simulation results that were much more accurate than OCTN1 distributions.  For talinolol, an influx transporter distribution for OATP1A2 and the efflux transporter P-glycoprotein distributed with increasing expression in the distal small intestine produced the best results.  The physiol. characteristics of the small and large intestines used in the ACAT model were able to accurately account for the positional and temporal changes in concn. and carrier-mediated transport of the three drugs included in this study.  The ACAT model reproduced the nonlinear dose dependence for each of these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHFmD6zWSCS7Vg90H21EOLACvtfcHk0lgWiEjdsu5m5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVWqs7vP&md5=a0f1c10c2d1d3f607ed8b2ccea0bc5ed</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1208%2Fs12248-009-9111-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-009-9111-6%26sid%3Dliteratum%253Aachs%26aulast%3DBolger%26aufirst%3DM.%2BB.%26aulast%3DLukacova%26aufirst%3DV.%26aulast%3DWoltosz%26aufirst%3DW.%2BS.%26atitle%3DSimulations%2520of%2520the%2520nonlinear%2520dose%2520dependence%2520for%2520substrates%2520of%2520influx%2520and%2520efflux%2520transporters%2520in%2520the%2520human%2520intestine%26jtitle%3DAAPS%2520J.%26date%3D2009%26volume%3D11%26spage%3D353%26epage%3D363%26doi%3D10.1208%2Fs12248-009-9111-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abuasal, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolger, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaddoumi, A.</span></span> <span> </span><span class="NLM_article-title">In silico modeling for the nonlinear absorption kinetics of uk-343,664: a p-gp and CYP3A4 substrate</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">492</span>– <span class="NLM_lpage">504</span>, <span class="refDoi"> DOI: 10.1021/mp200275j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp200275j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC38XpslGgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=492-504&author=B.+S.+Abuasalauthor=M.+B.+Bolgerauthor=D.+K.+Walkerauthor=A.+Kaddoumi&title=In+silico+modeling+for+the+nonlinear+absorption+kinetics+of+uk-343%2C664%3A+a+p-gp+and+CYP3A4+substrate&doi=10.1021%2Fmp200275j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">In Silico Modeling for the Nonlinear Absorption Kinetics of UK-343,664: A P-gp and CYP3A4 Substrate</span></div><div class="casAuthors">Abuasal, Bilal S.; Bolger, Michael B.; Walker, Don K.; Kaddoumi, Amal</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">492-504</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The aim of this work was to extrapolate in vitro and preclin. animal data to simulate the pharmacokinetic parameters of UK-343,664, a P-glycoprotein (P-gp) and CYP3A4 substrate, in human.  In addn., we aimed to develop a simulation model to demonstrate the involvement and the controversial complex interaction of intestinal P-gp and CYP3A4 in its nonlinear absorption, first-pass extn., and pharmacokinetics using the advanced compartmental absorption and transit (ACAT) model.  Finally, we aimed to compare the results predicted from the model to the reported findings in human clin. studies.  In situ perfusion, allometric scaling, PBPK Rodger mechanistic approach, in vitro metab., and fitting to in vivo data were used to mechanistically explain the absorption, distribution and metab., resp.  GastroPlus was used to build the integrated simulation model in human for UK-343,664 to mechanistically explain the obsd. clin. data at 30, 100, 200, 400, and 800 mg oral doses.  The measured in vitro value for CYP3A4 Km (465 μM) in rCYPs was converted to units of μg/mL, cor. for assumed microsomal binding (17.8%) and applied to all metabolic processes.  The measured in vitro values of Vmax for CYP3A4 (38.9 pmol/min/pmol), 2C8, 2C9, 2C19, and 2D6 were used along with the in vitro CYP3A4 Km to simulate liver first pass extn. and systemic clearance.  The measured in vitro values of Vmax for CYP3A4 and 2D6 were used along with the in vitro CYP3A4 Km to simulate gut first pass extn.  Vmax and Km values for P-gp were obtained by fitting to in vivo data and used to simulate gut efflux transport activity.  Investigation of the interaction mechanism of P-gp and CYP3A4 in the intestine was achieved by comparing the influence of a virtual knockout of P-gp or gut metab. on the fraction absorbed, fraction reaching the portal vein, and fraction metabolized in the gut.  Comparison between simulation and in vivo results showed that the in silico simulation provided a mechanistic explanation of the obsd. nonlinear absorption kinetics of UK-343,664 in human following its administration in the range of 30-800 mg as oral solns.  The simulation results of the pharmacokinetic parameters, AUC and Cmax, by GastroPlus were comparable with those obsd. in vivo.  This simulation model is one possible mechanistic explanation of the obsd. in vivo data and suggests that the nonlinear dose dependence could be attributed to satn. of both the efflux transport by P-gp and the intestinal metab.  However, the concn. ranges for either protein satn. did not overlap and resulted in much greater than dose proportional increases in AUC.  At low doses, producing intraenterocyte concns. below the fitted value of Km for P-gp, the influence of P-gp appears to be protective and results in a lower fraction of gut 3A4 metab.  At higher doses, as P-gp becomes satd. the fraction of gut 3A4 extn. increases, and eventually at the highest doses, where 3A4 becomes satd., the fraction of gut 3A4 extn. again decreases.  Such a complex interpretation of this in vitro-in vivo extrapolation (IVIVE) is another example of the value and insight obtained by physiol. based absorption simulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIsJkjLN89rLVg90H21EOLACvtfcHk0lgWiEjdsu5m5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpslGgsg%253D%253D&md5=4b0fa914ed5b029df6e2fde5d3cbaf61</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fmp200275j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp200275j%26sid%3Dliteratum%253Aachs%26aulast%3DAbuasal%26aufirst%3DB.%2BS.%26aulast%3DBolger%26aufirst%3DM.%2BB.%26aulast%3DWalker%26aufirst%3DD.%2BK.%26aulast%3DKaddoumi%26aufirst%3DA.%26atitle%3DIn%2520silico%2520modeling%2520for%2520the%2520nonlinear%2520absorption%2520kinetics%2520of%2520uk-343%252C664%253A%2520a%2520p-gp%2520and%2520CYP3A4%2520substrate%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26spage%3D492%26epage%3D504%26doi%3D10.1021%2Fmp200275j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/S0928-0987(00)00178-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1016%2FS0928-0987%2800%2900178-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=11121729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3cXot1yiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2000&pages=3-12&author=H.+Suzukiauthor=Y.+Sugiyama&title=Role+of+metabolic+enzymes+and+efflux+transporters+in+the+absorption+of+drugs+from+the+small+intestine&doi=10.1016%2FS0928-0987%2800%2900178-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine</span></div><div class="casAuthors">Suzuki, H.; Sugiyama, Y.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-12</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with over 90 refs.  It has been established that the absorption of many drugs from the small intestine is hindered by the detoxification systems which are present in this epithelial tissue.  In this article, we will summarize the significant role of small intestine in reducing the oral bioavailability of drugs, particularly focusing on the role of metabolic enzymes and efflux transporters.  Since the role of cytochrome P 450 3A (CYP3A) and MDR1 P-glycoprotein (P-gp) in intestinal drug disposition has been highlighted, the disposition of CYP3A substrates, P-gp substrates and CYP3A/P-gp bisubstrates are summarized.  Moreover, it is plausible that conjugative enzymes and/or carboxyesterases act synergistically with efflux transporters of org. anions, affecting the intestinal availability, i.e. many xenobiotics and ester-type prodrugs are metabolized to the corresponding glucuronide and sulfate conjugates and carboxylates (active drugs), resp., followed by cellular extrusion.  The characteristics of the efflux transporters of org. anions across the apical and basal membrane of enterocytes and Caco-2 cells are also summarized from this point of view.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmQiM2dVuEyLVg90H21EOLACvtfcHk0lhYmtJlEmCGXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXot1yiu74%253D&md5=d702f535de468889bc7ebbbb130e41af</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2FS0928-0987%2800%2900178-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0928-0987%252800%252900178-0%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DH.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DRole%2520of%2520metabolic%2520enzymes%2520and%2520efflux%2520transporters%2520in%2520the%2520absorption%2520of%2520drugs%2520from%2520the%2520small%2520intestine%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2000%26volume%3D12%26spage%3D3%26epage%3D12%26doi%3D10.1016%2FS0928-0987%2800%2900178-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paine, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludington, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haining, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rettie, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeldin, D. C.</span></span> <span> </span><span class="NLM_article-title">The human intestinal cytochrome P450 ″pie″</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">880</span>– <span class="NLM_lpage">886</span>, <span class="refDoi"> DOI: 10.1124/dmd.105.008672</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.105.008672" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=16467132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD28Xks1Skt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=880-886&author=M.+F.+Paineauthor=H.+L.+Hartauthor=S.+S.+Ludingtonauthor=R.+L.+Hainingauthor=A.+E.+Rettieauthor=D.+C.+Zeldin&title=The+human+intestinal+cytochrome+P450+%E2%80%B3pie%E2%80%B3&doi=10.1124%2Fdmd.105.008672"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">The human intestinal cytochrome P450 "PIE"</span></div><div class="casAuthors">Paine, Mary F.; Hart, Heather L.; Ludington, Shana S.; Haining, Robert L.; Rettie, Allan E.; Zeldin, Darryl C.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">880-886</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Cytochromes P 450 (P 450s) 3A, 2C, and 1A2 constitute the major "pieces" of the human liver P 450 "pie" and account, on av., for 40, 25, and 18%, resp., of total immunoquantified P 450s.  The P 450 profile in the human small intestine has not been fully characterized.  Therefore, microsomes prepd. from mucosal scrapings from the duodenal/jejunal portion of 31 human donor small intestines were analyzed by Western blot using selective P 450 antibodies.  P 450s 3A4, 2C9, 2C19, and 2J2 were detected in all individuals and ranged from 8.8 to 150, 2.9 to 27, <0.6 to 3.9, and <0.2 to 3.1 pmol/mg, resp.  CYP2D6 was detected in 29 individuals and ranged from <0.2 to 1.4 pmol/mg.  CYP3A5 was detected readily in 11 individuals, with a range (av.) of 4.9 to 25 (16) pmol/mg that represented from 3 to 50% of total CYP3A (CYP3A4 + CYP3A5) content.  CYP1A1 was detected readily in three individuals, with a range (av.) of 3.6 to 7.7 (5.6) pmol/mg.  P 450s 1A2, 2A6, 2B6, 2C8, and 2E1 were not or only faintly detected.  As anticipated, av. CYP3A content (50 pmol/mg) was the highest.  Excluding CYP1A1, the remaining enzymes had the following rank order: 2C9>2C19>2J2>2D6 (8.4, 1.1, 0.9, and 0.5 pmol/mg, resp.).  Anal. of a pooled prepn. of the 31 donor specimens substantiated these results.  In summary, as in the liver, large interindividual variation exists in the expression levels of individual P 450s.  On av., CYP3A and CYP2C9 represents the major pieces of the intestinal P 450 pie, accounting for 80 and 15%, resp., of total immunoquantified P 450s.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfnz4o-ZdSeLVg90H21EOLACvtfcHk0lhYmtJlEmCGXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xks1Skt7k%253D&md5=b17b714367cae7b365174bbd3a8f25f3</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1124%2Fdmd.105.008672&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.105.008672%26sid%3Dliteratum%253Aachs%26aulast%3DPaine%26aufirst%3DM.%2BF.%26aulast%3DHart%26aufirst%3DH.%2BL.%26aulast%3DLudington%26aufirst%3DS.%2BS.%26aulast%3DHaining%26aufirst%3DR.%2BL.%26aulast%3DRettie%26aufirst%3DA.%2BE.%26aulast%3DZeldin%26aufirst%3DD.%2BC.%26atitle%3DThe%2520human%2520intestinal%2520cytochrome%2520P450%2520%25E2%2580%25B3pie%25E2%2580%25B3%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26spage%3D880%26epage%3D886%26doi%3D10.1124%2Fdmd.105.008672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacono, L.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacokinetics and the impact of genetic polymorphism on a CYP2C19 substrate, BMS-823778, in healthy subjects</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">316</span>– <span class="NLM_lpage">325</span>, <span class="refDoi"> DOI: 10.1124/dmd.117.078824</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.117.078824" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=29311135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A280%3ADC%252BC1MzosVKquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=316-325&author=J.+Gongauthor=L.+Hansenauthor=L.+Iacono&title=Clinical+pharmacokinetics+and+the+impact+of+genetic+polymorphism+on+a+CYP2C19+substrate%2C+BMS-823778%2C+in+healthy+subjects&doi=10.1124%2Fdmd.117.078824"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Pharmacokinetics and the Impact of Genetic Polymorphism on a CYP2C19 Substrate, BMS-823778, in Healthy Subjects</span></div><div class="casAuthors">Gong Jiachang; Hansen Lars; Iacono Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Drug metabolism and disposition: the biological fate of chemicals</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">316-325</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BMS-823778 is a potent and selective inhibitor of 11β-HSD1, an enzyme that regulates tissue-specific intracellular glucocorticoid metabolism and is a compelling target for the treatment of metabolic diseases.  Metabolism of BMS-823778 was mediated mainly by polymorphic CYP2C19, with minor contributions from CYP3A4/5 and UGT1A4.  The clinical pharmacokinetics (PK) of BMS-823778 was first investigated in healthy volunteers after single and multiple ascending doses.  BMS-823778 was rapidly absorbed after the oral dose, and systemic exposure at steady state increased proportionally to the dose.  Large intersubject variability in BMS-823778 exposure was likely because of the polymorphism of metabolic enzymes.  The impact of genetic polymorphism of CYP2C19, UGT1A4, and CYP3A5 on BMS-823778 PK was assessed in healthy Chinese and Japanese subjects, as well as in a human absorption, distribution, metabolism, and excretion study in which all subjects were genotyped either before or after treatment.  A clear trend of high exposure and low clearance was seen in poor metabolizers (PMs) of CYP2C19 compared with extensive (EM) and intermediate metabolizer (IM) subjects.  The impact of UGT1A4 or CYP3A5 polymorphism on BMS-823778 PK was statistically not significant in CYP2C19 EM and IM subjects; however, in a subject with predicted CYP2C19 PM phenotype, the PK of BMS-823778 was affected significantly by UGT1A4 polymorphism.  Overall, BMS-823778 was safe and well tolerated in healthy subjects after single or multiple oral doses.  The PK of BMS-823778 was characterized by rapid absorption, and the systemic clearance directly correlated with the genetic polymorphism of CYP2C19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRa0SOUaIcjTXO4gDb7JggCfW6udTcc2eYQfH5lUf3Cvrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MzosVKquw%253D%253D&md5=0224decd6a1da1a4c855da0c11776e31</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1124%2Fdmd.117.078824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.117.078824%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DHansen%26aufirst%3DL.%26aulast%3DIacono%26aufirst%3DL.%26atitle%3DClinical%2520pharmacokinetics%2520and%2520the%2520impact%2520of%2520genetic%2520polymorphism%2520on%2520a%2520CYP2C19%2520substrate%252C%2520BMS-823778%252C%2520in%2520healthy%2520subjects%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2018%26volume%3D46%26spage%3D316%26epage%3D325%26doi%3D10.1124%2Fdmd.117.078824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacono, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span> <span> </span><span class="NLM_article-title">Physiologically-based pharmacokinetic modelling of a CYP2C19 substrate, BMS823778, utilizing pharmacogenetic data</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">1335</span>– <span class="NLM_lpage">1345</span>, <span class="refDoi"> DOI: 10.1111/bcp.13565</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1111%2Fbcp.13565" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=29469197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOmtb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2018&pages=1335-1345&author=J.+Gongauthor=L.+Iaconoauthor=R.+A.+Iyerauthor=W.+G.+Humphreysauthor=M.+Zheng&title=Physiologically-based+pharmacokinetic+modelling+of+a+CYP2C19+substrate%2C+BMS823778%2C+utilizing+pharmacogenetic+data&doi=10.1111%2Fbcp.13565"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Physiologically-based pharmacokinetic modelling of a CYP2C19 substrate, BMS-823778, utilizing pharmacogenetic data</span></div><div class="casAuthors">Gong, Jiachang; Iacono, Lisa; Iyer, Ramaswamy A.; Humphreys, William G.; Zheng, Ming</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1335-1345</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : Previous studies demonstrated direct correlation between CYP2C19 genotype and BMS-823778 clearance in healthy volunteers.  The objective of the present study was to develop a physiol.-based pharmacokinetic (PBPK) model for BMS-823778 and use the model to predict PK and drug-drug interaction (DDI) in virtual populations with multiple polymorphic genes.  Methods : The PBPK model was built and verified using existing clin. data.  The verified model was simulated to predict PK of BMS-823778 and significance of DDI with a strong CYP3A4 inhibitor in subjects with various CYP2C19 and UGT1A4 genotypes.  Results : The verified PBPK model of BMS-823778 accurately recovered obsd. PK in different populations.  In addn., the model was able to capture the exposure differences between subjects with different CYP2C19 genotypes.  PK simulation indicated higher exposures of BMS-823778 in CYP2C19 poor metabolizers who were also devoid of UGT1A4 activity, compared to those with normal UGT1A4 functionality.  Moderate DDI with itraconazole was predicted in subjects with wild-type CYP2C19 or UGT1A4.  However, in subjects without CYP2C19 or UGT1A4 functionality, significant DDI was predicted when BMS-823778 was coadministered with itraconazole.  Conclusions : A PBPK model was developed using clin. data that accurately predicted human PK in different population with various CYP2C19 phenotypes.  Simulations with the verified PBPK model indicated that UGT1A4 was probably an important clearance pathway in CYP2C19 poor metabolizers.  DDI with itraconazole is likely to be dependent on the genotypes of CYP2C19 and UGT1A4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKf4yqswq2F7Vg90H21EOLACvtfcHk0lgiXxbWcaeQRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOmtb%252FK&md5=af01439445b6778dd82e8d2d77e13126</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1111%2Fbcp.13565&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.13565%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DIacono%26aufirst%3DL.%26aulast%3DIyer%26aufirst%3DR.%2BA.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DZheng%26aufirst%3DM.%26atitle%3DPhysiologically-based%2520pharmacokinetic%2520modelling%2520of%2520a%2520CYP2C19%2520substrate%252C%2520BMS823778%252C%2520utilizing%2520pharmacogenetic%2520data%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2018%26volume%3D84%26spage%3D1335%26epage%3D1345%26doi%3D10.1111%2Fbcp.13565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knights, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miners, J. O.</span></span> <span> </span><span class="NLM_article-title">Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT)</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">602</span>, <span class="refDoi"> DOI: 10.1111/bcp.12086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1111%2Fbcp.12086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=23362865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFGgurrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2013&pages=587-602&author=K.+M.+Knightsauthor=A.+Rowlandauthor=J.+O.+Miners&title=Renal+drug+metabolism+in+humans%3A+the+potential+for+drug-endobiotic+interactions+involving+cytochrome+P450+%28CYP%29+and+UDP-glucuronosyltransferase+%28UGT%29&doi=10.1111%2Fbcp.12086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT)</span></div><div class="casAuthors">Knights, Kathleen M.; Rowland, Andrew; Miners, John O.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">587-602</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Although knowledge of human renal cytochrome P 450 (CYP) and UDP-glucuronosyltransferase (UGT) enzymes and their role in xenobiotic and endobiotic metab. is limited compared with hepatic drug and chem. metab., accumulating evidence indicates that human kidney has significant metabolic capacity.  Of the drug metabolizing P450s in families 1 to 3, there is definitive evidence for only CYP 2B6 and 3A5 expression in human kidney.  CYP 1A1, 1A2, 1B1, 2A6, 2C19, 2D6 and 2E1 are not expressed in human kidney, while data for CYP 2C8, 2C9 and 3A4 expression are equivocal.  It is further known that several P 450 enzymes involved in the metab. of arachidonic acid and eicosanoids are expressed in human kidney, CYP 4A11, 4F2, 4F8, 4F11 and 4F12.  With the current limited evidence of drug substrates for human renal P450s drug-endobiotic interactions arising from inhibition of renal P450s, particularly effects on arachidonic acid metab., appear unlikely.  With respect to the UGTs, 1A5, 1A6, 1A7, 1A9, 2B4, 2B7 and 2B17 are expressed in human kidney, whereas UGT 1A1, 1A3, 1A4, 1A8, 1A10, 2B10, 2B11 and 2B15 are not.  The most abundantly expressed renal UGTs are 1A9 and 2B7, which play a significant role in the glucuronidation of drugs, arachidonic acid, prostaglandins, leukotrienes and P 450 derived arachidonic acid metabolites.  Modulation by drug substrates (e.g. NSAIDs) of the intrarenal activity of UGT1A9 and UGT2B7 has the potential to perturb the metab. of renal mediators including aldosterone, prostaglandins and 20-hydroxyeicosatetraenoic acid, thus disrupting renal homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQROTBuuaXU7Vg90H21EOLACvtfcHk0lgiXxbWcaeQRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFGgurrN&md5=e0c5fbd4c98261dc0d8050035dfa206c</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1111%2Fbcp.12086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.12086%26sid%3Dliteratum%253Aachs%26aulast%3DKnights%26aufirst%3DK.%2BM.%26aulast%3DRowland%26aufirst%3DA.%26aulast%3DMiners%26aufirst%3DJ.%2BO.%26atitle%3DRenal%2520drug%2520metabolism%2520in%2520humans%253A%2520the%2520potential%2520for%2520drug-endobiotic%2520interactions%2520involving%2520cytochrome%2520P450%2520%2528CYP%2529%2520and%2520UDP-glucuronosyltransferase%2520%2528UGT%2529%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D76%26spage%3D587%26epage%3D602%26doi%3D10.1111%2Fbcp.12086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacono, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, J.</span></span> <span> </span><span class="NLM_article-title">Clinical significance of CYP2C19 polymorphisms on the metabolism and pharmacokinetics of 11β-hydroxysteroid dehydrogenase type-1 inhibitor BMS-823778</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">141</span>, <span class="refDoi"> DOI: 10.1111/bcp.13421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1111%2Fbcp.13421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=28850715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Sgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2018&pages=130-141&author=Y.+Chengauthor=L.+Wangauthor=L.+Iaconoauthor=D.+Zhangauthor=W.+Chenauthor=J.+Gongauthor=W.+G.+Humphreysauthor=J.+Gan&title=Clinical+significance+of+CYP2C19+polymorphisms+on+the+metabolism+and+pharmacokinetics+of+11%CE%B2-hydroxysteroid+dehydrogenase+type-1+inhibitor+BMS-823778&doi=10.1111%2Fbcp.13421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical significance of cyp2c19 polymorphisms on the metabolism and pharmacokinetics of 11β-hydroxysteroid dehydrogenase type-1 inhibitor bms-823778</span></div><div class="casAuthors">Cheng, Yaofeng; Wang, Lifei; Iacono, Lisa; Zhang, Donglu; Chen, Weiqi; Gong, Jiachang; Humphreys, William Griffith; Gan, Jinping</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">130-141</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : BMS-823778 is an inhibitor of 11β-hydroxysteroid dehydrogenase type-1, and thus a potential candidate for Type 2 diabetes treatment.  Here, we investigated the metab. and pharmacokinetics of BMS-823778 to understand its pharmacokinetic variations in early clin. trials.  Methods : The metab. of BMS-823778 was characterized in multiple in vitro assays.  Pharmacokinetics were evaluated in healthy volunteers, prescreened as CYP2C19 extensive metabolizers (EM) or poor metabolizers (PM), with a single oral dose of [14C]BMS-823778 (10 mg, 80μCi).  Results : Three metabolites (<5%) were identified in human hepatocytes and liver microsomes (HLM) incubations, including two hydroxylated metabolites (M1 and M2) and one glucuronide conjugate (M3).  As the most abundant metabolite, M1 was formed mainly through CYP2C19.  M1 formation was also correlated with CYP2C19 activities in genotyped HLM.  In humans, urinary excretion of dosed radioactivity was significantly higher in EM (68.8%; 95% confidence interval 61.3%, 76.3%) than in PM (47.0%; 43.5%, 50.6%); only small portions (<2%) were present in faeces or bile from both genotypes.  In plasma, BMS-823778 exposure in PM was significantly (5.3-fold, P = 0.0097) higher than in EM.  Furthermore, total radioactivity exposure was significantly higher (P < 0.01) than BMS-823778 exposure in all groups, indicating the presence of metabolites.  M1 was the only metabolite obsd. in plasma, and much lower in PM.  In urine, the amt. of M1 and its oxidative metabolite in EM was 7-fold of that in PM, while more glucuronide conjugates of BMS-823778 and M1 were excreted in PM.  Conclusions : CYP2C19 polymorphisms significantly impacted systemic exposure and metab. pathways of BMS-823778 in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPDxWjy1MHurVg90H21EOLACvtfcHk0lhuBhwJjpte1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Sgsg%253D%253D&md5=66db7f5fb592df7df59dc75db6455374</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1111%2Fbcp.13421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.13421%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DIacono%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DGan%26aufirst%3DJ.%26atitle%3DClinical%2520significance%2520of%2520CYP2C19%2520polymorphisms%2520on%2520the%2520metabolism%2520and%2520pharmacokinetics%2520of%252011%25CE%25B2-hydroxysteroid%2520dehydrogenase%2520type-1%2520inhibitor%2520BMS-823778%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2018%26volume%3D84%26spage%3D130%26epage%3D141%26doi%3D10.1111%2Fbcp.13421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koplowitz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komoroski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasichayanula, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Washburn, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellsworth, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whaley, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, W. G.</span></span> <span> </span><span class="NLM_article-title">In vitro characterization and pharmacokinetics of dapagliflozin (bms-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">414</span>, <span class="refDoi"> DOI: 10.1124/dmd.109.029165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.109.029165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=19996149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjt1Ort7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=405-414&author=M.+Obermeierauthor=M.+Yaoauthor=A.+Khannaauthor=B.+Koplowitzauthor=M.+Zhuauthor=W.+Liauthor=B.+Komoroskiauthor=S.+Kasichayanulaauthor=L.+Discenzaauthor=W.+Washburnauthor=W.+Mengauthor=B.+A.+Ellsworthauthor=J.+M.+Whaleyauthor=W.+G.+Humphreys&title=In+vitro+characterization+and+pharmacokinetics+of+dapagliflozin+%28bms-512148%29%2C+a+potent+sodium-glucose+cotransporter+type+II+inhibitor%2C+in+animals+and+humans&doi=10.1124%2Fdmd.109.029165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans</span></div><div class="casAuthors">Obermeier, M.; Yao, M.; Khanna, A.; Koplowitz, B.; Zhu, M.; Li, W.; Komoroski, B.; Kasichayanula, S.; Discenza, L.; Washburn, W.; Meng, W.; Ellsworth, B. A.; Whaley, J. M.; Humphreys, W. G.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">405-414</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">(2S,3R,4R,5S,6R)-2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyl- tetrahydro-2H-pyran-3,4,5-triol (dapagliflozin; BMS-512148) is a potent sodium-glucose cotransporter type II inhibitor in animals and humans and is currently under development for the treatment of type 2 diabetes.  The preclin. characterization of dapagliflozin, to allow compd. selection and prediction of pharmacol. and dispositional behavior in the clinic, involved Caco-2 cell permeability studies, cytochrome P 450 inhibition and induction studies, P 450 reaction phenotyping, metabolite identification in hepatocytes, and pharmacokinetics in rats, dogs, and monkeys.  Dapagliflozin was found to have good permeability across Caco-2 cell membranes.  It was found to be a substrate for P-glycoprotein (P-gp) but not a significant P-gp inhibitor.  Dapagliflozin was not found to be an inhibitor or an inducer of human P 450 enzymes.  The in vitro metabolic profiles of dapagliflozin after incubation with hepatocytes from mice, rats, dogs, monkeys, and humans were qual. similar.  Rat hepatocyte incubations showed the highest turnover, and dapagliflozin was most stable in human hepatocytes.  Prominent in vitro metabolic pathways obsd. were glucuronidation, hydroxylation, and O-deethylation.  Pharmacokinetic parameters for dapagliflozin in preclin. species revealed a compd. with adequate oral exposure, clearance, and elimination half-life, consistent with the potential for single daily dosing in humans.  The pharmacokinetics in humans after a single dose of 50 mg of [14C]dapagliflozin showed good exposure, low clearance, adequate half-life, and no metabolites with significant pharmacol. activity or toxicol. concern.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5vjA08QaWbLVg90H21EOLACvtfcHk0lhuBhwJjpte1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjt1Ort7o%253D&md5=0eab14ec9be81615d66eb091d5d5f2ac</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.029165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.029165%26sid%3Dliteratum%253Aachs%26aulast%3DObermeier%26aufirst%3DM.%26aulast%3DYao%26aufirst%3DM.%26aulast%3DKhanna%26aufirst%3DA.%26aulast%3DKoplowitz%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DKomoroski%26aufirst%3DB.%26aulast%3DKasichayanula%26aufirst%3DS.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DWashburn%26aufirst%3DW.%26aulast%3DMeng%26aufirst%3DW.%26aulast%3DEllsworth%26aufirst%3DB.%2BA.%26aulast%3DWhaley%26aufirst%3DJ.%2BM.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26atitle%3DIn%2520vitro%2520characterization%2520and%2520pharmacokinetics%2520of%2520dapagliflozin%2520%2528bms-512148%2529%252C%2520a%2520potent%2520sodium-glucose%2520cotransporter%2520type%2520II%2520inhibitor%252C%2520in%2520animals%2520and%2520humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D405%26epage%3D414%26doi%3D10.1124%2Fdmd.109.029165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeFronzo, R. A.</span></span> <span> </span><span class="NLM_article-title">Why do SGLT2 inhibitors inhibit only 30–50% of renal glucose reabsorption in humans?</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2199</span>– <span class="NLM_lpage">2204</span>, <span class="refDoi"> DOI: 10.2337/db12-0052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.2337%2Fdb12-0052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=22923645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlantbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2012&pages=2199-2204&author=J.+J.+Liuauthor=T.+Leeauthor=R.+A.+DeFronzo&title=Why+do+SGLT2+inhibitors+inhibit+only+30%E2%80%9350%25+of+renal+glucose+reabsorption+in+humans%3F&doi=10.2337%2Fdb12-0052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?</span></div><div class="casAuthors">Liu, Jiwen; Lee, TaeWeon; DeFronzo, Ralph A.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2199-2204</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">A review.  Sodium glucose cotransporter 2 (SGLT2) inhibition is a novel and promising treatment for diabetes under late-stage clin. development.  It generally is accepted that SGLT2 mediates 90% of renal glucose reabsorption.  However, SGLT2 inhibitors in clin. development inhibit only 30-50% of the filtered glucose load.  Why are they unable to inhibit 90% of glucose reabsorption in humans.  We will try to provide an explanation to this puzzle in this perspective anal. of the unique pharmacokinetic and pharmacodynamic profiles of SGLT2 inhibitors in clin. trials and examine possible mechanisms and mol. properties that may be responsible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7mlWVhal1BLVg90H21EOLACvtfcHk0lixDidoMUABsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlantbzM&md5=1b253c451e7151ab93238e99f6592aa2</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.2337%2Fdb12-0052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb12-0052%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%2BJ.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DDeFronzo%26aufirst%3DR.%2BA.%26atitle%3DWhy%2520do%2520SGLT2%2520inhibitors%2520inhibit%2520only%252030%25E2%2580%259350%2525%2520of%2520renal%2520glucose%2520reabsorption%2520in%2520humans%253F%26jtitle%3DDiabetes%26date%3D2012%26volume%3D61%26spage%3D2199%26epage%3D2204%26doi%3D10.2337%2Fdb12-0052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamaru, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, H.</span></span> <span> </span><span class="NLM_article-title">Physiologically based pharmacokinetic-pharmacodynamic modeling to predict concentrations and actions of sodium-dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">491</span>– <span class="NLM_lpage">506</span>, <span class="refDoi"> DOI: 10.1002/bdd.2040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1002%2Fbdd.2040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=27604638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVKqu73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=491-506&author=K.+Moriauthor=R.+Saitoauthor=Y.+Nakamaruauthor=M.+Shimizuauthor=H.+Yamazaki&title=Physiologically+based+pharmacokinetic-pharmacodynamic+modeling+to+predict+concentrations+and+actions+of+sodium-dependent+glucose+transporter+2+inhibitor+canagliflozin+in+human+intestines+and+renal+tubules&doi=10.1002%2Fbdd.2040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Physiologically based pharmacokinetic-pharmacodynamic modeling to predict concentrations and actions of sodium-dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules</span></div><div class="casAuthors">Mori, Kazumi; Saito, Ryuta; Nakamaru, Yoshinobu; Shimizu, Makiko; Yamazaki, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">491-506</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Canagliflozin is a recently developed sodium-glucose cotransporter (SGLT) 2 inhibitor that promotes renal glucose excretion and is considered to inhibit renal SGLT2 from the luminal side of proximal tubules.  Canagliflozin reportedly inhibits SGLT1 weakly and suppresses postprandial plasma glucose, suggesting that it also inhibits intestinal SGLT1.  However, it is difficult to measure the drug concns. of these assumed sites of action directly.  The pharmacokinetic-pharmacodynamic (PK/PD) relationships of canagliflozin remain poorly characterized.  Therefore, we developed a physiol. based pharmacokinetic (PBPK) model of canagliflozin based on clin. data from healthy volunteers and used it to simulate luminal concns. in intestines and renal tubules.  In small intestine simulations, inhibition ratios for SGLT1 were predicted to be 40%-60% after the oral administration of clin. doses (100-300 mg/day).  In contrast, inhibition ratios of canagliflozin for renal SGLT2 and SGLT1 were predicted to be approx. 100% and 0.2%-0.4%, resp.  These analyses suggest that canagliflozin only inhibits SGLT2 in the kidney.  Using the simulated proximal tubule luminal concns. of canagliflozin, the urinary glucose excretion rates in canagliflozin-treated diabetic patients were accurately predicted using the renal glucose reabsorption model as a PD model.  Because the simulation of canagliflozin pharmacokinetics was successful, this PBPK methodol. was further validated by successfully simulating the pharmacokinetics of dapagliflozin, another SGLT2 inhibitor.  The present results suggest the utility of this PBPK/PD model for predicting canagliflozin concns. at target sites and help elucidate the pharmacol. effects of SGLT1/2 inhibition in humans.  This article is protected by copyright.  All rights reserved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR3NwJI5DggLVg90H21EOLACvtfcHk0lixDidoMUABsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVKqu73M&md5=d3ef0a5b6b50f389a338fef730a75360</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1002%2Fbdd.2040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.2040%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DK.%26aulast%3DSaito%26aufirst%3DR.%26aulast%3DNakamaru%26aufirst%3DY.%26aulast%3DShimizu%26aufirst%3DM.%26aulast%3DYamazaki%26aufirst%3DH.%26atitle%3DPhysiologically%2520based%2520pharmacokinetic-pharmacodynamic%2520modeling%2520to%2520predict%2520concentrations%2520and%2520actions%2520of%2520sodium-dependent%2520glucose%2520transporter%25202%2520inhibitor%2520canagliflozin%2520in%2520human%2520intestines%2520and%2520renal%2520tubules%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D2016%26volume%3D37%26spage%3D491%26epage%3D506%26doi%3D10.1002%2Fbdd.2040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balazki, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eissing, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehr, T.</span></span> <span> </span><span class="NLM_article-title">A quantitative systems pharmacology kidney model of diabetes associated renal hyperfiltration and the effects of SGLT inhibitors</span>. <i>CPT: Pharmacometrics Syst. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">788</span>– <span class="NLM_lpage">797</span>, <span class="refDoi"> DOI: 10.1002/psp4.12359</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1002%2Fpsp4.12359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=30270578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFKju7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=788-797&author=P.+Balazkiauthor=S.+Schallerauthor=T.+Eissingauthor=T.+Lehr&title=A+quantitative+systems+pharmacology+kidney+model+of+diabetes+associated+renal+hyperfiltration+and+the+effects+of+SGLT+inhibitors&doi=10.1002%2Fpsp4.12359"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">A Quantitative Systems Pharmacology Kidney Model of Diabetes Associated Renal Hyperfiltration and the Effects of SGLT Inhibitors</span></div><div class="casAuthors">Balazki, Pavel; Schaller, Stephan; Eissing, Thomas; Lehr, Thorsten</div><div class="citationInfo"><span class="NLM_cas:title">CPT: Pharmacometrics & Systems Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">788-797</span>CODEN:
                <span class="NLM_cas:coden">CPSPBR</span>;
        ISSN:<span class="NLM_cas:issn">2163-8306</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The early stage of diabetes mellitus is characterized by increased glomerular filtration rate (GFR), known as hyperfiltration, which is believed to be one of the main causes leading to renal injury in diabetes.  Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been shown to be able to reverse hyperfiltration in some patients.  We developed a mechanistic computational model of the kidney that explains the interplay of hyperglycemia and hyperfiltration and integrates the pharmacokinetics/pharmacodynamics (PK/PD) of the SGLT2i dapagliflozin.  Based on simulation results, we propose kidney growth as the necessary process for hyperfiltration progression.  Further, the model indicates that renal SGLT1i could significantly improve hyperfiltration when added to SGTL2i.  Integrated into a physiol. based PK/PD (PBPK/PD) Diabetes Platform, the model presents a powerful tool for aiding drug development, prediction of hyperfiltration risk, and allows the assessment of the outcomes of individualized treatments with SGLT1-inhibitors and SGLT2-inhibitors and their co-administration with insulin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn-lTkzSonHrVg90H21EOLACvtfcHk0lixDidoMUABsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFKju7%252FM&md5=e947dd71a93e9cb04f26183105baa464</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1002%2Fpsp4.12359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsp4.12359%26sid%3Dliteratum%253Aachs%26aulast%3DBalazki%26aufirst%3DP.%26aulast%3DSchaller%26aufirst%3DS.%26aulast%3DEissing%26aufirst%3DT.%26aulast%3DLehr%26aufirst%3DT.%26atitle%3DA%2520quantitative%2520systems%2520pharmacology%2520kidney%2520model%2520of%2520diabetes%2520associated%2520renal%2520hyperfiltration%2520and%2520the%2520effects%2520of%2520SGLT%2520inhibitors%26jtitle%3DCPT%253A%2520Pharmacometrics%2520Syst.%2520Pharmacol.%26date%3D2018%26volume%3D7%26spage%3D788%26epage%3D797%26doi%3D10.1002%2Fpsp4.12359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luettgen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grace, J. E.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knabb, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wexler, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, S. J.</span></span> <span> </span><span class="NLM_article-title">Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor</span>. <i>Eur. J. Drug Metab. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">139</span>, <span class="refDoi"> DOI: 10.1007/s13318-011-0037-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1007%2Fs13318-011-0037-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=21461793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFaks7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2011&pages=129-139&author=K.+Heauthor=J.+M.+Luettgenauthor=D.+Zhangauthor=B.+Heauthor=J.+E.+Graceauthor=B.+Xinauthor=D.+J.+Pintoauthor=P.+C.+Wongauthor=R.+M.+Knabbauthor=P.+Y.+Lamauthor=R.+R.+Wexlerauthor=S.+J.+Grossman&title=Preclinical+pharmacokinetics+and+pharmacodynamics+of+apixaban%2C+a+potent+and+selective+factor+Xa+inhibitor&doi=10.1007%2Fs13318-011-0037-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor</span></div><div class="casAuthors">He, Kan; Luettgen, Joseph M.; Zhang, Donglu; He, Bing; Grace, James E., Jr.; Xin, Baomin; Pinto, Donald J. P.; Wong, Pancras C.; Knabb, Robert M.; Lam, Patrick Y. S.; Wexler, Ruth R.; Grossman, Scott J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">129-139</span>CODEN:
                <span class="NLM_cas:coden">EJDPD2</span>;
        ISSN:<span class="NLM_cas:issn">0378-7966</span>.
    
            (<span class="NLM_cas:orgname">Springer France</span>)
        </div><div class="casAbstract">Apixaban is a potent, highly selective, reversible, oral, direct factor Xa (fXa) inhibitor in development for thrombosis prevention and treatment.  The preclin. pharmacokinetic (PK) attributes of apixaban feature small vol. of distribution (Vd), low systemic clearance (CL), and good oral bioavailability.  Apixaban is well absorbed in rat, dog, and chimpanzee, with abs. oral bioavailability of approx. 50% or greater.  The steady-state Vd of apixaban is approx. 0.5, 0.2, and 0.17 l/kg in rats, dogs, and chimpanzees, while CL is approx. 0.9, 0.04, and 0.018 l/h/kg, resp.  In vitro metabolic clearance of apixaban is also low.  Renal clearance comprises approx. 10-30% of systemic clearance in rat, dog, and chimpanzee.  Anti-fXa activity, prothrombin time (PT), and HEPTEST clotting time (HCT) prolongation correlated well with plasma apixaban concn. in rat, dog and chimpanzee.  There was no lag time between apixaban plasma concn. and the pharmacodynamic (PD) markers, suggesting a rapid onset of action of apixaban.  The PK/PD analyses were performed using an inhibitory E max model for anti-fXa assay and a linear model for PT and HCT assays.  The IC50 values for anti-fXa activity were 0.73 ± 0.03 and 1.5 ± 0.15 μM for rat and dog, resp.  The apparent Ki values for PT were approx. 1.7, 6.6, and 4.8 μM for rat, dog and chimpanzee, resp.  The apparent Ki for HCT was approx. 1.3 μM for dog.  Apixaban exhibits desirable PK and PD properties for clin. development with good oral bioavailability, small Vd, low CL, and direct, predictable, concn.-dependent PD responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjZMn91_38O7Vg90H21EOLACvtfcHk0lj--EsN4SQdkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFaks7bL&md5=d9432f6f4e097ff4b3a96a9b93f11b98</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1007%2Fs13318-011-0037-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13318-011-0037-x%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DK.%26aulast%3DLuettgen%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DHe%26aufirst%3DB.%26aulast%3DGrace%26aufirst%3DJ.%2BE.%26aulast%3DXin%26aufirst%3DB.%26aulast%3DPinto%26aufirst%3DD.%2BJ.%26aulast%3DWong%26aufirst%3DP.%2BC.%26aulast%3DKnabb%26aufirst%3DR.%2BM.%26aulast%3DLam%26aufirst%3DP.%2BY.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DGrossman%26aufirst%3DS.%2BJ.%26atitle%3DPreclinical%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520apixaban%252C%2520a%2520potent%2520and%2520selective%2520factor%2520Xa%2520inhibitor%26jtitle%3DEur.%2520J.%2520Drug%2520Metab.%2520Pharmacokinet.%26date%3D2011%26volume%3D36%26spage%3D129%26epage%3D139%26doi%3D10.1007%2Fs13318-011-0037-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raghavan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonacorsi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span> <span> </span><span class="NLM_article-title">Apixaban metabolism and pharmacokinetics after oral administration to humans</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">74</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.023143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.108.023143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=18832478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVSmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=74-81&author=N.+Raghavanauthor=C.+E.+Frostauthor=Z.+Yuauthor=K.+Heauthor=H.+Zhangauthor=W.+G.+Humphreysauthor=D.+Pintoauthor=S.+Chenauthor=S.+Bonacorsiauthor=P.+C.+Wongauthor=D.+Zhang&title=Apixaban+metabolism+and+pharmacokinetics+after+oral+administration+to+humans&doi=10.1124%2Fdmd.108.023143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Apixaban metabolism and pharmacokinetics after oral administration to humans</span></div><div class="casAuthors">Raghavan, Nirmala; Frost, Charles E.; Yu, Zhigang; He, Kan; Zhang, Haiying; Humphreys, W. Griffith; Pinto, Donald; Chen, Shiangyuan; Bonacorsi, Samuel; Wong, Pancras C.; Zhang, Donglu</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">74-81</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The metab. and disposition of [14C]apixaban, an orally bioavailable, highly selective, and direct acting/reversible factor Xa inhibitor, was investigated in 10 healthy male subjects without (group 1, n = 6) and with bile collection (group 2, n = 4) after a single 20-mg oral dose.  Urine, blood, and feces samples were collected from all subjects.  Bile samples were also collected for 3 to 8 h after dosing from group 2 subjects.  There were no serious adverse events or discontinuations due to adverse effects.  In plasma, apixaban was the major circulating component and O-demethyl apixaban sulfate, a stable and water-sol. metabolite, was the significant metabolite.  The exposure of apixaban (Cmax and area under the plasma concn. vs. time curve) in subjects with bile collection was generally similar to that in subjects without bile collection.  The administered dose was recovered in feces (group 1, 56.0%; group 2, 46.7%) and urine (group 1, 24.5%; group 2, 28.8%), with the parent drug representing approx. half of the recovered dose.  Biliary excretion represented a minor elimination pathway (2.44% of the administered dose) from group 2 subjects within the limited collection period.  Metabolic pathways identified for apixaban included O-demethylation, hydroxylation, and sulfation of hydroxylated O-demethyl apixaban.  Thus, apixaban is an orally bioavailable inhibitor of factor Xa with elimination pathways that include metab. and renal excretion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqa3AirzsVA27Vg90H21EOLACvtfcHk0lj--EsN4SQdkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVSmtg%253D%253D&md5=fa456d3e5c0fac398b7c8ee61f76c5dc</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.023143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.023143%26sid%3Dliteratum%253Aachs%26aulast%3DRaghavan%26aufirst%3DN.%26aulast%3DFrost%26aufirst%3DC.%2BE.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DPinto%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DBonacorsi%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DP.%2BC.%26aulast%3DZhang%26aufirst%3DD.%26atitle%3DApixaban%2520metabolism%2520and%2520pharmacokinetics%2520after%2520oral%2520administration%2520to%2520humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D74%26epage%3D81%26doi%3D10.1124%2Fdmd.108.023143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lassen, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pineo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deitchman, D.</span></span> <span> </span><span class="NLM_article-title">The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement</span>. <i>J. Thromb. Haemostasis</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">2368</span>– <span class="NLM_lpage">2375</span>, <span class="refDoi"> DOI: 10.1111/j.1538-7836.2007.02764.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1111%2Fj.1538-7836.2007.02764.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=17868430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivFCg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2007&pages=2368-2375&author=M.+R.+Lassenauthor=B.+L.+Davidsonauthor=A.+Gallusauthor=G.+Pineoauthor=J.+Ansellauthor=D.+Deitchman&title=The+efficacy+and+safety+of+apixaban%2C+an+oral%2C+direct+factor+Xa+inhibitor%2C+as+thromboprophylaxis+in+patients+following+total+knee+replacement&doi=10.1111%2Fj.1538-7836.2007.02764.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement</span></div><div class="casAuthors">Lassen, M. R.; Davidson, B. L.; Gallus, A.; Pineo, G.; Ansell, J.; Deitchman, D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2368-2375</span>CODEN:
                <span class="NLM_cas:coden">JTHOA5</span>;
        ISSN:<span class="NLM_cas:issn">1538-7933</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing, Inc.</span>)
        </div><div class="casAbstract">Background: Heparins and warfarin are currently used as venous thromboembolism (VTE) prophylaxis in surgery.  Inhibition of factor (F) Xa provides a specific mechanism of anticoagulation and the potential for an improved benefit-risk profile.  Objectives: To evaluate the safety and efficacy of apixaban, a potent, direct, oral inhibitor of FXa, in patients following total knee replacement (TKR), and to investigate dose-response relationships.  Patients/methods: A total of 1238 patients were randomized to one of six double-blind apixaban doses [5, 10 or 20 mg day-1 administered as a single (q.d.) or a twice-daily divided dose (b.i.d.)], enoxaparin (30 mg b.i.d.) or open-label warfarin (titrated to an International Normalized Ratio of 1.8-3.0).  Treatment lasted 10-14 days, commencing 12-24 h after surgery with apixaban or enoxaparin, and on the evening of surgery with warfarin.  The primary efficacy outcome was a composite of VTE (mandatory venog.) and all-cause mortality during treatment.  The primary safety outcome was major bleeding.  Results: A total of 1217 patients were eligible for safety and 856 patients for efficacy anal.  All apixaban groups had lower primary efficacy event rates than either comparator.  The primary outcome rate decreased with increasing apixaban dose (P = 0.09 with q.d./b.i.d. regimens combined, P = 0.19 for q.d. and P = 0.13 for b.i.d. dosing).  A significant dose-related increase in the incidence of total adjudicated bleeding events was noted in the q.d. (P = 0.01) and b.i.d. (P = 0.02) apixaban groups; there was no difference between q.d. and b.i.d. regimens.  Conclusions: Apixaban in doses of 2.5 mg b.i.d. or 5 mg q.d. has a promising benefit-risk profile compared with the current stds. of care following TKR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgaRDmxArBA7Vg90H21EOLACvtfcHk0lj--EsN4SQdkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivFCg&md5=11247d815b89e5c7f9547da60c0c11f8</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1111%2Fj.1538-7836.2007.02764.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1538-7836.2007.02764.x%26sid%3Dliteratum%253Aachs%26aulast%3DLassen%26aufirst%3DM.%2BR.%26aulast%3DDavidson%26aufirst%3DB.%2BL.%26aulast%3DGallus%26aufirst%3DA.%26aulast%3DPineo%26aufirst%3DG.%26aulast%3DAnsell%26aufirst%3DJ.%26aulast%3DDeitchman%26aufirst%3DD.%26atitle%3DThe%2520efficacy%2520and%2520safety%2520of%2520apixaban%252C%2520an%2520oral%252C%2520direct%2520factor%2520Xa%2520inhibitor%252C%2520as%2520thromboprophylaxis%2520in%2520patients%2520following%2520total%2520knee%2520replacement%26jtitle%3DJ.%2520Thromb.%2520Haemostasis%26date%3D2007%26volume%3D5%26spage%3D2368%26epage%3D2375%26doi%3D10.1111%2Fj.1538-7836.2007.02764.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eikelboom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diener, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golitsyn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avezum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohnloser, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talajic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pais, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budaj, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkhomenko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Commerford, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Mieghem, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lip, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanas-Zanetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Hermosillo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dans, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munawar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afzal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yusuf, S.</span></span> <span> </span><span class="NLM_article-title">Apixaban in patients with atrial fibrillation</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">806</span>– <span class="NLM_lpage">817</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1007432</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1056%2FNEJMoa1007432" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=21309657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivV2kurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=806-817&author=S.+J.+Connollyauthor=J.+Eikelboomauthor=C.+Joynerauthor=H.+C.+Dienerauthor=R.+Hartauthor=S.+Golitsynauthor=G.+Flakerauthor=A.+Avezumauthor=S.+H.+Hohnloserauthor=R.+Diazauthor=M.+Talajicauthor=J.+Zhuauthor=P.+Paisauthor=A.+Budajauthor=A.+Parkhomenkoauthor=P.+Janskyauthor=P.+Commerfordauthor=R.+S.+Tanauthor=K.+H.+Simauthor=B.+S.+Lewisauthor=W.+Van+Mieghemauthor=G.+Y.+Lipauthor=J.+H.+Kimauthor=F.+Lanas-Zanettiauthor=A.+Gonzalez-Hermosilloauthor=A.+L.+Dansauthor=M.+Munawarauthor=M.+O%E2%80%99Donnellauthor=J.+Lawrenceauthor=G.+Lewisauthor=R.+Afzalauthor=S.+Yusuf&title=Apixaban+in+patients+with+atrial+fibrillation&doi=10.1056%2FNEJMoa1007432"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Apixaban in patients with atrial fibrillation</span></div><div class="casAuthors">Connolly, Stuart J.; Eikelboom, John; Joyner, Campbell; Diener, Hans-Christoph; Hart, Robert; Golitsyn, Sergey; Flaker, Greg; Avezum, Alvaro; Hohnloser, Stefan H.; Diaz, Rafael; Talajic, Mario; Zhu, Jun; Pais, Prem; Budaj, Andrzej; Parkhomenko, Alexander; Jansky, Petr; Commerford, Patrick; Tan, Ru San; Sim, Kui-Hian; Lewis, Basil S.; Van Mieghem, Walter; Lip, Gregory Y. H.; Kim, Jae Hyung; Lanas-Zanetti, Fernando; Gonzalez-Hermosillo, Antonio; Dans, Antonio L.; Munawar, Muhammad; O'Donnell, Martin; Lawrence, John; Lewis, Gayle; Afzal, Rizwan; Yusuf, Salim</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">806-817</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Vitamin K antagonists have been shown to prevent stroke in patients with atrial fibrillation.  However, many patients are not suitable candidates for or are unwilling to receive vitamin K antagonist therapy, and these patients have a high risk of stroke.  Apixaban, a novel factor Xa inhibitor, may be an alternative treatment for such patients.  METHODS: In a double-blind study, we randomly assigned 5599 patients with atrial fibrillation who were at increased risk for stroke and for whom vitamin K antagonist therapy was unsuitable to receive apixaban (at a dose of 5 mg twice daily) or aspirin (81 to 324 mg per day), to det. whether apixaban was superior.  The mean follow up period was 1.1 years.  The primary outcome was the occurrence of stroke or systemic embolism.  RESULTS: Before enrollment, 40% of the patients had used a vitamin K antagonist.  The data and safety monitoring board recommended early termination of the study because of a clear benefit in favor of apixaban.  There were 51 primary outcome events (1.6% per yr) among patients assigned to apixaban and 113 (3.7% per yr) among those assigned to aspirin (hazard ratio with apixaban, 0.45; 95% confidence interval [CI], 0.32 to 0.62; P < 0.001). The rates of death were 3.5% per yr in the apixaban group and 4.4% per yr in the aspirin group (hazard ratio, 0.79; 95% CI, 0.62 to 1.02; P = 0.07).  There were 44 cases of major bleeding (1.4% per yr) in the apixaban group and 39 (1.2% per yr) in the aspirin group (hazard ratio with apixaban, 1.13; 95% CI, 0.74 to 1.75; P = 0.57); there were 11 cases of intracranial bleeding with apixaban and 13 with aspirin.  The risk of a first hospitalization for cardiovascular causes was reduced with apixaban as compared with aspirin (12.6% per yr vs. 15.9% per yr, P < 0.001).  The treatment effects were consistent among important subgroups.  CONCLUSIONS: In patients with atrial fibrillation for whom vitamin K antagonist therapy was unsuitable, apixaban reduced the risk of stroke or systemic embolism without significantly increasing the risk of major bleeding or intracranial hemorrhage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph_98mFcDE4rVg90H21EOLACvtfcHk0ljc_3-xk9VAHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivV2kurc%253D&md5=248a2c0860315acdcce922612c7feb78</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1007432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1007432%26sid%3Dliteratum%253Aachs%26aulast%3DConnolly%26aufirst%3DS.%2BJ.%26aulast%3DEikelboom%26aufirst%3DJ.%26aulast%3DJoyner%26aufirst%3DC.%26aulast%3DDiener%26aufirst%3DH.%2BC.%26aulast%3DHart%26aufirst%3DR.%26aulast%3DGolitsyn%26aufirst%3DS.%26aulast%3DFlaker%26aufirst%3DG.%26aulast%3DAvezum%26aufirst%3DA.%26aulast%3DHohnloser%26aufirst%3DS.%2BH.%26aulast%3DDiaz%26aufirst%3DR.%26aulast%3DTalajic%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DPais%26aufirst%3DP.%26aulast%3DBudaj%26aufirst%3DA.%26aulast%3DParkhomenko%26aufirst%3DA.%26aulast%3DJansky%26aufirst%3DP.%26aulast%3DCommerford%26aufirst%3DP.%26aulast%3DTan%26aufirst%3DR.%2BS.%26aulast%3DSim%26aufirst%3DK.%2BH.%26aulast%3DLewis%26aufirst%3DB.%2BS.%26aulast%3DVan%2BMieghem%26aufirst%3DW.%26aulast%3DLip%26aufirst%3DG.%2BY.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DLanas-Zanetti%26aufirst%3DF.%26aulast%3DGonzalez-Hermosillo%26aufirst%3DA.%26aulast%3DDans%26aufirst%3DA.%2BL.%26aulast%3DMunawar%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DM.%26aulast%3DLawrence%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DG.%26aulast%3DAfzal%26aufirst%3DR.%26aulast%3DYusuf%26aufirst%3DS.%26atitle%3DApixaban%2520in%2520patients%2520with%2520atrial%2520fibrillation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D806%26epage%3D817%26doi%3D10.1056%2FNEJMoa1007432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Granger, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMurray, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hylek, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Khalidi, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avezum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahit, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easton, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezekowitz, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geraldes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gersh, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golitsyn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermosillo, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohnloser, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horowitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Sendon, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pais, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkhomenko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verheugt, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallentin, L.</span></span> <span> </span><span class="NLM_article-title">Apixaban versus warfarin in patients with atrial fibrillation</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">981</span>– <span class="NLM_lpage">992</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1107039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1056%2FNEJMoa1107039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=21870978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtF2ms7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2011&pages=981-992&author=C.+B.+Grangerauthor=J.+H.+Alexanderauthor=J.+J.+McMurrayauthor=R.+D.+Lopesauthor=E.+M.+Hylekauthor=M.+Hannaauthor=H.+R.+Al-Khalidiauthor=J.+Ansellauthor=D.+Atarauthor=A.+Avezumauthor=M.+C.+Bahitauthor=R.+Diazauthor=J.+D.+Eastonauthor=J.+A.+Ezekowitzauthor=G.+Flakerauthor=D.+Garciaauthor=M.+Geraldesauthor=B.+J.+Gershauthor=S.+Golitsynauthor=S.+Gotoauthor=A.+G.+Hermosilloauthor=S.+H.+Hohnloserauthor=J.+Horowitzauthor=P.+Mohanauthor=P.+Janskyauthor=B.+S.+Lewisauthor=J.+L.+Lopez-Sendonauthor=P.+Paisauthor=A.+Parkhomenkoauthor=F.+W.+Verheugtauthor=J.+Zhuauthor=L.+Wallentin&title=Apixaban+versus+warfarin+in+patients+with+atrial+fibrillation&doi=10.1056%2FNEJMoa1107039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Apixaban versus warfarin in patients with atrial fibrillation</span></div><div class="casAuthors">Granger, Christopher B.; Alexander, John H.; McMurray, Johnj. V.; Lopes, Renato D.; Hylek, Elaine M.; Hanna, Michael; Al-Khalidi, Hussein R.; Ansell, Jack; Atar, Dan; Avezum, Alvaro; Bahit, M. Cecilia; Diaz, Rafael; Easton, Onald; Ezekowitz, Justin A.; Flaker, Greg; Garcia, David; Geraldes, Margarida; Gersh, Bernard J.; Golitsyn, Sergey; Goto, Shinya; Hermosillo, Antonio G.; Hohnloser, Stefan H.; Horowitz, John; Mohan, Puneet; Jansky, Petr; Lewis, Basil S.; Lopez-Sendon, Jose Luis; Pais, Prem; Parkhomenko, Alexander; Verheugt, Freek W. A.; Zhu, Jun; Wallentin, Lars</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">981-992</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations.  Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a similar population in comparison with aspirin.  METHODS: In this randomized, double-blind trial, we compared apixaban (at a dose of 5 mg twice daily) with warfarin (target international normalized ratio, 2.0 to 3.0) in 18,201 patients with atrial fibrillation and at least one addnl. risk factor for stroke.  The primary outcome was ischemic or hemorrhagic stroke or systemic embolism.  The trial was designed to test for noninferiority, with key secondary objectives of testing for superiority with respect to the primary outcome and to the rates of major bleeding and death from any cause.  RESULTS: The median duration of follow-up was 1.8 years.  The rate of the primary outcome was 1.27% per yr in the apixaban group, as compared with 1.60% per yr in the warfarin group (hazard ratio with apixaban, 0.79; 95% confidence interval [CI], 0.66 to 0.95; P < 0.001 for noninferiority; P = 0.01 for superiority).  The rate of major bleeding was 2.13% per yr in the apixaban group, as compared with 3.09% per yr in the warfarin group (hazard ratio, 0.69; 95% CI, 0.60 to 0.80; P < 0.001), and the rates of death from any cause were 3.52% and 3.94%, resp. (hazard ratio, 0.89; 95% CI, 0.80 to 0.99; P = 0.047).  The rate of hemorrhagic stroke was 0.24% per yr in the apixaban group, as compared with 0.47% per yr in the warfarin group (hazard ratio, 0.51; 95% CI, 0.35 to 0.75; P < 0.001), and the rate of ischemic or uncertain type of stroke was 0.97% per yr in the apixaban group and 1.05% per yr in the warfarin group (hazard ratio, 0.92; 95% CI, 0.74 to 1.13; P = 0.42).  CONCLUSIONS: In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYkCU6dw4nZ7Vg90H21EOLACvtfcHk0ljc_3-xk9VAHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtF2ms7rN&md5=14cb7dbc3e754b65e33729da80b1c58b</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1107039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1107039%26sid%3Dliteratum%253Aachs%26aulast%3DGranger%26aufirst%3DC.%2BB.%26aulast%3DAlexander%26aufirst%3DJ.%2BH.%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%26aulast%3DLopes%26aufirst%3DR.%2BD.%26aulast%3DHylek%26aufirst%3DE.%2BM.%26aulast%3DHanna%26aufirst%3DM.%26aulast%3DAl-Khalidi%26aufirst%3DH.%2BR.%26aulast%3DAnsell%26aufirst%3DJ.%26aulast%3DAtar%26aufirst%3DD.%26aulast%3DAvezum%26aufirst%3DA.%26aulast%3DBahit%26aufirst%3DM.%2BC.%26aulast%3DDiaz%26aufirst%3DR.%26aulast%3DEaston%26aufirst%3DJ.%2BD.%26aulast%3DEzekowitz%26aufirst%3DJ.%2BA.%26aulast%3DFlaker%26aufirst%3DG.%26aulast%3DGarcia%26aufirst%3DD.%26aulast%3DGeraldes%26aufirst%3DM.%26aulast%3DGersh%26aufirst%3DB.%2BJ.%26aulast%3DGolitsyn%26aufirst%3DS.%26aulast%3DGoto%26aufirst%3DS.%26aulast%3DHermosillo%26aufirst%3DA.%2BG.%26aulast%3DHohnloser%26aufirst%3DS.%2BH.%26aulast%3DHorowitz%26aufirst%3DJ.%26aulast%3DMohan%26aufirst%3DP.%26aulast%3DJansky%26aufirst%3DP.%26aulast%3DLewis%26aufirst%3DB.%2BS.%26aulast%3DLopez-Sendon%26aufirst%3DJ.%2BL.%26aulast%3DPais%26aufirst%3DP.%26aulast%3DParkhomenko%26aufirst%3DA.%26aulast%3DVerheugt%26aufirst%3DF.%2BW.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DWallentin%26aufirst%3DL.%26atitle%3DApixaban%2520versus%2520warfarin%2520in%2520patients%2520with%2520atrial%2520fibrillation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D365%26spage%3D981%26epage%3D992%26doi%3D10.1056%2FNEJMoa1107039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghavan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitroka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maxwell, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knabb, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, S. J.</span></span> <span> </span><span class="NLM_article-title">Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1738</span>– <span class="NLM_lpage">1748</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.025981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.108.025981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=19420130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1MXps1ygtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=1738-1748&author=D.+Zhangauthor=K.+Heauthor=N.+Raghavanauthor=L.+Wangauthor=J.+Mitrokaauthor=B.+D.+Maxwellauthor=R.+M.+Knabbauthor=C.+Frostauthor=A.+Schusterauthor=F.+Haoauthor=Z.+Guauthor=W.+G.+Humphreysauthor=S.+J.+Grossman&title=Comparative+metabolism+of+14C-labeled+apixaban+in+mice%2C+rats%2C+rabbits%2C+dogs%2C+and+humans&doi=10.1124%2Fdmd.108.025981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans</span></div><div class="casAuthors">Zhang, Donglu; He, Kan; Raghavan, Nirmala; Wang, Lifei; Mitroka, James; Maxwell, Brad D.; Knabb, Robert M.; Frost, Charles; Schuster, Alan; Hao, Feng; Gu, Zheming; Humphreys, W. Griffith; Grossman, Scott J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1738-1748</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The metab. and disposition of [14C]apixaban, a potent, reversible, and direct inhibitor of coagulation factor Xa, were investigated in mice, rats, rabbits, dogs, and humans after a single oral administration and in incubations with hepatocytes.  In plasma, the parent compd. was the major circulating component in mice, rats, dogs, and humans.  O-Demethyl apixaban sulfate (M1) represented approx. 25% of the parent area under the time curve in human plasma.  This sulfate metabolite was present, but in lower amts. relative to the parent, in plasma from mice, rats, and dogs.  Rabbits showed a plasma metabolite profile distinct from that of other species with apixaban as a minor component and M2 (O-demethyl apixaban) and M14 (O-demethyl apixaban glucuronide) as prominent components.  The fecal route was a major elimination pathway, accounting for >54% of the dose in animals and >46% in humans.  The urinary route accounted for <15% of the dose in animals and 25 to 28% in humans.  Apixaban was the major component in feces of every species and in urine of all species except rabbit.  M1 and M2 were common prominent metabolites in urine and feces of all species as well as in bile of rats and humans.  In vivo metabolite profiles showed quant. differences between species and from in vitro metabolite profiles, but all human metabolites were found in animal species.  After i.v. administration of [14C]apixaban to bile duct-cannulated rats, the significant portion (approx. 22%) of the dose was recovered as parent drug in the feces, suggesting direct excretion of the drug from gastrointestinal tracts of rats.  Overall, apixaban was effectively eliminated via multiple elimination pathways in animals and humans, including oxidative metab., and direct renal and intestinal excretion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwA4D_G952O7Vg90H21EOLACvtfcHk0lgQhgjrqkshoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXps1ygtLs%253D&md5=9c16ff8a76bef8c8e4c01f16d6313c2e</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.025981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.025981%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DHe%26aufirst%3DK.%26aulast%3DRaghavan%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMitroka%26aufirst%3DJ.%26aulast%3DMaxwell%26aufirst%3DB.%2BD.%26aulast%3DKnabb%26aufirst%3DR.%2BM.%26aulast%3DFrost%26aufirst%3DC.%26aulast%3DSchuster%26aufirst%3DA.%26aulast%3DHao%26aufirst%3DF.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DGrossman%26aufirst%3DS.%2BJ.%26atitle%3DComparative%2520metabolism%2520of%252014C-labeled%2520apixaban%2520in%2520mice%252C%2520rats%252C%2520rabbits%252C%2520dogs%252C%2520and%2520humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D1738%26epage%3D1748%26doi%3D10.1124%2Fdmd.108.025981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span> <span> </span><span class="NLM_article-title">Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor</span>. <i>J. Thromb. Thrombolysis</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">478</span>– <span class="NLM_lpage">492</span>, <span class="refDoi"> DOI: 10.1007/s11239-011-0551-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1007%2Fs11239-011-0551-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=21318583" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvFSqtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=478-492&author=P.+C.+Wongauthor=D.+J.+Pintoauthor=D.+Zhang&title=Preclinical+discovery+of+apixaban%2C+a+direct+and+orally+bioavailable+factor+Xa+inhibitor&doi=10.1007%2Fs11239-011-0551-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor</span></div><div class="casAuthors">Wong, Pancras C.; Pinto, Donald J. P.; Zhang, Donglu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Thrombolysis</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">478-492</span>CODEN:
                <span class="NLM_cas:coden">JTTHFF</span>;
        ISSN:<span class="NLM_cas:issn">0929-5305</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Apixaban (BMS-562247; 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide), a direct inhibitor of activated factor X (FXa), is in development for the prevention and treatment of various thromboembolic diseases.  With an inhibitory const. of 0.08 nM for human FXa, apixaban has greater than 30,000-fold selectivity for FXa over other human coagulation proteases.  It produces a rapid onset of inhibition of FXa with assocn. rate const. of 20 μM-1/s approx. and inhibits free as well as prothrombinase- and clot-bound FXa activity in vitro.  Apixaban also inhibits FXa from rabbits, rats and dogs, an activity which parallels its antithrombotic potency in these species.  Although apixaban has no direct effects on platelet aggregation, it indirectly inhibits this process by reducing thrombin generation.  Pre-clin. studies of apixaban in animal models have demonstrated dose-dependent antithrombotic efficacy at doses that preserved hemostasis.  Apixaban improves pre-clin. antithrombotic activity, without excessive increases in bleeding times, when added on top of aspirin or aspirin plus clopidogrel at their clin. relevant doses.  Apixaban has good bioavailability, low clearance and a small vol. of distribution in animals and humans, and a low potential for drug-drug interactions.  Elimination pathways for apixaban include renal excretion, metab. and biliary/intestinal excretion.  Although a sulfate conjugate of O-demethyl apixaban (O-demethyl apixaban sulfate) has been identified as the major circulating metabolite of apixaban in humans, it is inactive against human FXa.  Together, these non-clin. findings have established the favorable pharmacol. profile of apixaban, and support the potential use of apixaban in the clinic for the prevention and treatment of various thromboembolic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosf70y5okLwbVg90H21EOLACvtfcHk0lgQhgjrqkshoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvFSqtb4%253D&md5=97a2b3fa9a43f0eda48f19ba6e015d84</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1007%2Fs11239-011-0551-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11239-011-0551-3%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DP.%2BC.%26aulast%3DPinto%26aufirst%3DD.%2BJ.%26aulast%3DZhang%26aufirst%3DD.%26atitle%3DPreclinical%2520discovery%2520of%2520apixaban%252C%2520a%2520direct%2520and%2520orally%2520bioavailable%2520factor%2520Xa%2520inhibitor%26jtitle%3DJ.%2520Thromb.%2520Thrombolysis%26date%3D2011%26volume%3D31%26spage%3D478%26epage%3D492%26doi%3D10.1007%2Fs11239-011-0551-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frost, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosqueda-Garcia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacreta, F.</span></span> <span> </span><span class="NLM_article-title">Apixaban, an oral, direct factor Xa inhibitor: single-dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">476</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2012.04369.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1111%2Fj.1365-2125.2012.04369.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=22759198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3sXns1Klsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2013&pages=476-487&author=C.+Frostauthor=J.+Wangauthor=S.+Nepalauthor=A.+Schusterauthor=Y.+C.+Barrettauthor=R.+Mosqueda-Garciaauthor=R.+A.+Reevesauthor=F.+Lacreta&title=Apixaban%2C+an+oral%2C+direct+factor+Xa+inhibitor%3A+single-dose+safety%2C+pharmacokinetics%2C+pharmacodynamics+and+food+effect+in+healthy+subjects&doi=10.1111%2Fj.1365-2125.2012.04369.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects</span></div><div class="casAuthors">Frost, Charles; Wang, Jessie; Nepal, Sunil; Schuster, Alan; Barrett, Yu Chen; Mosqueda-Garcia, Rogelio; Reeves, Richard A.; LaCreta, Frank</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">476-487</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : To evaluate apixaban single dose safety, tolerability, pharmacokinetics and pharmacodynamics and assess the effect of food on apixaban pharmacokinetics.  Methods : A double-blind, placebo-controlled, single ascending-dose, first-in-human study assessed apixaban safety, pharmacokinetics and pharmacodynamics in healthy subjects randomized to oral apixaban (n = 43; 0.5-2.5 mg as soln. or 5-50 mg as tablets) or placebo (n = 14) under fasted conditions.  An open label, randomized, two treatment crossover study investigated apixaban pharmacokinetics/pharmacodynamics in healthy subjects (n = 21) administered apixaban 10 mg in fasted and fed states.  Both studies measured apixaban plasma concn., international normalized ratio (INR), activated partial thromboplastin time (aPTT) and prothrombin time (PT) or a modified PT (mPT).  Results : In the single ascending-dose study increases in apixaban exposure appeared dose-proportional.  Median tmax occurred 1.5-3.3 h following oral administration.  Mean terminal half-life ranged between 3.6 and 6.8 h following administration of soln. doses ≤2.5 mg and between 11.1 and 26.8 h for tablet doses ≥5 mg.  Concn.-related changes in pharmacodynamic assessments were obsd.  After a 50 mg dose, peak aPTT, INR and mPT increased by 1.2-, 1.6- and 2.9-fold, resp., from baseline.  In the food effect study: 90% confidence intervals of geometric mean ratios of apixaban Cmax and AUC in a fed vs. fasted state were within the predefined no effect (80-125%) range.  Apixaban half-life was approx. 11.5 h.  The effect of apixaban on INR, PT and aPTT was comparable following fed and fasted administration.  Conclusions : Single doses of apixaban were well tolerated with a predictable pharmacokinetic/pharmacodynamic profile and a half-life of approx. 12 h.  Apixaban can be administered with or without food.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPbr4OzJQAF7Vg90H21EOLACvtfcHk0lgQhgjrqkshoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXns1Klsg%253D%253D&md5=f272c96f3cbad896a55907840a368ac0</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2012.04369.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2012.04369.x%26sid%3Dliteratum%253Aachs%26aulast%3DFrost%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DNepal%26aufirst%3DS.%26aulast%3DSchuster%26aufirst%3DA.%26aulast%3DBarrett%26aufirst%3DY.%2BC.%26aulast%3DMosqueda-Garcia%26aufirst%3DR.%26aulast%3DReeves%26aufirst%3DR.%2BA.%26aulast%3DLacreta%26aufirst%3DF.%26atitle%3DApixaban%252C%2520an%2520oral%252C%2520direct%2520factor%2520Xa%2520inhibitor%253A%2520single-dose%2520safety%252C%2520pharmacokinetics%252C%2520pharmacodynamics%2520and%2520food%2520effect%2520in%2520healthy%2520subjects%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D75%26spage%3D476%26epage%3D487%26doi%3D10.1111%2Fj.1365-2125.2012.04369.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terucherai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, C. E.</span></span> <span> </span><span class="NLM_article-title">Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects</span>. <i>Am. J. Cardiovasc. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">154</span>, <span class="refDoi"> DOI: 10.1007/s40256-013-0055-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1007%2Fs40256-013-0055-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=24277644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFeitr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=147-154&author=X.+Wangauthor=S.+Mondalauthor=J.+Wangauthor=G.+Terucheraiauthor=D.+Zhangauthor=R.+A.+Boydauthor=C.+E.+Frost&title=Effect+of+activated+charcoal+on+apixaban+pharmacokinetics+in+healthy+subjects&doi=10.1007%2Fs40256-013-0055-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of Activated Charcoal on Apixaban Pharmacokinetics in Healthy Subjects</span></div><div class="casAuthors">Wang, Xiaoli; Mondal, Sabiha; Wang, Jessie; Tirucherai, Giridhar; Zhang, Donglu; Boyd, Rebecca A.; Frost, Charles</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Cardiovascular Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">147-154</span>CODEN:
                <span class="NLM_cas:coden">AJCDDJ</span>;
        ISSN:<span class="NLM_cas:issn">1175-3277</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Background Activated charcoal is commonly used to manage overdose or accidental ingestion of medicines.  This study evaluated the effect of activated charcoal on apixaban exposure in human subjects.  Methods This was an open-label, three-treatment, three-period, randomized, crossover study of single-dose apixaban (20 mg) administered alone and with activated charcoal given at 2 or 6 h post-dose to healthy subjects.  Blood samples for assay of plasma apixaban concn. were collected up to 72 h post-dose.  Pharmacokinetic parameters, including peak plasma concn. (Cmax), time to Cmax (Tmax), area under the concn.-time curve from time 0 to infinity (AUCINF), and terminal half-life (T1/2), were derived from apixaban plasma concn.-time data.  A general linear mixed-effect model anal. of Cmax and AUCINF was performed to est. the effect of activated charcoal on apixaban exposure.  Results A total of 18 subjects were treated and completed the study.  AUCINF for apixaban without activated charcoal decreased by 50 and 28 %, resp., when charcoal was administered at 2 and 6 h post-dose.  Apixaban Cmax and Tmax were similar across treatments.  The mean T1/2 for apixaban alone (13.4 h) decreased to ∼5 h when activated charcoal was administered at 2 or 6 h post-dose.  Overall, apixaban was well tolerated in this healthy population, and most adverse events were consistent with the known profile of activated charcoal.  Conclusion Administration of activated charcoal up to 6 h after apixaban reduced apixaban exposure and facilitated the elimination of apixaban.  These results suggest that activated charcoal may be useful in the management of apixaban overdose or accidental ingestion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpIgHCXhw6grVg90H21EOLACvtfcHk0lhXHwJ_tgc_OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFeitr0%253D&md5=d25d2ef475ece2d174a0d3f447676792</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1007%2Fs40256-013-0055-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40256-013-0055-y%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMondal%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DTerucherai%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DBoyd%26aufirst%3DR.%2BA.%26aulast%3DFrost%26aufirst%3DC.%2BE.%26atitle%3DEffect%2520of%2520activated%2520charcoal%2520on%2520apixaban%2520pharmacokinetics%2520in%2520healthy%2520subjects%26jtitle%3DAm.%2520J.%2520Cardiovasc.%2520Drugs%26date%3D2014%26volume%3D14%26spage%3D147%26epage%3D154%26doi%3D10.1007%2Fs40256-013-0055-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balimane, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, W. G.</span></span> <span> </span><span class="NLM_article-title">Characterization of efflux transporters involved in distribution and disposition of apixaban</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">827</span>– <span class="NLM_lpage">835</span>, <span class="refDoi"> DOI: 10.1124/dmd.112.050260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.112.050260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=23382458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3sXkslSkt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=827-835&author=D.+Zhangauthor=K.+Heauthor=J.+J.+Herbstauthor=J.+Kolbauthor=W.+Shouauthor=L.+Wangauthor=P.+V.+Balimaneauthor=Y.+H.+Hanauthor=J.+Ganauthor=C.+E.+Frostauthor=W.+G.+Humphreys&title=Characterization+of+efflux+transporters+involved+in+distribution+and+disposition+of+apixaban&doi=10.1124%2Fdmd.112.050260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of efflux transporters involved in distribution and disposition of apixaban</span></div><div class="casAuthors">Zhang, Donglu; He, Kan; Herbst, John J.; Kolb, Janet; Shou, Wilson; Wang, Lifei; Balimane, Praveen V.; Han, Yong-Hae; Gan, Jinping; Frost, Charles E.; Humphreys, W. Griffith</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">827-835</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The studies reported here were conducted to investigate the transport characteristics of apixaban (1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c]pyridine-3-carboxamide) and to understand the impact of transporters on apixaban distribution and disposition.  In human permeability glycoprotein (P-gp)- and breast cancer resistance protein (BCRP)-cDNA-transfected cell monolayers as well as Caco-2 cell monolayers, the apparent efflux ratio of basolateral-to-apical (PcB-A) vs. apical-to-basolateral permeability (PcA-B) of apixaban was >10.  The P-gp- and BCRP-facilitated transport of apixaban was concn.- and time-dependent and did not show satn. over a wide range of concns. (1-100 μM).  The efflux transport of apixaban was also demonstrated by the lower mucosal-to-serosal permeability than that of the serosal-to-mucosal direction in isolated rat jejunum segments.  Apixaban did not inhibit digoxin transport in Caco-2 cells.  Ketoconazole decreased the P-gp-mediated apixaban efflux in Caco-2 and the P-gp-cDNA-transfected cell monolayers, but did not affect the apixaban efflux to a meaningful extent in the BCRP-cDNA-transfected cell monolayers.  Coincubation of a P-gp inhibitor (ketoconazole or cyclosporin A) and a BCRP inhibitor (Ko134) provided more complete inhibition of apixaban efflux in Caco-2 cells than sep. inhibition by individual inhibitors.  Naproxen inhibited apixaban efflux in Caco-2 cells but showed only a minimal effect on apixaban transport in the BCRP-transfected cells.  Naproxen was the first nonsteroidal antiinflammatory drug that was demonstrated as a weak P-gp inhibitor.  These results demonstrate that apixaban is a substrate for efflux transporters P-gp and BCRP, which can help explain its low brain penetration, and low fetal exposures and high milk excretion in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrclGcXVqXv1LVg90H21EOLACvtfcHk0lhXHwJ_tgc_OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXkslSkt7Y%253D&md5=c52c460c36ca5c35836a0bdfb7a91bc5</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.050260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.050260%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DHe%26aufirst%3DK.%26aulast%3DHerbst%26aufirst%3DJ.%2BJ.%26aulast%3DKolb%26aufirst%3DJ.%26aulast%3DShou%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBalimane%26aufirst%3DP.%2BV.%26aulast%3DHan%26aufirst%3DY.%2BH.%26aulast%3DGan%26aufirst%3DJ.%26aulast%3DFrost%26aufirst%3DC.%2BE.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26atitle%3DCharacterization%2520of%2520efflux%2520transporters%2520involved%2520in%2520distribution%2520and%2520disposition%2520of%2520apixaban%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2013%26volume%3D41%26spage%3D827%26epage%3D835%26doi%3D10.1124%2Fdmd.112.050260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sinko, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waclawski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. R.</span></span> <span> </span><span class="NLM_article-title">Oral absorption of anti-AIDS nucleoside analogues. 1. Intestinal transport of didanosine in rat and rabbit preparations</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">959</span>– <span class="NLM_lpage">965</span>, <span class="refDoi"> DOI: 10.1002/jps.2600840811</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1002%2Fjps.2600840811" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=7500281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK2MXmvVKltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=1995&pages=959-965&author=P.+J.+Sinkoauthor=P.+Huauthor=A.+P.+Waclawskiauthor=N.+R.+Patel&title=Oral+absorption+of+anti-AIDS+nucleoside+analogues.+1.+Intestinal+transport+of+didanosine+in+rat+and+rabbit+preparations&doi=10.1002%2Fjps.2600840811"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Oral Absorption of Anti-AIDS Nucleoside Analogs. 1. Intestinal Transport of Didanosine in Rat and Rabbit Preparations</span></div><div class="casAuthors">Sinko, Patrick J.; Hu, Peidi; Waclawski, Anthony P.; Patel, Nisha R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">959-65</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The intestinal transport of didanosine (ddl), a nucleoside analog used in the treatment of human immunodeficiency virus (HIV) infection, was characterized using in situ and in vitro techniques.  The zero-trans uptake of ddl in rat intestinal brush border membrane vesicles (BBMV) was linear over the range of 1 μM to 50 mM, ruling out a significant carrier-mediated absorption component.  The lack of carrier-mediated transport was confirmed in a second species (rabbit).  In order to quantitate the convective (Pconv) and diffusive (Pdiff) components of ddl intestinal permeability, the steady state wall permeability (P*w) was detd. using an established perfusion technique in rats.  Even though baseline P*w (pH 6.5, 290 mosm/kg, no modulator) and fluid absorption results were similar to those of furosemide, the ratios of Pdiff and φ, the sieving coeff. (ddl:furosemide), were 0.31:1 and 1.70:1, resp., demonstrating that ddl's Pdiff is low and Pconv is high relative to furosemide's, suggesting significant paracellular absorption of ddl.  The apparent diffusive absorptive clearances (P'app) of ddl and furosemide were detd. in BBMV, which lack functional tight junctions, and the ratios (ddl:furosemide) of P'app in rat and rabbit were 0.23:1 and 0.24:1, resp.  The BBMV results demonstrate that the majority of ddl intestinal transport does not occur by passive membrane diffusion, confirming the single pass intestinal perfusion findings.  The results of these studies suggest that ddl is transported by nonfacilitated membrane and paracellular diffusion with paracellular transport being responsible for the majority of ddl absorption from the intestine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5mZ6v7SyetbVg90H21EOLACvtfcHk0lhXHwJ_tgc_OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmvVKltL8%253D&md5=bfba42100f3283e5c94b7666e01cfa7d</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1002%2Fjps.2600840811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.2600840811%26sid%3Dliteratum%253Aachs%26aulast%3DSinko%26aufirst%3DP.%2BJ.%26aulast%3DHu%26aufirst%3DP.%26aulast%3DWaclawski%26aufirst%3DA.%2BP.%26aulast%3DPatel%26aufirst%3DN.%2BR.%26atitle%3DOral%2520absorption%2520of%2520anti-AIDS%2520nucleoside%2520analogues.%25201.%2520Intestinal%2520transport%2520of%2520didanosine%2520in%2520rat%2520and%2520rabbit%2520preparations%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D1995%26volume%3D84%26spage%3D959%26epage%3D965%26doi%3D10.1002%2Fjps.2600840811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kilic, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirmagul, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yildirim, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erol, K.</span></span> <span> </span><span class="NLM_article-title">Intestinal absorption of digoxin and interaction with nimodipine in rats</span>. <i>Polym. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">141</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=15047988" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2004&pages=137-141&author=F.+S.+Kilicauthor=O.+Batuauthor=B.+Sirmagulauthor=E.+Yildirimauthor=K.+Erol&title=Intestinal+absorption+of+digoxin+and+interaction+with+nimodipine+in+rats"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKilic%26aufirst%3DF.%2BS.%26aulast%3DBatu%26aufirst%3DO.%26aulast%3DSirmagul%26aufirst%3DB.%26aulast%3DYildirim%26aufirst%3DE.%26aulast%3DErol%26aufirst%3DK.%26atitle%3DIntestinal%2520absorption%2520of%2520digoxin%2520and%2520interaction%2520with%2520nimodipine%2520in%2520rats%26jtitle%3DPolym.%2520J.%2520Pharmacol.%26date%3D2004%26volume%3D56%26spage%3D137%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, J.</span></span> <span> </span><span class="NLM_article-title">Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">880</span>– <span class="NLM_lpage">885</span>, <span class="refDoi"> DOI: 10.1016/0006-291X(91)91647-U</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1016%2F0006-291X%2891%2991647-U" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1673839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK3MXhslOrt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=1991&pages=880-885&author=P.+Arturssonauthor=J.+Karlsson&title=Correlation+between+oral+drug+absorption+in+humans+and+apparent+drug+permeability+coefficients+in+human+intestinal+epithelial+%28Caco-2%29+cells&doi=10.1016%2F0006-291X%2891%2991647-U"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells</span></div><div class="casAuthors">Artursson, P.; Karlsson, J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">880-5</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    </div><div class="casAbstract">Monolayers of a well differentiated human intestinal epithelial cell line, Caco-2, were used as a model to study passive drug absorption across the intestinal epithelium.  Absorption rate consts. (expressed as apparent permeability coeffs.) were detd. for 20 drugs and peptides with different structural properties.  The permeability coeffs. ranged from approx. 5 × 10-8 to 5 × 10-5 cm/s.  A good correlation was obtained between data on oral absorption in humans and the results in the Caco-2 model.  Drugs that are completely absorbed in humans had permeability coeffs. >1 × 10-6 cm/s.  Drugs that are absorbed to >1% but <100% had permeability coeffs. of 0.1-1.0 × 10-6 cm/s while drugs and peptides that are absorbed to <1% had permeability coeffs. of ≤1 × 10-7 cm/s.  The results indicate that Caco-2 monolayers can be used as a model for studies on intestinal drug absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdvsEluSXCILVg90H21EOLACvtfcHk0liqNJ0jKznSpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhslOrt7c%253D&md5=3b1e14cae3beb0345014284e3aa6a7c0</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1016%2F0006-291X%2891%2991647-U&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-291X%252891%252991647-U%26sid%3Dliteratum%253Aachs%26aulast%3DArtursson%26aufirst%3DP.%26aulast%3DKarlsson%26aufirst%3DJ.%26atitle%3DCorrelation%2520between%2520oral%2520drug%2520absorption%2520in%2520humans%2520and%2520apparent%2520drug%2520permeability%2520coefficients%2520in%2520human%2520intestinal%2520epithelial%2520%2528Caco-2%2529%2520cells%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1991%26volume%3D175%26spage%3D880%26epage%3D885%26doi%3D10.1016%2F0006-291X%2891%2991647-U" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dando, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, R. A.</span></span> <span> </span><span class="NLM_article-title">Evaluation of biocoat intestinal epithelium differentiation environment (3-day cultured Caco-2 cells) as an absorption screening model with improved productivity</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1835</span>– <span class="NLM_lpage">1837</span>, <span class="refDoi"> DOI: 10.1023/A:1012112820371</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1023%2FA%3A1012112820371" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=9453077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK1cXktFKhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=1835-1837&author=S.+Chongauthor=S.+A.+Dandoauthor=R.+A.+Morrison&title=Evaluation+of+biocoat+intestinal+epithelium+differentiation+environment+%283-day+cultured+Caco-2+cells%29+as+an+absorption+screening+model+with+improved+productivity&doi=10.1023%2FA%3A1012112820371"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of Biocoat intestinal epithelium differentiation environment (3-day cultured Caco-2 cells) as an absorption screening model with improved productivity</span></div><div class="casAuthors">Chong, Saeho; Dando, Sandra A.; Morrison, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1835-1837</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Plenum Publishing Corp.</span>)
        </div><div class="casAbstract">A reasonable correlation was demonstrated between the in vitro permeability through the Biocoat Intestinal Epithelium Differentiation Environment (BIEDE) Caco-2 cell monolayer and the extent of in vivo absorption in humans with a heterologous series of 18 passively absorbed drugs.  Both the BIEDE and 3-wk systems provided similar Pc values so that the Pc values detd. by the BIEDE system can be directly compared with the Pc values accumulated with the conventional 3-wk system.  Therefore, the BIEDE Caco-2 cell monolayer appears to be a more convenient and productive (i.e., reduced 8 or 9 labor-intensive medium replacement steps down to one, and was usable in 3 days) absorption screening tool compared to the conventional 3-wk system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofm54kcxk7t7Vg90H21EOLACvtfcHk0liqNJ0jKznSpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXktFKhtQ%253D%253D&md5=6e973c7c1d487d70044d736a45e7a7b7</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1023%2FA%3A1012112820371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1012112820371%26sid%3Dliteratum%253Aachs%26aulast%3DChong%26aufirst%3DS.%26aulast%3DDando%26aufirst%3DS.%2BA.%26aulast%3DMorrison%26aufirst%3DR.%2BA.%26atitle%3DEvaluation%2520of%2520biocoat%2520intestinal%2520epithelium%2520differentiation%2520environment%2520%25283-day%2520cultured%2520Caco-2%2520cells%2529%2520as%2520an%2520absorption%2520screening%2520model%2520with%2520improved%2520productivity%26jtitle%3DPharm.%2520Res.%26date%3D1997%26volume%3D14%26spage%3D1835%26epage%3D1837%26doi%3D10.1023%2FA%3A1012112820371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gres, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julian, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourrie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roques, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulenc, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabre, G.</span></span> <span> </span><span class="NLM_article-title">Correlation between oral drug absorption in humans, and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: comparison with the parental Caco-2 cell line</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">726</span>– <span class="NLM_lpage">733</span>, <span class="refDoi"> DOI: 10.1023/A:1011919003030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1023%2FA%3A1011919003030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=9619781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK1cXjtlWhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1998&pages=726-733&author=M.+C.+Gresauthor=B.+Julianauthor=M.+Bourrieauthor=V.+Meunierauthor=C.+Roquesauthor=M.+Bergerauthor=X.+Boulencauthor=Y.+Bergerauthor=G.+Fabre&title=Correlation+between+oral+drug+absorption+in+humans%2C+and+apparent+drug+permeability+in+TC-7+cells%2C+a+human+epithelial+intestinal+cell+line%3A+comparison+with+the+parental+Caco-2+cell+line&doi=10.1023%2FA%3A1011919003030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation between oral drug absorption in humans, and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: comparison with the parental Caco-2 cell line</span></div><div class="casAuthors">Gres, Marie-Catherine; Julian, Bernard; Bourrie, Martine; Meunier, Viviane; Roques, Claude; Berger, Marion; Boulenc, Xavier; Berger, Yves; Fabre, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">726-733</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Plenum Publishing Corp.</span>)
        </div><div class="casAbstract">To det. and compare the relation between in vivo oral absorption in humans and the apparent permeability coeffs. (Papp) obtained in vitro on two human intestinal epithelial cell lines, the parental Caco-2 and the TC-7 clone.  Both cell lines were grown for 5-35 days on tissue culture-treated inserts.  Cell monolayers were analyzed for their morphol. by transmission electron microg., and for their integrity with respect to transepithelial elec. resistance, mannitol and PEG-4000 transport, and cyclosporin efflux.  Papp were detd. for 20 compds. exhibiting large differences in chem. structure, mol. wt., transport mechanisms, and percentage of absorption in humans.  The TC-7 clone exhibits morphol. characteristics similar to those of the parental Caco-2 cell line, concerning apical brush border, microvilli, tight junctions and polarization of the cell line.  The TC-7 clone however appeared more homogeneous in terms of cell size.  Both cell lines achieved a similar monolayer integrity towards mannitol and PEG-4000.  Monolayer integrity was achieved earlier for the TC-7 clone, mainly due to its shorter doubling time, i.e. 26 vs. 30 h for parental Caco-2 cells.  When using cyclosporin A as a P-glycoprotein substrate, active efflux was lower in the TC-7 clone than in the parental Caco-2 cells.  The Papp and mechanisms of transport (paracellular or transcellular routes, passive diffusion and active transport) were detd. for 20 drugs.  A relation was established between the in vivo oral absorption in humans and Papp values, allowing to det. a threshold value for Papp of 2 10-6 cm/s, above for which a 100% oral absorption could be expected in humans.  Both correlation curves obtained with the two cell types, were almost completely superimposable.  These studies also confirmed that the dipeptide transporter is underexpressed in both cell lines.  On the basis of morphol. parameters, biochem. activity and drug transport characteristics, the TC-7 clone appeared to be a valuable alternative to the use of parental Caco-2 cells for drug absorption studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGradgOMm2cV-bVg90H21EOLACvtfcHk0liqNJ0jKznSpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjtlWhsLs%253D&md5=af26ddb3e017d5afbffcc7759f327eff</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1023%2FA%3A1011919003030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1011919003030%26sid%3Dliteratum%253Aachs%26aulast%3DGres%26aufirst%3DM.%2BC.%26aulast%3DJulian%26aufirst%3DB.%26aulast%3DBourrie%26aufirst%3DM.%26aulast%3DMeunier%26aufirst%3DV.%26aulast%3DRoques%26aufirst%3DC.%26aulast%3DBerger%26aufirst%3DM.%26aulast%3DBoulenc%26aufirst%3DX.%26aulast%3DBerger%26aufirst%3DY.%26aulast%3DFabre%26aufirst%3DG.%26atitle%3DCorrelation%2520between%2520oral%2520drug%2520absorption%2520in%2520humans%252C%2520and%2520apparent%2520drug%2520permeability%2520in%2520TC-7%2520cells%252C%2520a%2520human%2520epithelial%2520intestinal%2520cell%2520line%253A%2520comparison%2520with%2520the%2520parental%2520Caco-2%2520cell%2520line%26jtitle%3DPharm.%2520Res.%26date%3D1998%26volume%3D15%26spage%3D726%26epage%3D733%26doi%3D10.1023%2FA%3A1011919003030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shantsila, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lip, G. Y.</span></span> <span> </span><span class="NLM_article-title">Apixaban, an oral, direct inhibitor of activated Factor Xa</span>. <i>Curr. Opin. Investig. Drugs.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1020</span>– <span class="NLM_lpage">33</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=18729009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFKntr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=1020-33&author=E.+Shantsilaauthor=G.+Y.+Lip&title=Apixaban%2C+an+oral%2C+direct+inhibitor+of+activated+Factor+Xa"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91aR"><div class="casContent"><span class="casTitleNuber">91a</span><div class="casTitle"><span class="NLM_cas:atitle">Apixaban, an oral, direct inhibitor of activated Factor Xa</span></div><div class="casAuthors">Shantsila, Eduard; Lip, Gregory Y. H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Investigational Drugs (Thomson Scientific)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1020-1033</span>CODEN:
                <span class="NLM_cas:coden">COIDAZ</span>;
        ISSN:<span class="NLM_cas:issn">1472-4472</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review.  Apixaban is an oral, direct Factor Xa inhibitor that is being developed by Bristol-Myers Squibb Co and Pfizer Inc.  Apixaban is currently undergoing phase III clin. trials for cerebrovascular ischemia, deep vein thrombosis and lung embolism, and phase II clin. trials for coronary artery disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSQ2V3s_JMhLVg90H21EOLACvtfcHk0liqNJ0jKznSpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFKntr7E&md5=1d48763ed835bd4c1c8d66fc4b3ad2f2</span></div><a href="/servlet/linkout?suffix=cit91a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShantsila%26aufirst%3DE.%26aulast%3DLip%26aufirst%3DG.%2BY.%26atitle%3DApixaban%252C%2520an%2520oral%252C%2520direct%2520inhibitor%2520of%2520activated%2520Factor%2520Xa%26jtitle%3DCurr.%2520Opin.%2520Investig.%2520Drugs.%26date%3D2008%26volume%3D9%26spage%3D1020%26epage%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit91b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vakkalagadda, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byon, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dias, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaCreta, F.</span></span> <span> </span><span class="NLM_article-title">Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of Factor Xa</span>. <i>Am. J. Cardiovasc. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1007/s40256-015-0157-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1007%2Fs40256-015-0157-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=26749408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVakt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=119-27&issue=2&author=B.+Vakkalagaddaauthor=C.+Frostauthor=W.+Byonauthor=R.+A.+Boydauthor=J.+Wangauthor=D.+Zhangauthor=Z.+Yuauthor=C.+Diasauthor=A.+Shenkerauthor=F.+LaCreta&title=Effect+of+rifampin+on+the+pharmacokinetics+of+apixaban%2C+an+oral+direct+inhibitor+of+Factor+Xa&doi=10.1007%2Fs40256-015-0157-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91bR"><div class="casContent"><span class="casTitleNuber">91b</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa</span></div><div class="casAuthors">Vakkalagadda, Blisse; Frost, Charles; Byon, Wonkyung; Boyd, Rebecca A.; Wang, Jessie; Zhang, Donglu; Yu, Zhigang; Dias, Clapton; Shenker, Andrew; La Creta, Frank</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Cardiovascular Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">119-127</span>CODEN:
                <span class="NLM_cas:coden">AJCDDJ</span>;
        ISSN:<span class="NLM_cas:issn">1175-3277</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Objective: Apixaban is a substrate of cytochrome P 450 3A4 (CYP3A4) and P-glycoprotein.  The effects of rifampin, a strong inducer of CYP3A4 and P-glycoprotein, on the pharmacokinetics of oral and i.v. apixaban were evaluated in an open-label, randomized, sequential crossover study.  Methods: Twenty healthy participants received single doses of apixaban 5 mg i.v. on day 1 and 10 mg orally on day 3, followed by rifampin 600 mg once daily on days 5-15.  Finally, participants received single doses of apixaban 5 mg i.v. and 10 mg orally sep. on days 12 and 14 in one of two randomized sequences.  Results: Apixaban, given i.v. and orally, was safe and well tolerated when administered in the presence and absence of rifampin.  Apixaban abs. oral bioavailability was 49 % when administered alone and 39 % following induction by rifampin.  Rifampin reduced apixaban area under the plasma concn.-time curve from time zero to infinity (AUC∞) by 39 % after i.v. administration and by 54 % after oral administration.  Rifampin induction increased mean clearance by 1.6-fold for i.v. apixaban and mean apparent clearance by 2.1-fold for oral apixaban, indicating rifampin affected both pre-systemic and systemic apixaban elimination pathways.  Conclusion: Co-administration of apixaban with rifampin reduced apixaban exposure via both decreased bioavailability and increased systemic clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVLag-NTYEJ7Vg90H21EOLACvtfcHk0lgE21A-H6YEKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVakt7o%253D&md5=b6be1ef697642da3da25ec9bb56afc65</span></div><a href="/servlet/linkout?suffix=cit91b&amp;dbid=16384&amp;doi=10.1007%2Fs40256-015-0157-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40256-015-0157-9%26sid%3Dliteratum%253Aachs%26aulast%3DVakkalagadda%26aufirst%3DB.%26aulast%3DFrost%26aufirst%3DC.%26aulast%3DByon%26aufirst%3DW.%26aulast%3DBoyd%26aufirst%3DR.%2BA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DDias%26aufirst%3DC.%26aulast%3DShenker%26aufirst%3DA.%26aulast%3DLaCreta%26aufirst%3DF.%26atitle%3DEffect%2520of%2520rifampin%2520on%2520the%2520pharmacokinetics%2520of%2520apixaban%252C%2520an%2520oral%2520direct%2520inhibitor%2520of%2520Factor%2520Xa%26jtitle%3DAm.%2520J.%2520Cardiovasc.%2520Drugs%26date%3D2016%26volume%3D16%26issue%3D2%26spage%3D119%26epage%3D27%26doi%3D10.1007%2Fs40256-015-0157-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norinder, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergstrom, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span> <span> </span><span class="NLM_article-title">Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1816</span>– <span class="NLM_lpage">1831</span>, <span class="refDoi"> DOI: 10.1007/s11095-009-9896-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1007%2Fs11095-009-9896-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=19421845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFOmt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2009&pages=1816-1831&author=P.+Matssonauthor=J.+M.+Pedersenauthor=U.+Norinderauthor=C.+A.+Bergstromauthor=P.+Artursson&title=Identification+of+novel+specific+and+general+inhibitors+of+the+three+major+human+ATP-binding+cassette+transporters+P-gp%2C+BCRP+and+MRP2+among+registered+drugs&doi=10.1007%2Fs11095-009-9896-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Novel Specific and General Inhibitors of the Three Major Human ATP-Binding Cassette Transporters P-gp, BCRP and MRP2 Among Registered Drugs</span></div><div class="casAuthors">Matsson, Paer; Pedersen, Jenny M.; Norinder, Ulf; Bergstroem, Christel A. S.; Artursson, Per</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1816-1831</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: To study the inhibition patterns of the three major human ABC transporters P-gp (ABCB1), BCRP (ABCG2) and MRP2 (ABCC2), using a dataset of 122 structurally diverse drugs.  Methods: Inhibition was investigated in cellular and vesicular systems over-expressing single transporters.  Computational models discriminating either single or general inhibitors from non-inhibitors were developed using multivariate statistics.  Results: Specific (n = 23) and overlapping (n = 19) inhibitors of the three ABC transporters were identified.  GF120918 and Ko143 were verified to specifically inhibit P-gp/BCRP and BCRP in defined concn. intervals, whereas the MRP inhibitor MK571 was revealed to inhibit all three transporters within one log unit of concn.  Virtual docking expts. showed that MK571 binds to the ATP catalytic site, which could contribute to its multi-specific inhibition profile.  A computational model predicting general ABC inhibition correctly classified 80% of both ABC transporter inhibitors and non-inhibitors in an external test set.  Conclusions: The inhibitor specificities of P-gp, BCRP and MRP2 were shown to be highly overlapping.  General ABC inhibitors were more lipophilic and arom. than specific inhibitors and non-inhibitors.  The identified specific inhibitors can be used to delineate transport processes in complex exptl. systems, whereas the multi-specific inhibitors are useful in primary ABC transporter screening in drug discovery settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJZNTwQZwLgbVg90H21EOLACvtfcHk0lgE21A-H6YEKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFOmt70%253D&md5=596bf2ce79e2aa5eaffdf177762faa5d</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1007%2Fs11095-009-9896-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-009-9896-0%26sid%3Dliteratum%253Aachs%26aulast%3DMatsson%26aufirst%3DP.%26aulast%3DPedersen%26aufirst%3DJ.%2BM.%26aulast%3DNorinder%26aufirst%3DU.%26aulast%3DBergstrom%26aufirst%3DC.%2BA.%26aulast%3DArtursson%26aufirst%3DP.%26atitle%3DIdentification%2520of%2520novel%2520specific%2520and%2520general%2520inhibitors%2520of%2520the%2520three%2520major%2520human%2520ATP-binding%2520cassette%2520transporters%2520P-gp%252C%2520BCRP%2520and%2520MRP2%2520among%2520registered%2520drugs%26jtitle%3DPharm.%2520Res.%26date%3D2009%26volume%3D26%26spage%3D1816%26epage%3D1831%26doi%3D10.1007%2Fs11095-009-9896-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blatter, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seelig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seelig, J.</span></span> <span> </span><span class="NLM_article-title">Interaction of verapamil with lipid membranes and P-glycoprotein: connecting thermodynamics and membrane structure with functional activity</span>. <i>Biophys. J.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">2943</span>– <span class="NLM_lpage">2955</span>, <span class="refDoi"> DOI: 10.1529/biophysj.106.089581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1529%2Fbiophysj.106.089581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=16877510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVGls7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2006&pages=2943-2955&author=M.+Meierauthor=X.+L.+Blatterauthor=A.+Seeligauthor=J.+Seelig&title=Interaction+of+verapamil+with+lipid+membranes+and+P-glycoprotein%3A+connecting+thermodynamics+and+membrane+structure+with+functional+activity&doi=10.1529%2Fbiophysj.106.089581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of verapamil with lipid membranes and P-glycoprotein: connecting thermodynamics and membrane structure with functional activity</span></div><div class="casAuthors">Meier, M.; Li Blatter, X.; Seelig, A.; Seelig, J.</div><div class="citationInfo"><span class="NLM_cas:title">Biophysical Journal</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2943-2955</span>CODEN:
                <span class="NLM_cas:coden">BIOJAU</span>;
        ISSN:<span class="NLM_cas:issn">0006-3495</span>.
    
            (<span class="NLM_cas:orgname">Biophysical Society</span>)
        </div><div class="casAbstract">Verapamil and amlodipine are calcium ion influx inhibitors of wide clin. use.  They are partially charged at neutral pH and exhibit amphiphilic properties.  The noncharged species can easily cross the lipid membrane.  We have measured with solid-state NMR the structural changes induced by verapamil upon incorporation into phospholipid bilayers and have compared them with earlier data on amlodipine and nimodipine.  Verapamil and amlodipine produce a rotation of the phosphocholine headgroup away from the membrane surface and a disordering of the fatty acid chains.  We have detd. the thermodn. of verapamil partitioning into neutral and neg. charged membranes with isothermal titrn. calorimetry.  Verapamil undergoes a pK-shift of ΔpKa = 1.2 units in neutral lipid membranes and the percentage of the noncharged species increases from 5% to 45%.  Verapamil partitioning is increased for neg. charged membranes and the binding isotherms are strongly affected by the salt concn.  The electrostatic screening can be explained with the Gouy-Chapman theory.  Using a functional phosphate assay we have measured the affinity of verapamil, amlodipine, and nimodipine for P-glycoprotein, and have calcd. the free energy of drug binding from the aq. phase to the active center of P-glycoprotein in the lipid phase.  By combining the latter results with the lipid partitioning data it was possible, for the first time, to det. the true affinity of the three drugs for the P-glycoprotein active center if the reaction takes place exclusively in the lipid matrix.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAnJVSZCLdULVg90H21EOLACvtfcHk0lgE21A-H6YEKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVGls7jE&md5=baf0b7fb5822ec49b60a925cee568f64</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1529%2Fbiophysj.106.089581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1529%252Fbiophysj.106.089581%26sid%3Dliteratum%253Aachs%26aulast%3DMeier%26aufirst%3DM.%26aulast%3DBlatter%26aufirst%3DX.%2BL.%26aulast%3DSeelig%26aufirst%3DA.%26aulast%3DSeelig%26aufirst%3DJ.%26atitle%3DInteraction%2520of%2520verapamil%2520with%2520lipid%2520membranes%2520and%2520P-glycoprotein%253A%2520connecting%2520thermodynamics%2520and%2520membrane%2520structure%2520with%2520functional%2520activity%26jtitle%3DBiophys.%2520J.%26date%3D2006%26volume%3D91%26spage%3D2943%26epage%3D2955%26doi%3D10.1529%2Fbiophysj.106.089581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mori, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokooji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, T.</span></span> <span> </span><span class="NLM_article-title">Fate of quinidine, a P-glycoprotein substrate, in the gastrointestinal tract after oral administration in rats</span>. <i>Pharmazie</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">244</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=18444515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktVersbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2008&pages=241-244&author=N.+Moriauthor=T.+Yokoojiauthor=T.+Murakami&title=Fate+of+quinidine%2C+a+P-glycoprotein+substrate%2C+in+the+gastrointestinal+tract+after+oral+administration+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Fate of quinidine, a P-glycoprotein substrate, in the gastrointestinal tract after oral administration in rats</span></div><div class="casAuthors">Mori, N.; Yokooji, T.; Murakami, T.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmazie</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">241-244</span>CODEN:
                <span class="NLM_cas:coden">PHARAT</span>;
        ISSN:<span class="NLM_cas:issn">0031-7144</span>.
    
            (<span class="NLM_cas:orgname">Govi-Verlag Pharmazeutischer Verlag GmbH</span>)
        </div><div class="casAbstract">P-Glycoprotein (P-gp), an ATP-dependent efflux transporter, is expressed in brush-border membranes in the intestines of humans and rodents.  In this study, the fate of quinidine, a P-gp substrate, in the gastrointestinal tract after oral administration was examd. in conscious rats.  The animals received quinidine (3 mg/mL/kg) or FITC-dextran of mol. wt. of 10,000 (FD-10S, 5 mg/mL/kg, a poorly absorbable compd.) orally, and the remaining amt. of the compd. in the upper gastrointestinal tract was measured at designated time intervals.  As a control, FD-10S was distributed almost evenly throughout the gastrointestinal tract at 30 min, and most of FD-10S was accumulated in the distal small intestine at 60 min after administration.  In contrast, most of the orally administered quinidine disappeared at the proximal intestine, and only small amts. reached the distal region.  Also, the gastrointestinal transit of FD-10S was markedly slowed by stopping or inhibiting the bile flow, indicating that bile flow significantly affects the transit of drugs in the gastrointestinal tract.  In conclusion, this study has demonstrated that compds. with high soly. and high permeability, such as quinidine, can be absorbed rapidly at the proximal intestine, escaping the barrier function of P-gp, because P-gp is mostly expressed in the distal intestine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3fbollFO7QLVg90H21EOLACvtfcHk0liuZzn8gHC8yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktVersbw%253D&md5=439a0f20099e161978c589ed28614c2c</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DN.%26aulast%3DYokooji%26aufirst%3DT.%26aulast%3DMurakami%26aufirst%3DT.%26atitle%3DFate%2520of%2520quinidine%252C%2520a%2520P-glycoprotein%2520substrate%252C%2520in%2520the%2520gastrointestinal%2520tract%2520after%2520oral%2520administration%2520in%2520rats%26jtitle%3DPharmazie%26date%3D2008%26volume%3D63%26spage%3D241%26epage%3D244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unadkat, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Q.</span></span> <span> </span><span class="NLM_article-title">Effect of pregnancy on nitrofurantoin disposition in mice</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">4306</span>– <span class="NLM_lpage">4315</span>, <span class="refDoi"> DOI: 10.1002/jps.21698</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1002%2Fjps.21698" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=19422048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2qtLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2009&pages=4306-4315&author=Y.+Zhangauthor=L.+Zhouauthor=J.+D.+Unadkatauthor=Q.+Mao&title=Effect+of+pregnancy+on+nitrofurantoin+disposition+in+mice&doi=10.1002%2Fjps.21698"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of pregnancy on nitrofurantoin disposition in mice</span></div><div class="casAuthors">Zhang, Yi; Zhou, Lin; Unadkat, Jashvant D.; Mao, Qingcheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4306-4315</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">We investigated the effect of pregnancy on nitrofurantoin (NFT) disposition in wild-type and Bcrp1-/- mice.  Pregnant and non-pregnant mice were administered NFT i.v. (5 mg/kg) or orally (10 mg/kg).  Blood samples were collected at various times (5-60 min) after drug administration, plasma NFT concns. detd. by HPLC/UV, and pharmacokinetic parameters estd.  Dose-normalized area under the plasma concn.-time curve (AUC), terminal plasma half-life (T1/2), total plasma clearance (CL), and steady-state vol. of distribution (Vss) of i.v. NFT in wild-type or Bcrp1-/- mice were not altered by pregnancy.  After oral administration, pregnancy did not affect dose-normalized AUC of NFT in wild-type mice; however, dose-normalized AUC in Bcrp1-/- mice was decreased by approx. 70% by pregnancy.  In conclusion, since Bcrp1 plays a minor role in the systemic clearance of NFT in female mice, pregnancy did not affect disposition of i.v. NFT despite the fact that Bcrp1 expression in the liver and kidney of mice is significantly induced by pregnancy.  On the other hand, pregnancy may affect expression and activity of certain intestinal efflux transporters and/or metabolic enzymes in Bcrp1-/- mice, resulting in a drastic decrease in the systemic exposure of oral NFT in pregnant Bcrp1-/- mice. © 2009 Wiley-Liss, Inc. and the American Pharmacists Assocn. J Pharm Sci 98:4306-4315, 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqirYpzy_MxgbVg90H21EOLACvtfcHk0liuZzn8gHC8yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2qtLnM&md5=539844d38df2298e3fc33daaec4cff0f</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1002%2Fjps.21698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.21698%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DUnadkat%26aufirst%3DJ.%2BD.%26aulast%3DMao%26aufirst%3DQ.%26atitle%3DEffect%2520of%2520pregnancy%2520on%2520nitrofurantoin%2520disposition%2520in%2520mice%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2009%26volume%3D98%26spage%3D4306%26epage%3D4315%26doi%3D10.1002%2Fjps.21698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bundgaard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garmer, M.</span></span> <span> </span><span class="NLM_article-title">Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">466</span>, <span class="refDoi"> DOI: 10.1124/dmd.111.043083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.111.043083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=22112383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1Wqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=461-466&author=C.+Bundgaardauthor=C.+J.+Jensenauthor=M.+Garmer&title=Species+comparison+of+in+vivo+P-glycoprotein-mediated+brain+efflux+using+mdr1a-deficient+rats+and+mice&doi=10.1124%2Fdmd.111.043083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice</span></div><div class="casAuthors">Bundgaard, Christoffer; Jensen, Christian Jes Nyberg; Garmer, Mats</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">461-466</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The expts. described herein compared the extent of in vivo P-glycoprotein (P-gp)-mediated brain efflux between rats and mice for a set of known central nervous system compds.  With use of newly introduced genetically modified mdr1a-deficient rats and their gene-competent counterparts, the brain to plasma distribution was assessed and compared with the distribution pattern in mdr1a-deficient and wild-type mice.  Four compds. (aripiprazole, citalopram, risperidone, and venlafaxine) were administered using a continuous s.c. osmotic minipump infusion paradigm.  Steady-state brain and plasma concns. of the compds., including selected metabolites (9-hydroxyrisperidone, O-desmethyl-venlafaxine and N-desmethyl-venlafaxine) were measured in mdr1a-deficient rats and mice and their wild-type counterparts along with their free fractions to det. total and unbound brain to plasma distribution between genotypes within and between species.  The results revealed qual. as well as quant. similarities between P-gp functionality in vivo at the blood-brain barrier level in rats and mice.  All compds. tested were shown to have a significantly higher brain to plasma distribution in both mdr1a-deficient rats and mice compared with that in their wild-type counterparts.  Moreover, the relative enhancement in extent of brain penetration between mdr1a-deficient and wild-type rats could be directly correlated to the enhancement ratios obtained in mice.  From the unbound brain to unbound plasma distributions, the impact of P-gp on the overall brain penetration capabilities showed minor differences between rats and mice for the compds. tested.  In conclusion, a comparable functional role of P-gp between rats and mice with respect to brain efflux mediated by this transporter is suggested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLRDnbbGPf_rVg90H21EOLACvtfcHk0liuZzn8gHC8yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1Wqtbk%253D&md5=8d3f014fd5378ecdea433e0cb5c90eb8</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.043083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.043083%26sid%3Dliteratum%253Aachs%26aulast%3DBundgaard%26aufirst%3DC.%26aulast%3DJensen%26aufirst%3DC.%2BJ.%26aulast%3DGarmer%26aufirst%3DM.%26atitle%3DSpecies%2520comparison%2520of%2520in%2520vivo%2520P-glycoprotein-mediated%2520brain%2520efflux%2520using%2520mdr1a-deficient%2520rats%2520and%2520mice%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26spage%3D461%26epage%3D466%26doi%3D10.1124%2Fdmd.111.043083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittapalli, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sane, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmquist, W. F.</span></span> <span> </span><span class="NLM_article-title">Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-gp, BCRP, and P-gp/BCRP knockout mice</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1164</span>– <span class="NLM_lpage">1169</span>, <span class="refDoi"> DOI: 10.1124/dmd.112.044719</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.112.044719" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=22401960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC38XotlWns7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=1164-1169&author=S.+Agarwalauthor=Y.+Uchidaauthor=R.+K.+Mittapalliauthor=R.+Saneauthor=T.+Terasakiauthor=W.+F.+Elmquist&title=Quantitative+proteomics+of+transporter+expression+in+brain+capillary+endothelial+cells+isolated+from+P-gp%2C+BCRP%2C+and+P-gp%2FBCRP+knockout+mice&doi=10.1124%2Fdmd.112.044719"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice</span></div><div class="casAuthors">Agarwal, Sagar; Uchida, Yasuo; Mittapalli, Rajendar K.; Sane, Ramola; Terasaki, Tetsuya; Elmquist, William F.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1164-1169</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The objective of this study was to quant. examine the protein expression of relevant transporters and other proteins in the brain capillary endothelial cells isolated from wild-type mice and P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice.  After the isolation of brain capillary endothelial cells, a highly sensitive liq. chromatog.-tandem mass spectrometry method with multiple reaction monitoring was used to det. the quant. expression of membrane transporters at the blood-brain barrier (BBB) of the various mouse genotypes.  Quant. expression of 29 protein mols., including 12 ATP-binding cassette transporters, 10 solute carrier transporters, five receptors, and two housekeeping proteins, was examd. by quant. proteomics in the four mouse genotypes.  There was no significant difference in the expression of P-gp between the wild-type and Bcrp1(-/-) mice.  Likewise, Bcrp expression was not significantly different between the wild-type and Mdr1a/b(-/-) mice.  There was no significant difference in the expression of any of the measured proteins in the brain capillary endothelial cells across the genotypes, except for the lack of expression of the corresponding protein in the mice that had a genetic deletion of P-gp or Bcrp.  In conclusion, using a quant. proteomic approach, we have shown that there are no changes in the expression of several relevant transporters in brain capillary endothelial cells isolated from single and combination knockout mice.  These data suggest that the mechanism behind the functional compensation between P-gp and Bcrp at the BBB is not related to compensatory changes in transporter expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpInM6PmeijT7Vg90H21EOLACvtfcHk0lhLal3JF1IZRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotlWns7w%253D&md5=a0146188d8c58be92c996e8f9fa9c716</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.044719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.044719%26sid%3Dliteratum%253Aachs%26aulast%3DAgarwal%26aufirst%3DS.%26aulast%3DUchida%26aufirst%3DY.%26aulast%3DMittapalli%26aufirst%3DR.%2BK.%26aulast%3DSane%26aufirst%3DR.%26aulast%3DTerasaki%26aufirst%3DT.%26aulast%3DElmquist%26aufirst%3DW.%2BF.%26atitle%3DQuantitative%2520proteomics%2520of%2520transporter%2520expression%2520in%2520brain%2520capillary%2520endothelial%2520cells%2520isolated%2520from%2520P-gp%252C%2520BCRP%252C%2520and%2520P-gp%252FBCRP%2520knockout%2520mice%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26spage%3D1164%26epage%3D1169%26doi%3D10.1124%2Fdmd.112.044719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajapaksa, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobbi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drobnick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolesnikov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sujatha-Bhaskar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brightbill, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choo, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMent, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent benzolactam IRAK4 inhibitors with robust in vivo activity</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">333</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00380</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00380" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFeqs7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=327-333&author=N.+S.+Rajapaksaauthor=A.+Gobbiauthor=J.+Drobnickauthor=S.+Doauthor=A.+Kolesnikovauthor=J.+Liangauthor=Y.+Chenauthor=S.+Sujatha-Bhaskarauthor=Z.+Huangauthor=H.+Brightbillauthor=R.+Francisauthor=C.+Yuauthor=E.+F.+Chooauthor=K.+DeMentauthor=Y.+Ranauthor=L.+Anauthor=C.+Emsonauthor=J.+Maherauthor=J.+Waiauthor=B.+S.+McKenzieauthor=M.+C.+Bryan&title=Discovery+of+potent+benzolactam+IRAK4+inhibitors+with+robust+in+vivo+activity&doi=10.1021%2Facsmedchemlett.9b00380"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent Benzolactam IRAK4 Inhibitors with Robust in Vivo Activity</span></div><div class="casAuthors">Rajapaksa, Naomi S.; Gobbi, Alberto; Drobnick, Joy; Do, Steven; Kolesnikov, Aleksandr; Liang, Jun; Chen, Yongsheng; Sujatha-Bhaskar, Swathi; Huang, Zhiyu; Brightbill, Hans; Francis, Ross; Yu, Christine; Choo, Edna F.; De Ment, Kevin; Ran, Yingqing; An, Le; Emson, Claire; Maher, Jonathan; Wai, John; McKenzie, Brent S.; Lupardus, Patrick J.; Zarrin, Ali A.; Kiefer, James R.; Bryan, Marian C.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">327-333</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">IRAK4 kinase activity transduces signaling from multiple IL-1Rs and TLRs to regulate cytokines and chemokines implicated in inflammatory diseases.  As such, there is high interest in identifying selective IRAK4 inhibitors for the treatment of these disorders.  We previously reported the discovery of potent and selective dihydrobenzofuran inhibitors of IRAK4.  Subsequent studies, however, showed inconsistent inhibition in disease-relevant pharmacodynamic models.  Herein, we describe application of a human whole blood assay to the discovery of a series of benzolactam IRAK4 inhibitors.  We identified potent mol. 19 which achieves robust in vivo inhibition of cytokines relevant to human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod0j_X1oRRG7Vg90H21EOLACvtfcHk0lhLal3JF1IZRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFeqs7%252FJ&md5=2fd1d26eea65c726e463cbb8591303ef</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00380%26sid%3Dliteratum%253Aachs%26aulast%3DRajapaksa%26aufirst%3DN.%2BS.%26aulast%3DGobbi%26aufirst%3DA.%26aulast%3DDrobnick%26aufirst%3DJ.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DKolesnikov%26aufirst%3DA.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSujatha-Bhaskar%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DBrightbill%26aufirst%3DH.%26aulast%3DFrancis%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DChoo%26aufirst%3DE.%2BF.%26aulast%3DDeMent%26aufirst%3DK.%26aulast%3DRan%26aufirst%3DY.%26aulast%3DAn%26aufirst%3DL.%26aulast%3DEmson%26aufirst%3DC.%26aulast%3DMaher%26aufirst%3DJ.%26aulast%3DWai%26aufirst%3DJ.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DBryan%26aufirst%3DM.%2BC.%26atitle%3DDiscovery%2520of%2520potent%2520benzolactam%2520IRAK4%2520inhibitors%2520with%2520robust%2520in%2520vivo%2520activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D327%26epage%3D333%26doi%3D10.1021%2Facsmedchemlett.9b00380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avdeef, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ecker, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerebtzoff, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lennernaes, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senner, F.</span></span> <span> </span><span class="NLM_article-title">Coexistence of passive and carrier-mediated processes in drug transport</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">597</span>– <span class="NLM_lpage">614</span>, <span class="refDoi"> DOI: 10.1038/nrd3187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1038%2Fnrd3187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=20671764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCktrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=597-614&author=K.+Suganoauthor=M.+Kansyauthor=P.+Arturssonauthor=A.+Avdeefauthor=S.+Bendelsauthor=L.+Diauthor=G.+F.+Eckerauthor=B.+Fallerauthor=H.+Fischerauthor=G.+Gerebtzoffauthor=H.+Lennernaesauthor=F.+Senner&title=Coexistence+of+passive+and+carrier-mediated+processes+in+drug+transport&doi=10.1038%2Fnrd3187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Coexistence of passive and carrier-mediated processes in drug transport</span></div><div class="casAuthors">Sugano, Kiyohiko; Kansy, Manfred; Artursson, Per; Avdeef, Alex; Bendels, Stefanie; Di, Li; Ecker, Gerhard F.; Faller, Bernard; Fischer, Holger; Gerebtzoff, Gregori; Lennernaes, Hans; Senner, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">597-614</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The permeability of biol. membranes is one of the most important determinants of the pharmacokinetic processes of a drug.  Although it is often accepted that many drug substances are transported across biol. membranes by passive transcellular diffusion, a recent hypothesis speculated that carrier-mediated mechanisms might account for the majority of membrane drug transport processes in biol. systems.  Based on evidence of the physicochem. characteristics and of in vitro and in vivo findings for marketed drugs, as well as results from real-life discovery and development projects, the authors present the view that both passive transcellular processes and carrier-mediated processes coexist and contribute to drug transport activities across biol. membranes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppGdYhfY0-BbVg90H21EOLACvtfcHk0lhLal3JF1IZRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCktrk%253D&md5=6e332ad6fa2c2ac8b3b1dc7940e73caf</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1038%2Fnrd3187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3187%26sid%3Dliteratum%253Aachs%26aulast%3DSugano%26aufirst%3DK.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DArtursson%26aufirst%3DP.%26aulast%3DAvdeef%26aufirst%3DA.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DEcker%26aufirst%3DG.%2BF.%26aulast%3DFaller%26aufirst%3DB.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DGerebtzoff%26aufirst%3DG.%26aulast%3DLennernaes%26aufirst%3DH.%26aulast%3DSenner%26aufirst%3DF.%26atitle%3DCoexistence%2520of%2520passive%2520and%2520carrier-mediated%2520processes%2520in%2520drug%2520transport%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D597%26epage%3D614%26doi%3D10.1038%2Fnrd3187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litchfield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goosen, T. C.</span></span> <span> </span><span class="NLM_article-title">Physicochemical property space of hepato-biliary transport and computational models for predicting rat biliary excretion</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1527</span>– <span class="NLM_lpage">1537</span>, <span class="refDoi"> DOI: 10.1124/dmd.112.044628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.112.044628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=22580868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtF2iurnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=1527-1537&author=M.+V.+Varmaauthor=G.+Changauthor=Y.+Laiauthor=B.+Fengauthor=A.+F.+El-Kattanauthor=J.+Litchfieldauthor=T.+C.+Goosen&title=Physicochemical+property+space+of+hepato-biliary+transport+and+computational+models+for+predicting+rat+biliary+excretion&doi=10.1124%2Fdmd.112.044628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Physicochemical property space of hepatobiliary transport and computational models for predicting rat biliary excretion</span></div><div class="casAuthors">Varma, Manthena V. S.; Chang, George; Lai, Yurong; Feng, Bo; El-Kattan, Ayman F.; Litchfield, John; Goosen, Theunis C.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1527-1537</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Biliary excretion (BE) is a major elimination pathway, and its prediction is particularly important for optimization of systemic and/or target-site exposure of new mol. entities.  The objective is to characterize the physicochem. space assocd. with hepatobiliary transport and rat BE and to develop in silico models.  BE of 123 inhouse compds. was obtained using the bile-duct cannulated rat model.  Human and rat hepatic uptake transporters (hOATP1B1, hOATP1B3, hOATP2B1, and rOatp1b2) substrates (n = 183) were identified using transfected cells.  Furthermore, the datasets were extended by adding BE of 163 compds. and 97 org. anion transporting polypeptide (OATP) substrates from the literature.  Approx. 60% of compds. showing percentage of BE (%BE) ≥ 10 are anions, with mean BE of anions (36%) more than 3-fold higher than that of nonacids (11%).  Compds. with %BE ≥ 10 are found to have high mol. mass, large polar surface area, more rotatable bonds, and high H-bond count, whereas the lipophilicity and passive membrane permeability are lower compared with compds. with %BE < 10.  According to statistical anal. and principal component anal., hOATPs and rOatp1b2 substrates showed physicochem. characteristics that were similar to those of the %BE ≥ 10 dataset.  We further build categorical in silico models to predict rat BE, and the models (gradient boosting machine and scoring function) developed showed 80% predictability in identifying the rat BE bins (%BE ≥ 10 or < 10).  In conclusion, the significant overlap of the property space of OATP substrates and rat BE suggests a predominant role of sinusoidal uptake transporters in biliary elimination.  Categorical in silico models to predict rat BE were developed, and successful predictions were achieved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtzhzlEdDYLrVg90H21EOLACvtfcHk0limcpSKXsTfRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtF2iurnJ&md5=b12d68beb8be0755d0dc659dda79523f</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.044628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.044628%26sid%3Dliteratum%253Aachs%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DChang%26aufirst%3DG.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26aulast%3DLitchfield%26aufirst%3DJ.%26aulast%3DGoosen%26aufirst%3DT.%2BC.%26atitle%3DPhysicochemical%2520property%2520space%2520of%2520hepato-biliary%2520transport%2520and%2520computational%2520models%2520for%2520predicting%2520rat%2520biliary%2520excretion%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26spage%3D1527%26epage%3D1537%26doi%3D10.1124%2Fdmd.112.044628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagenbuch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stieger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, P. J.</span></span> <span> </span><span class="NLM_article-title">Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">10346</span>– <span class="NLM_lpage">10350</span>, <span class="refDoi"> DOI: 10.1073/pnas.94.19.10346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1073%2Fpnas.94.19.10346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=9294213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK2sXmt1Gjsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1997&pages=10346-10350&author=B.+Noeauthor=B.+Hagenbuchauthor=B.+Stiegerauthor=P.+J.+Meier&title=Isolation+of+a+multispecific+organic+anion+and+cardiac+glycoside+transporter+from+rat+brain&doi=10.1073%2Fpnas.94.19.10346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain</span></div><div class="casAuthors">Noe, Birgitta; Hagenbuch, Bruno; Stieger, Bruno; Meier, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">10346-10350</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A novel multispecific org. anion transporting polypeptide (oatp2) has been isolated from rat brain.  The cloned cDNA contains 3640 bp.  The coding region extends over 1983 nucleotides, thus encoding a polypeptide of 661 amino acids.  Oatp2 is homologous to other members of the oatp gene family of membrane transporters with 12 predicted transmembrane domains, five potential glycosylation, and six potential protein kinase C phosphorylation sites.  In functional expression studies in Xenopus laevis oocytes, oatp2 mediated uptake of the bile acids taurocholate (Km ≈ 35 μM) and cholate (Km ≈ 46 μM), the estrogen conjugates 17β-estradiol-glucuronide (Km ≈ 3 μM) and estrone-3-sulfate (Km ≈ 11 μM), and the cardiac glycosides ouabain (Km ≈ 470 μM) and digoxin (Km ≈ 0.24 μM).  Although most of the tested compds. are common substrates of several oatp-related transporters, high-affinity uptake of digoxin is a unique feature of the newly cloned oatp2.  On the basis of Northern blot anal. under high-stringency conditions, oatp2 is highly expressed in brain, liver, and kidney but not in heart, spleen, lung, skeletal muscle, and testes.  These results provide further support for the overall significance of oatps as a new family of multispecific org. anion transporters.  They indicate that oatp2 may play an esp. important role in the brain accumulation and toxicity of digoxin and in the hepatobiliary and renal excretion of cardiac glycosides from the body.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUx8x3QjRYKLVg90H21EOLACvtfcHk0limcpSKXsTfRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmt1Gjsbs%253D&md5=b7df5f2da772202a6797b39487db52e2</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1073%2Fpnas.94.19.10346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.94.19.10346%26sid%3Dliteratum%253Aachs%26aulast%3DNoe%26aufirst%3DB.%26aulast%3DHagenbuch%26aufirst%3DB.%26aulast%3DStieger%26aufirst%3DB.%26aulast%3DMeier%26aufirst%3DP.%2BJ.%26atitle%3DIsolation%2520of%2520a%2520multispecific%2520organic%2520anion%2520and%2520cardiac%2520glycoside%2520transporter%2520from%2520rat%2520brain%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1997%26volume%3D94%26spage%3D10346%26epage%3D10350%26doi%3D10.1073%2Fpnas.94.19.10346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gracely, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoffstall, J. M.</span></span> <span> </span><span class="NLM_article-title">Advantage of high-surface-area charcoal for gastrointestinal decontamination in a human acetaminophen ingestion model</span>. <i>Acad. Emerg. Med.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">174</span>, <span class="refDoi"> DOI: 10.1111/j.1553-2712.1997.tb03735.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1111%2Fj.1553-2712.1997.tb03735.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=9063541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A280%3ADyaK2s3hslGlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1997&pages=167-174&author=J.+R.+Robertsauthor=E.+J.+Gracelyauthor=J.+M.+Schoffstall&title=Advantage+of+high-surface-area+charcoal+for+gastrointestinal+decontamination+in+a+human+acetaminophen+ingestion+model&doi=10.1111%2Fj.1553-2712.1997.tb03735.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Advantage of high-surface-area charcoal for gastrointestinal decontamination in a human acetaminophen ingestion model</span></div><div class="casAuthors">Roberts J R; Gracely E J; Schoffstall J M</div><div class="citationInfo"><span class="NLM_cas:title">Academic emergency medicine : official journal of the Society for Academic Emergency Medicine</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">167-74</span>
        ISSN:<span class="NLM_cas:issn">1069-6563</span>.
    </div><div class="casAbstract">OBJECTIVE:  To compare the abilities of low-surface-area (LSA) vs 2 types of high-surface-area (HSA) activated charcoal given orally to adsorb acetaminophen in the gastrointestinal (GI) tract, as demonstrated by the impact of these agents on the serum levels and area under the curve (AUC) in a simulated human overdose model.  METHODS:  The main arm of the study was a prospective double-blind crossover trial in which 6 volunteers, serving as their own controls, ingested acetaminophen (50 mg/kg), followed randomly in 10 minutes by either powdered LSA charcoal (950 m2/g) or powdered HSA charcoal (2,000 m2/g) in a charcoal:drug ratio of 8:1.  In a second arm of the study, 3 subjects additionally ingested an equal dose of a granular preparation of the HSA charcoal.  Serial serum acetaminophen levels were analyzed at various intervals (30, 60, 90, 120, 180, 240, and 300 minutes postingestion), and a 5-hour AUC was calculated.  The subjects also rated the charcoal preparations for palatability.  RESULTS:  Serum acetaminophen levels were lower at all measured times in the groups receiving both forms of the HSA charcoal vs the LSA product.  With the powdered HSA charcoal, comparison serum levels were significantly lower at 120 minutes postingestion and all times thereafter (p < 0.05), reaching high significance at 4 and 5 hours (p < 0.001).  The subjects receiving the granular HSA charcoal also had consistently lower serum acetaminophen levels than did those receiving the LSA product, and the difference in mean serum levels was significant at the 4- and 5-hour sample (p = 0.012).  Compared with the LSA charcoal, at the 4-hour postingestion sample, serum acetaminophen levels were reduced by 44% to 85% by the powdered HSA charcoal.  The total AUC for the 5-hour study period was also significantly reduced by the powdered HSA product (p = 0.005) and the granular HSA product (p = 0.043).  All the subjects rated the powdered HSA charcoal to be more palatable and easier to drink than the powdered LSA charcoal.  CONCLUSION:  The surface area of oral activated charcoal is a major determining factor in its ability to limit acetaminophen absorption and to fulfill its adsorptive role in GI decontamination.  In a human acetaminophen overdose model, 2 types of HSA charcoal, when compared with equal doses of LSA charcoal, significantly reduced serum levels and total acetaminophen absorption as measured by the AUC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRh5wFRQg1QoVQKX3ooHxWjfW6udTcc2eZDvKiTot7_KLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s3hslGlsw%253D%253D&md5=1f485d61380153ec1b2e99538f77faa1</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1111%2Fj.1553-2712.1997.tb03735.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1553-2712.1997.tb03735.x%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DJ.%2BR.%26aulast%3DGracely%26aufirst%3DE.%2BJ.%26aulast%3DSchoffstall%26aufirst%3DJ.%2BM.%26atitle%3DAdvantage%2520of%2520high-surface-area%2520charcoal%2520for%2520gastrointestinal%2520decontamination%2520in%2520a%2520human%2520acetaminophen%2520ingestion%2520model%26jtitle%3DAcad.%2520Emerg.%2520Med.%26date%3D1997%26volume%3D4%26spage%3D167%26epage%3D174%26doi%3D10.1111%2Fj.1553-2712.1997.tb03735.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orisakwe, O. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogbonna, E.</span></span> <span> </span><span class="NLM_article-title">Effect of saline cathartics on gastrointestinal transit time of activated charcoal</span>. <i>Hum. Exp. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">403</span>– <span class="NLM_lpage">405</span>, <span class="refDoi"> DOI: 10.1177/096032719301200510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1177%2F096032719301200510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=7902117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK2cXpvVOqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1993&pages=403-405&author=O.+E.+Orisakweauthor=E.+Ogbonna&title=Effect+of+saline+cathartics+on+gastrointestinal+transit+time+of+activated+charcoal&doi=10.1177%2F096032719301200510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of saline cathartics on gastrointestinal transit time of activated charcoal</span></div><div class="casAuthors">Orisakwe, O.E.; Ogbonna, E.</div><div class="citationInfo"><span class="NLM_cas:title">Human & Experimental Toxicology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">403-405</span>CODEN:
                <span class="NLM_cas:coden">HETOEA</span>;
        ISSN:<span class="NLM_cas:issn">0960-3271</span>.
    </div><div class="casAbstract">The effects of saline cathartics on the gastrointestinal transit time of activated charcoal were investigated in 6 healthy volunteers.  The mean gastrointestinal transit times of charcoal alone were 29.3 h and 24.4, 15.4, 17.3, and 17.5 h with sodium chloride, sodium sulfate, magnesium sulfate alone and Andrew's Liver Salt, resp.  Some volunteers complained of slight abdominal discomfort in all the phases except the Andrew's Liver Salt phase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn0vzp6xOaS7Vg90H21EOLACvtfcHk0lg0dTYJ3SKe1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXpvVOqtw%253D%253D&md5=5c4ad8821d5113e9ce0d20632f2998dd</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1177%2F096032719301200510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F096032719301200510%26sid%3Dliteratum%253Aachs%26aulast%3DOrisakwe%26aufirst%3DO.%2BE.%26aulast%3DOgbonna%26aufirst%3DE.%26atitle%3DEffect%2520of%2520saline%2520cathartics%2520on%2520gastrointestinal%2520transit%2520time%2520of%2520activated%2520charcoal%26jtitle%3DHum.%2520Exp.%2520Toxicol.%26date%3D1993%26volume%3D12%26spage%3D403%26epage%3D405%26doi%3D10.1177%2F096032719301200510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parrott, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lave, T.</span></span> <span> </span><span class="NLM_article-title">Applications of physiologically based absorption models in drug discovery and development</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">760</span>– <span class="NLM_lpage">775</span>, <span class="refDoi"> DOI: 10.1021/mp8000155</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp8000155" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1cXntVyntrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2008&pages=760-775&author=N.+Parrottauthor=T.+Lave&title=Applications+of+physiologically+based+absorption+models+in+drug+discovery+and+development&doi=10.1021%2Fmp8000155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Applications of Physiologically Based Absorption Models in Drug Discovery and Development</span></div><div class="casAuthors">Parrott, Neil; Lave, Thierry</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">760-775</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This article describes the use of physiol. based models of intestinal drug absorption to guide the research and development of new drugs.  Applications range from lead optimization in the drug discovery phase through clin. candidate selection and extrapolation to human to phase 2 formulation development.  Early simulations in preclin. species integrate multiple screening data and add value by transforming these individual properties into a prediction of in vivo absorption.  Comparison of simulations to plasma levels measured after oral dosing in animals highlights unexpected behavior, and parameter sensitivity anal. can explore the impact of uncertainties in key properties, point toward factors which are limiting absorption and contribute to assessment of compd. developability.  Physiol. models provide reliable prediction of human absorption and with refinement based on phase 1 data are useful guides to further market formulation development.  Improvements in the accuracy of simulations are expected as better in vitro methods generate more in vivo relevant soly. and permeability data, and modeling will play a central role in the development of more predictive methods for transporter-related effects on drug absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSg5DYRhZl0bVg90H21EOLACvtfcHk0lg0dTYJ3SKe1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXntVyntrg%253D&md5=13de905308bc88383041bd1025f952a0</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1021%2Fmp8000155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp8000155%26sid%3Dliteratum%253Aachs%26aulast%3DParrott%26aufirst%3DN.%26aulast%3DLave%26aufirst%3DT.%26atitle%3DApplications%2520of%2520physiologically%2520based%2520absorption%2520models%2520in%2520drug%2520discovery%2520and%2520development%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2008%26volume%3D5%26spage%3D760%26epage%3D775%26doi%3D10.1021%2Fmp8000155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wakabayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hachimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohwada, T.</span></span> <span> </span><span class="NLM_article-title">Activated charcoal interrupts enteroenteric circulation of phenobarbital</span>. <i>J. Toxicol., Clin. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.3109/15563659409011043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.3109%2F15563659409011043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=8057401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK2cXmsVGjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1994&pages=419-424&author=Y.+Wakabayashiauthor=S.+Maruyamaauthor=K.+Hachimuraauthor=T.+Ohwada&title=Activated+charcoal+interrupts+enteroenteric+circulation+of+phenobarbital&doi=10.3109%2F15563659409011043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Activated charcoal interrupts enteroenteric circulation of phenobarbital</span></div><div class="casAuthors">Wakabayashi, Yasuhisa; Maruyama, Shigeyoshi; Hachimura, Kazoo; Ohwada, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Toxicology, Clinical Toxicology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">419-24</span>CODEN:
                <span class="NLM_cas:coden">JTCTDW</span>;
        ISSN:<span class="NLM_cas:issn">0731-3810</span>.
    </div><div class="casAbstract">The possibility of activated charcoal interrupting the enteroenteric circulation of phenobarbital was conducted in rabbits prepd. by colectomy biliary drainage to block enterohepatic circulation.  Fifty minutes after the administration of phenobarbital IV over ten minutes, activated charcoal (N = 7) or non-adsorbent gel (N = 8) were placed into the intestine at a dose of 4 g/kg.  Blood was taken hourly for 5 h from the femoral artery and portal vein for the detn. of phenobarbital concn. by the homogeneous enzyme immunoassay.  The arterioportal differences of phenobarbital concns. were significantly greater in the animals treated with the charcoal at 2, 3 and 4 h after the treatment.  There were significantly shorter plasma half lives of phenobarbital in the animals given charcoal (3.8 ± 0.3 h vs 6.9 ± 0.9 h, p < .02).  This study provided evidence of significant enteroenteric circulation of phenobarbital which can be interrupted by the activated charcoal and removed by the mechanism of intestinal dialysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDz5jhgE8sW7Vg90H21EOLACvtfcHk0lg0dTYJ3SKe1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmsVGjt7Y%253D&md5=bf86a46424362724f1c8de6af664f4f4</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.3109%2F15563659409011043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F15563659409011043%26sid%3Dliteratum%253Aachs%26aulast%3DWakabayashi%26aufirst%3DY.%26aulast%3DMaruyama%26aufirst%3DS.%26aulast%3DHachimura%26aufirst%3DK.%26aulast%3DOhwada%26aufirst%3DT.%26atitle%3DActivated%2520charcoal%2520interrupts%2520enteroenteric%2520circulation%2520of%2520phenobarbital%26jtitle%3DJ.%2520Toxicol.%252C%2520Clin.%2520Toxicol.%26date%3D1994%26volume%3D32%26spage%3D419%26epage%3D424%26doi%3D10.3109%2F15563659409011043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hersey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luscombe, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherborne, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, I.</span></span> <span> </span><span class="NLM_article-title">Evaluation of rat intestinal absorption data and correlation with human intestinal absorption</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1016/S0223-5234(03)00015-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1016%2FS0223-5234%2803%2900015-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=12667690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitlKisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=233-243&author=Y.+H.+Zhaoauthor=M.+H.+Abrahamauthor=J.+Leauthor=A.+Herseyauthor=C.+N.+Luscombeauthor=G.+Beckauthor=B.+Sherborneauthor=I.+Cooper&title=Evaluation+of+rat+intestinal+absorption+data+and+correlation+with+human+intestinal+absorption&doi=10.1016%2FS0223-5234%2803%2900015-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of rat intestinal absorption data and correlation with human intestinal absorption</span></div><div class="casAuthors">Zhao, Yuan H.; Abraham, Michael H.; Le, Joelle; Hersey, Anne; Luscombe, Chris N.; Beck, Gordon; Sherborne, Brad; Cooper, Ian</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">233-243</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">The absorption of drugs and drug-like compds. was evaluated from 111 refs. based on the ratio of urinary excretion of drugs following oral and i.v. administration to intact rats and biliary excretion of bile duct-cannulated rats.  Ninety-eight drug compds. for which both human and rat absorption data were available were selected for correlation anal. between the human and rat absorption.  The result shows that the extent of absorption in these two species is similar.  For 94% of the drugs the absorption difference between humans and rats is less than 20% and for 98% of drugs the difference is less than 30%.  There is only one drug for which human absorption is significantly different from rat absorption.  The std. deviation is 11% between human and rat absorption.  The linear relationship between human and rat absorption forced through the origin, as detd. by least squares regression, is %Absorption (human)=0.997%Absorption (rat) (n=98, SD=11).  It is suggested that the absorption in rats could be used as an alternative method to human absorption in pre-clin. oral absorption studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3AVjX4MF9m7Vg90H21EOLACvtfcHk0lgu2HJW1z4Q8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitlKisr4%253D&md5=8bacc16d7b840ef152df945b3c1f38f0</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2FS0223-5234%2803%2900015-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0223-5234%252803%252900015-1%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%2BH.%26aulast%3DAbraham%26aufirst%3DM.%2BH.%26aulast%3DLe%26aufirst%3DJ.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DLuscombe%26aufirst%3DC.%2BN.%26aulast%3DBeck%26aufirst%3DG.%26aulast%3DSherborne%26aufirst%3DB.%26aulast%3DCooper%26aufirst%3DI.%26atitle%3DEvaluation%2520of%2520rat%2520intestinal%2520absorption%2520data%2520and%2520correlation%2520with%2520human%2520intestinal%2520absorption%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2003%26volume%3D38%26spage%3D233%26epage%3D243%26doi%3D10.1016%2FS0223-5234%2803%2900015-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landowski, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lennernas, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amidon, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span> <span> </span><span class="NLM_article-title">Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1675</span>– <span class="NLM_lpage">1686</span>, <span class="refDoi"> DOI: 10.1007/s11095-006-9041-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1007%2Fs11095-006-9041-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=16841194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD28XnvVyms7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2006&pages=1675-1686&author=X.+Caoauthor=S.+T.+Gibbsauthor=L.+Fangauthor=H.+A.+Millerauthor=C.+P.+Landowskiauthor=H.+C.+Shinauthor=H.+Lennernasauthor=Y.+Zhongauthor=G.+L.+Amidonauthor=L.+X.+Yuauthor=D.+Sun&title=Why+is+it+challenging+to+predict+intestinal+drug+absorption+and+oral+bioavailability+in+human+using+rat+model&doi=10.1007%2Fs11095-006-9041-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Why is it Challenging to Predict Intestinal Drug Absorption and Oral Bioavailability in Human Using Rat Model</span></div><div class="casAuthors">Cao, Xianhua; Gibbs, Seth T.; Fang, Lanyan; Miller, Heather A.; Landowski, Christopher P.; Shin, Ho-Chul; Lennernas, Hans; Zhong, Yanqiang; Amidon, Gordon L.; Yu, Lawrence X.; Sun, Duxin</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1675-1686</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The aim of this study was to study the correlation of intestinal absorption for drugs with various absorption routes between human and rat, and to explore the underlying mol. mechanisms for the similarity in drug intestinal absorption and the differences in oral bioavailability between human and rat.  The intestinal permeabilities of 14 drugs and three drug-like compds. with different absorption mechanisms in rat and human jejunum were detd. by in situ intestinal perfusion.  A total of 48 drugs were selected for oral bioavailability comparison.  Expression profiles of transporters and metabolizing enzymes in both rat and human intestines (duodenum and colon) were measured using GeneChip anal.  No correlation (r2 = 0.29) was found in oral drug bioavailability between rat and human, while a correlation (r2 = 0.8) was obsd. for drug intestinal permeability with both carrier-mediated absorption and passive diffusion mechanisms between human and rat small intestine.  Moderate correlation (with r2 > 0.56) was also found for the expression levels of transporters in the duodenum of human and rat, which provides the mol. mechanisms for the similarity and correlation of drug absorption between two species.  In contrast, no correlation was found for the expressions of metabolizing enzymes between rat and human intestine, which indicates the difference in drug metab. and oral bioavailability in two species.  Detailed anal. indicates that many transporters (such as PepT1, SGLT-1, GLUT5, MRP2, NT2, and high affinity glutamate transporter) share similar expression levels in both human and rat with regional dependent expression patterns, which have high expression in the small intestine and low expression in the colon.  However, discrepancy was also obsd. for several other transporters (such as MDR1, MRP3, GLUT1, and GLUT3) in both the duodenum and colon of human and rat.  In addn., the expressions of metabolizing enzymes (CYP3A4/CYP3A9 and UDPG) showed 12 to 193-fold difference between human and rat intestine with distinct regional dependent expression patterns.  The data indicate that rat and human show similar drug intestinal absorption profiles and similar transporter expression patterns in the small intestine, while the two species exhibit distinct expression levels and patterns for metabolizing enzymes in the intestine.  Therefore, a rat model can be used to predict oral drug absorption in the small intestine of human, but not to predict drug metab. or oral bioavailability in human.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT0qlLZPbgU7Vg90H21EOLACvtfcHk0lgu2HJW1z4Q8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnvVyms7c%253D&md5=cdf16fabb2d3dbfde019797a5a76177c</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1007%2Fs11095-006-9041-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-006-9041-2%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DX.%26aulast%3DGibbs%26aufirst%3DS.%2BT.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DMiller%26aufirst%3DH.%2BA.%26aulast%3DLandowski%26aufirst%3DC.%2BP.%26aulast%3DShin%26aufirst%3DH.%2BC.%26aulast%3DLennernas%26aufirst%3DH.%26aulast%3DZhong%26aufirst%3DY.%26aulast%3DAmidon%26aufirst%3DG.%2BL.%26aulast%3DYu%26aufirst%3DL.%2BX.%26aulast%3DSun%26aufirst%3DD.%26atitle%3DWhy%2520is%2520it%2520challenging%2520to%2520predict%2520intestinal%2520drug%2520absorption%2520and%2520oral%2520bioavailability%2520in%2520human%2520using%2520rat%2520model%26jtitle%3DPharm.%2520Res.%26date%3D2006%26volume%3D23%26spage%3D1675%26epage%3D1686%26doi%3D10.1007%2Fs11095-006-9041-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazic, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachir-Cherif, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrott, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belli, S.</span></span> <span> </span><span class="NLM_article-title">Expression profiles of metabolic enzymes and drug transporters in the liver and along the intestine of beagle dogs</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1603</span>– <span class="NLM_lpage">1610</span>, <span class="refDoi"> DOI: 10.1124/dmd.112.045443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.112.045443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=22596220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtF2iurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=1603-1610&author=S.+Hallerauthor=F.+Schulerauthor=S.+E.+Lazicauthor=D.+Bachir-Cherifauthor=S.+D.+Kramerauthor=N.+J.+Parrottauthor=G.+Steinerauthor=S.+Belli&title=Expression+profiles+of+metabolic+enzymes+and+drug+transporters+in+the+liver+and+along+the+intestine+of+beagle+dogs&doi=10.1124%2Fdmd.112.045443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Expression profiles of metabolic enzymes and drug transporters in the liver and along the intestine of beagle dogs</span></div><div class="casAuthors">Haller, Stephanie; Schuler, Franz; Lazic, Stanley E.; Bachir-Cherif, Dalila; Kramer, Stefanie D.; Parrott, Neil J.; Steiner, Guido; Belli, Sara</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1603-1610</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Beagle dogs are widely used in preclin. pharmacokinetic, safety, and formulation studies.  However, little is known about intestinal and hepatic distribution of major enzymes and transporters involved in oral absorption and presystemic drug metab.  We characterized mRNA levels of CYP3A12, CYP3A26, CYP2D15, UGT1A6, ABCB1 (MDR1), ABCC1 (MRP1), ABCG2 (BCRP), SLC15A1 (PEPT1), and SLC22A1 (OCT1) in dog liver and along the intestine by real-time quant. reverse transcription-polymerase chain reaction.  Tissue protein levels of CYP2D15, MDR1, and PEPT1 were obtained by Western blot.  Gene distribution and expression variability was statistically described by a generalized additive mixed model smoothing function and correspondence anal.  Results were compared with the expression pattern known for the human orthologs.  Hepatic mRNA levels for metabolic enzymes were generally higher than those for membrane transporters, whereas in the intestine the opposite was obsd.  Hepatic mRNA levels followed the order CYP2D15 > UGT1A6 ≈ CYP3A26 > ABCB1 ≈ SLC15A1 ≈ SLC22A1 > ABCG2 > ABCC1 ≈ CYP3A12.  Along the gut, the genes were differentially distributed with greatest expression in duodenum/upper jejunum (ABCG2), middle jejunum (ABCB1 and SLC15A1), or in cecum/colon (ABCC1 and CYP2D15).  CYP3A12, CYP3A26, SLC22A1, and UGT1A6 had a rather uniform expression.  Intestinal mRNA profiles of CYP2D15, ABCB1, and SLC15A1 correlated with the resp. protein levels.  Canine CYP3A12/26, CYP2D15, and ABCB1 colonic distributions differed from those of human orthologs, whereas UGT1A6, ABCC1, ABCG2, SLC15A1, and SLC22A1 were comparable to those of humans in both small and large intestine.  We aim to apply these data to better interpret pharmacokinetic studies in dogs with respect to their human relevance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbKw9IZfNB6LVg90H21EOLACvtfcHk0lhZNe1luOttJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtF2iurfN&md5=b0a443663747cbf4af660637dde2ee88</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.045443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.045443%26sid%3Dliteratum%253Aachs%26aulast%3DHaller%26aufirst%3DS.%26aulast%3DSchuler%26aufirst%3DF.%26aulast%3DLazic%26aufirst%3DS.%2BE.%26aulast%3DBachir-Cherif%26aufirst%3DD.%26aulast%3DKramer%26aufirst%3DS.%2BD.%26aulast%3DParrott%26aufirst%3DN.%2BJ.%26aulast%3DSteiner%26aufirst%3DG.%26aulast%3DBelli%26aufirst%3DS.%26atitle%3DExpression%2520profiles%2520of%2520metabolic%2520enzymes%2520and%2520drug%2520transporters%2520in%2520the%2520liver%2520and%2520along%2520the%2520intestine%2520of%2520beagle%2520dogs%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26spage%3D1603%26epage%3D1610%26doi%3D10.1124%2Fdmd.112.045443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J. D.</span></span> <span> </span><span class="NLM_article-title">Comparative drug exsorption in the perfused rat intestine</span>. <i>J. Pharm. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">170</span>, <span class="refDoi"> DOI: 10.1111/j.2042-7158.1990.tb05378.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1111%2Fj.2042-7158.1990.tb05378.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2011&pages=167-170&author=J.+D.+Huang&title=Comparative+drug+exsorption+in+the+perfused+rat+intestine&doi=10.1111%2Fj.2042-7158.1990.tb05378.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1111%2Fj.2042-7158.1990.tb05378.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.2042-7158.1990.tb05378.x%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DJ.%2BD.%26atitle%3DComparative%2520drug%2520exsorption%2520in%2520the%2520perfused%2520rat%2520intestine%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D2011%26volume%3D42%26spage%3D167%26epage%3D170%26doi%3D10.1111%2Fj.2042-7158.1990.tb05378.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arimori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hidaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwakiri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamsaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okumura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takamura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, M.</span></span> <span> </span><span class="NLM_article-title">Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">910</span>– <span class="NLM_lpage">917</span>, <span class="refDoi"> DOI: 10.1023/A:1023847521767</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1023%2FA%3A1023847521767" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=12817897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjvFyis7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2003&pages=910-917&author=K.+Arimoriauthor=N.+Kurokiauthor=M.+Hidakaauthor=T.+Iwakiriauthor=K.+Yamsakiauthor=M.+Okumuraauthor=H.+Onoauthor=N.+Takamuraauthor=M.+Kikuchiauthor=M.+Nakano&title=Effect+of+P-glycoprotein+modulator%2C+cyclosporin+A%2C+on+the+gastrointestinal+excretion+of+irinotecan+and+its+metabolite+SN-38+in+rats&doi=10.1023%2FA%3A1023847521767"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats</span></div><div class="casAuthors">Arimori, Kazuhiko; Kuroki, Noriaki; Hidaka, Muneaki; Iwakiri, Tomomi; Yamasaki, Keishi; Okumura, Manabu; Ono, Hiroshige; Takamura, Norito; Kikuchi, Masahiko; Nakano, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">910-917</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic/Plenum Publishers</span>)
        </div><div class="casAbstract">The purpose of this work was to investigate the role of the hepatic and intestinal P-glycoprotein (P-gp) and canalicular multispecific org. anion transporter /multidrug resistance-assocd. protein 2 (cMOAT/MRP2) on both biliary excretion and intestinal exsorption of irinotecan hydrochloride (CPT-11) and its metabolite, SN-38, in the lactone and carboxylate forms.  Cyclosporin A (CsA) was used to modulate P-gp and cMOAT/MRP2.  The transcellular transport of CPT-11 and SN-38 was examd. by LLC-PK1 deriv. cell lines transfected with murine mdr1a both in the absence or in the presence of CsA.  The excretions of the compds. through the biliary and intestinal membrane routes were investigated by in situ perfusion technique.  Basolateral-to-apical transport of CPT-11 lactone in L-mdr1a cells was significantly decreased by CsA (10 μM).  The trans-cellular transport of SN-38 lactone showed similar behaviors as those of CPT-11 lactone.  The biliary excretion and the intestinal exsorption of both forms of CPT-11 and SN-38 were significantly inhibited when the drug was co-administered with CsA.  The transports of CPT-11 and SN-38 via the biliary route seem to be essentially related with cMOAT/MRP2, whereas those of both compds. via the intestinal membrane seem to be related with P-gp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU_JmsECpDybVg90H21EOLACvtfcHk0lhaWrheMu6Pcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjvFyis7g%253D&md5=3b036762203b694fb20898d50033340f</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1023%2FA%3A1023847521767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1023847521767%26sid%3Dliteratum%253Aachs%26aulast%3DArimori%26aufirst%3DK.%26aulast%3DKuroki%26aufirst%3DN.%26aulast%3DHidaka%26aufirst%3DM.%26aulast%3DIwakiri%26aufirst%3DT.%26aulast%3DYamsaki%26aufirst%3DK.%26aulast%3DOkumura%26aufirst%3DM.%26aulast%3DOno%26aufirst%3DH.%26aulast%3DTakamura%26aufirst%3DN.%26aulast%3DKikuchi%26aufirst%3DM.%26aulast%3DNakano%26aufirst%3DM.%26atitle%3DEffect%2520of%2520P-glycoprotein%2520modulator%252C%2520cyclosporin%2520A%252C%2520on%2520the%2520gastrointestinal%2520excretion%2520of%2520irinotecan%2520and%2520its%2520metabolite%2520SN-38%2520in%2520rats%26jtitle%3DPharm.%2520Res.%26date%3D2003%26volume%3D20%26spage%3D910%26epage%3D917%26doi%3D10.1023%2FA%3A1023847521767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuhmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doering, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fichtl, B.</span></span> <span> </span><span class="NLM_article-title">Influence of quinidine on the intestinal secretion of digoxin and digitoxin in guinea pigs</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1016/S0009-2797(85)80128-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1016%2FS0009-2797%2885%2980128-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=4064190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A280%3ADyaL28%252FltlKqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1985&pages=203-213&author=S.+G.+Schaferauthor=G.+Schuhmannauthor=W.+Doeringauthor=B.+Fichtl&title=Influence+of+quinidine+on+the+intestinal+secretion+of+digoxin+and+digitoxin+in+guinea+pigs&doi=10.1016%2FS0009-2797%2885%2980128-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of quinidine on the intestinal secretion of digoxin and digitoxin in guinea pigs</span></div><div class="casAuthors">Schafer S G; Schuhmann G; Doering W; Fichtl B</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-biological interactions</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">203-13</span>
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    </div><div class="casAbstract">The secretion of digoxin and digitoxin into in situ perfused jejunal and colonic segments of normal or quinidine treated guinea pigs was studied.  Quinidine was administered intravenously by constant rate infusion resulting in a quinidine plasma concentration of about 6 micrograms/ml.  After 2 h digoxin or digitoxin was injected i.v. (10 micrograms/kg).  The quinidine treatment enhanced the plasma concentration of [3H]digoxin to about 140% as compared to controls, whereas the [3H]digitoxin concentration was not influenced by the quinidine infusion.  Both, digoxin and digitoxin were secreted against a concentration gradient into the intestinal lumen.  During the experimental period of 180 min controls secreted 0.24% of the administered digoxin dose per cm of jejunal and 0.13% per cm of colonic segment.  Quinidine treatment resulted in a decrease of the jejunal digoxin secretion to about 80% of the control values.  In both, jejunum and colon the concentration ratio between lumen and plasma (L/P) was diminished by quinidine to 50% as compared with the controls.  The amount of [3H]digitoxin secreted into the intestinal segments was decreased by quinidine from 0.19% of the dose/cm to 0.13% in the jejunal and from 0.17% to 0.12% in the colonic segments, respectively.  The decrease of the L/P ratio for [3H]digitoxin was more pronounced in the colon (58%) than in the jejunum (77% of the control values).  As compared with controls the content of [3H]digoxin in the jejunal as well as colonic tissue was decreased by quinidine to 60% or 73%, respectively.  On the other hand quinidine increased the tissue content of [3H]digitoxin in jejunum (+56%) and colon (+88%).  In conclusion quinidine inhibits the intestinal secretion of both, digoxin and digitoxin, possibly by different mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1_ZDOT5CseJotVjB3IRIyfW6udTcc2eZU6pU7vzqzarntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL28%252FltlKqsw%253D%253D&md5=133cc91607f258886bc13ded5a8b8773</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2FS0009-2797%2885%2980128-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0009-2797%252885%252980128-9%26sid%3Dliteratum%253Aachs%26aulast%3DSchafer%26aufirst%3DS.%2BG.%26aulast%3DSchuhmann%26aufirst%3DG.%26aulast%3DDoering%26aufirst%3DW.%26aulast%3DFichtl%26aufirst%3DB.%26atitle%3DInfluence%2520of%2520quinidine%2520on%2520the%2520intestinal%2520secretion%2520of%2520digoxin%2520and%2520digitoxin%2520in%2520guinea%2520pigs%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D1985%26volume%3D55%26spage%3D203%26epage%3D213%26doi%3D10.1016%2FS0009-2797%2885%2980128-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dautrey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farinoti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinstein, E.</span></span> <span> </span><span class="NLM_article-title">Intestinal elimination of ciprofloxacin in rabbits</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">757</span>– <span class="NLM_lpage">760</span>, <span class="refDoi"> DOI: 10.1128/AAC.38.4.757</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1128%2FAAC.38.4.757" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=8031042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK2cXis1Sms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1994&pages=757-760&author=J.+Ramonauthor=S.+Dautreyauthor=R.+Farinotiauthor=C.+Carbonauthor=E.+Rubinstein&title=Intestinal+elimination+of+ciprofloxacin+in+rabbits&doi=10.1128%2FAAC.38.4.757"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal elimination of ciprofloxacin in rabbits</span></div><div class="casAuthors">Ramon, Jacob; Dautrey, Sophie; Farinoti, Robert; Carbon, Claude; Rubinstein, Ethan</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">757-60</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">The intestinal transepithelial elimination of ciprofloxacin was studied in a rabbit model.  Jejunal, ileal, and cecal segments along with their intact blood vessels were isolated and perfused, and their contents were collected over a 120-min period following administration of a single parenteral dose of 27 mg of ciprofloxacin per kg of body wt.  The intestinal elimination rates of ciprofloxacin were 0.126 ± 0.084, 0.235 ± 0.22, and 0.11 ± 0.084 μg/min/cm for the jejunal, ileal, and cecal segments, resp.  The calcd. fractions of ciprofloxacin eliminated were 3.3 mg from the jejunum and 13.8 mg from the ileum, representing 19% of the administered dose.  Addnl. amts. of 2.5 to 3.7 mg or 4.9 to 7.3% of the administered dose were eliminated from the cecum.  Elimination was probably not due to a passive diffusion process but rather due to an active transepithelial transport.  This intestinal elimination pattern of ciprofloxacin may explain the unusual activity of the fluoroquinolones in modifying the intestinal flora.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3tUtHY5TfnbVg90H21EOLACvtfcHk0lhaWrheMu6Pcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXis1Sms7s%253D&md5=cae20b7a0920fab55662fa9692494661</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1128%2FAAC.38.4.757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.38.4.757%26sid%3Dliteratum%253Aachs%26aulast%3DRamon%26aufirst%3DJ.%26aulast%3DDautrey%26aufirst%3DS.%26aulast%3DFarinoti%26aufirst%3DR.%26aulast%3DCarbon%26aufirst%3DC.%26aulast%3DRubinstein%26aufirst%3DE.%26atitle%3DIntestinal%2520elimination%2520of%2520ciprofloxacin%2520in%2520rabbits%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1994%26volume%3D38%26spage%3D757%26epage%3D760%26doi%3D10.1128%2FAAC.38.4.757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gramatte, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oertel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terhaag, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirch, W.</span></span> <span> </span><span class="NLM_article-title">Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">541</span>– <span class="NLM_lpage">549</span>, <span class="refDoi"> DOI: 10.1016/S0009-9236(96)90182-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1016%2FS0009-9236%2896%2990182-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=8646825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK28XjvFOktbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1996&pages=541-549&author=T.+Gramatteauthor=R.+Oertelauthor=B.+Terhaagauthor=W.+Kirch&title=Direct+demonstration+of+small+intestinal+secretion+and+site-dependent+absorption+of+the+beta-blocker+talinolol+in+humans&doi=10.1016%2FS0009-9236%2896%2990182-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Direct demonstration of small intestinal secretion and site-dependent absorption of the β-blocker talinolol in humans</span></div><div class="casAuthors">Gramatte, Thomas; Oertel, Reinhard; Terhaag, Bernd; Kirch, Wilhelm</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology and Therapeutics (St. Louis)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">541-549</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Mosby-Year Book</span>)
        </div><div class="casAbstract">The relevance of site-dependent small intestinal absorption for incomplete intestinal absorption of the poorly metabolized β1-adrenergic receptor antagonist talinolol was examd.  The intestinal steady-state perfusion technique (triple lumen tubing system with a 30 cm test segment) for intraluminal measurements was combined with simultaneous detn. of talinolol serum concns.  Dissolved talinolol was perfused over 160 min into different parts of the small intestine.  The middle of the test segment was located between 95 and 235 cm beyond the teeth.  Each of the six healthy subjects was studied twice with a proximal and a more distal site of perfusion to allow for comparisons within an individual subject.  The area under the curve for serum concns. from 0 to 480 min [AUC (0-480 min)] and the max. serum concn. after distal perfusions corresponded to only 15% to 73% and 7% to 90% of the proximal values, resp.  AUC decreased with increasing distance from the teeth.  The mean amt. of talinolol absorbed from the test segment per unit time (intestinal transport rate) corresponds to only one-tenth of the amt. of drug offered to the test segment (perfusion rate).  There was a direct correlation between the perfusion rate of talinolol and its transport rate for both regions and in all subjects investigated.  However, to achieve the same transport rate in the distal region a higher perfusion rate is required, compared to the proximal small intestine.  At perfusion rates lower than 600 μg/min, net secretion of talinolol into the intestinal lumen occurred against a steep concn. gradient blood:lumen of about 1:4200.  Evidently, talinolol oral bioavailability of 55% is due to a low absorption rate and a decrease of absorption capabilities along the small intestine.  Net absorption of talinolol is reduced by the involvement of active intestinal secretion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxlRygBROygLVg90H21EOLACvtfcHk0lhrxSsr003-dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjvFOktbg%253D&md5=28855d459cf298f305c8087a35720c38</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2FS0009-9236%2896%2990182-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0009-9236%252896%252990182-4%26sid%3Dliteratum%253Aachs%26aulast%3DGramatte%26aufirst%3DT.%26aulast%3DOertel%26aufirst%3DR.%26aulast%3DTerhaag%26aufirst%3DB.%26aulast%3DKirch%26aufirst%3DW.%26atitle%3DDirect%2520demonstration%2520of%2520small%2520intestinal%2520secretion%2520and%2520site-dependent%2520absorption%2520of%2520the%2520beta-blocker%2520talinolol%2520in%2520humans%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D1996%26volume%3D59%26spage%3D541%26epage%3D549%26doi%3D10.1016%2FS0009-9236%2896%2990182-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabbaa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dautrey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colas-Linhart, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farinotti, R.</span></span> <span> </span><span class="NLM_article-title">Intestinal elimination of ofloxacin enantiomers in the rat: evidence of a carrier-mediated process</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2126</span>– <span class="NLM_lpage">2130</span>, <span class="refDoi"> DOI: 10.1128/AAC.40.9.2126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1128%2FAAC.40.9.2126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=8878593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK28XlsVCht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1996&pages=2126-2130&author=L.+Rabbaaauthor=S.+Dautreyauthor=N.+Colas-Linhartauthor=C.+Carbonauthor=R.+Farinotti&title=Intestinal+elimination+of+ofloxacin+enantiomers+in+the+rat%3A+evidence+of+a+carrier-mediated+process&doi=10.1128%2FAAC.40.9.2126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal elimination of ofloxacin enantiomers in the rat: evidence of a carrier-mediated process</span></div><div class="casAuthors">Rabbaa, Lydia; Dautrey, Sophie; Colas-Linhart, Nicole; Carbon, Claude; Farinotti, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2126-2130</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The aim of this work was to examine the mechanism involved in intestinal elimination of the two optical isomers of ofloxacin in the rat.  An intestinal segment was isolated in situ and perfused with saline, while drug soln. was administered via the carotid artery.  Blood samples and intestinal effluents were collected and analyzed by a high-performance liq. chromatog. method.  We obsd. saturable and stereoselective intestinal elimination of the ofloxacin enantiomers.  The elimination process favored the R-(+) form of the mol.  After a parenteral dose of 20 mg of racemic ofloxacin per kg of body wt., intestinal clearances were 0.23 ± 0.03 vs. 0.30 ± 0.03 mL/min for S-(-)- and R-(+)-ofloxacin, resp.  Ciprofloxacin and pefloxacin interfered with ofloxacin elimination and significantly reduced the intestinal clearance of S-(-)- and R-(+)-ofloxacin.  With concomitant ciprofloxacin, intestinal clearances became 0.13 ± 0.02 vs. .17 ± 0.03 mL/min and 0.14 ± 0.01 vs. 0.19 ± 0.05 mL/min with pefloxacin for S-(-)- and R-(+)-ofloxacin, resp.  Those findings argue for the presence of a common transport system in the rat intestine with variable affinities for fluoroquinolones.  In addn., verapamil and quinidine, two P-glycoprotein blockers, significantly reduced the intestinal elimination of both ofloxacin isomers with concomitant verapamil, intestinal clearances were 0.12 ± 0.02 vs. 0.18 ± 0.03 mL/min for S-(-)- and R-(+)-ofloxacin, resp., while with concomitant quinidine, values were 0.18 ± 0.01 vs. 0.23 ± 0.01 mL/min without modifying their areas under the concn.-time curve in serum.  Similar results were found with another fluoroquinolone, ciprofloxacin, in previous work.  P-glycoprotein appears to be involved in the intestinal elimination of fluoroquinolones in rats.  The characterization of fluoroquinolone intestinal elimination has significant clin. relevance for the better evaluation of the influence of this secretory pathway on antibiotic efficacy and selection of resistant bacteria within the intestinal flora.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrw5HXibABO7Vg90H21EOLACvtfcHk0lhrxSsr003-dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XlsVCht7s%253D&md5=1ba7f62329e4edf9a7f371695f74b7f9</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1128%2FAAC.40.9.2126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.40.9.2126%26sid%3Dliteratum%253Aachs%26aulast%3DRabbaa%26aufirst%3DL.%26aulast%3DDautrey%26aufirst%3DS.%26aulast%3DColas-Linhart%26aufirst%3DN.%26aulast%3DCarbon%26aufirst%3DC.%26aulast%3DFarinotti%26aufirst%3DR.%26atitle%3DIntestinal%2520elimination%2520of%2520ofloxacin%2520enantiomers%2520in%2520the%2520rat%253A%2520evidence%2520of%2520a%2520carrier-mediated%2520process%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1996%26volume%3D40%26spage%3D2126%26epage%3D2130%26doi%3D10.1128%2FAAC.40.9.2126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Haim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shabtai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinstein, E.</span></span> <span> </span><span class="NLM_article-title">Transepithelial intestinal excretion of ciprofloxacin in humans</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">822</span>– <span class="NLM_lpage">823</span>, <span class="refDoi"> DOI: 10.1086/319206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1086%2F319206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=11229852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A280%3ADC%252BD3MvjsVGmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2001&pages=822-823&author=J.+Ramonauthor=M.+Ben-Haimauthor=M.+Shabtaiauthor=E.+Rubinstein&title=Transepithelial+intestinal+excretion+of+ciprofloxacin+in+humans&doi=10.1086%2F319206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Transepithelial intestinal excretion of ciprofloxacin in humans</span></div><div class="casAuthors">Ramon J; Ben-Haim M; Shabtai M; Rubinstein E</div><div class="citationInfo"><span class="NLM_cas:title">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">822-3</span>
        ISSN:<span class="NLM_cas:issn">1058-4838</span>.
    </div><div class="casAbstract">The excretion of ciprofloxacin in the small bowel was studied in 40 patients undergoing bowel surgery.  Ciprofloxacin (200 mg) was administered iv, and intestinal samples were collected over a 120-min period.  In ileal loops ciprofloxacin concentrations reached a peak of 4.0 mg/L, whereas in caecal fluid samples, concentrations were < 0.16 mg/L.  Ciprofloxacin administered directly into the ileal and caecal loops did not result in measurable blood levels for 2 h.  The results confirm that ciprofloxacin is selectively excreted into the small bowel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQXGZ1Y_EQEFMScOqQTSkOffW6udTcc2ea_g87xQy769Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MvjsVGmtQ%253D%253D&md5=5e9e2811c773bc169964aeb838ed2e41</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1086%2F319206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F319206%26sid%3Dliteratum%253Aachs%26aulast%3DRamon%26aufirst%3DJ.%26aulast%3DBen-Haim%26aufirst%3DM.%26aulast%3DShabtai%26aufirst%3DM.%26aulast%3DRubinstein%26aufirst%3DE.%26atitle%3DTransepithelial%2520intestinal%2520excretion%2520of%2520ciprofloxacin%2520in%2520humans%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2001%26volume%3D32%26spage%3D822%26epage%3D823%26doi%3D10.1086%2F319206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laffont, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toutain, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvinerie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bousquet-Melou, A.</span></span> <span> </span><span class="NLM_article-title">Intestinal secretion is a major route for parent ivermectin elimination in the rat</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">626</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.1124/dmd.30.6.626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.30.6.626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=12019186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD38XktFSlsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=626-630&author=C.+M.+Laffontauthor=P.+L.+Toutainauthor=M.+Alvinerieauthor=A.+Bousquet-Melou&title=Intestinal+secretion+is+a+major+route+for+parent+ivermectin+elimination+in+the+rat&doi=10.1124%2Fdmd.30.6.626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal secretion is a major route for parent ivermectin elimination in the rat</span></div><div class="casAuthors">Laffont, Celine M.; Toutain, Pierre-Louis; Alvinerie, Michel; Bousquet-Melou, Alain</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">626-630</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The transepithelial intestinal elimination of ivermectin was studied using the intestinal closed-loop model in the rat.  The common bile duct was cannulated, and duodenum, jejunum, and ileum were isolated in situ with their intact blood supplies.  Following administration of 100, 200, or 400 μg/kg b.wt. ivermectin via the carotid artery, the elimination of parent ivermectin into the small intestinal lumen over 90 min was approx. 5-fold higher than in bile.  The major amt. of secreted ivermectin was recovered in the jejunum, but the duodenum showed a higher intestinal elimination capacity than the other intestinal segments with respect to the intestinal length.  Systemic coadministration of the P-glycoprotein blocker verapamil significantly reduced the elimination capacity of jejunum by 50%, which resulted in a 30% decrease of ivermectin overall elimination by the small intestine.  In contrast, verapamil did not significantly affect ivermectin secretion in duodenum, ileum, or bile in the same animals.  Ivermectin small intestinal and biliary clearances were estd. to account for 27 and 5.5% of the total drug clearance, which was evaluated from a parallel in vivo expt. in which rats were given 200 μg/kg b.wt. ivermectin intra-arterially.  In conclusion, intestinal secretion plays a greater role than biliary secretion in the overall elimination of ivermectin in the rat, providing major amts. of active drug to the intestinal lumen and to feces.  This is discussed in terms of therapeutic efficacy against intestinal parasites in humans and animals and of ecotoxicity resulting from the contamination of livestock dung with parent drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjlJdmhWMezbVg90H21EOLACvtfcHk0ljEUCiWLlVV1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktFSlsLg%253D&md5=ba56fb23ea12fc9411456851eed7dbf1</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1124%2Fdmd.30.6.626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.30.6.626%26sid%3Dliteratum%253Aachs%26aulast%3DLaffont%26aufirst%3DC.%2BM.%26aulast%3DToutain%26aufirst%3DP.%2BL.%26aulast%3DAlvinerie%26aufirst%3DM.%26aulast%3DBousquet-Melou%26aufirst%3DA.%26atitle%3DIntestinal%2520secretion%2520is%2520a%2520major%2520route%2520for%2520parent%2520ivermectin%2520elimination%2520in%2520the%2520rat%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2002%26volume%3D30%26spage%3D626%26epage%3D630%26doi%3D10.1124%2Fdmd.30.6.626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakashita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terasawa, K.</span></span> <span> </span><span class="NLM_article-title">Enteric excretion of baicalein, a flavone of Scutellariae Radix, via glucuronidation in rat: involvement of multidrug resistance-associated protein 2</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2120</span>– <span class="NLM_lpage">2126</span>, <span class="refDoi"> DOI: 10.1023/B:PHAM.0000048205.02478.b5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1023%2FB%3APHAM.0000048205.02478.b5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=15587936" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpvVert78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2004&pages=2120-2126&author=T.+Akaoauthor=Y.+Sakashitaauthor=M.+Hanadaauthor=H.+Gotoauthor=Y.+Shimadaauthor=K.+Terasawa&title=Enteric+excretion+of+baicalein%2C+a+flavone+of+Scutellariae+Radix%2C+via+glucuronidation+in+rat%3A+involvement+of+multidrug+resistance-associated+protein+2&doi=10.1023%2FB%3APHAM.0000048205.02478.b5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Enteric Excretion of Baicalein, a Flavone of Scutellariae Radix, via Glucuronidation in Rat: Involvement of Multidrug Resistance-Associated Protein 2</span></div><div class="casAuthors">Akao, Teruaki; Sakashita, Yoko; Hanada, Masato; Goto, Hirozo; Shimada, Yutaka; Terasawa, Katsutoshi</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2120-2126</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer Science+Business Media, Inc.</span>)
        </div><div class="casAbstract">Baicalin (BG) and its aglycon, baicalein (B), are strong antioxidants and have various pharmacol. actions.  The purpose of this study was to evaluate efflux of BG from rat intestinal mucosal cell following glucuronidation of B absorbed after oral administration of B.  The absorption and excretion of BG and B were evaluated in rats using the in situ jejunal loop technique and in vitro jejunal everted sac expts.  BG and B levels were detd. by high-performance liq. chromatog. with electro-chem. detection to ensure selectivity and high sensitivity.  A large amt. (30.4% recovery) of BG, but no B, was detected in the intestinal lumens of germ-free rats 4 h after oral administration of B (12.1 mg/kg), in comparison with a substantial recovery (55.1%) of unabsorbed BG 4 h after its administration.  During the in situ rat jejunal loop absorption expt., B disappeared rapidly, and 8% of the lost B was excreted into the loop as BG 20 min after infusing 0.1 mM B.  In an in vitro absorption expt. using everted rat jejunal sac, BG also appeared outside the sac, accompanied by the disappearance of B from the outer (mucosal) side.  However, very little of B was transferred to the inner (serosal) side of the sac, and only a trace of BG was detected inside the sac.  Thus, in both the loop and the everted sac systems, the efflux of BG from the mucosal surface was satd. with the concn. of B added.  Moreover, the efflux rate of BG in the everted jejunal sac from Eisai hyperbilirubinemic rat (EHBR) was significantly lower by 56.4% than that from Sprague-Dawley rat.  These results indicate that, in rat, a large proportion of any B absorbed is retained, transformed into BG within the intestinal mucosal cells, and coordinately excreted through multidrug resistance-assocd. protein 2 (MRP2) into the intestinal lumen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXtluCPR_0kLVg90H21EOLACvtfcHk0ljW085s9zUl9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpvVert78%253D&md5=c869b9611ff3641278e0cb984fdb1eb4</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1023%2FB%3APHAM.0000048205.02478.b5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FB%253APHAM.0000048205.02478.b5%26sid%3Dliteratum%253Aachs%26aulast%3DAkao%26aufirst%3DT.%26aulast%3DSakashita%26aufirst%3DY.%26aulast%3DHanada%26aufirst%3DM.%26aulast%3DGoto%26aufirst%3DH.%26aulast%3DShimada%26aufirst%3DY.%26aulast%3DTerasawa%26aufirst%3DK.%26atitle%3DEnteric%2520excretion%2520of%2520baicalein%252C%2520a%2520flavone%2520of%2520Scutellariae%2520Radix%252C%2520via%2520glucuronidation%2520in%2520rat%253A%2520involvement%2520of%2520multidrug%2520resistance-associated%2520protein%25202%26jtitle%3DPharm.%2520Res.%26date%3D2004%26volume%3D21%26spage%3D2120%26epage%3D2126%26doi%3D10.1023%2FB%3APHAM.0000048205.02478.b5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballent, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lifschitz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virkel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sallovitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanusse, C.</span></span> <span> </span><span class="NLM_article-title">Modulation of the P-glycoprotein-mediated intestinal secretion of ivermectin: in vitro and in vivo assessments</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">463</span>, <span class="refDoi"> DOI: 10.1124/dmd.105.007757</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.105.007757" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=16381664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD28Xit1Sgt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=457-463&author=M.+Ballentauthor=A.+Lifschitzauthor=G.+Virkelauthor=J.+Sallovitzauthor=C.+Lanusse&title=Modulation+of+the+P-glycoprotein-mediated+intestinal+secretion+of+ivermectin%3A+in+vitro+and+in+vivo+assessments&doi=10.1124%2Fdmd.105.007757"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of the P-glycoprotein-mediated intestinal secretion of ivermectin: in vitro and in vivo assessments</span></div><div class="casAuthors">Ballent, M.; Lifschitz, A.; Virkel, G.; Sallovitz, J.; Lanusse, C.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">457-463</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The everted gut sac method was used to assess the role of the P-glycoprotein (P-gp) on the intestinal secretion of ivermectin (IVM), an antiparasitic widely used in human and veterinary medicine.  The work included the evaluation of two different P-gp modulators [itraconazole (ITZ) and valspodar (PSC833)] used at equimolar doses in the rat.  Furthermore, the influence of both P-gp modulator agents on the disposition kinetics of IVM in plasma, liver, and gastrointestinal tissues was characterized.  For the in vitro expts., ileal sacs were incubated with IVM (3 μM) in the presence or absence of either ITZ (10 μM) or PSC833 (10 μM).  In the in vivo expts., male Wistar rats were randomly allocated to three groups (n = 18) and s.c. treated with IVM (200 μg/kg-1), alone and coadministered with ITZ (5 mg, two doses) or PSC833 (8.6 mg, two doses).  Animals were sacrificed between 6 and 96 h.  Blood, liver, and gastrointestinal samples were collected.  IVM concns. were detd. by high performance liq. chromatog.  The rate of IVM accumulation in the intestinal wall of everted sacs was significantly higher after its incubation with ITZ (0.115 nmol/g/min) and PSC833 (0.238 nmol/g/min) than that obtained after the incubation without the P-gp modulators (0.016 nmol/g/min).  In agreement with the in vitro expt., the presence of ITZ and PSC833 induced an enhancement in the concns. of IVM in plasma and gastrointestinal tissues.  The results obtained in the current work, both under in vivo and in vitro conditions, confirm the relevance of P-gp-mediated transport to the intestinal secretion of IVM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr94g0sLsbVqLVg90H21EOLACvtfcHk0ljW085s9zUl9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xit1Sgt7o%253D&md5=8a6bc5d8bcf56f6f103cfba002f696ce</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1124%2Fdmd.105.007757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.105.007757%26sid%3Dliteratum%253Aachs%26aulast%3DBallent%26aufirst%3DM.%26aulast%3DLifschitz%26aufirst%3DA.%26aulast%3DVirkel%26aufirst%3DG.%26aulast%3DSallovitz%26aufirst%3DJ.%26aulast%3DLanusse%26aufirst%3DC.%26atitle%3DModulation%2520of%2520the%2520P-glycoprotein-mediated%2520intestinal%2520secretion%2520of%2520ivermectin%253A%2520in%2520vitro%2520and%2520in%2520vivo%2520assessments%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26spage%3D457%26epage%3D463%26doi%3D10.1124%2Fdmd.105.007757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garner, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decicco, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maduskuie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercer, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F. W.</span></span> <span> </span><span class="NLM_article-title">Role of P-glycoprotein and the intestine in the excretion of DPC 333 [(2R)-2-{(3R)-3-amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin- 1-yl}-N-hydroxy-4-methylpentanamide] in rodents</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1102</span>– <span class="NLM_lpage">1110</span>, <span class="refDoi"> DOI: 10.1124/dmd.107.017038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.107.017038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=18347085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVOmuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=1102-1110&author=C.+E.+Garnerauthor=E.+Solonauthor=C.+M.+Laiauthor=J.+Linauthor=G.+Luoauthor=K.+Jonesauthor=J.+Duanauthor=C.+P.+Deciccoauthor=T.+Maduskuieauthor=S.+E.+Mercerauthor=L.+S.+Ganauthor=M.+Qianauthor=S.+Prakashauthor=H.+S.+Shenauthor=F.+W.+Lee&title=Role+of+P-glycoprotein+and+the+intestine+in+the+excretion+of+DPC+333+%5B%282R%29-2-%7B%283R%29-3-amino-3-%5B4-%282-methylquinolin-4-ylmethoxy%29phenyl%5D-2-oxopyrrolidin-+1-yl%7D-N-hydroxy-4-methylpentanamide%5D+in+rodents&doi=10.1124%2Fdmd.107.017038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Role of P-glycoprotein and the intestine in the excretion of DPC 333 in rodents</span></div><div class="casAuthors">Garner, C. Edwin; Solon, Eric; Lai, Chii-Ming; Lin, Jianrong; Luo, Gang; Jones, Kevin; Duan, Jingwu; Decicco, Carl P.; Maduskuie, Thomas; Mercer, Stephen E.; Gan, Lian-Shen; Qian, Mingxin; Prakash, Shimoga; Shen, Huey-Shin; Lee, Frank W.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1102-1110</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The role of the intestine in the elimination of (2R)-2-{(3R)-3-amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide (DPC 333), a potent inhibitor of tissue necrosis factor α-converting enzyme, was investigated in mice and rats in vivo and in vitro.  In Madine-Darby canine kidney cells stably transfected with P-glycoprotein (P-gp) and DPC 333, the transport from B→A reservoirs exceeded the transport from A→B by approx. 7-fold.  In Caco-2 monolayers and isolated rat ileal mucosa, DPC 333 was transported from basolateral to apical reservoirs in a concn.-dependent, saturable manner, and transport was blocked by N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918), confirming the contribution of P-gp/breast cancer resistance protein in B→A efflux of DPC 333.  In quant. whole body autoradiog. studies with [14C]DPC 333 in mice and rats, radioactivity was distributed throughout the small intestine in both species.  In GF120918-pretreated bile duct-cannulated rats, radioactivity in feces was reduced 60%.  Using the in situ perfused rat intestine model, ∼20% of an i.v. dose of [14C]DPC 333 was measured in the intestinal lumen within 3 h postdose, 12% as parent.  Kinetic anal. of data suggested that excreted DPC 333 may be further metabolized in the gut.  Intestinal clearance was 0.2 to 0.35 l/h/kg.  The above data suggest that in the rodent the intestine serves as an organ of DPC 333 excretion, mediated in part by the transporter P-gp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJC8qgN4J267Vg90H21EOLACvtfcHk0ljW085s9zUl9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVOmuro%253D&md5=0a35c6293e5b076c709e088097c3fd48</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1124%2Fdmd.107.017038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.107.017038%26sid%3Dliteratum%253Aachs%26aulast%3DGarner%26aufirst%3DC.%2BE.%26aulast%3DSolon%26aufirst%3DE.%26aulast%3DLai%26aufirst%3DC.%2BM.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DG.%26aulast%3DJones%26aufirst%3DK.%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DDecicco%26aufirst%3DC.%2BP.%26aulast%3DMaduskuie%26aufirst%3DT.%26aulast%3DMercer%26aufirst%3DS.%2BE.%26aulast%3DGan%26aufirst%3DL.%2BS.%26aulast%3DQian%26aufirst%3DM.%26aulast%3DPrakash%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DH.%2BS.%26aulast%3DLee%26aufirst%3DF.%2BW.%26atitle%3DRole%2520of%2520P-glycoprotein%2520and%2520the%2520intestine%2520in%2520the%2520excretion%2520of%2520DPC%2520333%2520%255B%25282R%2529-2-%257B%25283R%2529-3-amino-3-%255B4-%25282-methylquinolin-4-ylmethoxy%2529phenyl%255D-2-oxopyrrolidin-%25201-yl%257D-N-hydroxy-4-methylpentanamide%255D%2520in%2520rodents%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26spage%3D1102%26epage%3D1110%26doi%3D10.1124%2Fdmd.107.017038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gnoth, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buetehorn, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muenster, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandmann, S.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>338</i></span>,  <span class="NLM_fpage">372</span>– <span class="NLM_lpage">380</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.180240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fjpet.111.180240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=21515813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFChs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2011&pages=372-380&author=M.+J.+Gnothauthor=U.+Buetehornauthor=U.+Muensterauthor=T.+Schwarzauthor=S.+Sandmann&title=In+vitro+and+in+vivo+P-glycoprotein+transport+characteristics+of+rivaroxaban&doi=10.1124%2Fjpet.111.180240"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban</span></div><div class="casAuthors">Gnoth, Mark Jean; Buetehorn, Ulf; Muenster, Uwe; Schwarz, Thomas; Sandmann, Steffen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">372-380</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Rivaroxaban, an oral, direct factor Xa inhibitor, has a dual mode of elimination in humans, with two-thirds metabolized by the liver and one-third renally excreted unchanged.  P-glycoprotein (P-gp) is known to be involved in the absorption, distribution, and excretion of drugs.  To investigate whether rivaroxaban is a substrate of P-gp, the bidirectional flux of rivaroxaban across Caco-2, wild-type, and P-gp-overexpressing LLC-PK1 cells was investigated.  Furthermore, the inhibitory effect of rivaroxaban toward P-gp was detd.  Rivaroxaban exhibited high permeability and polarized transport across Caco-2 cells.  Rivaroxaban was shown to be a substrate for, but not an inhibitor of, P-gp.  Of a set of potential P-gp inhibitors, ketoconazole and ritonavir, but not clarithromycin or erythromycin, inhibited P-gp-mediated transport of rivaroxaban, with half-maximal inhibitory concn. values in the range of therapeutic plasma concns.  These findings are in line with obsd. area under the plasma concn.-time curve increases in clin. drug-drug interaction studies indicating a possible involvement of P-gp in the distribution and excretion of rivaroxaban.  In vivo studies in wild-type and P-gp double-knockout mice demonstrated that the impact of P-gp alone on the pharmacokinetics of rivaroxaban is minor.  However, in P-gp double-knockout mice, a slight increase in brain concns. and decreased excretion into the gastrointestinal tract were obsd. compared with wild-type mice.  These studies also demonstrated that brain penetration of rivaroxaban is fairly low.  In addn. to P-gp, a further transport protein might be involved in the secretion of rivaroxaban.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFNMLFTnDZlrVg90H21EOLACvtfcHk0lhMthkPwyuQCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFChs7k%253D&md5=186c618f5b0a05635406bfa8a32e73ad</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.180240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.180240%26sid%3Dliteratum%253Aachs%26aulast%3DGnoth%26aufirst%3DM.%2BJ.%26aulast%3DBuetehorn%26aufirst%3DU.%26aulast%3DMuenster%26aufirst%3DU.%26aulast%3DSchwarz%26aufirst%3DT.%26aulast%3DSandmann%26aufirst%3DS.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520P-glycoprotein%2520transport%2520characteristics%2520of%2520rivaroxaban%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D338%26spage%3D372%26epage%3D380%26doi%3D10.1124%2Fjpet.111.180240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proost, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirakhur, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roest, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, J. M.</span></span> <span> </span><span class="NLM_article-title">Urinary, biliary and faecal excretion of rocuronium in humans</span>. <i>Br. J. Anaesth.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">717</span>– <span class="NLM_lpage">723</span>, <span class="refDoi"> DOI: 10.1093/bja/85.5.717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1093%2Fbja%2F85.5.717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=11094587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3cXosVSnsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2000&pages=717-723&author=J.+H.+Proostauthor=L.+I.+Erikssonauthor=R.+K.+Mirakhurauthor=G.+Roestauthor=J.+M.+Wierda&title=Urinary%2C+biliary+and+faecal+excretion+of+rocuronium+in+humans&doi=10.1093%2Fbja%2F85.5.717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Urinary, biliary and fecal excretion of rocuronium in humans</span></div><div class="casAuthors">Proost, J. H.; Eriksson, L. I.; Mirakhur, R. K.; Roest, G.; Wierda, J. M. K. H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Anaesthesia</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">717-723</span>CODEN:
                <span class="NLM_cas:coden">BJANAD</span>;
        ISSN:<span class="NLM_cas:issn">0007-0912</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The excretion of rocuronium and its potential metabolites was studied in 38 anesthetized patients, ASA I-III and 21-69 yr old.  Rocuronium bromide was administered as an i.v. bolus dose of 0.3 or 0.9 mg kg-1.  In Part A of the study, the excretion into urine and bile, and the liver content were studied.  Plasma kinetics (n=19) were similar to those reported previously.  Urinary recovery within 48 h after administration was 26 (8)% (mean (SD)) (n=8) of the dose.  In bile obtained from T-drains, the recovery within 48 h was 7 (6)% (n=11).  The rocuronium concn. in bile declined bi-exponentially, with half-lives of 2.3 (0.7) and 16 (11) h resp. (n=6).  In three patients from whom stoma fluid was collected, the amt. of rocuronium recovered ranged from 0.04 to 12.0% of the dose.  In liver tissue obtained from four patients undergoing hemihepatectomy, the estd. amt. of rocuronium at 2-5 h after administration ranged between 6.3 and 13.2% (n=4).  In the second part of the study (Part B), urine and feces were collected over 4-8 days and the recovery was 27 (13)% and 31 (23)% of the dose resp. (n=10).  In most samples, irresp. of the type of biol. material, only small amts. of the metabolite 17-desacetyl-rocuronium was found.  The results demonstrate that rocuronium is taken up by the liver and excreted into bile in high concns.  The fecal and urinary excretion of unchanged rocuronium are the major routes of rocuronium elimination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdPCrqI7fzT7Vg90H21EOLACvtfcHk0lhMthkPwyuQCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXosVSnsbk%253D&md5=1868056189e0fa0596555c3b9d1663d1</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1093%2Fbja%2F85.5.717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbja%252F85.5.717%26sid%3Dliteratum%253Aachs%26aulast%3DProost%26aufirst%3DJ.%2BH.%26aulast%3DEriksson%26aufirst%3DL.%2BI.%26aulast%3DMirakhur%26aufirst%3DR.%2BK.%26aulast%3DRoest%26aufirst%3DG.%26aulast%3DWierda%26aufirst%3DJ.%2BM.%26atitle%3DUrinary%252C%2520biliary%2520and%2520faecal%2520excretion%2520of%2520rocuronium%2520in%2520humans%26jtitle%3DBr.%2520J.%2520Anaesth.%26date%3D2000%26volume%3D85%26spage%3D717%26epage%3D723%26doi%3D10.1093%2Fbja%2F85.5.717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahmood, I.</span></span> <span> </span><span class="NLM_article-title">Interspecies scaling of biliary excreted drugs: a comparison of several methods</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">892</span>, <span class="refDoi"> DOI: 10.1002/jps.20313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1002%2Fjps.20313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=15736194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFCju70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2005&pages=883-892&author=I.+Mahmood&title=Interspecies+scaling+of+biliary+excreted+drugs%3A+a+comparison+of+several+methods&doi=10.1002%2Fjps.20313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Interspecies scaling of biliary excreted drugs: a comparison of several methods</span></div><div class="casAuthors">Mahmood, Iftekhar</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">883-892</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The objective of this study was to evaluate the predictive performance of several methods of interspecies scaling for the prediction of human clearance of drugs which are excreted in the bile.  Ten methods of allometric scaling were used to predict human clearance of biliary excreted drugs from animal data.  The methods included the simple allometric approach; the rule of exponents; the rule of exponents with a correction factor; the ratio of human and monkey liver blood flow × monkey clearance; product of clearance and bile flow; product of clearance and UDGPT; product of clearance, bile flow, and UDGPT; and a modified version of the last three approaches in assocn. with the rule of exponents.  The results of the study indicate that among these ten approaches, the rule of exponents with the correction factor is the best approach for the prediction of human clearance for drugs which are excreted in the bile.  The worst approach is the product of clearance, bile flow, and UDGPT.  The simple allometry and the monkey liver blood flow (MLBF) approaches gave almost similar results.  For some drugs the simple allometry predicted clearance better than the MLBF approach and vice versa.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoehFjQoAuRy7Vg90H21EOLACvtfcHk0lhMthkPwyuQCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFCju70%253D&md5=ac02d065621b2ca32897555c48ec59cd</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1002%2Fjps.20313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.20313%26sid%3Dliteratum%253Aachs%26aulast%3DMahmood%26aufirst%3DI.%26atitle%3DInterspecies%2520scaling%2520of%2520biliary%2520excreted%2520drugs%253A%2520a%2520comparison%2520of%2520several%2520methods%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2005%26volume%3D94%26spage%3D883%26epage%3D892%26doi%3D10.1002%2Fjps.20313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le Ferrec, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artusson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brayden, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabre, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gires, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousset, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubas, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarino, M. L.</span></span> <span> </span><span class="NLM_article-title">In vitro models of the intestinal barrier. The report and recommendations of ECVAM workshop 46. European Centre for the validation of alternative methods</span>. <i>ATLA, Altern. Lab. Anim.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">649</span>– <span class="NLM_lpage">668</span>, <span class="refDoi"> DOI: 10.1177/026119290102900604</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1177%2F026119290102900604" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=11709041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A280%3ADC%252BD3MnmtleksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2001&pages=649-668&author=E.+Le+Ferrecauthor=C.+Chesneauthor=P.+Artussonauthor=D.+Braydenauthor=G.+Fabreauthor=P.+Giresauthor=F.+Guillouauthor=M.+Roussetauthor=W.+Rubasauthor=M.+L.+Scarino&title=In+vitro+models+of+the+intestinal+barrier.+The+report+and+recommendations+of+ECVAM+workshop+46.+European+Centre+for+the+validation+of+alternative+methods&doi=10.1177%2F026119290102900604"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro models of the intestinal barrier. The report and recommendations of ECVAM Workshop 46. European Centre for the Validation of Alternative methods</span></div><div class="casAuthors">Le Ferrec E; Chesne C; Artusson P; Brayden D; Fabre G; Gires P; Guillou F; Rousset M; Rubas W; Scarino M L</div><div class="citationInfo"><span class="NLM_cas:title">Alternatives to laboratory animals : ATLA</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">649-68</span>
        ISSN:<span class="NLM_cas:issn">0261-1929</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT-6jih6S5J2uqrn-c4Of3KfW6udTcc2eYVH1Id084Pobntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MnmtleksA%253D%253D&md5=968fd11b8aaf0f72924cdc9ddecea7cd</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1177%2F026119290102900604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F026119290102900604%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BFerrec%26aufirst%3DE.%26aulast%3DChesne%26aufirst%3DC.%26aulast%3DArtusson%26aufirst%3DP.%26aulast%3DBrayden%26aufirst%3DD.%26aulast%3DFabre%26aufirst%3DG.%26aulast%3DGires%26aufirst%3DP.%26aulast%3DGuillou%26aufirst%3DF.%26aulast%3DRousset%26aufirst%3DM.%26aulast%3DRubas%26aufirst%3DW.%26aulast%3DScarino%26aufirst%3DM.%2BL.%26atitle%3DIn%2520vitro%2520models%2520of%2520the%2520intestinal%2520barrier.%2520The%2520report%2520and%2520recommendations%2520of%2520ECVAM%2520workshop%252046.%2520European%2520Centre%2520for%2520the%2520validation%2520of%2520alternative%2520methods%26jtitle%3DATLA%252C%2520Altern.%2520Lab.%2520Anim.%26date%3D2001%26volume%3D29%26spage%3D649%26epage%3D668%26doi%3D10.1177%2F026119290102900604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klaassen, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span> <span> </span><span class="NLM_article-title">Xenobiotic transporters: ascribing function from gene knockout and mutation studies</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">186</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfm214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1093%2Ftoxsci%2Fkfm214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=17698509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsV2rtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2008&pages=186-196&author=C.+D.+Klaassenauthor=H.+Lu&title=Xenobiotic+transporters%3A+ascribing+function+from+gene+knockout+and+mutation+studies&doi=10.1093%2Ftoxsci%2Fkfm214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Xenobiotic Transporters: Ascribing Function from Gene Knockout and Mutation Studies</span></div><div class="casAuthors">Klaassen, Curtis D.; Lu, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">186-196</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-6080</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Transporter-mediated absorption, secretion, and reabsorption of chems. are increasingly recognized as important determinants in the biol. activities of many xenobiotics.  In recent years, the rapid progress in generating and characterizing mice with targeted deletion of transporters has greatly increased our knowledge of the functions of transporters in the pharmacokinetics/toxicokinetics of xenobiotics.  In this introduction, we focus on functions of transporters learned from expts. on knockout mice as well as humans and rodents with natural mutations of these transporters.  We limit our discussion to transporters that either directly transport xenobiotics or are important in biliary excretion or cellular defenses, namely multidrug resistance, multidrug resistance-assocd. proteins, breast cancer resistance protein, org. anion transporting polypeptides, org. anion transporters, org. cation transporters, nucleoside transporters, peptide transporters, bile acid transporters, cholesterol transporters, and phospholipid transporters, as well as metal transporters.  Efflux transporters in intestine, liver, kidney, brain, testes, and placenta can efflux xenobiotics out of cells and serve as barriers against the entrance of xenobiotics into cells, whereas many xenobiotics enter the biol. system via uptake transporters.  The functional importance of a given transporter in each tissue depends on its substrate specificity, expression level, and the presence/absence of other transporters with overlapping substrate preferences.  Nevertheless, a transporter may affect a tissue independent of its local expression by altering systemic metab.  Further studies on the gene regulation and function of transporters, as well as the interrelationship between transporters and phase I/II xenobiotic-metabolizing enzymes, will provide a complete framework for developing novel strategies to protect us from xenobiotic insults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqU4LWgJUd-rVg90H21EOLACvtfcHk0lgLEcreWY6NJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsV2rtQ%253D%253D&md5=751acee436a176b80b6db33b11789cd2</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfm214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfm214%26sid%3Dliteratum%253Aachs%26aulast%3DKlaassen%26aufirst%3DC.%2BD.%26aulast%3DLu%26aufirst%3DH.%26atitle%3DXenobiotic%2520transporters%253A%2520ascribing%2520function%2520from%2520gene%2520knockout%2520and%2520mutation%2520studies%26jtitle%3DToxicol.%2520Sci.%26date%3D2008%26volume%3D101%26spage%3D186%26epage%3D196%26doi%3D10.1093%2Ftoxsci%2Fkfm214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jurgens, G</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groth Hoegberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graudal, N.</span></span> <span> </span><span class="NLM_article-title">The effect of activated charcoal on drug exposure in healthy volunteers: a meta-analysis</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">505</span>, <span class="refDoi"> DOI: 10.1038/clpt.2008.278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1038%2Fclpt.2008.278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=19194372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A280%3ADC%252BD1M3oslaksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2009&pages=501-505&author=G+Jurgensauthor=L.+Groth+Hoegbergauthor=N.+Graudal&title=The+effect+of+activated+charcoal+on+drug+exposure+in+healthy+volunteers%3A+a+meta-analysis&doi=10.1038%2Fclpt.2008.278"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of activated charcoal on drug exposure in healthy volunteers: a meta-analysis</span></div><div class="casAuthors">Jurgens G; Hoegberg L C Groth; Graudal N A</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">501-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The objective of the study was to estimate the effect of activated charcoal (AC) administered during the first 6 h after drug intake and the effect of drug properties on drug exposure.  Sixty-four controlled studies were integrated in a meta-analysis.  AC administered 0-5 min after administration of a drug reduced median drug exposure by 88.4% (25-75 percentile: 65.0-96.8) (P < 0.00001).  The effect of AC continued to be statistically significant when administered up to 4 h after drug intake (median reduction in drug exposure 27.4% (range 21.3-31.5%, P = 0.0006).  The reduction in drug exposure was correlated with the AC/drug ratio (rho = 0.69, P < 0.0001), the volume of distribution (Vd) (rho = 0.46, P = 0.0001), and time to peak concentration (rho = 0.40, P = 0.02).  We found that AC is most effective when given immediately after drug ingestion but has statistically significant effects even when given as long as 4 h after drug intake.  AC appears to be most effective when given in a large dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_TFq2eQOGRL9KldV63DuefW6udTcc2eYVH1Id084Pobntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M3oslaksg%253D%253D&md5=f8657819799162b787425e90b4a1d4e8</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2008.278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2008.278%26sid%3Dliteratum%253Aachs%26aulast%3DJurgens%26aufirst%3DG%26aulast%3DGroth%2BHoegberg%26aufirst%3DL.%26aulast%3DGraudal%26aufirst%3DN.%26atitle%3DThe%2520effect%2520of%2520activated%2520charcoal%2520on%2520drug%2520exposure%2520in%2520healthy%2520volunteers%253A%2520a%2520meta-analysis%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2009%26volume%3D85%26spage%3D501%26epage%3D505%26doi%3D10.1038%2Fclpt.2008.278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lapatto-Reiniluoto, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kivisto, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuvonen, P. J.</span></span> <span> </span><span class="NLM_article-title">Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">260</span>, <span class="refDoi"> DOI: 10.1067/mcp.2001.118184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1067%2Fmcp.2001.118184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=11557913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntlajurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2001&pages=255-260&author=O.+Lapatto-Reiniluotoauthor=K.+T.+Kivistoauthor=P.+J.+Neuvonen&title=Activated+charcoal+alone+and+followed+by+whole-bowel+irrigation+in+preventing+the+absorption+of+sustained-release+drugs&doi=10.1067%2Fmcp.2001.118184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs</span></div><div class="casAuthors">Lapatto-Reiniluoto, Outi; Kivisto, Kari T.; Neuvonen, Pertti J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">255-260</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">Our objective was to study the effect of activated charcoal on the absorption of sustained-release drugs ingested 1 h earlier and to examine whether whole-bowel irrigation affects the efficacy of charcoal.  In this randomized, 3-phase crossover study, 9 healthy subjects received, at the same time, 200 mg carbamazepine, 200 mg theophylline, and 120 mg verapamil.  All drugs were given as sustained-release tablets.  One hour after taking the tablets, the subjects were assigned to one of the following treatments: 25 g activated charcoal as a suspension, 25 g activated charcoal as a suspension followed by whole-bowel irrigation with polyethylene glycol (PEG) electrolyte lavage soln., or 200 mL water (control).  The absorption of the drugs was characterized by using the area under the plasma drug concn.-time curve from time zero to 24 h [AUC(0-24)], peak plasma concn. (Cmax), Cmax minus the plasma concn. at 1 h (CΔ), and time to peak (tmax).  Activated charcoal alone given 1 h after drug intake significantly (P < .001) reduced the absorption [AUC(0-24)] of all 3 drugs (by 62%-75%).  Also the Cmax and CΔ values of these drugs were significantly reduced by charcoal alone.  Whole-bowel irrigation did not increase significantly the effect of charcoal on any absorption parameters of the 3 drugs studied.  On the contrary, whole-bowel irrigation significantly (P < .01) decreased the efficacy of charcoal with respect to carbamazepine.  Activated charcoal alone given 1 h after intake of sustained-release drugs was effective in preventing the absorption of all 3 drugs studied.  Whole-bowel irrigation may even decrease the efficacy of charcoal if the drug is well adsorbable onto charcoal.  However, our study was performed with therapeutic drug doses only.  In overdoses their possible effects on gastrointestinal motility may modify the efficacy of decontamination methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqibQZbVwMkrrVg90H21EOLACvtfcHk0lgLEcreWY6NJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntlajurg%253D&md5=bd2373f70029ead65d6ceacf89cb80f7</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1067%2Fmcp.2001.118184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1067%252Fmcp.2001.118184%26sid%3Dliteratum%253Aachs%26aulast%3DLapatto-Reiniluoto%26aufirst%3DO.%26aulast%3DKivisto%26aufirst%3DK.%2BT.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DActivated%2520charcoal%2520alone%2520and%2520followed%2520by%2520whole-bowel%2520irrigation%2520in%2520preventing%2520the%2520absorption%2520of%2520sustained-release%2520drugs%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2001%26volume%3D70%26spage%3D255%26epage%3D260%26doi%3D10.1067%2Fmcp.2001.118184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">al-Meshal, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">el-Sayed, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">al-Angary, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">al-Dardiri, M. M.</span></span> <span> </span><span class="NLM_article-title">Effect of oral activated charcoal on propranolol pharmacokinetics following intravenous administration to rabbits</span>. <i>J. Clin. Pharm. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2710.1993.tb00564.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1111%2Fj.1365-2710.1993.tb00564.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=8473358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK3sXktF2rt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1993&pages=39-44&author=M.+A.+al-Meshalauthor=Y.+M.+el-Sayedauthor=A.+A.+al-Angaryauthor=M.+M.+al-Dardiri&title=Effect+of+oral+activated+charcoal+on+propranolol+pharmacokinetics+following+intravenous+administration+to+rabbits&doi=10.1111%2Fj.1365-2710.1993.tb00564.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of oral activated charcoal on propranolol pharmacokinetics following intravenous administration to rabbits</span></div><div class="casAuthors">Al-Meshal, M. A.; El-Sayed, Y. M.; Al-Angary, A. A.; Al-Dardiri, M. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacy and Therapeutics</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-44</span>CODEN:
                <span class="NLM_cas:coden">JCPTED</span>;
        ISSN:<span class="NLM_cas:issn">0269-4727</span>.
    </div><div class="casAbstract">The pharmacokinetics of propranolol following i.v. administration (1 mg/kg), with and without treatment with oral activated charcoal, was investigated in rabbits.  In charcoal-treated rabbits a significant redn. in propranolol serum concns. was obsd. compared to control animals.  Charcoal treatment significantly reduced the half-life of elimination (16.6%) and the men residence time (19%) of propranolol.  A 17% increase in the systemic clearance and 14% decrease in AUC were also noted.  Charcoal administration did not significantly alter the vol. of distribution (Vc' Varea and Vss) or the apparent distribution half-life.  A two-compartment model adequately described propranolol in control and treated rabbits.  The results indicate that administration of oral activated charcoal enhances the systemic elimination of propranolol.  This is presumably mediated by interruption of the enterohepatic circulation of propranolol by activated charcoal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2R072hTRZObVg90H21EOLACvtfcHk0lgtnpn53--84w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXktF2rt7w%253D&md5=853095315520fd43ad626aca817ddeb6</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2710.1993.tb00564.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2710.1993.tb00564.x%26sid%3Dliteratum%253Aachs%26aulast%3Dal-Meshal%26aufirst%3DM.%2BA.%26aulast%3Del-Sayed%26aufirst%3DY.%2BM.%26aulast%3Dal-Angary%26aufirst%3DA.%2BA.%26aulast%3Dal-Dardiri%26aufirst%3DM.%2BM.%26atitle%3DEffect%2520of%2520oral%2520activated%2520charcoal%2520on%2520propranolol%2520pharmacokinetics%2520following%2520intravenous%2520administration%2520to%2520rabbits%26jtitle%3DJ.%2520Clin.%2520Pharm.%2520Ther.%26date%3D1993%26volume%3D18%26spage%3D39%26epage%3D44%26doi%3D10.1111%2Fj.1365-2710.1993.tb00564.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theil, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsters, J. C.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khojasteh, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernillet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morinello, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hop, C. E.</span></span> <span> </span><span class="NLM_article-title">Interplay of dissolution, solubility, and nonsink permeation determines the oral absorption of the Hedgehog pathway inhibitor GDC-0449 in dogs: an investigation using preclinical studies and physiologically based pharmacokinetic modeling</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1029</span>– <span class="NLM_lpage">1038</span>, <span class="refDoi"> DOI: 10.1124/dmd.110.032680</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.110.032680" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=20406853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1Kls7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1029-1038&author=H.+Wongauthor=F.+P.+Theilauthor=Y.+Cuiauthor=J.+C.+Marstersauthor=S.+C.+Khojastehauthor=L.+Vernilletauthor=H.+Laauthor=X.+Songauthor=H.+Wangauthor=E.+J.+Morinelloauthor=Y.+Dengauthor=C.+E.+Hop&title=Interplay+of+dissolution%2C+solubility%2C+and+nonsink+permeation+determines+the+oral+absorption+of+the+Hedgehog+pathway+inhibitor+GDC-0449+in+dogs%3A+an+investigation+using+preclinical+studies+and+physiologically+based+pharmacokinetic+modeling&doi=10.1124%2Fdmd.110.032680"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Interplay of dissolution, solubility, and nonsink permeation determines the oral absorption of the hedgehog pathway inhibitor GDC-0449 in dogs: An investigation using preclinical studies and physiologically based pharmacokinetic modeling</span></div><div class="casAuthors">Wong, Harvey; Theil, Frank-Peter; Cui, Yong; Marsters, James C., Jr.; Khojasteh, S. Cyrus; Vernillet, Laurent; La, Hank; Song, Xiling; Wang, Hong; Morinello, Eric J.; Deng, Yuzhong; Hop, Cornelis E. C. A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1029-1038</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Factors detg. the pharmacokinetics of 2-chloro-N-(4-chloro-3-(pyridine-2-yl)phenyl)-4-(methylsulfonyl)benzamide (GDC-0449) were investigated using preclin. studies and physiol. based pharmacokinetic (PBPK) modeling.  Multiple-dose studies where dogs were given twice-daily oral doses of either 7.5 or 25 mg/kg GDC-0449 showed less than dose-proportional increases in exposure on day 1.  At steady state, exposures were comparable between the two dose groups.  Oral administration of activated charcoal to dogs receiving oral or i.v. GDC-0449 (25 mg) showed a more rapid decrease in plasma concns., suggesting that the concn. gradient driving intestinal membrane permeation was reversible.  The biliary clearance of GDC-0449 in dogs was low (0.04 mL/min/kg) and did not account for the majority of the estd. systemic clearance (∼19% of systemic clearance).  Likewise, in vitro studies using sandwich-cultured human hepatocytes showed negligible biliary excretion.  The effect of particle size on oral absorption was shown in a single-dose study where 150 mg of GDC-0449 of two particle sizes was administered.  An oral PBPK model was used to investigate mechanisms detg. the oral pharmacokinetics of GDC-0449.  The overall oral absorption of GDC-0449 appears to depend on the interplay between the dissoln. and intestinal membrane permeation processes.  A unique feature of GDC-0449 distinguishing it from other Biopharmaceutical Classification System II compds. was that incorporation of the effects of soly. rate-limited absorption and nonsink permeation on the intestinal membrane permeation process was necessary to describe its pharmacokinetic behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1OUx-orL8ibVg90H21EOLACvtfcHk0lgtnpn53--84w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1Kls7k%253D&md5=6169d4578f81846e562e6e06c71633fe</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.032680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.032680%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DH.%26aulast%3DTheil%26aufirst%3DF.%2BP.%26aulast%3DCui%26aufirst%3DY.%26aulast%3DMarsters%26aufirst%3DJ.%2BC.%26aulast%3DKhojasteh%26aufirst%3DS.%2BC.%26aulast%3DVernillet%26aufirst%3DL.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DMorinello%26aufirst%3DE.%2BJ.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DHop%26aufirst%3DC.%2BE.%26atitle%3DInterplay%2520of%2520dissolution%252C%2520solubility%252C%2520and%2520nonsink%2520permeation%2520determines%2520the%2520oral%2520absorption%2520of%2520the%2520Hedgehog%2520pathway%2520inhibitor%2520GDC-0449%2520in%2520dogs%253A%2520an%2520investigation%2520using%2520preclinical%2520studies%2520and%2520physiologically%2520based%2520pharmacokinetic%2520modeling%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D1029%26epage%3D1038%26doi%3D10.1124%2Fdmd.110.032680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saravanakumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadighi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhlaghi, F.</span></span> <span> </span><span class="NLM_article-title">Physicochemical properties, biotransformation, and transport pathways of established and newly approved medications: a systematic review of the top 200 most prescribed drugs vs. the FDA-approved drugs between 2005 and 2016</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1281</span>– <span class="NLM_lpage">1294</span>, <span class="refDoi"> DOI: 10.1007/s40262-019-00750-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1007%2Fs40262-019-00750-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=30972694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFWms7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=1281-1294&author=A.+Saravanakumarauthor=A.+Sadighiauthor=R.+Ryuauthor=F.+Akhlaghi&title=Physicochemical+properties%2C+biotransformation%2C+and+transport+pathways+of+established+and+newly+approved+medications%3A+a+systematic+review+of+the+top+200+most+prescribed+drugs+vs.+the+FDA-approved+drugs+between+2005+and+2016&doi=10.1007%2Fs40262-019-00750-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Physicochemical Properties, Biotransformation, and Transport Pathways of Established and Newly Approved Medications: A Systematic Review of the Top 200 Most Prescribed Drugs vs. the FDA-Approved Drugs Between 2005 and 2016</span></div><div class="casAuthors">Saravanakumar, Anitha; Sadighi, Armin; Ryu, Rachel; Akhlaghi, Fatemeh</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1281-1294</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Background: Enzyme-mediated biotransformation of pharmacol. agents is a crucial step in xenobiotic detoxification and drug disposition.  Herein, we investigated the metab. and physicochem. properties of the top 200 most prescribed drugs (established) as well as drugs approved by the US Food and Drug Administration (FDA) between 2005 and 2016 (newly approved).  Objective: Our objective was to capture the changing trends in the routes of administration, physicochem. properties, and prodrug medications, as well as the contributions of drug-metabolizing enzymes and transporters to drug clearance.  Methods: The University of Washington Drug Interaction Database (DIDB) as well as other online resources (e.g., CenterWatch.com, Drugs.com, DrugBank.ca, and PubChem.ncbi.nlm.nih.gov) was used to collect and stratify the dataset required for exploring the above-mentioned trends. Results: Analyses revealed that ~ 90% of all drugs in the established and newly approved drug lists were administered systemically (oral or i.v.). Meanwhile, the portion of biologics (mol. wt. > 1 kDa) was 15 times greater in the newly approved list than established drugs. Addnl., there was a 4.5-fold increase in the no. of compds. with a high calcd. partition coeff. (cLogP > 3) and a high total polar surface area (> 75 Å2) in the newly approved drug vs. the established category.  Further, prodrugs in established or newly approved lists were found to be converted to active compds. via hydrolysis, demethylases, and kinases.  The contribution of cytochrome P 450 (CYP) 3A4, as the major biotransformation pathway, has increased from 40% in the established drug list to 64% in the newly approved drug list.  Moreover, the role of CYP1A2, CYP2C19, and CYP2D6 were decreased as major metabolizing enzymes among the newly approved medications.  Among non-CYP major metabolizers, the contribution of alc. dehydrogenases/aldehyde dehydrogenases (ADH/ALDH) and sulfotransferases decreased in the newly approved drugs compared with the established list.  Furthermore, the highest contribution among uptake and efflux transporters was found for Org. Anion Transporting Polypeptide 1B1 (OATP1B1) and P-glycoprotein (P-gp), resp.  Conclusions: The higher portion of biologics in the newly approved drugs compared with the established list confirmed the growing demands for protein- and antibody-based therapies.  Moreover, the larger no. of hydrophilic drugs found in the newly approved list suggests that the probability of toxicity is likely to decrease.  With regard to CYP-mediated major metab., CYP3A5 showed an increased involvement owing to the identification of unique probe substrates to differentiate CYP3As.  Furthermore, the contribution of OATP1B1 and P-gp did not show a significant shift in the newly approved drugs as compared to the established list because of their broad substrate specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb6UtyKsUzCbVg90H21EOLACvtfcHk0ljNXiLsbgP6lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFWms7nJ&md5=cb1598cfe9c760522fd8df76d50e187c</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1007%2Fs40262-019-00750-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-019-00750-8%26sid%3Dliteratum%253Aachs%26aulast%3DSaravanakumar%26aufirst%3DA.%26aulast%3DSadighi%26aufirst%3DA.%26aulast%3DRyu%26aufirst%3DR.%26aulast%3DAkhlaghi%26aufirst%3DF.%26atitle%3DPhysicochemical%2520properties%252C%2520biotransformation%252C%2520and%2520transport%2520pathways%2520of%2520established%2520and%2520newly%2520approved%2520medications%253A%2520a%2520systematic%2520review%2520of%2520the%2520top%2520200%2520most%2520prescribed%2520drugs%2520vs.%2520the%2520FDA-approved%2520drugs%2520between%25202005%2520and%25202016%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2019%26volume%3D58%26spage%3D1281%26epage%3D1294%26doi%3D10.1007%2Fs40262-019-00750-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skolnik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span> <span> </span><span class="NLM_article-title">Towards prediction of in vivo intestinal absorption using a 96-well Caco-2 assay</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">3246</span>– <span class="NLM_lpage">3265</span>, <span class="refDoi"> DOI: 10.1002/jps.22080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1002%2Fjps.22080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=20166204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsVSrsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2010&pages=3246-3265&author=S.+Skolnikauthor=X.+Linauthor=J.+Wangauthor=X.+H.+Chenauthor=T.+Heauthor=B.+Zhang&title=Towards+prediction+of+in+vivo+intestinal+absorption+using+a+96-well+Caco-2+assay&doi=10.1002%2Fjps.22080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Towards prediction of in vivo intestinal absorption using a 96-well Caco-2 assay</span></div><div class="casAuthors">Skolnik, Suzanne; Lin, Xuena; Wang, Jianling; Chen, Xiao-Hui; He, Timothy; Zhang, Bailin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3246-3265</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">We systematically validated a robust 96-well Caco-2 assay via an extended set of 93 marketed drugs with diverse transport mechanisms and quantified by LC/MS/MS, to investigate its predictive utility while dealing with challenging discovery compds.  Utilizing nonlinear fit, the validation led to a good correlation (R2 = 0.76) between absorptive permeability, log Papp(A-B), from in vitro Caco-2 assay and reported human fraction of dose absorbed.  We obsd. that paracellular compds. could be flagged by log Papp(A-B) (<-5.5 cm/s) and physicochem. property space (c log P < 1).  Of 8000 Novartis discovery compds. examd. 13% were subject to low recovery (<30%).  Compd. loss was investigated by comparing cell monolayer and artificial membrane, while 0.5% bovine serum albumin (in both donor and acceptor compartments) was utilized to improve recovery.  The second focus of this study was to investigate the advantages and limitations of the current Caco-2 assay for predicting in vivo intestinal absorption.  Caco-2 measurements for compds. with high aq. soly. and low in vitro metabolic clearance were compared to 88 in vivo rat bioavailability studies.  Despite the challenges posed by discovery compds. with suboptimal physicochem. properties, Caco-2 data successfully projected low intestinal absorption.  This platform sets the stage for mechanistically evaluating compds. towards improving in vitro-in vivo correlations. © 2010 Wiley-Liss, Inc. and the American Pharmacists Assocn. J Pharm Sci 99:3246-3265, 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqio9beUaITm7Vg90H21EOLACvtfcHk0ljNXiLsbgP6lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsVSrsr0%253D&md5=43f7e35544e7b4a348271a53e958d3b9</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1002%2Fjps.22080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.22080%26sid%3Dliteratum%253Aachs%26aulast%3DSkolnik%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%2BH.%26aulast%3DHe%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DB.%26atitle%3DTowards%2520prediction%2520of%2520in%2520vivo%2520intestinal%2520absorption%2520using%2520a%252096-well%2520Caco-2%2520assay%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2010%26volume%3D99%26spage%3D3246%26epage%3D3265%26doi%3D10.1002%2Fjps.22080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sodhi, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L. Z.</span></span> <span> </span><span class="NLM_article-title">Intestinal efflux transporters P-gp and BCRP are not clinically relevant in apixaban disposition</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">208</span>, <span class="refDoi"> DOI: 10.1007/s11095-020-02927-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1007%2Fs11095-020-02927-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=32996065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFKnt77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2020&pages=208&author=J.+K.+Sodhiauthor=S.+Liuauthor=L.+Z.+Benet&title=Intestinal+efflux+transporters+P-gp+and+BCRP+are+not+clinically+relevant+in+apixaban+disposition&doi=10.1007%2Fs11095-020-02927-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131aR"><div class="casContent"><span class="casTitleNuber">131a</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal Efflux Transporters P-gp and BCRP Are Not Clinically Relevant in Apixaban Disposition</span></div><div class="casAuthors">Sodhi, Jasleen K.; Liu, Shuaibing; Benet, Leslie Z.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">208</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: Purpose: The involvement of the intestinally expressed xenobiotic transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) have been implicated in apixaban disposition based on in vitro studies.  Recommendations against co-administration of apixaban with inhibitors of these efflux transporters can be found throughout the literature as well as in the apixaban FDA label.  However, the clin. relevance of such findings is questionable due to the high permeability and high soly. characteristics of apixaban.  Methods: Using recently published methodologies to discern metabolic- from transporter- mediated drug-drug interactions, a crit. evaluation of all published apixaban drug-drug interaction studies was conducted to investigate the purported clin. significance of efflux transporters in apixaban disposition.  Results: Rational examn. of these clin. studies using basic pharmacokinetic theory does not support the clin. significance of intestinal efflux transporters in apixaban disposition.  Further, there is little evidence that efflux transporters are clin. significant determinants of systemic clearance.  Conclusions: Inhibition or induction of intestinal CYP3A4 can account for exposure changes of apixaban in all clin. significant drug-drug interactions, and lack of intestinal CYP3A4 inhibition can explain all studies with no exposure changes, regardless of the potential for these perpetrators to inhibit intestinal or systemic efflux transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB046FDjPETbVg90H21EOLACvtfcHk0ljNXiLsbgP6lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFKnt77P&md5=4afc81f1c78804188623cfc92f2c3323</span></div><a href="/servlet/linkout?suffix=cit131a&amp;dbid=16384&amp;doi=10.1007%2Fs11095-020-02927-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-020-02927-4%26sid%3Dliteratum%253Aachs%26aulast%3DSodhi%26aufirst%3DJ.%2BK.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DBenet%26aufirst%3DL.%2BZ.%26atitle%3DIntestinal%2520efflux%2520transporters%2520P-gp%2520and%2520BCRP%2520are%2520not%2520clinically%2520relevant%2520in%2520apixaban%2520disposition%26jtitle%3DPharm.%2520Res.%26date%3D2020%26volume%3D37%26spage%3D208%26doi%3D10.1007%2Fs11095-020-02927-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit131b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kryukov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sychev, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreev, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryzhikova, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grishina, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryabova, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loskutnikov, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smirnov, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konova, O. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsneva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bochkov, P. O.</span></span> <span> </span><span class="NLM_article-title">Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke</span>. <i>Pharmacogenomics Pers. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.2147/PGPM.S157111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.2147%2FPGPM.S157111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=29606886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVyls7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=43-49&author=A.+V.+Kryukovauthor=D.+A.+Sychevauthor=D.+A.+Andreevauthor=K.+A.+Ryzhikovaauthor=E.+A.+Grishinaauthor=A.+V.+Ryabovaauthor=M.+A.+Loskutnikovauthor=V.+V.+Smirnovauthor=O.+D.+Konovaauthor=I.+Matsnevaauthor=P.+O.+Bochkov&title=Influence+of+ABCB1+and+CYP3A5+gene+polymorphisms+on+pharmacokinetics+of+apixaban+in+patients+with+atrial+fibrillation+and+acute+stroke&doi=10.2147%2FPGPM.S157111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131bR"><div class="casContent"><span class="casTitleNuber">131b</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke</span></div><div class="casAuthors">Kryukov, Alexander Valerevich; Sychev, Dmitry Alekseevich; Andreev, Denis Anatolevich; Ryzhikova, Kristina Anatolievna; Grishina, Elena Anatolievna; Ryabova, Anastasia Vladislavovna; Loskutnikov, Mark Alekseevich; Smirnov, Valeriy Valerevich; Konova, Olga Dmitrievna; Matsneva, Irina Andreevna; Bochkov, Pavel Olegovich</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenomics and Personalized Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">43-49</span>CODEN:
                <span class="NLM_cas:coden">PPMHAD</span>;
        ISSN:<span class="NLM_cas:issn">1178-7066</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Introduction: Difficulties in non-vitamin K anticoagulant (NOAC) administration in acute stroke can be assocd. with changes in pharmacokinetic parameters of NOAC such as biotransformation, distribution, and excretion.  Therefore, obtaining data on pharmacokinetics of NOAC and factors that affect it may help develop algorithms for personalized use of this drug class in patients with acute cardioembolic stroke.  Patients and methods: Pharmacokinetics of apixaban in patients with acute stroke was studied earlier by Kryukov et al.  The present study enrolled 17 patients with cardioembolic stroke, who received 5 mg of apixaban.  In order to evaluate the pharmacokinetic parameters of apixaban, venous blood samples were collected before taking 5 mg of apixaban (point 0) and 1, 2, 3, 4, 10, and 12 h after drug intake.  Blood samples were centrifuged at 3000 rpm for 15 min.  Sep. plasma was aliquoted in Eppendorf tubes and frozen at -70°C until anal.  High-performance liq. chromatog. mass spectrometry anal. was used to det. apixaban plasma concn.  Genotyping was performed by real-time polymerase chain reaction.  CYP3A isoenzyme group activity was evaluated by detg. urinary concn. of endogenous substrate of the enzyme and its metabolite (6-β-hydroxycortisol to cortisol ratio).  Statistical anal. was performed using SPSS Statistics version 20.0.  The protocol of this study was reviewed and approved by the ethics committee; patients or their representatives signed an informed consent.  Results:ABCB1 (rs1045642 and rs4148738) gene polymorphisms do not affect the pharmacokinetics of apixaban as well as CYP3A5 (rs776746) gene polymorphisms.  Apixaban pharmacokinetics in groups with different genotypes did not differ statistically significantly.  Correlation anal. showed no statistically significant relationship between pharmacokinetic parameters of apixaban and the metabolic activity of CYP3A.  Conclusion: Questions such as depending on genotyping results for apixaban dosing and implementation of express genotyping in clin. practice remain open for NOACs.  Large population studies are required to clarify the clin. significance of genotyping for this drug class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYxNIsSO7ewLVg90H21EOLACvtfcHk0ljNXiLsbgP6lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVyls7vP&md5=24a32b46ff1aee8ec60a00fe6a5f9b16</span></div><a href="/servlet/linkout?suffix=cit131b&amp;dbid=16384&amp;doi=10.2147%2FPGPM.S157111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FPGPM.S157111%26sid%3Dliteratum%253Aachs%26aulast%3DKryukov%26aufirst%3DA.%2BV.%26aulast%3DSychev%26aufirst%3DD.%2BA.%26aulast%3DAndreev%26aufirst%3DD.%2BA.%26aulast%3DRyzhikova%26aufirst%3DK.%2BA.%26aulast%3DGrishina%26aufirst%3DE.%2BA.%26aulast%3DRyabova%26aufirst%3DA.%2BV.%26aulast%3DLoskutnikov%26aufirst%3DM.%2BA.%26aulast%3DSmirnov%26aufirst%3DV.%2BV.%26aulast%3DKonova%26aufirst%3DO.%2BD.%26aulast%3DMatsneva%26aufirst%3DI.%26aulast%3DBochkov%26aufirst%3DP.%2BO.%26atitle%3DInfluence%2520of%2520ABCB1%2520and%2520CYP3A5%2520gene%2520polymorphisms%2520on%2520pharmacokinetics%2520of%2520apixaban%2520in%2520patients%2520with%2520atrial%2520fibrillation%2520and%2520acute%2520stroke%26jtitle%3DPharmacogenomics%2520Pers.%2520Med.%26date%3D2018%26volume%3D11%26spage%3D43%26epage%3D49%26doi%3D10.2147%2FPGPM.S157111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit131c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ueshima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hira, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomitsuka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamane, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabuchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsura, T.</span></span> <span> </span><span class="NLM_article-title">Impact of ABCB1, ABCG2 and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in patients with atrial fibrillation</span>. <i>Pharmacogenet. Genomics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1097/FPC.0000000000000294</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1097%2FFPC.0000000000000294" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=28678049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1eqs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=329-336&author=S.+Ueshimaauthor=D.+Hiraauthor=R.+Fujiiauthor=Y.+Kimuraauthor=C.+Tomitsukaauthor=T.+Yamaneauthor=Y.+Tabuchiauthor=T.+Ozawaauthor=H.+Itohauthor=M.+Horieauthor=T.+Teradaauthor=T.+Katsura&title=Impact+of+ABCB1%2C+ABCG2+and+CYP3A5+polymorphisms+on+plasma+trough+concentrations+of+apixaban+in+patients+with+atrial+fibrillation&doi=10.1097%2FFPC.0000000000000294"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131cR"><div class="casContent"><span class="casTitleNuber">131c</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation</span></div><div class="casAuthors">Ueshima, Satoshi; Hira, Daiki; Fujii, Ryo; Kimura, Yuuma; Tomitsuka, Chiho; Yamane, Takuya; Tabuchi, Yohei; Ozawa, Tomoya; Itoh, Hideki; Horie, Minoru; Terada, Tomohiro; Katsura, Toshiya</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenetics and Genomics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">PGHEAI</span>;
        ISSN:<span class="NLM_cas:issn">1744-6872</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objectives: During anticoagulant therapy, major bleeding is one of the most severe adverse effects.  This study aimed to evaluate the relationships between ABCB1, ABCG2, and CYP3A5 polymorphisms and plasma trough concns. of apixaban, a direct inhibitor of coagulation factor X.  Patients and methods: A total of 70 plasma concns. of apixaban from 44 Japanese patients with atrial fibrillation were analyzed.  In these analyses, the plasma trough concn./dose (C/D) ratio of apixaban was used as a pharmacokinetic index and all data were stratified according to the presence of ABCB1 (ABCB1 1236C>T, 2677G>T/A, and 3435C>T), ABCG2 (ABCG2 421C>A), and CYP3A5 (CYP3A5*3) polymorphisms.  Influences of various clin. lab. parameters (age, serum creatinine, estd. glomerular filtration rate, aspartate amino transferase, and alanine amino transferase) on the plasma trough C/D ratio of apixaban were included in analyses.  Results: Although no ABCB1 polymorphisms affected the plasma trough C/D ratio of apixaban, the plasma trough C/D ratio of apixaban was significantly higher in patients with the ABCG2 421A/A genotype than in patients with the ABCG2 421C/C genotype (P<0.01).  The plasma trough C/D ratio of apixaban in patients with CYP3A5*1/*3 or *3/*3 genotypes was also significantly higher than that in patients with the CYP3A5*1/*1 genotype (P<0.05).  Furthermore, the plasma trough C/D ratio of apixaban decreased with increased estd. glomerular filtration rate.  Conclusion: These results indicate that ABCG2 421A/A and CYP3A5*3 genotypes and renal function are considered potential factors affecting trough concns. of apixaban.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9qxKLqAo_DbVg90H21EOLACvtfcHk0lhKAh16QOTijQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1eqs7vE&md5=f80a4ffdbb94f86a4239d5f29d9bd3da</span></div><a href="/servlet/linkout?suffix=cit131c&amp;dbid=16384&amp;doi=10.1097%2FFPC.0000000000000294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFPC.0000000000000294%26sid%3Dliteratum%253Aachs%26aulast%3DUeshima%26aufirst%3DS.%26aulast%3DHira%26aufirst%3DD.%26aulast%3DFujii%26aufirst%3DR.%26aulast%3DKimura%26aufirst%3DY.%26aulast%3DTomitsuka%26aufirst%3DC.%26aulast%3DYamane%26aufirst%3DT.%26aulast%3DTabuchi%26aufirst%3DY.%26aulast%3DOzawa%26aufirst%3DT.%26aulast%3DItoh%26aufirst%3DH.%26aulast%3DHorie%26aufirst%3DM.%26aulast%3DTerada%26aufirst%3DT.%26aulast%3DKatsura%26aufirst%3DT.%26atitle%3DImpact%2520of%2520ABCB1%252C%2520ABCG2%2520and%2520CYP3A5%2520polymorphisms%2520on%2520plasma%2520trough%2520concentrations%2520of%2520apixaban%2520in%2520patients%2520with%2520atrial%2520fibrillation%26jtitle%3DPharmacogenet.%2520Genomics%26date%3D2017%26volume%3D27%26spage%3D329%26epage%3D336%26doi%3D10.1097%2FFPC.0000000000000294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Arimori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, M.</span></span> <span> </span><span class="NLM_article-title">Transport of furosemide into the intestinal lumen and the lack of effect of gastrointestinal dialysis by charcoal in rats with acute renal failure</span>. <i>J. Pharmacobio-Dyn.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1248/bpb1978.11.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1248%2Fbpb1978.11.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=3385600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaL1cXhtVGqsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1988&pages=1-8&author=K.+Arimoriauthor=M.+Nakano&title=Transport+of+furosemide+into+the+intestinal+lumen+and+the+lack+of+effect+of+gastrointestinal+dialysis+by+charcoal+in+rats+with+acute+renal+failure&doi=10.1248%2Fbpb1978.11.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132aR"><div class="casContent"><span class="casTitleNuber">132a</span><div class="casTitle"><span class="NLM_cas:atitle">Transport of furosemide into the intestinal lumen and the lack of effect of gastrointestinal dialysis by charcoal in rats with acute renal failure</span></div><div class="casAuthors">Arimori, Kazuhiko; Nakano, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacobio-Dynamics</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">JOPHDQ</span>;
        ISSN:<span class="NLM_cas:issn">0386-846X</span>.
    </div><div class="casAbstract">The characteristics of exsorption and(or) excretion of furosemide into the small intestinal lumen in rats with acute renal failure (ARF rat) were investigated by an in situ single-pass perfusion technique.  The amt. of furosemide, which was exsorbed into the intestinal lumen after an i.v. administration of the drug to rats was very slight.  The exsorption rate of the drug was increased in ARF rats as compared with normal rats.  The av. amt. of the drug exsorbed into the perfusate in normal rats was 0.83% of dose, whereas that in ARF rats was 1.83% of dose.  The amts. of furosemide excreted into the bile in normal rats and ARF rats were 1.53 and 2.64%, resp.  The increased exsorption of furosemide in ARF rats appeared to be due primarily to the decreased binding of the drug to the serum protein, because only the unbound drug permeates through the intestinal membrane into the gastrointestinal (g.i.) tract, and, to some extent, to the increased nonrenal excretion caused by poor renal excretion.  Oral activated charcoal had little effect on the serum furosemide levels after i.v. administration of the drug at 10 mg/kg in ARF rats.  The lack of effect of activated charcoal on the elimination of the drug may be due to the small amt. of the drug excreted into the g.i. tract.  The relation of these results to the removal of toxic drugs from the blood is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxMk4it_HmM7Vg90H21EOLACvtfcHk0lhKAh16QOTijQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXhtVGqsLY%253D&md5=0d7e0d3d5ef56e4cb3f8b1f2c6830938</span></div><a href="/servlet/linkout?suffix=cit132a&amp;dbid=16384&amp;doi=10.1248%2Fbpb1978.11.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb1978.11.1%26sid%3Dliteratum%253Aachs%26aulast%3DArimori%26aufirst%3DK.%26aulast%3DNakano%26aufirst%3DM.%26atitle%3DTransport%2520of%2520furosemide%2520into%2520the%2520intestinal%2520lumen%2520and%2520the%2520lack%2520of%2520effect%2520of%2520gastrointestinal%2520dialysis%2520by%2520charcoal%2520in%2520rats%2520with%2520acute%2520renal%2520failure%26jtitle%3DJ.%2520Pharmacobio-Dyn.%26date%3D1988%26volume%3D11%26spage%3D1%26epage%3D8%26doi%3D10.1248%2Fbpb1978.11.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit132b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Arimori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakayama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, M.</span></span> <span> </span><span class="NLM_article-title">Increased transport of theophylline into gastrointestinal lumen and gastrointestinal dialysis by activated charcoal in rats with hepatic cirrhosis</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">3148</span>– <span class="NLM_lpage">3149</span>, <span class="refDoi"> DOI: 10.1248/cpb.37.3148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1248%2Fcpb.37.3148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=2632064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK3cXmvFelsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1989&pages=3148-3149&author=K.+Arimoriauthor=K.+Wakayamaauthor=M.+Nakano&title=Increased+transport+of+theophylline+into+gastrointestinal+lumen+and+gastrointestinal+dialysis+by+activated+charcoal+in+rats+with+hepatic+cirrhosis&doi=10.1248%2Fcpb.37.3148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132bR"><div class="casContent"><span class="casTitleNuber">132b</span><div class="casTitle"><span class="NLM_cas:atitle">Increased transport of theophylline into gastrointestinal lumen and gastrointestinal dialysis by activated charcoal in rats with hepatic cirrhosis</span></div><div class="casAuthors">Arimori, Kazuhiko; Wakayama, Katsumi; Nakano, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3148-9</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    </div><div class="casAbstract">The characteristics of exsorption and/or excretion of theophylline into the small intestinal lumen in rats with hepatic cirrhosis (HC rats) induced by CCl4 were investigated by an in situ single-pass perfusion technique.  The serum concns. of theophylline after i.v. administration of aminophylline (10 mg/kg) in the HC rats were higher than those in normal rats during the exptl. period.  Moreover, the exsorption of theophylline from blood into the intestinal lumen was increased in the HC rats compared with the normal rats.  Treatments with oral activated charcoal reduced the serum theophylline levels in the HC rats.  Consequently, gastrointestinal dialysis by oral administration of activated charcoal may be a useful method to remove poisonous drugs from the blood in patients with hepatic failure (including cirrhosis), which decreases the systemic clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIwLevifQ_obVg90H21EOLACvtfcHk0lhKAh16QOTijQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXmvFelsg%253D%253D&md5=5b385ef44c5f50b195b26de0a5c381bc</span></div><a href="/servlet/linkout?suffix=cit132b&amp;dbid=16384&amp;doi=10.1248%2Fcpb.37.3148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.37.3148%26sid%3Dliteratum%253Aachs%26aulast%3DArimori%26aufirst%3DK.%26aulast%3DWakayama%26aufirst%3DK.%26aulast%3DNakano%26aufirst%3DM.%26atitle%3DIncreased%2520transport%2520of%2520theophylline%2520into%2520gastrointestinal%2520lumen%2520and%2520gastrointestinal%2520dialysis%2520by%2520activated%2520charcoal%2520in%2520rats%2520with%2520hepatic%2520cirrhosis%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D1989%26volume%3D37%26spage%3D3148%26epage%3D3149%26doi%3D10.1248%2Fcpb.37.3148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L. Z.</span></span> <span> </span><span class="NLM_article-title">Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1007/s11095-004-9004-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1007%2Fs11095-004-9004-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=15771225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlCks70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2005&pages=11-23&author=C.+Y.+Wuauthor=L.+Z.+Benet&title=Predicting+drug+disposition+via+application+of+BCS%3A+transport%2Fabsorption%2F+elimination+interplay+and+development+of+a+biopharmaceutics+drug+disposition+classification+system&doi=10.1007%2Fs11095-004-9004-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System</span></div><div class="casAuthors">Wu, Chi-Yuan; Benet, Leslie Z.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-23</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The Biopharmaceutics Classification System (BCS) was developed to allow prediction of in vivo pharmacokinetic performance of drug products from measurements of permeability (detd. as the extent of oral absorption) and soly. Here, we suggest that a modified version of such a classification system may be useful in predicting overall drug disposition, including routes of drug elimination and the effects of efflux and absorptive transporters on oral drug absorption; when transporter-enzyme interplay will yield clin. significant effects (e.g., low bioavailability and drug-drug interactions); the direction, mechanism, and importance of food effects; and transporter effects on postabsorption systemic drug concns. following oral and i.v. dosing.  These predictions are supported by a series of studies from our lab. during the past few years investigating the effect of transporter inhibition and induction on drug metab.  We conclude by suggesting that a Biopharmaceutics Drug Disposition Classification System (BDDCS) using elimination criteria may expand the no. of Class 1 drugs eligible for a waiver of in vivo bioequivalence studies and provide predictability of drug disposition profiles for Classes 2, 3, and 4 compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-ZukfABDoNbVg90H21EOLACvtfcHk0li1bw6qIxHVyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlCks70%253D&md5=a8aa9533f337a4245b1b66ac859095fb</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1007%2Fs11095-004-9004-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-004-9004-4%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%2BY.%26aulast%3DBenet%26aufirst%3DL.%2BZ.%26atitle%3DPredicting%2520drug%2520disposition%2520via%2520application%2520of%2520BCS%253A%2520transport%252Fabsorption%252F%2520elimination%2520interplay%2520and%2520development%2520of%2520a%2520biopharmaceutics%2520drug%2520disposition%2520classification%2520system%26jtitle%3DPharm.%2520Res.%26date%3D2005%26volume%3D22%26spage%3D11%26epage%3D23%26doi%3D10.1007%2Fs11095-004-9004-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. M.</span></span> <span> </span><span class="NLM_article-title">Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1766</span>– <span class="NLM_lpage">1774</span>, <span class="refDoi"> DOI: 10.1021/mp900132e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp900132e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtl2qurjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=1766-1774&author=L.+Zhangauthor=Y.+Zhangauthor=S.+M.+Huang&title=Scientific+and+regulatory+perspectives+on+metabolizing+enzyme-transporter+interplay+and+its+role+in+drug+interactions%3A+challenges+in+predicting+drug+interactions&doi=10.1021%2Fmp900132e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Scientific and Regulatory Perspectives on Metabolizing Enzyme-Transporter Interplay and its Role in Drug Interactions: Challenges in Predicting Drug Interactions</span></div><div class="casAuthors">Zhang, Lei; Zhang, Yuanchao; Huang, Shiew-Mei</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1766-1774</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Both metabolizing enzymes and drug transporters play important roles in modulating drug absorption, distribution, metab. and elimination.  Acting alone or in concert with each other they can affect the pharmacokinetics and pharmacodynamics of a drug.  This paper will present cases from recent reviews of new drug application (NDA) and literature that exemplify the role of metabolizing enzyme-transporter interplay in a drug's disposition, and discuss challenges in predicting drug interactions.  Finally, the discussion will focus on the need to leverage current knowledge to obtain more meaningful drug interaction information.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp367gxPqTthLVg90H21EOLACvtfcHk0li1bw6qIxHVyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtl2qurjF&md5=b5b5c46d55c57dca43e80b6c2f0a4ae9</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1021%2Fmp900132e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp900132e%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DS.%2BM.%26atitle%3DScientific%2520and%2520regulatory%2520perspectives%2520on%2520metabolizing%2520enzyme-transporter%2520interplay%2520and%2520its%2520role%2520in%2520drug%2520interactions%253A%2520challenges%2520in%2520predicting%2520drug%2520interactions%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2009%26volume%3D6%26spage%3D1766%26epage%3D1774%26doi%3D10.1021%2Fmp900132e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, W. N.</span></span> <span> </span><span class="NLM_article-title">Intestinal lymphatic drug transport: an update</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">80</span>, <span class="refDoi"> DOI: 10.1016/S0169-409X(01)00151-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1016%2FS0169-409X%2801%2900151-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=11489334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlsF2js7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2001&pages=61-80&author=C.+J.+Porterauthor=W.+N.+Charman&title=Intestinal+lymphatic+drug+transport%3A+an+update&doi=10.1016%2FS0169-409X%2801%2900151-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal lymphatic drug transport: an update</span></div><div class="casAuthors">Porter, C. J. H.; Charman, W. N.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">61-80</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  The trend towards identification of poorly water-sol. and highly lipophilic candidate drug mols. has led to an increase in interest in intestinal lymphatic drug transport.  In this article we provide a brief background to the mechanism of access of drugs to the intestinal lymph and the role of lipid digestion and absorption in the stimulation of lymphatic transport.  The ability of different lipid types to stimulate lymphatic drug transport, is addressed, concg. specifically on the impact of the class, chain length and degree of unsatn. of co-administered lipids.  Comment is also made as to the relevance of dosing different lipid vols. to the rat and the possible complications this may provide when trying to assess the likely extent of intestinal lymphatic transport.  Recent studies are described in which the extent of lymphatic transport of a highly lipophilic antimalarial, halofantrine, was investigated after post-prandial administration to greyhound dogs.  Finally the possible future directions for studies of intestinal lymphatic transport are discussed, including the use of cell culture models and genetically modified animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGZPCxqz31PrVg90H21EOLACvtfcHk0li1bw6qIxHVyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlsF2js7g%253D&md5=1821acb0f76a521bac55ee7f05d28205</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2801%2900151-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252801%252900151-X%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DC.%2BJ.%26aulast%3DCharman%26aufirst%3DW.%2BN.%26atitle%3DIntestinal%2520lymphatic%2520drug%2520transport%253A%2520an%2520update%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2001%26volume%3D50%26spage%3D61%26epage%3D80%26doi%3D10.1016%2FS0169-409X%2801%2900151-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kagan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreifinger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mager, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, A.</span></span> <span> </span><span class="NLM_article-title">Role of P-glycoprotein in region-specific gastrointestinal absorption of talinolol in rats</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1560</span>– <span class="NLM_lpage">1566</span>, <span class="refDoi"> DOI: 10.1124/dmd.110.033019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.110.033019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=20538723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFegu73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1560-1566&author=L.+Kaganauthor=T.+Dreifingerauthor=D.+E.+Magerauthor=A.+Hoffman&title=Role+of+P-glycoprotein+in+region-specific+gastrointestinal+absorption+of+talinolol+in+rats&doi=10.1124%2Fdmd.110.033019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Role of P-glycoprotein in region-specific gastrointestinal absorption of talinolol in rats</span></div><div class="casAuthors">Kagan, Leonid; Dreifinger, Tali; Mager, Donald E.; Hoffman, Amnon</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1560-1566</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">P-Glycoprotein (PGP) is nonuniformly distributed along the gastrointestinal (GI) tract; however, the data regarding regional differences in PGP function in the intestine are controversial.  The aim of this work was to investigate the role of PGP efflux in region-specific absorption of talinolol from the GI tract in rats.  Plasma talinolol concns. were measured after several modes of administration, including high (40 mg/kg) and low (4 mg/kg) dose levels, to different segments of the GI tract (stomach vs. colon), and codosing with PGP inhibitors (verapamil or cyclosporine).  The bioavailability (F) of talinolol after high-dose administration to the stomach was significantly greater than that achieved by the low dose (approx. 18 vs. 2%).  Coadministration of low-dose talinolol with cyclosporine increased F by approx. 5-fold (p < 0.01).  For the high dose, codosing with PGP inhibitors did not increase the extent of absorption.  Talinolol demonstrated poor colonic absorption that was significantly increased by coadministration with cyclosporine (F = 0.76 vs. 8.1%).  Oral verapamil significantly increased systemic clearance and the steady state vol. of distribution of i.v. talinolol.  A semiphysiol. model was developed that successfully captured the pharmacokinetic profiles of talinolol after various modes of administration.  PGP-mediated efflux appears to be a major factor responsible for GI region-specific absorption of talinolol in rats, and gastroretentive dosage forms may provide an advantage in the delivery of talinolol and PGP substrate drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHyQ3Oihi8UrVg90H21EOLACvtfcHk0lgyaYYA82Y5Qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFegu73E&md5=ece6a2a77eaf51c551fb02dec917dfdd</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.033019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.033019%26sid%3Dliteratum%253Aachs%26aulast%3DKagan%26aufirst%3DL.%26aulast%3DDreifinger%26aufirst%3DT.%26aulast%3DMager%26aufirst%3DD.%2BE.%26aulast%3DHoffman%26aufirst%3DA.%26atitle%3DRole%2520of%2520P-glycoprotein%2520in%2520region-specific%2520gastrointestinal%2520absorption%2520of%2520talinolol%2520in%2520rats%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D1560%26epage%3D1566%26doi%3D10.1124%2Fdmd.110.033019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fagerholm, U.</span></span> <span> </span><span class="NLM_article-title">Prediction of human pharmacokinetics-biliary and intestinal clearance and enterohepatic circulation</span>. <i>J. Pharm. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">535</span>– <span class="NLM_lpage">542</span>, <span class="refDoi"> DOI: 10.1211/jpp.60.5.0001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1211%2Fjpp.60.5.0001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2010&pages=535-542&author=U.+Fagerholm&title=Prediction+of+human+pharmacokinetics-biliary+and+intestinal+clearance+and+enterohepatic+circulation&doi=10.1211%2Fjpp.60.5.0001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1211%2Fjpp.60.5.0001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1211%252Fjpp.60.5.0001%26sid%3Dliteratum%253Aachs%26aulast%3DFagerholm%26aufirst%3DU.%26atitle%3DPrediction%2520of%2520human%2520pharmacokinetics-biliary%2520and%2520intestinal%2520clearance%2520and%2520enterohepatic%2520circulation%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D2010%26volume%3D60%26spage%3D535%26epage%3D542%26doi%3D10.1211%2Fjpp.60.5.0001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chyka, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krenzelok, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vale, J. A.</span></span> <span> </span><span class="NLM_article-title">Position paper: single-dose activated charcoal</span>. <i>Clin. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1081/CLT-200051867</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1081%2FCLT-51867" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A280%3ADC%252BD2M7ovFGisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2005&pages=61-87&author=P.+A.+Chykaauthor=D.+Segerauthor=E.+P.+Krenzelokauthor=J.+A.+Vale&title=Position+paper%3A+single-dose+activated+charcoal&doi=10.1081%2FCLT-200051867"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Position paper: Single-dose activated charcoal</span></div><div class="casAuthors">Chyka P A; Seger D; Krenzelok E P; Vale J A</div><div class="citationInfo"><span class="NLM_cas:title">Clinical toxicology (Philadelphia, Pa.)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">61-87</span>
        ISSN:<span class="NLM_cas:issn">1556-3650</span>.
    </div><div class="casAbstract">Single-dose activated charcoal therapy involves the oral administration or instillation by nasogastric tube of an aqueous preparation of activated charcoal after the ingestion of a poison.  Volunteer studies demonstrate that the effectiveness of activated charcoal decreases with time.  Data using at least 50 g of activated charcoal, showed a mean reduction in absorption of 47.3%, 40.07%, 16.5% and 21.13%, when activated charcoal was administered at 30 minutes, 60 minutes, 120 minutes and 180 minutes, respectively, after dosing.  There are no satisfactorily designed clinical studies assessing benefit from single-dose activated charcoal to guide the use of this therapy.  Single-dose activated charcoal should not be administered routinely in the management of poisoned patients.  Based on volunteer studies, the administration of activated charcoal may be considered if a patient has ingested a potentially toxic amount of a poison (which is known to be adsorbed to charcoal) up to one hour previously.  Although volunteer studies demonstrate that the reduction of drug absorption decreases to values of questionable clinical importance when charcoal is administered at times greater than one hour, the potential for benefit after one hour cannot be excluded.  There is no evidence that the administration of activated charcoal improves clinical outcome.  Unless a patient has an intact or protected airway, the administration of charcoal is contraindicated.  A review of the literature since the preparation of the 1997 Single-dose Activated Charcoal Position Statement revealed no new evidence that would require a revision of the conclusions of the Statement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT56uSW4BEPM8rRqEXsZufAfW6udTcc2eY4_-exEQNVF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M7ovFGisw%253D%253D&md5=f7258ca07e3f2dbab1d5bd9417dd1ad7</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1081%2FCLT-51867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1081%252FCLT-51867%26sid%3Dliteratum%253Aachs%26aulast%3DChyka%26aufirst%3DP.%2BA.%26aulast%3DSeger%26aufirst%3DD.%26aulast%3DKrenzelok%26aufirst%3DE.%2BP.%26aulast%3DVale%26aufirst%3DJ.%2BA.%26atitle%3DPosition%2520paper%253A%2520single-dose%2520activated%2520charcoal%26jtitle%3DClin.%2520Toxicol.%26date%3D2005%26volume%3D43%26spage%3D61%26epage%3D87%26doi%3D10.1081%2FCLT-200051867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghavan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maxwell, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goosen, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, S. J.</span></span> <span> </span><span class="NLM_article-title">In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">448</span>– <span class="NLM_lpage">458</span>, <span class="refDoi"> DOI: 10.1124/dmd.109.029694</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.109.029694" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=19940026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjt1Ort7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=448-458&author=L.+Wangauthor=D.+Zhangauthor=N.+Raghavanauthor=M.+Yaoauthor=L.+Maauthor=C.+E.+Frostauthor=B.+D.+Maxwellauthor=S.+Y.+Chenauthor=K.+Heauthor=T.+C.+Goosenauthor=W.+G.+Humphreysauthor=S.+J.+Grossman&title=In+vitro+assessment+of+metabolic+drug-drug+interaction+potential+of+apixaban+through+cytochrome+P450+phenotyping%2C+inhibition%2C+and+induction+studies&doi=10.1124%2Fdmd.109.029694"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies</span></div><div class="casAuthors">Wang, Lifei; Zhang, Donglu; Raghavan, Nirmala; Yao, Ming; Ma, Li; Frost, Charles A.; Maxwell, Brad D.; Chen, Shiang-yuan; He, Kan; Goosen, Theunis C.; Humphreys, W. Griffith; Grossman, Scott J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">448-458</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Apixaban is an oral, direct, and highly selective factor Xa inhibitor in late-stage clin. development for the prevention and treatment of thromboembolic diseases.  The metabolic drug-drug interaction potential of apixaban was evaluated in vitro.  The compd. did not show cytochrome P 450 inhibition (IC50 values > 20 μM) in incubations of human liver microsomes with the probe substrates of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4/5.  Apixaban did not show any effect at concns. up to 20 μM on enzyme activities or mRNA levels of selected P 450 enzymes (CYP1A2, 2B6, and 3A4/5) that are sensitive to induction in incubations with primary human hepatocytes.  Apixaban showed a slow metabolic turnover in incubations of human liver microsomes with formation of O-demethylation (M2) and hydroxylation products (M4 and M7) as prominent in vitro metabolites.  Expts. with human cDNA-expressed P 450 enzymes and P 450 chem. inhibitors and correlation with P 450 activities in individual human liver microsomes demonstrated that the oxidative metab. of apixaban for formation of all metabolites was predominantly catalyzed by CYP3A4/5 with a minor contribution of CYP1A2 and CYP2J2 for formation of M2.  The contribution of CYP2C8, 2C9, and 2C19 to metab. of apixaban was less significant.  In addn., a human absorption, distribution, metab., and excretion study showed that more than half of the dose was excreted as unchanged parent (fm CYP <0.5), thus significantly reducing the overall metabolic drug-drug interaction potential of apixaban.  Together with a low clin. efficacious concn. and multiple clearance pathways, these results demonstrate that the metabolic drug-drug interaction potential between apixaban and coadministered drugs is low.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOeDRJ6ezxeLVg90H21EOLACvtfcHk0lgyaYYA82Y5Qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjt1Ort7c%253D&md5=934e9d2bbd934e263783b64d442c6c1c</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.029694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.029694%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DRaghavan%26aufirst%3DN.%26aulast%3DYao%26aufirst%3DM.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DFrost%26aufirst%3DC.%2BE.%26aulast%3DMaxwell%26aufirst%3DB.%2BD.%26aulast%3DChen%26aufirst%3DS.%2BY.%26aulast%3DHe%26aufirst%3DK.%26aulast%3DGoosen%26aufirst%3DT.%2BC.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DGrossman%26aufirst%3DS.%2BJ.%26atitle%3DIn%2520vitro%2520assessment%2520of%2520metabolic%2520drug-drug%2520interaction%2520potential%2520of%2520apixaban%2520through%2520cytochrome%2520P450%2520phenotyping%252C%2520inhibition%252C%2520and%2520induction%2520studies%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D448%26epage%3D458%26doi%3D10.1124%2Fdmd.109.029694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pang, K. S.</span></span> <span> </span><span class="NLM_article-title">Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series)</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1507</span>– <span class="NLM_lpage">1519</span>, <span class="refDoi"> DOI: 10.1124/dmd.31.12.1507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.31.12.1507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=14625347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpt1KgsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2003&pages=1507-1519&author=K.+S.+Pang&title=Modeling+of+intestinal+drug+absorption%3A+roles+of+transporters+and+metabolic+enzymes+%28for+the+Gillette+Review+Series%29&doi=10.1124%2Fdmd.31.12.1507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling of intestinal drug absorption: Roles of transporters and metabolic enzymes (for the Gillete review series)</span></div><div class="casAuthors">Pang, K. Sandy</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1507-1519</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review describes the processes governing drug bioavailability when the drug is already in soln., and emphasizes the roles of intestinal transporters and metab. on oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxUcibeQ0oY7Vg90H21EOLACvtfcHk0ljoKFog1OpfKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpt1KgsLo%253D&md5=5f775a511055198f6d7a3d2182880890</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1124%2Fdmd.31.12.1507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.31.12.1507%26sid%3Dliteratum%253Aachs%26aulast%3DPang%26aufirst%3DK.%2BS.%26atitle%3DModeling%2520of%2520intestinal%2520drug%2520absorption%253A%2520roles%2520of%2520transporters%2520and%2520metabolic%2520enzymes%2520%2528for%2520the%2520Gillette%2520Review%2520Series%2529%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2003%26volume%3D31%26spage%3D1507%26epage%3D1519%26doi%3D10.1124%2Fdmd.31.12.1507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosset, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attkins, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurrell, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logan, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bungay, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, I. B.</span></span> <span> </span><span class="NLM_article-title">Application of PBPK modelling in drug discovery and development at Pfizer</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">106</span>, <span class="refDoi"> DOI: 10.3109/00498254.2011.627477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.3109%2F00498254.2011.627477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=22035569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFKgtbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2012&pages=94-106&author=H.+M.+Jonesauthor=M.+Dickinsauthor=K.+Youdimauthor=J.+R.+Gossetauthor=N.+J.+Attkinsauthor=T.+L.+Hayauthor=I.+K.+Gurrellauthor=Y.+R.+Loganauthor=P.+J.+Bungayauthor=B.+C.+Jonesauthor=I.+B.+Gardner&title=Application+of+PBPK+modelling+in+drug+discovery+and+development+at+Pfizer&doi=10.3109%2F00498254.2011.627477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Application of PBPK modelling in drug discovery and development at Pfizer</span></div><div class="casAuthors">Jones, Hannah M.; Dickins, Maurice; Youdim, Kuresh; Gosset, James R.; Attkins, Neil J.; Hay, Tanya L.; Gurrell, Ian K.; Logan, Y. Raj; Bungay, Peter J.; Jones, Barry C.; Gardner, Iain B.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-106</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Early prediction of human pharmacokinetics (PK) and drug-drug interactions (DDI) in drug discovery and development allows for more informed decision making.  Physiol. based pharmacokinetic (PBPK) modeling can be used to answer a no. of questions throughout the process of drug discovery and development and is thus becoming a very popular tool.  PBPK models provide the opportunity to integrate key input parameters from different sources to not only est. PK parameters and plasma concn.-time profiles, but also to gain mechanistic insight into compd. properties.  Using examples from the literature and our own company, we have shown how PBPK techniques can be utilized through the stages of drug discovery and development to increase efficiency, reduce the need for animal studies, replace clin. trials and to increase PK understanding.  Given the mechanistic nature of these models, the future use of PBPK modeling in drug discovery and development is promising, however, some limitations need to be addressed to realize its application and utility more broadly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW2ut1VBSKzrVg90H21EOLACvtfcHk0ljoKFog1OpfKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFKgtbnI&md5=6a487c3b384bf6e19b4cd45c4f0bd6ec</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.3109%2F00498254.2011.627477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498254.2011.627477%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DH.%2BM.%26aulast%3DDickins%26aufirst%3DM.%26aulast%3DYoudim%26aufirst%3DK.%26aulast%3DGosset%26aufirst%3DJ.%2BR.%26aulast%3DAttkins%26aufirst%3DN.%2BJ.%26aulast%3DHay%26aufirst%3DT.%2BL.%26aulast%3DGurrell%26aufirst%3DI.%2BK.%26aulast%3DLogan%26aufirst%3DY.%2BR.%26aulast%3DBungay%26aufirst%3DP.%2BJ.%26aulast%3DJones%26aufirst%3DB.%2BC.%26aulast%3DGardner%26aufirst%3DI.%2BB.%26atitle%3DApplication%2520of%2520PBPK%2520modelling%2520in%2520drug%2520discovery%2520and%2520development%2520at%2520Pfizer%26jtitle%3DXenobiotica%26date%3D2012%26volume%3D42%26spage%3D94%26epage%3D106%26doi%3D10.3109%2F00498254.2011.627477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45a','cit45b','cit45c','cit45d'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91a','cit91b'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131a','cit131b','cit131c'],'ref132':['cit132a','cit132b'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c01720/20210602/images/medium/jm0c01720_0003.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c01720/20210602/images/large/jm0c01720_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01720&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c01720/20210602/images/medium/jm0c01720_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c01720/20210602/images/large/jm0c01720_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Drug recycling mechanisms through reabsorption in the intestine and renal tubule: enterohepatic recirculation (EHR), enteroenteric recirculation (EER), and renal tubule reabsorption (RTR) and the effect of activated charcoal (AC). The color yellow means urine; green means bile; black arrows from intestine or renal tubule mean reabsorption. Intestine is colored brown. GFR only represents approximately 10% of renal blood flow.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c01720/20210602/images/large/jm0c01720_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01720&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c01720/20210602/images/medium/jm0c01720_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c01720/20210602/images/large/jm0c01720_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of selected drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-11/acs.jmedchem.0c01720/20210602/images/large/jm0c01720_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01720&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i41">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57723" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57723" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 141 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kotal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Veere, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinaasappel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elferink, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitek, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodanova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fevery, J.</span></span> <span> </span><span class="NLM_article-title">Intestinal excretion of unconjugated bilirubin in man and rats with inherited unconjugated hyperbilirubinemia</span>. <i>Pediatr. Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">200</span>, <span class="refDoi"> DOI: 10.1203/00006450-199708000-00011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1203%2F00006450-199708000-00011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=9262222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK2sXltlKlu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1997&pages=195-200&author=P.+Kotalauthor=C.+N.+Van+der+Veereauthor=M.+Sinaasappelauthor=R.+O.+Elferinkauthor=L.+Vitekauthor=M.+Brodanovaauthor=P.+L.+Jansenauthor=J.+Fevery&title=Intestinal+excretion+of+unconjugated+bilirubin+in+man+and+rats+with+inherited+unconjugated+hyperbilirubinemia&doi=10.1203%2F00006450-199708000-00011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal excretion of unconjugated bilirubin in man and rats with inherited unconjugated hyperbilirubinemia</span></div><div class="casAuthors">Kotal, Petr; Van Der Veere, Crista N.; Sinaasappel, Maarten; Oude Elferink, Ronald; Vitek, Libor; Brodanova, Marie; Jansen, Peter L. M.; Fevery, Johan</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-200</span>CODEN:
                <span class="NLM_cas:coden">PEREBL</span>;
        ISSN:<span class="NLM_cas:issn">0031-3998</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">Patients with Crigler-Najjar syndrome and Gunn rats cannot form bilirubin glucuronides owing to a lack of bilirubin UDP-glucuronosyltransferase activity.  Because increased serum and tissue bilirubin levels remain const., an alternative excretory route has to substitute for this deficiency.  Gunn rats excrete in bile only 2-13% of the bilirubins eliminated in Wistar rats.  In contrast, the biliary excretion rate of urobilinogen in Gunn and Wistar rats is comparable.  The sum of bilirubins and urobilinogen excreted in the bile of Gunn rats amts. to 10-30% of pigments excreted in Wistar rats.  Despite this low biliary excretion, the intestinal content and fecal excretion of bile pigments in Gunn and Wistar rats were similar.  These data support an extrabiliary entrance of unconjugated bilirubin into the intestine.  Addnl. proof for this was found in that the intestinal lumen of Gunn rats still contains a high amt. of bilirubins and urobilinogen after 3 d of external biliary drainage.  A similar procedure in Wistar rats resulted in the complete disappearance of bile pigments from the intestine.  The direct transmural transport of bilirubin from blood to all parts of the intestinal lumen was demonstrated by injecting 14C-bilirubin i.v. into Gunn rats with isolated parts of small and large intestine.  In Crigler-Najjar and Gilbert's syndrome patients, the biliary excretion of bile pigments has previously been shown to be strongly reduced.  Their stools, however, contained approx. the same amt. of bile pigments as in normal subjects.  Although only traces of unconjugated bilirubin were detected in the stool of normal persons (4% of total bile pigments), higher amts. were found in patients with Crigler-Najjar disease (20&).  These results suggest a direct intestinal permeation of unconjugated bilirubin in severe unconjugated hyperbilirubinemia both in man and rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomX8SfW--u1LVg90H21EOLACvtfcHk0ljA2xXu092n9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXltlKlu7s%253D&md5=0e31e47adc02b1eb5a8a65a081f02d4d</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1203%2F00006450-199708000-00011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1203%252F00006450-199708000-00011%26sid%3Dliteratum%253Aachs%26aulast%3DKotal%26aufirst%3DP.%26aulast%3DVan%2Bder%2BVeere%26aufirst%3DC.%2BN.%26aulast%3DSinaasappel%26aufirst%3DM.%26aulast%3DElferink%26aufirst%3DR.%2BO.%26aulast%3DVitek%26aufirst%3DL.%26aulast%3DBrodanova%26aufirst%3DM.%26aulast%3DJansen%26aufirst%3DP.%2BL.%26aulast%3DFevery%26aufirst%3DJ.%26atitle%3DIntestinal%2520excretion%2520of%2520unconjugated%2520bilirubin%2520in%2520man%2520and%2520rats%2520with%2520inherited%2520unconjugated%2520hyperbilirubinemia%26jtitle%3DPediatr.%2520Res.%26date%3D1997%26volume%3D42%26spage%3D195%26epage%3D200%26doi%3D10.1203%2F00006450-199708000-00011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
der Velde, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vrins, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Oever, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oude Elferink, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuipers, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groen, A. K.</span></span> <span> </span><span class="NLM_article-title">Direct intestinal cholesterol secretion contributes significantly to total fecal neutral sterol excretion in mice</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">967</span>– <span class="NLM_lpage">975</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2007.06.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1053%2Fj.gastro.2007.06.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=17854600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFars77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2007&pages=967-975&author=A.+E.+van%0Ader+Veldeauthor=C.+L.+Vrinsauthor=K.+van+den+Oeverauthor=C.+Kunneauthor=R.+P.+Oude+Elferinkauthor=F.+Kuipersauthor=A.+K.+Groen&title=Direct+intestinal+cholesterol+secretion+contributes+significantly+to+total+fecal+neutral+sterol+excretion+in+mice&doi=10.1053%2Fj.gastro.2007.06.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Direct intestinal cholesterol secretion contributes significantly to total fecal neutral sterol excretion in mice</span></div><div class="casAuthors">van der Velde, Astrid E.; Vrins, Carlos L. J.; van den Oever, Karin; Kunne, Cindy; Elferink, Ronald P. J. Oude; Kuipers, Folkert; Groen, Albert K.</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">967-975</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background & Aims: Hepatobiliary secretion is generally believed to be an integral step in the pathway of cholesterol excretion from the body.  Here we have investigated the validity of this paradigm in mice.  Methods: Cholesterol balance was assessed by measuring intake, excretion, and biliary output in different mouse models.  Direct secretion of cholesterol from the luminal side of enterocytes was studied by perfusion of isolated segments of the small intestine in mice.  Results: Cholesterol input and output measurements in different mouse models revealed that fecal neutral sterol excretion was higher than the sum of dietary cholesterol intake and biliary cholesterol secretion indicating the existence of an alternative pathway.  Here we show that substantial amts. of cholesterol can be secreted directly by enterocytes.  Transintestinal cholesterol secretion is a specific process obsd. throughout the small intestine (proximal > medial > distal).  Secretion depended on the presence of a cholesterol acceptor and was strongly stimulated by bile salts and phospholipids.  The capacity of the pathway was sufficient to account for the missing cholesterol in the balance studies.  The contribution of this pathway to cholesterol excretion in mice is approx. twice that of the biliary pathway.  Conclusions: In mice, the intestine plays a significant role in removal of cholesterol from the body.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra_m9HZXMLyrVg90H21EOLACvtfcHk0ljA2xXu092n9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFars77I&md5=b5b43c8a2c38ce477b9c16f6f13831bc</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2007.06.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2007.06.019%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BVelde%26aufirst%3DA.%2BE.%26aulast%3DVrins%26aufirst%3DC.%2BL.%26aulast%3Dvan%2Bden%2BOever%26aufirst%3DK.%26aulast%3DKunne%26aufirst%3DC.%26aulast%3DOude%2BElferink%26aufirst%3DR.%2BP.%26aulast%3DKuipers%26aufirst%3DF.%26aulast%3DGroen%26aufirst%3DA.%2BK.%26atitle%3DDirect%2520intestinal%2520cholesterol%2520secretion%2520contributes%2520significantly%2520to%2520total%2520fecal%2520neutral%2520sterol%2520excretion%2520in%2520mice%26jtitle%3DGastroenterology%26date%3D2007%26volume%3D133%26spage%3D967%26epage%3D975%26doi%3D10.1053%2Fj.gastro.2007.06.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagenaar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijnen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smit, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Asperen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinkel, A. H.</span></span> <span> </span><span class="NLM_article-title">Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">1038</span>– <span class="NLM_lpage">1044</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.1996.tb15775.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1111%2Fj.1476-5381.1996.tb15775.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=8922756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK28XmvVSmtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=1996&pages=1038-1044&author=U.+Mayerauthor=E.+Wagenaarauthor=J.+H.+Beijnenauthor=J.+W.+Smitauthor=D.+K.+Meijerauthor=J.+van+Asperenauthor=P.+Borstauthor=A.+H.+Schinkel&title=Substantial+excretion+of+digoxin+via+the+intestinal+mucosa+and+prevention+of+long-term+digoxin+accumulation+in+the+brain+by+the+mdr+1a+P-glycoprotein&doi=10.1111%2Fj.1476-5381.1996.tb15775.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr1a P-glycoprotein</span></div><div class="casAuthors">Mayer, Ulrich; Wagenaar, Els; Beijnen, Jos H.; Smit, Johan W.; Meijer, Dirk K. F.; Van Asperen, Judith; Borst, Piet; Schinkel, Alfred H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1038-1044</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">We have used mice with a disrupted mdr1a P-glycoprotein gene (mdr1a (-/-) mice) to study the role of P-glycoprotein in the pharmacokinetics of digoxin, a model P-glycoprotein substrate.  [3H]-digoxin at a dose of 0.2 mg kg-1 was administered as a single i.v. or oral bolus injection.  We focussed on intestinal mucosa and brain endothelial cells, two major pharmacol. barriers, as the mdr1a P-glycoprotein is the only P-glycoprotein normally present in these tissues.  Predominant fecal excretion of [3H]-digoxin in wild-type mice shifted towards predominantly urinary excretion in mdr1a (-/-) mice.  After interruption of the biliary excretion into the intestine, we found a substantial excretion of [3H]-digoxin via the gut mucosa in wild-type mice (16% of administered dose over 90 min).  This was only 2% in mdr1a (-/-) mice.  Biliary excretion of [3H]-digoxin was not dramatically decreased (24% in wild-type mice vs. 16% in mdr1a (-/-) mice).  After a single bolus injection, brain levels of [3H]-digoxin in wild-type mice remained very low, whereas in mdr1a (-/-) mice these levels continuously increased over a period of 3 days, resulting in a ∼200 fold higher concn. than in wild-type mice.  These data demonstrate in vivo contribution of intestinal P-glycoprotein to direct elimination of [3H]-digoxin from the systemic circulation and to the pattern of [3H]-digoxin disposition, and they underline the importance of P-glycoprotein for the blood-brain barrier.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAdILv56pwjrVg90H21EOLACvtfcHk0lhivtH_F9NiQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmvVSmtrs%253D&md5=6449111aedfb27ef34d6c00ffe4180d4</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1996.tb15775.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1996.tb15775.x%26sid%3Dliteratum%253Aachs%26aulast%3DMayer%26aufirst%3DU.%26aulast%3DWagenaar%26aufirst%3DE.%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3DSmit%26aufirst%3DJ.%2BW.%26aulast%3DMeijer%26aufirst%3DD.%2BK.%26aulast%3Dvan%2BAsperen%26aufirst%3DJ.%26aulast%3DBorst%26aufirst%3DP.%26aulast%3DSchinkel%26aufirst%3DA.%2BH.%26atitle%3DSubstantial%2520excretion%2520of%2520digoxin%2520via%2520the%2520intestinal%2520mucosa%2520and%2520prevention%2520of%2520long-term%2520digoxin%2520accumulation%2520in%2520the%2520brain%2520by%2520the%2520mdr%25201a%2520P-glycoprotein%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1996%26volume%3D119%26spage%3D1038%26epage%3D1044%26doi%3D10.1111%2Fj.1476-5381.1996.tb15775.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sparreboom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Asperen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinkel, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smit, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nooijen, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijnen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Tellingen, O.</span></span> <span> </span><span class="NLM_article-title">Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">2031</span>– <span class="NLM_lpage">2035</span>, <span class="refDoi"> DOI: 10.1073/pnas.94.5.2031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1073%2Fpnas.94.5.2031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=9050899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK2sXhslCjs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1997&pages=2031-2035&author=A.+Sparreboomauthor=J.+van+Asperenauthor=U.+Mayerauthor=A.+H.+Schinkelauthor=J.+W.+Smitauthor=D.+K.+Meijerauthor=P.+Borstauthor=W.+J.+Nooijenauthor=J.+H.+Beijnenauthor=O.+van+Tellingen&title=Limited+oral+bioavailability+and+active+epithelial+excretion+of+paclitaxel+%28Taxol%29+caused+by+P-glycoprotein+in+the+intestine&doi=10.1073%2Fpnas.94.5.2031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Limited oral bioavailability and active epithelial excretion of paclitaxel (taxol) caused by P-glycoprotein in the intestine</span></div><div class="casAuthors">Sparreboom, Alex; van Asperen, Judith; Mayer, Ulrich; Schinkel, Alfred H.; Smit, Johan W.; Meijer, Dirk K.; Borst, Piet; Nooijen, Willem J.; Beijnen, Jos H.; van Tellingen, Olaf</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2031-2035</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">In mice, the mdr1a and mdr1b genes encode drug-transporting proteins that can cause multidrug resistance in tumor cells by lowering intracellular drug levels. These P-glycoproteins are also found in various normal tissues such as the intestine.  Because mdr1b P-glycoprotein is not detectable in the intestine, mice with a homozygously disrupted mdr1a gene [mdr1a(-/-) mice] do not contain functional P-glycoprotein in this organ.  We have used these mdr1a(-/-) mice to study the effect of gut P-glycoprotein on the pharmacokinetics of paclitaxel.  The area under the plasma concn.-time curves was 2- and 6-fold higher in mdr1a(-/-) mice than in wild-type (wt) mice after i.v. and oral drug administration, resp.  Consequently, the oral bioavailability in mice receiving 10 mg paclitaxel per kg body wt. increased from only 11% in wt mice to 35% in mdr1a(-/-) mice.  The cumulative fecal excretion (0-96 h) was markedly reduced from 40% (after i.v. administration) and 87% (after oral administration) of the administered dose in wt mice to below 3% in mdr1a(-/-) mice.  Biliary excretion was not significantly different in wt and mdr1a(-/-) mice.  Interestingly, after i.v. drug administration of paclitaxel (10 mg/kg) to mice with a cannulated gall bladder, 11% of the dose was recovered within 90 min in the intestinal contents of wt mice vs. >3% in mdr1a(-/-) mice.  We conclude that P-glycoprotein limits the oral uptake of paclitaxel and mediates direct excretion of the drug from the systemic circulation into the intestinal lumen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEl7SLdJ6UDLVg90H21EOLACvtfcHk0lhivtH_F9NiQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhslCjs7o%253D&md5=ef6e923e94df1f148437261b6e5425e1</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1073%2Fpnas.94.5.2031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.94.5.2031%26sid%3Dliteratum%253Aachs%26aulast%3DSparreboom%26aufirst%3DA.%26aulast%3Dvan%2BAsperen%26aufirst%3DJ.%26aulast%3DMayer%26aufirst%3DU.%26aulast%3DSchinkel%26aufirst%3DA.%2BH.%26aulast%3DSmit%26aufirst%3DJ.%2BW.%26aulast%3DMeijer%26aufirst%3DD.%2BK.%26aulast%3DBorst%26aufirst%3DP.%26aulast%3DNooijen%26aufirst%3DW.%2BJ.%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3Dvan%2BTellingen%26aufirst%3DO.%26atitle%3DLimited%2520oral%2520bioavailability%2520and%2520active%2520epithelial%2520excretion%2520of%2520paclitaxel%2520%2528Taxol%2529%2520caused%2520by%2520P-glycoprotein%2520in%2520the%2520intestine%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1997%26volume%3D94%26spage%3D2031%26epage%3D2035%26doi%3D10.1073%2Fpnas.94.5.2031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gramatte, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oertel, R.</span></span> <span> </span><span class="NLM_article-title">Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1016/S0009-9236(99)70031-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1016%2FS0009-9236%2899%2970031-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10511059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK1MXmsFOjtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=1999&pages=239-245&author=T.+Gramatteauthor=R.+Oertel&title=Intestinal+secretion+of+intravenous+talinolol+is+inhibited+by+luminal+R-verapamil&doi=10.1016%2FS0009-9236%2899%2970031-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil</span></div><div class="casAuthors">Gramatte, Thomas; Oertel, Reinhard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">239-245</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">Objective: To examine the secretion of the β1-adrenergic receptor antagonist talinolol into the small intestine during its i.v. administration and to show the relevance of the P-glycoprotein-modulating drug verapamil for this secretory transport mechanism in humans.  Methods: In 6 healthy volunteers, the intestinal steady-state perfusion technique (triple lumen tubing system) was used for measuring the appearance of talinolol within the small intestine while the drug was infused i.v.  During 4 of the 7 perfusions performed, the perfusion fluid was changed from a verapamil-free soln. and talinolol appearance was measured while a R-verapamil-contg. soln. (565 μmol/L) was perfused.  Results: Talinolol was transported into the intestinal lumen up to a concn. gradient between lumen and blood of ∼5.5:1.  While perfusing the small intestine with a verapamil-free soln., the intestinal secretion rate of talinolol ranged from 1.94 to 6.62 μg/min per 30 cm length of the intestine (median values).  Perfusion of a R-verapamil-contg. perfusion fluid resulted in lower secretion rates (0.59-3.71 μg/30 cm·min), corresponding to 29%-56% of the values obtained without verapamil supplied intraluminally.  Conclusion: I.v. administered talinolol is actively secreted into the human small intestine.  This secretion is reduced by the intraluminal supply of the P-glycoprotein-modulating drug R-verapamil.  This gives further rationale for P-glycoprotein-mediated intestinal drug secretion as a cause for incomplete oral bioavailability and for drug interactions during intestinal absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRkb4gR5JfzLVg90H21EOLACvtfcHk0lhivtH_F9NiQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmsFOjtL8%253D&md5=cca1ec2832077e00ecce3380fc416c49</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0009-9236%2899%2970031-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0009-9236%252899%252970031-7%26sid%3Dliteratum%253Aachs%26aulast%3DGramatte%26aufirst%3DT.%26aulast%3DOertel%26aufirst%3DR.%26atitle%3DIntestinal%2520secretion%2520of%2520intravenous%2520talinolol%2520is%2520inhibited%2520by%2520luminal%2520R-verapamil%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D1999%26volume%3D66%26spage%3D239%26epage%3D245%26doi%3D10.1016%2FS0009-9236%2899%2970031-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dayton, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Israili, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, J. D.</span></span> <span> </span><span class="NLM_article-title">Elimination of drugs by passive diffusion from blood to intestinal lumen: factors influencing nonbiliary excretion by the intestinal tract</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1193</span>– <span class="NLM_lpage">1206</span>, <span class="refDoi"> DOI: 10.3109/03602538308991427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.3109%2F03602538308991427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=6373210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaL2cXlsVehtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1983&pages=1193-1206&author=P.+G.+Daytonauthor=Z.+H.+Israiliauthor=J.+D.+Henderson&title=Elimination+of+drugs+by+passive+diffusion+from+blood+to+intestinal+lumen%3A+factors+influencing+nonbiliary+excretion+by+the+intestinal+tract&doi=10.3109%2F03602538308991427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Elimination of drugs by passive diffusion from blood to intestinal lumen:  factors influencing nonbiliary excretion by the intestinal tract</span></div><div class="casAuthors">Dayton, Peter G.; Israili, Zafar H.; Henderson, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1193-206</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    </div><div class="casAbstract">A review with 80 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopNm7j4ETnZLVg90H21EOLACvtfcHk0ljSYQhZQT4UWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXlsVehtL4%253D&md5=f0aef1e2e8700d2d736793a039d5e9a0</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3109%2F03602538308991427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03602538308991427%26sid%3Dliteratum%253Aachs%26aulast%3DDayton%26aufirst%3DP.%2BG.%26aulast%3DIsraili%26aufirst%3DZ.%2BH.%26aulast%3DHenderson%26aufirst%3DJ.%2BD.%26atitle%3DElimination%2520of%2520drugs%2520by%2520passive%2520diffusion%2520from%2520blood%2520to%2520intestinal%2520lumen%253A%2520factors%2520influencing%2520nonbiliary%2520excretion%2520by%2520the%2520intestinal%2520tract%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D1983%26volume%3D14%26spage%3D1193%26epage%3D1206%26doi%3D10.3109%2F03602538308991427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Israili, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayton, P. G.</span></span> <span> </span><span class="NLM_article-title">Enhancement of xenobiotic elimination: role of intestinal excretion</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1123</span>– <span class="NLM_lpage">1159</span>, <span class="refDoi"> DOI: 10.3109/03602538409033559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.3109%2F03602538409033559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=6396054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaL2MXntlGruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1984&pages=1123-1159&author=Z.+H.+Israiliauthor=P.+G.+Dayton&title=Enhancement+of+xenobiotic+elimination%3A+role+of+intestinal+excretion&doi=10.3109%2F03602538409033559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancement of xenobiotic elimination:  role of intestinal excretion</span></div><div class="casAuthors">Israili, Z. H.; Dayton, P. G.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">1123-59</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    </div><div class="casAbstract">A review with 190 refs. on the exploitation of intestinal excretion as a means of detoxication of xenobiotics in man, including the use of nonabsorbable substances to enhance the excretion process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVhgZWG_yF-rVg90H21EOLACvtfcHk0ljSYQhZQT4UWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXntlGruw%253D%253D&md5=e7906021d447c7e84f6896c32d7470fe</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.3109%2F03602538409033559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03602538409033559%26sid%3Dliteratum%253Aachs%26aulast%3DIsraili%26aufirst%3DZ.%2BH.%26aulast%3DDayton%26aufirst%3DP.%2BG.%26atitle%3DEnhancement%2520of%2520xenobiotic%2520elimination%253A%2520role%2520of%2520intestinal%2520excretion%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D1984%26volume%3D15%26spage%3D1123%26epage%3D1159%26doi%3D10.3109%2F03602538409033559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arimori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, M.</span></span> <span> </span><span class="NLM_article-title">Drug exsorption from blood into the gastrointestinal tract</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">376</span>, <span class="refDoi"> DOI: 10.1023/A:1011959828103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1023%2FA%3A1011959828103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=9563065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK1cXisVGruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1998&pages=371-376&author=K.+Arimoriauthor=M.+Nakano&title=Drug+exsorption+from+blood+into+the+gastrointestinal+tract&doi=10.1023%2FA%3A1011959828103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Drug exsorption from blood into the gastrointestinal tract</span></div><div class="casAuthors">Arimori, Kazuhiko; Nakano, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">371-376</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Plenum Publishing Corp.</span>)
        </div><div class="casAbstract">Drugs are exsorbed from the blood across the gastrointestinal membranes by passive or active processes.  In the case of a passive transport mechanism, the exsorption of drugs depends on the concn. gradients between the serosal and mucosal sides.  The extent of secretion (exsorption) is detd. by numerous factors such as extent of binding to serum proteins, distribution vol., lipophilicity, pKa and mol. size of drugs, and the blood flow rate in the gut.  Specific transport systems such as P-glycoprotein (P-gp), org. cation and org. anion transporters are involved in active intestinal secretion of drugs.  Intestinal secretory transport systems reduce the extent of drug absorption sometimes resulting in low oral bioavailability.  It is, therefore, important to know whether poor drug absorption is due to the involvement of specialized secretory transport systems.  Modulation of intestinal secretory transport can be a means to enhance absorption of drugs with low oral bioavailability if exsorption of drugs is based on active secretion pathways that are open for control from the outside.  A review with 50 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU_woIJZ_s3LVg90H21EOLACvtfcHk0ljSYQhZQT4UWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXisVGruro%253D&md5=7c6fe96dd777ead00f3567e15ea6c29d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1023%2FA%3A1011959828103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1011959828103%26sid%3Dliteratum%253Aachs%26aulast%3DArimori%26aufirst%3DK.%26aulast%3DNakano%26aufirst%3DM.%26atitle%3DDrug%2520exsorption%2520from%2520blood%2520into%2520the%2520gastrointestinal%2520tract%26jtitle%3DPharm.%2520Res.%26date%3D1998%26volume%3D15%26spage%3D371%26epage%3D376%26doi%3D10.1023%2FA%3A1011959828103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abruzzo, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krogmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rishi, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D. D.</span></span> <span> </span><span class="NLM_article-title">A multidrug resistance transporter from human MCF-7 breast cancer cells</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">15665</span>– <span class="NLM_lpage">15670</span>, <span class="refDoi"> DOI: 10.1073/pnas.95.26.15665</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1073%2Fpnas.95.26.15665" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=9861027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK1MXhvFeitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=15665-15670&author=L.+A.+Doyleauthor=W.+Yangauthor=L.+V.+Abruzzoauthor=T.+Krogmannauthor=Y.+Gaoauthor=A.+K.+Rishiauthor=D.+D.+Ross&title=A+multidrug+resistance+transporter+from+human+MCF-7+breast+cancer+cells&doi=10.1073%2Fpnas.95.26.15665"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">A multidrug resistance transporter from human MCF-7 breast cancer cells</span></div><div class="casAuthors">Doyle, L. Austin; Yang, Weidong; Abruzzo, Lynne V.; Krogmann, Tammy; Gao, Yongming; Rishi, Arun K.; Ross, Douglas D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">15665-15670</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">MCF-7/AdrVp is a multidrug-resistant human breast cancer subline that displays an ATP-dependent redn. in the intracellular accumulation of anthracycline anticancer drugs in the absence of overexpression of known multidrug resistance transporters such as P glycoprotein or the multidrug resistance protein.  RNA fingerprinting led to the identification of a 2.4-kb mRNA that is overexpressed in MCF-7/AdrVp cells relative to parental MCF-7 cells.  The mRNA encodes a 663-aa member of the ATP-binding cassette superfamily of transporters that we term breast cancer resistance protein (BCRP).  Enforced expression of the full-length BCRP cDNA in MCF-7 breast cancer cells confers resistance to mitoxantrone, doxorubicin, and daunorubicin, reduces daunorubicin accumulation and retention, and causes an ATP-dependent enhancement of the efflux of rhodamine 123 in the cloned transfected cells.  BCRP is a xenobiotic transporter that appears to play a major role in the multidrug resistance phenotype of MCF-7/AdrVp human breast cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowbckt6jTJYLVg90H21EOLACvtfcHk0ljSYQhZQT4UWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhvFeitQ%253D%253D&md5=ef3e4ddd772833b363ba458401e3331a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.26.15665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.26.15665%26sid%3Dliteratum%253Aachs%26aulast%3DDoyle%26aufirst%3DL.%2BA.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DAbruzzo%26aufirst%3DL.%2BV.%26aulast%3DKrogmann%26aufirst%3DT.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DRishi%26aufirst%3DA.%2BK.%26aulast%3DRoss%26aufirst%3DD.%2BD.%26atitle%3DA%2520multidrug%2520resistance%2520transporter%2520from%2520human%2520MCF-7%2520breast%2520cancer%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26spage%3D15665%26epage%3D15670%26doi%3D10.1073%2Fpnas.95.26.15665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, M.</span></span> <span> </span><span class="NLM_article-title">Clinical relevance of P-glycoprotein in drug therapy</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">417</span>– <span class="NLM_lpage">454</span>, <span class="refDoi"> DOI: 10.1081/DMR-120026871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1081%2FDMR-120026871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=14705869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1ygsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2003&pages=417-454&author=J.+H.+Linauthor=M.+Yamazaki&title=Clinical+relevance+of+P-glycoprotein+in+drug+therapy&doi=10.1081%2FDMR-120026871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Relevance of P-Glycoprotein in Drug Therapy</span></div><div class="casAuthors">Lin, Jiunn H.; Yamazaki, Masayo</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">417-454</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Marcel Dekker, Inc.</span>)
        </div><div class="casAbstract">A review.  The drug efflux transporter P-glycoprotein (P-gp) is known to confer multidrug resistance in cancer chemotherapy.  The P-gp is highly expressed in many types of tumor cells, as well as many normal tissues, including the apical surface of intestinal epithelial cells, and the luminal surface of capillary endothelial cells in the brain.  Because of its expression and localization, it has been suggested that P-gp plays an important role in cancer chemotherapy, intestinal absorption, and brain uptake.  This review addresses the significance of the role of P-gp in cancer chemotherapy, drug absorption, and brain uptake.  Based on the clin. and animal studies with P-gp modulators, it has become apparent that the role of P-gp in multidrug resistance is far less important compared to other biol. factors.  Although P-gp is highly expressed in both intestinal epithelial cells and endothelial cells of brain capillaries and functions as an efflux transporter in both organs, the magnitude of P-gp's impact on intestinal absorption and brain uptake of drugs is quant. very different.  From animal and clin. studies, it is evident that P-gp plays a very important role in CNS penetration of drugs, whereas the effect of P-gp on drug absorption is not as important as generally believed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyF-MM7RjqZLVg90H21EOLACvtfcHk0li18bFDyeoWcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1ygsLw%253D&md5=22c8b47bccd0f577ca0f8589d442402f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1081%2FDMR-120026871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1081%252FDMR-120026871%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DJ.%2BH.%26aulast%3DYamazaki%26aufirst%3DM.%26atitle%3DClinical%2520relevance%2520of%2520P-glycoprotein%2520in%2520drug%2520therapy%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2003%26volume%3D35%26spage%3D417%26epage%3D454%26doi%3D10.1081%2FDMR-120026871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forsell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tevell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persson, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedeland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondesson, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lennernas, H.</span></span> <span> </span><span class="NLM_article-title">Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">214</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2006.04.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1016%2Fj.ejps.2006.04.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=16806856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFentrzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2006&pages=205-214&author=E.+Bergmanauthor=P.+Forsellauthor=A.+Tevellauthor=E.+M.+Perssonauthor=M.+Hedelandauthor=U.+Bondessonauthor=L.+Knutsonauthor=H.+Lennernas&title=Biliary+secretion+of+rosuvastatin+and+bile+acids+in+humans+during+the+absorption+phase&doi=10.1016%2Fj.ejps.2006.04.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase</span></div><div class="casAuthors">Bergman, Ebba; Forsell, Patrik; Tevell, Annica; Persson, Eva M.; Hedeland, Mikael; Bondesson, Ulf; Knutson, Lars; Lennernaes, Hans</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">205-214</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Aim: The aim of this study was to investigate the biliary secretion of rosuvastatin in healthy volunteers using an intestinal perfusion method after administration of 10 mg rosuvastatin dispersion in the intestine.  Methods: The Loc-I-Gut tube was positioned in the distal duodenum/proximal jejunum and a semi-open segment was created by inflating the proximal balloon in ten volunteers.  A dispersion of 10 mg rosuvastatin was administered below the inflated balloon and bile was collected proximally of the inflated balloon.  Bile and plasma samples were withdrawn every 20 min during a 4 h period (absorption phase) and addnl. plasma samples were collected 24 and 48 h post-dose.  Results: The study showed that there is a substantial and immediate transport of rosuvastatin into the human bile, with the max. concn. appearing 42 min after dosing, 39,000±31,000 ng/mL.  Approx. 11% of the administered intestinal dose was recovered in the bile after 240 min.  At all time points the biliary concn. exceeded the plasma concn., and the av. bile to plasma ratio was 5200±9200 (range 89-33,900, median 2000).  We were unable to identify any bile-specific metabolites of rosuvastatin in the present study.  Conclusion: Rosuvastatin is excreted via the biliary route in humans, and the transport and accumulation of rosuvastatin in bile compared to that in plasma is rapid and extensive.  This intestinal perfusion technique offers a successful way to est. the biliary secretion for drugs, metabolites and endogenous substances during the absorption phase in healthy volunteers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob6CzYdWMFwLVg90H21EOLACvtfcHk0li18bFDyeoWcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFentrzI&md5=74e5da460a1d7df951bd28277b7b2fe5</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2006.04.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2006.04.015%26sid%3Dliteratum%253Aachs%26aulast%3DBergman%26aufirst%3DE.%26aulast%3DForsell%26aufirst%3DP.%26aulast%3DTevell%26aufirst%3DA.%26aulast%3DPersson%26aufirst%3DE.%2BM.%26aulast%3DHedeland%26aufirst%3DM.%26aulast%3DBondesson%26aufirst%3DU.%26aulast%3DKnutson%26aufirst%3DL.%26aulast%3DLennernas%26aufirst%3DH.%26atitle%3DBiliary%2520secretion%2520of%2520rosuvastatin%2520and%2520bile%2520acids%2520in%2520humans%2520during%2520the%2520absorption%2520phase%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2006%26volume%3D29%26spage%3D205%26epage%3D214%26doi%3D10.1016%2Fj.ejps.2006.04.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lennernas, H.</span></span> <span> </span><span class="NLM_article-title">Intestinal permeability and its relevance for absorption and elimination</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1015</span>– <span class="NLM_lpage">1051</span>, <span class="refDoi"> DOI: 10.1080/00498250701704819</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1080%2F00498250701704819" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=17968735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A280%3ADC%252BD2snksVSntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2007&pages=1015-1051&author=H.+Lennernas&title=Intestinal+permeability+and+its+relevance+for+absorption+and+elimination&doi=10.1080%2F00498250701704819"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal permeability and its relevance for absorption and elimination</span></div><div class="casAuthors">Lennernas H</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica; the fate of foreign compounds in biological systems</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">10-11</span>),
    <span class="NLM_cas:pages">1015-51</span>
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    </div><div class="casAbstract">Human jejunal permeability (P(eff)) is determined in the intestinal region with the highest expression of carrier proteins and largest surface area.  Intestinal P(eff) are often based on multiple parallel transport processes.  Site-specific jejunal P(eff) cannot reflect the permeability along the intestinal tract, but they are useful for approximating the fraction oral dose absorbed.  It seems like drugs with a jejunal P(eff) > 1.5 x 10(-4) cm s(-1) will be completely absorbed no matter which transport mechanism(s) are utilized.  Many drugs that are significantly effluxed in vitro have a rapid and complete intestinal absorption (i.e. >85%) mediated by passive transcellular diffusion.  The determined jejunal P(eff) for drugs transported mainly by absorptive carriers (such as peptide and amino acid transporters) will accurately predict the fraction of the dose absorbed as a consequence of the regional expression.  The data also show that: (1) the human intestinal epithelium has a large resistance towards large and hydrophilic compounds; and (2) the paracellular route has a low contribution for compounds larger than approximately molecular weight 200.  There is a need for more exploratory in vivo studies to clarify drug absorption and first-pass extraction along the intestine.  One is encouraged to develop in vivo perfusion techniques for more distal parts of the gastrointestinal tract in humans.  This would stimulate the development of more relevant and complex in vitro absorption models and form the basis for an accurate physiologically based pharmacokinetic modelling of oral drug absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmVh_0AWtT6Oqrn-c4Of3KfW6udTcc2eYUgAiVe8sCQ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2snksVSntg%253D%253D&md5=27b3346470288543293996b323269642</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1080%2F00498250701704819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00498250701704819%26sid%3Dliteratum%253Aachs%26aulast%3DLennernas%26aufirst%3DH.%26atitle%3DIntestinal%2520permeability%2520and%2520its%2520relevance%2520for%2520absorption%2520and%2520elimination%26jtitle%3DXenobiotica%26date%3D2007%26volume%3D37%26spage%3D1015%26epage%3D1051%26doi%3D10.1080%2F00498250701704819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goosen, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, W. G.</span></span> <span> </span><span class="NLM_article-title">Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">906</span>– <span class="NLM_lpage">915</span>, <span class="refDoi"> DOI: 10.1124/dmd.112.050575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.112.050575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=23386703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3sXkslSktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=906-915&author=D.+Zhangauthor=C.+E.+Frostauthor=K.+Heauthor=A.+D.+Rodriguesauthor=X.+Wangauthor=L.+Wangauthor=T.+C.+Goosenauthor=W.+G.+Humphreys&title=Investigating+the+enteroenteric+recirculation+of+apixaban%2C+a+factor+Xa+inhibitor%3A+administration+of+activated+charcoal+to+bile+duct-cannulated+rats+and+dogs+receiving+an+intravenous+dose+and+use+of+drug+transporter+knockout+rats&doi=10.1124%2Fdmd.112.050575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats</span></div><div class="casAuthors">Zhang, Donglu; Frost, Charles E.; He, Kan; Rodrigues, A. David; Wang, Xiaoli; Wang, Lifei; Goosen, Theunis C.; Humphreys, W. Griffith</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">906-915</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The study described here investigated the impact of intestinal excretion (IE; excretion of drug directly from circulation to intestinal lumen), enteroenteric recirculation (EER), and renal tubule recirculation (RTR) on apixaban pharmacokinetics and disposition.  The exptl. approaches involve integrating apixaban elimination pathways with pharmacokinetic profiles obtained from bile duct-cannulated (BDC) rats and dogs receiving i.v. doses together with oral administration of activated charcoal (AC).  Addnl., the role of P-gp (P-glycoprotein; abcb1) and BCRP (breast cancer resistance protein; abcg2) in apixaban disposition was evaluated in expts. using transporter inhibitors and transporter knockout (KO) rats.  Approx. 20-50% of an apixaban i.v. dose was found in feces of BDC rats and dogs, suggesting IE leading to fecal elimination and intestinal clearance (IC).  The fecal elimination, IC, and systemic clearance of apixaban were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with GF-120918, a dual BCRP and P-gp inhibitor).  BCRP appeared to play a more important role for absorption and intestinal and renal elimination of apixaban than P-gp in transporter-KO rats after oral and i.v. dosing, which led to a higher level of active renal excretion in rat than other species.  These data demonstrate that apixaban undergoes IE, EER, and RTR that are facilitated by efflux transporters.  Intestinal reabsorption of apixaban could be interrupted by AC even at 3 h post-drug dose in dogs (late charcoal effect).  This study demonstrates that the intestine is an organ for direct clearance and redistribution of apixaban.  The IE, EER, and RTR contribute to overall pharmacokinetic profiles of apixaban.  IE as a clearance pathway, balanced with metab. and renal excretion, helps decrease the impacts of intrinsic (renal or hepatic impairment) and extrinsic (drug-drug interactions) factors on apixaban disposition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV6UUBOTf7mLVg90H21EOLACvtfcHk0lgEywviUyavjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXkslSktLg%253D&md5=23612e18f5faa52a1ae05abb87d0fbeb</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.050575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.050575%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DFrost%26aufirst%3DC.%2BE.%26aulast%3DHe%26aufirst%3DK.%26aulast%3DRodrigues%26aufirst%3DA.%2BD.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DGoosen%26aufirst%3DT.%2BC.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26atitle%3DInvestigating%2520the%2520enteroenteric%2520recirculation%2520of%2520apixaban%252C%2520a%2520factor%2520Xa%2520inhibitor%253A%2520administration%2520of%2520activated%2520charcoal%2520to%2520bile%2520duct-cannulated%2520rats%2520and%2520dogs%2520receiving%2520an%2520intravenous%2520dose%2520and%2520use%2520of%2520drug%2520transporter%2520knockout%2520rats%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2013%26volume%3D41%26spage%3D906%26epage%3D915%26doi%3D10.1124%2Fdmd.112.050575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burczynski, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, M.</span></span> <span> </span><span class="NLM_article-title">Enterohepatic circulation: physiological, pharmacokinetic and clinical implications</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">751</span>– <span class="NLM_lpage">790</span>, <span class="refDoi"> DOI: 10.2165/00003088-200241100-00005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.2165%2F00003088-200241100-00005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=12162761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD38XntFyru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2002&pages=751-790&author=M.+S.+Robertsauthor=B.+M.+Magnussonauthor=F.+J.+Burczynskiauthor=M.+Weiss&title=Enterohepatic+circulation%3A+physiological%2C+pharmacokinetic+and+clinical+implications&doi=10.2165%2F00003088-200241100-00005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Enterohepatic circulation: physiological, pharmacokinetic and clinical implications</span></div><div class="casAuthors">Roberts, Michael S.; Magnusson, Beatrice M.; Burczynski, Frank J.; Weiss, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">751-790</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Enterohepatic recycling occurs by biliary excretion and intestinal reabsorption of a solute, sometimes with hepatic conjugation and intestinal deconjugation.  Cycling is often assocd. with multiple peaks and a longer apparent half-life in a plasma concn.-time profile.  Factors affecting biliary excretion include drug characteristics (chem. structure, polarity and mol. size), transport across sinusoidal plasma membrane and canniculae membranes, biotransformation and possible reabsorption from intrahepatic bile ductules.  Intestinal reabsorption to complete the enterohepatic cycle may depend on hydrolysis of a drug conjugate by gut bacteria.  Bioavailability is also affected by the extent of intestinal absorption, gut-wall P-glycoprotein efflux and gut-wall metab.  Recently, there has been a considerable increase in our understanding of the role of transporters, of gene expression of intestinal and hepatic enzymes, and of hepatic zonation.  Drugs, disease and genetics may result in induced or inhibited activity of transporters and metabolizing enzymes.  Reduced expression of one transporter, for example hepatic canalicular multidrug resistance-assocd. protein (MRP) 2, is often assocd. with enhanced expression of others, for example the usually quiescent basolateral efflux MRP3, to limit hepatic toxicity.  In addn., physiol. relevant pharmacokinetic models, which describe enterohepatic recirculation in terms of its determinants (such as sporadic gall bladder emptying), have been developed.  In general, enterohepatic recirculation may prolong the pharmacol. effect of certain drugs and drug metabolites.  Of particular importance is the potential amplifying effect of enterohepatic variability in defining differences in the bioavailability, apparent vol. of distribution and clearance of a given compd.  Genetic abnormalities, disease states, orally administered adsorbents and certain co-administered drugs all affect enterohepatic recycling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDmTzuEhf7QLVg90H21EOLACvtfcHk0lgEywviUyavjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntFyru78%253D&md5=514a6ffb4ee275ccd2a7082fe2fe3d87</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2165%2F00003088-200241100-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-200241100-00005%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DM.%2BS.%26aulast%3DMagnusson%26aufirst%3DB.%2BM.%26aulast%3DBurczynski%26aufirst%3DF.%2BJ.%26aulast%3DWeiss%26aufirst%3DM.%26atitle%3DEnterohepatic%2520circulation%253A%2520physiological%252C%2520pharmacokinetic%2520and%2520clinical%2520implications%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2002%26volume%3D41%26spage%3D751%26epage%3D790%26doi%3D10.2165%2F00003088-200241100-00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maliepaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffer, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faneyte, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gastelen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pijnenborg, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinkel, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van De
Vijver, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheper, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H.</span></span> <span> </span><span class="NLM_article-title">Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues</span>. <i>Cancer. Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3458</span>– <span class="NLM_lpage">3464</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=11309308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjtFSju7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=3458-3464&author=M.+Maliepaardauthor=G.+L.+Schefferauthor=I.+F.+Faneyteauthor=M.+A.+van+Gastelenauthor=A.+C.+Pijnenborgauthor=A.+H.+Schinkelauthor=M.+J.+van+De%0AVijverauthor=R.+J.+Scheperauthor=J.+H.+Schellens&title=Subcellular+localization+and+distribution+of+the+breast+cancer+resistance+protein+transporter+in+normal+human+tissues"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues</span></div><div class="casAuthors">Maliepaard, Marc; Scheffer, George L.; Faneyte, Ian F.; Van Gastelen, Margot A.; Pijnenborg, Adriana C. L. M.; Schinkel, Alfred H.; Van de Vijver, Marc J.; Scheper, Rik J.; Schellens, Jan H. M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3458-3464</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">High expression of the Breast Cancer Resistance Protein (BCRP) gene has been shown to be involved in resistance to chemotherapeutic drugs.  Knowledge of the localization of BCRP protein in normal tissues may help unravel the normal function of this protein.  Therefore, we characterized the tissue distribution and cellular localization of BCRP in frozen sections of normal human tissues.  For this purpose, we used the recently described monoclonal antibody BXP-34 and another independently developed monoclonal antibody directed against BCRP, BXP-21.  Both monoclonal antibodies show specific BCRP plasma membrane staining on cytospins obtained from topotecan- or mitoxantrone-selected cell lines, as well as from BCRP-transfected cell lines.  Immunopptn. expts. using either BXP-21 or BXP-34 yielded a clear Mr 72,000 BCRP band from BCRP-overexpressing tumor cells.  In the topotecan-selected T8 and mitoxantrone-selected MX3 tumor cell lines, BCRP turned out to be differentially glycosylated.  In contrast to BXP-34, BXP-21 is able to detect the Mr 72,000 BCRP protein on immunoblots and is reactive with BCRP in formalin-fixed, paraffin-embedded tissues.  Using BXP-21 and BXP-34, prominent staining of BCRP was obsd. in placental syncytiotrophoblasts, in the epithelium of the small intestine and colon, in the liver canalicular membrane, and in ducts and lobules of the breast.  Furthermore, BCRP was present in veinous and capillary endothelium, but not in arterial endothelium in all of the tissues investigated.  In the tissues studied, the mRNA levels of BCRP were assessed using reverse transcription-PCR, and these corresponded with the levels of BCRP protein estd. from immunohistochem. staining.  The presence of BCRP at the placental syncytiotrophoblasts is consistent with the hypothesis of a protective role of BCRP for the fetus.  The apical localization in the epithelium of the small intestine and colon indicates a possible role of BCRP in the regulation of the uptake of p.o. administered BCRP substrates by back-transport of substrate drugs entering from the gut lumen.  Therefore, it may be useful to attempt to modulate the uptake of p.o. delivered BCRP substrates, e.g., topotecan or irinotecan, by using a BCRP inhibitor.  Clin. trials testing this hypothesis have been initiated in our institute.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZsMtlFEL7dbVg90H21EOLACvtfcHk0lhvkRjl2lk9Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjtFSju7o%253D&md5=91aaea85737ec13ca50a670abdc665d9</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMaliepaard%26aufirst%3DM.%26aulast%3DScheffer%26aufirst%3DG.%2BL.%26aulast%3DFaneyte%26aufirst%3DI.%2BF.%26aulast%3Dvan%2BGastelen%26aufirst%3DM.%2BA.%26aulast%3DPijnenborg%26aufirst%3DA.%2BC.%26aulast%3DSchinkel%26aufirst%3DA.%2BH.%26aulast%3Dvan%2BDe%2BVijver%26aufirst%3DM.%2BJ.%26aulast%3DScheper%26aufirst%3DR.%2BJ.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26atitle%3DSubcellular%2520localization%2520and%2520distribution%2520of%2520the%2520breast%2520cancer%2520resistance%2520protein%2520transporter%2520in%2520normal%2520human%2520tissues%26jtitle%3DCancer.%2520Res.%26date%3D2001%26volume%3D61%26spage%3D3458%26epage%3D3464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Austin
Doyle, L</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D. D</span></span> <span> </span><span class="NLM_article-title">Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">7340</span>– <span class="NLM_lpage">7358</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1206938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1038%2Fsj.onc.1206938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=14576842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotlajur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=7340-7358&author=L+Austin%0ADoyleauthor=D.+D+Ross&title=Multidrug+resistance+mediated+by+the+breast+cancer+resistance+protein+BCRP+%28ABCG2%29&doi=10.1038%2Fsj.onc.1206938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)</span></div><div class="casAuthors">Austin Doyle, L.; Ross, Douglas D.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">7340-7358</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Observations of functional ATP-dependent drug efflux in certain multidrug-resistant cancer cell lines without overexpression of P-glycoprotein or multidrug resistance protein (MRP) family members suggested the existence of another ATP-binding cassette (ABC) transporter capable of causing cancer drug resistance.  In one such cell line (MCF-7/AdrVp), the overexpression of a novel member of the G subfamily of ABC transporters was found.  The new transporter was termed the breast cancer resistance protein (BCRP), because of its identification in MCF-7 human breast carcinoma cells.  BCRP is a 655 amino-acid polypeptide, formally designated as ABCG2.  Like all members of the ABC G (white) subfamily, BCRP is a half transporter.  Transfection and enforced overexpression of BCRP in drug-sensitive MCF-7 or MDA-MB-231 cells recapitulates the drug-resistance phenotype of MCF-7/AdrVp cells, consistent with current evidence suggesting that functional BCRP is a homodimer.  BCRP maps to chromosome 4q22, downstream from a TATA-less promoter.  The spectrum of anticancer drugs effluxed by BCRP includes mitoxantrone, camptothecin-derived and indolocarbazole topoisomerase I inhibitors, methotrexate, flavopiridol, and quinazoline ErbB1 inhibitors.  Transport of anthracyclines is variable and appears to depend on the presence of a BCRP mutation at codon 482.  Potent and specific inhibitors of BCRP are now being developed, opening the door to clin. applications of BCRP inhibition.  Owing to tissue localization in the placenta, bile canaliculi, colon, small bowel, and brain microvessel endothelium, BCRP may play a role in protecting the organism from potentially harmful xenobiotics.  BCRP expression has also been demonstrated in pluripotential side population' stem cells, responsible for the characteristic ability of these cells to exclude Hoechst 33342 dye, and possibly for the maintenance of the stem cell phenotype.  Studies are emerging on the role of BCRP expression in drug resistance in clin. cancers.  More prospective studies are needed, preferably combining BCRP protein or mRNA quantification with functional assays, in order to det. the contribution of BCRP to drug resistance in human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYJbHmQOSZILVg90H21EOLACvtfcHk0lhvY2VTWV0TiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotlajur0%253D&md5=fa0c4ae3b5e15c73efd4cba939b847ae</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1206938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1206938%26sid%3Dliteratum%253Aachs%26aulast%3DAustin%2BDoyle%26aufirst%3DL%26aulast%3DRoss%26aufirst%3DD.%2BD%26atitle%3DMultidrug%2520resistance%2520mediated%2520by%2520the%2520breast%2520cancer%2520resistance%2520protein%2520BCRP%2520%2528ABCG2%2529%26jtitle%3DOncogene%26date%3D2003%26volume%3D22%26spage%3D7340%26epage%3D7358%26doi%3D10.1038%2Fsj.onc.1206938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Unadkat, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vijay, S.</span></span> <span> </span><span class="NLM_article-title">Placental drug transporters</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.2174/1389200043489171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.2174%2F1389200043489171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=14965255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvVCisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=125-131&author=J.+D.+Unadkatauthor=A.+Dahlinauthor=S.+Vijay&title=Placental+drug+transporters&doi=10.2174%2F1389200043489171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Placental drug transporters</span></div><div class="casAuthors">Unadkat, Jashvant D.; Dahlin, Amber; Vijay, Shashi</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">125-131</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Any treatment of a pregnant woman with medication (drugs) de facto results in the treatment of her unborn child, even when her unborn child is not the target of drug therapy.  This is because, in most instances, the placenta is not a complete barrier to the passage of drugs from the maternal to the fetal compartment.  This barrier is in part due to the presence of various efflux transporters in the placenta.  The placenta is also richly endowed with influx transporters.  In this article, we will review the physiol. characteristics of the placenta and how it functions as a barrier to passage of drugs into the fetal compartment.  In addn., we will review placental transporters that are important in modulating the exposure of the fetus to drugs and, therefore, the efficacy and toxicity of such drugs towards the fetus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQYs8ns1yx17Vg90H21EOLACvtfcHk0lh8XpnCFXjbNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvVCisb4%253D&md5=0de1ea445c06e9ef21e122b6a9e57619</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.2174%2F1389200043489171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200043489171%26sid%3Dliteratum%253Aachs%26aulast%3DUnadkat%26aufirst%3DJ.%2BD.%26aulast%3DDahlin%26aufirst%3DA.%26aulast%3DVijay%26aufirst%3DS.%26atitle%3DPlacental%2520drug%2520transporters%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2004%26volume%3D5%26spage%3D125%26epage%3D131%26doi%3D10.2174%2F1389200043489171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unadkat, J. D.</span></span> <span> </span><span class="NLM_article-title">Role of the breast cancer resistance protein (ABCG2) in drug transport</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">E118</span>– <span class="NLM_lpage">133</span>, <span class="refDoi"> DOI: 10.1208/aapsj070112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1208%2Faapsj070112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=16146333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltlOqtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=E118-133&author=Q.+Maoauthor=J.+D.+Unadkat&title=Role+of+the+breast+cancer+resistance+protein+%28ABCG2%29+in+drug+transport&doi=10.1208%2Faapsj070112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the breast cancer resistance protein (ABCG2) in drug transport</span></div><div class="casAuthors">Mao, Qingcheng; Unadkat, Jashvant D.</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">E118-E133</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">American Association of Pharmaceutical Scientists</span>)
        </div><div class="casAbstract">A review.  The 72-kDa breast cancer resistance protein (BCRP) is the second member of the subfamily G of the human ATP binding cassette (ABC) transporter superfamily and thus also designated as ABCG2.  Unlike P-glycoprotein and MRP1, which are arranged in 2 repeated halves, BCRP is a half-transporter consisting of only 1 nucleotide binding domain followed by 1 membrane-spanning domain.  Current exptl. evidence suggests that BCRP may function as a homodimer or homotetramer.  Overexpression of BCRP is assocd. with high levels of resistance to a variety of anticancer agents, including anthracyclines, mitoxantrone, and the camptothecins, by enhancing drug efflux.  BCRP expression has been detected in a large no. of hematol. malignancies and solid tumors, indicating that this transporter may play an important role in clin. drug resistance of cancers.  In addn. to its role to confer resistance against chemotherapeutic agents, BCRP actively transports structurally diverse org. mols., conjugated or unconjugated, such as estrone-3-sulfate, 17β-estradiol 17-(β-D-glucuronide), and methotrexate.  BCRP is highly expressed in the placental syncytiotrophoblasts, in the apical membrane of the epithelium in the small intestine, in the liver canalicular membrane, and at the luminal surface of the endothelial cells of human brain microvessels.  This strategic and substantial tissue localization indicates that BCRP also plays an important role in absorption, distribution, and elimination of drugs that are BCRP substrates.  This review summarizes current knowledge of BCRP and its relevance to multidrug resistance and drug disposition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTv1Fin0ok0bVg90H21EOLACvtfcHk0lh8XpnCFXjbNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltlOqtrs%253D&md5=3eb43fcf4d36648844d5e729c6ce9487</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1208%2Faapsj070112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Faapsj070112%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DQ.%26aulast%3DUnadkat%26aufirst%3DJ.%2BD.%26atitle%3DRole%2520of%2520the%2520breast%2520cancer%2520resistance%2520protein%2520%2528ABCG2%2529%2520in%2520drug%2520transport%26jtitle%3DAAPS%2520J.%26date%3D2005%26volume%3D7%26spage%3DE118%26epage%3D133%26doi%3D10.1208%2Faapsj070112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krishnamurthy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuetz, J. D.</span></span> <span> </span><span class="NLM_article-title">Role of ABCG2/BCRP in biology and medicine</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">381</span>– <span class="NLM_lpage">410</span>, <span class="refDoi"> DOI: 10.1146/annurev.pharmtox.46.120604.141238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1146%2Fannurev.pharmtox.46.120604.141238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=16402910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD28XisFKltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2006&pages=381-410&author=P.+Krishnamurthyauthor=J.+D.+Schuetz&title=Role+of+ABCG2%2FBCRP+in+biology+and+medicine&doi=10.1146%2Fannurev.pharmtox.46.120604.141238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Role of ABCG2/BCRP in biology and medicine</span></div><div class="casAuthors">Krishnamurthy, P.; Schuetz, J. D.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">381-410, 1 plate</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The protein variously named ABCG2/BCRP/MXR/ABCP is a recently described ATP-binding cassette (ABC) transporter originally identified by its ability to confer drug resistance that is independent of Mrp1 (multidrug-resistance protein 1) and Pgp (P-glycoprotein).  Unlike Mrp1 and Pgp, ABCG2 is a half-transporter that must homodimerize to acquire transport activity.  ABCG2 is found in a variety of stem cells and may protect them from exogenous and endogenous toxins.  ABCG2 expression is upregulated under low-oxygen conditions, consistent with its high expression in tissues exposed to low-oxygen environments.  ABCG2 interacts with heme and other porphyrins and protects cells and/or tissues from protoporphyrin accumulation under hypoxic conditions.  Individuals who carry ABCG2 alleles that have impaired function may be more susceptible to porphyrin-induced toxicity.  Abcg2 knock-out models have allowed in vivo studies of Abcg2 function in host and cellular defense.  In combination with immunohistochem. analyses, these studies have revealed how ABCG2 influences the absorption, distribution, and excretion of drugs and cytotoxins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr74986FK6FwLVg90H21EOLACvtfcHk0liIhaebIiSRRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XisFKltbg%253D&md5=5605477a8544d3a52039c7750956bfb8</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.46.120604.141238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.46.120604.141238%26sid%3Dliteratum%253Aachs%26aulast%3DKrishnamurthy%26aufirst%3DP.%26aulast%3DSchuetz%26aufirst%3DJ.%2BD.%26atitle%3DRole%2520of%2520ABCG2%252FBCRP%2520in%2520biology%2520and%2520medicine%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2006%26volume%3D46%26spage%3D381%26epage%3D410%26doi%3D10.1146%2Fannurev.pharmtox.46.120604.141238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huls, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windass, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den
Heuvel, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heemskerk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russel, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masereeuw, R.</span></span> <span> </span><span class="NLM_article-title">The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane</span>. <i>Kidney Int.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">220</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.1038/sj.ki.5002645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1038%2Fsj.ki.5002645" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=17978814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVyltL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=220-225&author=M.+Hulsauthor=C.+D.+Brownauthor=A.+S.+Windassauthor=R.+Sayerauthor=J.+J.+van+den%0AHeuvelauthor=S.+Heemskerkauthor=F.+G.+Russelauthor=R.+Masereeuw&title=The+breast+cancer+resistance+protein+transporter+ABCG2+is+expressed+in+the+human+kidney+proximal+tubule+apical+membrane&doi=10.1038%2Fsj.ki.5002645"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane</span></div><div class="casAuthors">Huls, M.; Brown, C. D. A.; Windass, A. S.; Sayer, R.; van den Heuvel, J. J. M. W.; Heemskerk, S.; Russel, F. G. M.; Masereeuw, R.</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">220-225</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Breast Cancer Resistance Protein (BCRP/ABCG2) is a transporter restricting absorption and enhancing excretion of many compds. including anticancer drugs.  This transporter is highly expressed in many tissues; however, in human kidney, only the mRNA was found in contrast to the mouse kidney, where the transporter is abundant.  In bcrp/abcg2(-/-) mice, the expression of two sterol transporter genes, abcg5 and abcg8, was strongly increased in the kidney, perhaps as a compensatory mechanism to upregulate efflux.  We found using immunohistochem. anal. clear localization of BCRP/ABCG2 to the proximal tubule brush border membrane of the human kidney comparable to that of other ABC transporters such as P-glycoprotein/ABCB1, MRP2/ABCC2, and MRP4/ABCC4.  Hoechst 33342 dye efflux from primary human proximal tubule cells was significantly reduced by the BCRP/ABCG2 inhibitors fumitremorgin C and nelfinavir.  Our study shows that in addn. to other apical ABC transporters, BCRP/ABCG2 may be important in renal drug excretion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpw55Qg1-1RxrVg90H21EOLACvtfcHk0liIhaebIiSRRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVyltL7M&md5=2ae7bf9bd93b59bc2cab42a8101bbd11</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fsj.ki.5002645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.ki.5002645%26sid%3Dliteratum%253Aachs%26aulast%3DHuls%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DC.%2BD.%26aulast%3DWindass%26aufirst%3DA.%2BS.%26aulast%3DSayer%26aufirst%3DR.%26aulast%3Dvan%2Bden%2BHeuvel%26aufirst%3DJ.%2BJ.%26aulast%3DHeemskerk%26aufirst%3DS.%26aulast%3DRussel%26aufirst%3DF.%2BG.%26aulast%3DMasereeuw%26aufirst%3DR.%26atitle%3DThe%2520breast%2520cancer%2520resistance%2520protein%2520transporter%2520ABCG2%2520is%2520expressed%2520in%2520the%2520human%2520kidney%2520proximal%2520tubule%2520apical%2520membrane%26jtitle%3DKidney%2520Int.%26date%3D2008%26volume%3D73%26spage%3D220%26epage%3D225%26doi%3D10.1038%2Fsj.ki.5002645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koshiba, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakabayashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, T.</span></span> <span> </span><span class="NLM_article-title">Human ABC transporters ABCG2 (BCRP) and ABCG4</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">863</span>– <span class="NLM_lpage">888</span>, <span class="refDoi"> DOI: 10.1080/00498250801986944</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1080%2F00498250801986944" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=18668433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpt1Snurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2008&pages=863-888&author=S.+Koshibaauthor=R.+Anauthor=H.+Saitoauthor=K.+Wakabayashiauthor=A.+Tamuraauthor=T.+Ishikawa&title=Human+ABC+transporters+ABCG2+%28BCRP%29+and+ABCG4&doi=10.1080%2F00498250801986944"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Human ABC transporters ABCG2 (BCRP) and ABCG4</span></div><div class="casAuthors">Koshiba, S.; An, R.; Saito, H.; Wakabayashi, K.; Tamura, A.; Ishikawa, T.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">863-888</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The human ABC transporter ABCG2 is regarded as a member of the phase III system for xenobiotic metab., and it has been suggested that this efflux pump is responsible for protecting the body from toxic xenobiotics and for removing metabolites.  This review paper will address post-translational modifications (i.e., disulfide bond formation, ubiquitination, and endoplasmic reticulum-assocd. degrdn.) of the ABCG2 protein, high-speed screening, and quant. structure-activity relationship (QSAR) anal. to evaluate ABCG2-drug interactions, and genetic polymorphisms potentially assocd. with photosensitivity.  In addn., new aspects of human ABCG4 and mouse Abcg4 are presented with respect to their mol. properties and potential physiol. roles.  Considering the high sequence similarity between ABCG1 and ABCG4, both Abcg4 and ABCG4 may be involved in the transport of cholesterol from neurons and astrocytes.  Furthermore, high expression of the mouse Abcg4 protein in the testis implicates its involvement in transport of certain sex hormones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGputEgOyfcC_LVg90H21EOLACvtfcHk0liIhaebIiSRRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpt1Snurg%253D&md5=9937f7ce8258b148975b76e429647cc0</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1080%2F00498250801986944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00498250801986944%26sid%3Dliteratum%253Aachs%26aulast%3DKoshiba%26aufirst%3DS.%26aulast%3DAn%26aufirst%3DR.%26aulast%3DSaito%26aufirst%3DH.%26aulast%3DWakabayashi%26aufirst%3DK.%26aulast%3DTamura%26aufirst%3DA.%26aulast%3DIshikawa%26aufirst%3DT.%26atitle%3DHuman%2520ABC%2520transporters%2520ABCG2%2520%2528BCRP%2529%2520and%2520ABCG4%26jtitle%3DXenobiotica%26date%3D2008%26volume%3D38%26spage%3D863%26epage%3D888%26doi%3D10.1080%2F00498250801986944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S. F.</span></span> <span> </span><span class="NLM_article-title">Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">802</span>– <span class="NLM_lpage">832</span>, <span class="refDoi"> DOI: 10.1080/00498250701867889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1080%2F00498250701867889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=18668431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpt1SnurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2008&pages=802-832&author=S.+F.+Zhou&title=Structure%2C+function+and+regulation+of+P-glycoprotein+and+its+clinical+relevance+in+drug+disposition&doi=10.1080%2F00498250701867889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition</span></div><div class="casAuthors">Zhou, S.-F.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">802-832</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  P-glycoprotein (P-gp/MDR1), one of the most clin. important transmembrane transporters in humans, is encoded by the ABCB1/MDR1 gene.  Recent insights into the structural features of P-gp/MDR1 enable a re-evaluation of the biochem. evidence on the binding and transport of drugs by P-gp/MDR1.  P-gp/MDR1 is found in various human tissues in addn. to being expressed in tumors cells.  It is located on the apical surface of intestinal epithelial cells, bile canaliculi, renal tubular cells, and placenta and the luminal surface of capillary endothelial cells in the brain and testes.  P-gp/MDR1 confers a multi-drug resistance (MDR) phenotype to cancer cells that have developed resistance to chemotherapy drugs.  P-gp/MDR1 activity is also of great clin. importance in non-cancer-related drug therapy due to its wide-ranging effects on the absorption and excretion of a variety of drugs.  P-gp/MDR1 excretes xenobiotics such as cytotoxic compds. into the gastrointestinal tract, bile and urine.  It also participates in the function of the blood-brain barrier.  One of the most interesting characteristics of P-gp/MDR1 is that its many substrates vary greatly in their structure and functionality, ranging from small mols. such as org. cations, carbohydrates, amino acids and some antibiotics to macromols. such as polysaccharides and proteins.  Quite a no. of single nucleotide polymorphisms have been found for the MDR1 gene.  These single nucleotide polymorphisms are assocd. with altered oral bioavailability of P-gp/MDR1 substrates, drug resistance, and a susceptibility to some human diseases.  Altered P-gp/MDR1 activity due to induction and/or inhibition can cause drug-drug interactions with altered drug pharmacokinetics and response.  Further studies are warranted to explore the physiol. function and pharmacol. role of P-gp/MDR1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMHCldae2e9rVg90H21EOLACvtfcHk0liIhaebIiSRRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpt1SnurY%253D&md5=362c30e9c4fef1b58b1c7fd3ff55603d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1080%2F00498250701867889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00498250701867889%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DS.%2BF.%26atitle%3DStructure%252C%2520function%2520and%2520regulation%2520of%2520P-glycoprotein%2520and%2520its%2520clinical%2520relevance%2520in%2520drug%2520disposition%26jtitle%3DXenobiotica%26date%3D2008%26volume%3D38%26spage%3D802%26epage%3D832%26doi%3D10.1080%2F00498250701867889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphrey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warhurst, G.</span></span> <span> </span><span class="NLM_article-title">Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a (−/−) mice</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">2038</span>– <span class="NLM_lpage">2046</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0704668</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1038%2Fsj.bjp.0704668" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=11959808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD38Xjtlels7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2002&pages=2038-2046&author=R.+H.+Stephensauthor=C.+A.+O%E2%80%99Neillauthor=J.+Bennettauthor=M.+Humphreyauthor=B.+Henryauthor=M.+Rowlandauthor=G.+Warhurst&title=Resolution+of+P-glycoprotein+and+non-P-glycoprotein+effects+on+drug+permeability+using+intestinal+tissues+from+mdr1a+%28%E2%88%92%2F%E2%88%92%29+mice&doi=10.1038%2Fsj.bjp.0704668"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a (-/-) mice</span></div><div class="casAuthors">Stephens, R. H.; O'Neill, C. A.; Bennett, J.; Humphrey, M.; Henry, B.; Rowland, M.; Warhurst, G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2038-2046</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Intestinal xenobiotic transporters are a significant barrier to the absorption of many orally administered drugs.  P-glycoprotein (PGP) is the best known, but several others, including members of the multidrug resistance-assocd. protein (MRP) family, are also expressed.  Definitive information on their precise effect on intestinal drug permeability is scarce due to a lack of specific inhibitors and the difficulty of studying non-PGP activity in the presence of high PGP expression.  We have investigated the in vitro use of intestinal tissues from PGP knockout (mdr1a (-/-)) mice as a tool for dissecting the mechanisms of intestinal drug efflux.  The permeability characteristics of digoxin (DIG), paclitaxel (TAX) and etoposide (ETOP) were measured in ileum from mdr1a (-/-) and wild-type (FVB) mice mounted in Ussing chambers.  DIG and TAX exhibited marked efflux across FVB tissues (B-A:A-B apparent permeability (Papp) ratio 10 and 17 resp.) which was absent in mdr1a (-/-) tissues, confirming that PGP is the sole route of intestinal efflux for these compds.  The A-B Papp of both compds. was 3-5 fold higher in mdr1a (-/-) than in FVB.  Polarized transport of ETOP in FVB tissues was reduced but not abolished in mdr1a (-/-) tissues.  Residual ETOP efflux in mdr1a (-/-) tissues was abolished by the MRP inhibitor MK571, indicating involvement of both PGP and MRP.  MK571 abolished calcein efflux in mdr1a (-/-) tissues, while quinidine had no parallel effect in FVB tissues, suggesting involvement of MRP but not PGP.  Tissues from mdr1a (-/-) mice provide a novel approach for investigating the influence of PGP ablation on intestinal permeability and for resolving PGP and non-PGP mechanisms that modulate drug permeability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq1txHOVMhELVg90H21EOLACvtfcHk0lhyhDTISYOtPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xjtlels7o%253D&md5=3abb5edb89ca2ba6be17cf98002a1f97</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0704668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0704668%26sid%3Dliteratum%253Aachs%26aulast%3DStephens%26aufirst%3DR.%2BH.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DC.%2BA.%26aulast%3DBennett%26aufirst%3DJ.%26aulast%3DHumphrey%26aufirst%3DM.%26aulast%3DHenry%26aufirst%3DB.%26aulast%3DRowland%26aufirst%3DM.%26aulast%3DWarhurst%26aufirst%3DG.%26atitle%3DResolution%2520of%2520P-glycoprotein%2520and%2520non-P-glycoprotein%2520effects%2520on%2520drug%2520permeability%2520using%2520intestinal%2520tissues%2520from%2520mdr1a%2520%2528%25E2%2588%2592%252F%25E2%2588%2592%2529%2520mice%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2002%26volume%3D135%26spage%3D2038%26epage%3D2046%26doi%3D10.1038%2Fsj.bjp.0704668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takano, M.</span></span> <span> </span><span class="NLM_article-title">Intestinal efflux transporters and drug absorption</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">923</span>– <span class="NLM_lpage">939</span>, <span class="refDoi"> DOI: 10.1517/17425255.4.7.923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1517%2F17425255.4.7.923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=18624680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1cXos1Chur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=923-939&author=T.+Murakamiauthor=M.+Takano&title=Intestinal+efflux+transporters+and+drug+absorption&doi=10.1517%2F17425255.4.7.923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal efflux transporters and drug absorption</span></div><div class="casAuthors">Murakami, Teruo; Takano, Mikihisa</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">923-939</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The intestinal epithelial membrane expresses ATP-binding cassette (ABC) transporters such as P-glycoprotein (P-gp), multi-drug resistance-assocd. proteins (MRPs) and breast cancer resistance protein (BCRP), in addn. to various solute carrier (SLC) transporters.  These ABC transporters affect the oral bioavailability of their substrate drugs.  To review the contribution of ABC efflux transporters such as P-gp, MRP2, MRP3, and BCRP in the intestinal absorption of substrate drugs.  Discussion was made by focusing on the site-specific expression and function of these ABC transporters, and the soly. and permeability of their substrate compds.  The increase in the soly. and permeability of orally administered drugs could be the key to escape barrier function of ABC transporters, esp. P-gp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHGPw_FFSMp7Vg90H21EOLACvtfcHk0lhyhDTISYOtPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXos1Chur4%253D&md5=d14373b20de260afd5b94042f62dac3d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1517%2F17425255.4.7.923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.4.7.923%26sid%3Dliteratum%253Aachs%26aulast%3DMurakami%26aufirst%3DT.%26aulast%3DTakano%26aufirst%3DM.%26atitle%3DIntestinal%2520efflux%2520transporters%2520and%2520drug%2520absorption%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2008%26volume%3D4%26spage%3D923%26epage%3D939%26doi%3D10.1517%2F17425255.4.7.923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shugarts, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L. Z.</span></span> <span> </span><span class="NLM_article-title">The role of transporters in the pharmacokinetics of orally administered drugs</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2039</span>– <span class="NLM_lpage">2054</span>, <span class="refDoi"> DOI: 10.1007/s11095-009-9924-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1007%2Fs11095-009-9924-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=19568696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnvFKgu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2009&pages=2039-2054&author=S.+Shugartsauthor=L.+Z.+Benet&title=The+role+of+transporters+in+the+pharmacokinetics+of+orally+administered+drugs&doi=10.1007%2Fs11095-009-9924-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs</span></div><div class="casAuthors">Shugarts, Sarah; Benet, Leslie Z.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2039-2054</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Drug transporters are recognized as key players in the processes of drug absorption, distribution, metab., and elimination.  The localization of uptake and efflux transporters in organs responsible for drug biotransformation and excretion gives transporter proteins a unique gatekeeper function in controlling drug access to metabolizing enzymes and excretory pathways.  This review seeks to discuss the influence intestinal and hepatic drug transporters have on pharmacokinetic parameters, including bioavailability, exposure, clearance, vol. of distribution, and half-life, for orally dosed drugs.  This review also describes in detail the Biopharmaceutics Drug Disposition Classification System (BDDCS) and explains how many of the effects drug transporters exert on oral drug pharmacokinetic parameters can be predicted by this classification scheme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG3kU38e57LrVg90H21EOLACvtfcHk0lhyhDTISYOtPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnvFKgu7w%253D&md5=5fe75b8025fd8395a8cf722beaf6b62d</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs11095-009-9924-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-009-9924-0%26sid%3Dliteratum%253Aachs%26aulast%3DShugarts%26aufirst%3DS.%26aulast%3DBenet%26aufirst%3DL.%2BZ.%26atitle%3DThe%2520role%2520of%2520transporters%2520in%2520the%2520pharmacokinetics%2520of%2520orally%2520administered%2520drugs%26jtitle%3DPharm.%2520Res.%26date%3D2009%26volume%3D26%26spage%3D2039%26epage%3D2054%26doi%3D10.1007%2Fs11095-009-9924-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schinkel, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonker, J. W.</span></span> <span> </span><span class="NLM_article-title">Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/S0169-409X(02)00169-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1016%2FS0169-409X%2802%2900169-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=12535572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3sXivVWnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2003&pages=3-29&author=A.+H.+Schinkelauthor=J.+W.+Jonker&title=Mammalian+drug+efflux+transporters+of+the+ATP+binding+cassette+%28ABC%29+family%3A+an+overview&doi=10.1016%2FS0169-409X%2802%2900169-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview</span></div><div class="casAuthors">Schinkel, Alfred H.; Jonker, Johan W.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-29</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Active drug efflux transporters of the ATP binding cassette (ABC)-contg. family of proteins have a major impact on the pharmacol. behavior of most of the drugs in use today.  Pharmacol. properties affected by ABC transporters include the oral bioavailability, hepatobiliary, direct intestinal, and urinary excretion of drugs and drug-metabolites and -conjugates.  Moreover, the penetration of drugs into a range of important pharmacol. sanctuaries, such as brain, testis, and fetus, and the penetration into specific cell- and tissue compartments can be extensively limited by ABC transporters.  These interactions with ABC transporters det. to a large extent the clin. usefulness, side effects and toxicity risks of drugs.  Many other xenotoxins, (pre-)carcinogens and endogenous compds. are also influenced by the ABC transporters, with corresponding consequences for the well-being of the individual.  We aim to provide an overview of properties of the mammalian ABC transporters known to mediate significant transport of clin. relevant drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaUGQEMir1wbVg90H21EOLACvtfcHk0lh5DD8atNO7TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXivVWnsQ%253D%253D&md5=e5edc6f3a530eab7868e7eb245849c12</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2802%2900169-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252802%252900169-2%26sid%3Dliteratum%253Aachs%26aulast%3DSchinkel%26aufirst%3DA.%2BH.%26aulast%3DJonker%26aufirst%3DJ.%2BW.%26atitle%3DMammalian%2520drug%2520efflux%2520transporters%2520of%2520the%2520ATP%2520binding%2520cassette%2520%2528ABC%2529%2520family%253A%2520an%2520overview%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2003%26volume%3D55%26spage%3D3%26epage%3D29%26doi%3D10.1016%2FS0169-409X%2802%2900169-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinkel, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">923</span>– <span class="NLM_lpage">928</span>, <span class="refDoi"> DOI: 10.1124/mol.104.007393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fmol.104.007393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=15598971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitlaqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2005&pages=923-928&author=Y.+Adachiauthor=H.+Suzukiauthor=A.+H.+Schinkelauthor=Y.+Sugiyama&title=Role+of+breast+cancer+resistance+protein+%28Bcrp1%2FAbcg2%29+in+the+extrusion+of+glucuronide+and+sulfate+conjugates+from+enterocytes+to+intestinal+lumen&doi=10.1124%2Fmol.104.007393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen</span></div><div class="casAuthors">Adachi, Yasuhisa; Suzuki, Hiroshi; Schinkel, Alfred H.; Sugiyama, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">923-928</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The purpose of this study is to examine the significance of efflux transporters in the small intestine to extrude glucuronide (G) and sulfate (S) conjugates into the intestinal lumen.  From this standpoint, we performed in situ intestinal perfusion expts. by using Eisai hyperbilirubinemic rats (EHBRs) in which the multidrug resistance protein 2 (Mrp2/Abcc2) is hereditarily defective and breast cancer resistance protein (Bcrp1/Abcg2) knockout mice.  The intestinal lumen of EHBRs and Bcrp1 (-/-) mice was perfused with medium contg. 4-methylumbelliferone (4MU) and E3040 [6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole] to det. the efflux of metabolites into the outflow.  The efflux of E3040-glucuronide (G) in EHBRs was significantly lower compared with that in normal rats.  However, no significant difference was obsd. for the efflux of 4MU-G, 4MU-sulfate (S), and E3040-S between EHBRs and normal rats.  In contrast, the efflux of intracellularly formed 4MU-G, 4MU-S, and E3040-G in Bcrp1 (-/-) mice was significantly lower than that in normal mice.  Therefore, Bcrp1 has an important role in extruding glucuronide and sulfate conjugates formed in enterocytes into the intestinal lumen, whereas Mrp2 is responsible for the efflux of some glucuronide conjugates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwHRlDYS21yrVg90H21EOLACvtfcHk0lh5DD8atNO7TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitlaqtr8%253D&md5=d3ce43c29e9ad822bf60ace06127e8fe</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1124%2Fmol.104.007393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.104.007393%26sid%3Dliteratum%253Aachs%26aulast%3DAdachi%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DH.%26aulast%3DSchinkel%26aufirst%3DA.%2BH.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DRole%2520of%2520breast%2520cancer%2520resistance%2520protein%2520%2528Bcrp1%252FAbcg2%2529%2520in%2520the%2520extrusion%2520of%2520glucuronide%2520and%2520sulfate%2520conjugates%2520from%2520enterocytes%2520to%2520intestinal%2520lumen%26jtitle%3DMol.%2520Pharmacol.%26date%3D2005%26volume%3D67%26spage%3D923%26epage%3D928%26doi%3D10.1124%2Fmol.104.007393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, R. B.</span></span> <span> </span><span class="NLM_article-title">Transporters and drug therapy: implications for drug disposition and disease</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">260</span>– <span class="NLM_lpage">277</span>, <span class="refDoi"> DOI: 10.1016/j.clpt.2005.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1016%2Fj.clpt.2005.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=16153397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvV2rt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2005&pages=260-277&author=R.+H.+Hoauthor=R.+B.+Kim&title=Transporters+and+drug+therapy%3A+implications+for+drug+disposition+and+disease&doi=10.1016%2Fj.clpt.2005.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Transporters and drug therapy: Implications for drug disposition and disease</span></div><div class="casAuthors">Ho, Richard H.; Kim, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">260-277</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The efficacy of drug therapy results from the complex interplay of multiple processes that govern drug disposition and response.  Most studies to date have focused on the contribution of drug-metabolizing enzymes to the drug disposition process.  However, over the past decade, it has become increasingly apparent that carrier-mediated processes, or transporters, also play crit. roles in the overall disposition of numerous drugs in clin. use.  In addn. to their roles in xenobiotic transport, drug transporters often mediate important physiol. functions via transport of endogenous substrates such as amino acids, bile acids, and hormones that are crit. for maintenance of normal homeostasis.  In this review we focus on the emerging field of transporter proteins in relation to the drug disposition process, with particular emphasis on clin. implications of transporters to drug-drug interactions and subsequent development of adverse effects, interindividual variability in drug response, and human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp32hrC_dzQUrVg90H21EOLACvtfcHk0lh5DD8atNO7TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvV2rt78%253D&md5=a2d08e434c1e8ba795f0ae15c463b619</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.clpt.2005.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clpt.2005.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DR.%2BH.%26aulast%3DKim%26aufirst%3DR.%2BB.%26atitle%3DTransporters%2520and%2520drug%2520therapy%253A%2520implications%2520for%2520drug%2520disposition%2520and%2520disease%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2005%26volume%3D78%26spage%3D260%26epage%3D277%26doi%3D10.1016%2Fj.clpt.2005.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusuhara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans</span>. <i>J. Pharmacokinet. Pharmacodyn.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">590</span>, <span class="refDoi"> DOI: 10.1007/s10928-010-9176-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1007%2Fs10928-010-9176-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=21063755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2gurnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2010&pages=575-590&author=T.+Watanabeauthor=H.+Kusuharaauthor=Y.+Sugiyama&title=Application+of+physiologically+based+pharmacokinetic+modeling+and+clearance+concept+to+drugs+showing+transporter-mediated+distribution+and+clearance+in+humans&doi=10.1007%2Fs10928-010-9176-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans</span></div><div class="casAuthors">Watanabe, Takao; Kusuhara, Hiroyuki; Sugiyama, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacokinetics and Pharmacodynamics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">575-590</span>CODEN:
                <span class="NLM_cas:coden">JPPOAH</span>;
        ISSN:<span class="NLM_cas:issn">1567-567X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">This review illustrates the concept of a rate-detg. process in the overall hepatic elimination of anionic drugs that involves transporters in the uptake process.  A kinetic study in rats has demonstrated that uptake is the rate-detg. process for most anionic drugs, and this is likely to hold true for the hepatic elimination of statins in humans.  To simulate the effects of variations in the transporter activities on systemic and liver exposure, a physiol. based pharmacokinetic model was constructed for pravastatin, the overall elimination of which involves OATP1B1 and MRP2 in the hepatic uptake and canalicular efflux, resp.  The plasma concns. of pravastatin in humans were successfully reproduced using the kinetic parameters extrapolated from in vitro data obtained using human hepatocytes and canalicular membrane vesicles and the scaling factors detd. in rats.  Sensitivity analyses showed that a variation in hepatic uptake altered the plasma concn. of pravastatin markedly, but had a small effect on the liver concn., and vice versa for the canalicular efflux.  Therefore, variation in the OATP1B1 activities will have small and large impacts on the therapeutic efficacy and adverse effect (myopathy) of pravastatin, resp., whereas that affecting the MRP2 activities may have an opposite effect (i.e., large and small impacts on the therapeutic efficacy and side effect).  This pharmacokinetic characteristics likely hold true for other anionic statins, i.e., variation of OATP1B1 is assocd. with the risk of adverse reactions, whereas that of sequestration mechanisms causes the variation of their pharmacol. effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDZdm25H13LbVg90H21EOLACvtfcHk0ljaCy9v-X-t_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2gurnN&md5=2e49d2767ec5aad2135dc7127ae84726</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2Fs10928-010-9176-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10928-010-9176-y%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DKusuhara%26aufirst%3DH.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DApplication%2520of%2520physiologically%2520based%2520pharmacokinetic%2520modeling%2520and%2520clearance%2520concept%2520to%2520drugs%2520showing%2520transporter-mediated%2520distribution%2520and%2520clearance%2520in%2520humans%26jtitle%3DJ.%2520Pharmacokinet.%2520Pharmacodyn.%26date%3D2010%26volume%3D37%26spage%3D575%26epage%3D590%26doi%3D10.1007%2Fs10928-010-9176-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fenner, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempshall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, H. A.</span></span> <span> </span><span class="NLM_article-title">The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.3109/00498254.2011.626464</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.3109%2F00498254.2011.626464" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=22077101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFKgtbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2012&pages=28-45&author=K.+S.+Fennerauthor=H.+M.+Jonesauthor=M.+Ullahauthor=S.+Kempshallauthor=M.+Dickinsauthor=Y.+Laiauthor=P.+Morganauthor=H.+A.+Barton&title=The+evolution+of+the+OATP+hepatic+uptake+transport+protein+family+in+DMPK+sciences%3A+from+obscure+liver+transporters+to+key+determinants+of+hepatobiliary+clearance&doi=10.3109%2F00498254.2011.626464"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance</span></div><div class="casAuthors">Fenner, Katherine S.; Jones, Hannah M.; Ullah, Mohammed; Kempshall, Sarah; Dickins, Maurice; Lai, Yurong; Morgan, Paul; Barton, Hugh A.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-45</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Over the last two decades the impact on drug pharmacokinetics of the org. anion transporting polypeptides (OATPs: OATP-1B1, 1B3 and 2B1), expressed on the sinusoidal membrane of the hepatocyte, has been increasingly recognized.  OATP-mediated uptake into the hepatocyte coupled with subsequent excretion into bile via efflux proteins, such as MRP2, is often referred to as hepatobiliary excretion.  OATP transporter proteins can impact some drugs in several ways including pharmacokinetic variability, pharmacodynamic response and drug-drug interactions (DDIs).  The impact of transporter mediated hepatic clearance is illustrated with case examples, from the literature and also from the Pfizer portfolio.  The currently available in vitro techniques to study the hepatic transporter proteins involved in the hepatobiliary clearance of drugs are reviewed herein along with recent advances in using these in vitro data to predict the human clearance of compds. recognized by hepatic uptake transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKl9Q265UcjrVg90H21EOLACvtfcHk0ljaCy9v-X-t_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFKgtbvK&md5=869e56bc156cb5a548b2cf2135dba562</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.3109%2F00498254.2011.626464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498254.2011.626464%26sid%3Dliteratum%253Aachs%26aulast%3DFenner%26aufirst%3DK.%2BS.%26aulast%3DJones%26aufirst%3DH.%2BM.%26aulast%3DUllah%26aufirst%3DM.%26aulast%3DKempshall%26aufirst%3DS.%26aulast%3DDickins%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DMorgan%26aufirst%3DP.%26aulast%3DBarton%26aufirst%3DH.%2BA.%26atitle%3DThe%2520evolution%2520of%2520the%2520OATP%2520hepatic%2520uptake%2520transport%2520protein%2520family%2520in%2520DMPK%2520sciences%253A%2520from%2520obscure%2520liver%2520transporters%2520to%2520key%2520determinants%2520of%2520hepatobiliary%2520clearance%26jtitle%3DXenobiotica%26date%3D2012%26volume%3D42%26spage%3D28%26epage%3D45%26doi%3D10.3109%2F00498254.2011.626464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gotoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirohashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>292</i></span>,  <span class="NLM_fpage">433</span>– <span class="NLM_lpage">439</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10604980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhslGqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2000&pages=433-439&author=Y.+Gotohauthor=H.+Suzukiauthor=S.+Kinoshitaauthor=T.+Hirohashiauthor=Y.+Katoauthor=Y.+Sugiyama&title=Involvement+of+an+organic+anion+transporter+%28canalicular+multispecific+organic+anion+transporter%2Fmultidrug+resistance-associated+protein+2%29+in+gastrointestinal+secretion+of+glutathione+conjugates+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats</span></div><div class="casAuthors">Gotoh, Yasumasa; Suzuki, Hiroshi; Kinoshita, Setsuo; Hirohashi, Tomoko; Kato, Yukio; Sugiyama, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">433-439</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We investigated the role of cMOAT/MRP2 (canalicular multispecific org. anion transporter/multidrug resistance-assocd. protein 2) in the intestinal secretion of org. anions by comparing the behavior in Sprague-Dawley (SD) rats and Eisai hyperbilirubinemic rat (EHBR) whose cMOAT/MRP2 is hereditarily defective.  After i.v. administration of 1-chloro-2,4-dinitrobenzene (30 μmol/kg), the biliary and intestinal excretion of its glutathione conjugate 2,4-dinitrophenyl-S-glutathione (DNP-SG), a substrate for cMOAT/MRP2, was significantly reduced in EHBR compared with SD rats.  This result also was confirmed by Ussing chamber studies; DNP-SG showed 1.5-fold greater serosal-to-mucosal flux compared with the mucosal-to-serosal flux in SD rats, whereas a similar flux was obsd. in both directions in EHBR.  In addn., metabolic inhibitors reduced the preferential serosal-to-mucosal flux of DNP-SG in SD rats.  In everted sac studies, intestinal secretion clearance, defined as the efflux rate of DNP-SG into the mucosal side divided by the area under the curve on the serosal side, was significantly lower in the jejunum of EHBR than that in SD rats.  Northern blot analyses demonstrated the highest mRNA level of cMOAT/MRP2 in the jejunum, which is in good agreement with the results of the everted sac studies.  These results suggest that cMOAT/MRP2 is involved in the secretion of org. anions in the small intestine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFEdUUlQ4atrVg90H21EOLACvtfcHk0ljaCy9v-X-t_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhslGqtg%253D%253D&md5=390a160e5e02cab9168d93c6b795e496</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGotoh%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DH.%26aulast%3DKinoshita%26aufirst%3DS.%26aulast%3DHirohashi%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DInvolvement%2520of%2520an%2520organic%2520anion%2520transporter%2520%2528canalicular%2520multispecific%2520organic%2520anion%2520transporter%252Fmultidrug%2520resistance-associated%2520protein%25202%2529%2520in%2520gastrointestinal%2520secretion%2520of%2520glutathione%2520conjugates%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2000%26volume%3D292%26spage%3D433%26epage%3D439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mottino, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vore, M.</span></span> <span> </span><span class="NLM_article-title">Expression and localization of multidrug resistant protein mrp2 in rat small intestine</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>293</i></span>,  <span class="NLM_fpage">717</span>– <span class="NLM_lpage">723</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10869369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjsleksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2000&pages=717-723&author=A.+D.+Mottinoauthor=T.+Hoffmanauthor=L.+Jennesauthor=M.+Vore&title=Expression+and+localization+of+multidrug+resistant+protein+mrp2+in+rat+small+intestine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Expression and localization of multidrug resistant protein mrp2 in rat small intestine</span></div><div class="casAuthors">Mottino, Aldo D.; Hoffman, Tim; Jennes, Lothar; Vore, Mary</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">293</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">717-723</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The expression of multidrug resistance-assocd. protein isoform 2 (mrp2), the ATP-dependent export pump that mediates the transport of glucuronic acid-, glutathione-, and sulfate-conjugated derivs., was studied in rat small intestine.  The small intestine was divided into 9 equal segments, and the mrp2 content was analyzed in homogenate and brush border membrane prepns. by Western anal.  The mrp2 protein was present mainly in brush border membrane of the proximal segments and gradually decreased from jejunum to the distal ileum.  The authors also analyzed the content of mrp2 in 3 different populations of proximal enterocytes obtained from the upper and lower villus and the crypt regions.  The export pump was mainly expressed in the villus cells and to a lesser degree in the crypt cells of the epithelium.  Immunohistochem. anal. performed in duodenum, jejunum, and ileum confirmed in situ the Western blot findings.  Anal. of mRNA encoding mrp2 in proximal and distal segments revealed a similar content in both regions, whereas distribution along the villus-crypt axis was similar to the protein gradient.  Because conjugating enzymes were distributed similarly to mrp2, it was concluded that they may act coordinately to contribute to 1st-pass metab. of drugs and other xenobiotics in the proximal small intestine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFh-wvB6pHmbVg90H21EOLACvtfcHk0lixDJk0RbbFMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjsleksrY%253D&md5=1b7af5c9d564f1dcc29d928fa7361143</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMottino%26aufirst%3DA.%2BD.%26aulast%3DHoffman%26aufirst%3DT.%26aulast%3DJennes%26aufirst%3DL.%26aulast%3DVore%26aufirst%3DM.%26atitle%3DExpression%2520and%2520localization%2520of%2520multidrug%2520resistant%2520protein%2520mrp2%2520in%2520rat%2520small%2520intestine%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2000%26volume%3D293%26spage%3D717%26epage%3D723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mouly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paine, M. F.</span></span> <span> </span><span class="NLM_article-title">P-glycoprotein increases from proximal to distal regions of human small intestine</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1595</span>– <span class="NLM_lpage">1599</span>, <span class="refDoi"> DOI: 10.1023/A:1026183200740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1023%2FA%3A1026183200740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=14620513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotFClsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2003&pages=1595-1599&author=S.+Moulyauthor=M.+F.+Paine&title=P-glycoprotein+increases+from+proximal+to+distal+regions+of+human+small+intestine&doi=10.1023%2FA%3A1026183200740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">P-Glycoprotein Increases from Proximal to Distal Regions of Human Small Intestine</span></div><div class="casAuthors">Mouly, Stephane; Paine, Mary F.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1595-1599</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic/Plenum Publishers</span>)
        </div><div class="casAbstract">The contribution of the efflux transporter P-glycoprotein (P-gp) as a barrier to drug absorption may depend on its level of expression at the site of absorption.  Accordingly, the distribution of P-gp was examd. along the entire length of the human small intestine.  Homogenates prepd. from mucosal scrapings from every other 30-cm segment of 4 unrelated human donor small intestines were analyzed for P-gp and the control protein villin by Western blot.  In each donor intestine, relative P-gp expression (P-gp/villin integrated optical d. ratio) progressively increased from proximal to distal regions.  Among individuals, relative P-gp levels varied 2.1-fold in the duodenal/proximal jejunal region, 1.5- to 2.0-fold in the middle/distal jejunal region, and 1.2- to 1.9-fold in the ileal region.  Within-donor variation was somewhat greater, from 1.5- to 3.0-fold.  These results provide further evidence that the site of absorption can represent another source for the interindividual variation in the oral bioavailability of drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF7jGQikX3P7Vg90H21EOLACvtfcHk0lixDJk0RbbFMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotFClsrY%253D&md5=3669fdd5bcada5d89d6dc3ccdadc1c3b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1023%2FA%3A1026183200740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1026183200740%26sid%3Dliteratum%253Aachs%26aulast%3DMouly%26aufirst%3DS.%26aulast%3DPaine%26aufirst%3DM.%2BF.%26atitle%3DP-glycoprotein%2520increases%2520from%2520proximal%2520to%2520distal%2520regions%2520of%2520human%2520small%2520intestine%26jtitle%3DPharm.%2520Res.%26date%3D2003%26volume%3D20%26spage%3D1595%26epage%3D1599%26doi%3D10.1023%2FA%3A1026183200740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Englund, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rorsman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronnblom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlbom, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazorova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasjo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindmark, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span> <span> </span><span class="NLM_article-title">Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">277</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2006.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1016%2Fj.ejps.2006.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=16822659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFentr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2006&pages=269-277&author=G.+Englundauthor=F.+Rorsmanauthor=A.+Ronnblomauthor=U.+Karlbomauthor=L.+Lazorovaauthor=J.+Grasjoauthor=A.+Kindmarkauthor=P.+Artursson&title=Regional+levels+of+drug+transporters+along+the+human+intestinal+tract%3A+co-expression+of+ABC+and+SLC+transporters+and+comparison+with+Caco-2+cells&doi=10.1016%2Fj.ejps.2006.04.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells</span></div><div class="casAuthors">Englund, Gunilla; Rorsman, Fredrik; Roennblom, Anders; Karlbom, Urban; Lazorova, Lucia; Grasjoe, Johan; Kindmark, Andreas; Artursson, Per</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">269-277</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A vast no. of drugs are subjected to active or facilitated transport and multiple transport mechanism may contribute to the net flux during drug absorption.  The main objective of this study was to quantify the regional mRNA expression and det. the co-expression of drug transporters from the ABC (Pgp, BCRP, MRP2, MRP3) and SLC (PEPT1, MCT1, OATPB, OCTN2, OCT1) families along the human intestine (duodenum, jejunum, ileum, and colon).  A second objective was to compare the transporter expression between the different intestinal regions and Caco-2 cells.  Eight out of nine of the investigated transporters exhibited significant regional differences in expression.  OATPB was the only transporter that did not show a region-dependency in the expression along the human intestinal canal.  The expression of Pgp, BCRP, OCTN2 and MCT1 differed along the small intestine, but the expression differences were greater than five-fold only for Pgp.  The rank order of transcript prevalence was identical in the ileum and the jejunum.  Between the ileum and colon, seven transcripts were differentially expressed, and MCT1, OCTN2 and MRP3 were expressed at higher levels in the colon than in the small intestine.  The expression of transporters in Caco-2 was closest to the expression pattern in the small intestine, although the expression of OATPB, BCRP and MRP2 differed more than five-fold between the Caco-2 cells and ileum.  In conclusion, this study provides quant. data on the expression of transporters from the ABC and SLC families along the human intestine, which can be useful in the interpretation of clin. studies where more than one intestinal transporter contribute to the net transport and in the computer modeling of drug absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJACMwULElcLVg90H21EOLACvtfcHk0lixDJk0RbbFMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFentr3E&md5=093c6e8695f07b3ad39398731e368d55</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2006.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2006.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DEnglund%26aufirst%3DG.%26aulast%3DRorsman%26aufirst%3DF.%26aulast%3DRonnblom%26aufirst%3DA.%26aulast%3DKarlbom%26aufirst%3DU.%26aulast%3DLazorova%26aufirst%3DL.%26aulast%3DGrasjo%26aufirst%3DJ.%26aulast%3DKindmark%26aufirst%3DA.%26aulast%3DArtursson%26aufirst%3DP.%26atitle%3DRegional%2520levels%2520of%2520drug%2520transporters%2520along%2520the%2520human%2520intestinal%2520tract%253A%2520co-expression%2520of%2520ABC%2520and%2520SLC%2520transporters%2520and%2520comparison%2520with%2520Caco-2%2520cells%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2006%26volume%3D29%26spage%3D269%26epage%3D277%26doi%3D10.1016%2Fj.ejps.2006.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Enokizono, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusuhara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Regional expression and activity of breast cancer resistance protein (Bcrp/Abcg2) in mouse intestine: overlapping distribution with sulfotransferases</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">922</span>– <span class="NLM_lpage">928</span>, <span class="refDoi"> DOI: 10.1124/dmd.106.011239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.106.011239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=17353350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmt1aitLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=922-928&author=J.+Enokizonoauthor=H.+Kusuharaauthor=Y.+Sugiyama&title=Regional+expression+and+activity+of+breast+cancer+resistance+protein+%28Bcrp%2FAbcg2%29+in+mouse+intestine%3A+overlapping+distribution+with+sulfotransferases&doi=10.1124%2Fdmd.106.011239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Regional expression and activity of breast cancer resistance protein (Bcrp/Abcg2) in mouse intestine: overlapping distribution with sulfotransferases</span></div><div class="casAuthors">Enokizono, Junichi; Kusuhara, Hiroyuki; Sugiyama, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">922-928</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Breast cancer resistance protein (Bcrp/Abcg2) is a member of the ATP-binding cassette transporter family with the ability to transport a variety of sulfate conjugates.  In the present study, the regional expression and activity of Bcrp and sulfotransferases (SULTs/Sults) were investigated in mouse intestine.  Western blotting anal. revealed the highest expression of Bcrp in the ileum over the duodenum, jejunum, and colon.  Functional anal. of Bcrp was performed in everted intestinal sacs using 4-methylumbelliferone (4MU).  The mucosal secretion clearance of 4MU sulfate formed in the enterocytes was markedly reduced in the jejunum, ileum, and colon of Bcrp (-/-) mice in comparison with wild-type mice, whereas a slight and nonsignificant redn. was obsd. in the duodenum.  The redn. in the mucosal secretion clearance was most marked in the ileum followed by the colon and jejunum.  In addn., the mucosal secretion clearance of minoxidil sulfate, an active metabolite of minoxidil, was also significantly reduced in the intestine of Bcrp (-/-) mice.  The sulfation activity of 4MU was higher in the colon than in the small intestine where glucuronidation activity was somewhat higher than the sulfation activity.  Real-time polymerase chain reaction anal. showed that the expression of sulfotransferases, such as Sult1a1/2, Sult1b1, and Sult1d1, was also highest in the colon.  These results suggest that Bcrp activity is higher in the mid to lower intestine and that the cooperation of Bcrp and SULT provides an important detoxification pathway, particularly in the colon.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2z118DQNnDbVg90H21EOLACvtfcHk0lixDJk0RbbFMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmt1aitLg%253D&md5=863ee317f6eafa5704da37590cdcf664</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1124%2Fdmd.106.011239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.106.011239%26sid%3Dliteratum%253Aachs%26aulast%3DEnokizono%26aufirst%3DJ.%26aulast%3DKusuhara%26aufirst%3DH.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DRegional%2520expression%2520and%2520activity%2520of%2520breast%2520cancer%2520resistance%2520protein%2520%2528Bcrp%252FAbcg2%2529%2520in%2520mouse%2520intestine%253A%2520overlapping%2520distribution%2520with%2520sulfotransferases%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2007%26volume%3D35%26spage%3D922%26epage%3D928%26doi%3D10.1124%2Fdmd.106.011239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hilgendorf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahlin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seithel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungell, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, J.</span></span> <span> </span><span class="NLM_article-title">Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1333</span>– <span class="NLM_lpage">1340</span>, <span class="refDoi"> DOI: 10.1124/dmd.107.014902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.107.014902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=17496207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVKqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=1333-1340&author=C.+Hilgendorfauthor=G.+Ahlinauthor=A.+Seithelauthor=P.+Arturssonauthor=A.+L.+Ungellauthor=J.+Karlsson&title=Expression+of+thirty-six+drug+transporter+genes+in+human+intestine%2C+liver%2C+kidney%2C+and+organotypic+cell+lines&doi=10.1124%2Fdmd.107.014902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines</span></div><div class="casAuthors">Hilgendorf, Constanze; Ahlin, Gustav; Seithel, Annick; Artursson, Per; Ungell, Anna-Lena; Karlsson, Johan</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1333-1340</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">This study was designed to quant. assess the mRNA expression of 36 important drug transporters in human jejunum, colon, liver, and kidney.  Expression of these transporters in human organs was compared with expression in commonly used cell lines (Caco-2, HepG2, and Caki-1) originating from these organs to assess their value as in vitro transporter system models, and was also compared with data obtained from the literature on expression in rat tissues to assess species differences.  Transporters that were highly expressed in the intestine included HPT1, PEPT1, BCRP, MRP2, and MDR1, whereas, in the liver, OCT1, MRP2, OATP-C, NTCP and BSEP were the main transporters.  In the kidney, OAT1 was expressed at the highest levels, followed by OAT3, OAT4, MCT5, MDR1, MRP2, OCT2, and OCTN2.  The best agreement between human tissue and the representative cell line was obsd. for human jejunum and Caco-2 cells.  Expression in liver and kidney orthol. cell lines was not correlated with that in the assocd. tissue.  Comparisons with rat transporter gene expression revealed significant species differences.  Our results allowed a comprehensive quant. comparison of drug transporter expression in human intestine, liver, and kidney.  We suggest that it would be beneficial for predictive pharmacokinetic research to focus on the most highly expressed transporters.  We hope that our comparison of rat and human tissue will help to explain the obsd. species differences in in vivo models, increase understanding of the impact of active transport processes on pharmacokinetics and distribution, and improve the quality of predictions from animal studies to humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC3qvmG8tTf7Vg90H21EOLACvtfcHk0liMK0aXXUXenw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVKqtbg%253D&md5=edfef89a8c422dbdcc0a097425b2ad2e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1124%2Fdmd.107.014902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.107.014902%26sid%3Dliteratum%253Aachs%26aulast%3DHilgendorf%26aufirst%3DC.%26aulast%3DAhlin%26aufirst%3DG.%26aulast%3DSeithel%26aufirst%3DA.%26aulast%3DArtursson%26aufirst%3DP.%26aulast%3DUngell%26aufirst%3DA.%2BL.%26aulast%3DKarlsson%26aufirst%3DJ.%26atitle%3DExpression%2520of%2520thirty-six%2520drug%2520transporter%2520genes%2520in%2520human%2520intestine%252C%2520liver%252C%2520kidney%252C%2520and%2520organotypic%2520cell%2520lines%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2007%26volume%3D35%26spage%3D1333%26epage%3D1340%26doi%3D10.1124%2Fdmd.107.014902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moenning, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fricker, G.</span></span> <span> </span><span class="NLM_article-title">Closing the gaps: a full scan of the intestinal expression of p-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in male and female rats</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1249</span>– <span class="NLM_lpage">1254</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.020859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.108.020859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=18378562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotVegurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=1249-1254&author=C.+MacLeanauthor=U.+Moenningauthor=A.+Reichelauthor=G.+Fricker&title=Closing+the+gaps%3A+a+full+scan+of+the+intestinal+expression+of+p-glycoprotein%2C+breast+cancer+resistance+protein%2C+and+multidrug+resistance-associated+protein+2+in+male+and+female+rats&doi=10.1124%2Fdmd.108.020859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Closing the gaps: a full scan of the intestinal expression of P-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in male and female rats</span></div><div class="casAuthors">MacLean, Caroline; Moenning, Ulla; Reichel, Andreas; Fricker, Gert</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1249-1254</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Intestinal ATP binding cassette (ABC) transporters may affect the bioavailability and effectiveness of orally administered drugs.  Available studies on regional expression of intestinal efflux transporters were done with selected intestinal segments only and inconsistent with regard to the variability of transporter expression and the course of expression along the intestine.  For an evaluation of the consistency between mRNA and protein expression, relative expression levels of P-glycoprotein (Pgp; ABCB1), breast cancer resistance protein (Bcrp; ABCG2), and multidrug resistance-assocd. protein (Mrp) 2 (ABCC2) were detd. using quant. real-time-polymerase chain reaction and Western blot in rat intestinal segments from duodenum, jejunum, ileum, and colon.  In addn., the protein expression of Pgp, Bcrp, and Mrp2 from the entire rat intestine was studied by a complete 3-cm segmentation to evaluate the predictive power of expression analyses from selected intestinal segments.  Pgp showed an increase from proximal to distal regions, Bcrp showed an arcuate pattern with highest expression toward the end of small intestine, and Mrp2 decreased along the intestinal axis from proximal to distal parts.  No gender specific differences could be obsd.  Regarding the concordance of mRNA and protein expression, Pgp and Bcrp mRNA samples allow good estns. about the corresponding protein expression (for Pgp limited to the mdr1a isoform), but for Mrp2, pronounced deviation could be obsd.  All transporters showed considerable intra- and interindividual variability, esp. at the protein level, making it problematic to take transporter expressions of small sections exemplary for general assumptions on intestinal abundances.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZE4PQg_IZvLVg90H21EOLACvtfcHk0liMK0aXXUXenw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotVegurk%253D&md5=fd2d9a1e1cdd9cdaa575928a1fa3e7d2</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.020859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.020859%26sid%3Dliteratum%253Aachs%26aulast%3DMacLean%26aufirst%3DC.%26aulast%3DMoenning%26aufirst%3DU.%26aulast%3DReichel%26aufirst%3DA.%26aulast%3DFricker%26aufirst%3DG.%26atitle%3DClosing%2520the%2520gaps%253A%2520a%2520full%2520scan%2520of%2520the%2520intestinal%2520expression%2520of%2520p-glycoprotein%252C%2520breast%2520cancer%2520resistance%2520protein%252C%2520and%2520multidrug%2520resistance-associated%2520protein%25202%2520in%2520male%2520and%2520female%2520rats%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26spage%3D1249%26epage%3D1254%26doi%3D10.1124%2Fdmd.108.020859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haslam, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Reilly, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherlock, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, N. L.</span></span> <span> </span><span class="NLM_article-title">Intestinal ciprofloxacin efflux: the role of breast cancer resistance protein (ABCG2)</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">2321</span>– <span class="NLM_lpage">2328</span>, <span class="refDoi"> DOI: 10.1124/dmd.111.038323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.111.038323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=21930826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCru77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=2321-2328&author=I.+S.+Haslamauthor=J.+A.+Wrightauthor=D.+A.+O%E2%80%99Reillyauthor=D.+J.+Sherlockauthor=T.+Colemanauthor=N.+L.+Simmons&title=Intestinal+ciprofloxacin+efflux%3A+the+role+of+breast+cancer+resistance+protein+%28ABCG2%29&doi=10.1124%2Fdmd.111.038323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal ciprofloxacin efflux: the role of breast cancer resistance protein (ABCG2)</span></div><div class="casAuthors">Haslam, I. S.; Wright, J. A.; O'Reilly, D. A.; Sherlock, D. J.; Coleman, T.; Simmons, N. L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2321-2328</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Intestinal secretory movement of the fluoroquinolone antibiotic, ciprofloxacin, may limit its oral bioavailability.  Active ATP-binding cassette (ABC) transporters such as breast cancer resistance protein (BCRP) have been implicated in ciprofloxacin transport.  The aim of this study was to test the hypothesis that BCRP alone mediates intestinal ciprofloxacin secretion.  The involvement of ABC transport proteins in ciprofloxacin secretory flux was investigated with the combined use of transfected cell lines [bcrp1/BCRP-Madin-Darby canine kidney II (MDCKII) and multidrug resistance-related protein 4 (MRP4)-human embryonic kidney (HEK) 293] and human intestinal Caco-2 cells, combined with pharmacol. inhibition using 3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6, 7,12,12a-octahydropyrazino[1',2':1,6]pyrido[3,4-b]indol-3-yl)-propionic acid tert-Bu ester (Ko143), cyclosporine, 3-[[3-[2-(7-chloroquinolin-2-yl)vinyl]phenyl]-(2-dimethylcarbamoylethylsulfanyl)methylsulfanyl] propionic acid (MK571), and verapamil as ABC-selective inhibitors.  In addn., the regional variation in secretory capacity was investigated using male Han Wistar rat intestine mounted in Ussing chambers, and the first indicative measurements of ciprofloxacin transport by ex vivo human jejunum were made.  Active, Ko143-sensitive ciprofloxacin secretion was obsd. in bcrp1-MDCKII cell layers, but in low-passage (BCRP-expressing) Caco-2 cell layers only a 54% fraction was Ko143-sensitive.  Ciprofloxacin accumulation was lower in MRP4-HEK293 cells than in the parent line, indicating that ciprofloxacin is also a substrate for this transporter.  Ciprofloxacin secretion by Caco-2 cell layers was not inhibited by MK571.  Secretory flux showed marked regional variability in the rat intestine, increasing from the duodenum to peak in the ileum.  Ciprofloxacin secretion was present in human jejunum and was reduced by Ko143 but showed marked interindividual variability.  Ciprofloxacin is a substrate for human and rodent BCRP.  An addnl. pathway for ciprofloxacin secretion exists in Caco-2 cells, which is unlikely to be MRP(4)-mediated.  BCRP is likely to be the dominant transport mechanism for ciprofloxacin efflux in both rat and human jejunum.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWW3kSbnN3sLVg90H21EOLACvtfcHk0liMK0aXXUXenw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCru77O&md5=9021b5fb2d0675d51416fef22c1c3e65</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.038323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.038323%26sid%3Dliteratum%253Aachs%26aulast%3DHaslam%26aufirst%3DI.%2BS.%26aulast%3DWright%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DD.%2BA.%26aulast%3DSherlock%26aufirst%3DD.%2BJ.%26aulast%3DColeman%26aufirst%3DT.%26aulast%3DSimmons%26aufirst%3DN.%2BL.%26atitle%3DIntestinal%2520ciprofloxacin%2520efflux%253A%2520the%2520role%2520of%2520breast%2520cancer%2520resistance%2520protein%2520%2528ABCG2%2529%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D2321%26epage%3D2328%26doi%3D10.1124%2Fdmd.111.038323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gutmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beglinger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewe, J.</span></span> <span> </span><span class="NLM_article-title">Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">695</span>– <span class="NLM_lpage">699</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2005.05.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1016%2Fj.bcp.2005.05.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=15998509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvFSisrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2005&pages=695-699&author=H.+Gutmannauthor=P.+Hruzauthor=C.+Zimmermannauthor=C.+Beglingerauthor=J.+Drewe&title=Distribution+of+breast+cancer+resistance+protein+%28BCRP%2FABCG2%29+mRNA+expression+along+the+human+GI+tract&doi=10.1016%2Fj.bcp.2005.05.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract</span></div><div class="casAuthors">Gutmann, Heike; Hruz, Petr; Zimmermann, Christian; Beglinger, Christoph; Drewe, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">695-699</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Human breast cancer resistance protein (BCRP/ABCG2) is an ABC-transporter that is present on the luminal membrane of intestinal epithelial cells and restricts absorption of anticancer drugs such as methotrexate, topotecan, mitoxantrone, and doxorubicin.  The exact anat. distribution of BCRP along the gastrointestinal (GI) tract, however, has not been detd. before.  The aim of this study was, therefore to investigate BCRP mRNA expression pattern along the GI tract in 14 healthy subjects.  Furthermore, BCRP duodenal mRNA expression was compared with MDR1/ABCB1 mRNA.  Addnl., BCRP mRNA expression was investigated in two human intestinal cell lines (Caco-2 and LS180).  Since previous animal studies have suggested sex specific differences in BCRP expression, we analyzed intestinal BCRP expression with respect to sex.  Biopsies were taken from different gut segments (duodenum, terminal ileum and ascending, transverse, descending and sigmoid colon).  Gene expression was assessed by quant. real-time PCR (Taqman).  BCRP mRNA expression was maximal in the duodenum and decreased continuously down to the rectum (terminal ileum 93.7%, ascending colon 75.8%, transverse colon 66.6%, descending colon 62.8%, and sigmoid colon 50.1% compared to duodenum, resp.).  BCRP expression in the duodenum was comparable to MDR1/ABCB1 gene expression.  Caco-2 cells showed a comparable expression of BCRP as human duodenal tissue.  Gender specific differences in BCRP expression were not obsd.  These findings represent the first systematic site-specific anal. of BCRP expression along the GI tract.  This information might be helpful to develop target strategies for orally administered anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCnsu7rhgT4LVg90H21EOLACvtfcHk0lg8-tB5y4_dlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvFSisrc%253D&md5=265175e10bd1812474eaf59ab7581093</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2005.05.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2005.05.031%26sid%3Dliteratum%253Aachs%26aulast%3DGutmann%26aufirst%3DH.%26aulast%3DHruz%26aufirst%3DP.%26aulast%3DZimmermann%26aufirst%3DC.%26aulast%3DBeglinger%26aufirst%3DC.%26aulast%3DDrewe%26aufirst%3DJ.%26atitle%3DDistribution%2520of%2520breast%2520cancer%2520resistance%2520protein%2520%2528BCRP%252FABCG2%2529%2520mRNA%2520expression%2520along%2520the%2520human%2520GI%2520tract%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2005%26volume%3D70%26spage%3D695%26epage%3D699%26doi%3D10.1016%2Fj.bcp.2005.05.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taipalensuu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tornblom, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindberg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einarsson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjoqvist, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melhus, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjostrom, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundgren, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span> <span> </span><span class="NLM_article-title">Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>299</i></span>,  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">170</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=11561076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntFWlt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2001&pages=164-170&author=J.+Taipalensuuauthor=H.+Tornblomauthor=G.+Lindbergauthor=C.+Einarssonauthor=F.+Sjoqvistauthor=H.+Melhusauthor=P.+Garbergauthor=B.+Sjostromauthor=B.+Lundgrenauthor=P.+Artursson&title=Correlation+of+gene+expression+of+ten+drug+efflux+proteins+of+the+ATP-binding+cassette+transporter+family+in+normal+human+jejunum+and+in+human+intestinal+epithelial+Caco-2+cell+monolayers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers</span></div><div class="casAuthors">Taipalensuu, Jan; Tornblom, Hans; Lindberg, Greger; Einarsson, Curt; Sjoqvist, Folke; Melhus, Hakan; Garberg, Per; Sjostrom, Brita; Lundgren, Bo; Artursson, Per</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">299</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">164-170</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">This investigation describes the expression and interindividual variability in transcript levels of multiple drug efflux systems in the human jejunum and compares the expression profiles in these cells with that of the commonly used Caco-2 cell drug absorption model.  Transcript levels of ten-drug efflux proteins of the ATP-binding cassette (ABC) transporter family [MDR1, MDR3, ABCB5, MRP1-6, and breast cancer resistance protein (BCRP)], lung resistance-related protein (LRP), and CYP3A4 were detd. using quant. polymerase chain reaction in jejunal biopsies from 13 healthy human subjects and in Caco-2 cells.  All genes except ABCB5 were expressed, and transcript levels varied between individuals only by a factor of 2 to 3.  Surprisingly, BCRP and MRP2 transcripts were more abundant in jejunum than MDR1 transcripts.  Jejunal transcript levels of the different ABC transporters spanned a range of three log units with the rank order: BCRP ≈ MRP2 > MDR1 ≈ MRP3 ≈ MRP6 ≈ MRP5 ≈ MRP1 > MRP4 > MDR3.  Furthermore, transcript levels of 9 of 10 ABC transporters correlated well between jejunum and Caco-2 cells (r2 = 0.90).  However, BCRP exhibited a 100-fold lower transcript level in Caco-2 cells compared with jejunum.  Thus, the expression of a no. of efflux protein transcripts in jejunum are equal to, or even higher than, that of MDR1, suggesting that the roles of these proteins (in particular BCRP and MRP2) in intestinal drug efflux have been underestimated.  Also, we tentatively conclude that the Caco-2 cell line is a useful model of jejunal drug efflux, if the low expression of BCRP is taken into account.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1f-Z1mGAtjbVg90H21EOLACvtfcHk0lg8-tB5y4_dlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntFWlt7Y%253D&md5=1a2ef81848fcaafda43d4980f6987856</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTaipalensuu%26aufirst%3DJ.%26aulast%3DTornblom%26aufirst%3DH.%26aulast%3DLindberg%26aufirst%3DG.%26aulast%3DEinarsson%26aufirst%3DC.%26aulast%3DSjoqvist%26aufirst%3DF.%26aulast%3DMelhus%26aufirst%3DH.%26aulast%3DGarberg%26aufirst%3DP.%26aulast%3DSjostrom%26aufirst%3DB.%26aulast%3DLundgren%26aufirst%3DB.%26aulast%3DArtursson%26aufirst%3DP.%26atitle%3DCorrelation%2520of%2520gene%2520expression%2520of%2520ten%2520drug%2520efflux%2520proteins%2520of%2520the%2520ATP-binding%2520cassette%2520transporter%2520family%2520in%2520normal%2520human%2520jejunum%2520and%2520in%2520human%2520intestinal%2520epithelial%2520Caco-2%2520cell%2520monolayers%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2001%26volume%3D299%26spage%3D164%26epage%3D170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harwood, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pathak, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuhoff, S.</span></span> <span> </span><span class="NLM_article-title">The regional-specific relative and absolute expression of gut transporters in adult caucasians: a meta-analysis</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">854</span>– <span class="NLM_lpage">864</span>, <span class="refDoi"> DOI: 10.1124/dmd.119.086959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.119.086959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=31076413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFSgtr7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2019&pages=854-864&issue=8&author=M.+D.+Harwoodauthor=M.+Zhangauthor=S.+M.+Pathakauthor=S.+Neuhoff&title=The+regional-specific+relative+and+absolute+expression+of+gut+transporters+in+adult+caucasians%3A+a+meta-analysis&doi=10.1124%2Fdmd.119.086959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The regional-specific relative and absolute expression of gut transporters in adult caucasians: a meta-analysis</span></div><div class="casAuthors">Harwood, Matthew D.; Zhang, Mian; Pathak, Shriram M.; Neuhoff, Sibylle</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">854-864</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The aim of this study was to derive region-specific transporter expression data suitable for in vitro-to-in vivo extrapolation (IVIVE) within a physiol. based pharmacokinetic (PBPK) modeling framework.  A meta-anal. was performed whereby literary sources reporting region-specific transporter expression obtained via abs. and relative quantification approaches were considered in healthy adult Caucasian individuals.  Furthermore, intestinal total membrane protein yield was calcd. to enable mechanistic IVIVE via abs. transporter abundances.  Where required, authors were contacted for addnl. information.  A refined database was constructed where samples were excluded based on quantification in, non-Caucasian subjects, disease tissue, subjects <18 years old, duplicated samples, non-total membrane matrix, pooled matrixes, or cDNA.  Demog. data were collected where available.  The weighted and geometric mean, coeff. of variation, and between-study homogeneity was calcd. in each of eight gut segments (duodenum, two jejunum, four ileum, and colon) for 16 transporters.  Expression data were normalized to that in the proximal jejunum.  From a total of 47 articles, the final database consisted of 2238 measurements for 16 transporters.  The solute carrier peptide transporter 1 (PepT1) showed the highest jejunal abundance, while multidrug resistance-assocd. protein (MRP) 2 was the highest abundance ATP-binding cassette transporter.  Transporters displaying significant region-specific expression included the ileal bile acid transporter, which showed 18-fold greater terminal ileum expression compared with the proximal jejunum, while MRP3, org. cation transporter type 1 (OCTN1), and OCT1 showed >2-fold higher expression in other regions compared with the proximal jejunum.  This is the first systematic anal. incorporating abs. quantification methodol. to det. region-specific intestinal transporter expression.  It is expected to be beneficial for mechanistic transporter IVIVE in healthy adult Caucasians.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5agTSyUl4gbVg90H21EOLACvtfcHk0lj9td13Hu6y9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFSgtr7M&md5=8104f8371cb2544c81ccc6f94936336e</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1124%2Fdmd.119.086959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.119.086959%26sid%3Dliteratum%253Aachs%26aulast%3DHarwood%26aufirst%3DM.%2BD.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DPathak%26aufirst%3DS.%2BM.%26aulast%3DNeuhoff%26aufirst%3DS.%26atitle%3DThe%2520regional-specific%2520relative%2520and%2520absolute%2520expression%2520of%2520gut%2520transporters%2520in%2520adult%2520caucasians%253A%2520a%2520meta-analysis%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2019%26volume%3D47%26issue%3D8%26spage%3D854%26epage%3D864%26doi%3D10.1124%2Fdmd.119.086959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fagerholm, U.</span></span> <span> </span><span class="NLM_article-title">Prediction of human pharmacokinetics - renal metabolic and excretion clearance</span>. <i>J. Pharm. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1463</span>– <span class="NLM_lpage">1471</span>, <span class="refDoi"> DOI: 10.1211/jpp.59.11.0002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1211%2Fjpp.59.11.0002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2010&pages=1463-1471&author=U.+Fagerholm&title=Prediction+of+human+pharmacokinetics+-+renal+metabolic+and+excretion+clearance&doi=10.1211%2Fjpp.59.11.0002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1211%2Fjpp.59.11.0002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1211%252Fjpp.59.11.0002%26sid%3Dliteratum%253Aachs%26aulast%3DFagerholm%26aufirst%3DU.%26atitle%3DPrediction%2520of%2520human%2520pharmacokinetics%2520-%2520renal%2520metabolic%2520and%2520excretion%2520clearance%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D2010%26volume%3D59%26spage%3D1463%26epage%3D1471%26doi%3D10.1211%2Fjpp.59.11.0002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troutman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chupka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan</span></span> <span> </span><span class="NLM_article-title">A physicochemical determinants of human renal clearance</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">4844</span>– <span class="NLM_lpage">4852</span>, <span class="refDoi"> DOI: 10.1021/jm900403j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900403j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlvFOnt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4844-4852&author=M.+V.+Varmaauthor=B.+Fengauthor=R.+S.+Obachauthor=M.+D.+Troutmanauthor=J.+Chupkaauthor=H.+R.+Millerauthor=+El-Kattan&title=A+physicochemical+determinants+of+human+renal+clearance&doi=10.1021%2Fjm900403j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Physicochemical Determinants of Human Renal Clearance</span></div><div class="casAuthors">Varma, Manthena V. S.; Feng, Bo; Obach, R. Scott; Troutman, Matthew D.; Chupka, Jonathan; Miller, Howard R.; El-Kattan, Ayman</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4844-4852</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kidney plays an important role in the elimination of drugs, esp. with low or negligible hepatic clearance.  An anal. of the interrelation of physicochem. properties and the human renal clearance for a data set of 391 drugs or compds. tested in humans is presented.  The data set indicated that lipophilicity shows a neg. relationship while polar descriptors show a pos. relationship with renal clearance.  Anal. of net secreted and net reabsorbed subsets revealed that hydrophilic ionized compds. are probable compds. to show net secretion and a possible drug-drug interaction due to their likely interaction with uptake transporters and inherent low passive reabsorption.  The physicochem. space and renal clearance were also statistically analyzed by therapeutic area.  In conclusion, ionization state, lipophilicity, and polar descriptors are found to be the physicochem. determinants of renal clearance.  These fundamental properties can be valuable in early prediction of human renal clearance and can aid the chemist in structural modifications to optimize drug disposition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorGLq4kYGi_LVg90H21EOLACvtfcHk0lj9td13Hu6y9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlvFOnt7s%253D&md5=a99ccaa1651d04ed7f7c0a49679f55f6</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm900403j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900403j%26sid%3Dliteratum%253Aachs%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26aulast%3DChupka%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DH.%2BR.%26aulast%3DEl-Kattan%26atitle%3DA%2520physicochemical%2520determinants%2520of%2520human%2520renal%2520clearance%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4844%26epage%3D4852%26doi%3D10.1021%2Fjm900403j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scotcher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rostami-Hodjegan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galetin, A.</span></span> <span> </span><span class="NLM_article-title">Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2016.03.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1016%2Fj.ejps.2016.03.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=27033147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC28XlslelsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2016&pages=59-71&author=D.+Scotcherauthor=C.+Jonesauthor=A.+Rostami-Hodjeganauthor=A.+Galetin&title=Novel+minimal+physiologically-based+model+for+the+prediction+of+passive+tubular+reabsorption+and+renal+excretion+clearance&doi=10.1016%2Fj.ejps.2016.03.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance</span></div><div class="casAuthors">Scotcher, Daniel; Jones, Christopher; Rostami-Hodjegan, Amin; Galetin, Aleksandra</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59-71</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Develop a minimal mechanistic model based on in vitro-in vivo extrapolation (IVIVE) principles to predict extent of passive tubular reabsorption.  Assess the ability of the model developed to predict extent of passive tubular reabsorption (Freab) and renal excretion clearance (CLR) from in vitro permeability data and tubular physiol. parameters.  Model system parameters were informed by physiol. data collated following extensive literature anal.  A database of clin. CLR was collated for 157 drugs.  A subset of 45 drugs was selected for model validation; for those, Caco-2 permeability (Papp) data were measured under pH 6.5-7.4 gradient conditions and used to predict Freab and subsequently CLR.  An empirical calibration approach was proposed to account for the effect of inter-assay/lab. variation in Papp on the IVIVE of Freab.  The 5-compartmental model accounted for regional differences in tubular surface area and flow rates and successfully predicted the extent of tubular reabsorption of 45 drugs for which filtration and reabsorption were contributing to renal excretion.  Subsequently, predicted CLR was within 3-fold of the obsd. values for 87% of drugs in this dataset, with an overall gmfe of 1.96.  Consideration of the empirical calibration method improved overall prediction of CLR (gmfe = 1.73 for 34 drugs in the internal validation dataset), in particular for basic drugs and drugs with low extent of tubular reabsorption.  The novel 5-compartment model represents an important addn. to the IVIVE toolbox for physiol.-based prediction of renal tubular reabsorption and CLR.  Physiol. basis of the model proposed allows its application in future mechanistic kidney models in preclin. species and human.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHGRtkbpoQLrVg90H21EOLACvtfcHk0lhKXxeHk5kYqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlslelsLk%253D&md5=b8bbc2b34ae6aeb297d676322c8bc2e0</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2016.03.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2016.03.018%26sid%3Dliteratum%253Aachs%26aulast%3DScotcher%26aufirst%3DD.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DRostami-Hodjegan%26aufirst%3DA.%26aulast%3DGaletin%26aufirst%3DA.%26atitle%3DNovel%2520minimal%2520physiologically-based%2520model%2520for%2520the%2520prediction%2520of%2520passive%2520tubular%2520reabsorption%2520and%2520renal%2520excretion%2520clearance%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2016%26volume%3D94%26spage%3D59%26epage%3D71%26doi%3D10.1016%2Fj.ejps.2016.03.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czuba, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isoherranen, N.</span></span> <span> </span><span class="NLM_article-title">Mechanistic PBPK modeling of urine pH effect on renal and systemic disposition of methamphetamine and amphetamine</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">488</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1124/jpet.120.264994</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fjpet.120.264994" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=32198137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlejur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2020&pages=488-501&author=W.+Huangauthor=L.+C.+Czubaauthor=N.+Isoherranen&title=Mechanistic+PBPK+modeling+of+urine+pH+effect+on+renal+and+systemic+disposition+of+methamphetamine+and+amphetamine&doi=10.1124%2Fjpet.120.264994"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45aR"><div class="casContent"><span class="casTitleNuber">45a</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic PBPK modeling of urine pH effect on renal and systemic disposition of methamphetamine and amphetamine</span></div><div class="casAuthors">Huang, Weize; Czuba, Lindsay C.; Isoherranen, Nina</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">488-501</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">In this study, we hypothesized that physiol. based pharmacokinetic (PBPK) modeling could be used as a cost-effective method to examine potential urine pH effect on drug and metabolite disposition.  Our previously developed and verified mechanistic kidney model was integrated with a full-body PBPK model to simulate renal clearance and area under the plasma concn.-time curve (AUC) with varying urine pH statuses using methamphetamine and amphetamine as model compds.  We first developed and verified drug models for methamphetamine and amphetamine under normal urine pH condition [abs. av. fold error (AAFE) < 1.25 at study level].  Then, acidic and alk. urine scenarios were simulated.  Our simulation results show that the renal excretion and plasma concn.-time profiles for methamphetamine and amphetamine could be recapitulated under different urine pH (AAFE < 2 at individual level).  The methamphetamine-amphetamine parent-metabolite full-body PBPK model also successfully simulated amphetamine plasma concn.-time profiles (AAFE < 1.25 at study level) and amphetamine/methamphetamine urinary concn. ratios (AAFE < 2 at individual level) after dosing methamphetamine.  This demonstrates that our mechanistic PBPK model can predict urine pH effect on systemic and urinary disposition of drugs and metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7Q73VLmXhxbVg90H21EOLACvtfcHk0lhKXxeHk5kYqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlejur7I&md5=766856f7fda555dd7703d3c5dd5a356e</span></div><a href="/servlet/linkout?suffix=cit45a&amp;dbid=16384&amp;doi=10.1124%2Fjpet.120.264994&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.120.264994%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DCzuba%26aufirst%3DL.%2BC.%26aulast%3DIsoherranen%26aufirst%3DN.%26atitle%3DMechanistic%2520PBPK%2520modeling%2520of%2520urine%2520pH%2520effect%2520on%2520renal%2520and%2520systemic%2520disposition%2520of%2520methamphetamine%2520and%2520amphetamine%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2020%26volume%3D373%26spage%3D488%26epage%3D501%26doi%3D10.1124%2Fjpet.120.264994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit45b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strauss, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caplan, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodico, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, D. M.</span></span> <span> </span><span class="NLM_article-title">Urine pH: the effects of time and temperature after collection</span>. <i>J. Anal. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">496</span>, <span class="refDoi"> DOI: 10.1093/jat/31.8.486</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1093%2Fjat%2F31.8.486" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=17988463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1WnsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2007&pages=486-496&author=J.+D.+Cookauthor=K.+A.+Straussauthor=Y.+H.+Caplanauthor=C.+P.+Lodicoauthor=D.+M.+Bush&title=Urine+pH%3A+the+effects+of+time+and+temperature+after+collection&doi=10.1093%2Fjat%2F31.8.486"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45bR"><div class="casContent"><span class="casTitleNuber">45b</span><div class="casTitle"><span class="NLM_cas:atitle">Urine pH: the effects of time and temperature after collection</span></div><div class="casAuthors">Cook, Janine D.; Strauss, Kathy A.; Caplan, Yale H.; LoDico, Charles P.; Bush, Donna M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Analytical Toxicology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">486-496</span>CODEN:
                <span class="NLM_cas:coden">JATOD3</span>;
        ISSN:<span class="NLM_cas:issn">0146-4760</span>.
    
            (<span class="NLM_cas:orgname">Preston Publications</span>)
        </div><div class="casAbstract">The Mandatory Guidelines for Federal Workplace Drug Testing Programs provide criteria for specimen validity testing, including urine pH cut-offs, to report a urine specimen as adulterated or invalid.  Since the urine pH criteria for invalid classifications, ≥ 3 and < 4.5 or ≥ 9 and < 11, became effective in Nov. 2004, a no. of specimens with results within the upper invalid limits, typically in the range of 9.1 to 9.3, were reported with no evidence of adulteration.  This study evaluated the hypothesis that these pH findings were the result of exposure to increased environmental temps. during specimen standing and transport.  Indeed, increased storage temps. were assocd. with increased urine pH, with the magnitude of the change related to both storage time and temp.  The pH values of specimens stored at -20°C are relatively stable, whereas pH results > 9 are achieved at storage temps. of room temp. or higher.  It is noteworthy that no condition(s) produced a specimen with a pH > 9.5.  Degrdn. of nitrogenous urine analytes is most likely responsible for the noted increases in pH.  These findings are intended to supplement information used by the Medical Review Officers who are responsible for interpreting such marginally invalid pH results.  (c) 2007 Preston Publications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8E9xXtiSa6rVg90H21EOLACvtfcHk0lgDu977B6uHqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1WnsbbM&md5=d7908eb28087e36212620d67efc31f4a</span></div><a href="/servlet/linkout?suffix=cit45b&amp;dbid=16384&amp;doi=10.1093%2Fjat%2F31.8.486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjat%252F31.8.486%26sid%3Dliteratum%253Aachs%26aulast%3DCook%26aufirst%3DJ.%2BD.%26aulast%3DStrauss%26aufirst%3DK.%2BA.%26aulast%3DCaplan%26aufirst%3DY.%2BH.%26aulast%3DLodico%26aufirst%3DC.%2BP.%26aulast%3DBush%26aufirst%3DD.%2BM.%26atitle%3DUrine%2520pH%253A%2520the%2520effects%2520of%2520time%2520and%2520temperature%2520after%2520collection%26jtitle%3DJ.%2520Anal.%2520Toxicol.%26date%3D2007%26volume%3D31%26spage%3D486%26epage%3D496%26doi%3D10.1093%2Fjat%2F31.8.486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit45c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Freudenthaler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meineke, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreeb, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boakye, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gundert-Remy, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleiter, G. H.</span></span> <span> </span><span class="NLM_article-title">Influence of urine pH and urinary flow on the renal excretion of memantine</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">541</span>– <span class="NLM_lpage">546</span>, <span class="refDoi"> DOI: 10.1046/j.1365-2125.1998.00819.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1046%2Fj.1365-2125.1998.00819.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK1MXntFOm" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=1998&pages=541-546&author=S.+Freudenthalerauthor=I.+Meinekeauthor=K.+H.+Schreebauthor=E.+Boakyeauthor=U.+Gundert-Remyauthor=G.+H.+Gleiter&title=Influence+of+urine+pH+and+urinary+flow+on+the+renal+excretion+of+memantine&doi=10.1046%2Fj.1365-2125.1998.00819.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45cR"><div class="casContent"><span class="casTitleNuber">45c</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of urine pH and urinary flow on the renal excretion of memantine</span></div><div class="casAuthors">Freudenthaler, S.; Meineke, I.; Schreeb, K.-H.; Boakye, E.; Gundert-Remy, U.; Gleiter, C. H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">541-546</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">The present study assessed the influence of urinary flow rate and urine pH on the renal excretion of the NMDA-receptor antagonist memantine.  In a randomized, open, four-period cross-over trial, 12 healthy male volunteers received 10 mg memantine daily for 43 days.  After reaching steady state conditions the volunteers were allocated to four different regiments to alter urine pH and urinary flow, which were each sepd. by a 1 wk period while the study medication continued (A: acidification of urine pH, low urinary flow; B: acidification of urine pH, high urinary flow; C: alkalinization of urine pH, low urinary flow: D: alkalinization of urine pH, high urinary flow).  The renal clearance of memantine (CLR) in regimen A and B was 7-10 fold higher in comparison with regimen C and D (P<0.05).  There were small but statistically significant differences of CLR between the two regimens with acidic urine pH (A: median: 210.2 mL min-1 vs B: median: 218.7 mL min-1) and between the two regimens with alk. urine pH (C: median: 19.4 mL min-1 vs D: median: 30.5 mL min-1).  The amt. of memantine excreted into the urine within one regimen (Ae0-24 h) was 5.7-7.4 fold higher in regimens A and B than C and D (P<0.05).  Differences of the AUC(0,24 h) and Cmax/AUC(0,24 h) were significant (P<0.05) between each of the regimens with acidic urine pH (A, B) and regimens (C, D) with alk. urine pH (A vs C, A vs D, B vs C, B vs D) but not between regimens A vs B or C vs D.  The present study demonstrated a considerable effect of urine pH, whereas no clin. relevant change of the renal excretion of memantine with urinary flow could be detected.  As the renal excretion of memantine may have an impact on therapeutic efficacy changes of dietary habits that may alter urine pH should be avoided during treatment with memantine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPD7FZws8DybVg90H21EOLACvtfcHk0lgDu977B6uHqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntFOm&md5=a19e1cca3cb1d61c0793dfaaeba07589</span></div><a href="/servlet/linkout?suffix=cit45c&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2125.1998.00819.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2125.1998.00819.x%26sid%3Dliteratum%253Aachs%26aulast%3DFreudenthaler%26aufirst%3DS.%26aulast%3DMeineke%26aufirst%3DI.%26aulast%3DSchreeb%26aufirst%3DK.%2BH.%26aulast%3DBoakye%26aufirst%3DE.%26aulast%3DGundert-Remy%26aufirst%3DU.%26aulast%3DGleiter%26aufirst%3DG.%2BH.%26atitle%3DInfluence%2520of%2520urine%2520pH%2520and%2520urinary%2520flow%2520on%2520the%2520renal%2520excretion%2520of%2520memantine%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D1998%26volume%3D46%26spage%3D541%26epage%3D546%26doi%3D10.1046%2Fj.1365-2125.1998.00819.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit45d"><span><span class="NLM_label">d. </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Neuvonen, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karkkainen, S.</span></span> <span> </span><span class="NLM_article-title">Effect of charcoal, sodium bicarbonate, and ammonium chloride on chlorpropamide kinetics</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">386</span>– <span class="NLM_lpage">393</span>, <span class="refDoi"> DOI: 10.1038/clpt.1983.50</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1038%2Fclpt.1983.50" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=6297841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaL3sXhslamsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1983&pages=386-393&author=P.+J.+Neuvonenauthor=S.+Karkkainen&title=Effect+of+charcoal%2C+sodium+bicarbonate%2C+and+ammonium+chloride+on+chlorpropamide+kinetics&doi=10.1038%2Fclpt.1983.50"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45dR"><div class="casContent"><span class="casTitleNuber">45d.</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of charcoal, sodium bicarbonate, and ammonium chloride on chlorpropamide kinetics</span></div><div class="casAuthors">Neuvonen, Pertti J.; Karkkainen, Seija</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">386-93</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    </div><div class="casAbstract">The effects of activated charcoal, Na2CO3, and NH4Cl, given orally, on chlorpropamide (I)  [94-20-2] kinetics was studied in healthy subjects.  Activated charcoal, 50 g, given immediately after 250 mg chlorpropamide reduced its absorption by 90%, but when given in repeated doses from 6 h on (50 g followed by 12.5 g at 6-h intervals) it did not shorten the chlorpropamide half-life (t1/2).  The t1/2 of chlorpropamide was shortened from 49.7 to 12.8 h by Na2CO3 and prolonged to 68.5 h by NH4Cl.  The 72-h urinary excretion of chlorpropamide was increased 4-fold by alkalinization and decreased to 1/20 of baseline by acidification of the urine.  The renal clearance of chlorpropamide correlated with urinary pH, ranging from 1 to 1000 mL/h at the pH from 5 to 8.  Urinary pH is likely to explain at least a part of great interindividual differences in the serum chlorpropamide concns. during steady-state and variations in amt. of urinary metabolites.  In chlorpropamide intoxications, activated charcoal can reduce absorption of the drug and alkalinization of the urine can accelerate its elimination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-JCUEykGZN7Vg90H21EOLACvtfcHk0lgDu977B6uHqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXhslamsLs%253D&md5=373098de498d5733bebb75f0940e3c3c</span></div><a href="/servlet/linkout?suffix=cit45d&amp;dbid=16384&amp;doi=10.1038%2Fclpt.1983.50&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.1983.50%26sid%3Dliteratum%253Aachs%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26aulast%3DKarkkainen%26aufirst%3DS.%26atitle%3DEffect%2520of%2520charcoal%252C%2520sodium%2520bicarbonate%252C%2520and%2520ammonium%2520chloride%2520on%2520chlorpropamide%2520kinetics%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D1983%26volume%3D33%26spage%3D386%26epage%3D393%26doi%3D10.1038%2Fclpt.1983.50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shatzer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span> <span> </span><span class="NLM_article-title">Glucuronidation: driving factors and their impact on glucuronide disposition</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1080/03602532.2017.1293682</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1080%2F03602532.2017.1293682" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=28266877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC2sXos1ars7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2017&pages=105-138&author=G.+Yangauthor=S.+Geauthor=R.+Singhauthor=S.+Basuauthor=K.+Shatzerauthor=M.+Zenauthor=J.+Liuauthor=Y.+Tuauthor=C.+Zhangauthor=J.+Weiauthor=J.+Shiauthor=L.+Zhuauthor=Z.+Liuauthor=Y.+Wangauthor=S.+Gaoauthor=M.+Hu&title=Glucuronidation%3A+driving+factors+and+their+impact+on+glucuronide+disposition&doi=10.1080%2F03602532.2017.1293682"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Glucuronidation: driving factors and their impact on glucuronide disposition</span></div><div class="casAuthors">Yang, Guangyi; Ge, Shufan; Singh, Rashim; Basu, Sumit; Shatzer, Katherine; Ming, Zen; Liu, Jiong; Tu, Yifan; Zhang, Chenning; Wei, Jinbao; Shi, Jian; Zhu, Lijun; Liu, Zhongqiu; Wang, Yuan; Gao, Song; Hu, Ming</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">105-138</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Glucuronidation is a well-recognized phase II metabolic pathway for a variety of chems. including drugs and endogenous substances.  Although it is usually the secondary metabolic pathway for a compd. preceded by phase I hydroxylation, glucuronidation alone could serve as the dominant metabolic pathway for many compds., including some with high aq. soly.  Glucuronidation involves the metab. of parent compd. by UDP-glucuronosyltransferases (UGTs) into hydrophilic and neg. charged glucuronides that cannot exit the cell without the aid of efflux transporters.  Therefore, elimination of parent compd. via glucuronidation in a metabolic active cell is controlled by two driving forces: the formation of glucuronides by UGT enzymes and the (polarized) excretion of these glucuronides by efflux transporters located on the cell surfaces in various drug disposition organs.  Contrary to the common assumption that the glucuronides reaching the systemic circulation were destined for urinary excretion, recent evidences suggest that hepatocytes are capable of highly efficient biliary clearance of the gut-generated glucuronides.  Furthermore, the biliary- and enteric-eliminated glucuronides participate into recycling schemes involving intestinal microbes, which often prolong their local and systemic exposure, albeit at low systemic concns.  Taken together, these recent research advances indicate that although UGT dets. the rate and extent of glucuronide generation, the efflux and uptake transporters det. the distribution of these glucuronides into blood and then to various organs for elimination.  Recycling schemes impact the apparent plasma half-life of parent compds. and their glucuronides that reach intestinal lumen, in addn. to prolonging their gut and colon exposure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooH5Ec2SdwRrVg90H21EOLACvtfcHk0lgiBW95lVHFFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXos1ars7g%253D&md5=ffae3e1cc6210706ff7c833202523084</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1080%2F03602532.2017.1293682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F03602532.2017.1293682%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DG.%26aulast%3DGe%26aufirst%3DS.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DBasu%26aufirst%3DS.%26aulast%3DShatzer%26aufirst%3DK.%26aulast%3DZen%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DM.%26atitle%3DGlucuronidation%253A%2520driving%2520factors%2520and%2520their%2520impact%2520on%2520glucuronide%2520disposition%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2017%26volume%3D49%26spage%3D105%26epage%3D138%26doi%3D10.1080%2F03602532.2017.1293682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gadgil, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damle, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, A. B.</span></span> <span> </span><span class="NLM_article-title">Effect of activated charcoal on the pharmacokinetics of high-dose methotrexate</span>. <i>Cancer Treat Rep.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1169</span>– <span class="NLM_lpage">1171</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=7083219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A280%3ADyaL383gvVensQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=1982&pages=1169-1171&author=S.+D.+Gadgilauthor=S.+R.+Damleauthor=S.+H.+Advaniauthor=A.+B.+Vaidya&title=Effect+of+activated+charcoal+on+the+pharmacokinetics+of+high-dose+methotrexate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of activated charcoal on the pharmacokinetics of high-dose methotrexate</span></div><div class="casAuthors">Gadgil S D; Damle S R; Advani S H; Vaidya A B</div><div class="citationInfo"><span class="NLM_cas:title">Cancer treatment reports</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1169-71</span>
        ISSN:<span class="NLM_cas:issn">0361-5960</span>.
    </div><div class="casAbstract">The serum methotrexate (MTX) concentrations were estimated in two groups of patients after 6-hour iv infusion of 1 g/m2 of MTX and leucovorin rescue.  One group (seven patients) received 25 g of activated charcoal orally at 12, 18, 24, 36, and 48 hours, while the other group served as a control (eight patients).  Pharmacokinetic analysis revealed a significant reduction in the area under concentration curve from 18 hours until the serum MTX levels reached 10(-8) M.  The MTX concentrations were significantly lower in the group that received charcoal than in the control group, at 18, 24, 36, 48, 60, and 72 hours from the end of infusion.  First and second half-life values for the control and the charcoal-treated groups did not differ significantly.  The data suggest that charcoal aids in the elimination of MTX from the body by interruption of the enterohepatic circulation of the drug.  Activated charcoal did not cause any undesirable effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6fL2BdWfWCH6HPRus0rAafW6udTcc2eZtDjO_zAS6BLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL383gvVensQ%253D%253D&md5=08a7c78621575c7b0c9196c3d5892985</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGadgil%26aufirst%3DS.%2BD.%26aulast%3DDamle%26aufirst%3DS.%2BR.%26aulast%3DAdvani%26aufirst%3DS.%2BH.%26aulast%3DVaidya%26aufirst%3DA.%2BB.%26atitle%3DEffect%2520of%2520activated%2520charcoal%2520on%2520the%2520pharmacokinetics%2520of%2520high-dose%2520methotrexate%26jtitle%3DCancer%2520Treat%2520Rep.%26date%3D1982%26volume%3D66%26spage%3D1169%26epage%3D1171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stass, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubitza, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moller, J.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delesen, H.</span></span> <span> </span><span class="NLM_article-title">Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">536</span>– <span class="NLM_lpage">541</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2005.02357.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1111%2Fj.1365-2125.2005.02357.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=15842551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltFGgtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2005&pages=536-541&author=H.+Stassauthor=D.+Kubitzaauthor=J.-G.+Mollerauthor=H.+Delesen&title=Influence+of+activated+charcoal+on+the+pharmacokinetics+of+moxifloxacin+following+intravenous+and+oral+administration+of+a+400+mg+single+dose+to+healthy+males&doi=10.1111%2Fj.1365-2125.2005.02357.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males</span></div><div class="casAuthors">Stass, H.; Kubitza, D.; Moeller, J.-G.; Delesen, H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">536-541</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">To evaluate the extent to which enterohepatic recycling circulation contributes to moxifloxacin bioavailability in healthy, males by administration of activated charcoal and to evaluate the efficacy of activated charcoal administration in decreasing systemic concns. of moxifloxacin in the event of overdose.  Nine healthy males, mean age 34 years (range 23-45 years) participated in a single center, randomized, nonplacebo-controlled, three way crossover study.  The pharmacokinetics of moxifloxacin in plasma and urine were detd. for up to 96 h following a 400 mg single dose randomly administered on three sep. occasions with a min. washout phase of 1 wk.  Treatment A was 400 mg moxifloxacin IV as a 1 h infusion, treatment B was 400 mg moxifloxacin IV as a 1 h infusion with oral activated charcoal (5 g directly before the start of the infusion, 5 g immediately after the end of the infusion, and 10 g at 2, 4 and 8 h after the start of the infusion), treatment C was 400 mg oral moxifloxacin with activated charcoal (10 g 15 min before and at 2, 4 and 8 h after drug administration).  The subjects underwent a series of clin. and lab. tests.  Single 400 mg doses of moxifloxacin (PO and/or IV) were safe and well tolerated.  The bioavailability of moxifloxacin was significantly decreased when given with charcoal (AUC = 35.5 (IV ref.) vs 5.40 (PO) vs 28.5 (IV) mg l-1 h).  Concurrently peak concns. were lowered Cmax = 3.38 (IV ref.) vs 0.62(PO) vs 2.97 (IV) mg l-1 by approx. 85% (P < 0.05) following oral administration and by 20% after IV treatment (P < 0.05).  Bioavailability amounted to 15.4% (95% confidence interval 9.6, 25.0%) for treatment B while it was 80.4% (95% confidence interval 76.3.6, 84.6%) for treatment C.  Terminal half-lives were not affected.  The kinetics of urinary excretion corroborated these findings.  The results of this study show that moxifloxacin undergoes pronounced enteric recycling after systemic uptake.  In addn., these findings confirm that activated charcoal may be useful in treating moxifloxacin overdose by preventing its absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeDX6VMLxibrVg90H21EOLACvtfcHk0lgiBW95lVHFFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltFGgtrw%253D&md5=accb4ed3be8c230690600a0e06c2d728</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2005.02357.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2005.02357.x%26sid%3Dliteratum%253Aachs%26aulast%3DStass%26aufirst%3DH.%26aulast%3DKubitza%26aufirst%3DD.%26aulast%3DMoller%26aufirst%3DJ.-G.%26aulast%3DDelesen%26aufirst%3DH.%26atitle%3DInfluence%2520of%2520activated%2520charcoal%2520on%2520the%2520pharmacokinetics%2520of%2520moxifloxacin%2520following%2520intravenous%2520and%2520oral%2520administration%2520of%2520a%2520400%2520mg%2520single%2520dose%2520to%2520healthy%2520males%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2005%26volume%3D59%26spage%3D536%26epage%3D541%26doi%3D10.1111%2Fj.1365-2125.2005.02357.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusuhara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Prediction of the hepatic and renal clearance of transporter substrates in rats using in vitro uptake experiments</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1471</span>– <span class="NLM_lpage">1479</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.026062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.108.026062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=19364828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFemsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=1471-1479&author=T.+Watanabeauthor=K.+Maedaauthor=T.+Kondoauthor=H.+Nakayamaauthor=S.+Horitaauthor=H.+Kusuharaauthor=Y.+Sugiyama&title=Prediction+of+the+hepatic+and+renal+clearance+of+transporter+substrates+in+rats+using+in+vitro+uptake+experiments&doi=10.1124%2Fdmd.108.026062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of the hepatic and renal clearance of transporter substrates in rats using in vitro uptake experiments</span></div><div class="casAuthors">Watanabe, Tomoko; Maeda, Kazuya; Kondo, Tsunenori; Nakayama, Hideki; Horita, Shigeru; Kusuhara, Hiroyuki; Sugiyama, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1471-1479</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The clearance route and the abs. values for hepatic and renal clearance of drugs are important criteria for the selection of drug candidates.  Based on pharmacokinetic theory, by assuming that uptake is the rate-detg. process for the billary excretion of drugs, organ intrinsic clearance should be simply estd. by the intrinsic uptake.  In this study, to investigate whether organ clearance can be predicted from the in vitro uptake activity, we performed uptake expts. using isolated hepatocytes and kidney slices, integration plot analyses, and in vivo pharmacokinetic studies using 12 barely metabolized drugs in rats.  The in vivo hepatic and renal clearance could be approximated by uptake clearance estd. from integration plot analyses, except for the renal clearance of some drugs that was relatively small.  The comparison of intrinsic uptake clearance from in vitro expts. and integration plot studies revealed that in vivo hepatic uptake was well explained by uptake into isolated hepatocytes, whereas in kidney, in vivo uptake clearance was 10 to 100 times that in kidney slices and a scaling factor is required for its prediction from in vitro expts.  The organ clearance and the fraction excreted into urine could be predicted from in vitro studies except for drugs whose renal clearance was relatively small.  This study suggests that the uptake process is the detg. factor for organ clearance of minimally metabolized drugs, and uptake assays using isolated hepatocytes and kidney slices are useful for evaluating the uptake clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDk_F4boRQNrVg90H21EOLACvtfcHk0lhx_A3v_rZ77Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFemsrY%253D&md5=c47805a89cab2b3742a533d7d84be0b5</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.026062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.026062%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DKondo%26aufirst%3DT.%26aulast%3DNakayama%26aufirst%3DH.%26aulast%3DHorita%26aufirst%3DS.%26aulast%3DKusuhara%26aufirst%3DH.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DPrediction%2520of%2520the%2520hepatic%2520and%2520renal%2520clearance%2520of%2520transporter%2520substrates%2520in%2520rats%2520using%2520in%2520vitro%2520uptake%2520experiments%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D1471%26epage%3D1479%26doi%3D10.1124%2Fdmd.108.026062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, T.</span></span> <span> </span><span class="NLM_article-title">Physiological parameters in laboratory animals and humans</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1093</span>– <span class="NLM_lpage">1095</span>, <span class="refDoi"> DOI: 10.1023/A:1018943613122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1023%2FA%3A1018943613122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=8378254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A280%3ADyaK3szptFaqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1993&pages=1093-1095&author=B.+Daviesauthor=T.+Morris&title=Physiological+parameters+in+laboratory+animals+and+humans&doi=10.1023%2FA%3A1018943613122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Physiological parameters in laboratory animals and humans</span></div><div class="casAuthors">Davies B; Morris T</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical research</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1093-5</span>
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDDwka3A6hEYYPsCkJIw00fW6udTcc2eZn_LTWPZEyYrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3szptFaqsg%253D%253D&md5=094cdd17306b58cc17c8cf4fd5db9927</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1023%2FA%3A1018943613122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1018943613122%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DB.%26aulast%3DMorris%26aufirst%3DT.%26atitle%3DPhysiological%2520parameters%2520in%2520laboratory%2520animals%2520and%2520humans%26jtitle%3DPharm.%2520Res.%26date%3D1993%26volume%3D10%26spage%3D1093%26epage%3D1095%26doi%3D10.1023%2FA%3A1018943613122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matheson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrison, R. N.</span></span> <span> </span><span class="NLM_article-title">Regulation of intestinal blood flow</span>. <i>J. Surg. Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">182</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1006/jsre.2000.5862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1006%2Fjsre.2000.5862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10945962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A280%3ADC%252BD3cvlvFGgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2000&pages=182-196&author=P.+J.+Mathesonauthor=M.+A.+Wilsonauthor=R.+N.+Garrison&title=Regulation+of+intestinal+blood+flow&doi=10.1006%2Fjsre.2000.5862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of intestinal blood flow</span></div><div class="casAuthors">Matheson P J; Wilson M A; Garrison R N</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of surgical research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">182-96</span>
        ISSN:<span class="NLM_cas:issn">0022-4804</span>.
    </div><div class="casAbstract">The gastrointestinal system anatomically is positioned to perform two distinct functions: to digest and absorb ingested nutrients and to sustain barrier function to prevent transepithelial migration of bacteria and antigens.  Alterations in these basic functions contribute to a variety of clinical scenarios.  These primary functions intrinsically require splanchnic blood flow at both the macrovascular and microvascular levels of perfusion.  Therefore, a greater understanding of the mechanisms that regulate intestinal vascular perfusion in the normal state and during pathophysiological conditions would be beneficial.  The purpose of this review is to summarize the current understanding regarding the regulatory mechanisms of intestinal blood flow in fasted and fed conditions and during pathological stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTG8HJbt-qWD0NoizSOkG_FfW6udTcc2eZn_LTWPZEyYrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3cvlvFGgsA%253D%253D&md5=a264cab361d7cdfcd89a2bbece7decd7</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1006%2Fjsre.2000.5862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjsre.2000.5862%26sid%3Dliteratum%253Aachs%26aulast%3DMatheson%26aufirst%3DP.%2BJ.%26aulast%3DWilson%26aufirst%3DM.%2BA.%26aulast%3DGarrison%26aufirst%3DR.%2BN.%26atitle%3DRegulation%2520of%2520intestinal%2520blood%2520flow%26jtitle%3DJ.%2520Surg.%2520Res.%26date%3D2000%26volume%3D93%26spage%3D182%26epage%3D196%26doi%3D10.1006%2Fjsre.2000.5862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jamei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuhoff, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rostami-Hodjegan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, G.</span></span> <span> </span><span class="NLM_article-title">Population-based mechanistic prediction of oral drug absorption</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1208/s12248-009-9099-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1208%2Fs12248-009-9099-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=19381840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVWqs7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=225-237&author=M.+Jameiauthor=D.+Turnerauthor=J.+Yangauthor=S.+Neuhoffauthor=S.+Polakauthor=A.+Rostami-Hodjeganauthor=G.+Tucker&title=Population-based+mechanistic+prediction+of+oral+drug+absorption&doi=10.1208%2Fs12248-009-9099-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Population-based mechanistic prediction of oral drug absorption</span></div><div class="casAuthors">Jamei, Masoud; Turner, David; Yang, Jiansong; Neuhoff, Sibylle; Polak, Sebastian; Rostami-Hodjegan, Amin; Tucker, Geoffrey</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">225-237</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The bioavailability of drugs from oral formulations is influenced by many physiol. factors including gastrointestinal fluid compn., pH and dynamics, transit and motility, and metab. and transport, each of which may vary with age, gender, race, food, and disease.  Therefore, oral bioavailability, particularly of poorly sol. and/or poorly permeable compds. and those that are extensively metabolized, often exhibits a high degree of inter- and intra-individual variability.  While several models and algorithms have been developed to predict bioavailability in an av. person, efforts to accommodate intrinsic variability in the component processes are less common.  An approach that incorporates such variability for human populations within a mechanistic framework is described together with examples of its application to drug and formulation development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovj0j3YTSYCLVg90H21EOLACvtfcHk0lhx_A3v_rZ77Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVWqs7rN&md5=649562cac5b547916fd4362121f3b43d</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1208%2Fs12248-009-9099-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-009-9099-y%26sid%3Dliteratum%253Aachs%26aulast%3DJamei%26aufirst%3DM.%26aulast%3DTurner%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DNeuhoff%26aufirst%3DS.%26aulast%3DPolak%26aufirst%3DS.%26aulast%3DRostami-Hodjegan%26aufirst%3DA.%26aulast%3DTucker%26aufirst%3DG.%26atitle%3DPopulation-based%2520mechanistic%2520prediction%2520of%2520oral%2520drug%2520absorption%26jtitle%3DAAPS%2520J.%26date%3D2009%26volume%3D11%26spage%3D225%26epage%3D237%26doi%3D10.1208%2Fs12248-009-9099-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wohnsland, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faller, B.</span></span> <span> </span><span class="NLM_article-title">High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">923</span>– <span class="NLM_lpage">930</span>, <span class="refDoi"> DOI: 10.1021/jm001020e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm001020e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3MXosFSltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=923-930&author=F.+Wohnslandauthor=B.+Faller&title=High-throughput+permeability+pH+profile+and+high-throughput+alkane%2Fwater+log+P+with+artificial+membranes&doi=10.1021%2Fjm001020e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">High-Throughput Permeability pH Profile and High-Throughput Alkane/Water log P with Artificial Membranes</span></div><div class="casAuthors">Wohnsland, Frank; Faller, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">923-930</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This study reports on a novel, high-throughput assay, designed to predict passive, transcellular permeability in early drug discovery.  The assay is carried out in 96-well microtiterplates and measures the ability of compds. to diffuse from a donor to an acceptor compartment which are sepd. by a 9-10 μm hexadecane liq. layer.  A set of 32 well-characterized, chem. diverse drugs was used to validate the method.  The permeability values derived from the flux factors between donor and acceptor compartments show a good correlation with gastrointestinal absorption in humans.  For comparison, correlations based on exptl. or calcd. octanol/water distribution coeffs. (log Do/w,6.8) were significantly lower.  In addn., this simple and robust assay allows detn. of pH permeability profiles, crit. information to predict gastrointestinal absorption of ionizable drugs and difficult to obtain from cell culture expts.  Correction for the unstirred water layer effect allows to differentiate between effective and intrinsic membrane permeability and opens up the dynamic range of the method.  In addn., alkane/water partition coeffs. can be derived from intrinsic membrane permeabilities, making this assay the first high-throughput method able to measure alkane/water log P in the microtiterplate format.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXoYADWFOUn7Vg90H21EOLACvtfcHk0lgGm2Tt8w43Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXosFSltA%253D%253D&md5=de19e881e03d62d48a8acfea729790b4</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fjm001020e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm001020e%26sid%3Dliteratum%253Aachs%26aulast%3DWohnsland%26aufirst%3DF.%26aulast%3DFaller%26aufirst%3DB.%26atitle%3DHigh-throughput%2520permeability%2520pH%2520profile%2520and%2520high-throughput%2520alkane%252Fwater%2520log%2520P%2520with%2520artificial%2520membranes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D923%26epage%3D930%26doi%3D10.1021%2Fjm001020e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meier, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sztul, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuben, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, J. L.</span></span> <span> </span><span class="NLM_article-title">Structural and functional polarity of canalicular and basolateral plasma membrane vesicles isolated in high yield from rat liver</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">991</span>– <span class="NLM_lpage">1000</span>, <span class="refDoi"> DOI: 10.1083/jcb.98.3.991</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1083%2Fjcb.98.3.991" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=6699096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaL2cXhslWju7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=1984&pages=991-1000&author=P.+J.+Meierauthor=E.+S.+Sztulauthor=A.+Reubenauthor=J.+L.+Boyer&title=Structural+and+functional+polarity+of+canalicular+and+basolateral+plasma+membrane+vesicles+isolated+in+high+yield+from+rat+liver&doi=10.1083%2Fjcb.98.3.991"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and functional polarity of canalicular and basolateral plasma membrane vesicles isolated in high yield from rat liver</span></div><div class="casAuthors">Meier, Peter J.; Sztul, Elizabeth S.; Reuben, Adrian; Boyer, James L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">991-1000</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    </div><div class="casAbstract">A method was developed for routine high yield sepn. of canalicular (cLPM) from basolateral (blLPM) liver plasma membrane vesicles of rat liver.  By using a combination of rate zonal floatation and high speed centrifugation through discontinuous sucrose gradients, 9-16 mg of cLPM and 15-28 mg of blLPM protein can be isolated in 1 day.  CLPM are free of the basolateral markers Na+/K+-ATPase and glucagon-stimulatable adenylate cyclase activities, but are highly enriched with respect to homogenate in the canalicular marker enzyme activities leucylnaphthylamidase (48-fold), γ-glutamyltranspeptidase (60-fold), 5'-nucleotidase (64-fold), alk. phosphatase (71-fold), Mg2+-ATPase (83-fold), and alk. phosphodiesterase I (116-fold).  In contrast, blLPM are 34-fold enriched in Na+/K+-ATPase activity, exhibit considerable glucagon-stimulatable adenylate cyclase activity, and demonstrate a 4- to 15-fold increase over the homogenate in the various canalicular markers.  CLPM have a 2-fold higher content of sialic acids, cholesterol, and sphingomyelin compared with blLPM.  At least three canalicular- (130,000, 100,000, and 58,000 mol. wt.) and several basolateral-specific protein bands have been detected after SDS polyacrylamide gel electrophoresis of the 2 LPM subfractions.  Specifically, the immunoglobin A-binding secretory component is restricted to blLPM as demonstrated by immunochem. techniques.  These data indicate virtually complete sepn. of basolateral from canalicular LPM and demonstrate multiple functional and compositional polarity between the 2 surface domains of hepatocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2VeE25vmdarVg90H21EOLACvtfcHk0lgGm2Tt8w43Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXhslWju7o%253D&md5=bd5010a7b92cdd3f1716abe7b2a70f2e</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1083%2Fjcb.98.3.991&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.98.3.991%26sid%3Dliteratum%253Aachs%26aulast%3DMeier%26aufirst%3DP.%2BJ.%26aulast%3DSztul%26aufirst%3DE.%2BS.%26aulast%3DReuben%26aufirst%3DA.%26aulast%3DBoyer%26aufirst%3DJ.%2BL.%26atitle%3DStructural%2520and%2520functional%2520polarity%2520of%2520canalicular%2520and%2520basolateral%2520plasma%2520membrane%2520vesicles%2520isolated%2520in%2520high%2520yield%2520from%2520rat%2520liver%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D1984%26volume%3D98%26spage%3D991%26epage%3D1000%26doi%3D10.1083%2Fjcb.98.3.991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsushima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>314</i></span>,  <span class="NLM_fpage">1059</span>– <span class="NLM_lpage">1067</span>, <span class="refDoi"> DOI: 10.1124/jpet.105.085589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fjpet.105.085589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=15901800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvFSqsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=314&publication_year=2005&pages=1059-1067&author=S.+Matsushimaauthor=K.+Maedaauthor=C.+Kondoauthor=M.+Hiranoauthor=M.+Sasakiauthor=H.+Suzukiauthor=Y.+Sugiyama&title=Identification+of+the+hepatic+efflux+transporters+of+organic+anions+using+double-transfected+Madin-Darby+canine+kidney+II+cells+expressing+human+organic+anion-transporting+polypeptide+1B1+%28OATP1B1%29%2Fmultidrug+resistance-associated+protein+2%2C+OATP1B1%2Fmultidrug+resistance+1%2C+and+OATP1B1%2Fbreast+cancer+resistance+protein&doi=10.1124%2Fjpet.105.085589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein</span></div><div class="casAuthors">Matsushima, Soichiro; Maeda, Kazuya; Kondo, Chihiro; Hirano, Masaru; Sasaki, Makoto; Suzuki, Hiroshi; Sugiyama, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">314</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1059-1067</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Until recently, it was generally believed that the transport of various org. anions across the bile canalicular membrane was mainly mediated by multidrug resistance-assocd. protein 2 (MRP2/ABCC2).  However, a no. of new reports have shown that some org. anions are also substrates of multidrug resistance 1 (MDR1/ABCB1) and/or breast cancer resistance protein (BCRP/ABCG2), implying MDR1 and BCRP could also be involved in the biliary excretion of org. anions in humans.  In the present study, we constructed new double-transfected Madin-Darby canine kidney II (MDCKII) cells expressing org. anion-transporting polypeptide 1B1 (OATP1B1)/MDR1 and OATP1B1/BCRP, and we investigated the transcellular transport of four kinds of org. anions, estradiol-17β-D-glucuronide (EG), estrone-3-sulfate (ES), pravastatin (PRA), and cerivastatin (CER), to identify which efflux transporters mediate the biliary excretion of compds. using double-transfected cells.  We obsd. the vectorial transport of EG and ES in all the double transfectants.  MRP2 showed the highest efflux clearance of EG among these efflux transporters, whereas BCRP-mediated clearance of ES was the highest in these double transfectants.  In addn., two kinds of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, CER and PRA, were also substrates of all these efflux transporters.  The rank order of the efflux clearance of PRA mediated by each transporter was the same as that of EG, whereas the contribution of MDR1 to the efflux of CER was relatively greater than for PRA.  This exptl. system is very useful for identifying which transporters are involved in the biliary excretion of org. anions that cannot easily penetrate the plasma membrane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpClnguN0ejVrVg90H21EOLACvtfcHk0lgGm2Tt8w43Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvFSqsrk%253D&md5=625443764f3ecaf6a32edc23f1d6d9cd</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.085589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.085589%26sid%3Dliteratum%253Aachs%26aulast%3DMatsushima%26aufirst%3DS.%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DKondo%26aufirst%3DC.%26aulast%3DHirano%26aufirst%3DM.%26aulast%3DSasaki%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DH.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DIdentification%2520of%2520the%2520hepatic%2520efflux%2520transporters%2520of%2520organic%2520anions%2520using%2520double-transfected%2520Madin-Darby%2520canine%2520kidney%2520II%2520cells%2520expressing%2520human%2520organic%2520anion-transporting%2520polypeptide%25201B1%2520%2528OATP1B1%2529%252Fmultidrug%2520resistance-associated%2520protein%25202%252C%2520OATP1B1%252Fmultidrug%2520resistance%25201%252C%2520and%2520OATP1B1%252Fbreast%2520cancer%2520resistance%2520protein%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D314%26spage%3D1059%26epage%3D1067%26doi%3D10.1124%2Fjpet.105.085589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greiner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichelbaum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreichgauer, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Richter, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zundler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, H. K.</span></span> <span> </span><span class="NLM_article-title">The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">153</span>, <span class="refDoi"> DOI: 10.1172/JCI6663</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1172%2FJCI6663" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10411543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK1MXkslSmsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=1999&pages=147-153&author=B.+Greinerauthor=M.+Eichelbaumauthor=P.+Fritzauthor=H.+P.+Kreichgauerauthor=O.+von+Richterauthor=J.+Zundlerauthor=H.+K.+Kroemer&title=The+role+of+intestinal+P-glycoprotein+in+the+interaction+of+digoxin+and+rifampin&doi=10.1172%2FJCI6663"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin</span></div><div class="casAuthors">Greiner, Bernd; Eichelbaum, Michel; Fritz, Peter; Kreichgauer, Hans-Peter; Von Richter, Oliver; Zundler, Johannes; Kroemer, Heyo K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">147-153</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Recent data point to the contribution of P-glycoprotein (P-gp) to digoxin elimination.  On the basis of clin. observations of patients in whom digoxin levels decreased considerably when treated with rifampin, we hypothesized that concomitant rifampin therapy may affect digoxin disposition in humans by induction of P-gp.  We compared single-dose (1 mg oral and 1 mg i.v.) pharmacokinetics of digoxin before and after coadministration of rifampin (600 mg/d for 10 days) in 8 healthy volunteers.  Duodenal biopsies were obtained from each volunteer before and after administration of rifampin.  The area under the plasma concn. time curve (AUC) of oral digoxin was significantly lower during rifampin treatment; the effect was less pronounced after i.v. administration of digoxin.  Renal clearance and half-life of digoxin were not altered by rifampin.  Rifampin treatment increased intestinal P-gp content 3.5±2.1-fold, which correlated with the AUC after oral digoxin but not after i.v. digoxin.  P-gp is a determinant of the disposition of digoxin.  Concomitant administration of rifampin reduced digoxin plasma concns. substantially after oral administration but to a lesser extent after i.v. administration.  The rifampin-digoxin interaction appears to occur largely at the level of the intestine.  Therefore, induction of intestinal P-gp could explain this new type of drug-drug interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn4Eg89l8j67Vg90H21EOLACvtfcHk0ljAmvDFMZ3FWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXkslSmsb8%253D&md5=e024d8db90e18ebc72cda21d020403f3</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1172%2FJCI6663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI6663%26sid%3Dliteratum%253Aachs%26aulast%3DGreiner%26aufirst%3DB.%26aulast%3DEichelbaum%26aufirst%3DM.%26aulast%3DFritz%26aufirst%3DP.%26aulast%3DKreichgauer%26aufirst%3DH.%2BP.%26aulast%3Dvon%2BRichter%26aufirst%3DO.%26aulast%3DZundler%26aufirst%3DJ.%26aulast%3DKroemer%26aufirst%3DH.%2BK.%26atitle%3DThe%2520role%2520of%2520intestinal%2520P-glycoprotein%2520in%2520the%2520interaction%2520of%2520digoxin%2520and%2520rifampin%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1999%26volume%3D104%26spage%3D147%26epage%3D153%26doi%3D10.1172%2FJCI6663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichelbaum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burk, O.</span></span> <span> </span><span class="NLM_article-title">Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">14581</span>– <span class="NLM_lpage">14587</span>, <span class="refDoi"> DOI: 10.1074/jbc.M010173200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1074%2Fjbc.M010173200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=11297522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjs1OktL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=14581-14587&author=A.+Geickauthor=M.+Eichelbaumauthor=O.+Burk&title=Nuclear+receptor+response+elements+mediate+induction+of+intestinal+MDR1+by+rifampin&doi=10.1074%2Fjbc.M010173200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin</span></div><div class="casAuthors">Geick, Anke; Eichelbaum, Michel; Burk, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">14581-14587</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Intestinal P-glycoprotein, which is encoded by the MDR1 gene, plays an important role in the absorption and presystemic elimination of many xenobiotics.  Hence, an understanding of the factors regulating its expression and function is of substantial interest.  In addn. to genetic factors, exposure to drugs such as rifampin can profoundly affect its expression.  So far, the mechanisms by which rifampin induces MDR1 expression are poorly understood.  Recent studies demonstrate that the nuclear receptor PXR (pregnane X receptor) is involved in xenobiotic induction of CYP3A4.  Because CYP3A4 and MDR1 are often co-induced, we investigated whether a similar mechanism is also involved in MDR1 induction.  The human colon carcinoma cell line LS174T was used as an intestinal model to study induction because in these cells the endogenous MDR1 gene is highly inducible by rifampin.  The 5'-upstream region of human MDR1 was examd. for the presence of potential PXR response elements.  Several binding sites were identified that form a complex regulatory cluster at about -8 kilobase pairs.  Only one DR4 motif within this cluster is necessary for induction by rifampin.  We conclude that induction of MDR1 is mediated by a DR4 motif in the upstream enhancer at about -8 kilobase pairs, to which PXR binds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDciMSSWDvqbVg90H21EOLACvtfcHk0ljAmvDFMZ3FWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjs1OktL0%253D&md5=756631447fee46a9a89df3bb5a263ea5</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M010173200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M010173200%26sid%3Dliteratum%253Aachs%26aulast%3DGeick%26aufirst%3DA.%26aulast%3DEichelbaum%26aufirst%3DM.%26aulast%3DBurk%26aufirst%3DO.%26atitle%3DNuclear%2520receptor%2520response%2520elements%2520mediate%2520induction%2520of%2520intestinal%2520MDR1%2520by%2520rifampin%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D14581%26epage%3D14587%26doi%3D10.1074%2Fjbc.M010173200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kage, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukahara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuruo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, Y.</span></span> <span> </span><span class="NLM_article-title">C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">611</span>– <span class="NLM_lpage">616</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=12479221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsFSlsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=611-616&author=Y.+Imaiauthor=M.+Nakaneauthor=K.+Kageauthor=S.+Tsukaharaauthor=E.+Ishikawaauthor=T.+Tsuruoauthor=Y.+Mikiauthor=Y.+Sugimoto&title=C421A+polymorphism+in+the+human+breast+cancer+resistance+protein+gene+is+associated+with+low+expression+of+Q141K+protein+and+low-level+drug+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance</span></div><div class="casAuthors">Imai, Yasuo; Nakane, Minoru; Kage, Kumie; Tsukahara, Satomi; Ishikawa, Etsuko; Tsuruo, Takashi; Miki, Yoshio; Sugimoto, Yoshikazu</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">611-616</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Breast cancer resistance protein (BCRP) confers multidrug resistance to cancer cells against agents such as SN-38 (an active metabolite of irinotecan), mitoxantrone, and topotecan.  Among 59 human tumor cell lines tested, 6 cell lines, A549, NCI-H460, KM-12, HT-29, OVCAR-5, and RPMI8226, showed high BCRP expression.  BCRP cDNA was isolated from 11 cancer cell lines and three variant cDNAs [G34A substituting Met for Val-12 (V12M), C421A substituting Lys for Gln-141 (Q141K), and 944-949 deletion lacking Ala-315 and Thr-316 (Δ315-6)] were identified.  G34A and C421A variants were polymorphisms, and 944-949 deletion was a splicing variant.  C421A BCRP-transfected PA317 cells showed markedly decreased protein expression and low-level drug resistance compared with wild-type BCRP-transfected cells when transfectants expressed similar levels of BCRP mRNA.  G34A or 944-949-deleted BCRP-transfected PA317 cells showed similar or somewhat lower protein expression and drug resistance compared with wild-type BCRP-transfected cells.  Of 124 healthy Japanese volunteers, 67 were wild-type, 48 were heterozygous, and 9 were homozygous for the C421A allele.  These results suggest that some people possess the C421A polymorphic BCRP gene and express low amts. of Q141K BCRP.  In addn. to that, C376T polymorphism in exon 4 substituting stop codon for Gln-126 was found in 3 of the 124 general Japanese population.  This C376T polymorphism may also have high impact because active BCRP protein will not be expressed from the C376T allele.  Therefore, people with C376T and/or C421A polymorphisms may express low amts. of BCRP, and this low BCRP expression might result in hypersensitivity of normal cells to such anticancer drugs as irinotecan and mitoxantrone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi90iPFF_n7rVg90H21EOLACvtfcHk0liXYpzfDX3kIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsFSlsr4%253D&md5=48bfdec1e84e6d6d74dad9d54daeee40</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DImai%26aufirst%3DY.%26aulast%3DNakane%26aufirst%3DM.%26aulast%3DKage%26aufirst%3DK.%26aulast%3DTsukahara%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DE.%26aulast%3DTsuruo%26aufirst%3DT.%26aulast%3DMiki%26aufirst%3DY.%26aulast%3DSugimoto%26aufirst%3DY.%26atitle%3DC421A%2520polymorphism%2520in%2520the%2520human%2520breast%2520cancer%2520resistance%2520protein%2520gene%2520is%2520associated%2520with%2520low%2520expression%2520of%2520Q141K%2520protein%2520and%2520low-level%2520drug%2520resistance%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2002%26volume%3D1%26spage%3D611%26epage%3D616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegsmund, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkmann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffeler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weirich, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwab, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichelbaum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burk, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alken, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenpieler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerb, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmeyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brauch, H.</span></span> <span> </span><span class="NLM_article-title">Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors</span>. <i>J. Am. Soc. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1847</span>– <span class="NLM_lpage">1854</span>, <span class="refDoi"> DOI: 10.1097/01.ASN.0000019412.87412.BC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1097%2F01.ASN.0000019412.87412.BC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=12089380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvVSqt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2002&pages=1847-1854&author=M.+Siegsmundauthor=U.+Brinkmannauthor=E.+Schaffelerauthor=G.+Weirichauthor=M.+Schwabauthor=M.+Eichelbaumauthor=P.+Fritzauthor=O.+Burkauthor=J.+Deckerauthor=P.+Alkenauthor=U.+Rothenpielerauthor=R.+Kerbauthor=S.+Hoffmeyerauthor=H.+Brauch&title=Association+of+the+P-glycoprotein+transporter+MDR1%28C3435T%29+polymorphism+with+the+susceptibility+to+renal+epithelial+tumors&doi=10.1097%2F01.ASN.0000019412.87412.BC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Association of the P-glycoprotein transporter MDR1C3435T polymorphism with the susceptibility to renal epithelial tumors</span></div><div class="casAuthors">Siegsmund, Michael; Brinkmann, Ulrich; Schaffeler, Elke; Weirich, Gregor; Schwab, Matthias; Eichelbaum, Michel; Fritz, Peter; Burk, Oliver; Decker, Jochen; Alken, Peter; Rothenpieler, Uwe; Kerb, Reinhold; Hoffmeyer, Sven; Brauch, Hiltrud</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Society of Nephrology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1847-1854</span>CODEN:
                <span class="NLM_cas:coden">JASNEU</span>;
        ISSN:<span class="NLM_cas:issn">1046-6673</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Except for hereditary disease, genetic factors that contribute to the development of renal epithelial tumors are unknown.  There is a possibility that the MDR1 encoded plasma membrane transporter P-glycoprotein (PGP) influences the risk of development of renal neoplasms.  PGP is known to be involved in uptake, binding, transport, and distribution of xenobiotics.  There is evidence that the MDR1C3435T polymorphism drives expression and modulates disease risk.  In an explorational case-control study, constitutional genotype frequencies were established at MDR1C3435T of 537 healthy control subjects and compared with those of 212 patients with renal epithelial tumors.  There were 179 clear cell renal cell carcinoma (CCRCC) and 33 tumors collectively assigned as non-CCRCC.  In a second study, genotypes of another 150 healthy control subjects and 50 patients with three non-CCRCC types (26 papillary RCC, 11 chromophobe RCC, and 13 renal oncocytic adenoma) were compared.  PCR-restriction fragment length polymorphism-based anal. of constitutional DNA, and statistical anal. were applied.  PGP expression was analyzed by quant. immunohistochem.  The explorational study showed a significant assocn. between T allele frequency and the occurrence of tumors (P = 0.007).  When tumors were histopathol. distinguished into frequent CCRCC and less frequent non-CCRCC, both patient groups contributed to this effect with a seemingly strong influence by the latter (P = 0.0419).  The second study established the T allele as a risk factor esp. for non-CCRCC (P = 0.0005) with the highest risk for homozygote TT allele carriers (P < 0.0001).  Independently, MDR1C3435T genotype assocd. variations in PGP expression were shown in normal renal parenchyma with a 1.5-fold difference of median values (TT, 1.9; CC, 2.8; P = 0.0065).  The data provide evidence for PGP to influence the susceptibility to develop renal epithelial tumors by virtue of its MDR1C3435T polymorphism and changes in expression.  Esp. T and TT carriers are at risk for developing non-CCRCC, i.e., papillary and chromophobe RCC as well as oncocytic adenomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC5F-bzIgWjbVg90H21EOLACvtfcHk0liXYpzfDX3kIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvVSqt7w%253D&md5=5ccbb9bcd2d00ff7adc101261a5d8aae</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1097%2F01.ASN.0000019412.87412.BC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.ASN.0000019412.87412.BC%26sid%3Dliteratum%253Aachs%26aulast%3DSiegsmund%26aufirst%3DM.%26aulast%3DBrinkmann%26aufirst%3DU.%26aulast%3DSchaffeler%26aufirst%3DE.%26aulast%3DWeirich%26aufirst%3DG.%26aulast%3DSchwab%26aufirst%3DM.%26aulast%3DEichelbaum%26aufirst%3DM.%26aulast%3DFritz%26aufirst%3DP.%26aulast%3DBurk%26aufirst%3DO.%26aulast%3DDecker%26aufirst%3DJ.%26aulast%3DAlken%26aufirst%3DP.%26aulast%3DRothenpieler%26aufirst%3DU.%26aulast%3DKerb%26aufirst%3DR.%26aulast%3DHoffmeyer%26aufirst%3DS.%26aulast%3DBrauch%26aufirst%3DH.%26atitle%3DAssociation%2520of%2520the%2520P-glycoprotein%2520transporter%2520MDR1%2528C3435T%2529%2520polymorphism%2520with%2520the%2520susceptibility%2520to%2520renal%2520epithelial%2520tumors%26jtitle%3DJ.%2520Am.%2520Soc.%2520Nephrol.%26date%3D2002%26volume%3D13%26spage%3D1847%26epage%3D1854%26doi%3D10.1097%2F01.ASN.0000019412.87412.BC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferraris, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, J. M.</span></span> <span> </span><span class="NLM_article-title">Origin of regional and species differences in intestinal glucose uptake</span>. <i>Am. J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>257</i></span>,  <span class="NLM_fpage">G689</span>– <span class="NLM_lpage">697</span>, <span class="refDoi"> DOI: 10.1152/ajpgi.1989.257.5.G689</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1152%2Fajpgi.1989.257.5.G689" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=2596605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK3cXhvFansw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=257&publication_year=1989&pages=G689-697&author=R.+P.+Ferrarisauthor=P.+P.+Leeauthor=J.+M.+Diamond&title=Origin+of+regional+and+species+differences+in+intestinal+glucose+uptake&doi=10.1152%2Fajpgi.1989.257.5.G689"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Origin of regional and species differences in intestinal glucose uptake</span></div><div class="casAuthors">Ferraris, Ronaldo P.; Lee, Peter P.; Diamond, Jared M.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Physiology</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">257</span>
        (<span class="NLM_cas:issue">5, Pt. 1</span>),
    <span class="NLM_cas:pages">G689-G697</span>CODEN:
                <span class="NLM_cas:coden">AJPHAP</span>;
        ISSN:<span class="NLM_cas:issn">0002-9513</span>.
    </div><div class="casAbstract">The origin of differences in glucose (I) absorption was examd. among 3 species (mouse, desert wood rat (Neotoma lepida), and desert iguana (Dipsosaurus dorsalis)) and among 3 intestinal regions in 2 of these species.  Turnover nos. ranged from 6900 to 32,300 I mols./min/site.  Microvilli amplify intestinal area by a larger factor (36-96-fold) than did villi (2-14-fold), so that the intestine's actual area is ≥110-1280-fold the nominal area of the equiv. smooth-bore cylinder.  Species comparisons among mammals yielded the striking result that the area of the whole length of the small intestine at the microvillus level varied nearly linearly with the mammal's metabolic live mass.  For the species studied, all the anatomical and biochem. factors studied proved to make significant contributions to species and regional differences in I uptake.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7mfZilYp9i7Vg90H21EOLACvtfcHk0lgRa9DkELNggg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXhvFansw%253D%253D&md5=ab3eafe95f95d35c9d511a68d94d6763</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1152%2Fajpgi.1989.257.5.G689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpgi.1989.257.5.G689%26sid%3Dliteratum%253Aachs%26aulast%3DFerraris%26aufirst%3DR.%2BP.%26aulast%3DLee%26aufirst%3DP.%2BP.%26aulast%3DDiamond%26aufirst%3DJ.%2BM.%26atitle%3DOrigin%2520of%2520regional%2520and%2520species%2520differences%2520in%2520intestinal%2520glucose%2520uptake%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1989%26volume%3D257%26spage%3DG689%26epage%3D697%26doi%3D10.1152%2Fajpgi.1989.257.5.G689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kararli, T. T.</span></span> <span> </span><span class="NLM_article-title">Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">380</span>, <span class="refDoi"> DOI: 10.1002/bdd.2510160502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1002%2Fbdd.2510160502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=8527686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK2MXmvFOls70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1995&pages=351-380&author=T.+T.+Kararli&title=Comparison+of+the+gastrointestinal+anatomy%2C+physiology%2C+and+biochemistry+of+humans+and+commonly+used+laboratory+animals&doi=10.1002%2Fbdd.2510160502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals</span></div><div class="casAuthors">Kararli, Tugrul T.</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">351-80</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">Wiley</span>)
        </div><div class="casAbstract">A review with 79 refs. on the anatomical, physiol., and biochem. differences between the G.I. tracts of humans and commonly used lab. animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm5RocAmNVwLVg90H21EOLACvtfcHk0lgRa9DkELNggg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmvFOls70%253D&md5=28a96f8348eadac3ab82ef3248c1bad8</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1002%2Fbdd.2510160502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.2510160502%26sid%3Dliteratum%253Aachs%26aulast%3DKararli%26aufirst%3DT.%2BT.%26atitle%3DComparison%2520of%2520the%2520gastrointestinal%2520anatomy%252C%2520physiology%252C%2520and%2520biochemistry%2520of%2520humans%2520and%2520commonly%2520used%2520laboratory%2520animals%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D1995%26volume%3D16%26spage%3D351%26epage%3D380%26doi%3D10.1002%2Fbdd.2510160502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simons, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renouf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, P. A.</span></span> <span> </span><span class="NLM_article-title">Human gut microbial degradation of flavonoids: structure-function relationships</span>. <i>J. Agric. Food Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">4258</span>– <span class="NLM_lpage">4263</span>, <span class="refDoi"> DOI: 10.1021/jf0500177</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jf0500177" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsFahtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2005&pages=4258-4263&author=A.+L.+Simonsauthor=M.+Renoufauthor=S.+Hendrichauthor=P.+A.+Murphy&title=Human+gut+microbial+degradation+of+flavonoids%3A+structure-function+relationships&doi=10.1021%2Fjf0500177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Human gut microbial degradation of flavonoids: Structure-function relationships</span></div><div class="casAuthors">Simons, Andrean L.; Renouf, Mathieu; Hendrich, Suzanne; Murphy, Patricia A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Agricultural and Food Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4258-4263</span>CODEN:
                <span class="NLM_cas:coden">JAFCAU</span>;
        ISSN:<span class="NLM_cas:issn">0021-8561</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The relationship between chem. structure and gut microbial degrdn. rates of 14 flavonoids, flavone, apigenin, chrysin, naringenin, kaempferol, genistein, daidzein, daidzin, puerarin, 7,4'-dihydroxyflavone, 6,4'-dihydroxyflavone, 5,4'-dihydroxyflavone, 5,3'-dihydroxyflavone, and 4'-hydroxyflavone, was investigated by anaerobically fermenting the flavonoids with human gut microflora (n = 11 subjects).  Degrdn. rates for the 5,7,4'-trihydroxyl flavonoids, apigenin, genistein, naringenin, and kaempferol, were significantly faster than the other structural motifs.  Puerarin was resistant to degrdn. by the gut microflora.  Extensive degrdn. of flavonoids by gut microflora may result in lower overall bioavailability than those flavonoids that are slowly degraded because rapidly degrading flavonoids are less likely to be absorbed intact.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoukQX3NtHVyLVg90H21EOLACvtfcHk0ljp6urOBBylgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsFahtr8%253D&md5=6abf4bccf04ade027476a81bbe1c7ab0</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjf0500177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjf0500177%26sid%3Dliteratum%253Aachs%26aulast%3DSimons%26aufirst%3DA.%2BL.%26aulast%3DRenouf%26aufirst%3DM.%26aulast%3DHendrich%26aufirst%3DS.%26aulast%3DMurphy%26aufirst%3DP.%2BA.%26atitle%3DHuman%2520gut%2520microbial%2520degradation%2520of%2520flavonoids%253A%2520structure-function%2520relationships%26jtitle%3DJ.%2520Agric.%2520Food%2520Chem.%26date%3D2005%26volume%3D53%26spage%3D4258%26epage%3D4263%26doi%3D10.1021%2Fjf0500177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLeod, B. J.</span></span> <span> </span><span class="NLM_article-title">Physiology and pharmacology of the brushtail possum gastrointestinal tract: relationship to the human gastrointestinal tract</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1121</span>– <span class="NLM_lpage">1132</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2007.06.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1016%2Fj.addr.2007.06.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=17870201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1amsL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2007&pages=1121-1132&author=A.+McDowellauthor=B.+J.+McLeod&title=Physiology+and+pharmacology+of+the+brushtail+possum+gastrointestinal+tract%3A+relationship+to+the+human+gastrointestinal+tract&doi=10.1016%2Fj.addr.2007.06.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Physiology and pharmacology of the brushtail possum gastrointestinal tract: Relationship to the human gastrointestinal tract</span></div><div class="casAuthors">McDowell, Arlene; McLeod, Bernie J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1121-1132</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Oral formulations are typically based on studies from eutherian animal models.  This review introduces information relating to oral formulations for a marsupial species, the Australian brushtail possum (Trichosurus vulpecula) that has arisen from research into new methods for controlling this species - a major vertebrate pest in New Zealand.  Morphol., the gastrointestinal tract of the brushtail possum is similar to that of hindgut fermenting eutherian species, but there are some striking differences in function.  Limited data suggests that the pharmacokinetics and bioavailability of administered drugs are similar to that in eutherian species, but there is some evidence that possums may have specific mechanisms for handling the intake of plant toxins and xenobiotics.  The development of oral formulations for a free-ranging pest species presents several challenges above those encountered in the development of therapeutic formulations for humans and domestic animals.  Use of a marsupial animal model may lead to new strategies for oral formulations in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6rd8u6LoLMbVg90H21EOLACvtfcHk0ljp6urOBBylgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1amsL7O&md5=74f21941b5c9e8801987676e4e39d1b6</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2007.06.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2007.06.012%26sid%3Dliteratum%253Aachs%26aulast%3DMcDowell%26aufirst%3DA.%26aulast%3DMcLeod%26aufirst%3DB.%2BJ.%26atitle%3DPhysiology%2520and%2520pharmacology%2520of%2520the%2520brushtail%2520possum%2520gastrointestinal%2520tract%253A%2520relationship%2520to%2520the%2520human%2520gastrointestinal%2520tract%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2007%26volume%3D59%26spage%3D1121%26epage%3D1132%26doi%3D10.1016%2Fj.addr.2007.06.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolger, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukacova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woltosz, W. S.</span></span> <span> </span><span class="NLM_article-title">Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">363</span>, <span class="refDoi"> DOI: 10.1208/s12248-009-9111-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1208%2Fs12248-009-9111-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=19434502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVWqs7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=353-363&author=M.+B.+Bolgerauthor=V.+Lukacovaauthor=W.+S.+Woltosz&title=Simulations+of+the+nonlinear+dose+dependence+for+substrates+of+influx+and+efflux+transporters+in+the+human+intestine&doi=10.1208%2Fs12248-009-9111-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine</span></div><div class="casAuthors">Bolger, Michael B.; Lukacova, Viera; Woltosz, Walter S.</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">353-363</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The purpose of this study was to develop simulation and modeling methods for the evaluation of pharmacokinetics when intestinal influx and efflux transporters are involved in gastrointestinal absorption.  The advanced compartmental absorption and transit (ACAT) model as part of the computer program GastroPlus was used to simulate the absorption and pharmacokinetics of valacyclovir, gabapentin, and talinolol.  Each of these drugs is a substrate for an influx or efflux transporter and all show nonlinear dose dependence within the normal therapeutic range.  These simulations incorporated the exptl. derived gastrointestinal distributions of transporter expression levels for oligopeptide transporters PepT1 and HPT1 (valacyclovir): System L-amino acid transporter LAT2 and org. cation transporter OCTN1 (gabapentin); and org. anion transporter (OATP1A2) and P-glycoprotein (talinolol).  By assuming a uniform distribution of oligopeptide transporter and by application of the in vitro Km value for valacyclovir, the simulations accurately reproduced the exptl. nonlinear dose dependence.  For gabapentin, LAT2 distribution produced simulation results that were much more accurate than OCTN1 distributions.  For talinolol, an influx transporter distribution for OATP1A2 and the efflux transporter P-glycoprotein distributed with increasing expression in the distal small intestine produced the best results.  The physiol. characteristics of the small and large intestines used in the ACAT model were able to accurately account for the positional and temporal changes in concn. and carrier-mediated transport of the three drugs included in this study.  The ACAT model reproduced the nonlinear dose dependence for each of these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHFmD6zWSCS7Vg90H21EOLACvtfcHk0ljp6urOBBylgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVWqs7vP&md5=a0f1c10c2d1d3f607ed8b2ccea0bc5ed</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1208%2Fs12248-009-9111-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-009-9111-6%26sid%3Dliteratum%253Aachs%26aulast%3DBolger%26aufirst%3DM.%2BB.%26aulast%3DLukacova%26aufirst%3DV.%26aulast%3DWoltosz%26aufirst%3DW.%2BS.%26atitle%3DSimulations%2520of%2520the%2520nonlinear%2520dose%2520dependence%2520for%2520substrates%2520of%2520influx%2520and%2520efflux%2520transporters%2520in%2520the%2520human%2520intestine%26jtitle%3DAAPS%2520J.%26date%3D2009%26volume%3D11%26spage%3D353%26epage%3D363%26doi%3D10.1208%2Fs12248-009-9111-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abuasal, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolger, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaddoumi, A.</span></span> <span> </span><span class="NLM_article-title">In silico modeling for the nonlinear absorption kinetics of uk-343,664: a p-gp and CYP3A4 substrate</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">492</span>– <span class="NLM_lpage">504</span>, <span class="refDoi"> DOI: 10.1021/mp200275j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp200275j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC38XpslGgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=492-504&author=B.+S.+Abuasalauthor=M.+B.+Bolgerauthor=D.+K.+Walkerauthor=A.+Kaddoumi&title=In+silico+modeling+for+the+nonlinear+absorption+kinetics+of+uk-343%2C664%3A+a+p-gp+and+CYP3A4+substrate&doi=10.1021%2Fmp200275j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">In Silico Modeling for the Nonlinear Absorption Kinetics of UK-343,664: A P-gp and CYP3A4 Substrate</span></div><div class="casAuthors">Abuasal, Bilal S.; Bolger, Michael B.; Walker, Don K.; Kaddoumi, Amal</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">492-504</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The aim of this work was to extrapolate in vitro and preclin. animal data to simulate the pharmacokinetic parameters of UK-343,664, a P-glycoprotein (P-gp) and CYP3A4 substrate, in human.  In addn., we aimed to develop a simulation model to demonstrate the involvement and the controversial complex interaction of intestinal P-gp and CYP3A4 in its nonlinear absorption, first-pass extn., and pharmacokinetics using the advanced compartmental absorption and transit (ACAT) model.  Finally, we aimed to compare the results predicted from the model to the reported findings in human clin. studies.  In situ perfusion, allometric scaling, PBPK Rodger mechanistic approach, in vitro metab., and fitting to in vivo data were used to mechanistically explain the absorption, distribution and metab., resp.  GastroPlus was used to build the integrated simulation model in human for UK-343,664 to mechanistically explain the obsd. clin. data at 30, 100, 200, 400, and 800 mg oral doses.  The measured in vitro value for CYP3A4 Km (465 μM) in rCYPs was converted to units of μg/mL, cor. for assumed microsomal binding (17.8%) and applied to all metabolic processes.  The measured in vitro values of Vmax for CYP3A4 (38.9 pmol/min/pmol), 2C8, 2C9, 2C19, and 2D6 were used along with the in vitro CYP3A4 Km to simulate liver first pass extn. and systemic clearance.  The measured in vitro values of Vmax for CYP3A4 and 2D6 were used along with the in vitro CYP3A4 Km to simulate gut first pass extn.  Vmax and Km values for P-gp were obtained by fitting to in vivo data and used to simulate gut efflux transport activity.  Investigation of the interaction mechanism of P-gp and CYP3A4 in the intestine was achieved by comparing the influence of a virtual knockout of P-gp or gut metab. on the fraction absorbed, fraction reaching the portal vein, and fraction metabolized in the gut.  Comparison between simulation and in vivo results showed that the in silico simulation provided a mechanistic explanation of the obsd. nonlinear absorption kinetics of UK-343,664 in human following its administration in the range of 30-800 mg as oral solns.  The simulation results of the pharmacokinetic parameters, AUC and Cmax, by GastroPlus were comparable with those obsd. in vivo.  This simulation model is one possible mechanistic explanation of the obsd. in vivo data and suggests that the nonlinear dose dependence could be attributed to satn. of both the efflux transport by P-gp and the intestinal metab.  However, the concn. ranges for either protein satn. did not overlap and resulted in much greater than dose proportional increases in AUC.  At low doses, producing intraenterocyte concns. below the fitted value of Km for P-gp, the influence of P-gp appears to be protective and results in a lower fraction of gut 3A4 metab.  At higher doses, as P-gp becomes satd. the fraction of gut 3A4 extn. increases, and eventually at the highest doses, where 3A4 becomes satd., the fraction of gut 3A4 extn. again decreases.  Such a complex interpretation of this in vitro-in vivo extrapolation (IVIVE) is another example of the value and insight obtained by physiol. based absorption simulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIsJkjLN89rLVg90H21EOLACvtfcHk0li3kB_aJQ7KOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpslGgsg%253D%253D&md5=4b0fa914ed5b029df6e2fde5d3cbaf61</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fmp200275j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp200275j%26sid%3Dliteratum%253Aachs%26aulast%3DAbuasal%26aufirst%3DB.%2BS.%26aulast%3DBolger%26aufirst%3DM.%2BB.%26aulast%3DWalker%26aufirst%3DD.%2BK.%26aulast%3DKaddoumi%26aufirst%3DA.%26atitle%3DIn%2520silico%2520modeling%2520for%2520the%2520nonlinear%2520absorption%2520kinetics%2520of%2520uk-343%252C664%253A%2520a%2520p-gp%2520and%2520CYP3A4%2520substrate%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26spage%3D492%26epage%3D504%26doi%3D10.1021%2Fmp200275j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/S0928-0987(00)00178-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1016%2FS0928-0987%2800%2900178-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=11121729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3cXot1yiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2000&pages=3-12&author=H.+Suzukiauthor=Y.+Sugiyama&title=Role+of+metabolic+enzymes+and+efflux+transporters+in+the+absorption+of+drugs+from+the+small+intestine&doi=10.1016%2FS0928-0987%2800%2900178-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine</span></div><div class="casAuthors">Suzuki, H.; Sugiyama, Y.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-12</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with over 90 refs.  It has been established that the absorption of many drugs from the small intestine is hindered by the detoxification systems which are present in this epithelial tissue.  In this article, we will summarize the significant role of small intestine in reducing the oral bioavailability of drugs, particularly focusing on the role of metabolic enzymes and efflux transporters.  Since the role of cytochrome P 450 3A (CYP3A) and MDR1 P-glycoprotein (P-gp) in intestinal drug disposition has been highlighted, the disposition of CYP3A substrates, P-gp substrates and CYP3A/P-gp bisubstrates are summarized.  Moreover, it is plausible that conjugative enzymes and/or carboxyesterases act synergistically with efflux transporters of org. anions, affecting the intestinal availability, i.e. many xenobiotics and ester-type prodrugs are metabolized to the corresponding glucuronide and sulfate conjugates and carboxylates (active drugs), resp., followed by cellular extrusion.  The characteristics of the efflux transporters of org. anions across the apical and basal membrane of enterocytes and Caco-2 cells are also summarized from this point of view.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmQiM2dVuEyLVg90H21EOLACvtfcHk0li3kB_aJQ7KOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXot1yiu74%253D&md5=d702f535de468889bc7ebbbb130e41af</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2FS0928-0987%2800%2900178-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0928-0987%252800%252900178-0%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DH.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DRole%2520of%2520metabolic%2520enzymes%2520and%2520efflux%2520transporters%2520in%2520the%2520absorption%2520of%2520drugs%2520from%2520the%2520small%2520intestine%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2000%26volume%3D12%26spage%3D3%26epage%3D12%26doi%3D10.1016%2FS0928-0987%2800%2900178-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paine, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludington, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haining, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rettie, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeldin, D. C.</span></span> <span> </span><span class="NLM_article-title">The human intestinal cytochrome P450 ″pie″</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">880</span>– <span class="NLM_lpage">886</span>, <span class="refDoi"> DOI: 10.1124/dmd.105.008672</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.105.008672" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=16467132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD28Xks1Skt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=880-886&author=M.+F.+Paineauthor=H.+L.+Hartauthor=S.+S.+Ludingtonauthor=R.+L.+Hainingauthor=A.+E.+Rettieauthor=D.+C.+Zeldin&title=The+human+intestinal+cytochrome+P450+%E2%80%B3pie%E2%80%B3&doi=10.1124%2Fdmd.105.008672"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">The human intestinal cytochrome P450 "PIE"</span></div><div class="casAuthors">Paine, Mary F.; Hart, Heather L.; Ludington, Shana S.; Haining, Robert L.; Rettie, Allan E.; Zeldin, Darryl C.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">880-886</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Cytochromes P 450 (P 450s) 3A, 2C, and 1A2 constitute the major "pieces" of the human liver P 450 "pie" and account, on av., for 40, 25, and 18%, resp., of total immunoquantified P 450s.  The P 450 profile in the human small intestine has not been fully characterized.  Therefore, microsomes prepd. from mucosal scrapings from the duodenal/jejunal portion of 31 human donor small intestines were analyzed by Western blot using selective P 450 antibodies.  P 450s 3A4, 2C9, 2C19, and 2J2 were detected in all individuals and ranged from 8.8 to 150, 2.9 to 27, <0.6 to 3.9, and <0.2 to 3.1 pmol/mg, resp.  CYP2D6 was detected in 29 individuals and ranged from <0.2 to 1.4 pmol/mg.  CYP3A5 was detected readily in 11 individuals, with a range (av.) of 4.9 to 25 (16) pmol/mg that represented from 3 to 50% of total CYP3A (CYP3A4 + CYP3A5) content.  CYP1A1 was detected readily in three individuals, with a range (av.) of 3.6 to 7.7 (5.6) pmol/mg.  P 450s 1A2, 2A6, 2B6, 2C8, and 2E1 were not or only faintly detected.  As anticipated, av. CYP3A content (50 pmol/mg) was the highest.  Excluding CYP1A1, the remaining enzymes had the following rank order: 2C9>2C19>2J2>2D6 (8.4, 1.1, 0.9, and 0.5 pmol/mg, resp.).  Anal. of a pooled prepn. of the 31 donor specimens substantiated these results.  In summary, as in the liver, large interindividual variation exists in the expression levels of individual P 450s.  On av., CYP3A and CYP2C9 represents the major pieces of the intestinal P 450 pie, accounting for 80 and 15%, resp., of total immunoquantified P 450s.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfnz4o-ZdSeLVg90H21EOLACvtfcHk0li3kB_aJQ7KOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xks1Skt7k%253D&md5=b17b714367cae7b365174bbd3a8f25f3</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1124%2Fdmd.105.008672&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.105.008672%26sid%3Dliteratum%253Aachs%26aulast%3DPaine%26aufirst%3DM.%2BF.%26aulast%3DHart%26aufirst%3DH.%2BL.%26aulast%3DLudington%26aufirst%3DS.%2BS.%26aulast%3DHaining%26aufirst%3DR.%2BL.%26aulast%3DRettie%26aufirst%3DA.%2BE.%26aulast%3DZeldin%26aufirst%3DD.%2BC.%26atitle%3DThe%2520human%2520intestinal%2520cytochrome%2520P450%2520%25E2%2580%25B3pie%25E2%2580%25B3%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26spage%3D880%26epage%3D886%26doi%3D10.1124%2Fdmd.105.008672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacono, L.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacokinetics and the impact of genetic polymorphism on a CYP2C19 substrate, BMS-823778, in healthy subjects</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">316</span>– <span class="NLM_lpage">325</span>, <span class="refDoi"> DOI: 10.1124/dmd.117.078824</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.117.078824" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=29311135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A280%3ADC%252BC1MzosVKquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=316-325&author=J.+Gongauthor=L.+Hansenauthor=L.+Iacono&title=Clinical+pharmacokinetics+and+the+impact+of+genetic+polymorphism+on+a+CYP2C19+substrate%2C+BMS-823778%2C+in+healthy+subjects&doi=10.1124%2Fdmd.117.078824"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Pharmacokinetics and the Impact of Genetic Polymorphism on a CYP2C19 Substrate, BMS-823778, in Healthy Subjects</span></div><div class="casAuthors">Gong Jiachang; Hansen Lars; Iacono Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Drug metabolism and disposition: the biological fate of chemicals</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">316-325</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BMS-823778 is a potent and selective inhibitor of 11β-HSD1, an enzyme that regulates tissue-specific intracellular glucocorticoid metabolism and is a compelling target for the treatment of metabolic diseases.  Metabolism of BMS-823778 was mediated mainly by polymorphic CYP2C19, with minor contributions from CYP3A4/5 and UGT1A4.  The clinical pharmacokinetics (PK) of BMS-823778 was first investigated in healthy volunteers after single and multiple ascending doses.  BMS-823778 was rapidly absorbed after the oral dose, and systemic exposure at steady state increased proportionally to the dose.  Large intersubject variability in BMS-823778 exposure was likely because of the polymorphism of metabolic enzymes.  The impact of genetic polymorphism of CYP2C19, UGT1A4, and CYP3A5 on BMS-823778 PK was assessed in healthy Chinese and Japanese subjects, as well as in a human absorption, distribution, metabolism, and excretion study in which all subjects were genotyped either before or after treatment.  A clear trend of high exposure and low clearance was seen in poor metabolizers (PMs) of CYP2C19 compared with extensive (EM) and intermediate metabolizer (IM) subjects.  The impact of UGT1A4 or CYP3A5 polymorphism on BMS-823778 PK was statistically not significant in CYP2C19 EM and IM subjects; however, in a subject with predicted CYP2C19 PM phenotype, the PK of BMS-823778 was affected significantly by UGT1A4 polymorphism.  Overall, BMS-823778 was safe and well tolerated in healthy subjects after single or multiple oral doses.  The PK of BMS-823778 was characterized by rapid absorption, and the systemic clearance directly correlated with the genetic polymorphism of CYP2C19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRa0SOUaIcjTXO4gDb7JggCfW6udTcc2eY8jaH30g3sfrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MzosVKquw%253D%253D&md5=0224decd6a1da1a4c855da0c11776e31</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1124%2Fdmd.117.078824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.117.078824%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DHansen%26aufirst%3DL.%26aulast%3DIacono%26aufirst%3DL.%26atitle%3DClinical%2520pharmacokinetics%2520and%2520the%2520impact%2520of%2520genetic%2520polymorphism%2520on%2520a%2520CYP2C19%2520substrate%252C%2520BMS-823778%252C%2520in%2520healthy%2520subjects%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2018%26volume%3D46%26spage%3D316%26epage%3D325%26doi%3D10.1124%2Fdmd.117.078824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacono, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span> <span> </span><span class="NLM_article-title">Physiologically-based pharmacokinetic modelling of a CYP2C19 substrate, BMS823778, utilizing pharmacogenetic data</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">1335</span>– <span class="NLM_lpage">1345</span>, <span class="refDoi"> DOI: 10.1111/bcp.13565</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1111%2Fbcp.13565" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=29469197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOmtb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2018&pages=1335-1345&author=J.+Gongauthor=L.+Iaconoauthor=R.+A.+Iyerauthor=W.+G.+Humphreysauthor=M.+Zheng&title=Physiologically-based+pharmacokinetic+modelling+of+a+CYP2C19+substrate%2C+BMS823778%2C+utilizing+pharmacogenetic+data&doi=10.1111%2Fbcp.13565"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Physiologically-based pharmacokinetic modelling of a CYP2C19 substrate, BMS-823778, utilizing pharmacogenetic data</span></div><div class="casAuthors">Gong, Jiachang; Iacono, Lisa; Iyer, Ramaswamy A.; Humphreys, William G.; Zheng, Ming</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1335-1345</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : Previous studies demonstrated direct correlation between CYP2C19 genotype and BMS-823778 clearance in healthy volunteers.  The objective of the present study was to develop a physiol.-based pharmacokinetic (PBPK) model for BMS-823778 and use the model to predict PK and drug-drug interaction (DDI) in virtual populations with multiple polymorphic genes.  Methods : The PBPK model was built and verified using existing clin. data.  The verified model was simulated to predict PK of BMS-823778 and significance of DDI with a strong CYP3A4 inhibitor in subjects with various CYP2C19 and UGT1A4 genotypes.  Results : The verified PBPK model of BMS-823778 accurately recovered obsd. PK in different populations.  In addn., the model was able to capture the exposure differences between subjects with different CYP2C19 genotypes.  PK simulation indicated higher exposures of BMS-823778 in CYP2C19 poor metabolizers who were also devoid of UGT1A4 activity, compared to those with normal UGT1A4 functionality.  Moderate DDI with itraconazole was predicted in subjects with wild-type CYP2C19 or UGT1A4.  However, in subjects without CYP2C19 or UGT1A4 functionality, significant DDI was predicted when BMS-823778 was coadministered with itraconazole.  Conclusions : A PBPK model was developed using clin. data that accurately predicted human PK in different population with various CYP2C19 phenotypes.  Simulations with the verified PBPK model indicated that UGT1A4 was probably an important clearance pathway in CYP2C19 poor metabolizers.  DDI with itraconazole is likely to be dependent on the genotypes of CYP2C19 and UGT1A4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKf4yqswq2F7Vg90H21EOLACvtfcHk0lgo6yuTpgyqEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOmtb%252FK&md5=af01439445b6778dd82e8d2d77e13126</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1111%2Fbcp.13565&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.13565%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DIacono%26aufirst%3DL.%26aulast%3DIyer%26aufirst%3DR.%2BA.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DZheng%26aufirst%3DM.%26atitle%3DPhysiologically-based%2520pharmacokinetic%2520modelling%2520of%2520a%2520CYP2C19%2520substrate%252C%2520BMS823778%252C%2520utilizing%2520pharmacogenetic%2520data%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2018%26volume%3D84%26spage%3D1335%26epage%3D1345%26doi%3D10.1111%2Fbcp.13565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knights, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miners, J. O.</span></span> <span> </span><span class="NLM_article-title">Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT)</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">602</span>, <span class="refDoi"> DOI: 10.1111/bcp.12086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1111%2Fbcp.12086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=23362865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFGgurrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2013&pages=587-602&author=K.+M.+Knightsauthor=A.+Rowlandauthor=J.+O.+Miners&title=Renal+drug+metabolism+in+humans%3A+the+potential+for+drug-endobiotic+interactions+involving+cytochrome+P450+%28CYP%29+and+UDP-glucuronosyltransferase+%28UGT%29&doi=10.1111%2Fbcp.12086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT)</span></div><div class="casAuthors">Knights, Kathleen M.; Rowland, Andrew; Miners, John O.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">587-602</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Although knowledge of human renal cytochrome P 450 (CYP) and UDP-glucuronosyltransferase (UGT) enzymes and their role in xenobiotic and endobiotic metab. is limited compared with hepatic drug and chem. metab., accumulating evidence indicates that human kidney has significant metabolic capacity.  Of the drug metabolizing P450s in families 1 to 3, there is definitive evidence for only CYP 2B6 and 3A5 expression in human kidney.  CYP 1A1, 1A2, 1B1, 2A6, 2C19, 2D6 and 2E1 are not expressed in human kidney, while data for CYP 2C8, 2C9 and 3A4 expression are equivocal.  It is further known that several P 450 enzymes involved in the metab. of arachidonic acid and eicosanoids are expressed in human kidney, CYP 4A11, 4F2, 4F8, 4F11 and 4F12.  With the current limited evidence of drug substrates for human renal P450s drug-endobiotic interactions arising from inhibition of renal P450s, particularly effects on arachidonic acid metab., appear unlikely.  With respect to the UGTs, 1A5, 1A6, 1A7, 1A9, 2B4, 2B7 and 2B17 are expressed in human kidney, whereas UGT 1A1, 1A3, 1A4, 1A8, 1A10, 2B10, 2B11 and 2B15 are not.  The most abundantly expressed renal UGTs are 1A9 and 2B7, which play a significant role in the glucuronidation of drugs, arachidonic acid, prostaglandins, leukotrienes and P 450 derived arachidonic acid metabolites.  Modulation by drug substrates (e.g. NSAIDs) of the intrarenal activity of UGT1A9 and UGT2B7 has the potential to perturb the metab. of renal mediators including aldosterone, prostaglandins and 20-hydroxyeicosatetraenoic acid, thus disrupting renal homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQROTBuuaXU7Vg90H21EOLACvtfcHk0lgo6yuTpgyqEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFGgurrN&md5=e0c5fbd4c98261dc0d8050035dfa206c</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1111%2Fbcp.12086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.12086%26sid%3Dliteratum%253Aachs%26aulast%3DKnights%26aufirst%3DK.%2BM.%26aulast%3DRowland%26aufirst%3DA.%26aulast%3DMiners%26aufirst%3DJ.%2BO.%26atitle%3DRenal%2520drug%2520metabolism%2520in%2520humans%253A%2520the%2520potential%2520for%2520drug-endobiotic%2520interactions%2520involving%2520cytochrome%2520P450%2520%2528CYP%2529%2520and%2520UDP-glucuronosyltransferase%2520%2528UGT%2529%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D76%26spage%3D587%26epage%3D602%26doi%3D10.1111%2Fbcp.12086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacono, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, J.</span></span> <span> </span><span class="NLM_article-title">Clinical significance of CYP2C19 polymorphisms on the metabolism and pharmacokinetics of 11β-hydroxysteroid dehydrogenase type-1 inhibitor BMS-823778</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">141</span>, <span class="refDoi"> DOI: 10.1111/bcp.13421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1111%2Fbcp.13421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=28850715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Sgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2018&pages=130-141&author=Y.+Chengauthor=L.+Wangauthor=L.+Iaconoauthor=D.+Zhangauthor=W.+Chenauthor=J.+Gongauthor=W.+G.+Humphreysauthor=J.+Gan&title=Clinical+significance+of+CYP2C19+polymorphisms+on+the+metabolism+and+pharmacokinetics+of+11%CE%B2-hydroxysteroid+dehydrogenase+type-1+inhibitor+BMS-823778&doi=10.1111%2Fbcp.13421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical significance of cyp2c19 polymorphisms on the metabolism and pharmacokinetics of 11β-hydroxysteroid dehydrogenase type-1 inhibitor bms-823778</span></div><div class="casAuthors">Cheng, Yaofeng; Wang, Lifei; Iacono, Lisa; Zhang, Donglu; Chen, Weiqi; Gong, Jiachang; Humphreys, William Griffith; Gan, Jinping</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">130-141</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : BMS-823778 is an inhibitor of 11β-hydroxysteroid dehydrogenase type-1, and thus a potential candidate for Type 2 diabetes treatment.  Here, we investigated the metab. and pharmacokinetics of BMS-823778 to understand its pharmacokinetic variations in early clin. trials.  Methods : The metab. of BMS-823778 was characterized in multiple in vitro assays.  Pharmacokinetics were evaluated in healthy volunteers, prescreened as CYP2C19 extensive metabolizers (EM) or poor metabolizers (PM), with a single oral dose of [14C]BMS-823778 (10 mg, 80μCi).  Results : Three metabolites (<5%) were identified in human hepatocytes and liver microsomes (HLM) incubations, including two hydroxylated metabolites (M1 and M2) and one glucuronide conjugate (M3).  As the most abundant metabolite, M1 was formed mainly through CYP2C19.  M1 formation was also correlated with CYP2C19 activities in genotyped HLM.  In humans, urinary excretion of dosed radioactivity was significantly higher in EM (68.8%; 95% confidence interval 61.3%, 76.3%) than in PM (47.0%; 43.5%, 50.6%); only small portions (<2%) were present in faeces or bile from both genotypes.  In plasma, BMS-823778 exposure in PM was significantly (5.3-fold, P = 0.0097) higher than in EM.  Furthermore, total radioactivity exposure was significantly higher (P < 0.01) than BMS-823778 exposure in all groups, indicating the presence of metabolites.  M1 was the only metabolite obsd. in plasma, and much lower in PM.  In urine, the amt. of M1 and its oxidative metabolite in EM was 7-fold of that in PM, while more glucuronide conjugates of BMS-823778 and M1 were excreted in PM.  Conclusions : CYP2C19 polymorphisms significantly impacted systemic exposure and metab. pathways of BMS-823778 in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPDxWjy1MHurVg90H21EOLACvtfcHk0lgo6yuTpgyqEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Sgsg%253D%253D&md5=66db7f5fb592df7df59dc75db6455374</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1111%2Fbcp.13421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.13421%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DIacono%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DGan%26aufirst%3DJ.%26atitle%3DClinical%2520significance%2520of%2520CYP2C19%2520polymorphisms%2520on%2520the%2520metabolism%2520and%2520pharmacokinetics%2520of%252011%25CE%25B2-hydroxysteroid%2520dehydrogenase%2520type-1%2520inhibitor%2520BMS-823778%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2018%26volume%3D84%26spage%3D130%26epage%3D141%26doi%3D10.1111%2Fbcp.13421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koplowitz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komoroski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasichayanula, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Washburn, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellsworth, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whaley, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, W. G.</span></span> <span> </span><span class="NLM_article-title">In vitro characterization and pharmacokinetics of dapagliflozin (bms-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">414</span>, <span class="refDoi"> DOI: 10.1124/dmd.109.029165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.109.029165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=19996149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjt1Ort7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=405-414&author=M.+Obermeierauthor=M.+Yaoauthor=A.+Khannaauthor=B.+Koplowitzauthor=M.+Zhuauthor=W.+Liauthor=B.+Komoroskiauthor=S.+Kasichayanulaauthor=L.+Discenzaauthor=W.+Washburnauthor=W.+Mengauthor=B.+A.+Ellsworthauthor=J.+M.+Whaleyauthor=W.+G.+Humphreys&title=In+vitro+characterization+and+pharmacokinetics+of+dapagliflozin+%28bms-512148%29%2C+a+potent+sodium-glucose+cotransporter+type+II+inhibitor%2C+in+animals+and+humans&doi=10.1124%2Fdmd.109.029165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans</span></div><div class="casAuthors">Obermeier, M.; Yao, M.; Khanna, A.; Koplowitz, B.; Zhu, M.; Li, W.; Komoroski, B.; Kasichayanula, S.; Discenza, L.; Washburn, W.; Meng, W.; Ellsworth, B. A.; Whaley, J. M.; Humphreys, W. G.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">405-414</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">(2S,3R,4R,5S,6R)-2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyl- tetrahydro-2H-pyran-3,4,5-triol (dapagliflozin; BMS-512148) is a potent sodium-glucose cotransporter type II inhibitor in animals and humans and is currently under development for the treatment of type 2 diabetes.  The preclin. characterization of dapagliflozin, to allow compd. selection and prediction of pharmacol. and dispositional behavior in the clinic, involved Caco-2 cell permeability studies, cytochrome P 450 inhibition and induction studies, P 450 reaction phenotyping, metabolite identification in hepatocytes, and pharmacokinetics in rats, dogs, and monkeys.  Dapagliflozin was found to have good permeability across Caco-2 cell membranes.  It was found to be a substrate for P-glycoprotein (P-gp) but not a significant P-gp inhibitor.  Dapagliflozin was not found to be an inhibitor or an inducer of human P 450 enzymes.  The in vitro metabolic profiles of dapagliflozin after incubation with hepatocytes from mice, rats, dogs, monkeys, and humans were qual. similar.  Rat hepatocyte incubations showed the highest turnover, and dapagliflozin was most stable in human hepatocytes.  Prominent in vitro metabolic pathways obsd. were glucuronidation, hydroxylation, and O-deethylation.  Pharmacokinetic parameters for dapagliflozin in preclin. species revealed a compd. with adequate oral exposure, clearance, and elimination half-life, consistent with the potential for single daily dosing in humans.  The pharmacokinetics in humans after a single dose of 50 mg of [14C]dapagliflozin showed good exposure, low clearance, adequate half-life, and no metabolites with significant pharmacol. activity or toxicol. concern.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5vjA08QaWbLVg90H21EOLACvtfcHk0lgZBhR-PyAURA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjt1Ort7o%253D&md5=0eab14ec9be81615d66eb091d5d5f2ac</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.029165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.029165%26sid%3Dliteratum%253Aachs%26aulast%3DObermeier%26aufirst%3DM.%26aulast%3DYao%26aufirst%3DM.%26aulast%3DKhanna%26aufirst%3DA.%26aulast%3DKoplowitz%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DKomoroski%26aufirst%3DB.%26aulast%3DKasichayanula%26aufirst%3DS.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DWashburn%26aufirst%3DW.%26aulast%3DMeng%26aufirst%3DW.%26aulast%3DEllsworth%26aufirst%3DB.%2BA.%26aulast%3DWhaley%26aufirst%3DJ.%2BM.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26atitle%3DIn%2520vitro%2520characterization%2520and%2520pharmacokinetics%2520of%2520dapagliflozin%2520%2528bms-512148%2529%252C%2520a%2520potent%2520sodium-glucose%2520cotransporter%2520type%2520II%2520inhibitor%252C%2520in%2520animals%2520and%2520humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D405%26epage%3D414%26doi%3D10.1124%2Fdmd.109.029165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeFronzo, R. A.</span></span> <span> </span><span class="NLM_article-title">Why do SGLT2 inhibitors inhibit only 30–50% of renal glucose reabsorption in humans?</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2199</span>– <span class="NLM_lpage">2204</span>, <span class="refDoi"> DOI: 10.2337/db12-0052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.2337%2Fdb12-0052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=22923645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlantbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2012&pages=2199-2204&author=J.+J.+Liuauthor=T.+Leeauthor=R.+A.+DeFronzo&title=Why+do+SGLT2+inhibitors+inhibit+only+30%E2%80%9350%25+of+renal+glucose+reabsorption+in+humans%3F&doi=10.2337%2Fdb12-0052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?</span></div><div class="casAuthors">Liu, Jiwen; Lee, TaeWeon; DeFronzo, Ralph A.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2199-2204</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">A review.  Sodium glucose cotransporter 2 (SGLT2) inhibition is a novel and promising treatment for diabetes under late-stage clin. development.  It generally is accepted that SGLT2 mediates 90% of renal glucose reabsorption.  However, SGLT2 inhibitors in clin. development inhibit only 30-50% of the filtered glucose load.  Why are they unable to inhibit 90% of glucose reabsorption in humans.  We will try to provide an explanation to this puzzle in this perspective anal. of the unique pharmacokinetic and pharmacodynamic profiles of SGLT2 inhibitors in clin. trials and examine possible mechanisms and mol. properties that may be responsible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7mlWVhal1BLVg90H21EOLACvtfcHk0lgZBhR-PyAURA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlantbzM&md5=1b253c451e7151ab93238e99f6592aa2</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.2337%2Fdb12-0052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb12-0052%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%2BJ.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DDeFronzo%26aufirst%3DR.%2BA.%26atitle%3DWhy%2520do%2520SGLT2%2520inhibitors%2520inhibit%2520only%252030%25E2%2580%259350%2525%2520of%2520renal%2520glucose%2520reabsorption%2520in%2520humans%253F%26jtitle%3DDiabetes%26date%3D2012%26volume%3D61%26spage%3D2199%26epage%3D2204%26doi%3D10.2337%2Fdb12-0052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamaru, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, H.</span></span> <span> </span><span class="NLM_article-title">Physiologically based pharmacokinetic-pharmacodynamic modeling to predict concentrations and actions of sodium-dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">491</span>– <span class="NLM_lpage">506</span>, <span class="refDoi"> DOI: 10.1002/bdd.2040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1002%2Fbdd.2040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=27604638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVKqu73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=491-506&author=K.+Moriauthor=R.+Saitoauthor=Y.+Nakamaruauthor=M.+Shimizuauthor=H.+Yamazaki&title=Physiologically+based+pharmacokinetic-pharmacodynamic+modeling+to+predict+concentrations+and+actions+of+sodium-dependent+glucose+transporter+2+inhibitor+canagliflozin+in+human+intestines+and+renal+tubules&doi=10.1002%2Fbdd.2040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Physiologically based pharmacokinetic-pharmacodynamic modeling to predict concentrations and actions of sodium-dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules</span></div><div class="casAuthors">Mori, Kazumi; Saito, Ryuta; Nakamaru, Yoshinobu; Shimizu, Makiko; Yamazaki, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">491-506</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Canagliflozin is a recently developed sodium-glucose cotransporter (SGLT) 2 inhibitor that promotes renal glucose excretion and is considered to inhibit renal SGLT2 from the luminal side of proximal tubules.  Canagliflozin reportedly inhibits SGLT1 weakly and suppresses postprandial plasma glucose, suggesting that it also inhibits intestinal SGLT1.  However, it is difficult to measure the drug concns. of these assumed sites of action directly.  The pharmacokinetic-pharmacodynamic (PK/PD) relationships of canagliflozin remain poorly characterized.  Therefore, we developed a physiol. based pharmacokinetic (PBPK) model of canagliflozin based on clin. data from healthy volunteers and used it to simulate luminal concns. in intestines and renal tubules.  In small intestine simulations, inhibition ratios for SGLT1 were predicted to be 40%-60% after the oral administration of clin. doses (100-300 mg/day).  In contrast, inhibition ratios of canagliflozin for renal SGLT2 and SGLT1 were predicted to be approx. 100% and 0.2%-0.4%, resp.  These analyses suggest that canagliflozin only inhibits SGLT2 in the kidney.  Using the simulated proximal tubule luminal concns. of canagliflozin, the urinary glucose excretion rates in canagliflozin-treated diabetic patients were accurately predicted using the renal glucose reabsorption model as a PD model.  Because the simulation of canagliflozin pharmacokinetics was successful, this PBPK methodol. was further validated by successfully simulating the pharmacokinetics of dapagliflozin, another SGLT2 inhibitor.  The present results suggest the utility of this PBPK/PD model for predicting canagliflozin concns. at target sites and help elucidate the pharmacol. effects of SGLT1/2 inhibition in humans.  This article is protected by copyright.  All rights reserved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR3NwJI5DggLVg90H21EOLACvtfcHk0lgoGA-I_bpC8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVKqu73M&md5=d3ef0a5b6b50f389a338fef730a75360</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1002%2Fbdd.2040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.2040%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DK.%26aulast%3DSaito%26aufirst%3DR.%26aulast%3DNakamaru%26aufirst%3DY.%26aulast%3DShimizu%26aufirst%3DM.%26aulast%3DYamazaki%26aufirst%3DH.%26atitle%3DPhysiologically%2520based%2520pharmacokinetic-pharmacodynamic%2520modeling%2520to%2520predict%2520concentrations%2520and%2520actions%2520of%2520sodium-dependent%2520glucose%2520transporter%25202%2520inhibitor%2520canagliflozin%2520in%2520human%2520intestines%2520and%2520renal%2520tubules%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D2016%26volume%3D37%26spage%3D491%26epage%3D506%26doi%3D10.1002%2Fbdd.2040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balazki, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eissing, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehr, T.</span></span> <span> </span><span class="NLM_article-title">A quantitative systems pharmacology kidney model of diabetes associated renal hyperfiltration and the effects of SGLT inhibitors</span>. <i>CPT: Pharmacometrics Syst. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">788</span>– <span class="NLM_lpage">797</span>, <span class="refDoi"> DOI: 10.1002/psp4.12359</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1002%2Fpsp4.12359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=30270578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFKju7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=788-797&author=P.+Balazkiauthor=S.+Schallerauthor=T.+Eissingauthor=T.+Lehr&title=A+quantitative+systems+pharmacology+kidney+model+of+diabetes+associated+renal+hyperfiltration+and+the+effects+of+SGLT+inhibitors&doi=10.1002%2Fpsp4.12359"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">A Quantitative Systems Pharmacology Kidney Model of Diabetes Associated Renal Hyperfiltration and the Effects of SGLT Inhibitors</span></div><div class="casAuthors">Balazki, Pavel; Schaller, Stephan; Eissing, Thomas; Lehr, Thorsten</div><div class="citationInfo"><span class="NLM_cas:title">CPT: Pharmacometrics & Systems Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">788-797</span>CODEN:
                <span class="NLM_cas:coden">CPSPBR</span>;
        ISSN:<span class="NLM_cas:issn">2163-8306</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The early stage of diabetes mellitus is characterized by increased glomerular filtration rate (GFR), known as hyperfiltration, which is believed to be one of the main causes leading to renal injury in diabetes.  Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been shown to be able to reverse hyperfiltration in some patients.  We developed a mechanistic computational model of the kidney that explains the interplay of hyperglycemia and hyperfiltration and integrates the pharmacokinetics/pharmacodynamics (PK/PD) of the SGLT2i dapagliflozin.  Based on simulation results, we propose kidney growth as the necessary process for hyperfiltration progression.  Further, the model indicates that renal SGLT1i could significantly improve hyperfiltration when added to SGTL2i.  Integrated into a physiol. based PK/PD (PBPK/PD) Diabetes Platform, the model presents a powerful tool for aiding drug development, prediction of hyperfiltration risk, and allows the assessment of the outcomes of individualized treatments with SGLT1-inhibitors and SGLT2-inhibitors and their co-administration with insulin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn-lTkzSonHrVg90H21EOLACvtfcHk0lgoGA-I_bpC8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFKju7%252FM&md5=e947dd71a93e9cb04f26183105baa464</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1002%2Fpsp4.12359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsp4.12359%26sid%3Dliteratum%253Aachs%26aulast%3DBalazki%26aufirst%3DP.%26aulast%3DSchaller%26aufirst%3DS.%26aulast%3DEissing%26aufirst%3DT.%26aulast%3DLehr%26aufirst%3DT.%26atitle%3DA%2520quantitative%2520systems%2520pharmacology%2520kidney%2520model%2520of%2520diabetes%2520associated%2520renal%2520hyperfiltration%2520and%2520the%2520effects%2520of%2520SGLT%2520inhibitors%26jtitle%3DCPT%253A%2520Pharmacometrics%2520Syst.%2520Pharmacol.%26date%3D2018%26volume%3D7%26spage%3D788%26epage%3D797%26doi%3D10.1002%2Fpsp4.12359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luettgen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grace, J. E.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knabb, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wexler, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, S. J.</span></span> <span> </span><span class="NLM_article-title">Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor</span>. <i>Eur. J. Drug Metab. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">139</span>, <span class="refDoi"> DOI: 10.1007/s13318-011-0037-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1007%2Fs13318-011-0037-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=21461793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFaks7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2011&pages=129-139&author=K.+Heauthor=J.+M.+Luettgenauthor=D.+Zhangauthor=B.+Heauthor=J.+E.+Graceauthor=B.+Xinauthor=D.+J.+Pintoauthor=P.+C.+Wongauthor=R.+M.+Knabbauthor=P.+Y.+Lamauthor=R.+R.+Wexlerauthor=S.+J.+Grossman&title=Preclinical+pharmacokinetics+and+pharmacodynamics+of+apixaban%2C+a+potent+and+selective+factor+Xa+inhibitor&doi=10.1007%2Fs13318-011-0037-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor</span></div><div class="casAuthors">He, Kan; Luettgen, Joseph M.; Zhang, Donglu; He, Bing; Grace, James E., Jr.; Xin, Baomin; Pinto, Donald J. P.; Wong, Pancras C.; Knabb, Robert M.; Lam, Patrick Y. S.; Wexler, Ruth R.; Grossman, Scott J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">129-139</span>CODEN:
                <span class="NLM_cas:coden">EJDPD2</span>;
        ISSN:<span class="NLM_cas:issn">0378-7966</span>.
    
            (<span class="NLM_cas:orgname">Springer France</span>)
        </div><div class="casAbstract">Apixaban is a potent, highly selective, reversible, oral, direct factor Xa (fXa) inhibitor in development for thrombosis prevention and treatment.  The preclin. pharmacokinetic (PK) attributes of apixaban feature small vol. of distribution (Vd), low systemic clearance (CL), and good oral bioavailability.  Apixaban is well absorbed in rat, dog, and chimpanzee, with abs. oral bioavailability of approx. 50% or greater.  The steady-state Vd of apixaban is approx. 0.5, 0.2, and 0.17 l/kg in rats, dogs, and chimpanzees, while CL is approx. 0.9, 0.04, and 0.018 l/h/kg, resp.  In vitro metabolic clearance of apixaban is also low.  Renal clearance comprises approx. 10-30% of systemic clearance in rat, dog, and chimpanzee.  Anti-fXa activity, prothrombin time (PT), and HEPTEST clotting time (HCT) prolongation correlated well with plasma apixaban concn. in rat, dog and chimpanzee.  There was no lag time between apixaban plasma concn. and the pharmacodynamic (PD) markers, suggesting a rapid onset of action of apixaban.  The PK/PD analyses were performed using an inhibitory E max model for anti-fXa assay and a linear model for PT and HCT assays.  The IC50 values for anti-fXa activity were 0.73 ± 0.03 and 1.5 ± 0.15 μM for rat and dog, resp.  The apparent Ki values for PT were approx. 1.7, 6.6, and 4.8 μM for rat, dog and chimpanzee, resp.  The apparent Ki for HCT was approx. 1.3 μM for dog.  Apixaban exhibits desirable PK and PD properties for clin. development with good oral bioavailability, small Vd, low CL, and direct, predictable, concn.-dependent PD responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjZMn91_38O7Vg90H21EOLACvtfcHk0lgy_wSg9a82AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFaks7bL&md5=d9432f6f4e097ff4b3a96a9b93f11b98</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1007%2Fs13318-011-0037-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13318-011-0037-x%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DK.%26aulast%3DLuettgen%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DHe%26aufirst%3DB.%26aulast%3DGrace%26aufirst%3DJ.%2BE.%26aulast%3DXin%26aufirst%3DB.%26aulast%3DPinto%26aufirst%3DD.%2BJ.%26aulast%3DWong%26aufirst%3DP.%2BC.%26aulast%3DKnabb%26aufirst%3DR.%2BM.%26aulast%3DLam%26aufirst%3DP.%2BY.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DGrossman%26aufirst%3DS.%2BJ.%26atitle%3DPreclinical%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520apixaban%252C%2520a%2520potent%2520and%2520selective%2520factor%2520Xa%2520inhibitor%26jtitle%3DEur.%2520J.%2520Drug%2520Metab.%2520Pharmacokinet.%26date%3D2011%26volume%3D36%26spage%3D129%26epage%3D139%26doi%3D10.1007%2Fs13318-011-0037-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raghavan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonacorsi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span> <span> </span><span class="NLM_article-title">Apixaban metabolism and pharmacokinetics after oral administration to humans</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">74</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.023143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.108.023143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=18832478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVSmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=74-81&author=N.+Raghavanauthor=C.+E.+Frostauthor=Z.+Yuauthor=K.+Heauthor=H.+Zhangauthor=W.+G.+Humphreysauthor=D.+Pintoauthor=S.+Chenauthor=S.+Bonacorsiauthor=P.+C.+Wongauthor=D.+Zhang&title=Apixaban+metabolism+and+pharmacokinetics+after+oral+administration+to+humans&doi=10.1124%2Fdmd.108.023143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Apixaban metabolism and pharmacokinetics after oral administration to humans</span></div><div class="casAuthors">Raghavan, Nirmala; Frost, Charles E.; Yu, Zhigang; He, Kan; Zhang, Haiying; Humphreys, W. Griffith; Pinto, Donald; Chen, Shiangyuan; Bonacorsi, Samuel; Wong, Pancras C.; Zhang, Donglu</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">74-81</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The metab. and disposition of [14C]apixaban, an orally bioavailable, highly selective, and direct acting/reversible factor Xa inhibitor, was investigated in 10 healthy male subjects without (group 1, n = 6) and with bile collection (group 2, n = 4) after a single 20-mg oral dose.  Urine, blood, and feces samples were collected from all subjects.  Bile samples were also collected for 3 to 8 h after dosing from group 2 subjects.  There were no serious adverse events or discontinuations due to adverse effects.  In plasma, apixaban was the major circulating component and O-demethyl apixaban sulfate, a stable and water-sol. metabolite, was the significant metabolite.  The exposure of apixaban (Cmax and area under the plasma concn. vs. time curve) in subjects with bile collection was generally similar to that in subjects without bile collection.  The administered dose was recovered in feces (group 1, 56.0%; group 2, 46.7%) and urine (group 1, 24.5%; group 2, 28.8%), with the parent drug representing approx. half of the recovered dose.  Biliary excretion represented a minor elimination pathway (2.44% of the administered dose) from group 2 subjects within the limited collection period.  Metabolic pathways identified for apixaban included O-demethylation, hydroxylation, and sulfation of hydroxylated O-demethyl apixaban.  Thus, apixaban is an orally bioavailable inhibitor of factor Xa with elimination pathways that include metab. and renal excretion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqa3AirzsVA27Vg90H21EOLACvtfcHk0lgy_wSg9a82AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVSmtg%253D%253D&md5=fa456d3e5c0fac398b7c8ee61f76c5dc</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.023143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.023143%26sid%3Dliteratum%253Aachs%26aulast%3DRaghavan%26aufirst%3DN.%26aulast%3DFrost%26aufirst%3DC.%2BE.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DPinto%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DBonacorsi%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DP.%2BC.%26aulast%3DZhang%26aufirst%3DD.%26atitle%3DApixaban%2520metabolism%2520and%2520pharmacokinetics%2520after%2520oral%2520administration%2520to%2520humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D74%26epage%3D81%26doi%3D10.1124%2Fdmd.108.023143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lassen, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pineo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deitchman, D.</span></span> <span> </span><span class="NLM_article-title">The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement</span>. <i>J. Thromb. Haemostasis</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">2368</span>– <span class="NLM_lpage">2375</span>, <span class="refDoi"> DOI: 10.1111/j.1538-7836.2007.02764.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1111%2Fj.1538-7836.2007.02764.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=17868430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivFCg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2007&pages=2368-2375&author=M.+R.+Lassenauthor=B.+L.+Davidsonauthor=A.+Gallusauthor=G.+Pineoauthor=J.+Ansellauthor=D.+Deitchman&title=The+efficacy+and+safety+of+apixaban%2C+an+oral%2C+direct+factor+Xa+inhibitor%2C+as+thromboprophylaxis+in+patients+following+total+knee+replacement&doi=10.1111%2Fj.1538-7836.2007.02764.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement</span></div><div class="casAuthors">Lassen, M. R.; Davidson, B. L.; Gallus, A.; Pineo, G.; Ansell, J.; Deitchman, D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2368-2375</span>CODEN:
                <span class="NLM_cas:coden">JTHOA5</span>;
        ISSN:<span class="NLM_cas:issn">1538-7933</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing, Inc.</span>)
        </div><div class="casAbstract">Background: Heparins and warfarin are currently used as venous thromboembolism (VTE) prophylaxis in surgery.  Inhibition of factor (F) Xa provides a specific mechanism of anticoagulation and the potential for an improved benefit-risk profile.  Objectives: To evaluate the safety and efficacy of apixaban, a potent, direct, oral inhibitor of FXa, in patients following total knee replacement (TKR), and to investigate dose-response relationships.  Patients/methods: A total of 1238 patients were randomized to one of six double-blind apixaban doses [5, 10 or 20 mg day-1 administered as a single (q.d.) or a twice-daily divided dose (b.i.d.)], enoxaparin (30 mg b.i.d.) or open-label warfarin (titrated to an International Normalized Ratio of 1.8-3.0).  Treatment lasted 10-14 days, commencing 12-24 h after surgery with apixaban or enoxaparin, and on the evening of surgery with warfarin.  The primary efficacy outcome was a composite of VTE (mandatory venog.) and all-cause mortality during treatment.  The primary safety outcome was major bleeding.  Results: A total of 1217 patients were eligible for safety and 856 patients for efficacy anal.  All apixaban groups had lower primary efficacy event rates than either comparator.  The primary outcome rate decreased with increasing apixaban dose (P = 0.09 with q.d./b.i.d. regimens combined, P = 0.19 for q.d. and P = 0.13 for b.i.d. dosing).  A significant dose-related increase in the incidence of total adjudicated bleeding events was noted in the q.d. (P = 0.01) and b.i.d. (P = 0.02) apixaban groups; there was no difference between q.d. and b.i.d. regimens.  Conclusions: Apixaban in doses of 2.5 mg b.i.d. or 5 mg q.d. has a promising benefit-risk profile compared with the current stds. of care following TKR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgaRDmxArBA7Vg90H21EOLACvtfcHk0lgy_wSg9a82AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivFCg&md5=11247d815b89e5c7f9547da60c0c11f8</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1111%2Fj.1538-7836.2007.02764.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1538-7836.2007.02764.x%26sid%3Dliteratum%253Aachs%26aulast%3DLassen%26aufirst%3DM.%2BR.%26aulast%3DDavidson%26aufirst%3DB.%2BL.%26aulast%3DGallus%26aufirst%3DA.%26aulast%3DPineo%26aufirst%3DG.%26aulast%3DAnsell%26aufirst%3DJ.%26aulast%3DDeitchman%26aufirst%3DD.%26atitle%3DThe%2520efficacy%2520and%2520safety%2520of%2520apixaban%252C%2520an%2520oral%252C%2520direct%2520factor%2520Xa%2520inhibitor%252C%2520as%2520thromboprophylaxis%2520in%2520patients%2520following%2520total%2520knee%2520replacement%26jtitle%3DJ.%2520Thromb.%2520Haemostasis%26date%3D2007%26volume%3D5%26spage%3D2368%26epage%3D2375%26doi%3D10.1111%2Fj.1538-7836.2007.02764.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eikelboom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diener, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golitsyn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avezum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohnloser, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talajic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pais, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budaj, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkhomenko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Commerford, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Mieghem, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lip, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanas-Zanetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Hermosillo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dans, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munawar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afzal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yusuf, S.</span></span> <span> </span><span class="NLM_article-title">Apixaban in patients with atrial fibrillation</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">806</span>– <span class="NLM_lpage">817</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1007432</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1056%2FNEJMoa1007432" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=21309657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivV2kurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=806-817&author=S.+J.+Connollyauthor=J.+Eikelboomauthor=C.+Joynerauthor=H.+C.+Dienerauthor=R.+Hartauthor=S.+Golitsynauthor=G.+Flakerauthor=A.+Avezumauthor=S.+H.+Hohnloserauthor=R.+Diazauthor=M.+Talajicauthor=J.+Zhuauthor=P.+Paisauthor=A.+Budajauthor=A.+Parkhomenkoauthor=P.+Janskyauthor=P.+Commerfordauthor=R.+S.+Tanauthor=K.+H.+Simauthor=B.+S.+Lewisauthor=W.+Van+Mieghemauthor=G.+Y.+Lipauthor=J.+H.+Kimauthor=F.+Lanas-Zanettiauthor=A.+Gonzalez-Hermosilloauthor=A.+L.+Dansauthor=M.+Munawarauthor=M.+O%E2%80%99Donnellauthor=J.+Lawrenceauthor=G.+Lewisauthor=R.+Afzalauthor=S.+Yusuf&title=Apixaban+in+patients+with+atrial+fibrillation&doi=10.1056%2FNEJMoa1007432"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Apixaban in patients with atrial fibrillation</span></div><div class="casAuthors">Connolly, Stuart J.; Eikelboom, John; Joyner, Campbell; Diener, Hans-Christoph; Hart, Robert; Golitsyn, Sergey; Flaker, Greg; Avezum, Alvaro; Hohnloser, Stefan H.; Diaz, Rafael; Talajic, Mario; Zhu, Jun; Pais, Prem; Budaj, Andrzej; Parkhomenko, Alexander; Jansky, Petr; Commerford, Patrick; Tan, Ru San; Sim, Kui-Hian; Lewis, Basil S.; Van Mieghem, Walter; Lip, Gregory Y. H.; Kim, Jae Hyung; Lanas-Zanetti, Fernando; Gonzalez-Hermosillo, Antonio; Dans, Antonio L.; Munawar, Muhammad; O'Donnell, Martin; Lawrence, John; Lewis, Gayle; Afzal, Rizwan; Yusuf, Salim</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">806-817</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Vitamin K antagonists have been shown to prevent stroke in patients with atrial fibrillation.  However, many patients are not suitable candidates for or are unwilling to receive vitamin K antagonist therapy, and these patients have a high risk of stroke.  Apixaban, a novel factor Xa inhibitor, may be an alternative treatment for such patients.  METHODS: In a double-blind study, we randomly assigned 5599 patients with atrial fibrillation who were at increased risk for stroke and for whom vitamin K antagonist therapy was unsuitable to receive apixaban (at a dose of 5 mg twice daily) or aspirin (81 to 324 mg per day), to det. whether apixaban was superior.  The mean follow up period was 1.1 years.  The primary outcome was the occurrence of stroke or systemic embolism.  RESULTS: Before enrollment, 40% of the patients had used a vitamin K antagonist.  The data and safety monitoring board recommended early termination of the study because of a clear benefit in favor of apixaban.  There were 51 primary outcome events (1.6% per yr) among patients assigned to apixaban and 113 (3.7% per yr) among those assigned to aspirin (hazard ratio with apixaban, 0.45; 95% confidence interval [CI], 0.32 to 0.62; P < 0.001). The rates of death were 3.5% per yr in the apixaban group and 4.4% per yr in the aspirin group (hazard ratio, 0.79; 95% CI, 0.62 to 1.02; P = 0.07).  There were 44 cases of major bleeding (1.4% per yr) in the apixaban group and 39 (1.2% per yr) in the aspirin group (hazard ratio with apixaban, 1.13; 95% CI, 0.74 to 1.75; P = 0.57); there were 11 cases of intracranial bleeding with apixaban and 13 with aspirin.  The risk of a first hospitalization for cardiovascular causes was reduced with apixaban as compared with aspirin (12.6% per yr vs. 15.9% per yr, P < 0.001).  The treatment effects were consistent among important subgroups.  CONCLUSIONS: In patients with atrial fibrillation for whom vitamin K antagonist therapy was unsuitable, apixaban reduced the risk of stroke or systemic embolism without significantly increasing the risk of major bleeding or intracranial hemorrhage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph_98mFcDE4rVg90H21EOLACvtfcHk0lh4ZHiaWKBn4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivV2kurc%253D&md5=248a2c0860315acdcce922612c7feb78</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1007432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1007432%26sid%3Dliteratum%253Aachs%26aulast%3DConnolly%26aufirst%3DS.%2BJ.%26aulast%3DEikelboom%26aufirst%3DJ.%26aulast%3DJoyner%26aufirst%3DC.%26aulast%3DDiener%26aufirst%3DH.%2BC.%26aulast%3DHart%26aufirst%3DR.%26aulast%3DGolitsyn%26aufirst%3DS.%26aulast%3DFlaker%26aufirst%3DG.%26aulast%3DAvezum%26aufirst%3DA.%26aulast%3DHohnloser%26aufirst%3DS.%2BH.%26aulast%3DDiaz%26aufirst%3DR.%26aulast%3DTalajic%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DPais%26aufirst%3DP.%26aulast%3DBudaj%26aufirst%3DA.%26aulast%3DParkhomenko%26aufirst%3DA.%26aulast%3DJansky%26aufirst%3DP.%26aulast%3DCommerford%26aufirst%3DP.%26aulast%3DTan%26aufirst%3DR.%2BS.%26aulast%3DSim%26aufirst%3DK.%2BH.%26aulast%3DLewis%26aufirst%3DB.%2BS.%26aulast%3DVan%2BMieghem%26aufirst%3DW.%26aulast%3DLip%26aufirst%3DG.%2BY.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DLanas-Zanetti%26aufirst%3DF.%26aulast%3DGonzalez-Hermosillo%26aufirst%3DA.%26aulast%3DDans%26aufirst%3DA.%2BL.%26aulast%3DMunawar%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DM.%26aulast%3DLawrence%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DG.%26aulast%3DAfzal%26aufirst%3DR.%26aulast%3DYusuf%26aufirst%3DS.%26atitle%3DApixaban%2520in%2520patients%2520with%2520atrial%2520fibrillation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D806%26epage%3D817%26doi%3D10.1056%2FNEJMoa1007432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Granger, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMurray, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hylek, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Khalidi, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avezum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahit, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easton, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezekowitz, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geraldes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gersh, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golitsyn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermosillo, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohnloser, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horowitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Sendon, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pais, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkhomenko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verheugt, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallentin, L.</span></span> <span> </span><span class="NLM_article-title">Apixaban versus warfarin in patients with atrial fibrillation</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">981</span>– <span class="NLM_lpage">992</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1107039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1056%2FNEJMoa1107039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=21870978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtF2ms7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2011&pages=981-992&author=C.+B.+Grangerauthor=J.+H.+Alexanderauthor=J.+J.+McMurrayauthor=R.+D.+Lopesauthor=E.+M.+Hylekauthor=M.+Hannaauthor=H.+R.+Al-Khalidiauthor=J.+Ansellauthor=D.+Atarauthor=A.+Avezumauthor=M.+C.+Bahitauthor=R.+Diazauthor=J.+D.+Eastonauthor=J.+A.+Ezekowitzauthor=G.+Flakerauthor=D.+Garciaauthor=M.+Geraldesauthor=B.+J.+Gershauthor=S.+Golitsynauthor=S.+Gotoauthor=A.+G.+Hermosilloauthor=S.+H.+Hohnloserauthor=J.+Horowitzauthor=P.+Mohanauthor=P.+Janskyauthor=B.+S.+Lewisauthor=J.+L.+Lopez-Sendonauthor=P.+Paisauthor=A.+Parkhomenkoauthor=F.+W.+Verheugtauthor=J.+Zhuauthor=L.+Wallentin&title=Apixaban+versus+warfarin+in+patients+with+atrial+fibrillation&doi=10.1056%2FNEJMoa1107039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Apixaban versus warfarin in patients with atrial fibrillation</span></div><div class="casAuthors">Granger, Christopher B.; Alexander, John H.; McMurray, Johnj. V.; Lopes, Renato D.; Hylek, Elaine M.; Hanna, Michael; Al-Khalidi, Hussein R.; Ansell, Jack; Atar, Dan; Avezum, Alvaro; Bahit, M. Cecilia; Diaz, Rafael; Easton, Onald; Ezekowitz, Justin A.; Flaker, Greg; Garcia, David; Geraldes, Margarida; Gersh, Bernard J.; Golitsyn, Sergey; Goto, Shinya; Hermosillo, Antonio G.; Hohnloser, Stefan H.; Horowitz, John; Mohan, Puneet; Jansky, Petr; Lewis, Basil S.; Lopez-Sendon, Jose Luis; Pais, Prem; Parkhomenko, Alexander; Verheugt, Freek W. A.; Zhu, Jun; Wallentin, Lars</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">981-992</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations.  Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a similar population in comparison with aspirin.  METHODS: In this randomized, double-blind trial, we compared apixaban (at a dose of 5 mg twice daily) with warfarin (target international normalized ratio, 2.0 to 3.0) in 18,201 patients with atrial fibrillation and at least one addnl. risk factor for stroke.  The primary outcome was ischemic or hemorrhagic stroke or systemic embolism.  The trial was designed to test for noninferiority, with key secondary objectives of testing for superiority with respect to the primary outcome and to the rates of major bleeding and death from any cause.  RESULTS: The median duration of follow-up was 1.8 years.  The rate of the primary outcome was 1.27% per yr in the apixaban group, as compared with 1.60% per yr in the warfarin group (hazard ratio with apixaban, 0.79; 95% confidence interval [CI], 0.66 to 0.95; P < 0.001 for noninferiority; P = 0.01 for superiority).  The rate of major bleeding was 2.13% per yr in the apixaban group, as compared with 3.09% per yr in the warfarin group (hazard ratio, 0.69; 95% CI, 0.60 to 0.80; P < 0.001), and the rates of death from any cause were 3.52% and 3.94%, resp. (hazard ratio, 0.89; 95% CI, 0.80 to 0.99; P = 0.047).  The rate of hemorrhagic stroke was 0.24% per yr in the apixaban group, as compared with 0.47% per yr in the warfarin group (hazard ratio, 0.51; 95% CI, 0.35 to 0.75; P < 0.001), and the rate of ischemic or uncertain type of stroke was 0.97% per yr in the apixaban group and 1.05% per yr in the warfarin group (hazard ratio, 0.92; 95% CI, 0.74 to 1.13; P = 0.42).  CONCLUSIONS: In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYkCU6dw4nZ7Vg90H21EOLACvtfcHk0lh4ZHiaWKBn4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtF2ms7rN&md5=14cb7dbc3e754b65e33729da80b1c58b</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1107039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1107039%26sid%3Dliteratum%253Aachs%26aulast%3DGranger%26aufirst%3DC.%2BB.%26aulast%3DAlexander%26aufirst%3DJ.%2BH.%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%26aulast%3DLopes%26aufirst%3DR.%2BD.%26aulast%3DHylek%26aufirst%3DE.%2BM.%26aulast%3DHanna%26aufirst%3DM.%26aulast%3DAl-Khalidi%26aufirst%3DH.%2BR.%26aulast%3DAnsell%26aufirst%3DJ.%26aulast%3DAtar%26aufirst%3DD.%26aulast%3DAvezum%26aufirst%3DA.%26aulast%3DBahit%26aufirst%3DM.%2BC.%26aulast%3DDiaz%26aufirst%3DR.%26aulast%3DEaston%26aufirst%3DJ.%2BD.%26aulast%3DEzekowitz%26aufirst%3DJ.%2BA.%26aulast%3DFlaker%26aufirst%3DG.%26aulast%3DGarcia%26aufirst%3DD.%26aulast%3DGeraldes%26aufirst%3DM.%26aulast%3DGersh%26aufirst%3DB.%2BJ.%26aulast%3DGolitsyn%26aufirst%3DS.%26aulast%3DGoto%26aufirst%3DS.%26aulast%3DHermosillo%26aufirst%3DA.%2BG.%26aulast%3DHohnloser%26aufirst%3DS.%2BH.%26aulast%3DHorowitz%26aufirst%3DJ.%26aulast%3DMohan%26aufirst%3DP.%26aulast%3DJansky%26aufirst%3DP.%26aulast%3DLewis%26aufirst%3DB.%2BS.%26aulast%3DLopez-Sendon%26aufirst%3DJ.%2BL.%26aulast%3DPais%26aufirst%3DP.%26aulast%3DParkhomenko%26aufirst%3DA.%26aulast%3DVerheugt%26aufirst%3DF.%2BW.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DWallentin%26aufirst%3DL.%26atitle%3DApixaban%2520versus%2520warfarin%2520in%2520patients%2520with%2520atrial%2520fibrillation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D365%26spage%3D981%26epage%3D992%26doi%3D10.1056%2FNEJMoa1107039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghavan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitroka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maxwell, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knabb, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, S. J.</span></span> <span> </span><span class="NLM_article-title">Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1738</span>– <span class="NLM_lpage">1748</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.025981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.108.025981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=19420130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1MXps1ygtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=1738-1748&author=D.+Zhangauthor=K.+Heauthor=N.+Raghavanauthor=L.+Wangauthor=J.+Mitrokaauthor=B.+D.+Maxwellauthor=R.+M.+Knabbauthor=C.+Frostauthor=A.+Schusterauthor=F.+Haoauthor=Z.+Guauthor=W.+G.+Humphreysauthor=S.+J.+Grossman&title=Comparative+metabolism+of+14C-labeled+apixaban+in+mice%2C+rats%2C+rabbits%2C+dogs%2C+and+humans&doi=10.1124%2Fdmd.108.025981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans</span></div><div class="casAuthors">Zhang, Donglu; He, Kan; Raghavan, Nirmala; Wang, Lifei; Mitroka, James; Maxwell, Brad D.; Knabb, Robert M.; Frost, Charles; Schuster, Alan; Hao, Feng; Gu, Zheming; Humphreys, W. Griffith; Grossman, Scott J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1738-1748</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The metab. and disposition of [14C]apixaban, a potent, reversible, and direct inhibitor of coagulation factor Xa, were investigated in mice, rats, rabbits, dogs, and humans after a single oral administration and in incubations with hepatocytes.  In plasma, the parent compd. was the major circulating component in mice, rats, dogs, and humans.  O-Demethyl apixaban sulfate (M1) represented approx. 25% of the parent area under the time curve in human plasma.  This sulfate metabolite was present, but in lower amts. relative to the parent, in plasma from mice, rats, and dogs.  Rabbits showed a plasma metabolite profile distinct from that of other species with apixaban as a minor component and M2 (O-demethyl apixaban) and M14 (O-demethyl apixaban glucuronide) as prominent components.  The fecal route was a major elimination pathway, accounting for >54% of the dose in animals and >46% in humans.  The urinary route accounted for <15% of the dose in animals and 25 to 28% in humans.  Apixaban was the major component in feces of every species and in urine of all species except rabbit.  M1 and M2 were common prominent metabolites in urine and feces of all species as well as in bile of rats and humans.  In vivo metabolite profiles showed quant. differences between species and from in vitro metabolite profiles, but all human metabolites were found in animal species.  After i.v. administration of [14C]apixaban to bile duct-cannulated rats, the significant portion (approx. 22%) of the dose was recovered as parent drug in the feces, suggesting direct excretion of the drug from gastrointestinal tracts of rats.  Overall, apixaban was effectively eliminated via multiple elimination pathways in animals and humans, including oxidative metab., and direct renal and intestinal excretion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwA4D_G952O7Vg90H21EOLACvtfcHk0lh-MpcW8fr8FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXps1ygtLs%253D&md5=9c16ff8a76bef8c8e4c01f16d6313c2e</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.025981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.025981%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DHe%26aufirst%3DK.%26aulast%3DRaghavan%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMitroka%26aufirst%3DJ.%26aulast%3DMaxwell%26aufirst%3DB.%2BD.%26aulast%3DKnabb%26aufirst%3DR.%2BM.%26aulast%3DFrost%26aufirst%3DC.%26aulast%3DSchuster%26aufirst%3DA.%26aulast%3DHao%26aufirst%3DF.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DGrossman%26aufirst%3DS.%2BJ.%26atitle%3DComparative%2520metabolism%2520of%252014C-labeled%2520apixaban%2520in%2520mice%252C%2520rats%252C%2520rabbits%252C%2520dogs%252C%2520and%2520humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D1738%26epage%3D1748%26doi%3D10.1124%2Fdmd.108.025981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span> <span> </span><span class="NLM_article-title">Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor</span>. <i>J. Thromb. Thrombolysis</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">478</span>– <span class="NLM_lpage">492</span>, <span class="refDoi"> DOI: 10.1007/s11239-011-0551-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1007%2Fs11239-011-0551-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=21318583" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvFSqtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=478-492&author=P.+C.+Wongauthor=D.+J.+Pintoauthor=D.+Zhang&title=Preclinical+discovery+of+apixaban%2C+a+direct+and+orally+bioavailable+factor+Xa+inhibitor&doi=10.1007%2Fs11239-011-0551-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor</span></div><div class="casAuthors">Wong, Pancras C.; Pinto, Donald J. P.; Zhang, Donglu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Thrombolysis</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">478-492</span>CODEN:
                <span class="NLM_cas:coden">JTTHFF</span>;
        ISSN:<span class="NLM_cas:issn">0929-5305</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Apixaban (BMS-562247; 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide), a direct inhibitor of activated factor X (FXa), is in development for the prevention and treatment of various thromboembolic diseases.  With an inhibitory const. of 0.08 nM for human FXa, apixaban has greater than 30,000-fold selectivity for FXa over other human coagulation proteases.  It produces a rapid onset of inhibition of FXa with assocn. rate const. of 20 μM-1/s approx. and inhibits free as well as prothrombinase- and clot-bound FXa activity in vitro.  Apixaban also inhibits FXa from rabbits, rats and dogs, an activity which parallels its antithrombotic potency in these species.  Although apixaban has no direct effects on platelet aggregation, it indirectly inhibits this process by reducing thrombin generation.  Pre-clin. studies of apixaban in animal models have demonstrated dose-dependent antithrombotic efficacy at doses that preserved hemostasis.  Apixaban improves pre-clin. antithrombotic activity, without excessive increases in bleeding times, when added on top of aspirin or aspirin plus clopidogrel at their clin. relevant doses.  Apixaban has good bioavailability, low clearance and a small vol. of distribution in animals and humans, and a low potential for drug-drug interactions.  Elimination pathways for apixaban include renal excretion, metab. and biliary/intestinal excretion.  Although a sulfate conjugate of O-demethyl apixaban (O-demethyl apixaban sulfate) has been identified as the major circulating metabolite of apixaban in humans, it is inactive against human FXa.  Together, these non-clin. findings have established the favorable pharmacol. profile of apixaban, and support the potential use of apixaban in the clinic for the prevention and treatment of various thromboembolic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosf70y5okLwbVg90H21EOLACvtfcHk0lh-MpcW8fr8FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvFSqtb4%253D&md5=97a2b3fa9a43f0eda48f19ba6e015d84</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1007%2Fs11239-011-0551-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11239-011-0551-3%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DP.%2BC.%26aulast%3DPinto%26aufirst%3DD.%2BJ.%26aulast%3DZhang%26aufirst%3DD.%26atitle%3DPreclinical%2520discovery%2520of%2520apixaban%252C%2520a%2520direct%2520and%2520orally%2520bioavailable%2520factor%2520Xa%2520inhibitor%26jtitle%3DJ.%2520Thromb.%2520Thrombolysis%26date%3D2011%26volume%3D31%26spage%3D478%26epage%3D492%26doi%3D10.1007%2Fs11239-011-0551-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frost, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosqueda-Garcia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacreta, F.</span></span> <span> </span><span class="NLM_article-title">Apixaban, an oral, direct factor Xa inhibitor: single-dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">476</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2012.04369.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1111%2Fj.1365-2125.2012.04369.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=22759198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3sXns1Klsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2013&pages=476-487&author=C.+Frostauthor=J.+Wangauthor=S.+Nepalauthor=A.+Schusterauthor=Y.+C.+Barrettauthor=R.+Mosqueda-Garciaauthor=R.+A.+Reevesauthor=F.+Lacreta&title=Apixaban%2C+an+oral%2C+direct+factor+Xa+inhibitor%3A+single-dose+safety%2C+pharmacokinetics%2C+pharmacodynamics+and+food+effect+in+healthy+subjects&doi=10.1111%2Fj.1365-2125.2012.04369.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects</span></div><div class="casAuthors">Frost, Charles; Wang, Jessie; Nepal, Sunil; Schuster, Alan; Barrett, Yu Chen; Mosqueda-Garcia, Rogelio; Reeves, Richard A.; LaCreta, Frank</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">476-487</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : To evaluate apixaban single dose safety, tolerability, pharmacokinetics and pharmacodynamics and assess the effect of food on apixaban pharmacokinetics.  Methods : A double-blind, placebo-controlled, single ascending-dose, first-in-human study assessed apixaban safety, pharmacokinetics and pharmacodynamics in healthy subjects randomized to oral apixaban (n = 43; 0.5-2.5 mg as soln. or 5-50 mg as tablets) or placebo (n = 14) under fasted conditions.  An open label, randomized, two treatment crossover study investigated apixaban pharmacokinetics/pharmacodynamics in healthy subjects (n = 21) administered apixaban 10 mg in fasted and fed states.  Both studies measured apixaban plasma concn., international normalized ratio (INR), activated partial thromboplastin time (aPTT) and prothrombin time (PT) or a modified PT (mPT).  Results : In the single ascending-dose study increases in apixaban exposure appeared dose-proportional.  Median tmax occurred 1.5-3.3 h following oral administration.  Mean terminal half-life ranged between 3.6 and 6.8 h following administration of soln. doses ≤2.5 mg and between 11.1 and 26.8 h for tablet doses ≥5 mg.  Concn.-related changes in pharmacodynamic assessments were obsd.  After a 50 mg dose, peak aPTT, INR and mPT increased by 1.2-, 1.6- and 2.9-fold, resp., from baseline.  In the food effect study: 90% confidence intervals of geometric mean ratios of apixaban Cmax and AUC in a fed vs. fasted state were within the predefined no effect (80-125%) range.  Apixaban half-life was approx. 11.5 h.  The effect of apixaban on INR, PT and aPTT was comparable following fed and fasted administration.  Conclusions : Single doses of apixaban were well tolerated with a predictable pharmacokinetic/pharmacodynamic profile and a half-life of approx. 12 h.  Apixaban can be administered with or without food.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPbr4OzJQAF7Vg90H21EOLACvtfcHk0ljw5DwM8o3grA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXns1Klsg%253D%253D&md5=f272c96f3cbad896a55907840a368ac0</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2012.04369.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2012.04369.x%26sid%3Dliteratum%253Aachs%26aulast%3DFrost%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DNepal%26aufirst%3DS.%26aulast%3DSchuster%26aufirst%3DA.%26aulast%3DBarrett%26aufirst%3DY.%2BC.%26aulast%3DMosqueda-Garcia%26aufirst%3DR.%26aulast%3DReeves%26aufirst%3DR.%2BA.%26aulast%3DLacreta%26aufirst%3DF.%26atitle%3DApixaban%252C%2520an%2520oral%252C%2520direct%2520factor%2520Xa%2520inhibitor%253A%2520single-dose%2520safety%252C%2520pharmacokinetics%252C%2520pharmacodynamics%2520and%2520food%2520effect%2520in%2520healthy%2520subjects%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D75%26spage%3D476%26epage%3D487%26doi%3D10.1111%2Fj.1365-2125.2012.04369.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terucherai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, C. E.</span></span> <span> </span><span class="NLM_article-title">Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects</span>. <i>Am. J. Cardiovasc. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">154</span>, <span class="refDoi"> DOI: 10.1007/s40256-013-0055-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1007%2Fs40256-013-0055-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=24277644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFeitr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=147-154&author=X.+Wangauthor=S.+Mondalauthor=J.+Wangauthor=G.+Terucheraiauthor=D.+Zhangauthor=R.+A.+Boydauthor=C.+E.+Frost&title=Effect+of+activated+charcoal+on+apixaban+pharmacokinetics+in+healthy+subjects&doi=10.1007%2Fs40256-013-0055-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of Activated Charcoal on Apixaban Pharmacokinetics in Healthy Subjects</span></div><div class="casAuthors">Wang, Xiaoli; Mondal, Sabiha; Wang, Jessie; Tirucherai, Giridhar; Zhang, Donglu; Boyd, Rebecca A.; Frost, Charles</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Cardiovascular Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">147-154</span>CODEN:
                <span class="NLM_cas:coden">AJCDDJ</span>;
        ISSN:<span class="NLM_cas:issn">1175-3277</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Background Activated charcoal is commonly used to manage overdose or accidental ingestion of medicines.  This study evaluated the effect of activated charcoal on apixaban exposure in human subjects.  Methods This was an open-label, three-treatment, three-period, randomized, crossover study of single-dose apixaban (20 mg) administered alone and with activated charcoal given at 2 or 6 h post-dose to healthy subjects.  Blood samples for assay of plasma apixaban concn. were collected up to 72 h post-dose.  Pharmacokinetic parameters, including peak plasma concn. (Cmax), time to Cmax (Tmax), area under the concn.-time curve from time 0 to infinity (AUCINF), and terminal half-life (T1/2), were derived from apixaban plasma concn.-time data.  A general linear mixed-effect model anal. of Cmax and AUCINF was performed to est. the effect of activated charcoal on apixaban exposure.  Results A total of 18 subjects were treated and completed the study.  AUCINF for apixaban without activated charcoal decreased by 50 and 28 %, resp., when charcoal was administered at 2 and 6 h post-dose.  Apixaban Cmax and Tmax were similar across treatments.  The mean T1/2 for apixaban alone (13.4 h) decreased to ∼5 h when activated charcoal was administered at 2 or 6 h post-dose.  Overall, apixaban was well tolerated in this healthy population, and most adverse events were consistent with the known profile of activated charcoal.  Conclusion Administration of activated charcoal up to 6 h after apixaban reduced apixaban exposure and facilitated the elimination of apixaban.  These results suggest that activated charcoal may be useful in the management of apixaban overdose or accidental ingestion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpIgHCXhw6grVg90H21EOLACvtfcHk0ljw5DwM8o3grA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFeitr0%253D&md5=d25d2ef475ece2d174a0d3f447676792</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1007%2Fs40256-013-0055-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40256-013-0055-y%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMondal%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DTerucherai%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DBoyd%26aufirst%3DR.%2BA.%26aulast%3DFrost%26aufirst%3DC.%2BE.%26atitle%3DEffect%2520of%2520activated%2520charcoal%2520on%2520apixaban%2520pharmacokinetics%2520in%2520healthy%2520subjects%26jtitle%3DAm.%2520J.%2520Cardiovasc.%2520Drugs%26date%3D2014%26volume%3D14%26spage%3D147%26epage%3D154%26doi%3D10.1007%2Fs40256-013-0055-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balimane, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, W. G.</span></span> <span> </span><span class="NLM_article-title">Characterization of efflux transporters involved in distribution and disposition of apixaban</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">827</span>– <span class="NLM_lpage">835</span>, <span class="refDoi"> DOI: 10.1124/dmd.112.050260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.112.050260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=23382458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3sXkslSkt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=827-835&author=D.+Zhangauthor=K.+Heauthor=J.+J.+Herbstauthor=J.+Kolbauthor=W.+Shouauthor=L.+Wangauthor=P.+V.+Balimaneauthor=Y.+H.+Hanauthor=J.+Ganauthor=C.+E.+Frostauthor=W.+G.+Humphreys&title=Characterization+of+efflux+transporters+involved+in+distribution+and+disposition+of+apixaban&doi=10.1124%2Fdmd.112.050260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of efflux transporters involved in distribution and disposition of apixaban</span></div><div class="casAuthors">Zhang, Donglu; He, Kan; Herbst, John J.; Kolb, Janet; Shou, Wilson; Wang, Lifei; Balimane, Praveen V.; Han, Yong-Hae; Gan, Jinping; Frost, Charles E.; Humphreys, W. Griffith</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">827-835</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The studies reported here were conducted to investigate the transport characteristics of apixaban (1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo [3,4-c]pyridine-3-carboxamide) and to understand the impact of transporters on apixaban distribution and disposition.  In human permeability glycoprotein (P-gp)- and breast cancer resistance protein (BCRP)-cDNA-transfected cell monolayers as well as Caco-2 cell monolayers, the apparent efflux ratio of basolateral-to-apical (PcB-A) vs. apical-to-basolateral permeability (PcA-B) of apixaban was >10.  The P-gp- and BCRP-facilitated transport of apixaban was concn.- and time-dependent and did not show satn. over a wide range of concns. (1-100 μM).  The efflux transport of apixaban was also demonstrated by the lower mucosal-to-serosal permeability than that of the serosal-to-mucosal direction in isolated rat jejunum segments.  Apixaban did not inhibit digoxin transport in Caco-2 cells.  Ketoconazole decreased the P-gp-mediated apixaban efflux in Caco-2 and the P-gp-cDNA-transfected cell monolayers, but did not affect the apixaban efflux to a meaningful extent in the BCRP-cDNA-transfected cell monolayers.  Coincubation of a P-gp inhibitor (ketoconazole or cyclosporin A) and a BCRP inhibitor (Ko134) provided more complete inhibition of apixaban efflux in Caco-2 cells than sep. inhibition by individual inhibitors.  Naproxen inhibited apixaban efflux in Caco-2 cells but showed only a minimal effect on apixaban transport in the BCRP-transfected cells.  Naproxen was the first nonsteroidal antiinflammatory drug that was demonstrated as a weak P-gp inhibitor.  These results demonstrate that apixaban is a substrate for efflux transporters P-gp and BCRP, which can help explain its low brain penetration, and low fetal exposures and high milk excretion in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrclGcXVqXv1LVg90H21EOLACvtfcHk0ljw5DwM8o3grA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXkslSkt7Y%253D&md5=c52c460c36ca5c35836a0bdfb7a91bc5</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.050260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.050260%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DHe%26aufirst%3DK.%26aulast%3DHerbst%26aufirst%3DJ.%2BJ.%26aulast%3DKolb%26aufirst%3DJ.%26aulast%3DShou%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBalimane%26aufirst%3DP.%2BV.%26aulast%3DHan%26aufirst%3DY.%2BH.%26aulast%3DGan%26aufirst%3DJ.%26aulast%3DFrost%26aufirst%3DC.%2BE.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26atitle%3DCharacterization%2520of%2520efflux%2520transporters%2520involved%2520in%2520distribution%2520and%2520disposition%2520of%2520apixaban%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2013%26volume%3D41%26spage%3D827%26epage%3D835%26doi%3D10.1124%2Fdmd.112.050260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sinko, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waclawski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. R.</span></span> <span> </span><span class="NLM_article-title">Oral absorption of anti-AIDS nucleoside analogues. 1. Intestinal transport of didanosine in rat and rabbit preparations</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">959</span>– <span class="NLM_lpage">965</span>, <span class="refDoi"> DOI: 10.1002/jps.2600840811</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1002%2Fjps.2600840811" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=7500281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK2MXmvVKltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=1995&pages=959-965&author=P.+J.+Sinkoauthor=P.+Huauthor=A.+P.+Waclawskiauthor=N.+R.+Patel&title=Oral+absorption+of+anti-AIDS+nucleoside+analogues.+1.+Intestinal+transport+of+didanosine+in+rat+and+rabbit+preparations&doi=10.1002%2Fjps.2600840811"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Oral Absorption of Anti-AIDS Nucleoside Analogs. 1. Intestinal Transport of Didanosine in Rat and Rabbit Preparations</span></div><div class="casAuthors">Sinko, Patrick J.; Hu, Peidi; Waclawski, Anthony P.; Patel, Nisha R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">959-65</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The intestinal transport of didanosine (ddl), a nucleoside analog used in the treatment of human immunodeficiency virus (HIV) infection, was characterized using in situ and in vitro techniques.  The zero-trans uptake of ddl in rat intestinal brush border membrane vesicles (BBMV) was linear over the range of 1 μM to 50 mM, ruling out a significant carrier-mediated absorption component.  The lack of carrier-mediated transport was confirmed in a second species (rabbit).  In order to quantitate the convective (Pconv) and diffusive (Pdiff) components of ddl intestinal permeability, the steady state wall permeability (P*w) was detd. using an established perfusion technique in rats.  Even though baseline P*w (pH 6.5, 290 mosm/kg, no modulator) and fluid absorption results were similar to those of furosemide, the ratios of Pdiff and φ, the sieving coeff. (ddl:furosemide), were 0.31:1 and 1.70:1, resp., demonstrating that ddl's Pdiff is low and Pconv is high relative to furosemide's, suggesting significant paracellular absorption of ddl.  The apparent diffusive absorptive clearances (P'app) of ddl and furosemide were detd. in BBMV, which lack functional tight junctions, and the ratios (ddl:furosemide) of P'app in rat and rabbit were 0.23:1 and 0.24:1, resp.  The BBMV results demonstrate that the majority of ddl intestinal transport does not occur by passive membrane diffusion, confirming the single pass intestinal perfusion findings.  The results of these studies suggest that ddl is transported by nonfacilitated membrane and paracellular diffusion with paracellular transport being responsible for the majority of ddl absorption from the intestine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5mZ6v7SyetbVg90H21EOLACvtfcHk0ljOYz0yZ_MkPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmvVKltL8%253D&md5=bfba42100f3283e5c94b7666e01cfa7d</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1002%2Fjps.2600840811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.2600840811%26sid%3Dliteratum%253Aachs%26aulast%3DSinko%26aufirst%3DP.%2BJ.%26aulast%3DHu%26aufirst%3DP.%26aulast%3DWaclawski%26aufirst%3DA.%2BP.%26aulast%3DPatel%26aufirst%3DN.%2BR.%26atitle%3DOral%2520absorption%2520of%2520anti-AIDS%2520nucleoside%2520analogues.%25201.%2520Intestinal%2520transport%2520of%2520didanosine%2520in%2520rat%2520and%2520rabbit%2520preparations%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D1995%26volume%3D84%26spage%3D959%26epage%3D965%26doi%3D10.1002%2Fjps.2600840811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kilic, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirmagul, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yildirim, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erol, K.</span></span> <span> </span><span class="NLM_article-title">Intestinal absorption of digoxin and interaction with nimodipine in rats</span>. <i>Polym. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">141</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=15047988" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2004&pages=137-141&author=F.+S.+Kilicauthor=O.+Batuauthor=B.+Sirmagulauthor=E.+Yildirimauthor=K.+Erol&title=Intestinal+absorption+of+digoxin+and+interaction+with+nimodipine+in+rats"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKilic%26aufirst%3DF.%2BS.%26aulast%3DBatu%26aufirst%3DO.%26aulast%3DSirmagul%26aufirst%3DB.%26aulast%3DYildirim%26aufirst%3DE.%26aulast%3DErol%26aufirst%3DK.%26atitle%3DIntestinal%2520absorption%2520of%2520digoxin%2520and%2520interaction%2520with%2520nimodipine%2520in%2520rats%26jtitle%3DPolym.%2520J.%2520Pharmacol.%26date%3D2004%26volume%3D56%26spage%3D137%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, J.</span></span> <span> </span><span class="NLM_article-title">Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">880</span>– <span class="NLM_lpage">885</span>, <span class="refDoi"> DOI: 10.1016/0006-291X(91)91647-U</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1016%2F0006-291X%2891%2991647-U" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1673839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK3MXhslOrt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=1991&pages=880-885&author=P.+Arturssonauthor=J.+Karlsson&title=Correlation+between+oral+drug+absorption+in+humans+and+apparent+drug+permeability+coefficients+in+human+intestinal+epithelial+%28Caco-2%29+cells&doi=10.1016%2F0006-291X%2891%2991647-U"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells</span></div><div class="casAuthors">Artursson, P.; Karlsson, J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">880-5</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    </div><div class="casAbstract">Monolayers of a well differentiated human intestinal epithelial cell line, Caco-2, were used as a model to study passive drug absorption across the intestinal epithelium.  Absorption rate consts. (expressed as apparent permeability coeffs.) were detd. for 20 drugs and peptides with different structural properties.  The permeability coeffs. ranged from approx. 5 × 10-8 to 5 × 10-5 cm/s.  A good correlation was obtained between data on oral absorption in humans and the results in the Caco-2 model.  Drugs that are completely absorbed in humans had permeability coeffs. >1 × 10-6 cm/s.  Drugs that are absorbed to >1% but <100% had permeability coeffs. of 0.1-1.0 × 10-6 cm/s while drugs and peptides that are absorbed to <1% had permeability coeffs. of ≤1 × 10-7 cm/s.  The results indicate that Caco-2 monolayers can be used as a model for studies on intestinal drug absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdvsEluSXCILVg90H21EOLACvtfcHk0ljOYz0yZ_MkPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhslOrt7c%253D&md5=3b1e14cae3beb0345014284e3aa6a7c0</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1016%2F0006-291X%2891%2991647-U&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-291X%252891%252991647-U%26sid%3Dliteratum%253Aachs%26aulast%3DArtursson%26aufirst%3DP.%26aulast%3DKarlsson%26aufirst%3DJ.%26atitle%3DCorrelation%2520between%2520oral%2520drug%2520absorption%2520in%2520humans%2520and%2520apparent%2520drug%2520permeability%2520coefficients%2520in%2520human%2520intestinal%2520epithelial%2520%2528Caco-2%2529%2520cells%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1991%26volume%3D175%26spage%3D880%26epage%3D885%26doi%3D10.1016%2F0006-291X%2891%2991647-U" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dando, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, R. A.</span></span> <span> </span><span class="NLM_article-title">Evaluation of biocoat intestinal epithelium differentiation environment (3-day cultured Caco-2 cells) as an absorption screening model with improved productivity</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1835</span>– <span class="NLM_lpage">1837</span>, <span class="refDoi"> DOI: 10.1023/A:1012112820371</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1023%2FA%3A1012112820371" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=9453077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK1cXktFKhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=1835-1837&author=S.+Chongauthor=S.+A.+Dandoauthor=R.+A.+Morrison&title=Evaluation+of+biocoat+intestinal+epithelium+differentiation+environment+%283-day+cultured+Caco-2+cells%29+as+an+absorption+screening+model+with+improved+productivity&doi=10.1023%2FA%3A1012112820371"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of Biocoat intestinal epithelium differentiation environment (3-day cultured Caco-2 cells) as an absorption screening model with improved productivity</span></div><div class="casAuthors">Chong, Saeho; Dando, Sandra A.; Morrison, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1835-1837</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Plenum Publishing Corp.</span>)
        </div><div class="casAbstract">A reasonable correlation was demonstrated between the in vitro permeability through the Biocoat Intestinal Epithelium Differentiation Environment (BIEDE) Caco-2 cell monolayer and the extent of in vivo absorption in humans with a heterologous series of 18 passively absorbed drugs.  Both the BIEDE and 3-wk systems provided similar Pc values so that the Pc values detd. by the BIEDE system can be directly compared with the Pc values accumulated with the conventional 3-wk system.  Therefore, the BIEDE Caco-2 cell monolayer appears to be a more convenient and productive (i.e., reduced 8 or 9 labor-intensive medium replacement steps down to one, and was usable in 3 days) absorption screening tool compared to the conventional 3-wk system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofm54kcxk7t7Vg90H21EOLACvtfcHk0ljOYz0yZ_MkPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXktFKhtQ%253D%253D&md5=6e973c7c1d487d70044d736a45e7a7b7</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1023%2FA%3A1012112820371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1012112820371%26sid%3Dliteratum%253Aachs%26aulast%3DChong%26aufirst%3DS.%26aulast%3DDando%26aufirst%3DS.%2BA.%26aulast%3DMorrison%26aufirst%3DR.%2BA.%26atitle%3DEvaluation%2520of%2520biocoat%2520intestinal%2520epithelium%2520differentiation%2520environment%2520%25283-day%2520cultured%2520Caco-2%2520cells%2529%2520as%2520an%2520absorption%2520screening%2520model%2520with%2520improved%2520productivity%26jtitle%3DPharm.%2520Res.%26date%3D1997%26volume%3D14%26spage%3D1835%26epage%3D1837%26doi%3D10.1023%2FA%3A1012112820371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gres, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julian, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourrie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roques, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulenc, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabre, G.</span></span> <span> </span><span class="NLM_article-title">Correlation between oral drug absorption in humans, and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: comparison with the parental Caco-2 cell line</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">726</span>– <span class="NLM_lpage">733</span>, <span class="refDoi"> DOI: 10.1023/A:1011919003030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1023%2FA%3A1011919003030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=9619781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK1cXjtlWhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1998&pages=726-733&author=M.+C.+Gresauthor=B.+Julianauthor=M.+Bourrieauthor=V.+Meunierauthor=C.+Roquesauthor=M.+Bergerauthor=X.+Boulencauthor=Y.+Bergerauthor=G.+Fabre&title=Correlation+between+oral+drug+absorption+in+humans%2C+and+apparent+drug+permeability+in+TC-7+cells%2C+a+human+epithelial+intestinal+cell+line%3A+comparison+with+the+parental+Caco-2+cell+line&doi=10.1023%2FA%3A1011919003030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation between oral drug absorption in humans, and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: comparison with the parental Caco-2 cell line</span></div><div class="casAuthors">Gres, Marie-Catherine; Julian, Bernard; Bourrie, Martine; Meunier, Viviane; Roques, Claude; Berger, Marion; Boulenc, Xavier; Berger, Yves; Fabre, Gerard</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">726-733</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Plenum Publishing Corp.</span>)
        </div><div class="casAbstract">To det. and compare the relation between in vivo oral absorption in humans and the apparent permeability coeffs. (Papp) obtained in vitro on two human intestinal epithelial cell lines, the parental Caco-2 and the TC-7 clone.  Both cell lines were grown for 5-35 days on tissue culture-treated inserts.  Cell monolayers were analyzed for their morphol. by transmission electron microg., and for their integrity with respect to transepithelial elec. resistance, mannitol and PEG-4000 transport, and cyclosporin efflux.  Papp were detd. for 20 compds. exhibiting large differences in chem. structure, mol. wt., transport mechanisms, and percentage of absorption in humans.  The TC-7 clone exhibits morphol. characteristics similar to those of the parental Caco-2 cell line, concerning apical brush border, microvilli, tight junctions and polarization of the cell line.  The TC-7 clone however appeared more homogeneous in terms of cell size.  Both cell lines achieved a similar monolayer integrity towards mannitol and PEG-4000.  Monolayer integrity was achieved earlier for the TC-7 clone, mainly due to its shorter doubling time, i.e. 26 vs. 30 h for parental Caco-2 cells.  When using cyclosporin A as a P-glycoprotein substrate, active efflux was lower in the TC-7 clone than in the parental Caco-2 cells.  The Papp and mechanisms of transport (paracellular or transcellular routes, passive diffusion and active transport) were detd. for 20 drugs.  A relation was established between the in vivo oral absorption in humans and Papp values, allowing to det. a threshold value for Papp of 2 10-6 cm/s, above for which a 100% oral absorption could be expected in humans.  Both correlation curves obtained with the two cell types, were almost completely superimposable.  These studies also confirmed that the dipeptide transporter is underexpressed in both cell lines.  On the basis of morphol. parameters, biochem. activity and drug transport characteristics, the TC-7 clone appeared to be a valuable alternative to the use of parental Caco-2 cells for drug absorption studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGradgOMm2cV-bVg90H21EOLACvtfcHk0lh_TEyI78taAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjtlWhsLs%253D&md5=af26ddb3e017d5afbffcc7759f327eff</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1023%2FA%3A1011919003030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1011919003030%26sid%3Dliteratum%253Aachs%26aulast%3DGres%26aufirst%3DM.%2BC.%26aulast%3DJulian%26aufirst%3DB.%26aulast%3DBourrie%26aufirst%3DM.%26aulast%3DMeunier%26aufirst%3DV.%26aulast%3DRoques%26aufirst%3DC.%26aulast%3DBerger%26aufirst%3DM.%26aulast%3DBoulenc%26aufirst%3DX.%26aulast%3DBerger%26aufirst%3DY.%26aulast%3DFabre%26aufirst%3DG.%26atitle%3DCorrelation%2520between%2520oral%2520drug%2520absorption%2520in%2520humans%252C%2520and%2520apparent%2520drug%2520permeability%2520in%2520TC-7%2520cells%252C%2520a%2520human%2520epithelial%2520intestinal%2520cell%2520line%253A%2520comparison%2520with%2520the%2520parental%2520Caco-2%2520cell%2520line%26jtitle%3DPharm.%2520Res.%26date%3D1998%26volume%3D15%26spage%3D726%26epage%3D733%26doi%3D10.1023%2FA%3A1011919003030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shantsila, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lip, G. Y.</span></span> <span> </span><span class="NLM_article-title">Apixaban, an oral, direct inhibitor of activated Factor Xa</span>. <i>Curr. Opin. Investig. Drugs.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1020</span>– <span class="NLM_lpage">33</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=18729009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFKntr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=1020-33&author=E.+Shantsilaauthor=G.+Y.+Lip&title=Apixaban%2C+an+oral%2C+direct+inhibitor+of+activated+Factor+Xa"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91aR"><div class="casContent"><span class="casTitleNuber">91a</span><div class="casTitle"><span class="NLM_cas:atitle">Apixaban, an oral, direct inhibitor of activated Factor Xa</span></div><div class="casAuthors">Shantsila, Eduard; Lip, Gregory Y. H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Investigational Drugs (Thomson Scientific)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1020-1033</span>CODEN:
                <span class="NLM_cas:coden">COIDAZ</span>;
        ISSN:<span class="NLM_cas:issn">1472-4472</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review.  Apixaban is an oral, direct Factor Xa inhibitor that is being developed by Bristol-Myers Squibb Co and Pfizer Inc.  Apixaban is currently undergoing phase III clin. trials for cerebrovascular ischemia, deep vein thrombosis and lung embolism, and phase II clin. trials for coronary artery disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSQ2V3s_JMhLVg90H21EOLACvtfcHk0lh_TEyI78taAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFKntr7E&md5=1d48763ed835bd4c1c8d66fc4b3ad2f2</span></div><a href="/servlet/linkout?suffix=cit91a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShantsila%26aufirst%3DE.%26aulast%3DLip%26aufirst%3DG.%2BY.%26atitle%3DApixaban%252C%2520an%2520oral%252C%2520direct%2520inhibitor%2520of%2520activated%2520Factor%2520Xa%26jtitle%3DCurr.%2520Opin.%2520Investig.%2520Drugs.%26date%3D2008%26volume%3D9%26spage%3D1020%26epage%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit91b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vakkalagadda, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byon, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dias, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaCreta, F.</span></span> <span> </span><span class="NLM_article-title">Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of Factor Xa</span>. <i>Am. J. Cardiovasc. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1007/s40256-015-0157-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1007%2Fs40256-015-0157-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=26749408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVakt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=119-27&issue=2&author=B.+Vakkalagaddaauthor=C.+Frostauthor=W.+Byonauthor=R.+A.+Boydauthor=J.+Wangauthor=D.+Zhangauthor=Z.+Yuauthor=C.+Diasauthor=A.+Shenkerauthor=F.+LaCreta&title=Effect+of+rifampin+on+the+pharmacokinetics+of+apixaban%2C+an+oral+direct+inhibitor+of+Factor+Xa&doi=10.1007%2Fs40256-015-0157-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91bR"><div class="casContent"><span class="casTitleNuber">91b</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa</span></div><div class="casAuthors">Vakkalagadda, Blisse; Frost, Charles; Byon, Wonkyung; Boyd, Rebecca A.; Wang, Jessie; Zhang, Donglu; Yu, Zhigang; Dias, Clapton; Shenker, Andrew; La Creta, Frank</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Cardiovascular Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">119-127</span>CODEN:
                <span class="NLM_cas:coden">AJCDDJ</span>;
        ISSN:<span class="NLM_cas:issn">1175-3277</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Objective: Apixaban is a substrate of cytochrome P 450 3A4 (CYP3A4) and P-glycoprotein.  The effects of rifampin, a strong inducer of CYP3A4 and P-glycoprotein, on the pharmacokinetics of oral and i.v. apixaban were evaluated in an open-label, randomized, sequential crossover study.  Methods: Twenty healthy participants received single doses of apixaban 5 mg i.v. on day 1 and 10 mg orally on day 3, followed by rifampin 600 mg once daily on days 5-15.  Finally, participants received single doses of apixaban 5 mg i.v. and 10 mg orally sep. on days 12 and 14 in one of two randomized sequences.  Results: Apixaban, given i.v. and orally, was safe and well tolerated when administered in the presence and absence of rifampin.  Apixaban abs. oral bioavailability was 49 % when administered alone and 39 % following induction by rifampin.  Rifampin reduced apixaban area under the plasma concn.-time curve from time zero to infinity (AUC∞) by 39 % after i.v. administration and by 54 % after oral administration.  Rifampin induction increased mean clearance by 1.6-fold for i.v. apixaban and mean apparent clearance by 2.1-fold for oral apixaban, indicating rifampin affected both pre-systemic and systemic apixaban elimination pathways.  Conclusion: Co-administration of apixaban with rifampin reduced apixaban exposure via both decreased bioavailability and increased systemic clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVLag-NTYEJ7Vg90H21EOLACvtfcHk0lh_TEyI78taAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVakt7o%253D&md5=b6be1ef697642da3da25ec9bb56afc65</span></div><a href="/servlet/linkout?suffix=cit91b&amp;dbid=16384&amp;doi=10.1007%2Fs40256-015-0157-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40256-015-0157-9%26sid%3Dliteratum%253Aachs%26aulast%3DVakkalagadda%26aufirst%3DB.%26aulast%3DFrost%26aufirst%3DC.%26aulast%3DByon%26aufirst%3DW.%26aulast%3DBoyd%26aufirst%3DR.%2BA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DDias%26aufirst%3DC.%26aulast%3DShenker%26aufirst%3DA.%26aulast%3DLaCreta%26aufirst%3DF.%26atitle%3DEffect%2520of%2520rifampin%2520on%2520the%2520pharmacokinetics%2520of%2520apixaban%252C%2520an%2520oral%2520direct%2520inhibitor%2520of%2520Factor%2520Xa%26jtitle%3DAm.%2520J.%2520Cardiovasc.%2520Drugs%26date%3D2016%26volume%3D16%26issue%3D2%26spage%3D119%26epage%3D27%26doi%3D10.1007%2Fs40256-015-0157-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norinder, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergstrom, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span> <span> </span><span class="NLM_article-title">Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1816</span>– <span class="NLM_lpage">1831</span>, <span class="refDoi"> DOI: 10.1007/s11095-009-9896-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1007%2Fs11095-009-9896-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=19421845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFOmt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2009&pages=1816-1831&author=P.+Matssonauthor=J.+M.+Pedersenauthor=U.+Norinderauthor=C.+A.+Bergstromauthor=P.+Artursson&title=Identification+of+novel+specific+and+general+inhibitors+of+the+three+major+human+ATP-binding+cassette+transporters+P-gp%2C+BCRP+and+MRP2+among+registered+drugs&doi=10.1007%2Fs11095-009-9896-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Novel Specific and General Inhibitors of the Three Major Human ATP-Binding Cassette Transporters P-gp, BCRP and MRP2 Among Registered Drugs</span></div><div class="casAuthors">Matsson, Paer; Pedersen, Jenny M.; Norinder, Ulf; Bergstroem, Christel A. S.; Artursson, Per</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1816-1831</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: To study the inhibition patterns of the three major human ABC transporters P-gp (ABCB1), BCRP (ABCG2) and MRP2 (ABCC2), using a dataset of 122 structurally diverse drugs.  Methods: Inhibition was investigated in cellular and vesicular systems over-expressing single transporters.  Computational models discriminating either single or general inhibitors from non-inhibitors were developed using multivariate statistics.  Results: Specific (n = 23) and overlapping (n = 19) inhibitors of the three ABC transporters were identified.  GF120918 and Ko143 were verified to specifically inhibit P-gp/BCRP and BCRP in defined concn. intervals, whereas the MRP inhibitor MK571 was revealed to inhibit all three transporters within one log unit of concn.  Virtual docking expts. showed that MK571 binds to the ATP catalytic site, which could contribute to its multi-specific inhibition profile.  A computational model predicting general ABC inhibition correctly classified 80% of both ABC transporter inhibitors and non-inhibitors in an external test set.  Conclusions: The inhibitor specificities of P-gp, BCRP and MRP2 were shown to be highly overlapping.  General ABC inhibitors were more lipophilic and arom. than specific inhibitors and non-inhibitors.  The identified specific inhibitors can be used to delineate transport processes in complex exptl. systems, whereas the multi-specific inhibitors are useful in primary ABC transporter screening in drug discovery settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJZNTwQZwLgbVg90H21EOLACvtfcHk0liX6SYRXEPBQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFOmt70%253D&md5=596bf2ce79e2aa5eaffdf177762faa5d</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1007%2Fs11095-009-9896-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-009-9896-0%26sid%3Dliteratum%253Aachs%26aulast%3DMatsson%26aufirst%3DP.%26aulast%3DPedersen%26aufirst%3DJ.%2BM.%26aulast%3DNorinder%26aufirst%3DU.%26aulast%3DBergstrom%26aufirst%3DC.%2BA.%26aulast%3DArtursson%26aufirst%3DP.%26atitle%3DIdentification%2520of%2520novel%2520specific%2520and%2520general%2520inhibitors%2520of%2520the%2520three%2520major%2520human%2520ATP-binding%2520cassette%2520transporters%2520P-gp%252C%2520BCRP%2520and%2520MRP2%2520among%2520registered%2520drugs%26jtitle%3DPharm.%2520Res.%26date%3D2009%26volume%3D26%26spage%3D1816%26epage%3D1831%26doi%3D10.1007%2Fs11095-009-9896-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blatter, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seelig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seelig, J.</span></span> <span> </span><span class="NLM_article-title">Interaction of verapamil with lipid membranes and P-glycoprotein: connecting thermodynamics and membrane structure with functional activity</span>. <i>Biophys. J.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">2943</span>– <span class="NLM_lpage">2955</span>, <span class="refDoi"> DOI: 10.1529/biophysj.106.089581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1529%2Fbiophysj.106.089581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=16877510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVGls7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2006&pages=2943-2955&author=M.+Meierauthor=X.+L.+Blatterauthor=A.+Seeligauthor=J.+Seelig&title=Interaction+of+verapamil+with+lipid+membranes+and+P-glycoprotein%3A+connecting+thermodynamics+and+membrane+structure+with+functional+activity&doi=10.1529%2Fbiophysj.106.089581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of verapamil with lipid membranes and P-glycoprotein: connecting thermodynamics and membrane structure with functional activity</span></div><div class="casAuthors">Meier, M.; Li Blatter, X.; Seelig, A.; Seelig, J.</div><div class="citationInfo"><span class="NLM_cas:title">Biophysical Journal</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2943-2955</span>CODEN:
                <span class="NLM_cas:coden">BIOJAU</span>;
        ISSN:<span class="NLM_cas:issn">0006-3495</span>.
    
            (<span class="NLM_cas:orgname">Biophysical Society</span>)
        </div><div class="casAbstract">Verapamil and amlodipine are calcium ion influx inhibitors of wide clin. use.  They are partially charged at neutral pH and exhibit amphiphilic properties.  The noncharged species can easily cross the lipid membrane.  We have measured with solid-state NMR the structural changes induced by verapamil upon incorporation into phospholipid bilayers and have compared them with earlier data on amlodipine and nimodipine.  Verapamil and amlodipine produce a rotation of the phosphocholine headgroup away from the membrane surface and a disordering of the fatty acid chains.  We have detd. the thermodn. of verapamil partitioning into neutral and neg. charged membranes with isothermal titrn. calorimetry.  Verapamil undergoes a pK-shift of ΔpKa = 1.2 units in neutral lipid membranes and the percentage of the noncharged species increases from 5% to 45%.  Verapamil partitioning is increased for neg. charged membranes and the binding isotherms are strongly affected by the salt concn.  The electrostatic screening can be explained with the Gouy-Chapman theory.  Using a functional phosphate assay we have measured the affinity of verapamil, amlodipine, and nimodipine for P-glycoprotein, and have calcd. the free energy of drug binding from the aq. phase to the active center of P-glycoprotein in the lipid phase.  By combining the latter results with the lipid partitioning data it was possible, for the first time, to det. the true affinity of the three drugs for the P-glycoprotein active center if the reaction takes place exclusively in the lipid matrix.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAnJVSZCLdULVg90H21EOLACvtfcHk0liX6SYRXEPBQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVGls7jE&md5=baf0b7fb5822ec49b60a925cee568f64</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1529%2Fbiophysj.106.089581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1529%252Fbiophysj.106.089581%26sid%3Dliteratum%253Aachs%26aulast%3DMeier%26aufirst%3DM.%26aulast%3DBlatter%26aufirst%3DX.%2BL.%26aulast%3DSeelig%26aufirst%3DA.%26aulast%3DSeelig%26aufirst%3DJ.%26atitle%3DInteraction%2520of%2520verapamil%2520with%2520lipid%2520membranes%2520and%2520P-glycoprotein%253A%2520connecting%2520thermodynamics%2520and%2520membrane%2520structure%2520with%2520functional%2520activity%26jtitle%3DBiophys.%2520J.%26date%3D2006%26volume%3D91%26spage%3D2943%26epage%3D2955%26doi%3D10.1529%2Fbiophysj.106.089581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mori, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokooji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, T.</span></span> <span> </span><span class="NLM_article-title">Fate of quinidine, a P-glycoprotein substrate, in the gastrointestinal tract after oral administration in rats</span>. <i>Pharmazie</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">244</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=18444515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktVersbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2008&pages=241-244&author=N.+Moriauthor=T.+Yokoojiauthor=T.+Murakami&title=Fate+of+quinidine%2C+a+P-glycoprotein+substrate%2C+in+the+gastrointestinal+tract+after+oral+administration+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Fate of quinidine, a P-glycoprotein substrate, in the gastrointestinal tract after oral administration in rats</span></div><div class="casAuthors">Mori, N.; Yokooji, T.; Murakami, T.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmazie</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">241-244</span>CODEN:
                <span class="NLM_cas:coden">PHARAT</span>;
        ISSN:<span class="NLM_cas:issn">0031-7144</span>.
    
            (<span class="NLM_cas:orgname">Govi-Verlag Pharmazeutischer Verlag GmbH</span>)
        </div><div class="casAbstract">P-Glycoprotein (P-gp), an ATP-dependent efflux transporter, is expressed in brush-border membranes in the intestines of humans and rodents.  In this study, the fate of quinidine, a P-gp substrate, in the gastrointestinal tract after oral administration was examd. in conscious rats.  The animals received quinidine (3 mg/mL/kg) or FITC-dextran of mol. wt. of 10,000 (FD-10S, 5 mg/mL/kg, a poorly absorbable compd.) orally, and the remaining amt. of the compd. in the upper gastrointestinal tract was measured at designated time intervals.  As a control, FD-10S was distributed almost evenly throughout the gastrointestinal tract at 30 min, and most of FD-10S was accumulated in the distal small intestine at 60 min after administration.  In contrast, most of the orally administered quinidine disappeared at the proximal intestine, and only small amts. reached the distal region.  Also, the gastrointestinal transit of FD-10S was markedly slowed by stopping or inhibiting the bile flow, indicating that bile flow significantly affects the transit of drugs in the gastrointestinal tract.  In conclusion, this study has demonstrated that compds. with high soly. and high permeability, such as quinidine, can be absorbed rapidly at the proximal intestine, escaping the barrier function of P-gp, because P-gp is mostly expressed in the distal intestine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3fbollFO7QLVg90H21EOLACvtfcHk0liX6SYRXEPBQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktVersbw%253D&md5=439a0f20099e161978c589ed28614c2c</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DN.%26aulast%3DYokooji%26aufirst%3DT.%26aulast%3DMurakami%26aufirst%3DT.%26atitle%3DFate%2520of%2520quinidine%252C%2520a%2520P-glycoprotein%2520substrate%252C%2520in%2520the%2520gastrointestinal%2520tract%2520after%2520oral%2520administration%2520in%2520rats%26jtitle%3DPharmazie%26date%3D2008%26volume%3D63%26spage%3D241%26epage%3D244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unadkat, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Q.</span></span> <span> </span><span class="NLM_article-title">Effect of pregnancy on nitrofurantoin disposition in mice</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">4306</span>– <span class="NLM_lpage">4315</span>, <span class="refDoi"> DOI: 10.1002/jps.21698</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1002%2Fjps.21698" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=19422048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2qtLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2009&pages=4306-4315&author=Y.+Zhangauthor=L.+Zhouauthor=J.+D.+Unadkatauthor=Q.+Mao&title=Effect+of+pregnancy+on+nitrofurantoin+disposition+in+mice&doi=10.1002%2Fjps.21698"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of pregnancy on nitrofurantoin disposition in mice</span></div><div class="casAuthors">Zhang, Yi; Zhou, Lin; Unadkat, Jashvant D.; Mao, Qingcheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4306-4315</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">We investigated the effect of pregnancy on nitrofurantoin (NFT) disposition in wild-type and Bcrp1-/- mice.  Pregnant and non-pregnant mice were administered NFT i.v. (5 mg/kg) or orally (10 mg/kg).  Blood samples were collected at various times (5-60 min) after drug administration, plasma NFT concns. detd. by HPLC/UV, and pharmacokinetic parameters estd.  Dose-normalized area under the plasma concn.-time curve (AUC), terminal plasma half-life (T1/2), total plasma clearance (CL), and steady-state vol. of distribution (Vss) of i.v. NFT in wild-type or Bcrp1-/- mice were not altered by pregnancy.  After oral administration, pregnancy did not affect dose-normalized AUC of NFT in wild-type mice; however, dose-normalized AUC in Bcrp1-/- mice was decreased by approx. 70% by pregnancy.  In conclusion, since Bcrp1 plays a minor role in the systemic clearance of NFT in female mice, pregnancy did not affect disposition of i.v. NFT despite the fact that Bcrp1 expression in the liver and kidney of mice is significantly induced by pregnancy.  On the other hand, pregnancy may affect expression and activity of certain intestinal efflux transporters and/or metabolic enzymes in Bcrp1-/- mice, resulting in a drastic decrease in the systemic exposure of oral NFT in pregnant Bcrp1-/- mice. © 2009 Wiley-Liss, Inc. and the American Pharmacists Assocn. J Pharm Sci 98:4306-4315, 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqirYpzy_MxgbVg90H21EOLACvtfcHk0liX6SYRXEPBQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2qtLnM&md5=539844d38df2298e3fc33daaec4cff0f</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1002%2Fjps.21698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.21698%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DUnadkat%26aufirst%3DJ.%2BD.%26aulast%3DMao%26aufirst%3DQ.%26atitle%3DEffect%2520of%2520pregnancy%2520on%2520nitrofurantoin%2520disposition%2520in%2520mice%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2009%26volume%3D98%26spage%3D4306%26epage%3D4315%26doi%3D10.1002%2Fjps.21698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bundgaard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garmer, M.</span></span> <span> </span><span class="NLM_article-title">Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">466</span>, <span class="refDoi"> DOI: 10.1124/dmd.111.043083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.111.043083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=22112383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1Wqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=461-466&author=C.+Bundgaardauthor=C.+J.+Jensenauthor=M.+Garmer&title=Species+comparison+of+in+vivo+P-glycoprotein-mediated+brain+efflux+using+mdr1a-deficient+rats+and+mice&doi=10.1124%2Fdmd.111.043083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice</span></div><div class="casAuthors">Bundgaard, Christoffer; Jensen, Christian Jes Nyberg; Garmer, Mats</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">461-466</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The expts. described herein compared the extent of in vivo P-glycoprotein (P-gp)-mediated brain efflux between rats and mice for a set of known central nervous system compds.  With use of newly introduced genetically modified mdr1a-deficient rats and their gene-competent counterparts, the brain to plasma distribution was assessed and compared with the distribution pattern in mdr1a-deficient and wild-type mice.  Four compds. (aripiprazole, citalopram, risperidone, and venlafaxine) were administered using a continuous s.c. osmotic minipump infusion paradigm.  Steady-state brain and plasma concns. of the compds., including selected metabolites (9-hydroxyrisperidone, O-desmethyl-venlafaxine and N-desmethyl-venlafaxine) were measured in mdr1a-deficient rats and mice and their wild-type counterparts along with their free fractions to det. total and unbound brain to plasma distribution between genotypes within and between species.  The results revealed qual. as well as quant. similarities between P-gp functionality in vivo at the blood-brain barrier level in rats and mice.  All compds. tested were shown to have a significantly higher brain to plasma distribution in both mdr1a-deficient rats and mice compared with that in their wild-type counterparts.  Moreover, the relative enhancement in extent of brain penetration between mdr1a-deficient and wild-type rats could be directly correlated to the enhancement ratios obtained in mice.  From the unbound brain to unbound plasma distributions, the impact of P-gp on the overall brain penetration capabilities showed minor differences between rats and mice for the compds. tested.  In conclusion, a comparable functional role of P-gp between rats and mice with respect to brain efflux mediated by this transporter is suggested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLRDnbbGPf_rVg90H21EOLACvtfcHk0lhoujWVrBHo2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1Wqtbk%253D&md5=8d3f014fd5378ecdea433e0cb5c90eb8</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.043083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.043083%26sid%3Dliteratum%253Aachs%26aulast%3DBundgaard%26aufirst%3DC.%26aulast%3DJensen%26aufirst%3DC.%2BJ.%26aulast%3DGarmer%26aufirst%3DM.%26atitle%3DSpecies%2520comparison%2520of%2520in%2520vivo%2520P-glycoprotein-mediated%2520brain%2520efflux%2520using%2520mdr1a-deficient%2520rats%2520and%2520mice%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26spage%3D461%26epage%3D466%26doi%3D10.1124%2Fdmd.111.043083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittapalli, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sane, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmquist, W. F.</span></span> <span> </span><span class="NLM_article-title">Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-gp, BCRP, and P-gp/BCRP knockout mice</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1164</span>– <span class="NLM_lpage">1169</span>, <span class="refDoi"> DOI: 10.1124/dmd.112.044719</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.112.044719" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=22401960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC38XotlWns7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=1164-1169&author=S.+Agarwalauthor=Y.+Uchidaauthor=R.+K.+Mittapalliauthor=R.+Saneauthor=T.+Terasakiauthor=W.+F.+Elmquist&title=Quantitative+proteomics+of+transporter+expression+in+brain+capillary+endothelial+cells+isolated+from+P-gp%2C+BCRP%2C+and+P-gp%2FBCRP+knockout+mice&doi=10.1124%2Fdmd.112.044719"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice</span></div><div class="casAuthors">Agarwal, Sagar; Uchida, Yasuo; Mittapalli, Rajendar K.; Sane, Ramola; Terasaki, Tetsuya; Elmquist, William F.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1164-1169</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The objective of this study was to quant. examine the protein expression of relevant transporters and other proteins in the brain capillary endothelial cells isolated from wild-type mice and P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice.  After the isolation of brain capillary endothelial cells, a highly sensitive liq. chromatog.-tandem mass spectrometry method with multiple reaction monitoring was used to det. the quant. expression of membrane transporters at the blood-brain barrier (BBB) of the various mouse genotypes.  Quant. expression of 29 protein mols., including 12 ATP-binding cassette transporters, 10 solute carrier transporters, five receptors, and two housekeeping proteins, was examd. by quant. proteomics in the four mouse genotypes.  There was no significant difference in the expression of P-gp between the wild-type and Bcrp1(-/-) mice.  Likewise, Bcrp expression was not significantly different between the wild-type and Mdr1a/b(-/-) mice.  There was no significant difference in the expression of any of the measured proteins in the brain capillary endothelial cells across the genotypes, except for the lack of expression of the corresponding protein in the mice that had a genetic deletion of P-gp or Bcrp.  In conclusion, using a quant. proteomic approach, we have shown that there are no changes in the expression of several relevant transporters in brain capillary endothelial cells isolated from single and combination knockout mice.  These data suggest that the mechanism behind the functional compensation between P-gp and Bcrp at the BBB is not related to compensatory changes in transporter expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpInM6PmeijT7Vg90H21EOLACvtfcHk0lhoujWVrBHo2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotlWns7w%253D&md5=a0146188d8c58be92c996e8f9fa9c716</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.044719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.044719%26sid%3Dliteratum%253Aachs%26aulast%3DAgarwal%26aufirst%3DS.%26aulast%3DUchida%26aufirst%3DY.%26aulast%3DMittapalli%26aufirst%3DR.%2BK.%26aulast%3DSane%26aufirst%3DR.%26aulast%3DTerasaki%26aufirst%3DT.%26aulast%3DElmquist%26aufirst%3DW.%2BF.%26atitle%3DQuantitative%2520proteomics%2520of%2520transporter%2520expression%2520in%2520brain%2520capillary%2520endothelial%2520cells%2520isolated%2520from%2520P-gp%252C%2520BCRP%252C%2520and%2520P-gp%252FBCRP%2520knockout%2520mice%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26spage%3D1164%26epage%3D1169%26doi%3D10.1124%2Fdmd.112.044719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajapaksa, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobbi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drobnick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolesnikov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sujatha-Bhaskar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brightbill, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choo, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMent, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent benzolactam IRAK4 inhibitors with robust in vivo activity</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">333</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00380</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00380" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFeqs7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=327-333&author=N.+S.+Rajapaksaauthor=A.+Gobbiauthor=J.+Drobnickauthor=S.+Doauthor=A.+Kolesnikovauthor=J.+Liangauthor=Y.+Chenauthor=S.+Sujatha-Bhaskarauthor=Z.+Huangauthor=H.+Brightbillauthor=R.+Francisauthor=C.+Yuauthor=E.+F.+Chooauthor=K.+DeMentauthor=Y.+Ranauthor=L.+Anauthor=C.+Emsonauthor=J.+Maherauthor=J.+Waiauthor=B.+S.+McKenzieauthor=M.+C.+Bryan&title=Discovery+of+potent+benzolactam+IRAK4+inhibitors+with+robust+in+vivo+activity&doi=10.1021%2Facsmedchemlett.9b00380"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent Benzolactam IRAK4 Inhibitors with Robust in Vivo Activity</span></div><div class="casAuthors">Rajapaksa, Naomi S.; Gobbi, Alberto; Drobnick, Joy; Do, Steven; Kolesnikov, Aleksandr; Liang, Jun; Chen, Yongsheng; Sujatha-Bhaskar, Swathi; Huang, Zhiyu; Brightbill, Hans; Francis, Ross; Yu, Christine; Choo, Edna F.; De Ment, Kevin; Ran, Yingqing; An, Le; Emson, Claire; Maher, Jonathan; Wai, John; McKenzie, Brent S.; Lupardus, Patrick J.; Zarrin, Ali A.; Kiefer, James R.; Bryan, Marian C.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">327-333</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">IRAK4 kinase activity transduces signaling from multiple IL-1Rs and TLRs to regulate cytokines and chemokines implicated in inflammatory diseases.  As such, there is high interest in identifying selective IRAK4 inhibitors for the treatment of these disorders.  We previously reported the discovery of potent and selective dihydrobenzofuran inhibitors of IRAK4.  Subsequent studies, however, showed inconsistent inhibition in disease-relevant pharmacodynamic models.  Herein, we describe application of a human whole blood assay to the discovery of a series of benzolactam IRAK4 inhibitors.  We identified potent mol. 19 which achieves robust in vivo inhibition of cytokines relevant to human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod0j_X1oRRG7Vg90H21EOLACvtfcHk0lhoujWVrBHo2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFeqs7%252FJ&md5=2fd1d26eea65c726e463cbb8591303ef</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00380%26sid%3Dliteratum%253Aachs%26aulast%3DRajapaksa%26aufirst%3DN.%2BS.%26aulast%3DGobbi%26aufirst%3DA.%26aulast%3DDrobnick%26aufirst%3DJ.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DKolesnikov%26aufirst%3DA.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSujatha-Bhaskar%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DBrightbill%26aufirst%3DH.%26aulast%3DFrancis%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DChoo%26aufirst%3DE.%2BF.%26aulast%3DDeMent%26aufirst%3DK.%26aulast%3DRan%26aufirst%3DY.%26aulast%3DAn%26aufirst%3DL.%26aulast%3DEmson%26aufirst%3DC.%26aulast%3DMaher%26aufirst%3DJ.%26aulast%3DWai%26aufirst%3DJ.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DBryan%26aufirst%3DM.%2BC.%26atitle%3DDiscovery%2520of%2520potent%2520benzolactam%2520IRAK4%2520inhibitors%2520with%2520robust%2520in%2520vivo%2520activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D327%26epage%3D333%26doi%3D10.1021%2Facsmedchemlett.9b00380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avdeef, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ecker, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerebtzoff, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lennernaes, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senner, F.</span></span> <span> </span><span class="NLM_article-title">Coexistence of passive and carrier-mediated processes in drug transport</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">597</span>– <span class="NLM_lpage">614</span>, <span class="refDoi"> DOI: 10.1038/nrd3187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1038%2Fnrd3187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=20671764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCktrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=597-614&author=K.+Suganoauthor=M.+Kansyauthor=P.+Arturssonauthor=A.+Avdeefauthor=S.+Bendelsauthor=L.+Diauthor=G.+F.+Eckerauthor=B.+Fallerauthor=H.+Fischerauthor=G.+Gerebtzoffauthor=H.+Lennernaesauthor=F.+Senner&title=Coexistence+of+passive+and+carrier-mediated+processes+in+drug+transport&doi=10.1038%2Fnrd3187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Coexistence of passive and carrier-mediated processes in drug transport</span></div><div class="casAuthors">Sugano, Kiyohiko; Kansy, Manfred; Artursson, Per; Avdeef, Alex; Bendels, Stefanie; Di, Li; Ecker, Gerhard F.; Faller, Bernard; Fischer, Holger; Gerebtzoff, Gregori; Lennernaes, Hans; Senner, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">597-614</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The permeability of biol. membranes is one of the most important determinants of the pharmacokinetic processes of a drug.  Although it is often accepted that many drug substances are transported across biol. membranes by passive transcellular diffusion, a recent hypothesis speculated that carrier-mediated mechanisms might account for the majority of membrane drug transport processes in biol. systems.  Based on evidence of the physicochem. characteristics and of in vitro and in vivo findings for marketed drugs, as well as results from real-life discovery and development projects, the authors present the view that both passive transcellular processes and carrier-mediated processes coexist and contribute to drug transport activities across biol. membranes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppGdYhfY0-BbVg90H21EOLACvtfcHk0li3ixxn6zJg3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCktrk%253D&md5=6e332ad6fa2c2ac8b3b1dc7940e73caf</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1038%2Fnrd3187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3187%26sid%3Dliteratum%253Aachs%26aulast%3DSugano%26aufirst%3DK.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DArtursson%26aufirst%3DP.%26aulast%3DAvdeef%26aufirst%3DA.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DEcker%26aufirst%3DG.%2BF.%26aulast%3DFaller%26aufirst%3DB.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DGerebtzoff%26aufirst%3DG.%26aulast%3DLennernaes%26aufirst%3DH.%26aulast%3DSenner%26aufirst%3DF.%26atitle%3DCoexistence%2520of%2520passive%2520and%2520carrier-mediated%2520processes%2520in%2520drug%2520transport%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D597%26epage%3D614%26doi%3D10.1038%2Fnrd3187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litchfield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goosen, T. C.</span></span> <span> </span><span class="NLM_article-title">Physicochemical property space of hepato-biliary transport and computational models for predicting rat biliary excretion</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1527</span>– <span class="NLM_lpage">1537</span>, <span class="refDoi"> DOI: 10.1124/dmd.112.044628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.112.044628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=22580868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtF2iurnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=1527-1537&author=M.+V.+Varmaauthor=G.+Changauthor=Y.+Laiauthor=B.+Fengauthor=A.+F.+El-Kattanauthor=J.+Litchfieldauthor=T.+C.+Goosen&title=Physicochemical+property+space+of+hepato-biliary+transport+and+computational+models+for+predicting+rat+biliary+excretion&doi=10.1124%2Fdmd.112.044628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Physicochemical property space of hepatobiliary transport and computational models for predicting rat biliary excretion</span></div><div class="casAuthors">Varma, Manthena V. S.; Chang, George; Lai, Yurong; Feng, Bo; El-Kattan, Ayman F.; Litchfield, John; Goosen, Theunis C.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1527-1537</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Biliary excretion (BE) is a major elimination pathway, and its prediction is particularly important for optimization of systemic and/or target-site exposure of new mol. entities.  The objective is to characterize the physicochem. space assocd. with hepatobiliary transport and rat BE and to develop in silico models.  BE of 123 inhouse compds. was obtained using the bile-duct cannulated rat model.  Human and rat hepatic uptake transporters (hOATP1B1, hOATP1B3, hOATP2B1, and rOatp1b2) substrates (n = 183) were identified using transfected cells.  Furthermore, the datasets were extended by adding BE of 163 compds. and 97 org. anion transporting polypeptide (OATP) substrates from the literature.  Approx. 60% of compds. showing percentage of BE (%BE) ≥ 10 are anions, with mean BE of anions (36%) more than 3-fold higher than that of nonacids (11%).  Compds. with %BE ≥ 10 are found to have high mol. mass, large polar surface area, more rotatable bonds, and high H-bond count, whereas the lipophilicity and passive membrane permeability are lower compared with compds. with %BE < 10.  According to statistical anal. and principal component anal., hOATPs and rOatp1b2 substrates showed physicochem. characteristics that were similar to those of the %BE ≥ 10 dataset.  We further build categorical in silico models to predict rat BE, and the models (gradient boosting machine and scoring function) developed showed 80% predictability in identifying the rat BE bins (%BE ≥ 10 or < 10).  In conclusion, the significant overlap of the property space of OATP substrates and rat BE suggests a predominant role of sinusoidal uptake transporters in biliary elimination.  Categorical in silico models to predict rat BE were developed, and successful predictions were achieved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtzhzlEdDYLrVg90H21EOLACvtfcHk0li3ixxn6zJg3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtF2iurnJ&md5=b12d68beb8be0755d0dc659dda79523f</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.044628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.044628%26sid%3Dliteratum%253Aachs%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DChang%26aufirst%3DG.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26aulast%3DLitchfield%26aufirst%3DJ.%26aulast%3DGoosen%26aufirst%3DT.%2BC.%26atitle%3DPhysicochemical%2520property%2520space%2520of%2520hepato-biliary%2520transport%2520and%2520computational%2520models%2520for%2520predicting%2520rat%2520biliary%2520excretion%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26spage%3D1527%26epage%3D1537%26doi%3D10.1124%2Fdmd.112.044628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagenbuch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stieger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, P. J.</span></span> <span> </span><span class="NLM_article-title">Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">10346</span>– <span class="NLM_lpage">10350</span>, <span class="refDoi"> DOI: 10.1073/pnas.94.19.10346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1073%2Fpnas.94.19.10346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=9294213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK2sXmt1Gjsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1997&pages=10346-10350&author=B.+Noeauthor=B.+Hagenbuchauthor=B.+Stiegerauthor=P.+J.+Meier&title=Isolation+of+a+multispecific+organic+anion+and+cardiac+glycoside+transporter+from+rat+brain&doi=10.1073%2Fpnas.94.19.10346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain</span></div><div class="casAuthors">Noe, Birgitta; Hagenbuch, Bruno; Stieger, Bruno; Meier, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">10346-10350</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A novel multispecific org. anion transporting polypeptide (oatp2) has been isolated from rat brain.  The cloned cDNA contains 3640 bp.  The coding region extends over 1983 nucleotides, thus encoding a polypeptide of 661 amino acids.  Oatp2 is homologous to other members of the oatp gene family of membrane transporters with 12 predicted transmembrane domains, five potential glycosylation, and six potential protein kinase C phosphorylation sites.  In functional expression studies in Xenopus laevis oocytes, oatp2 mediated uptake of the bile acids taurocholate (Km ≈ 35 μM) and cholate (Km ≈ 46 μM), the estrogen conjugates 17β-estradiol-glucuronide (Km ≈ 3 μM) and estrone-3-sulfate (Km ≈ 11 μM), and the cardiac glycosides ouabain (Km ≈ 470 μM) and digoxin (Km ≈ 0.24 μM).  Although most of the tested compds. are common substrates of several oatp-related transporters, high-affinity uptake of digoxin is a unique feature of the newly cloned oatp2.  On the basis of Northern blot anal. under high-stringency conditions, oatp2 is highly expressed in brain, liver, and kidney but not in heart, spleen, lung, skeletal muscle, and testes.  These results provide further support for the overall significance of oatps as a new family of multispecific org. anion transporters.  They indicate that oatp2 may play an esp. important role in the brain accumulation and toxicity of digoxin and in the hepatobiliary and renal excretion of cardiac glycosides from the body.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUx8x3QjRYKLVg90H21EOLACvtfcHk0li3ixxn6zJg3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmt1Gjsbs%253D&md5=b7df5f2da772202a6797b39487db52e2</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1073%2Fpnas.94.19.10346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.94.19.10346%26sid%3Dliteratum%253Aachs%26aulast%3DNoe%26aufirst%3DB.%26aulast%3DHagenbuch%26aufirst%3DB.%26aulast%3DStieger%26aufirst%3DB.%26aulast%3DMeier%26aufirst%3DP.%2BJ.%26atitle%3DIsolation%2520of%2520a%2520multispecific%2520organic%2520anion%2520and%2520cardiac%2520glycoside%2520transporter%2520from%2520rat%2520brain%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1997%26volume%3D94%26spage%3D10346%26epage%3D10350%26doi%3D10.1073%2Fpnas.94.19.10346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gracely, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoffstall, J. M.</span></span> <span> </span><span class="NLM_article-title">Advantage of high-surface-area charcoal for gastrointestinal decontamination in a human acetaminophen ingestion model</span>. <i>Acad. Emerg. Med.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">174</span>, <span class="refDoi"> DOI: 10.1111/j.1553-2712.1997.tb03735.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1111%2Fj.1553-2712.1997.tb03735.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=9063541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A280%3ADyaK2s3hslGlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1997&pages=167-174&author=J.+R.+Robertsauthor=E.+J.+Gracelyauthor=J.+M.+Schoffstall&title=Advantage+of+high-surface-area+charcoal+for+gastrointestinal+decontamination+in+a+human+acetaminophen+ingestion+model&doi=10.1111%2Fj.1553-2712.1997.tb03735.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Advantage of high-surface-area charcoal for gastrointestinal decontamination in a human acetaminophen ingestion model</span></div><div class="casAuthors">Roberts J R; Gracely E J; Schoffstall J M</div><div class="citationInfo"><span class="NLM_cas:title">Academic emergency medicine : official journal of the Society for Academic Emergency Medicine</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">167-74</span>
        ISSN:<span class="NLM_cas:issn">1069-6563</span>.
    </div><div class="casAbstract">OBJECTIVE:  To compare the abilities of low-surface-area (LSA) vs 2 types of high-surface-area (HSA) activated charcoal given orally to adsorb acetaminophen in the gastrointestinal (GI) tract, as demonstrated by the impact of these agents on the serum levels and area under the curve (AUC) in a simulated human overdose model.  METHODS:  The main arm of the study was a prospective double-blind crossover trial in which 6 volunteers, serving as their own controls, ingested acetaminophen (50 mg/kg), followed randomly in 10 minutes by either powdered LSA charcoal (950 m2/g) or powdered HSA charcoal (2,000 m2/g) in a charcoal:drug ratio of 8:1.  In a second arm of the study, 3 subjects additionally ingested an equal dose of a granular preparation of the HSA charcoal.  Serial serum acetaminophen levels were analyzed at various intervals (30, 60, 90, 120, 180, 240, and 300 minutes postingestion), and a 5-hour AUC was calculated.  The subjects also rated the charcoal preparations for palatability.  RESULTS:  Serum acetaminophen levels were lower at all measured times in the groups receiving both forms of the HSA charcoal vs the LSA product.  With the powdered HSA charcoal, comparison serum levels were significantly lower at 120 minutes postingestion and all times thereafter (p < 0.05), reaching high significance at 4 and 5 hours (p < 0.001).  The subjects receiving the granular HSA charcoal also had consistently lower serum acetaminophen levels than did those receiving the LSA product, and the difference in mean serum levels was significant at the 4- and 5-hour sample (p = 0.012).  Compared with the LSA charcoal, at the 4-hour postingestion sample, serum acetaminophen levels were reduced by 44% to 85% by the powdered HSA charcoal.  The total AUC for the 5-hour study period was also significantly reduced by the powdered HSA product (p = 0.005) and the granular HSA product (p = 0.043).  All the subjects rated the powdered HSA charcoal to be more palatable and easier to drink than the powdered LSA charcoal.  CONCLUSION:  The surface area of oral activated charcoal is a major determining factor in its ability to limit acetaminophen absorption and to fulfill its adsorptive role in GI decontamination.  In a human acetaminophen overdose model, 2 types of HSA charcoal, when compared with equal doses of LSA charcoal, significantly reduced serum levels and total acetaminophen absorption as measured by the AUC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRh5wFRQg1QoVQKX3ooHxWjfW6udTcc2eYHPkmCAFBvurntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s3hslGlsw%253D%253D&md5=1f485d61380153ec1b2e99538f77faa1</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1111%2Fj.1553-2712.1997.tb03735.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1553-2712.1997.tb03735.x%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DJ.%2BR.%26aulast%3DGracely%26aufirst%3DE.%2BJ.%26aulast%3DSchoffstall%26aufirst%3DJ.%2BM.%26atitle%3DAdvantage%2520of%2520high-surface-area%2520charcoal%2520for%2520gastrointestinal%2520decontamination%2520in%2520a%2520human%2520acetaminophen%2520ingestion%2520model%26jtitle%3DAcad.%2520Emerg.%2520Med.%26date%3D1997%26volume%3D4%26spage%3D167%26epage%3D174%26doi%3D10.1111%2Fj.1553-2712.1997.tb03735.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orisakwe, O. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogbonna, E.</span></span> <span> </span><span class="NLM_article-title">Effect of saline cathartics on gastrointestinal transit time of activated charcoal</span>. <i>Hum. Exp. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">403</span>– <span class="NLM_lpage">405</span>, <span class="refDoi"> DOI: 10.1177/096032719301200510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1177%2F096032719301200510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=7902117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK2cXpvVOqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1993&pages=403-405&author=O.+E.+Orisakweauthor=E.+Ogbonna&title=Effect+of+saline+cathartics+on+gastrointestinal+transit+time+of+activated+charcoal&doi=10.1177%2F096032719301200510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of saline cathartics on gastrointestinal transit time of activated charcoal</span></div><div class="casAuthors">Orisakwe, O.E.; Ogbonna, E.</div><div class="citationInfo"><span class="NLM_cas:title">Human & Experimental Toxicology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">403-405</span>CODEN:
                <span class="NLM_cas:coden">HETOEA</span>;
        ISSN:<span class="NLM_cas:issn">0960-3271</span>.
    </div><div class="casAbstract">The effects of saline cathartics on the gastrointestinal transit time of activated charcoal were investigated in 6 healthy volunteers.  The mean gastrointestinal transit times of charcoal alone were 29.3 h and 24.4, 15.4, 17.3, and 17.5 h with sodium chloride, sodium sulfate, magnesium sulfate alone and Andrew's Liver Salt, resp.  Some volunteers complained of slight abdominal discomfort in all the phases except the Andrew's Liver Salt phase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn0vzp6xOaS7Vg90H21EOLACvtfcHk0lifMksPVKcc2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXpvVOqtw%253D%253D&md5=5c4ad8821d5113e9ce0d20632f2998dd</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1177%2F096032719301200510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F096032719301200510%26sid%3Dliteratum%253Aachs%26aulast%3DOrisakwe%26aufirst%3DO.%2BE.%26aulast%3DOgbonna%26aufirst%3DE.%26atitle%3DEffect%2520of%2520saline%2520cathartics%2520on%2520gastrointestinal%2520transit%2520time%2520of%2520activated%2520charcoal%26jtitle%3DHum.%2520Exp.%2520Toxicol.%26date%3D1993%26volume%3D12%26spage%3D403%26epage%3D405%26doi%3D10.1177%2F096032719301200510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parrott, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lave, T.</span></span> <span> </span><span class="NLM_article-title">Applications of physiologically based absorption models in drug discovery and development</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">760</span>– <span class="NLM_lpage">775</span>, <span class="refDoi"> DOI: 10.1021/mp8000155</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp8000155" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1cXntVyntrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2008&pages=760-775&author=N.+Parrottauthor=T.+Lave&title=Applications+of+physiologically+based+absorption+models+in+drug+discovery+and+development&doi=10.1021%2Fmp8000155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Applications of Physiologically Based Absorption Models in Drug Discovery and Development</span></div><div class="casAuthors">Parrott, Neil; Lave, Thierry</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">760-775</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This article describes the use of physiol. based models of intestinal drug absorption to guide the research and development of new drugs.  Applications range from lead optimization in the drug discovery phase through clin. candidate selection and extrapolation to human to phase 2 formulation development.  Early simulations in preclin. species integrate multiple screening data and add value by transforming these individual properties into a prediction of in vivo absorption.  Comparison of simulations to plasma levels measured after oral dosing in animals highlights unexpected behavior, and parameter sensitivity anal. can explore the impact of uncertainties in key properties, point toward factors which are limiting absorption and contribute to assessment of compd. developability.  Physiol. models provide reliable prediction of human absorption and with refinement based on phase 1 data are useful guides to further market formulation development.  Improvements in the accuracy of simulations are expected as better in vitro methods generate more in vivo relevant soly. and permeability data, and modeling will play a central role in the development of more predictive methods for transporter-related effects on drug absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSg5DYRhZl0bVg90H21EOLACvtfcHk0lifMksPVKcc2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXntVyntrg%253D&md5=13de905308bc88383041bd1025f952a0</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1021%2Fmp8000155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp8000155%26sid%3Dliteratum%253Aachs%26aulast%3DParrott%26aufirst%3DN.%26aulast%3DLave%26aufirst%3DT.%26atitle%3DApplications%2520of%2520physiologically%2520based%2520absorption%2520models%2520in%2520drug%2520discovery%2520and%2520development%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2008%26volume%3D5%26spage%3D760%26epage%3D775%26doi%3D10.1021%2Fmp8000155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wakabayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hachimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohwada, T.</span></span> <span> </span><span class="NLM_article-title">Activated charcoal interrupts enteroenteric circulation of phenobarbital</span>. <i>J. Toxicol., Clin. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.3109/15563659409011043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.3109%2F15563659409011043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=8057401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK2cXmsVGjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1994&pages=419-424&author=Y.+Wakabayashiauthor=S.+Maruyamaauthor=K.+Hachimuraauthor=T.+Ohwada&title=Activated+charcoal+interrupts+enteroenteric+circulation+of+phenobarbital&doi=10.3109%2F15563659409011043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Activated charcoal interrupts enteroenteric circulation of phenobarbital</span></div><div class="casAuthors">Wakabayashi, Yasuhisa; Maruyama, Shigeyoshi; Hachimura, Kazoo; Ohwada, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Toxicology, Clinical Toxicology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">419-24</span>CODEN:
                <span class="NLM_cas:coden">JTCTDW</span>;
        ISSN:<span class="NLM_cas:issn">0731-3810</span>.
    </div><div class="casAbstract">The possibility of activated charcoal interrupting the enteroenteric circulation of phenobarbital was conducted in rabbits prepd. by colectomy biliary drainage to block enterohepatic circulation.  Fifty minutes after the administration of phenobarbital IV over ten minutes, activated charcoal (N = 7) or non-adsorbent gel (N = 8) were placed into the intestine at a dose of 4 g/kg.  Blood was taken hourly for 5 h from the femoral artery and portal vein for the detn. of phenobarbital concn. by the homogeneous enzyme immunoassay.  The arterioportal differences of phenobarbital concns. were significantly greater in the animals treated with the charcoal at 2, 3 and 4 h after the treatment.  There were significantly shorter plasma half lives of phenobarbital in the animals given charcoal (3.8 ± 0.3 h vs 6.9 ± 0.9 h, p < .02).  This study provided evidence of significant enteroenteric circulation of phenobarbital which can be interrupted by the activated charcoal and removed by the mechanism of intestinal dialysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDz5jhgE8sW7Vg90H21EOLACvtfcHk0lifMksPVKcc2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmsVGjt7Y%253D&md5=bf86a46424362724f1c8de6af664f4f4</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.3109%2F15563659409011043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F15563659409011043%26sid%3Dliteratum%253Aachs%26aulast%3DWakabayashi%26aufirst%3DY.%26aulast%3DMaruyama%26aufirst%3DS.%26aulast%3DHachimura%26aufirst%3DK.%26aulast%3DOhwada%26aufirst%3DT.%26atitle%3DActivated%2520charcoal%2520interrupts%2520enteroenteric%2520circulation%2520of%2520phenobarbital%26jtitle%3DJ.%2520Toxicol.%252C%2520Clin.%2520Toxicol.%26date%3D1994%26volume%3D32%26spage%3D419%26epage%3D424%26doi%3D10.3109%2F15563659409011043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hersey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luscombe, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherborne, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, I.</span></span> <span> </span><span class="NLM_article-title">Evaluation of rat intestinal absorption data and correlation with human intestinal absorption</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1016/S0223-5234(03)00015-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1016%2FS0223-5234%2803%2900015-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=12667690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitlKisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=233-243&author=Y.+H.+Zhaoauthor=M.+H.+Abrahamauthor=J.+Leauthor=A.+Herseyauthor=C.+N.+Luscombeauthor=G.+Beckauthor=B.+Sherborneauthor=I.+Cooper&title=Evaluation+of+rat+intestinal+absorption+data+and+correlation+with+human+intestinal+absorption&doi=10.1016%2FS0223-5234%2803%2900015-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of rat intestinal absorption data and correlation with human intestinal absorption</span></div><div class="casAuthors">Zhao, Yuan H.; Abraham, Michael H.; Le, Joelle; Hersey, Anne; Luscombe, Chris N.; Beck, Gordon; Sherborne, Brad; Cooper, Ian</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">233-243</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">The absorption of drugs and drug-like compds. was evaluated from 111 refs. based on the ratio of urinary excretion of drugs following oral and i.v. administration to intact rats and biliary excretion of bile duct-cannulated rats.  Ninety-eight drug compds. for which both human and rat absorption data were available were selected for correlation anal. between the human and rat absorption.  The result shows that the extent of absorption in these two species is similar.  For 94% of the drugs the absorption difference between humans and rats is less than 20% and for 98% of drugs the difference is less than 30%.  There is only one drug for which human absorption is significantly different from rat absorption.  The std. deviation is 11% between human and rat absorption.  The linear relationship between human and rat absorption forced through the origin, as detd. by least squares regression, is %Absorption (human)=0.997%Absorption (rat) (n=98, SD=11).  It is suggested that the absorption in rats could be used as an alternative method to human absorption in pre-clin. oral absorption studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3AVjX4MF9m7Vg90H21EOLACvtfcHk0lhdCSJyGmlvfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitlKisr4%253D&md5=8bacc16d7b840ef152df945b3c1f38f0</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2FS0223-5234%2803%2900015-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0223-5234%252803%252900015-1%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%2BH.%26aulast%3DAbraham%26aufirst%3DM.%2BH.%26aulast%3DLe%26aufirst%3DJ.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DLuscombe%26aufirst%3DC.%2BN.%26aulast%3DBeck%26aufirst%3DG.%26aulast%3DSherborne%26aufirst%3DB.%26aulast%3DCooper%26aufirst%3DI.%26atitle%3DEvaluation%2520of%2520rat%2520intestinal%2520absorption%2520data%2520and%2520correlation%2520with%2520human%2520intestinal%2520absorption%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2003%26volume%3D38%26spage%3D233%26epage%3D243%26doi%3D10.1016%2FS0223-5234%2803%2900015-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landowski, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lennernas, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amidon, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span> <span> </span><span class="NLM_article-title">Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1675</span>– <span class="NLM_lpage">1686</span>, <span class="refDoi"> DOI: 10.1007/s11095-006-9041-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1007%2Fs11095-006-9041-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=16841194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD28XnvVyms7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2006&pages=1675-1686&author=X.+Caoauthor=S.+T.+Gibbsauthor=L.+Fangauthor=H.+A.+Millerauthor=C.+P.+Landowskiauthor=H.+C.+Shinauthor=H.+Lennernasauthor=Y.+Zhongauthor=G.+L.+Amidonauthor=L.+X.+Yuauthor=D.+Sun&title=Why+is+it+challenging+to+predict+intestinal+drug+absorption+and+oral+bioavailability+in+human+using+rat+model&doi=10.1007%2Fs11095-006-9041-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Why is it Challenging to Predict Intestinal Drug Absorption and Oral Bioavailability in Human Using Rat Model</span></div><div class="casAuthors">Cao, Xianhua; Gibbs, Seth T.; Fang, Lanyan; Miller, Heather A.; Landowski, Christopher P.; Shin, Ho-Chul; Lennernas, Hans; Zhong, Yanqiang; Amidon, Gordon L.; Yu, Lawrence X.; Sun, Duxin</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1675-1686</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The aim of this study was to study the correlation of intestinal absorption for drugs with various absorption routes between human and rat, and to explore the underlying mol. mechanisms for the similarity in drug intestinal absorption and the differences in oral bioavailability between human and rat.  The intestinal permeabilities of 14 drugs and three drug-like compds. with different absorption mechanisms in rat and human jejunum were detd. by in situ intestinal perfusion.  A total of 48 drugs were selected for oral bioavailability comparison.  Expression profiles of transporters and metabolizing enzymes in both rat and human intestines (duodenum and colon) were measured using GeneChip anal.  No correlation (r2 = 0.29) was found in oral drug bioavailability between rat and human, while a correlation (r2 = 0.8) was obsd. for drug intestinal permeability with both carrier-mediated absorption and passive diffusion mechanisms between human and rat small intestine.  Moderate correlation (with r2 > 0.56) was also found for the expression levels of transporters in the duodenum of human and rat, which provides the mol. mechanisms for the similarity and correlation of drug absorption between two species.  In contrast, no correlation was found for the expressions of metabolizing enzymes between rat and human intestine, which indicates the difference in drug metab. and oral bioavailability in two species.  Detailed anal. indicates that many transporters (such as PepT1, SGLT-1, GLUT5, MRP2, NT2, and high affinity glutamate transporter) share similar expression levels in both human and rat with regional dependent expression patterns, which have high expression in the small intestine and low expression in the colon.  However, discrepancy was also obsd. for several other transporters (such as MDR1, MRP3, GLUT1, and GLUT3) in both the duodenum and colon of human and rat.  In addn., the expressions of metabolizing enzymes (CYP3A4/CYP3A9 and UDPG) showed 12 to 193-fold difference between human and rat intestine with distinct regional dependent expression patterns.  The data indicate that rat and human show similar drug intestinal absorption profiles and similar transporter expression patterns in the small intestine, while the two species exhibit distinct expression levels and patterns for metabolizing enzymes in the intestine.  Therefore, a rat model can be used to predict oral drug absorption in the small intestine of human, but not to predict drug metab. or oral bioavailability in human.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT0qlLZPbgU7Vg90H21EOLACvtfcHk0lhdCSJyGmlvfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnvVyms7c%253D&md5=cdf16fabb2d3dbfde019797a5a76177c</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1007%2Fs11095-006-9041-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-006-9041-2%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DX.%26aulast%3DGibbs%26aufirst%3DS.%2BT.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DMiller%26aufirst%3DH.%2BA.%26aulast%3DLandowski%26aufirst%3DC.%2BP.%26aulast%3DShin%26aufirst%3DH.%2BC.%26aulast%3DLennernas%26aufirst%3DH.%26aulast%3DZhong%26aufirst%3DY.%26aulast%3DAmidon%26aufirst%3DG.%2BL.%26aulast%3DYu%26aufirst%3DL.%2BX.%26aulast%3DSun%26aufirst%3DD.%26atitle%3DWhy%2520is%2520it%2520challenging%2520to%2520predict%2520intestinal%2520drug%2520absorption%2520and%2520oral%2520bioavailability%2520in%2520human%2520using%2520rat%2520model%26jtitle%3DPharm.%2520Res.%26date%3D2006%26volume%3D23%26spage%3D1675%26epage%3D1686%26doi%3D10.1007%2Fs11095-006-9041-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazic, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachir-Cherif, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrott, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belli, S.</span></span> <span> </span><span class="NLM_article-title">Expression profiles of metabolic enzymes and drug transporters in the liver and along the intestine of beagle dogs</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1603</span>– <span class="NLM_lpage">1610</span>, <span class="refDoi"> DOI: 10.1124/dmd.112.045443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.112.045443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=22596220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtF2iurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=1603-1610&author=S.+Hallerauthor=F.+Schulerauthor=S.+E.+Lazicauthor=D.+Bachir-Cherifauthor=S.+D.+Kramerauthor=N.+J.+Parrottauthor=G.+Steinerauthor=S.+Belli&title=Expression+profiles+of+metabolic+enzymes+and+drug+transporters+in+the+liver+and+along+the+intestine+of+beagle+dogs&doi=10.1124%2Fdmd.112.045443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Expression profiles of metabolic enzymes and drug transporters in the liver and along the intestine of beagle dogs</span></div><div class="casAuthors">Haller, Stephanie; Schuler, Franz; Lazic, Stanley E.; Bachir-Cherif, Dalila; Kramer, Stefanie D.; Parrott, Neil J.; Steiner, Guido; Belli, Sara</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1603-1610</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Beagle dogs are widely used in preclin. pharmacokinetic, safety, and formulation studies.  However, little is known about intestinal and hepatic distribution of major enzymes and transporters involved in oral absorption and presystemic drug metab.  We characterized mRNA levels of CYP3A12, CYP3A26, CYP2D15, UGT1A6, ABCB1 (MDR1), ABCC1 (MRP1), ABCG2 (BCRP), SLC15A1 (PEPT1), and SLC22A1 (OCT1) in dog liver and along the intestine by real-time quant. reverse transcription-polymerase chain reaction.  Tissue protein levels of CYP2D15, MDR1, and PEPT1 were obtained by Western blot.  Gene distribution and expression variability was statistically described by a generalized additive mixed model smoothing function and correspondence anal.  Results were compared with the expression pattern known for the human orthologs.  Hepatic mRNA levels for metabolic enzymes were generally higher than those for membrane transporters, whereas in the intestine the opposite was obsd.  Hepatic mRNA levels followed the order CYP2D15 > UGT1A6 ≈ CYP3A26 > ABCB1 ≈ SLC15A1 ≈ SLC22A1 > ABCG2 > ABCC1 ≈ CYP3A12.  Along the gut, the genes were differentially distributed with greatest expression in duodenum/upper jejunum (ABCG2), middle jejunum (ABCB1 and SLC15A1), or in cecum/colon (ABCC1 and CYP2D15).  CYP3A12, CYP3A26, SLC22A1, and UGT1A6 had a rather uniform expression.  Intestinal mRNA profiles of CYP2D15, ABCB1, and SLC15A1 correlated with the resp. protein levels.  Canine CYP3A12/26, CYP2D15, and ABCB1 colonic distributions differed from those of human orthologs, whereas UGT1A6, ABCC1, ABCG2, SLC15A1, and SLC22A1 were comparable to those of humans in both small and large intestine.  We aim to apply these data to better interpret pharmacokinetic studies in dogs with respect to their human relevance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbKw9IZfNB6LVg90H21EOLACvtfcHk0lhdCSJyGmlvfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtF2iurfN&md5=b0a443663747cbf4af660637dde2ee88</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.045443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.045443%26sid%3Dliteratum%253Aachs%26aulast%3DHaller%26aufirst%3DS.%26aulast%3DSchuler%26aufirst%3DF.%26aulast%3DLazic%26aufirst%3DS.%2BE.%26aulast%3DBachir-Cherif%26aufirst%3DD.%26aulast%3DKramer%26aufirst%3DS.%2BD.%26aulast%3DParrott%26aufirst%3DN.%2BJ.%26aulast%3DSteiner%26aufirst%3DG.%26aulast%3DBelli%26aufirst%3DS.%26atitle%3DExpression%2520profiles%2520of%2520metabolic%2520enzymes%2520and%2520drug%2520transporters%2520in%2520the%2520liver%2520and%2520along%2520the%2520intestine%2520of%2520beagle%2520dogs%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26spage%3D1603%26epage%3D1610%26doi%3D10.1124%2Fdmd.112.045443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J. D.</span></span> <span> </span><span class="NLM_article-title">Comparative drug exsorption in the perfused rat intestine</span>. <i>J. Pharm. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">170</span>, <span class="refDoi"> DOI: 10.1111/j.2042-7158.1990.tb05378.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1111%2Fj.2042-7158.1990.tb05378.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2011&pages=167-170&author=J.+D.+Huang&title=Comparative+drug+exsorption+in+the+perfused+rat+intestine&doi=10.1111%2Fj.2042-7158.1990.tb05378.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1111%2Fj.2042-7158.1990.tb05378.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.2042-7158.1990.tb05378.x%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DJ.%2BD.%26atitle%3DComparative%2520drug%2520exsorption%2520in%2520the%2520perfused%2520rat%2520intestine%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D2011%26volume%3D42%26spage%3D167%26epage%3D170%26doi%3D10.1111%2Fj.2042-7158.1990.tb05378.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arimori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hidaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwakiri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamsaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okumura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takamura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, M.</span></span> <span> </span><span class="NLM_article-title">Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">910</span>– <span class="NLM_lpage">917</span>, <span class="refDoi"> DOI: 10.1023/A:1023847521767</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1023%2FA%3A1023847521767" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=12817897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjvFyis7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2003&pages=910-917&author=K.+Arimoriauthor=N.+Kurokiauthor=M.+Hidakaauthor=T.+Iwakiriauthor=K.+Yamsakiauthor=M.+Okumuraauthor=H.+Onoauthor=N.+Takamuraauthor=M.+Kikuchiauthor=M.+Nakano&title=Effect+of+P-glycoprotein+modulator%2C+cyclosporin+A%2C+on+the+gastrointestinal+excretion+of+irinotecan+and+its+metabolite+SN-38+in+rats&doi=10.1023%2FA%3A1023847521767"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats</span></div><div class="casAuthors">Arimori, Kazuhiko; Kuroki, Noriaki; Hidaka, Muneaki; Iwakiri, Tomomi; Yamasaki, Keishi; Okumura, Manabu; Ono, Hiroshige; Takamura, Norito; Kikuchi, Masahiko; Nakano, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">910-917</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic/Plenum Publishers</span>)
        </div><div class="casAbstract">The purpose of this work was to investigate the role of the hepatic and intestinal P-glycoprotein (P-gp) and canalicular multispecific org. anion transporter /multidrug resistance-assocd. protein 2 (cMOAT/MRP2) on both biliary excretion and intestinal exsorption of irinotecan hydrochloride (CPT-11) and its metabolite, SN-38, in the lactone and carboxylate forms.  Cyclosporin A (CsA) was used to modulate P-gp and cMOAT/MRP2.  The transcellular transport of CPT-11 and SN-38 was examd. by LLC-PK1 deriv. cell lines transfected with murine mdr1a both in the absence or in the presence of CsA.  The excretions of the compds. through the biliary and intestinal membrane routes were investigated by in situ perfusion technique.  Basolateral-to-apical transport of CPT-11 lactone in L-mdr1a cells was significantly decreased by CsA (10 μM).  The trans-cellular transport of SN-38 lactone showed similar behaviors as those of CPT-11 lactone.  The biliary excretion and the intestinal exsorption of both forms of CPT-11 and SN-38 were significantly inhibited when the drug was co-administered with CsA.  The transports of CPT-11 and SN-38 via the biliary route seem to be essentially related with cMOAT/MRP2, whereas those of both compds. via the intestinal membrane seem to be related with P-gp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU_JmsECpDybVg90H21EOLACvtfcHk0liRoRITVo1j9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjvFyis7g%253D&md5=3b036762203b694fb20898d50033340f</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1023%2FA%3A1023847521767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1023847521767%26sid%3Dliteratum%253Aachs%26aulast%3DArimori%26aufirst%3DK.%26aulast%3DKuroki%26aufirst%3DN.%26aulast%3DHidaka%26aufirst%3DM.%26aulast%3DIwakiri%26aufirst%3DT.%26aulast%3DYamsaki%26aufirst%3DK.%26aulast%3DOkumura%26aufirst%3DM.%26aulast%3DOno%26aufirst%3DH.%26aulast%3DTakamura%26aufirst%3DN.%26aulast%3DKikuchi%26aufirst%3DM.%26aulast%3DNakano%26aufirst%3DM.%26atitle%3DEffect%2520of%2520P-glycoprotein%2520modulator%252C%2520cyclosporin%2520A%252C%2520on%2520the%2520gastrointestinal%2520excretion%2520of%2520irinotecan%2520and%2520its%2520metabolite%2520SN-38%2520in%2520rats%26jtitle%3DPharm.%2520Res.%26date%3D2003%26volume%3D20%26spage%3D910%26epage%3D917%26doi%3D10.1023%2FA%3A1023847521767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuhmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doering, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fichtl, B.</span></span> <span> </span><span class="NLM_article-title">Influence of quinidine on the intestinal secretion of digoxin and digitoxin in guinea pigs</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1016/S0009-2797(85)80128-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1016%2FS0009-2797%2885%2980128-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=4064190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A280%3ADyaL28%252FltlKqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1985&pages=203-213&author=S.+G.+Schaferauthor=G.+Schuhmannauthor=W.+Doeringauthor=B.+Fichtl&title=Influence+of+quinidine+on+the+intestinal+secretion+of+digoxin+and+digitoxin+in+guinea+pigs&doi=10.1016%2FS0009-2797%2885%2980128-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of quinidine on the intestinal secretion of digoxin and digitoxin in guinea pigs</span></div><div class="casAuthors">Schafer S G; Schuhmann G; Doering W; Fichtl B</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-biological interactions</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">203-13</span>
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    </div><div class="casAbstract">The secretion of digoxin and digitoxin into in situ perfused jejunal and colonic segments of normal or quinidine treated guinea pigs was studied.  Quinidine was administered intravenously by constant rate infusion resulting in a quinidine plasma concentration of about 6 micrograms/ml.  After 2 h digoxin or digitoxin was injected i.v. (10 micrograms/kg).  The quinidine treatment enhanced the plasma concentration of [3H]digoxin to about 140% as compared to controls, whereas the [3H]digitoxin concentration was not influenced by the quinidine infusion.  Both, digoxin and digitoxin were secreted against a concentration gradient into the intestinal lumen.  During the experimental period of 180 min controls secreted 0.24% of the administered digoxin dose per cm of jejunal and 0.13% per cm of colonic segment.  Quinidine treatment resulted in a decrease of the jejunal digoxin secretion to about 80% of the control values.  In both, jejunum and colon the concentration ratio between lumen and plasma (L/P) was diminished by quinidine to 50% as compared with the controls.  The amount of [3H]digitoxin secreted into the intestinal segments was decreased by quinidine from 0.19% of the dose/cm to 0.13% in the jejunal and from 0.17% to 0.12% in the colonic segments, respectively.  The decrease of the L/P ratio for [3H]digitoxin was more pronounced in the colon (58%) than in the jejunum (77% of the control values).  As compared with controls the content of [3H]digoxin in the jejunal as well as colonic tissue was decreased by quinidine to 60% or 73%, respectively.  On the other hand quinidine increased the tissue content of [3H]digitoxin in jejunum (+56%) and colon (+88%).  In conclusion quinidine inhibits the intestinal secretion of both, digoxin and digitoxin, possibly by different mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1_ZDOT5CseJotVjB3IRIyfW6udTcc2eZvoWGI6Za61Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL28%252FltlKqsw%253D%253D&md5=133cc91607f258886bc13ded5a8b8773</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2FS0009-2797%2885%2980128-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0009-2797%252885%252980128-9%26sid%3Dliteratum%253Aachs%26aulast%3DSchafer%26aufirst%3DS.%2BG.%26aulast%3DSchuhmann%26aufirst%3DG.%26aulast%3DDoering%26aufirst%3DW.%26aulast%3DFichtl%26aufirst%3DB.%26atitle%3DInfluence%2520of%2520quinidine%2520on%2520the%2520intestinal%2520secretion%2520of%2520digoxin%2520and%2520digitoxin%2520in%2520guinea%2520pigs%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D1985%26volume%3D55%26spage%3D203%26epage%3D213%26doi%3D10.1016%2FS0009-2797%2885%2980128-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dautrey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farinoti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinstein, E.</span></span> <span> </span><span class="NLM_article-title">Intestinal elimination of ciprofloxacin in rabbits</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">757</span>– <span class="NLM_lpage">760</span>, <span class="refDoi"> DOI: 10.1128/AAC.38.4.757</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1128%2FAAC.38.4.757" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=8031042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK2cXis1Sms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1994&pages=757-760&author=J.+Ramonauthor=S.+Dautreyauthor=R.+Farinotiauthor=C.+Carbonauthor=E.+Rubinstein&title=Intestinal+elimination+of+ciprofloxacin+in+rabbits&doi=10.1128%2FAAC.38.4.757"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal elimination of ciprofloxacin in rabbits</span></div><div class="casAuthors">Ramon, Jacob; Dautrey, Sophie; Farinoti, Robert; Carbon, Claude; Rubinstein, Ethan</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">757-60</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">The intestinal transepithelial elimination of ciprofloxacin was studied in a rabbit model.  Jejunal, ileal, and cecal segments along with their intact blood vessels were isolated and perfused, and their contents were collected over a 120-min period following administration of a single parenteral dose of 27 mg of ciprofloxacin per kg of body wt.  The intestinal elimination rates of ciprofloxacin were 0.126 ± 0.084, 0.235 ± 0.22, and 0.11 ± 0.084 μg/min/cm for the jejunal, ileal, and cecal segments, resp.  The calcd. fractions of ciprofloxacin eliminated were 3.3 mg from the jejunum and 13.8 mg from the ileum, representing 19% of the administered dose.  Addnl. amts. of 2.5 to 3.7 mg or 4.9 to 7.3% of the administered dose were eliminated from the cecum.  Elimination was probably not due to a passive diffusion process but rather due to an active transepithelial transport.  This intestinal elimination pattern of ciprofloxacin may explain the unusual activity of the fluoroquinolones in modifying the intestinal flora.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3tUtHY5TfnbVg90H21EOLACvtfcHk0ljfjRbSg8Zj7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXis1Sms7s%253D&md5=cae20b7a0920fab55662fa9692494661</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1128%2FAAC.38.4.757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.38.4.757%26sid%3Dliteratum%253Aachs%26aulast%3DRamon%26aufirst%3DJ.%26aulast%3DDautrey%26aufirst%3DS.%26aulast%3DFarinoti%26aufirst%3DR.%26aulast%3DCarbon%26aufirst%3DC.%26aulast%3DRubinstein%26aufirst%3DE.%26atitle%3DIntestinal%2520elimination%2520of%2520ciprofloxacin%2520in%2520rabbits%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1994%26volume%3D38%26spage%3D757%26epage%3D760%26doi%3D10.1128%2FAAC.38.4.757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gramatte, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oertel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terhaag, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirch, W.</span></span> <span> </span><span class="NLM_article-title">Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">541</span>– <span class="NLM_lpage">549</span>, <span class="refDoi"> DOI: 10.1016/S0009-9236(96)90182-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1016%2FS0009-9236%2896%2990182-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=8646825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK28XjvFOktbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1996&pages=541-549&author=T.+Gramatteauthor=R.+Oertelauthor=B.+Terhaagauthor=W.+Kirch&title=Direct+demonstration+of+small+intestinal+secretion+and+site-dependent+absorption+of+the+beta-blocker+talinolol+in+humans&doi=10.1016%2FS0009-9236%2896%2990182-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Direct demonstration of small intestinal secretion and site-dependent absorption of the β-blocker talinolol in humans</span></div><div class="casAuthors">Gramatte, Thomas; Oertel, Reinhard; Terhaag, Bernd; Kirch, Wilhelm</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology and Therapeutics (St. Louis)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">541-549</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Mosby-Year Book</span>)
        </div><div class="casAbstract">The relevance of site-dependent small intestinal absorption for incomplete intestinal absorption of the poorly metabolized β1-adrenergic receptor antagonist talinolol was examd.  The intestinal steady-state perfusion technique (triple lumen tubing system with a 30 cm test segment) for intraluminal measurements was combined with simultaneous detn. of talinolol serum concns.  Dissolved talinolol was perfused over 160 min into different parts of the small intestine.  The middle of the test segment was located between 95 and 235 cm beyond the teeth.  Each of the six healthy subjects was studied twice with a proximal and a more distal site of perfusion to allow for comparisons within an individual subject.  The area under the curve for serum concns. from 0 to 480 min [AUC (0-480 min)] and the max. serum concn. after distal perfusions corresponded to only 15% to 73% and 7% to 90% of the proximal values, resp.  AUC decreased with increasing distance from the teeth.  The mean amt. of talinolol absorbed from the test segment per unit time (intestinal transport rate) corresponds to only one-tenth of the amt. of drug offered to the test segment (perfusion rate).  There was a direct correlation between the perfusion rate of talinolol and its transport rate for both regions and in all subjects investigated.  However, to achieve the same transport rate in the distal region a higher perfusion rate is required, compared to the proximal small intestine.  At perfusion rates lower than 600 μg/min, net secretion of talinolol into the intestinal lumen occurred against a steep concn. gradient blood:lumen of about 1:4200.  Evidently, talinolol oral bioavailability of 55% is due to a low absorption rate and a decrease of absorption capabilities along the small intestine.  Net absorption of talinolol is reduced by the involvement of active intestinal secretion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxlRygBROygLVg90H21EOLACvtfcHk0ljfjRbSg8Zj7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjvFOktbg%253D&md5=28855d459cf298f305c8087a35720c38</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2FS0009-9236%2896%2990182-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0009-9236%252896%252990182-4%26sid%3Dliteratum%253Aachs%26aulast%3DGramatte%26aufirst%3DT.%26aulast%3DOertel%26aufirst%3DR.%26aulast%3DTerhaag%26aufirst%3DB.%26aulast%3DKirch%26aufirst%3DW.%26atitle%3DDirect%2520demonstration%2520of%2520small%2520intestinal%2520secretion%2520and%2520site-dependent%2520absorption%2520of%2520the%2520beta-blocker%2520talinolol%2520in%2520humans%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D1996%26volume%3D59%26spage%3D541%26epage%3D549%26doi%3D10.1016%2FS0009-9236%2896%2990182-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabbaa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dautrey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colas-Linhart, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farinotti, R.</span></span> <span> </span><span class="NLM_article-title">Intestinal elimination of ofloxacin enantiomers in the rat: evidence of a carrier-mediated process</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2126</span>– <span class="NLM_lpage">2130</span>, <span class="refDoi"> DOI: 10.1128/AAC.40.9.2126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1128%2FAAC.40.9.2126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=8878593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK28XlsVCht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1996&pages=2126-2130&author=L.+Rabbaaauthor=S.+Dautreyauthor=N.+Colas-Linhartauthor=C.+Carbonauthor=R.+Farinotti&title=Intestinal+elimination+of+ofloxacin+enantiomers+in+the+rat%3A+evidence+of+a+carrier-mediated+process&doi=10.1128%2FAAC.40.9.2126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal elimination of ofloxacin enantiomers in the rat: evidence of a carrier-mediated process</span></div><div class="casAuthors">Rabbaa, Lydia; Dautrey, Sophie; Colas-Linhart, Nicole; Carbon, Claude; Farinotti, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2126-2130</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The aim of this work was to examine the mechanism involved in intestinal elimination of the two optical isomers of ofloxacin in the rat.  An intestinal segment was isolated in situ and perfused with saline, while drug soln. was administered via the carotid artery.  Blood samples and intestinal effluents were collected and analyzed by a high-performance liq. chromatog. method.  We obsd. saturable and stereoselective intestinal elimination of the ofloxacin enantiomers.  The elimination process favored the R-(+) form of the mol.  After a parenteral dose of 20 mg of racemic ofloxacin per kg of body wt., intestinal clearances were 0.23 ± 0.03 vs. 0.30 ± 0.03 mL/min for S-(-)- and R-(+)-ofloxacin, resp.  Ciprofloxacin and pefloxacin interfered with ofloxacin elimination and significantly reduced the intestinal clearance of S-(-)- and R-(+)-ofloxacin.  With concomitant ciprofloxacin, intestinal clearances became 0.13 ± 0.02 vs. .17 ± 0.03 mL/min and 0.14 ± 0.01 vs. 0.19 ± 0.05 mL/min with pefloxacin for S-(-)- and R-(+)-ofloxacin, resp.  Those findings argue for the presence of a common transport system in the rat intestine with variable affinities for fluoroquinolones.  In addn., verapamil and quinidine, two P-glycoprotein blockers, significantly reduced the intestinal elimination of both ofloxacin isomers with concomitant verapamil, intestinal clearances were 0.12 ± 0.02 vs. 0.18 ± 0.03 mL/min for S-(-)- and R-(+)-ofloxacin, resp., while with concomitant quinidine, values were 0.18 ± 0.01 vs. 0.23 ± 0.01 mL/min without modifying their areas under the concn.-time curve in serum.  Similar results were found with another fluoroquinolone, ciprofloxacin, in previous work.  P-glycoprotein appears to be involved in the intestinal elimination of fluoroquinolones in rats.  The characterization of fluoroquinolone intestinal elimination has significant clin. relevance for the better evaluation of the influence of this secretory pathway on antibiotic efficacy and selection of resistant bacteria within the intestinal flora.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrw5HXibABO7Vg90H21EOLACvtfcHk0ljfjRbSg8Zj7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XlsVCht7s%253D&md5=1ba7f62329e4edf9a7f371695f74b7f9</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1128%2FAAC.40.9.2126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.40.9.2126%26sid%3Dliteratum%253Aachs%26aulast%3DRabbaa%26aufirst%3DL.%26aulast%3DDautrey%26aufirst%3DS.%26aulast%3DColas-Linhart%26aufirst%3DN.%26aulast%3DCarbon%26aufirst%3DC.%26aulast%3DFarinotti%26aufirst%3DR.%26atitle%3DIntestinal%2520elimination%2520of%2520ofloxacin%2520enantiomers%2520in%2520the%2520rat%253A%2520evidence%2520of%2520a%2520carrier-mediated%2520process%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1996%26volume%3D40%26spage%3D2126%26epage%3D2130%26doi%3D10.1128%2FAAC.40.9.2126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Haim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shabtai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinstein, E.</span></span> <span> </span><span class="NLM_article-title">Transepithelial intestinal excretion of ciprofloxacin in humans</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">822</span>– <span class="NLM_lpage">823</span>, <span class="refDoi"> DOI: 10.1086/319206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1086%2F319206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=11229852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A280%3ADC%252BD3MvjsVGmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2001&pages=822-823&author=J.+Ramonauthor=M.+Ben-Haimauthor=M.+Shabtaiauthor=E.+Rubinstein&title=Transepithelial+intestinal+excretion+of+ciprofloxacin+in+humans&doi=10.1086%2F319206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Transepithelial intestinal excretion of ciprofloxacin in humans</span></div><div class="casAuthors">Ramon J; Ben-Haim M; Shabtai M; Rubinstein E</div><div class="citationInfo"><span class="NLM_cas:title">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">822-3</span>
        ISSN:<span class="NLM_cas:issn">1058-4838</span>.
    </div><div class="casAbstract">The excretion of ciprofloxacin in the small bowel was studied in 40 patients undergoing bowel surgery.  Ciprofloxacin (200 mg) was administered iv, and intestinal samples were collected over a 120-min period.  In ileal loops ciprofloxacin concentrations reached a peak of 4.0 mg/L, whereas in caecal fluid samples, concentrations were < 0.16 mg/L.  Ciprofloxacin administered directly into the ileal and caecal loops did not result in measurable blood levels for 2 h.  The results confirm that ciprofloxacin is selectively excreted into the small bowel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQXGZ1Y_EQEFMScOqQTSkOffW6udTcc2eaLc_VKsbgeT7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MvjsVGmtQ%253D%253D&md5=5e9e2811c773bc169964aeb838ed2e41</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1086%2F319206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F319206%26sid%3Dliteratum%253Aachs%26aulast%3DRamon%26aufirst%3DJ.%26aulast%3DBen-Haim%26aufirst%3DM.%26aulast%3DShabtai%26aufirst%3DM.%26aulast%3DRubinstein%26aufirst%3DE.%26atitle%3DTransepithelial%2520intestinal%2520excretion%2520of%2520ciprofloxacin%2520in%2520humans%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2001%26volume%3D32%26spage%3D822%26epage%3D823%26doi%3D10.1086%2F319206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laffont, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toutain, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvinerie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bousquet-Melou, A.</span></span> <span> </span><span class="NLM_article-title">Intestinal secretion is a major route for parent ivermectin elimination in the rat</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">626</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.1124/dmd.30.6.626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.30.6.626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=12019186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD38XktFSlsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=626-630&author=C.+M.+Laffontauthor=P.+L.+Toutainauthor=M.+Alvinerieauthor=A.+Bousquet-Melou&title=Intestinal+secretion+is+a+major+route+for+parent+ivermectin+elimination+in+the+rat&doi=10.1124%2Fdmd.30.6.626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal secretion is a major route for parent ivermectin elimination in the rat</span></div><div class="casAuthors">Laffont, Celine M.; Toutain, Pierre-Louis; Alvinerie, Michel; Bousquet-Melou, Alain</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">626-630</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The transepithelial intestinal elimination of ivermectin was studied using the intestinal closed-loop model in the rat.  The common bile duct was cannulated, and duodenum, jejunum, and ileum were isolated in situ with their intact blood supplies.  Following administration of 100, 200, or 400 μg/kg b.wt. ivermectin via the carotid artery, the elimination of parent ivermectin into the small intestinal lumen over 90 min was approx. 5-fold higher than in bile.  The major amt. of secreted ivermectin was recovered in the jejunum, but the duodenum showed a higher intestinal elimination capacity than the other intestinal segments with respect to the intestinal length.  Systemic coadministration of the P-glycoprotein blocker verapamil significantly reduced the elimination capacity of jejunum by 50%, which resulted in a 30% decrease of ivermectin overall elimination by the small intestine.  In contrast, verapamil did not significantly affect ivermectin secretion in duodenum, ileum, or bile in the same animals.  Ivermectin small intestinal and biliary clearances were estd. to account for 27 and 5.5% of the total drug clearance, which was evaluated from a parallel in vivo expt. in which rats were given 200 μg/kg b.wt. ivermectin intra-arterially.  In conclusion, intestinal secretion plays a greater role than biliary secretion in the overall elimination of ivermectin in the rat, providing major amts. of active drug to the intestinal lumen and to feces.  This is discussed in terms of therapeutic efficacy against intestinal parasites in humans and animals and of ecotoxicity resulting from the contamination of livestock dung with parent drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjlJdmhWMezbVg90H21EOLACvtfcHk0ljDeuVHQhG8LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktFSlsLg%253D&md5=ba56fb23ea12fc9411456851eed7dbf1</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1124%2Fdmd.30.6.626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.30.6.626%26sid%3Dliteratum%253Aachs%26aulast%3DLaffont%26aufirst%3DC.%2BM.%26aulast%3DToutain%26aufirst%3DP.%2BL.%26aulast%3DAlvinerie%26aufirst%3DM.%26aulast%3DBousquet-Melou%26aufirst%3DA.%26atitle%3DIntestinal%2520secretion%2520is%2520a%2520major%2520route%2520for%2520parent%2520ivermectin%2520elimination%2520in%2520the%2520rat%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2002%26volume%3D30%26spage%3D626%26epage%3D630%26doi%3D10.1124%2Fdmd.30.6.626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakashita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terasawa, K.</span></span> <span> </span><span class="NLM_article-title">Enteric excretion of baicalein, a flavone of Scutellariae Radix, via glucuronidation in rat: involvement of multidrug resistance-associated protein 2</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2120</span>– <span class="NLM_lpage">2126</span>, <span class="refDoi"> DOI: 10.1023/B:PHAM.0000048205.02478.b5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1023%2FB%3APHAM.0000048205.02478.b5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=15587936" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpvVert78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2004&pages=2120-2126&author=T.+Akaoauthor=Y.+Sakashitaauthor=M.+Hanadaauthor=H.+Gotoauthor=Y.+Shimadaauthor=K.+Terasawa&title=Enteric+excretion+of+baicalein%2C+a+flavone+of+Scutellariae+Radix%2C+via+glucuronidation+in+rat%3A+involvement+of+multidrug+resistance-associated+protein+2&doi=10.1023%2FB%3APHAM.0000048205.02478.b5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Enteric Excretion of Baicalein, a Flavone of Scutellariae Radix, via Glucuronidation in Rat: Involvement of Multidrug Resistance-Associated Protein 2</span></div><div class="casAuthors">Akao, Teruaki; Sakashita, Yoko; Hanada, Masato; Goto, Hirozo; Shimada, Yutaka; Terasawa, Katsutoshi</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2120-2126</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer Science+Business Media, Inc.</span>)
        </div><div class="casAbstract">Baicalin (BG) and its aglycon, baicalein (B), are strong antioxidants and have various pharmacol. actions.  The purpose of this study was to evaluate efflux of BG from rat intestinal mucosal cell following glucuronidation of B absorbed after oral administration of B.  The absorption and excretion of BG and B were evaluated in rats using the in situ jejunal loop technique and in vitro jejunal everted sac expts.  BG and B levels were detd. by high-performance liq. chromatog. with electro-chem. detection to ensure selectivity and high sensitivity.  A large amt. (30.4% recovery) of BG, but no B, was detected in the intestinal lumens of germ-free rats 4 h after oral administration of B (12.1 mg/kg), in comparison with a substantial recovery (55.1%) of unabsorbed BG 4 h after its administration.  During the in situ rat jejunal loop absorption expt., B disappeared rapidly, and 8% of the lost B was excreted into the loop as BG 20 min after infusing 0.1 mM B.  In an in vitro absorption expt. using everted rat jejunal sac, BG also appeared outside the sac, accompanied by the disappearance of B from the outer (mucosal) side.  However, very little of B was transferred to the inner (serosal) side of the sac, and only a trace of BG was detected inside the sac.  Thus, in both the loop and the everted sac systems, the efflux of BG from the mucosal surface was satd. with the concn. of B added.  Moreover, the efflux rate of BG in the everted jejunal sac from Eisai hyperbilirubinemic rat (EHBR) was significantly lower by 56.4% than that from Sprague-Dawley rat.  These results indicate that, in rat, a large proportion of any B absorbed is retained, transformed into BG within the intestinal mucosal cells, and coordinately excreted through multidrug resistance-assocd. protein 2 (MRP2) into the intestinal lumen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXtluCPR_0kLVg90H21EOLACvtfcHk0ljDeuVHQhG8LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpvVert78%253D&md5=c869b9611ff3641278e0cb984fdb1eb4</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1023%2FB%3APHAM.0000048205.02478.b5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FB%253APHAM.0000048205.02478.b5%26sid%3Dliteratum%253Aachs%26aulast%3DAkao%26aufirst%3DT.%26aulast%3DSakashita%26aufirst%3DY.%26aulast%3DHanada%26aufirst%3DM.%26aulast%3DGoto%26aufirst%3DH.%26aulast%3DShimada%26aufirst%3DY.%26aulast%3DTerasawa%26aufirst%3DK.%26atitle%3DEnteric%2520excretion%2520of%2520baicalein%252C%2520a%2520flavone%2520of%2520Scutellariae%2520Radix%252C%2520via%2520glucuronidation%2520in%2520rat%253A%2520involvement%2520of%2520multidrug%2520resistance-associated%2520protein%25202%26jtitle%3DPharm.%2520Res.%26date%3D2004%26volume%3D21%26spage%3D2120%26epage%3D2126%26doi%3D10.1023%2FB%3APHAM.0000048205.02478.b5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballent, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lifschitz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virkel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sallovitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanusse, C.</span></span> <span> </span><span class="NLM_article-title">Modulation of the P-glycoprotein-mediated intestinal secretion of ivermectin: in vitro and in vivo assessments</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">463</span>, <span class="refDoi"> DOI: 10.1124/dmd.105.007757</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.105.007757" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=16381664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD28Xit1Sgt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=457-463&author=M.+Ballentauthor=A.+Lifschitzauthor=G.+Virkelauthor=J.+Sallovitzauthor=C.+Lanusse&title=Modulation+of+the+P-glycoprotein-mediated+intestinal+secretion+of+ivermectin%3A+in+vitro+and+in+vivo+assessments&doi=10.1124%2Fdmd.105.007757"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of the P-glycoprotein-mediated intestinal secretion of ivermectin: in vitro and in vivo assessments</span></div><div class="casAuthors">Ballent, M.; Lifschitz, A.; Virkel, G.; Sallovitz, J.; Lanusse, C.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">457-463</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The everted gut sac method was used to assess the role of the P-glycoprotein (P-gp) on the intestinal secretion of ivermectin (IVM), an antiparasitic widely used in human and veterinary medicine.  The work included the evaluation of two different P-gp modulators [itraconazole (ITZ) and valspodar (PSC833)] used at equimolar doses in the rat.  Furthermore, the influence of both P-gp modulator agents on the disposition kinetics of IVM in plasma, liver, and gastrointestinal tissues was characterized.  For the in vitro expts., ileal sacs were incubated with IVM (3 μM) in the presence or absence of either ITZ (10 μM) or PSC833 (10 μM).  In the in vivo expts., male Wistar rats were randomly allocated to three groups (n = 18) and s.c. treated with IVM (200 μg/kg-1), alone and coadministered with ITZ (5 mg, two doses) or PSC833 (8.6 mg, two doses).  Animals were sacrificed between 6 and 96 h.  Blood, liver, and gastrointestinal samples were collected.  IVM concns. were detd. by high performance liq. chromatog.  The rate of IVM accumulation in the intestinal wall of everted sacs was significantly higher after its incubation with ITZ (0.115 nmol/g/min) and PSC833 (0.238 nmol/g/min) than that obtained after the incubation without the P-gp modulators (0.016 nmol/g/min).  In agreement with the in vitro expt., the presence of ITZ and PSC833 induced an enhancement in the concns. of IVM in plasma and gastrointestinal tissues.  The results obtained in the current work, both under in vivo and in vitro conditions, confirm the relevance of P-gp-mediated transport to the intestinal secretion of IVM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr94g0sLsbVqLVg90H21EOLACvtfcHk0ljDeuVHQhG8LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xit1Sgt7o%253D&md5=8a6bc5d8bcf56f6f103cfba002f696ce</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1124%2Fdmd.105.007757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.105.007757%26sid%3Dliteratum%253Aachs%26aulast%3DBallent%26aufirst%3DM.%26aulast%3DLifschitz%26aufirst%3DA.%26aulast%3DVirkel%26aufirst%3DG.%26aulast%3DSallovitz%26aufirst%3DJ.%26aulast%3DLanusse%26aufirst%3DC.%26atitle%3DModulation%2520of%2520the%2520P-glycoprotein-mediated%2520intestinal%2520secretion%2520of%2520ivermectin%253A%2520in%2520vitro%2520and%2520in%2520vivo%2520assessments%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26spage%3D457%26epage%3D463%26doi%3D10.1124%2Fdmd.105.007757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garner, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decicco, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maduskuie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercer, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F. W.</span></span> <span> </span><span class="NLM_article-title">Role of P-glycoprotein and the intestine in the excretion of DPC 333 [(2R)-2-{(3R)-3-amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin- 1-yl}-N-hydroxy-4-methylpentanamide] in rodents</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1102</span>– <span class="NLM_lpage">1110</span>, <span class="refDoi"> DOI: 10.1124/dmd.107.017038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.107.017038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=18347085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVOmuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=1102-1110&author=C.+E.+Garnerauthor=E.+Solonauthor=C.+M.+Laiauthor=J.+Linauthor=G.+Luoauthor=K.+Jonesauthor=J.+Duanauthor=C.+P.+Deciccoauthor=T.+Maduskuieauthor=S.+E.+Mercerauthor=L.+S.+Ganauthor=M.+Qianauthor=S.+Prakashauthor=H.+S.+Shenauthor=F.+W.+Lee&title=Role+of+P-glycoprotein+and+the+intestine+in+the+excretion+of+DPC+333+%5B%282R%29-2-%7B%283R%29-3-amino-3-%5B4-%282-methylquinolin-4-ylmethoxy%29phenyl%5D-2-oxopyrrolidin-+1-yl%7D-N-hydroxy-4-methylpentanamide%5D+in+rodents&doi=10.1124%2Fdmd.107.017038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Role of P-glycoprotein and the intestine in the excretion of DPC 333 in rodents</span></div><div class="casAuthors">Garner, C. Edwin; Solon, Eric; Lai, Chii-Ming; Lin, Jianrong; Luo, Gang; Jones, Kevin; Duan, Jingwu; Decicco, Carl P.; Maduskuie, Thomas; Mercer, Stephen E.; Gan, Lian-Shen; Qian, Mingxin; Prakash, Shimoga; Shen, Huey-Shin; Lee, Frank W.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1102-1110</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The role of the intestine in the elimination of (2R)-2-{(3R)-3-amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide (DPC 333), a potent inhibitor of tissue necrosis factor α-converting enzyme, was investigated in mice and rats in vivo and in vitro.  In Madine-Darby canine kidney cells stably transfected with P-glycoprotein (P-gp) and DPC 333, the transport from B→A reservoirs exceeded the transport from A→B by approx. 7-fold.  In Caco-2 monolayers and isolated rat ileal mucosa, DPC 333 was transported from basolateral to apical reservoirs in a concn.-dependent, saturable manner, and transport was blocked by N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918), confirming the contribution of P-gp/breast cancer resistance protein in B→A efflux of DPC 333.  In quant. whole body autoradiog. studies with [14C]DPC 333 in mice and rats, radioactivity was distributed throughout the small intestine in both species.  In GF120918-pretreated bile duct-cannulated rats, radioactivity in feces was reduced 60%.  Using the in situ perfused rat intestine model, ∼20% of an i.v. dose of [14C]DPC 333 was measured in the intestinal lumen within 3 h postdose, 12% as parent.  Kinetic anal. of data suggested that excreted DPC 333 may be further metabolized in the gut.  Intestinal clearance was 0.2 to 0.35 l/h/kg.  The above data suggest that in the rodent the intestine serves as an organ of DPC 333 excretion, mediated in part by the transporter P-gp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJC8qgN4J267Vg90H21EOLACvtfcHk0liHK0u_td-hGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVOmuro%253D&md5=0a35c6293e5b076c709e088097c3fd48</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1124%2Fdmd.107.017038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.107.017038%26sid%3Dliteratum%253Aachs%26aulast%3DGarner%26aufirst%3DC.%2BE.%26aulast%3DSolon%26aufirst%3DE.%26aulast%3DLai%26aufirst%3DC.%2BM.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DG.%26aulast%3DJones%26aufirst%3DK.%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DDecicco%26aufirst%3DC.%2BP.%26aulast%3DMaduskuie%26aufirst%3DT.%26aulast%3DMercer%26aufirst%3DS.%2BE.%26aulast%3DGan%26aufirst%3DL.%2BS.%26aulast%3DQian%26aufirst%3DM.%26aulast%3DPrakash%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DH.%2BS.%26aulast%3DLee%26aufirst%3DF.%2BW.%26atitle%3DRole%2520of%2520P-glycoprotein%2520and%2520the%2520intestine%2520in%2520the%2520excretion%2520of%2520DPC%2520333%2520%255B%25282R%2529-2-%257B%25283R%2529-3-amino-3-%255B4-%25282-methylquinolin-4-ylmethoxy%2529phenyl%255D-2-oxopyrrolidin-%25201-yl%257D-N-hydroxy-4-methylpentanamide%255D%2520in%2520rodents%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26spage%3D1102%26epage%3D1110%26doi%3D10.1124%2Fdmd.107.017038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gnoth, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buetehorn, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muenster, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandmann, S.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>338</i></span>,  <span class="NLM_fpage">372</span>– <span class="NLM_lpage">380</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.180240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fjpet.111.180240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=21515813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFChs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2011&pages=372-380&author=M.+J.+Gnothauthor=U.+Buetehornauthor=U.+Muensterauthor=T.+Schwarzauthor=S.+Sandmann&title=In+vitro+and+in+vivo+P-glycoprotein+transport+characteristics+of+rivaroxaban&doi=10.1124%2Fjpet.111.180240"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban</span></div><div class="casAuthors">Gnoth, Mark Jean; Buetehorn, Ulf; Muenster, Uwe; Schwarz, Thomas; Sandmann, Steffen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">372-380</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Rivaroxaban, an oral, direct factor Xa inhibitor, has a dual mode of elimination in humans, with two-thirds metabolized by the liver and one-third renally excreted unchanged.  P-glycoprotein (P-gp) is known to be involved in the absorption, distribution, and excretion of drugs.  To investigate whether rivaroxaban is a substrate of P-gp, the bidirectional flux of rivaroxaban across Caco-2, wild-type, and P-gp-overexpressing LLC-PK1 cells was investigated.  Furthermore, the inhibitory effect of rivaroxaban toward P-gp was detd.  Rivaroxaban exhibited high permeability and polarized transport across Caco-2 cells.  Rivaroxaban was shown to be a substrate for, but not an inhibitor of, P-gp.  Of a set of potential P-gp inhibitors, ketoconazole and ritonavir, but not clarithromycin or erythromycin, inhibited P-gp-mediated transport of rivaroxaban, with half-maximal inhibitory concn. values in the range of therapeutic plasma concns.  These findings are in line with obsd. area under the plasma concn.-time curve increases in clin. drug-drug interaction studies indicating a possible involvement of P-gp in the distribution and excretion of rivaroxaban.  In vivo studies in wild-type and P-gp double-knockout mice demonstrated that the impact of P-gp alone on the pharmacokinetics of rivaroxaban is minor.  However, in P-gp double-knockout mice, a slight increase in brain concns. and decreased excretion into the gastrointestinal tract were obsd. compared with wild-type mice.  These studies also demonstrated that brain penetration of rivaroxaban is fairly low.  In addn. to P-gp, a further transport protein might be involved in the secretion of rivaroxaban.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFNMLFTnDZlrVg90H21EOLACvtfcHk0liHK0u_td-hGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFChs7k%253D&md5=186c618f5b0a05635406bfa8a32e73ad</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.180240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.180240%26sid%3Dliteratum%253Aachs%26aulast%3DGnoth%26aufirst%3DM.%2BJ.%26aulast%3DBuetehorn%26aufirst%3DU.%26aulast%3DMuenster%26aufirst%3DU.%26aulast%3DSchwarz%26aufirst%3DT.%26aulast%3DSandmann%26aufirst%3DS.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520P-glycoprotein%2520transport%2520characteristics%2520of%2520rivaroxaban%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D338%26spage%3D372%26epage%3D380%26doi%3D10.1124%2Fjpet.111.180240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proost, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirakhur, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roest, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, J. M.</span></span> <span> </span><span class="NLM_article-title">Urinary, biliary and faecal excretion of rocuronium in humans</span>. <i>Br. J. Anaesth.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">717</span>– <span class="NLM_lpage">723</span>, <span class="refDoi"> DOI: 10.1093/bja/85.5.717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1093%2Fbja%2F85.5.717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=11094587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3cXosVSnsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2000&pages=717-723&author=J.+H.+Proostauthor=L.+I.+Erikssonauthor=R.+K.+Mirakhurauthor=G.+Roestauthor=J.+M.+Wierda&title=Urinary%2C+biliary+and+faecal+excretion+of+rocuronium+in+humans&doi=10.1093%2Fbja%2F85.5.717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Urinary, biliary and fecal excretion of rocuronium in humans</span></div><div class="casAuthors">Proost, J. H.; Eriksson, L. I.; Mirakhur, R. K.; Roest, G.; Wierda, J. M. K. H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Anaesthesia</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">717-723</span>CODEN:
                <span class="NLM_cas:coden">BJANAD</span>;
        ISSN:<span class="NLM_cas:issn">0007-0912</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The excretion of rocuronium and its potential metabolites was studied in 38 anesthetized patients, ASA I-III and 21-69 yr old.  Rocuronium bromide was administered as an i.v. bolus dose of 0.3 or 0.9 mg kg-1.  In Part A of the study, the excretion into urine and bile, and the liver content were studied.  Plasma kinetics (n=19) were similar to those reported previously.  Urinary recovery within 48 h after administration was 26 (8)% (mean (SD)) (n=8) of the dose.  In bile obtained from T-drains, the recovery within 48 h was 7 (6)% (n=11).  The rocuronium concn. in bile declined bi-exponentially, with half-lives of 2.3 (0.7) and 16 (11) h resp. (n=6).  In three patients from whom stoma fluid was collected, the amt. of rocuronium recovered ranged from 0.04 to 12.0% of the dose.  In liver tissue obtained from four patients undergoing hemihepatectomy, the estd. amt. of rocuronium at 2-5 h after administration ranged between 6.3 and 13.2% (n=4).  In the second part of the study (Part B), urine and feces were collected over 4-8 days and the recovery was 27 (13)% and 31 (23)% of the dose resp. (n=10).  In most samples, irresp. of the type of biol. material, only small amts. of the metabolite 17-desacetyl-rocuronium was found.  The results demonstrate that rocuronium is taken up by the liver and excreted into bile in high concns.  The fecal and urinary excretion of unchanged rocuronium are the major routes of rocuronium elimination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdPCrqI7fzT7Vg90H21EOLACvtfcHk0liHK0u_td-hGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXosVSnsbk%253D&md5=1868056189e0fa0596555c3b9d1663d1</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1093%2Fbja%2F85.5.717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbja%252F85.5.717%26sid%3Dliteratum%253Aachs%26aulast%3DProost%26aufirst%3DJ.%2BH.%26aulast%3DEriksson%26aufirst%3DL.%2BI.%26aulast%3DMirakhur%26aufirst%3DR.%2BK.%26aulast%3DRoest%26aufirst%3DG.%26aulast%3DWierda%26aufirst%3DJ.%2BM.%26atitle%3DUrinary%252C%2520biliary%2520and%2520faecal%2520excretion%2520of%2520rocuronium%2520in%2520humans%26jtitle%3DBr.%2520J.%2520Anaesth.%26date%3D2000%26volume%3D85%26spage%3D717%26epage%3D723%26doi%3D10.1093%2Fbja%2F85.5.717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahmood, I.</span></span> <span> </span><span class="NLM_article-title">Interspecies scaling of biliary excreted drugs: a comparison of several methods</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">892</span>, <span class="refDoi"> DOI: 10.1002/jps.20313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1002%2Fjps.20313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=15736194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFCju70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2005&pages=883-892&author=I.+Mahmood&title=Interspecies+scaling+of+biliary+excreted+drugs%3A+a+comparison+of+several+methods&doi=10.1002%2Fjps.20313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Interspecies scaling of biliary excreted drugs: a comparison of several methods</span></div><div class="casAuthors">Mahmood, Iftekhar</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">883-892</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The objective of this study was to evaluate the predictive performance of several methods of interspecies scaling for the prediction of human clearance of drugs which are excreted in the bile.  Ten methods of allometric scaling were used to predict human clearance of biliary excreted drugs from animal data.  The methods included the simple allometric approach; the rule of exponents; the rule of exponents with a correction factor; the ratio of human and monkey liver blood flow × monkey clearance; product of clearance and bile flow; product of clearance and UDGPT; product of clearance, bile flow, and UDGPT; and a modified version of the last three approaches in assocn. with the rule of exponents.  The results of the study indicate that among these ten approaches, the rule of exponents with the correction factor is the best approach for the prediction of human clearance for drugs which are excreted in the bile.  The worst approach is the product of clearance, bile flow, and UDGPT.  The simple allometry and the monkey liver blood flow (MLBF) approaches gave almost similar results.  For some drugs the simple allometry predicted clearance better than the MLBF approach and vice versa.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoehFjQoAuRy7Vg90H21EOLACvtfcHk0liHK0u_td-hGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFCju70%253D&md5=ac02d065621b2ca32897555c48ec59cd</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1002%2Fjps.20313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.20313%26sid%3Dliteratum%253Aachs%26aulast%3DMahmood%26aufirst%3DI.%26atitle%3DInterspecies%2520scaling%2520of%2520biliary%2520excreted%2520drugs%253A%2520a%2520comparison%2520of%2520several%2520methods%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2005%26volume%3D94%26spage%3D883%26epage%3D892%26doi%3D10.1002%2Fjps.20313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le Ferrec, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artusson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brayden, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabre, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gires, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousset, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubas, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarino, M. L.</span></span> <span> </span><span class="NLM_article-title">In vitro models of the intestinal barrier. The report and recommendations of ECVAM workshop 46. European Centre for the validation of alternative methods</span>. <i>ATLA, Altern. Lab. Anim.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">649</span>– <span class="NLM_lpage">668</span>, <span class="refDoi"> DOI: 10.1177/026119290102900604</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1177%2F026119290102900604" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=11709041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A280%3ADC%252BD3MnmtleksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2001&pages=649-668&author=E.+Le+Ferrecauthor=C.+Chesneauthor=P.+Artussonauthor=D.+Braydenauthor=G.+Fabreauthor=P.+Giresauthor=F.+Guillouauthor=M.+Roussetauthor=W.+Rubasauthor=M.+L.+Scarino&title=In+vitro+models+of+the+intestinal+barrier.+The+report+and+recommendations+of+ECVAM+workshop+46.+European+Centre+for+the+validation+of+alternative+methods&doi=10.1177%2F026119290102900604"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro models of the intestinal barrier. The report and recommendations of ECVAM Workshop 46. European Centre for the Validation of Alternative methods</span></div><div class="casAuthors">Le Ferrec E; Chesne C; Artusson P; Brayden D; Fabre G; Gires P; Guillou F; Rousset M; Rubas W; Scarino M L</div><div class="citationInfo"><span class="NLM_cas:title">Alternatives to laboratory animals : ATLA</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">649-68</span>
        ISSN:<span class="NLM_cas:issn">0261-1929</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT-6jih6S5J2uqrn-c4Of3KfW6udTcc2eax8t3iuAS1Krntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MnmtleksA%253D%253D&md5=968fd11b8aaf0f72924cdc9ddecea7cd</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1177%2F026119290102900604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F026119290102900604%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BFerrec%26aufirst%3DE.%26aulast%3DChesne%26aufirst%3DC.%26aulast%3DArtusson%26aufirst%3DP.%26aulast%3DBrayden%26aufirst%3DD.%26aulast%3DFabre%26aufirst%3DG.%26aulast%3DGires%26aufirst%3DP.%26aulast%3DGuillou%26aufirst%3DF.%26aulast%3DRousset%26aufirst%3DM.%26aulast%3DRubas%26aufirst%3DW.%26aulast%3DScarino%26aufirst%3DM.%2BL.%26atitle%3DIn%2520vitro%2520models%2520of%2520the%2520intestinal%2520barrier.%2520The%2520report%2520and%2520recommendations%2520of%2520ECVAM%2520workshop%252046.%2520European%2520Centre%2520for%2520the%2520validation%2520of%2520alternative%2520methods%26jtitle%3DATLA%252C%2520Altern.%2520Lab.%2520Anim.%26date%3D2001%26volume%3D29%26spage%3D649%26epage%3D668%26doi%3D10.1177%2F026119290102900604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klaassen, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span> <span> </span><span class="NLM_article-title">Xenobiotic transporters: ascribing function from gene knockout and mutation studies</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">186</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfm214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1093%2Ftoxsci%2Fkfm214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=17698509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsV2rtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2008&pages=186-196&author=C.+D.+Klaassenauthor=H.+Lu&title=Xenobiotic+transporters%3A+ascribing+function+from+gene+knockout+and+mutation+studies&doi=10.1093%2Ftoxsci%2Fkfm214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Xenobiotic Transporters: Ascribing Function from Gene Knockout and Mutation Studies</span></div><div class="casAuthors">Klaassen, Curtis D.; Lu, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">186-196</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-6080</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Transporter-mediated absorption, secretion, and reabsorption of chems. are increasingly recognized as important determinants in the biol. activities of many xenobiotics.  In recent years, the rapid progress in generating and characterizing mice with targeted deletion of transporters has greatly increased our knowledge of the functions of transporters in the pharmacokinetics/toxicokinetics of xenobiotics.  In this introduction, we focus on functions of transporters learned from expts. on knockout mice as well as humans and rodents with natural mutations of these transporters.  We limit our discussion to transporters that either directly transport xenobiotics or are important in biliary excretion or cellular defenses, namely multidrug resistance, multidrug resistance-assocd. proteins, breast cancer resistance protein, org. anion transporting polypeptides, org. anion transporters, org. cation transporters, nucleoside transporters, peptide transporters, bile acid transporters, cholesterol transporters, and phospholipid transporters, as well as metal transporters.  Efflux transporters in intestine, liver, kidney, brain, testes, and placenta can efflux xenobiotics out of cells and serve as barriers against the entrance of xenobiotics into cells, whereas many xenobiotics enter the biol. system via uptake transporters.  The functional importance of a given transporter in each tissue depends on its substrate specificity, expression level, and the presence/absence of other transporters with overlapping substrate preferences.  Nevertheless, a transporter may affect a tissue independent of its local expression by altering systemic metab.  Further studies on the gene regulation and function of transporters, as well as the interrelationship between transporters and phase I/II xenobiotic-metabolizing enzymes, will provide a complete framework for developing novel strategies to protect us from xenobiotic insults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqU4LWgJUd-rVg90H21EOLACvtfcHk0liQyKzmRkCwuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsV2rtQ%253D%253D&md5=751acee436a176b80b6db33b11789cd2</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfm214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfm214%26sid%3Dliteratum%253Aachs%26aulast%3DKlaassen%26aufirst%3DC.%2BD.%26aulast%3DLu%26aufirst%3DH.%26atitle%3DXenobiotic%2520transporters%253A%2520ascribing%2520function%2520from%2520gene%2520knockout%2520and%2520mutation%2520studies%26jtitle%3DToxicol.%2520Sci.%26date%3D2008%26volume%3D101%26spage%3D186%26epage%3D196%26doi%3D10.1093%2Ftoxsci%2Fkfm214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jurgens, G</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groth Hoegberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graudal, N.</span></span> <span> </span><span class="NLM_article-title">The effect of activated charcoal on drug exposure in healthy volunteers: a meta-analysis</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">505</span>, <span class="refDoi"> DOI: 10.1038/clpt.2008.278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1038%2Fclpt.2008.278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=19194372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A280%3ADC%252BD1M3oslaksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2009&pages=501-505&author=G+Jurgensauthor=L.+Groth+Hoegbergauthor=N.+Graudal&title=The+effect+of+activated+charcoal+on+drug+exposure+in+healthy+volunteers%3A+a+meta-analysis&doi=10.1038%2Fclpt.2008.278"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of activated charcoal on drug exposure in healthy volunteers: a meta-analysis</span></div><div class="casAuthors">Jurgens G; Hoegberg L C Groth; Graudal N A</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">501-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The objective of the study was to estimate the effect of activated charcoal (AC) administered during the first 6 h after drug intake and the effect of drug properties on drug exposure.  Sixty-four controlled studies were integrated in a meta-analysis.  AC administered 0-5 min after administration of a drug reduced median drug exposure by 88.4% (25-75 percentile: 65.0-96.8) (P < 0.00001).  The effect of AC continued to be statistically significant when administered up to 4 h after drug intake (median reduction in drug exposure 27.4% (range 21.3-31.5%, P = 0.0006).  The reduction in drug exposure was correlated with the AC/drug ratio (rho = 0.69, P < 0.0001), the volume of distribution (Vd) (rho = 0.46, P = 0.0001), and time to peak concentration (rho = 0.40, P = 0.02).  We found that AC is most effective when given immediately after drug ingestion but has statistically significant effects even when given as long as 4 h after drug intake.  AC appears to be most effective when given in a large dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_TFq2eQOGRL9KldV63DuefW6udTcc2eazPCIksx-AaLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M3oslaksg%253D%253D&md5=f8657819799162b787425e90b4a1d4e8</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2008.278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2008.278%26sid%3Dliteratum%253Aachs%26aulast%3DJurgens%26aufirst%3DG%26aulast%3DGroth%2BHoegberg%26aufirst%3DL.%26aulast%3DGraudal%26aufirst%3DN.%26atitle%3DThe%2520effect%2520of%2520activated%2520charcoal%2520on%2520drug%2520exposure%2520in%2520healthy%2520volunteers%253A%2520a%2520meta-analysis%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2009%26volume%3D85%26spage%3D501%26epage%3D505%26doi%3D10.1038%2Fclpt.2008.278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lapatto-Reiniluoto, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kivisto, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuvonen, P. J.</span></span> <span> </span><span class="NLM_article-title">Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">260</span>, <span class="refDoi"> DOI: 10.1067/mcp.2001.118184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1067%2Fmcp.2001.118184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=11557913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntlajurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2001&pages=255-260&author=O.+Lapatto-Reiniluotoauthor=K.+T.+Kivistoauthor=P.+J.+Neuvonen&title=Activated+charcoal+alone+and+followed+by+whole-bowel+irrigation+in+preventing+the+absorption+of+sustained-release+drugs&doi=10.1067%2Fmcp.2001.118184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs</span></div><div class="casAuthors">Lapatto-Reiniluoto, Outi; Kivisto, Kari T.; Neuvonen, Pertti J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">255-260</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">Our objective was to study the effect of activated charcoal on the absorption of sustained-release drugs ingested 1 h earlier and to examine whether whole-bowel irrigation affects the efficacy of charcoal.  In this randomized, 3-phase crossover study, 9 healthy subjects received, at the same time, 200 mg carbamazepine, 200 mg theophylline, and 120 mg verapamil.  All drugs were given as sustained-release tablets.  One hour after taking the tablets, the subjects were assigned to one of the following treatments: 25 g activated charcoal as a suspension, 25 g activated charcoal as a suspension followed by whole-bowel irrigation with polyethylene glycol (PEG) electrolyte lavage soln., or 200 mL water (control).  The absorption of the drugs was characterized by using the area under the plasma drug concn.-time curve from time zero to 24 h [AUC(0-24)], peak plasma concn. (Cmax), Cmax minus the plasma concn. at 1 h (CΔ), and time to peak (tmax).  Activated charcoal alone given 1 h after drug intake significantly (P < .001) reduced the absorption [AUC(0-24)] of all 3 drugs (by 62%-75%).  Also the Cmax and CΔ values of these drugs were significantly reduced by charcoal alone.  Whole-bowel irrigation did not increase significantly the effect of charcoal on any absorption parameters of the 3 drugs studied.  On the contrary, whole-bowel irrigation significantly (P < .01) decreased the efficacy of charcoal with respect to carbamazepine.  Activated charcoal alone given 1 h after intake of sustained-release drugs was effective in preventing the absorption of all 3 drugs studied.  Whole-bowel irrigation may even decrease the efficacy of charcoal if the drug is well adsorbable onto charcoal.  However, our study was performed with therapeutic drug doses only.  In overdoses their possible effects on gastrointestinal motility may modify the efficacy of decontamination methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqibQZbVwMkrrVg90H21EOLACvtfcHk0ljXPWhOcZCibw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntlajurg%253D&md5=bd2373f70029ead65d6ceacf89cb80f7</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1067%2Fmcp.2001.118184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1067%252Fmcp.2001.118184%26sid%3Dliteratum%253Aachs%26aulast%3DLapatto-Reiniluoto%26aufirst%3DO.%26aulast%3DKivisto%26aufirst%3DK.%2BT.%26aulast%3DNeuvonen%26aufirst%3DP.%2BJ.%26atitle%3DActivated%2520charcoal%2520alone%2520and%2520followed%2520by%2520whole-bowel%2520irrigation%2520in%2520preventing%2520the%2520absorption%2520of%2520sustained-release%2520drugs%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2001%26volume%3D70%26spage%3D255%26epage%3D260%26doi%3D10.1067%2Fmcp.2001.118184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">al-Meshal, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">el-Sayed, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">al-Angary, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">al-Dardiri, M. M.</span></span> <span> </span><span class="NLM_article-title">Effect of oral activated charcoal on propranolol pharmacokinetics following intravenous administration to rabbits</span>. <i>J. Clin. Pharm. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2710.1993.tb00564.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1111%2Fj.1365-2710.1993.tb00564.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=8473358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK3sXktF2rt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1993&pages=39-44&author=M.+A.+al-Meshalauthor=Y.+M.+el-Sayedauthor=A.+A.+al-Angaryauthor=M.+M.+al-Dardiri&title=Effect+of+oral+activated+charcoal+on+propranolol+pharmacokinetics+following+intravenous+administration+to+rabbits&doi=10.1111%2Fj.1365-2710.1993.tb00564.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of oral activated charcoal on propranolol pharmacokinetics following intravenous administration to rabbits</span></div><div class="casAuthors">Al-Meshal, M. A.; El-Sayed, Y. M.; Al-Angary, A. A.; Al-Dardiri, M. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacy and Therapeutics</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-44</span>CODEN:
                <span class="NLM_cas:coden">JCPTED</span>;
        ISSN:<span class="NLM_cas:issn">0269-4727</span>.
    </div><div class="casAbstract">The pharmacokinetics of propranolol following i.v. administration (1 mg/kg), with and without treatment with oral activated charcoal, was investigated in rabbits.  In charcoal-treated rabbits a significant redn. in propranolol serum concns. was obsd. compared to control animals.  Charcoal treatment significantly reduced the half-life of elimination (16.6%) and the men residence time (19%) of propranolol.  A 17% increase in the systemic clearance and 14% decrease in AUC were also noted.  Charcoal administration did not significantly alter the vol. of distribution (Vc' Varea and Vss) or the apparent distribution half-life.  A two-compartment model adequately described propranolol in control and treated rabbits.  The results indicate that administration of oral activated charcoal enhances the systemic elimination of propranolol.  This is presumably mediated by interruption of the enterohepatic circulation of propranolol by activated charcoal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2R072hTRZObVg90H21EOLACvtfcHk0lgCVkH94E4zaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXktF2rt7w%253D&md5=853095315520fd43ad626aca817ddeb6</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2710.1993.tb00564.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2710.1993.tb00564.x%26sid%3Dliteratum%253Aachs%26aulast%3Dal-Meshal%26aufirst%3DM.%2BA.%26aulast%3Del-Sayed%26aufirst%3DY.%2BM.%26aulast%3Dal-Angary%26aufirst%3DA.%2BA.%26aulast%3Dal-Dardiri%26aufirst%3DM.%2BM.%26atitle%3DEffect%2520of%2520oral%2520activated%2520charcoal%2520on%2520propranolol%2520pharmacokinetics%2520following%2520intravenous%2520administration%2520to%2520rabbits%26jtitle%3DJ.%2520Clin.%2520Pharm.%2520Ther.%26date%3D1993%26volume%3D18%26spage%3D39%26epage%3D44%26doi%3D10.1111%2Fj.1365-2710.1993.tb00564.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theil, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsters, J. C.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khojasteh, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernillet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morinello, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hop, C. E.</span></span> <span> </span><span class="NLM_article-title">Interplay of dissolution, solubility, and nonsink permeation determines the oral absorption of the Hedgehog pathway inhibitor GDC-0449 in dogs: an investigation using preclinical studies and physiologically based pharmacokinetic modeling</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1029</span>– <span class="NLM_lpage">1038</span>, <span class="refDoi"> DOI: 10.1124/dmd.110.032680</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.110.032680" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=20406853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1Kls7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1029-1038&author=H.+Wongauthor=F.+P.+Theilauthor=Y.+Cuiauthor=J.+C.+Marstersauthor=S.+C.+Khojastehauthor=L.+Vernilletauthor=H.+Laauthor=X.+Songauthor=H.+Wangauthor=E.+J.+Morinelloauthor=Y.+Dengauthor=C.+E.+Hop&title=Interplay+of+dissolution%2C+solubility%2C+and+nonsink+permeation+determines+the+oral+absorption+of+the+Hedgehog+pathway+inhibitor+GDC-0449+in+dogs%3A+an+investigation+using+preclinical+studies+and+physiologically+based+pharmacokinetic+modeling&doi=10.1124%2Fdmd.110.032680"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Interplay of dissolution, solubility, and nonsink permeation determines the oral absorption of the hedgehog pathway inhibitor GDC-0449 in dogs: An investigation using preclinical studies and physiologically based pharmacokinetic modeling</span></div><div class="casAuthors">Wong, Harvey; Theil, Frank-Peter; Cui, Yong; Marsters, James C., Jr.; Khojasteh, S. Cyrus; Vernillet, Laurent; La, Hank; Song, Xiling; Wang, Hong; Morinello, Eric J.; Deng, Yuzhong; Hop, Cornelis E. C. A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1029-1038</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Factors detg. the pharmacokinetics of 2-chloro-N-(4-chloro-3-(pyridine-2-yl)phenyl)-4-(methylsulfonyl)benzamide (GDC-0449) were investigated using preclin. studies and physiol. based pharmacokinetic (PBPK) modeling.  Multiple-dose studies where dogs were given twice-daily oral doses of either 7.5 or 25 mg/kg GDC-0449 showed less than dose-proportional increases in exposure on day 1.  At steady state, exposures were comparable between the two dose groups.  Oral administration of activated charcoal to dogs receiving oral or i.v. GDC-0449 (25 mg) showed a more rapid decrease in plasma concns., suggesting that the concn. gradient driving intestinal membrane permeation was reversible.  The biliary clearance of GDC-0449 in dogs was low (0.04 mL/min/kg) and did not account for the majority of the estd. systemic clearance (∼19% of systemic clearance).  Likewise, in vitro studies using sandwich-cultured human hepatocytes showed negligible biliary excretion.  The effect of particle size on oral absorption was shown in a single-dose study where 150 mg of GDC-0449 of two particle sizes was administered.  An oral PBPK model was used to investigate mechanisms detg. the oral pharmacokinetics of GDC-0449.  The overall oral absorption of GDC-0449 appears to depend on the interplay between the dissoln. and intestinal membrane permeation processes.  A unique feature of GDC-0449 distinguishing it from other Biopharmaceutical Classification System II compds. was that incorporation of the effects of soly. rate-limited absorption and nonsink permeation on the intestinal membrane permeation process was necessary to describe its pharmacokinetic behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1OUx-orL8ibVg90H21EOLACvtfcHk0lgCVkH94E4zaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1Kls7k%253D&md5=6169d4578f81846e562e6e06c71633fe</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.032680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.032680%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DH.%26aulast%3DTheil%26aufirst%3DF.%2BP.%26aulast%3DCui%26aufirst%3DY.%26aulast%3DMarsters%26aufirst%3DJ.%2BC.%26aulast%3DKhojasteh%26aufirst%3DS.%2BC.%26aulast%3DVernillet%26aufirst%3DL.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DMorinello%26aufirst%3DE.%2BJ.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DHop%26aufirst%3DC.%2BE.%26atitle%3DInterplay%2520of%2520dissolution%252C%2520solubility%252C%2520and%2520nonsink%2520permeation%2520determines%2520the%2520oral%2520absorption%2520of%2520the%2520Hedgehog%2520pathway%2520inhibitor%2520GDC-0449%2520in%2520dogs%253A%2520an%2520investigation%2520using%2520preclinical%2520studies%2520and%2520physiologically%2520based%2520pharmacokinetic%2520modeling%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D1029%26epage%3D1038%26doi%3D10.1124%2Fdmd.110.032680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saravanakumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadighi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhlaghi, F.</span></span> <span> </span><span class="NLM_article-title">Physicochemical properties, biotransformation, and transport pathways of established and newly approved medications: a systematic review of the top 200 most prescribed drugs vs. the FDA-approved drugs between 2005 and 2016</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1281</span>– <span class="NLM_lpage">1294</span>, <span class="refDoi"> DOI: 10.1007/s40262-019-00750-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1007%2Fs40262-019-00750-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=30972694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFWms7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=1281-1294&author=A.+Saravanakumarauthor=A.+Sadighiauthor=R.+Ryuauthor=F.+Akhlaghi&title=Physicochemical+properties%2C+biotransformation%2C+and+transport+pathways+of+established+and+newly+approved+medications%3A+a+systematic+review+of+the+top+200+most+prescribed+drugs+vs.+the+FDA-approved+drugs+between+2005+and+2016&doi=10.1007%2Fs40262-019-00750-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Physicochemical Properties, Biotransformation, and Transport Pathways of Established and Newly Approved Medications: A Systematic Review of the Top 200 Most Prescribed Drugs vs. the FDA-Approved Drugs Between 2005 and 2016</span></div><div class="casAuthors">Saravanakumar, Anitha; Sadighi, Armin; Ryu, Rachel; Akhlaghi, Fatemeh</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1281-1294</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Background: Enzyme-mediated biotransformation of pharmacol. agents is a crucial step in xenobiotic detoxification and drug disposition.  Herein, we investigated the metab. and physicochem. properties of the top 200 most prescribed drugs (established) as well as drugs approved by the US Food and Drug Administration (FDA) between 2005 and 2016 (newly approved).  Objective: Our objective was to capture the changing trends in the routes of administration, physicochem. properties, and prodrug medications, as well as the contributions of drug-metabolizing enzymes and transporters to drug clearance.  Methods: The University of Washington Drug Interaction Database (DIDB) as well as other online resources (e.g., CenterWatch.com, Drugs.com, DrugBank.ca, and PubChem.ncbi.nlm.nih.gov) was used to collect and stratify the dataset required for exploring the above-mentioned trends. Results: Analyses revealed that ~ 90% of all drugs in the established and newly approved drug lists were administered systemically (oral or i.v.). Meanwhile, the portion of biologics (mol. wt. > 1 kDa) was 15 times greater in the newly approved list than established drugs. Addnl., there was a 4.5-fold increase in the no. of compds. with a high calcd. partition coeff. (cLogP > 3) and a high total polar surface area (> 75 Å2) in the newly approved drug vs. the established category.  Further, prodrugs in established or newly approved lists were found to be converted to active compds. via hydrolysis, demethylases, and kinases.  The contribution of cytochrome P 450 (CYP) 3A4, as the major biotransformation pathway, has increased from 40% in the established drug list to 64% in the newly approved drug list.  Moreover, the role of CYP1A2, CYP2C19, and CYP2D6 were decreased as major metabolizing enzymes among the newly approved medications.  Among non-CYP major metabolizers, the contribution of alc. dehydrogenases/aldehyde dehydrogenases (ADH/ALDH) and sulfotransferases decreased in the newly approved drugs compared with the established list.  Furthermore, the highest contribution among uptake and efflux transporters was found for Org. Anion Transporting Polypeptide 1B1 (OATP1B1) and P-glycoprotein (P-gp), resp.  Conclusions: The higher portion of biologics in the newly approved drugs compared with the established list confirmed the growing demands for protein- and antibody-based therapies.  Moreover, the larger no. of hydrophilic drugs found in the newly approved list suggests that the probability of toxicity is likely to decrease.  With regard to CYP-mediated major metab., CYP3A5 showed an increased involvement owing to the identification of unique probe substrates to differentiate CYP3As.  Furthermore, the contribution of OATP1B1 and P-gp did not show a significant shift in the newly approved drugs as compared to the established list because of their broad substrate specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb6UtyKsUzCbVg90H21EOLACvtfcHk0lgR_pYQoTT7mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFWms7nJ&md5=cb1598cfe9c760522fd8df76d50e187c</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1007%2Fs40262-019-00750-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-019-00750-8%26sid%3Dliteratum%253Aachs%26aulast%3DSaravanakumar%26aufirst%3DA.%26aulast%3DSadighi%26aufirst%3DA.%26aulast%3DRyu%26aufirst%3DR.%26aulast%3DAkhlaghi%26aufirst%3DF.%26atitle%3DPhysicochemical%2520properties%252C%2520biotransformation%252C%2520and%2520transport%2520pathways%2520of%2520established%2520and%2520newly%2520approved%2520medications%253A%2520a%2520systematic%2520review%2520of%2520the%2520top%2520200%2520most%2520prescribed%2520drugs%2520vs.%2520the%2520FDA-approved%2520drugs%2520between%25202005%2520and%25202016%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2019%26volume%3D58%26spage%3D1281%26epage%3D1294%26doi%3D10.1007%2Fs40262-019-00750-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skolnik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span> <span> </span><span class="NLM_article-title">Towards prediction of in vivo intestinal absorption using a 96-well Caco-2 assay</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">3246</span>– <span class="NLM_lpage">3265</span>, <span class="refDoi"> DOI: 10.1002/jps.22080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1002%2Fjps.22080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=20166204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsVSrsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2010&pages=3246-3265&author=S.+Skolnikauthor=X.+Linauthor=J.+Wangauthor=X.+H.+Chenauthor=T.+Heauthor=B.+Zhang&title=Towards+prediction+of+in+vivo+intestinal+absorption+using+a+96-well+Caco-2+assay&doi=10.1002%2Fjps.22080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Towards prediction of in vivo intestinal absorption using a 96-well Caco-2 assay</span></div><div class="casAuthors">Skolnik, Suzanne; Lin, Xuena; Wang, Jianling; Chen, Xiao-Hui; He, Timothy; Zhang, Bailin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3246-3265</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">We systematically validated a robust 96-well Caco-2 assay via an extended set of 93 marketed drugs with diverse transport mechanisms and quantified by LC/MS/MS, to investigate its predictive utility while dealing with challenging discovery compds.  Utilizing nonlinear fit, the validation led to a good correlation (R2 = 0.76) between absorptive permeability, log Papp(A-B), from in vitro Caco-2 assay and reported human fraction of dose absorbed.  We obsd. that paracellular compds. could be flagged by log Papp(A-B) (<-5.5 cm/s) and physicochem. property space (c log P < 1).  Of 8000 Novartis discovery compds. examd. 13% were subject to low recovery (<30%).  Compd. loss was investigated by comparing cell monolayer and artificial membrane, while 0.5% bovine serum albumin (in both donor and acceptor compartments) was utilized to improve recovery.  The second focus of this study was to investigate the advantages and limitations of the current Caco-2 assay for predicting in vivo intestinal absorption.  Caco-2 measurements for compds. with high aq. soly. and low in vitro metabolic clearance were compared to 88 in vivo rat bioavailability studies.  Despite the challenges posed by discovery compds. with suboptimal physicochem. properties, Caco-2 data successfully projected low intestinal absorption.  This platform sets the stage for mechanistically evaluating compds. towards improving in vitro-in vivo correlations. © 2010 Wiley-Liss, Inc. and the American Pharmacists Assocn. J Pharm Sci 99:3246-3265, 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqio9beUaITm7Vg90H21EOLACvtfcHk0lgR_pYQoTT7mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsVSrsr0%253D&md5=43f7e35544e7b4a348271a53e958d3b9</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1002%2Fjps.22080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.22080%26sid%3Dliteratum%253Aachs%26aulast%3DSkolnik%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%2BH.%26aulast%3DHe%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DB.%26atitle%3DTowards%2520prediction%2520of%2520in%2520vivo%2520intestinal%2520absorption%2520using%2520a%252096-well%2520Caco-2%2520assay%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2010%26volume%3D99%26spage%3D3246%26epage%3D3265%26doi%3D10.1002%2Fjps.22080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sodhi, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L. Z.</span></span> <span> </span><span class="NLM_article-title">Intestinal efflux transporters P-gp and BCRP are not clinically relevant in apixaban disposition</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">208</span>, <span class="refDoi"> DOI: 10.1007/s11095-020-02927-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1007%2Fs11095-020-02927-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=32996065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFKnt77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2020&pages=208&author=J.+K.+Sodhiauthor=S.+Liuauthor=L.+Z.+Benet&title=Intestinal+efflux+transporters+P-gp+and+BCRP+are+not+clinically+relevant+in+apixaban+disposition&doi=10.1007%2Fs11095-020-02927-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131aR"><div class="casContent"><span class="casTitleNuber">131a</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal Efflux Transporters P-gp and BCRP Are Not Clinically Relevant in Apixaban Disposition</span></div><div class="casAuthors">Sodhi, Jasleen K.; Liu, Shuaibing; Benet, Leslie Z.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">208</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: Purpose: The involvement of the intestinally expressed xenobiotic transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) have been implicated in apixaban disposition based on in vitro studies.  Recommendations against co-administration of apixaban with inhibitors of these efflux transporters can be found throughout the literature as well as in the apixaban FDA label.  However, the clin. relevance of such findings is questionable due to the high permeability and high soly. characteristics of apixaban.  Methods: Using recently published methodologies to discern metabolic- from transporter- mediated drug-drug interactions, a crit. evaluation of all published apixaban drug-drug interaction studies was conducted to investigate the purported clin. significance of efflux transporters in apixaban disposition.  Results: Rational examn. of these clin. studies using basic pharmacokinetic theory does not support the clin. significance of intestinal efflux transporters in apixaban disposition.  Further, there is little evidence that efflux transporters are clin. significant determinants of systemic clearance.  Conclusions: Inhibition or induction of intestinal CYP3A4 can account for exposure changes of apixaban in all clin. significant drug-drug interactions, and lack of intestinal CYP3A4 inhibition can explain all studies with no exposure changes, regardless of the potential for these perpetrators to inhibit intestinal or systemic efflux transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB046FDjPETbVg90H21EOLACvtfcHk0lgR_pYQoTT7mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFKnt77P&md5=4afc81f1c78804188623cfc92f2c3323</span></div><a href="/servlet/linkout?suffix=cit131a&amp;dbid=16384&amp;doi=10.1007%2Fs11095-020-02927-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-020-02927-4%26sid%3Dliteratum%253Aachs%26aulast%3DSodhi%26aufirst%3DJ.%2BK.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DBenet%26aufirst%3DL.%2BZ.%26atitle%3DIntestinal%2520efflux%2520transporters%2520P-gp%2520and%2520BCRP%2520are%2520not%2520clinically%2520relevant%2520in%2520apixaban%2520disposition%26jtitle%3DPharm.%2520Res.%26date%3D2020%26volume%3D37%26spage%3D208%26doi%3D10.1007%2Fs11095-020-02927-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit131b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kryukov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sychev, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreev, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryzhikova, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grishina, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryabova, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loskutnikov, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smirnov, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konova, O. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsneva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bochkov, P. O.</span></span> <span> </span><span class="NLM_article-title">Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke</span>. <i>Pharmacogenomics Pers. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.2147/PGPM.S157111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.2147%2FPGPM.S157111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=29606886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVyls7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=43-49&author=A.+V.+Kryukovauthor=D.+A.+Sychevauthor=D.+A.+Andreevauthor=K.+A.+Ryzhikovaauthor=E.+A.+Grishinaauthor=A.+V.+Ryabovaauthor=M.+A.+Loskutnikovauthor=V.+V.+Smirnovauthor=O.+D.+Konovaauthor=I.+Matsnevaauthor=P.+O.+Bochkov&title=Influence+of+ABCB1+and+CYP3A5+gene+polymorphisms+on+pharmacokinetics+of+apixaban+in+patients+with+atrial+fibrillation+and+acute+stroke&doi=10.2147%2FPGPM.S157111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131bR"><div class="casContent"><span class="casTitleNuber">131b</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke</span></div><div class="casAuthors">Kryukov, Alexander Valerevich; Sychev, Dmitry Alekseevich; Andreev, Denis Anatolevich; Ryzhikova, Kristina Anatolievna; Grishina, Elena Anatolievna; Ryabova, Anastasia Vladislavovna; Loskutnikov, Mark Alekseevich; Smirnov, Valeriy Valerevich; Konova, Olga Dmitrievna; Matsneva, Irina Andreevna; Bochkov, Pavel Olegovich</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenomics and Personalized Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">43-49</span>CODEN:
                <span class="NLM_cas:coden">PPMHAD</span>;
        ISSN:<span class="NLM_cas:issn">1178-7066</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Introduction: Difficulties in non-vitamin K anticoagulant (NOAC) administration in acute stroke can be assocd. with changes in pharmacokinetic parameters of NOAC such as biotransformation, distribution, and excretion.  Therefore, obtaining data on pharmacokinetics of NOAC and factors that affect it may help develop algorithms for personalized use of this drug class in patients with acute cardioembolic stroke.  Patients and methods: Pharmacokinetics of apixaban in patients with acute stroke was studied earlier by Kryukov et al.  The present study enrolled 17 patients with cardioembolic stroke, who received 5 mg of apixaban.  In order to evaluate the pharmacokinetic parameters of apixaban, venous blood samples were collected before taking 5 mg of apixaban (point 0) and 1, 2, 3, 4, 10, and 12 h after drug intake.  Blood samples were centrifuged at 3000 rpm for 15 min.  Sep. plasma was aliquoted in Eppendorf tubes and frozen at -70°C until anal.  High-performance liq. chromatog. mass spectrometry anal. was used to det. apixaban plasma concn.  Genotyping was performed by real-time polymerase chain reaction.  CYP3A isoenzyme group activity was evaluated by detg. urinary concn. of endogenous substrate of the enzyme and its metabolite (6-β-hydroxycortisol to cortisol ratio).  Statistical anal. was performed using SPSS Statistics version 20.0.  The protocol of this study was reviewed and approved by the ethics committee; patients or their representatives signed an informed consent.  Results:ABCB1 (rs1045642 and rs4148738) gene polymorphisms do not affect the pharmacokinetics of apixaban as well as CYP3A5 (rs776746) gene polymorphisms.  Apixaban pharmacokinetics in groups with different genotypes did not differ statistically significantly.  Correlation anal. showed no statistically significant relationship between pharmacokinetic parameters of apixaban and the metabolic activity of CYP3A.  Conclusion: Questions such as depending on genotyping results for apixaban dosing and implementation of express genotyping in clin. practice remain open for NOACs.  Large population studies are required to clarify the clin. significance of genotyping for this drug class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYxNIsSO7ewLVg90H21EOLACvtfcHk0ljB0ntvIhpuuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVyls7vP&md5=24a32b46ff1aee8ec60a00fe6a5f9b16</span></div><a href="/servlet/linkout?suffix=cit131b&amp;dbid=16384&amp;doi=10.2147%2FPGPM.S157111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FPGPM.S157111%26sid%3Dliteratum%253Aachs%26aulast%3DKryukov%26aufirst%3DA.%2BV.%26aulast%3DSychev%26aufirst%3DD.%2BA.%26aulast%3DAndreev%26aufirst%3DD.%2BA.%26aulast%3DRyzhikova%26aufirst%3DK.%2BA.%26aulast%3DGrishina%26aufirst%3DE.%2BA.%26aulast%3DRyabova%26aufirst%3DA.%2BV.%26aulast%3DLoskutnikov%26aufirst%3DM.%2BA.%26aulast%3DSmirnov%26aufirst%3DV.%2BV.%26aulast%3DKonova%26aufirst%3DO.%2BD.%26aulast%3DMatsneva%26aufirst%3DI.%26aulast%3DBochkov%26aufirst%3DP.%2BO.%26atitle%3DInfluence%2520of%2520ABCB1%2520and%2520CYP3A5%2520gene%2520polymorphisms%2520on%2520pharmacokinetics%2520of%2520apixaban%2520in%2520patients%2520with%2520atrial%2520fibrillation%2520and%2520acute%2520stroke%26jtitle%3DPharmacogenomics%2520Pers.%2520Med.%26date%3D2018%26volume%3D11%26spage%3D43%26epage%3D49%26doi%3D10.2147%2FPGPM.S157111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit131c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ueshima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hira, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomitsuka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamane, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabuchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsura, T.</span></span> <span> </span><span class="NLM_article-title">Impact of ABCB1, ABCG2 and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in patients with atrial fibrillation</span>. <i>Pharmacogenet. Genomics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1097/FPC.0000000000000294</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1097%2FFPC.0000000000000294" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=28678049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1eqs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=329-336&author=S.+Ueshimaauthor=D.+Hiraauthor=R.+Fujiiauthor=Y.+Kimuraauthor=C.+Tomitsukaauthor=T.+Yamaneauthor=Y.+Tabuchiauthor=T.+Ozawaauthor=H.+Itohauthor=M.+Horieauthor=T.+Teradaauthor=T.+Katsura&title=Impact+of+ABCB1%2C+ABCG2+and+CYP3A5+polymorphisms+on+plasma+trough+concentrations+of+apixaban+in+patients+with+atrial+fibrillation&doi=10.1097%2FFPC.0000000000000294"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131cR"><div class="casContent"><span class="casTitleNuber">131c</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation</span></div><div class="casAuthors">Ueshima, Satoshi; Hira, Daiki; Fujii, Ryo; Kimura, Yuuma; Tomitsuka, Chiho; Yamane, Takuya; Tabuchi, Yohei; Ozawa, Tomoya; Itoh, Hideki; Horie, Minoru; Terada, Tomohiro; Katsura, Toshiya</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenetics and Genomics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">PGHEAI</span>;
        ISSN:<span class="NLM_cas:issn">1744-6872</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objectives: During anticoagulant therapy, major bleeding is one of the most severe adverse effects.  This study aimed to evaluate the relationships between ABCB1, ABCG2, and CYP3A5 polymorphisms and plasma trough concns. of apixaban, a direct inhibitor of coagulation factor X.  Patients and methods: A total of 70 plasma concns. of apixaban from 44 Japanese patients with atrial fibrillation were analyzed.  In these analyses, the plasma trough concn./dose (C/D) ratio of apixaban was used as a pharmacokinetic index and all data were stratified according to the presence of ABCB1 (ABCB1 1236C>T, 2677G>T/A, and 3435C>T), ABCG2 (ABCG2 421C>A), and CYP3A5 (CYP3A5*3) polymorphisms.  Influences of various clin. lab. parameters (age, serum creatinine, estd. glomerular filtration rate, aspartate amino transferase, and alanine amino transferase) on the plasma trough C/D ratio of apixaban were included in analyses.  Results: Although no ABCB1 polymorphisms affected the plasma trough C/D ratio of apixaban, the plasma trough C/D ratio of apixaban was significantly higher in patients with the ABCG2 421A/A genotype than in patients with the ABCG2 421C/C genotype (P<0.01).  The plasma trough C/D ratio of apixaban in patients with CYP3A5*1/*3 or *3/*3 genotypes was also significantly higher than that in patients with the CYP3A5*1/*1 genotype (P<0.05).  Furthermore, the plasma trough C/D ratio of apixaban decreased with increased estd. glomerular filtration rate.  Conclusion: These results indicate that ABCG2 421A/A and CYP3A5*3 genotypes and renal function are considered potential factors affecting trough concns. of apixaban.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9qxKLqAo_DbVg90H21EOLACvtfcHk0ljB0ntvIhpuuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1eqs7vE&md5=f80a4ffdbb94f86a4239d5f29d9bd3da</span></div><a href="/servlet/linkout?suffix=cit131c&amp;dbid=16384&amp;doi=10.1097%2FFPC.0000000000000294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFPC.0000000000000294%26sid%3Dliteratum%253Aachs%26aulast%3DUeshima%26aufirst%3DS.%26aulast%3DHira%26aufirst%3DD.%26aulast%3DFujii%26aufirst%3DR.%26aulast%3DKimura%26aufirst%3DY.%26aulast%3DTomitsuka%26aufirst%3DC.%26aulast%3DYamane%26aufirst%3DT.%26aulast%3DTabuchi%26aufirst%3DY.%26aulast%3DOzawa%26aufirst%3DT.%26aulast%3DItoh%26aufirst%3DH.%26aulast%3DHorie%26aufirst%3DM.%26aulast%3DTerada%26aufirst%3DT.%26aulast%3DKatsura%26aufirst%3DT.%26atitle%3DImpact%2520of%2520ABCB1%252C%2520ABCG2%2520and%2520CYP3A5%2520polymorphisms%2520on%2520plasma%2520trough%2520concentrations%2520of%2520apixaban%2520in%2520patients%2520with%2520atrial%2520fibrillation%26jtitle%3DPharmacogenet.%2520Genomics%26date%3D2017%26volume%3D27%26spage%3D329%26epage%3D336%26doi%3D10.1097%2FFPC.0000000000000294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Arimori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, M.</span></span> <span> </span><span class="NLM_article-title">Transport of furosemide into the intestinal lumen and the lack of effect of gastrointestinal dialysis by charcoal in rats with acute renal failure</span>. <i>J. Pharmacobio-Dyn.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1248/bpb1978.11.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1248%2Fbpb1978.11.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=3385600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaL1cXhtVGqsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1988&pages=1-8&author=K.+Arimoriauthor=M.+Nakano&title=Transport+of+furosemide+into+the+intestinal+lumen+and+the+lack+of+effect+of+gastrointestinal+dialysis+by+charcoal+in+rats+with+acute+renal+failure&doi=10.1248%2Fbpb1978.11.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132aR"><div class="casContent"><span class="casTitleNuber">132a</span><div class="casTitle"><span class="NLM_cas:atitle">Transport of furosemide into the intestinal lumen and the lack of effect of gastrointestinal dialysis by charcoal in rats with acute renal failure</span></div><div class="casAuthors">Arimori, Kazuhiko; Nakano, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacobio-Dynamics</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">JOPHDQ</span>;
        ISSN:<span class="NLM_cas:issn">0386-846X</span>.
    </div><div class="casAbstract">The characteristics of exsorption and(or) excretion of furosemide into the small intestinal lumen in rats with acute renal failure (ARF rat) were investigated by an in situ single-pass perfusion technique.  The amt. of furosemide, which was exsorbed into the intestinal lumen after an i.v. administration of the drug to rats was very slight.  The exsorption rate of the drug was increased in ARF rats as compared with normal rats.  The av. amt. of the drug exsorbed into the perfusate in normal rats was 0.83% of dose, whereas that in ARF rats was 1.83% of dose.  The amts. of furosemide excreted into the bile in normal rats and ARF rats were 1.53 and 2.64%, resp.  The increased exsorption of furosemide in ARF rats appeared to be due primarily to the decreased binding of the drug to the serum protein, because only the unbound drug permeates through the intestinal membrane into the gastrointestinal (g.i.) tract, and, to some extent, to the increased nonrenal excretion caused by poor renal excretion.  Oral activated charcoal had little effect on the serum furosemide levels after i.v. administration of the drug at 10 mg/kg in ARF rats.  The lack of effect of activated charcoal on the elimination of the drug may be due to the small amt. of the drug excreted into the g.i. tract.  The relation of these results to the removal of toxic drugs from the blood is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxMk4it_HmM7Vg90H21EOLACvtfcHk0lgCOkuDYrOE9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXhtVGqsLY%253D&md5=0d7e0d3d5ef56e4cb3f8b1f2c6830938</span></div><a href="/servlet/linkout?suffix=cit132a&amp;dbid=16384&amp;doi=10.1248%2Fbpb1978.11.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb1978.11.1%26sid%3Dliteratum%253Aachs%26aulast%3DArimori%26aufirst%3DK.%26aulast%3DNakano%26aufirst%3DM.%26atitle%3DTransport%2520of%2520furosemide%2520into%2520the%2520intestinal%2520lumen%2520and%2520the%2520lack%2520of%2520effect%2520of%2520gastrointestinal%2520dialysis%2520by%2520charcoal%2520in%2520rats%2520with%2520acute%2520renal%2520failure%26jtitle%3DJ.%2520Pharmacobio-Dyn.%26date%3D1988%26volume%3D11%26spage%3D1%26epage%3D8%26doi%3D10.1248%2Fbpb1978.11.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit132b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Arimori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakayama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, M.</span></span> <span> </span><span class="NLM_article-title">Increased transport of theophylline into gastrointestinal lumen and gastrointestinal dialysis by activated charcoal in rats with hepatic cirrhosis</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">3148</span>– <span class="NLM_lpage">3149</span>, <span class="refDoi"> DOI: 10.1248/cpb.37.3148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1248%2Fcpb.37.3148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=2632064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADyaK3cXmvFelsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1989&pages=3148-3149&author=K.+Arimoriauthor=K.+Wakayamaauthor=M.+Nakano&title=Increased+transport+of+theophylline+into+gastrointestinal+lumen+and+gastrointestinal+dialysis+by+activated+charcoal+in+rats+with+hepatic+cirrhosis&doi=10.1248%2Fcpb.37.3148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132bR"><div class="casContent"><span class="casTitleNuber">132b</span><div class="casTitle"><span class="NLM_cas:atitle">Increased transport of theophylline into gastrointestinal lumen and gastrointestinal dialysis by activated charcoal in rats with hepatic cirrhosis</span></div><div class="casAuthors">Arimori, Kazuhiko; Wakayama, Katsumi; Nakano, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3148-9</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    </div><div class="casAbstract">The characteristics of exsorption and/or excretion of theophylline into the small intestinal lumen in rats with hepatic cirrhosis (HC rats) induced by CCl4 were investigated by an in situ single-pass perfusion technique.  The serum concns. of theophylline after i.v. administration of aminophylline (10 mg/kg) in the HC rats were higher than those in normal rats during the exptl. period.  Moreover, the exsorption of theophylline from blood into the intestinal lumen was increased in the HC rats compared with the normal rats.  Treatments with oral activated charcoal reduced the serum theophylline levels in the HC rats.  Consequently, gastrointestinal dialysis by oral administration of activated charcoal may be a useful method to remove poisonous drugs from the blood in patients with hepatic failure (including cirrhosis), which decreases the systemic clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIwLevifQ_obVg90H21EOLACvtfcHk0lgUccgzGEk0Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXmvFelsg%253D%253D&md5=5b385ef44c5f50b195b26de0a5c381bc</span></div><a href="/servlet/linkout?suffix=cit132b&amp;dbid=16384&amp;doi=10.1248%2Fcpb.37.3148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.37.3148%26sid%3Dliteratum%253Aachs%26aulast%3DArimori%26aufirst%3DK.%26aulast%3DWakayama%26aufirst%3DK.%26aulast%3DNakano%26aufirst%3DM.%26atitle%3DIncreased%2520transport%2520of%2520theophylline%2520into%2520gastrointestinal%2520lumen%2520and%2520gastrointestinal%2520dialysis%2520by%2520activated%2520charcoal%2520in%2520rats%2520with%2520hepatic%2520cirrhosis%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D1989%26volume%3D37%26spage%3D3148%26epage%3D3149%26doi%3D10.1248%2Fcpb.37.3148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L. Z.</span></span> <span> </span><span class="NLM_article-title">Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1007/s11095-004-9004-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1007%2Fs11095-004-9004-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=15771225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlCks70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2005&pages=11-23&author=C.+Y.+Wuauthor=L.+Z.+Benet&title=Predicting+drug+disposition+via+application+of+BCS%3A+transport%2Fabsorption%2F+elimination+interplay+and+development+of+a+biopharmaceutics+drug+disposition+classification+system&doi=10.1007%2Fs11095-004-9004-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System</span></div><div class="casAuthors">Wu, Chi-Yuan; Benet, Leslie Z.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-23</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The Biopharmaceutics Classification System (BCS) was developed to allow prediction of in vivo pharmacokinetic performance of drug products from measurements of permeability (detd. as the extent of oral absorption) and soly. Here, we suggest that a modified version of such a classification system may be useful in predicting overall drug disposition, including routes of drug elimination and the effects of efflux and absorptive transporters on oral drug absorption; when transporter-enzyme interplay will yield clin. significant effects (e.g., low bioavailability and drug-drug interactions); the direction, mechanism, and importance of food effects; and transporter effects on postabsorption systemic drug concns. following oral and i.v. dosing.  These predictions are supported by a series of studies from our lab. during the past few years investigating the effect of transporter inhibition and induction on drug metab.  We conclude by suggesting that a Biopharmaceutics Drug Disposition Classification System (BDDCS) using elimination criteria may expand the no. of Class 1 drugs eligible for a waiver of in vivo bioequivalence studies and provide predictability of drug disposition profiles for Classes 2, 3, and 4 compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-ZukfABDoNbVg90H21EOLACvtfcHk0lgUccgzGEk0Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlCks70%253D&md5=a8aa9533f337a4245b1b66ac859095fb</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1007%2Fs11095-004-9004-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-004-9004-4%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%2BY.%26aulast%3DBenet%26aufirst%3DL.%2BZ.%26atitle%3DPredicting%2520drug%2520disposition%2520via%2520application%2520of%2520BCS%253A%2520transport%252Fabsorption%252F%2520elimination%2520interplay%2520and%2520development%2520of%2520a%2520biopharmaceutics%2520drug%2520disposition%2520classification%2520system%26jtitle%3DPharm.%2520Res.%26date%3D2005%26volume%3D22%26spage%3D11%26epage%3D23%26doi%3D10.1007%2Fs11095-004-9004-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. M.</span></span> <span> </span><span class="NLM_article-title">Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1766</span>– <span class="NLM_lpage">1774</span>, <span class="refDoi"> DOI: 10.1021/mp900132e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp900132e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtl2qurjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=1766-1774&author=L.+Zhangauthor=Y.+Zhangauthor=S.+M.+Huang&title=Scientific+and+regulatory+perspectives+on+metabolizing+enzyme-transporter+interplay+and+its+role+in+drug+interactions%3A+challenges+in+predicting+drug+interactions&doi=10.1021%2Fmp900132e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Scientific and Regulatory Perspectives on Metabolizing Enzyme-Transporter Interplay and its Role in Drug Interactions: Challenges in Predicting Drug Interactions</span></div><div class="casAuthors">Zhang, Lei; Zhang, Yuanchao; Huang, Shiew-Mei</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1766-1774</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Both metabolizing enzymes and drug transporters play important roles in modulating drug absorption, distribution, metab. and elimination.  Acting alone or in concert with each other they can affect the pharmacokinetics and pharmacodynamics of a drug.  This paper will present cases from recent reviews of new drug application (NDA) and literature that exemplify the role of metabolizing enzyme-transporter interplay in a drug's disposition, and discuss challenges in predicting drug interactions.  Finally, the discussion will focus on the need to leverage current knowledge to obtain more meaningful drug interaction information.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp367gxPqTthLVg90H21EOLACvtfcHk0lgUccgzGEk0Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtl2qurjF&md5=b5b5c46d55c57dca43e80b6c2f0a4ae9</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1021%2Fmp900132e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp900132e%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DS.%2BM.%26atitle%3DScientific%2520and%2520regulatory%2520perspectives%2520on%2520metabolizing%2520enzyme-transporter%2520interplay%2520and%2520its%2520role%2520in%2520drug%2520interactions%253A%2520challenges%2520in%2520predicting%2520drug%2520interactions%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2009%26volume%3D6%26spage%3D1766%26epage%3D1774%26doi%3D10.1021%2Fmp900132e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charman, W. N.</span></span> <span> </span><span class="NLM_article-title">Intestinal lymphatic drug transport: an update</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">80</span>, <span class="refDoi"> DOI: 10.1016/S0169-409X(01)00151-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1016%2FS0169-409X%2801%2900151-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=11489334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlsF2js7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2001&pages=61-80&author=C.+J.+Porterauthor=W.+N.+Charman&title=Intestinal+lymphatic+drug+transport%3A+an+update&doi=10.1016%2FS0169-409X%2801%2900151-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal lymphatic drug transport: an update</span></div><div class="casAuthors">Porter, C. J. H.; Charman, W. N.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">61-80</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  The trend towards identification of poorly water-sol. and highly lipophilic candidate drug mols. has led to an increase in interest in intestinal lymphatic drug transport.  In this article we provide a brief background to the mechanism of access of drugs to the intestinal lymph and the role of lipid digestion and absorption in the stimulation of lymphatic transport.  The ability of different lipid types to stimulate lymphatic drug transport, is addressed, concg. specifically on the impact of the class, chain length and degree of unsatn. of co-administered lipids.  Comment is also made as to the relevance of dosing different lipid vols. to the rat and the possible complications this may provide when trying to assess the likely extent of intestinal lymphatic transport.  Recent studies are described in which the extent of lymphatic transport of a highly lipophilic antimalarial, halofantrine, was investigated after post-prandial administration to greyhound dogs.  Finally the possible future directions for studies of intestinal lymphatic transport are discussed, including the use of cell culture models and genetically modified animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGZPCxqz31PrVg90H21EOLACvtfcHk0ljN0UrCaD_ibg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlsF2js7g%253D&md5=1821acb0f76a521bac55ee7f05d28205</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2801%2900151-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252801%252900151-X%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DC.%2BJ.%26aulast%3DCharman%26aufirst%3DW.%2BN.%26atitle%3DIntestinal%2520lymphatic%2520drug%2520transport%253A%2520an%2520update%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2001%26volume%3D50%26spage%3D61%26epage%3D80%26doi%3D10.1016%2FS0169-409X%2801%2900151-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kagan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreifinger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mager, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, A.</span></span> <span> </span><span class="NLM_article-title">Role of P-glycoprotein in region-specific gastrointestinal absorption of talinolol in rats</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1560</span>– <span class="NLM_lpage">1566</span>, <span class="refDoi"> DOI: 10.1124/dmd.110.033019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.110.033019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=20538723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFegu73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1560-1566&author=L.+Kaganauthor=T.+Dreifingerauthor=D.+E.+Magerauthor=A.+Hoffman&title=Role+of+P-glycoprotein+in+region-specific+gastrointestinal+absorption+of+talinolol+in+rats&doi=10.1124%2Fdmd.110.033019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Role of P-glycoprotein in region-specific gastrointestinal absorption of talinolol in rats</span></div><div class="casAuthors">Kagan, Leonid; Dreifinger, Tali; Mager, Donald E.; Hoffman, Amnon</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1560-1566</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">P-Glycoprotein (PGP) is nonuniformly distributed along the gastrointestinal (GI) tract; however, the data regarding regional differences in PGP function in the intestine are controversial.  The aim of this work was to investigate the role of PGP efflux in region-specific absorption of talinolol from the GI tract in rats.  Plasma talinolol concns. were measured after several modes of administration, including high (40 mg/kg) and low (4 mg/kg) dose levels, to different segments of the GI tract (stomach vs. colon), and codosing with PGP inhibitors (verapamil or cyclosporine).  The bioavailability (F) of talinolol after high-dose administration to the stomach was significantly greater than that achieved by the low dose (approx. 18 vs. 2%).  Coadministration of low-dose talinolol with cyclosporine increased F by approx. 5-fold (p < 0.01).  For the high dose, codosing with PGP inhibitors did not increase the extent of absorption.  Talinolol demonstrated poor colonic absorption that was significantly increased by coadministration with cyclosporine (F = 0.76 vs. 8.1%).  Oral verapamil significantly increased systemic clearance and the steady state vol. of distribution of i.v. talinolol.  A semiphysiol. model was developed that successfully captured the pharmacokinetic profiles of talinolol after various modes of administration.  PGP-mediated efflux appears to be a major factor responsible for GI region-specific absorption of talinolol in rats, and gastroretentive dosage forms may provide an advantage in the delivery of talinolol and PGP substrate drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHyQ3Oihi8UrVg90H21EOLACvtfcHk0ljN0UrCaD_ibg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFegu73E&md5=ece6a2a77eaf51c551fb02dec917dfdd</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.033019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.033019%26sid%3Dliteratum%253Aachs%26aulast%3DKagan%26aufirst%3DL.%26aulast%3DDreifinger%26aufirst%3DT.%26aulast%3DMager%26aufirst%3DD.%2BE.%26aulast%3DHoffman%26aufirst%3DA.%26atitle%3DRole%2520of%2520P-glycoprotein%2520in%2520region-specific%2520gastrointestinal%2520absorption%2520of%2520talinolol%2520in%2520rats%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D1560%26epage%3D1566%26doi%3D10.1124%2Fdmd.110.033019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fagerholm, U.</span></span> <span> </span><span class="NLM_article-title">Prediction of human pharmacokinetics-biliary and intestinal clearance and enterohepatic circulation</span>. <i>J. Pharm. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">535</span>– <span class="NLM_lpage">542</span>, <span class="refDoi"> DOI: 10.1211/jpp.60.5.0001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1211%2Fjpp.60.5.0001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2010&pages=535-542&author=U.+Fagerholm&title=Prediction+of+human+pharmacokinetics-biliary+and+intestinal+clearance+and+enterohepatic+circulation&doi=10.1211%2Fjpp.60.5.0001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1211%2Fjpp.60.5.0001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1211%252Fjpp.60.5.0001%26sid%3Dliteratum%253Aachs%26aulast%3DFagerholm%26aufirst%3DU.%26atitle%3DPrediction%2520of%2520human%2520pharmacokinetics-biliary%2520and%2520intestinal%2520clearance%2520and%2520enterohepatic%2520circulation%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D2010%26volume%3D60%26spage%3D535%26epage%3D542%26doi%3D10.1211%2Fjpp.60.5.0001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chyka, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krenzelok, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vale, J. A.</span></span> <span> </span><span class="NLM_article-title">Position paper: single-dose activated charcoal</span>. <i>Clin. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1081/CLT-200051867</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1081%2FCLT-51867" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A280%3ADC%252BD2M7ovFGisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2005&pages=61-87&author=P.+A.+Chykaauthor=D.+Segerauthor=E.+P.+Krenzelokauthor=J.+A.+Vale&title=Position+paper%3A+single-dose+activated+charcoal&doi=10.1081%2FCLT-200051867"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Position paper: Single-dose activated charcoal</span></div><div class="casAuthors">Chyka P A; Seger D; Krenzelok E P; Vale J A</div><div class="citationInfo"><span class="NLM_cas:title">Clinical toxicology (Philadelphia, Pa.)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">61-87</span>
        ISSN:<span class="NLM_cas:issn">1556-3650</span>.
    </div><div class="casAbstract">Single-dose activated charcoal therapy involves the oral administration or instillation by nasogastric tube of an aqueous preparation of activated charcoal after the ingestion of a poison.  Volunteer studies demonstrate that the effectiveness of activated charcoal decreases with time.  Data using at least 50 g of activated charcoal, showed a mean reduction in absorption of 47.3%, 40.07%, 16.5% and 21.13%, when activated charcoal was administered at 30 minutes, 60 minutes, 120 minutes and 180 minutes, respectively, after dosing.  There are no satisfactorily designed clinical studies assessing benefit from single-dose activated charcoal to guide the use of this therapy.  Single-dose activated charcoal should not be administered routinely in the management of poisoned patients.  Based on volunteer studies, the administration of activated charcoal may be considered if a patient has ingested a potentially toxic amount of a poison (which is known to be adsorbed to charcoal) up to one hour previously.  Although volunteer studies demonstrate that the reduction of drug absorption decreases to values of questionable clinical importance when charcoal is administered at times greater than one hour, the potential for benefit after one hour cannot be excluded.  There is no evidence that the administration of activated charcoal improves clinical outcome.  Unless a patient has an intact or protected airway, the administration of charcoal is contraindicated.  A review of the literature since the preparation of the 1997 Single-dose Activated Charcoal Position Statement revealed no new evidence that would require a revision of the conclusions of the Statement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT56uSW4BEPM8rRqEXsZufAfW6udTcc2eaKRuagf7vlJ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M7ovFGisw%253D%253D&md5=f7258ca07e3f2dbab1d5bd9417dd1ad7</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1081%2FCLT-51867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1081%252FCLT-51867%26sid%3Dliteratum%253Aachs%26aulast%3DChyka%26aufirst%3DP.%2BA.%26aulast%3DSeger%26aufirst%3DD.%26aulast%3DKrenzelok%26aufirst%3DE.%2BP.%26aulast%3DVale%26aufirst%3DJ.%2BA.%26atitle%3DPosition%2520paper%253A%2520single-dose%2520activated%2520charcoal%26jtitle%3DClin.%2520Toxicol.%26date%3D2005%26volume%3D43%26spage%3D61%26epage%3D87%26doi%3D10.1081%2FCLT-200051867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghavan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maxwell, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goosen, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, S. J.</span></span> <span> </span><span class="NLM_article-title">In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">448</span>– <span class="NLM_lpage">458</span>, <span class="refDoi"> DOI: 10.1124/dmd.109.029694</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.109.029694" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=19940026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjt1Ort7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=448-458&author=L.+Wangauthor=D.+Zhangauthor=N.+Raghavanauthor=M.+Yaoauthor=L.+Maauthor=C.+E.+Frostauthor=B.+D.+Maxwellauthor=S.+Y.+Chenauthor=K.+Heauthor=T.+C.+Goosenauthor=W.+G.+Humphreysauthor=S.+J.+Grossman&title=In+vitro+assessment+of+metabolic+drug-drug+interaction+potential+of+apixaban+through+cytochrome+P450+phenotyping%2C+inhibition%2C+and+induction+studies&doi=10.1124%2Fdmd.109.029694"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies</span></div><div class="casAuthors">Wang, Lifei; Zhang, Donglu; Raghavan, Nirmala; Yao, Ming; Ma, Li; Frost, Charles A.; Maxwell, Brad D.; Chen, Shiang-yuan; He, Kan; Goosen, Theunis C.; Humphreys, W. Griffith; Grossman, Scott J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">448-458</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Apixaban is an oral, direct, and highly selective factor Xa inhibitor in late-stage clin. development for the prevention and treatment of thromboembolic diseases.  The metabolic drug-drug interaction potential of apixaban was evaluated in vitro.  The compd. did not show cytochrome P 450 inhibition (IC50 values > 20 μM) in incubations of human liver microsomes with the probe substrates of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4/5.  Apixaban did not show any effect at concns. up to 20 μM on enzyme activities or mRNA levels of selected P 450 enzymes (CYP1A2, 2B6, and 3A4/5) that are sensitive to induction in incubations with primary human hepatocytes.  Apixaban showed a slow metabolic turnover in incubations of human liver microsomes with formation of O-demethylation (M2) and hydroxylation products (M4 and M7) as prominent in vitro metabolites.  Expts. with human cDNA-expressed P 450 enzymes and P 450 chem. inhibitors and correlation with P 450 activities in individual human liver microsomes demonstrated that the oxidative metab. of apixaban for formation of all metabolites was predominantly catalyzed by CYP3A4/5 with a minor contribution of CYP1A2 and CYP2J2 for formation of M2.  The contribution of CYP2C8, 2C9, and 2C19 to metab. of apixaban was less significant.  In addn., a human absorption, distribution, metab., and excretion study showed that more than half of the dose was excreted as unchanged parent (fm CYP <0.5), thus significantly reducing the overall metabolic drug-drug interaction potential of apixaban.  Together with a low clin. efficacious concn. and multiple clearance pathways, these results demonstrate that the metabolic drug-drug interaction potential between apixaban and coadministered drugs is low.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOeDRJ6ezxeLVg90H21EOLACvtfcHk0lhy6CpQM5-40g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjt1Ort7c%253D&md5=934e9d2bbd934e263783b64d442c6c1c</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.029694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.029694%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DRaghavan%26aufirst%3DN.%26aulast%3DYao%26aufirst%3DM.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DFrost%26aufirst%3DC.%2BE.%26aulast%3DMaxwell%26aufirst%3DB.%2BD.%26aulast%3DChen%26aufirst%3DS.%2BY.%26aulast%3DHe%26aufirst%3DK.%26aulast%3DGoosen%26aufirst%3DT.%2BC.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DGrossman%26aufirst%3DS.%2BJ.%26atitle%3DIn%2520vitro%2520assessment%2520of%2520metabolic%2520drug-drug%2520interaction%2520potential%2520of%2520apixaban%2520through%2520cytochrome%2520P450%2520phenotyping%252C%2520inhibition%252C%2520and%2520induction%2520studies%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D448%26epage%3D458%26doi%3D10.1124%2Fdmd.109.029694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pang, K. S.</span></span> <span> </span><span class="NLM_article-title">Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series)</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1507</span>– <span class="NLM_lpage">1519</span>, <span class="refDoi"> DOI: 10.1124/dmd.31.12.1507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.1124%2Fdmd.31.12.1507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=14625347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpt1KgsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2003&pages=1507-1519&author=K.+S.+Pang&title=Modeling+of+intestinal+drug+absorption%3A+roles+of+transporters+and+metabolic+enzymes+%28for+the+Gillette+Review+Series%29&doi=10.1124%2Fdmd.31.12.1507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling of intestinal drug absorption: Roles of transporters and metabolic enzymes (for the Gillete review series)</span></div><div class="casAuthors">Pang, K. Sandy</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1507-1519</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review describes the processes governing drug bioavailability when the drug is already in soln., and emphasizes the roles of intestinal transporters and metab. on oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxUcibeQ0oY7Vg90H21EOLACvtfcHk0lhy6CpQM5-40g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpt1KgsLo%253D&md5=5f775a511055198f6d7a3d2182880890</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1124%2Fdmd.31.12.1507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.31.12.1507%26sid%3Dliteratum%253Aachs%26aulast%3DPang%26aufirst%3DK.%2BS.%26atitle%3DModeling%2520of%2520intestinal%2520drug%2520absorption%253A%2520roles%2520of%2520transporters%2520and%2520metabolic%2520enzymes%2520%2528for%2520the%2520Gillette%2520Review%2520Series%2529%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2003%26volume%3D31%26spage%3D1507%26epage%3D1519%26doi%3D10.1124%2Fdmd.31.12.1507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosset, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attkins, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurrell, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logan, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bungay, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, I. B.</span></span> <span> </span><span class="NLM_article-title">Application of PBPK modelling in drug discovery and development at Pfizer</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">106</span>, <span class="refDoi"> DOI: 10.3109/00498254.2011.627477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=10.3109%2F00498254.2011.627477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=22035569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFKgtbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2012&pages=94-106&author=H.+M.+Jonesauthor=M.+Dickinsauthor=K.+Youdimauthor=J.+R.+Gossetauthor=N.+J.+Attkinsauthor=T.+L.+Hayauthor=I.+K.+Gurrellauthor=Y.+R.+Loganauthor=P.+J.+Bungayauthor=B.+C.+Jonesauthor=I.+B.+Gardner&title=Application+of+PBPK+modelling+in+drug+discovery+and+development+at+Pfizer&doi=10.3109%2F00498254.2011.627477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Application of PBPK modelling in drug discovery and development at Pfizer</span></div><div class="casAuthors">Jones, Hannah M.; Dickins, Maurice; Youdim, Kuresh; Gosset, James R.; Attkins, Neil J.; Hay, Tanya L.; Gurrell, Ian K.; Logan, Y. Raj; Bungay, Peter J.; Jones, Barry C.; Gardner, Iain B.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-106</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Early prediction of human pharmacokinetics (PK) and drug-drug interactions (DDI) in drug discovery and development allows for more informed decision making.  Physiol. based pharmacokinetic (PBPK) modeling can be used to answer a no. of questions throughout the process of drug discovery and development and is thus becoming a very popular tool.  PBPK models provide the opportunity to integrate key input parameters from different sources to not only est. PK parameters and plasma concn.-time profiles, but also to gain mechanistic insight into compd. properties.  Using examples from the literature and our own company, we have shown how PBPK techniques can be utilized through the stages of drug discovery and development to increase efficiency, reduce the need for animal studies, replace clin. trials and to increase PK understanding.  Given the mechanistic nature of these models, the future use of PBPK modeling in drug discovery and development is promising, however, some limitations need to be addressed to realize its application and utility more broadly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW2ut1VBSKzrVg90H21EOLACvtfcHk0lhy6CpQM5-40g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFKgtbnI&md5=6a487c3b384bf6e19b4cd45c4f0bd6ec</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.3109%2F00498254.2011.627477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498254.2011.627477%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DH.%2BM.%26aulast%3DDickins%26aufirst%3DM.%26aulast%3DYoudim%26aufirst%3DK.%26aulast%3DGosset%26aufirst%3DJ.%2BR.%26aulast%3DAttkins%26aufirst%3DN.%2BJ.%26aulast%3DHay%26aufirst%3DT.%2BL.%26aulast%3DGurrell%26aufirst%3DI.%2BK.%26aulast%3DLogan%26aufirst%3DY.%2BR.%26aulast%3DBungay%26aufirst%3DP.%2BJ.%26aulast%3DJones%26aufirst%3DB.%2BC.%26aulast%3DGardner%26aufirst%3DI.%2BB.%26atitle%3DApplication%2520of%2520PBPK%2520modelling%2520in%2520drug%2520discovery%2520and%2520development%2520at%2520Pfizer%26jtitle%3DXenobiotica%26date%3D2012%26volume%3D42%26spage%3D94%26epage%3D106%26doi%3D10.3109%2F00498254.2011.627477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i29"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01720">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_61433"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01720?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01720</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Table S1. Pharmacokinetic parameters of digoxin and nitrofurantoin following single IV dose of radiolabels to male bile-cannulated Sprague–Dawley rats (WT = wild-type) and P-gp-KO or BCRP-KO rats. Table S2. Intestinal clearance, renal clearance, and biliary clearance of apixaban, digoxin, and nitrofurantoin in Sprague–Dawley rats. Table S3. Study designs in dogs and rats following oral and intravenous administration of apixaban, [<sup>14</sup>C]apixaban, [<sup>14</sup>C]digoxin, and [<sup>14</sup>C]nitrofurantoin with and without oral administration of activated charcoal. Table S4. Percent recoveries of radioactivity (±SD) following a single IV dose of [<sup>3</sup>H]digoxin, [<sup>14</sup>C]nitrofurantoin, or [<sup>14</sup>C]apixaban to male bile-cannulated Sprague–Dawley rats (WT = wild-type; P-gp-KO = P-gp-KO; BCRP-KO = BCRP-KO) following a single 1 mg/kg IV dose of [<sup>14</sup>C]apixaban to male intact and bile-cannulated Beagle dogs. Table S5. Classes of drugs that are substrates of intestinal efflux transporters. Table S6. Selected studies that tested the effects of activated charcoal on pharmacokinetics and pharmacodynamics of drugs. Figure S1. Chemical structures used in Table S5 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01720/suppl_file/jm0c01720_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01720/suppl_file/jm0c01720_si_001.pdf">jm0c01720_si_001.pdf (360.77 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01720&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-11%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01720%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01720" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                1MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679aae5dfb593c5e","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
